ID AKT1_HUMAN Reviewed; 480 AA. AC P31749; B2RAM5; B7Z5R1; Q9BWB6; DT 01-JUL-1993, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-2005, sequence version 2. DT 28-JAN-2026, entry version 272. DE RecName: Full=RAC-alpha serine/threonine-protein kinase; DE EC=2.7.11.1 {ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:15861136, ECO:0000269|PubMed:29343641, ECO:0000269|PubMed:32322062, ECO:0000269|PubMed:33594058}; DE AltName: Full=Protein kinase B; DE Short=PKB; DE AltName: Full=Protein kinase B alpha; DE Short=PKB alpha; DE AltName: Full=Proto-oncogene c-Akt; DE AltName: Full=RAC-PK-alpha; GN Name=AKT1 {ECO:0000312|HGNC:HGNC:391}; Synonyms=PKB, RAC; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CATALYTIC ACTIVITY. RX PubMed=1851997; DOI=10.1073/pnas.88.10.4171; RA Jones P.F., Jakubowicz T., Pitossi F.J., Maurer F., Hemmings B.A.; RT "Molecular cloning and identification of a serine/threonine protein kinase RT of the second-messenger subfamily."; RL Proc. Natl. Acad. Sci. U.S.A. 88:4171-4175(1991). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=11508278; DOI=10.1007/s001250100577; RA Matsubara A., Wasson J.C., Donelan S.S., Welling C.M., Glaser B., RA Permutt M.A.; RT "Isolation and characterization of the human AKT1 gene, identification of RT 13 single nucleotide polymorphisms (SNPs), and their lack of association RT with Type II diabetes."; RL Diabetologia 44:910-913(2001). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Adrenal gland; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=19054851; DOI=10.1038/nmeth.1273; RA Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R., RA Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y., RA Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B., RA Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y., RA Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A., RA Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y., RA Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T., RA Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y., RA Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S., RA Nomura N.; RT "Human protein factory for converting the transcriptome into an in vitro- RT expressed proteome."; RL Nat. Methods 5:1011-1017(2008). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12508121; DOI=10.1038/nature01348; RA Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C., RA Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A., RA Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H., RA Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T., RA Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B., RA Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D., RA Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R., RA Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S., RA Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C., RA Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S., RA Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., RA Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., RA Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M., RA Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V., RA Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J., RA Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F., RA Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F., RA Waterston R., Hood L., Weissenbach J.; RT "The DNA sequence and analysis of human chromosome 14."; RL Nature 421:601-607(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Muscle, and Ovary; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 63-480 (ISOFORM 1), FUNCTION, CATALYTIC RP ACTIVITY, AND TISSUE SPECIFICITY. RC TISSUE=Foreskin; RX PubMed=1718748; DOI=10.1111/j.1432-1033.1991.tb16305.x; RA Coffer P.J., Woodgett J.R.; RT "Molecular cloning and characterisation of a novel putative protein-serine RT kinase related to the cAMP-dependent and protein kinase C families."; RL Eur. J. Biochem. 201:475-481(1991). RN [8] RP ERRATUM OF PUBMED:1718748, AND SEQUENCE REVISION. RX PubMed=1533586; RA Coffer P.J., Woodgett J.R.; RL Eur. J. Biochem. 205:1217-1218(1992). RN [9] RP FUNCTION IN PHOSPHORYLATION OF CREB1. RX PubMed=9829964; DOI=10.1074/jbc.273.49.32377; RA Du K., Montminy M.; RT "CREB is a regulatory target for the protein kinase Akt/PKB."; RL J. Biol. Chem. 273:32377-32379(1998). RN [10] RP ACTIVITY REGULATION, AND PHOSPHORYLATION AT SER-473. RX PubMed=9736715; DOI=10.1073/pnas.95.19.11211; RA Delcommenne M., Tan C., Gray V., Rue L., Woodgett J.R., Dedhar S.; RT "Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase RT kinase 3 and protein kinase B/AKT by the integrin-linked kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 95:11211-11216(1998). RN [11] RP MUTAGENESIS OF THR-308 AND SER-473, AND PHOSPHORYLATION AT THR-308 AND RP SER-473. RX PubMed=8978681; DOI=10.1002/j.1460-2075.1996.tb01045.x; RA Alessi D.R., Andjelkovic M., Caudwell F.B., Cron P., Morrice N., Cohen P., RA Hemmings B.A.; RT "Mechanism of activation of protein kinase B by insulin and IGF-1."; RL EMBO J. 15:6541-6551(1996). RN [12] RP FUNCTION, ACTIVITY REGULATION, AND PHOSPHORYLATION AT THR-308 BY PDPK1. RX PubMed=9512493; DOI=10.1042/bj3310299; RA Walker K.S., Deak M., Paterson A., Hudson K., Cohen P., Alessi D.R.; RT "Activation of protein kinase B beta and gamma isoforms by insulin in vivo RT and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison RT with protein kinase B alpha."; RL Biochem. J. 331:299-308(1998). RN [13] RP FUNCTION IN PHOSPHORYLATION OF FOXO1. RX PubMed=10358075; DOI=10.1074/jbc.274.24.17179; RA Rena G., Guo S., Cichy S.C., Unterman T.G., Cohen P.; RT "Phosphorylation of the transcription factor forkhead family member FKHR by RT protein kinase B."; RL J. Biol. Chem. 274:17179-17183(1999). RN [14] RP FUNCTION IN PHOSPHORYLATION OF RAF1, AND INTERACTION WITH RAF1. RX PubMed=10576742; DOI=10.1126/science.286.5445.1741; RA Zimmermann S., Moelling K.; RT "Phosphorylation and regulation of Raf by Akt (protein kinase B)."; RL Science 286:1741-1744(1999). RN [15] RP FUNCTION IN PHOSPHORYLATION OF BAD, AND INTERACTION WITH BAD AND PKN2. RX PubMed=10926925; DOI=10.1074/jbc.m001753200; RA Koh H., Lee K.H., Kim D., Kim S., Kim J.W., Chung J.; RT "Inhibition of Akt and its anti-apoptotic activities by tumor necrosis RT factor-induced protein kinase C-related kinase 2 (PRK2) cleavage."; RL J. Biol. Chem. 275:34451-34458(2000). RN [16] RP INTERACTION WITH MTCP1; TCL1A AND TCL1B. RX PubMed=10983986; DOI=10.1016/s1097-2765(00)00039-3; RA Laine J., Kuenstle G., Obata T., Sha M., Noguchi M.; RT "The protooncogene TCL1 is an Akt kinase coactivator."; RL Mol. Cell 6:395-407(2000). RN [17] RP INTERACTION WITH TCL1A. RX PubMed=10716693; DOI=10.1073/pnas.97.7.3028; RA Pekarsky Y., Koval A., Hallas C., Bichi R., Tresini M., Malstrom S., RA Russo G., Tsichlis P., Croce C.M.; RT "Tcl1 enhances Akt kinase activity and mediates its nuclear RT translocation."; RL Proc. Natl. Acad. Sci. U.S.A. 97:3028-3033(2000). RN [18] RP FUNCTION IN PHOSPHORYLATION OF MAP3K5, AND INTERACTION WITH MAP3K5. RX PubMed=11154276; DOI=10.1128/mcb.21.3.893-901.2001; RA Kim A.H., Khursigara G., Sun X., Franke T.F., Chao M.V.; RT "Akt phosphorylates and negatively regulates apoptosis signal-regulating RT kinase 1."; RL Mol. Cell. Biol. 21:893-901(2001). RN [19] RP INTERACTION WITH THEM4, AND SUBCELLULAR LOCATION. RX PubMed=11598301; DOI=10.1126/science.1062030; RA Maira S.-M., Galetic I., Brazil D.P., Kaech S., Ingley E., Thelen M., RA Hemmings B.A.; RT "Carboxyl-terminal modulator protein (CTMP), a negative regulator of RT PKB/Akt and v-Akt at the plasma membrane."; RL Science 294:374-380(2001). RN [20] RP FUNCTION IN PHOSPHORYLATION OF TBC1D4. RX PubMed=11994271; DOI=10.1074/jbc.c200198200; RA Kane S., Sano H., Liu S.C.H., Asara J.M., Lane W.S., Garner C.C., RA Lienhard G.E.; RT "A method to identify serine kinase substrates. Akt phosphorylates a novel RT adipocyte protein with a Rab GTPase-activating protein (GAP) domain."; RL J. Biol. Chem. 277:22115-22118(2002). RN [21] RP INTERACTION WITH CDKN1B, AND FUNCTION. RX PubMed=12042314; DOI=10.1074/jbc.m203668200; RA Fujita N., Sato S., Katayama K., Tsuruo T.; RT "Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and RT cytoplasmic localization."; RL J. Biol. Chem. 277:28706-28713(2002). RN [22] RP PHOSPHORYLATION AT TYR-474, AND MUTAGENESIS OF TYR-474. RX PubMed=12149249; DOI=10.1074/jbc.m203387200; RA Conus N.M., Hannan K.M., Cristiano B.E., Hemmings B.A., Pearson R.B.; RT "Direct identification of tyrosine 474 as a regulatory phosphorylation site RT for the Akt protein kinase."; RL J. Biol. Chem. 277:38021-38028(2002). RN [23] RP FUNCTION IN PHOSPHORYLATION OF TSC2. RX PubMed=12150915; DOI=10.1016/s1097-2765(02)00568-3; RA Manning B.D., Tee A.R., Logsdon M.N., Blenis J., Cantley L.C.; RT "Identification of the tuberous sclerosis complex-2 tumor suppressor gene RT product tuberin as a target of the phosphoinositide 3-kinase/akt pathway."; RL Mol. Cell 10:151-162(2002). RN [24] RP INTERACTION WITH TCL1A. RX PubMed=11839817; DOI=10.1128/mcb.22.5.1513-1525.2002; RA Kuenstle G., Laine J., Pierron G., Kagami S., Nakajima H., Hoh F., RA Roumestand C., Stern M.H., Noguchi M.; RT "Identification of Akt association and oligomerization domains of the Akt RT kinase coactivator TCL1."; RL Mol. Cell. Biol. 22:1513-1525(2002). RN [25] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-179. RX PubMed=12172553; DOI=10.1038/ncb839; RA Inoki K., Li Y., Zhu T., Wu J., Guan K.L.; RT "TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR RT signalling."; RL Nat. Cell Biol. 4:648-657(2002). RN [26] RP INTERACTION WITH CDKN1B, FUNCTION, AND MUTAGENESIS OF THR-308 AND SER-473. RX PubMed=12244301; DOI=10.1038/nm759; RA Shin I., Yakes F.M., Rojo F., Shin N.-Y., Bakin A.V., Baselga J., RA Arteaga C.L.; RT "PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at RT threonine 157 and modulation of its cellular localization."; RL Nat. Med. 8:1145-1152(2002). RN [27] RP FUNCTION IN PARTICIPATION IN KIT SIGNALING. RX PubMed=12878163; DOI=10.1016/s0014-4827(03)00206-4; RA Lennartsson J., Wernstedt C., Engstrom U., Hellman U., Ronnstrand L.; RT "Identification of Tyr900 in the kinase domain of c-Kit as a Src-dependent RT phosphorylation site mediating interaction with c-Crk."; RL Exp. Cell Res. 288:110-118(2003). RN [28] RP INTERACTION WITH AGAP2, AND PHOSPHORYLATION AT SER-473. RX PubMed=14761976; DOI=10.1074/jbc.m312175200; RA Ahn J.-Y., Rong R., Kroll T.G., Van Meir E.G., Snyder S.H., Ye K.; RT "PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt RT activity and mediates cellular invasion."; RL J. Biol. Chem. 279:16441-16451(2004). RN [29] RP PHOSPHORYLATION AT SER-473. RX PubMed=15047712; DOI=10.1074/jbc.m314192200; RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RT "LGI1, a putative tumor metastasis suppressor gene, controls in vitro RT invasiveness and expression of matrix metalloproteinases in glioma cells RT through the ERK1/2 pathway."; RL J. Biol. Chem. 279:23151-23157(2004). RN [30] RP ERRATUM OF PUBMED:15047712. RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RL J. Biol. Chem. 282:2752-2752(2007). RN [31] RP PHOSPHORYLATION AT SER-473. RX PubMed=15262962; DOI=10.1074/jbc.m406731200; RA Feng J., Park J., Cron P., Hess D., Hemmings B.A.; RT "Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA- RT dependent protein kinase."; RL J. Biol. Chem. 279:41189-41196(2004). RN [32] RP INTERACTION WITH AKTIP. RX PubMed=14749367; DOI=10.1128/mcb.24.4.1493-1504.2004; RA Remy I., Michnick S.W.; RT "Regulation of apoptosis by the Ft1 protein, a new modulator of protein RT kinase B/Akt."; RL Mol. Cell. Biol. 24:1493-1504(2004). RN [33] RP INTERACTION WITH AGAP2. RX PubMed=15118108; DOI=10.1073/pnas.0400921101; RA Ahn J.-Y., Hu Y., Kroll T.G., Allard P., Ye K.; RT "PIKE-A is amplified in human cancers and prevents apoptosis by up- RT regulating Akt."; RL Proc. Natl. Acad. Sci. U.S.A. 101:6993-6998(2004). RN [34] RP PHOSPHORYLATION AT SER-473 IN RESPONSE TO FLT3 SIGNALING. RX PubMed=16266983; DOI=10.1158/0008-5472.can-05-0422; RA Brandts C.H., Sargin B., Rode M., Biermann C., Lindtner B., Schwable J., RA Buerger H., Muller-Tidow C., Choudhary C., McMahon M., Berdel W.E., RA Serve H.; RT "Constitutive activation of Akt by Flt3 internal tandem duplications is RT necessary for increased survival, proliferation, and myeloid RT transformation."; RL Cancer Res. 65:9643-9650(2005). RN [35] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH CCDC88A. RX PubMed=16139227; DOI=10.1016/j.devcel.2005.08.001; RA Enomoto A., Murakami H., Asai N., Morone N., Watanabe T., Kawai K., RA Murakumo Y., Usukura J., Kaibuchi K., Takahashi M.; RT "Akt/PKB regulates actin organization and cell motility via Girdin/APE."; RL Dev. Cell 9:389-402(2005). RN [36] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15861136; DOI=10.1038/sj.emboj.7600648; RA Cartlidge R.A., Knebel A., Peggie M., Alexandrov A., Phizicky E.M., RA Cohen P.; RT "The tRNA methylase METTL1 is phosphorylated and inactivated by PKB and RSK RT in vitro and in cells."; RL EMBO J. 24:1696-1705(2005). RN [37] RP PHOSPHORYLATION AT THR-308, AND PHOSPHORYLATION AT SER-473 BY MTOR. RX PubMed=15718470; DOI=10.1126/science.1106148; RA Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M.; RT "Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex."; RL Science 307:1098-1101(2005). RN [38] RP PHOSPHORYLATION AT SER-473. RX PubMed=17013611; DOI=10.1007/s00401-006-0128-y; RA Schick V., Majores M., Engels G., Spitoni S., Koch A., Elger C.E., RA Simon M., Knobbe C., Bluemcke I., Becker A.J.; RT "Activation of Akt independent of PTEN and CTMP tumor-suppressor gene RT mutations in epilepsy-associated Taylor-type focal cortical dysplasias."; RL Acta Neuropathol. 112:715-725(2006). RN [39] RP INTERACTION WITH WDFY2, AND SUBCELLULAR LOCATION. RX PubMed=16792529; DOI=10.1042/bj20060511; RA Fritzius T., Burkard G., Haas E., Heinrich J., Schweneker M., Bosse M., RA Zimmermann S., Frey A.D., Caelers A., Bachmann A.S., Moelling K.; RT "A WD-FYVE protein binds to the kinases Akt and PKCzeta/lambda."; RL Biochem. J. 399:9-20(2006). RN [40] RP FUNCTION, AND INTERACTION WITH RARA. RX PubMed=16417524; DOI=10.1042/bj20051794; RA Srinivas H., Xia D., Moore N.L., Uray I.P., Kim H., Ma L., Weigel N.L., RA Brown P.H., Kurie J.M.; RT "Akt phosphorylates and suppresses the transactivation of retinoic acid RT receptor alpha."; RL Biochem. J. 395:653-662(2006). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-129, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [42] RP BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=16540465; DOI=10.1074/jbc.m601384200; RA Zhang X., Zhang S., Yamane H., Wahl R., Ali A., Lofgren J.A., Kendall R.L.; RT "Kinetic mechanism of AKT/PKB enzyme family."; RL J. Biol. Chem. 281:13949-13956(2006). RN [43] RP FUNCTION IN PHOSPHORYLATION OF CDKN1A. RX PubMed=16982699; DOI=10.1128/mcb.00201-06; RA Heron-Milhavet L., Franckhauser C., Rana V., Berthenet C., Fisher D., RA Hemmings B.A., Fernandez A., Lamb N.J.; RT "Only Akt1 is required for proliferation, while Akt2 promotes cell cycle RT exit through p21 binding."; RL Mol. Cell. Biol. 26:8267-8280(2006). RN [44] RP INTERACTION WITH STK4/MST1, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=17932490; DOI=10.1038/sj.emboj.7601872; RA Cinar B., Fang P.K., Lutchman M., Di Vizio D., Adam R.M., Pavlova N., RA Rubin M.A., Yelick P.C., Freeman M.R.; RT "The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct RT inhibitors of Akt1."; RL EMBO J. 26:4523-4534(2007). RN [45] RP FUNCTION, AND INTERACTION WITH STK4/MST1. RX PubMed=17726016; DOI=10.1074/jbc.m704542200; RA Jang S.W., Yang S.J., Srinivasan S., Ye K.; RT "Akt phosphorylates MstI and prevents its proteolytic activation, blocking RT FOXO3 phosphorylation and nuclear translocation."; RL J. Biol. Chem. 282:30836-30844(2007). RN [46] RP FUNCTION IN PHOSPHORYLATION OF PROHIBITIN. RX PubMed=18507042; RA Han E.K., Mcgonigal T., Butler C., Giranda V.L., Luo Y.; RT "Characterization of Akt overexpression in MiaPaCa-2 cells: prohibitin is RT an Akt substrate both in vitro and in cells."; RL Anticancer Res. 28:957-963(2008). RN [47] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-124; SER-126 AND SER-129, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [48] RP UBIQUITINATION BY TTC3. RX PubMed=20059950; DOI=10.1016/j.devcel.2009.09.007; RA Suizu F., Hiramuki Y., Okumura F., Matsuda M., Okumura A.J., Hirata N., RA Narita M., Kohno T., Yokota J., Bohgaki M., Obuse C., Hatakeyama S., RA Obata T., Noguchi M.; RT "The E3 ligase TTC3 facilitates ubiquitination and degradation of RT phosphorylated Akt."; RL Dev. Cell 17:800-810(2009). RN [49] RP FUNCTION IN PHOSPHORYLATION OF SRPK2, AND INTERACTION WITH SRPK2. RX PubMed=19592491; DOI=10.1074/jbc.m109.026237; RA Jang S.W., Liu X., Fu H., Rees H., Yepes M., Levey A., Ye K.; RT "Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell cycle RT and cell death in neurons."; RL J. Biol. Chem. 284:24512-24525(2009). RN [50] RP FUNCTION. RX PubMed=19934221; DOI=10.1242/jcs.053728; RA Bristow J.M., Sellers M.H., Majumdar D., Anderson B., Hu L., Webb D.J.; RT "The Rho-family GEF Asef2 activates Rac to modulate adhesion and actin RT dynamics and thereby regulate cell migration."; RL J. Cell Sci. 122:4535-4546(2009). RN [51] RP UBIQUITINATION, INTERACTION WITH TRAF6, MUTAGENESIS OF LYS-8 AND LYS-14, RP AND CHARACTERIZATION OF VARIANT BREAST CANCER LYS-17. RX PubMed=19713527; DOI=10.1126/science.1175065; RA Yang W.-L., Wang J., Chan C.-H., Lee S.-W., Campos A.D., Lamothe B., RA Hur L., Grabiner B.C., Lin X., Darnay B.G., Lin H.-K.; RT "The E3 ligase TRAF6 regulates Akt ubiquitination and activation."; RL Science 325:1134-1138(2009). RN [52] RP FUNCTION, AND INTERACTION WITH STK3/MST2. RX PubMed=20086174; DOI=10.1158/0008-5472.can-09-3147; RA Romano D., Matallanas D., Weitsman G., Preisinger C., Ng T., Kolch W.; RT "Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, RT Raf-1, and Akt."; RL Cancer Res. 70:1195-1203(2010). RN [53] RP RETRACTED PAPER. RX PubMed=19940129; DOI=10.1074/jbc.m109.059675; RA Yuan Z., Kim D., Shu S., Wu J., Guo J., Xiao L., Kaneko S., Coppola D., RA Cheng J.Q.; RT "Phosphoinositide 3-kinase/Akt inhibits MST1-mediated pro-apoptotic RT signaling through phosphorylation of threonine 120."; RL J. Biol. Chem. 285:3815-3824(2010). RN [54] RP RETRACTION NOTICE OF PUBMED:19940129. RX PubMed=27825096; DOI=10.1074/jbc.a109.059675; RA Yuan Z., Kim D., Shu S., Wu J., Guo J., Xiao L., Kaneko S., Coppola D., RA Cheng J.Q.; RL J. Biol. Chem. 291:22858-22858(2016). RN [55] RP FUNCTION, AND INTERACTION WITH CLK2. RX PubMed=20682768; DOI=10.1074/jbc.m110.122044; RA Nam S.Y., Seo H.H., Park H.S., An S., Kim J.Y., Yang K.H., Kim C.S., RA Jeong M., Jin Y.W.; RT "Phosphorylation of CLK2 at serine 34 and threonine 127 by AKT controls RT cell survival after ionizing radiation."; RL J. Biol. Chem. 285:31157-31163(2010). RN [56] RP FUNCTION IN PHOSPHORYLATION OF PALLD. RX PubMed=20471940; DOI=10.1016/j.molcel.2010.02.031; RA Chin Y.R., Toker A.; RT "The actin-bundling protein palladin is an Akt1-specific substrate that RT regulates breast cancer cell migration."; RL Mol. Cell 38:333-344(2010). RN [57] RP RETRACTED PAPER. RX PubMed=20231902; DOI=10.1371/journal.pone.0009616; RA Kim D., Shu S., Coppola M.D., Kaneko S., Yuan Z.Q., Cheng J.Q.; RT "Regulation of proapoptotic mammalian ste20-like kinase MST2 by the IGF1- RT Akt pathway."; RL PLoS ONE 5:E9616-E9616(2010). RN [58] RP CAUTION, AND RETRACTION NOTICE OF PUBMED:20231902. RX PubMed=37490513; DOI=10.1371/journal.pone.0289329; RG PLOS ONE Editors; RT "Retraction: Regulation of Proapoptotic Mammalian ste20-Like Kinase MST2 by RT the IGF1-Akt Pathway."; RL PLoS ONE 18:e0289329-e0289329(2023). RN [59] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-176; THR-308 AND RP SER-473, MUTAGENESIS OF TYR-176, INTERACTION WITH TNK2, AND TISSUE RP SPECIFICITY. RX PubMed=20333297; DOI=10.1371/journal.pone.0009646; RA Mahajan K., Coppola D., Challa S., Fang B., Chen Y.A., Zhu W., Lopez A.S., RA Koomen J., Engelman R.W., Rivera C., Muraoka-Cook R.S., Cheng J.Q., RA Schoenbrunn E., Sebti S.M., Earp H.S., Mahajan N.P.; RT "Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its RT activation."; RL PLoS ONE 5:E9646-E9646(2010). RN [60] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [61] RP INTERACTION WITH TRIM13, AND UBIQUITINATION. RX PubMed=21333377; DOI=10.1016/j.ejcb.2010.12.001; RA Joo H.M., Kim J.Y., Jeong J.B., Seong K.M., Nam S.Y., Yang K.H., Kim C.S., RA Kim H.S., Jeong M., An S., Jin Y.W.; RT "Ret finger protein 2 enhances ionizing radiation-induced apoptosis via RT degradation of AKT and MDM2."; RL Eur. J. Cell Biol. 90:420-431(2011). RN [62] RP INTERACTION WITH PPP2R5B, AND DEPHOSPHORYLATION. RX PubMed=21329884; DOI=10.1016/j.molcel.2011.02.007; RA Rodgers J.T., Vogel R.O., Puigserver P.; RT "Clk2 and B56-beta mediate insulin-regulated assembly of the PP2A RT phosphatase holoenzyme complex on Akt."; RL Mol. Cell 41:471-479(2011). RN [63] RP INTERACTION WITH FAM168A. RX PubMed=23251525; DOI=10.1371/journal.pone.0051413; RA Peng B., Gu Y., Xiong Y., Zheng G., He Z.; RT "Microarray-assisted pathway analysis identifies MT1X & NFkappaB as RT mediators of TCRP1-associated resistance to cisplatin in oral squamous cell RT carcinoma."; RL PLoS ONE 7:E51413-E51413(2012). RN [64] RP PROTEOLYTIC CLEAVAGE. RX PubMed=23152800; DOI=10.1371/journal.pone.0048770; RA Sen T., Sen N., Noordhuis M.G., Ravi R., Wu T.C., Ha P.K., Sidransky D., RA Hoque M.O.; RT "OGDHL is a modifier of AKT-dependent signaling and NF-kappaB function."; RL PLoS ONE 7:e48770-e48770(2012). RN [65] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-129, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [66] RP INTERACTION WITH FAM83B. RX PubMed=23676467; DOI=10.18632/oncotarget.1027; RA Cipriano R., Miskimen K.L., Bryson B.L., Foy C.R., Bartel C.A., RA Jackson M.W.; RT "FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to RT promote epithelial cell transformation and resistance to targeted RT therapies."; RL Oncotarget 4:729-738(2013). RN [67] RP REVIEW ON ROLE IN KIT SIGNALING. RX PubMed=15526160; DOI=10.1007/s00018-004-4189-6; RA Ronnstrand L.; RT "Signal transduction via the stem cell factor receptor/c-Kit."; RL Cell. Mol. Life Sci. 61:2535-2548(2004). RN [68] RP REVIEW ON FUNCTION. RX PubMed=11882383; DOI=10.1016/s0898-6568(01)00271-6; RA Nicholson K.M., Anderson N.G.; RT "The protein kinase B/Akt signalling pathway in human malignancy."; RL Cell. Signal. 14:381-395(2002). RN [69] RP PHOSPHORYLATION AT SER-473. RX PubMed=20978158; DOI=10.1158/1535-7163.mct-10-0730; RA Kunoh T., Noda T., Koseki K., Sekigawa M., Takagi M., Shin-ya K., RA Goshima N., Iemura S., Natsume T., Wada S., Mukai Y., Ohta S., Sasaki R., RA Mizukami T.; RT "A novel human dynactin-associated protein, dynAP, promotes activation of RT Akt, and ergosterol-related compounds induce dynAP-dependent apoptosis of RT human cancer cells."; RL Mol. Cancer Ther. 9:2934-2942(2010). RN [70] RP REVIEW ON FUNCTION. RX PubMed=21620960; DOI=10.1016/j.cellsig.2011.05.004; RA Hers I., Vincent E.E., Tavare J.M.; RT "Akt signalling in health and disease."; RL Cell. Signal. 23:1515-1527(2011). RN [71] RP REVIEW ON FUNCTION. RX PubMed=21432781; DOI=10.14670/hh-26.651; RA Heron-Milhavet L., Khouya N., Fernandez A., Lamb N.J.; RT "Akt1 and Akt2: differentiating the aktion."; RL Histol. Histopathol. 26:651-662(2011). RN [72] RP PHOSPHORYLATION AT THR-308 AND SER-473. RX PubMed=21464307; DOI=10.1073/pnas.1016132108; RA Xie X., Zhang D., Zhao B., Lu M.K., You M., Condorelli G., Wang C.Y., RA Guan K.L.; RT "IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct RT phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 108:6474-6479(2011). RN [73] RP INTERACTION WITH SIRT1, ACETYLATION AT LYS-14 AND LYS-20, DEACETYLATION AT RP LYS-14 AND LYS-20, AND MUTAGENESIS OF LYS-14; GLU-17 AND LYS-20. RX PubMed=21775285; DOI=10.1126/scisignal.2001465; RA Sundaresan N.R., Pillai V.B., Wolfgeher D., Samant S., Vasudevan P., RA Parekh V., Raghuraman H., Cunningham J.M., Gupta M., Gupta M.P.; RT "The deacetylase SIRT1 promotes membrane localization and activation of Akt RT and PDK1 during tumorigenesis and cardiac hypertrophy."; RL Sci. Signal. 4:RA46-RA46(2011). RN [74] RP UBIQUITINATION AT LYS-284. RX PubMed=22410793; DOI=10.1038/cr.2012.38; RA Bae S., Kim S.Y., Jung J.H., Yoon Y., Cha H.J., Lee H., Kim K., Kim J., RA An I.S., Kim J., Um H.D., Park I.C., Lee S.J., Nam S.Y., Jin Y.W., RA Lee J.H., An S.; RT "Akt is negatively regulated by the MULAN E3 ligase."; RL Cell Res. 22:873-885(2012). RN [75] RP GLYCOSYLATION AT SER-126; SER-129; THR-305 AND THR-312, SUBCELLULAR RP LOCATION, INTERACTION WITH PDPK1, AND MUTAGENESIS OF THR-305 AND THR-312. RX PubMed=22629392; DOI=10.1371/journal.pone.0037427; RA Wang S., Huang X., Sun D., Xin X., Pan Q., Peng S., Liang Z., Luo C., RA Yang Y., Jiang H., Huang M., Chai W., Ding J., Geng M.; RT "Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates RT Akt signaling."; RL PLoS ONE 7:E37427-E37427(2012). RN [76] RP PHOSPHORYLATION AT SER-473, AND DEPHOSPHORYLATION BY CPPED1. RX PubMed=23799035; DOI=10.1371/journal.pone.0065679; RA Zhuo D.X., Zhang X.W., Jin B., Zhang Z., Xie B.S., Wu C.L., Gong K., RA Mao Z.B.; RT "CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell RT apoptosis, and suppresses tumor growth of bladder cancer by directly RT dephosphorylating Akt at Ser473 site."; RL PLoS ONE 8:E65679-E65679(2013). RN [77] RP FUNCTION. RX PubMed=23431171; DOI=10.1073/pnas.1300490110; RA Rokudai S., Laptenko O., Arnal S.M., Taya Y., Kitabayashi I., Prives C.; RT "MOZ increases p53 acetylation and premature senescence through its complex RT formation with PML."; RL Proc. Natl. Acad. Sci. U.S.A. 110:3895-3900(2013). RN [78] RP INTERACTION WITH SYAP1. RX PubMed=23300339; DOI=10.1126/scisignal.2003295; RA Yao Y., Suraokar M., Darnay B.G., Hollier B.G., Shaiken T.E., Asano T., RA Chen C.H., Chang B.H., Lu Y., Mills G.B., Sarbassov D., Mani S.A., RA Abbruzzese J.L., Reddy S.A.; RT "BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress RT expression of FoxC2 and stimulate adipocyte differentiation."; RL Sci. Signal. 6:RA2-RA2(2013). RN [79] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-448 AND THR-450, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [80] RP PHOSPHORYLATION AT SER-477 AND THR-479, AND MUTAGENESIS OF 76-ARG--LEU-78 RP AND 273-ARG--LEU-275. RX PubMed=24670654; DOI=10.1038/nature13079; RA Liu P., Begley M., Michowski W., Inuzuka H., Ginzberg M., Gao D., Tsou P., RA Gan W., Papa A., Kim B.M., Wan L., Singh A., Zhai B., Yuan M., Wang Z., RA Gygi S.P., Lee T.H., Lu K.P., Toker A., Pandolfi P.P., Asara J.M., RA Kirschner M.W., Sicinski P., Cantley L., Wei W.; RT "Cell-cycle-regulated activation of Akt kinase by phosphorylation at its RT carboxyl terminus."; RL Nature 508:541-545(2014). RN [81] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=26440888; DOI=10.1016/j.celrep.2015.09.007; RA Seo G.J., Yang A., Tan B., Kim S., Liang Q., Choi Y., Yuan W., Feng P., RA Park H.S., Jung J.U.; RT "Akt kinase-mediated checkpoint of cGAS DNA sensing pathway."; RL Cell Rep. 13:440-449(2015). RN [82] RP INTERACTION WITH KIF14. RX PubMed=24784001; DOI=10.1016/j.neo.2014.03.008; RA Singel S.M., Cornelius C., Zaganjor E., Batten K., Sarode V.R., RA Buckley D.L., Peng Y., John G.B., Li H.C., Sadeghi N., Wright W.E., Lum L., RA Corson T.W., Shay J.W.; RT "KIF14 promotes AKT phosphorylation and contributes to chemoresistance in RT triple-negative breast cancer."; RL Neoplasia 16:247-256(2014). RN [83] RP PHOSPHORYLATION AT SER-473, DEPHOSPHORYLATION, AND INTERACTION WITH PHLPP1 RP AND FKBP5. RX PubMed=28147277; DOI=10.1016/j.celrep.2017.01.009; RA Yu J., Qin B., Wu F., Qin S., Nowsheen S., Shan S., Zayas J., Pei H., RA Lou Z., Wang L.; RT "Regulation of serine-threonine kinase Akt activation by NAD+-dependent RT deacetylase SIRT7."; RL Cell Rep. 18:1229-1240(2017). RN [84] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=29343641; DOI=10.1073/pnas.1705954115; RA Choppara S., Malonia S.K., Sankaran G., Green M.R., Santra M.K.; RT "Degradation of FBXO31 by APC/C is regulated by AKT- and ATM-mediated RT phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 115:998-1003(2018). RN [85] RP FUNCTION. RX PubMed=30504268; DOI=10.15252/embj.201899435; RA Marchi S., Corricelli M., Branchini A., Vitto V.A.M., Missiroli S., RA Morciano G., Perrone M., Ferrarese M., Giorgi C., Pinotti M., Galluzzi L., RA Kroemer G., Pinton P.; RT "Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca2+ levels RT and tumor growth."; RL EMBO J. 38:0-0(2019). RN [86] RP FUNCTION. RX PubMed=31204173; DOI=10.1016/j.devcel.2019.05.022; RA Walia V., Cuenca A., Vetter M., Insinna C., Perera S., Lu Q., Ritt D.A., RA Semler E., Specht S., Stauffer J., Morrison D.K., Lorentzen E., RA Westlake C.J.; RT "Akt Regulates a Rab11-Effector Switch Required for Ciliogenesis."; RL Dev. Cell 50:229-246(2019). RN [87] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=31548394; DOI=10.1073/pnas.1904774116; RA Padi S.K.R., Singh N., Bearss J.J., Olive V., Song J.H., Cardo-Vila M., RA Kraft A.S., Okumura K.; RT "Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases RT inhibition of mTORC1 and promotes tumor growth."; RL Proc. Natl. Acad. Sci. U.S.A. 116:20505-20510(2019). RN [88] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=32322062; DOI=10.1038/s41586-020-2183-2; RA Xu D., Wang Z., Xia Y., Shao F., Xia W., Wei Y., Li X., Qian X., Lee J.H., RA Du L., Zheng Y., Lv G., Leu J.S., Wang H., Xing D., Liang T., Hung M.C., RA Lu Z.; RT "The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis."; RL Nature 580:530-535(2020). RN [89] RP INTERACTION WITH TMEM175, AND FUNCTION. RX PubMed=32228865; DOI=10.7554/elife.53430; RA Oh S., Paknejad N., Hite R.K.; RT "Gating and selectivity mechanisms for the lysosomal K+ channel TMEM175."; RL Elife 9:0-0(2020). RN [90] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-179. RX PubMed=33594058; DOI=10.1038/s41467-021-21206-3; RA Li T., Wang X., Ju E., da Silva S.R., Chen L., Zhang X., Wei S., Gao S.J.; RT "RNF167 activates mTORC1 and promotes tumorigenesis by targeting CASTOR1 RT for ubiquitination and degradation."; RL Nat. Commun. 12:1055-1055(2021). RN [91] RP INTERACTION WITH SLC9D1, PHOSPHORYLATION AT THR-308 AND SER-473, AND RP SUBCELLULAR LOCATION. RX PubMed=40285646; DOI=10.1002/advs.202504187; RA Li X., Han M., Zhu H., Pan Y., Su C., Liu Y., Liao Z., Zhang B., Chen X.; RT "m6A-Mediated TMCO3 Promotes Hepatocellular Carcinoma Progression by RT Facilitating the Membrane Translocation and Activation of AKT."; RL Adv. Sci. 12:e2504187-e2504187(2025). RN [92] RP X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 1-123, FUNCTION, INTERACTION WITH RP PTDINS(3,4,5)P3 AND PTDINS(3,4)P2, MUTAGENESIS OF LYS-14; ARG-25 AND RP ARG-86, AND CHARACTERIZATION OF VARIANT CWS6 CYS-25. RX PubMed=12176338; DOI=10.1016/s0960-9822(02)00972-7; RA Thomas C.C., Deak M., Alessi D.R., van Aalten D.M.; RT "High-resolution structure of the pleckstrin homology domain of protein RT kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate."; RL Curr. Biol. 12:1256-1262(2002). RN [93] RP X-RAY CRYSTALLOGRAPHY (0.98 ANGSTROMS) OF 1-121, FUNCTION, AND INTERACTION RP WITH PTDINS(1,3,4,5)P4. RX PubMed=12964941; DOI=10.1042/bj20031229; RA Milburn C.C., Deak M., Kelly S.M., Price N.C., Alessi D.R., RA Van Aalten D.M.; RT "Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin RT homology domain of protein kinase B induces a conformational change."; RL Biochem. J. 375:531-538(2003). RN [94] {ECO:0007744|PDB:3CQU, ECO:0007744|PDB:3CQW} RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 144-480, PHOSPHORYLATION AT RP THR-308, AND ACTIVITY REGULATION. RX PubMed=18456494; DOI=10.1016/j.bmcl.2008.04.034; RA Lippa B., Pan G., Corbett M., Li C., Kauffman G.S., Pandit J., Robinson S., RA Wei L., Kozina E., Marr E.S., Borzillo G., Knauth E., Barbacci-Tobin E.G., RA Vincent P., Troutman M., Baker D., Rajamohan F., Kakar S., Clark T., RA Morris J.; RT "Synthesis and structure based optimization of novel Akt inhibitors."; RL Bioorg. Med. Chem. Lett. 18:3359-3363(2008). RN [95] {ECO:0007744|PDB:3OCB} RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 144-480, AND ACTIVITY REGULATION. RX PubMed=20810279; DOI=10.1016/j.bmcl.2010.08.053; RA Blake J.F., Kallan N.C., Xiao D., Xu R., Bencsik J.R., Skelton N.J., RA Spencer K.L., Mitchell I.S., Woessner R.D., Gloor S.L., Risom T., RA Gross S.D., Martinson M., Morales T.H., Vigers G.P., Brandhuber B.J.; RT "Discovery of pyrrolopyrimidine inhibitors of Akt."; RL Bioorg. Med. Chem. Lett. 20:5607-5612(2010). RN [96] {ECO:0007744|PDB:3MV5, ECO:0007744|PDB:3MVH} RP X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 144-480, PHOSPHORYLATION AT RP THR-308, AND ACTIVITY REGULATION. RX PubMed=20481595; DOI=10.1021/jm1003842; RA Freeman-Cook K.D., Autry C., Borzillo G., Gordon D., Barbacci-Tobin E., RA Bernardo V., Briere D., Clark T., Corbett M., Jakubczak J., Kakar S., RA Knauth E., Lippa B., Luzzio M.J., Mansour M., Martinelli G., Marx M., RA Nelson K., Pandit J., Rajamohan F., Robinson S., Subramanyam C., Wei L., RA Wythes M., Morris J.; RT "Design of selective, ATP-competitive inhibitors of Akt."; RL J. Med. Chem. 53:4615-4622(2010). RN [97] {ECO:0007744|PDB:3O96} RP X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 2-443, AND DISULFIDE BOND. RX PubMed=20886116; DOI=10.1371/journal.pone.0012913; RA Wu W.I., Voegtli W.C., Sturgis H.L., Dizon F.P., Vigers G.P., RA Brandhuber B.J.; RT "Crystal structure of human AKT1 with an allosteric inhibitor reveals a new RT mode of kinase inhibition."; RL PLoS ONE 5:E12913-E12913(2010). RN [98] {ECO:0007744|PDB:3QKK, ECO:0007744|PDB:3QKL} RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 144-480, AND ACTIVITY REGULATION. RX PubMed=21392984; DOI=10.1016/j.bmcl.2011.02.073; RA Kallan N.C., Spencer K.L., Blake J.F., Xu R., Heizer J., Bencsik J.R., RA Mitchell I.S., Gloor S.L., Martinson M., Risom T., Gross S.D., RA Morales T.H., Wu W.I., Vigers G.P., Brandhuber B.J., Skelton N.J.; RT "Discovery and SAR of spirochromane Akt inhibitors."; RL Bioorg. Med. Chem. Lett. 21:2410-2414(2011). RN [99] RP VARIANT BREAST CANCER LYS-17, AND CHARACTERIZATION OF VARIANT BREAST CANCER RP LYS-17. RX PubMed=17611497; DOI=10.1038/nature05933; RA Carpten J.D., Faber A.L., Horn C., Donoho G.P., Briggs S.L., Robbins C.M., RA Hostetter G., Boguslawski S., Moses T.Y., Savage S., Uhlik M., Lin A., RA Du J., Qian Y.-W., Zeckner D.J., Tucker-Kellogg G., Touchman J., Patel K., RA Mousses S., Bittner M., Schevitz R., Lai M.-H.T., Blanchard K.L., RA Thomas J.E.; RT "A transforming mutation in the pleckstrin homology domain of AKT1 in RT cancer."; RL Nature 448:439-444(2007). RN [100] RP CHARACTERIZATION OF VARIANT PROTEUSS LYS-17. RX PubMed=18954143; DOI=10.1021/bi801683k; RA Landgraf K.E., Pilling C., Falke J.J.; RT "Molecular mechanism of an oncogenic mutation that alters membrane RT targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH RT domain."; RL Biochemistry 47:12260-12269(2008). RN [101] RP VARIANT PROTEUSS LYS-17. RX PubMed=21793738; DOI=10.1056/nejmoa1104017; RA Lindhurst M.J., Sapp J.C., Teer J.K., Johnston J.J., Finn E.M., Peters K., RA Turner J., Cannons J.L., Bick D., Blakemore L., Blumhorst C., Brockmann K., RA Calder P., Cherman N., Deardorff M.A., Everman D.B., Golas G., RA Greenstein R.M., Kato B.M., Keppler-Noreuil K.M., Kuznetsov S.A., RA Miyamoto R.T., Newman K., Ng D., O'Brien K., Rothenberg S., RA Schwartzentruber D.J., Singhal V., Tirabosco R., Upton J., Wientroub S., RA Zackai E.H., Hoag K., Whitewood-Neal T., Robey P.G., Schwartzberg P.L., RA Darling T.N., Tosi L.L., Mullikin J.C., Biesecker L.G.; RT "A mosaic activating mutation in AKT1 associated with the Proteus RT syndrome."; RL N. Engl. J. Med. 365:611-619(2011). RN [102] RP VARIANTS CWS6 CYS-25 AND PRO-435. RX PubMed=23246288; DOI=10.1016/j.ajhg.2012.10.021; RA Orloff M.S., He X., Peterson C., Chen F., Chen J.L., Mester J.L., Eng C.; RT "Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes."; RL Am. J. Hum. Genet. 92:76-80(2013). CC -!- FUNCTION: AKT1 is one of 3 closely related serine/threonine-protein CC kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate CC many processes including metabolism, proliferation, cell survival, CC growth and angiogenesis (PubMed:11882383, PubMed:15526160, CC PubMed:15861136, PubMed:21432781, PubMed:21620960, PubMed:31204173). CC This is mediated through serine and/or threonine phosphorylation of a CC range of downstream substrates (PubMed:11882383, PubMed:15526160, CC PubMed:21432781, PubMed:21620960, PubMed:29343641, PubMed:31204173). CC Over 100 substrate candidates have been reported so far, but for most CC of them, no isoform specificity has been reported (PubMed:11882383, CC PubMed:15526160, PubMed:21432781, PubMed:21620960). AKT is responsible CC of the regulation of glucose uptake by mediating insulin-induced CC translocation of the SLC2A4/GLUT4 glucose transporter to the cell CC surface (By similarity). Phosphorylation of PTPN1 at 'Ser-50' CC negatively modulates its phosphatase activity preventing CC dephosphorylation of the insulin receptor and the attenuation of CC insulin signaling (By similarity). Phosphorylation of TBC1D4 triggers CC the binding of this effector to inhibitory 14-3-3 proteins, which is CC required for insulin-stimulated glucose transport (PubMed:11994271). CC AKT also regulates the storage of glucose in the form of glycogen by CC phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in CC inhibition of its kinase activity (By similarity). Phosphorylation of CC GSK3 isoforms by AKT is also thought to be one mechanism by which cell CC proliferation is driven (By similarity). AKT also regulates cell CC survival via the phosphorylation of MAP3K5 (apoptosis signal-related CC kinase) (PubMed:11154276). Phosphorylation of 'Ser-83' decreases MAP3K5 CC kinase activity stimulated by oxidative stress and thereby prevents CC apoptosis (PubMed:11154276). AKT mediates insulin-stimulated protein CC synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby CC activating the mTORC1 signaling pathway, and leading to both CC phosphorylation of 4E-BP1 and in activation of RPS6KB1 CC (PubMed:12150915, PubMed:12172553). Also regulates the mTORC1 signaling CC pathway by catalyzing phosphorylation of CASTOR1 and DEPDC5 CC (PubMed:31548394, PubMed:33594058). AKT plays a role as key modulator CC of the AKT-mTOR signaling pathway controlling the tempo of the process CC of newborn neurons integration during adult neurogenesis, including CC correct neuron positioning, dendritic development and synapse formation CC (By similarity). Part of a positive feedback loop of mTORC2 signaling CC by mediating phosphorylation of MAPKAP1/SIN1, promoting mTORC2 CC activation (By similarity). AKT is involved in the phosphorylation of CC members of the FOXO factors (Forkhead family of transcription factors), CC leading to binding of 14-3-3 proteins and cytoplasmic localization CC (PubMed:10358075). In particular, FOXO1 is phosphorylated at 'Thr-24', CC 'Ser-256' and 'Ser-319' (PubMed:10358075). FOXO3 and FOXO4 are CC phosphorylated on equivalent sites (PubMed:10358075). AKT has an CC important role in the regulation of NF-kappa-B-dependent gene CC transcription and positively regulates the activity of CREB1 (cyclic CC AMP (cAMP)-response element binding protein) (PubMed:9829964). The CC phosphorylation of CREB1 induces the binding of accessory proteins that CC are necessary for the transcription of pro-survival genes such as BCL2 CC and MCL1 (PubMed:9829964). AKT phosphorylates 'Ser-454' on ATP citrate CC lyase (ACLY), thereby potentially regulating ACLY activity and fatty CC acid synthesis (By similarity). Activates the 3B isoform of cyclic CC nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', CC resulting in reduced cyclic AMP levels and inhibition of lipolysis (By CC similarity). Phosphorylates PIKFYVE on 'Ser-318', which results in CC increased PI(3)P-5 activity (By similarity). The Rho GTPase-activating CC protein DLC1 is another substrate and its phosphorylation is implicated CC in the regulation cell proliferation and cell growth (By similarity). CC Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate CC the effects of various growth factors such as platelet-derived growth CC factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like CC growth factor 1 (IGF1) (PubMed:12176338, PubMed:12964941). AKT mediates CC the antiapoptotic effects of IGF1 (By similarity). Essential for the CC SPATA13-mediated regulation of cell migration and adhesion assembly and CC disassembly (PubMed:19934221). May be involved in the regulation of the CC placental development (By similarity). Phosphorylates STK4/MST1 at CC 'Thr-120' and 'Thr-387' leading to inhibition of its: kinase activity, CC nuclear translocation, autophosphorylation and ability to phosphorylate CC FOXO3 (PubMed:17726016). Phosphorylates STK3/MST2 at 'Thr-117' and CC 'Thr-384' leading to inhibition of its: cleavage, kinase activity, CC autophosphorylation at Thr-180, binding to RASSF1 and nuclear CC translocation (PubMed:20086174). Phosphorylates SRPK2 and enhances its CC kinase activity towards SRSF2 and ACIN1 and promotes its nuclear CC translocation (PubMed:19592491). Phosphorylates RAF1 at 'Ser-259' and CC negatively regulates its activity (PubMed:10576742). Phosphorylation of CC BAD stimulates its pro-apoptotic activity (PubMed:10926925). CC Phosphorylates KAT6A at 'Thr-369' and this phosphorylation inhibits the CC interaction of KAT6A with PML and negatively regulates its acetylation CC activity towards p53/TP53 (PubMed:23431171). Phosphorylates palladin CC (PALLD), modulating cytoskeletal organization and cell motility CC (PubMed:20471940). Phosphorylates prohibitin (PHB), playing an CC important role in cell metabolism and proliferation (PubMed:18507042). CC Phosphorylates CDKN1A, for which phosphorylation at 'Thr-145' induces CC its release from CDK2 and cytoplasmic relocalization (PubMed:16982699). CC These recent findings indicate that the AKT1 isoform has a more CC specific role in cell motility and proliferation (PubMed:16139227). CC Phosphorylates CLK2 thereby controlling cell survival to ionizing CC radiation (PubMed:20682768). Phosphorylates PCK1 at 'Ser-90', reducing CC the binding affinity of PCK1 to oxaloacetate and changing PCK1 into an CC atypical protein kinase activity using GTP as donor (PubMed:32322062). CC Also acts as an activator of TMEM175 potassium channel activity in CC response to growth factors: forms the lysoK(GF) complex together with CC TMEM175 and acts by promoting TMEM175 channel activation, independently CC of its protein kinase activity (PubMed:32228865). Acts as a regulator CC of mitochondrial calcium uptake by mediating phosphorylation of MICU1 CC in the mitochondrial intermembrane space, impairing MICU1 maturation CC (PubMed:30504268). Acts as an inhibitor of tRNA methylation by CC mediating phosphorylation of the N-terminus of METTL1, thereby CC inhibiting METTL1 methyltransferase activity (PubMed:15861136). In CC response to LPAR1 receptor pathway activation, phosphorylates CC Rabin8/RAB3IP which alters its activity and phosphorylates WDR44 which CC induces WDR44 binding to Rab11, thereby switching Rab11 vesicular CC function from preciliary trafficking to endocytic recycling CC (PubMed:31204173). {ECO:0000250|UniProtKB:P31750, CC ECO:0000250|UniProtKB:P47196, ECO:0000269|PubMed:10358075, CC ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10926925, CC ECO:0000269|PubMed:11154276, ECO:0000269|PubMed:11994271, CC ECO:0000269|PubMed:12150915, ECO:0000269|PubMed:12172553, CC ECO:0000269|PubMed:12176338, ECO:0000269|PubMed:12964941, CC ECO:0000269|PubMed:15861136, ECO:0000269|PubMed:16139227, CC ECO:0000269|PubMed:16982699, ECO:0000269|PubMed:17726016, CC ECO:0000269|PubMed:18507042, ECO:0000269|PubMed:19592491, CC ECO:0000269|PubMed:19934221, ECO:0000269|PubMed:20086174, CC ECO:0000269|PubMed:20471940, ECO:0000269|PubMed:20682768, CC ECO:0000269|PubMed:23431171, ECO:0000269|PubMed:30504268, CC ECO:0000269|PubMed:31204173, ECO:0000269|PubMed:31548394, CC ECO:0000269|PubMed:32228865, ECO:0000269|PubMed:32322062, CC ECO:0000269|PubMed:33594058, ECO:0000269|PubMed:9829964, CC ECO:0000303|PubMed:11882383, ECO:0000303|PubMed:15526160, CC ECO:0000303|PubMed:21432781, ECO:0000303|PubMed:21620960}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:15861136, CC ECO:0000269|PubMed:16139227, ECO:0000269|PubMed:1718748, CC ECO:0000269|PubMed:1851997, ECO:0000269|PubMed:26440888, CC ECO:0000269|PubMed:29343641, ECO:0000269|PubMed:31548394, CC ECO:0000269|PubMed:32322062, ECO:0000269|PubMed:33594058}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:16139227, CC ECO:0000269|PubMed:1718748, ECO:0000269|PubMed:1851997}; CC -!- ACTIVITY REGULATION: Three specific sites, one in the kinase domain CC (Thr-308) and the two other ones in the C-terminal regulatory region CC (Ser-473 and Tyr-474), need to be phosphorylated for its full CC activation (PubMed:15262962, PubMed:20481595, PubMed:21392984, CC PubMed:9512493, PubMed:9736715). Inhibited by pyrrolopyrimidine CC inhibitors like aniline triazole and spiroindoline (PubMed:18456494, CC PubMed:20810279). {ECO:0000269|PubMed:15262962, CC ECO:0000269|PubMed:18456494, ECO:0000269|PubMed:20481595, CC ECO:0000269|PubMed:20810279, ECO:0000269|PubMed:21392984, CC ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715, CC ECO:0000305|PubMed:20810279}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=52.8 uM for ATP (for purified and in vitro activated AKT1) CC {ECO:0000269|PubMed:16540465}; CC KM=0.5 uM for peptide substrate (for purified and in vitro activated CC AKT1) {ECO:0000269|PubMed:16540465}; CC KM=143.3 uM for ATP (for recombinant myristoylated AKT1 expressed and CC immunoprecipitated from Rat-1 cells) {ECO:0000269|PubMed:16540465}; CC KM=2.9 uM for peptide substrate (for recombinant myristoylated AKT1 CC expressed and immunoprecipitated from Rat-1 cells) CC {ECO:0000269|PubMed:16540465}; CC -!- SUBUNIT: Interacts with BTBD10 (By similarity). Interacts with KCTD20 CC (By similarity). Interacts (via the C-terminus) with CCDC88A (via its CC C-terminus). Interacts with GRB10; the interaction leads to GRB10 CC phosphorylation thus promoting YWHAE-binding (By similarity). Interacts CC with AGAP2 (isoform 2/PIKE-A); the interaction occurs in the presence CC of guanine nucleotides. Interacts with AKTIP. Interacts (via PH domain) CC with MTCP1, TCL1A and TCL1B. Interacts with CDKN1B; the interaction CC phosphorylates CDKN1B promoting 14-3-3 binding and cell-cycle CC progression. Interacts with MAP3K5 and TRAF6. Interacts with BAD, CC PPP2R5B, STK3 and STK4. Interacts (via PH domain) with SIRT1. Interacts CC with SRPK2 in a phosphorylation-dependent manner. Interacts with RAF1. CC Interacts with TRIM13; the interaction ubiquitinates AKT1 leading to CC its proteasomal degradation. Interacts with TNK2 and CLK2. Interacts CC (via the C-terminus) with THEM4 (via its C-terminus). Interacts with CC and phosphorylated by PDPK1. Interacts with PA2G4 (By similarity). CC Interacts with KIF14; the interaction is detected in the plasma CC membrane upon INS stimulation and promotes AKT1 phosphorylation CC (PubMed:24784001). Interacts with FAM83B; activates the PI3K/AKT CC signaling cascade (PubMed:23676467). Interacts with WDFY2 (via WD CC repeats 1-3) (PubMed:16792529). Forms a complex with WDFY2 and FOXO1 CC (By similarity). Interacts with FAM168A (PubMed:23251525). Interacts CC with SYAP1 (via phosphorylated form and BSD domain); this interaction CC is enhanced in a mTORC2-mediated manner in response to epidermal growth CC factor (EGF) stimulation and activates AKT1 (PubMed:23300339). CC Interacts with PKHM3 (By similarity). Interacts with FKBP5/FKBP51; CC promoting interaction between Akt/AKT1 and PHLPP1, thereby enhancing CC dephosphorylation and subsequent activation of Akt/AKT1 CC (PubMed:28147277). Interacts with TMEM175; leading to formation of the CC lysoK(GF) complex (PubMed:32228865). Acts as a negative regulator of CC the cGAS-STING pathway by mediating phosphorylation of CGAS during CC mitosis, leading to its inhibition (PubMed:26440888). Interacts with CC SLC9D1 (when phosphorylated); the interaction facilitates the membrane CC translocation and activation of AKT1 (PubMed:40285646). CC {ECO:0000250|UniProtKB:P31750, ECO:0000250|UniProtKB:P47196, CC ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10716693, CC ECO:0000269|PubMed:10926925, ECO:0000269|PubMed:10983986, CC ECO:0000269|PubMed:11154276, ECO:0000269|PubMed:11598301, CC ECO:0000269|PubMed:11839817, ECO:0000269|PubMed:12042314, CC ECO:0000269|PubMed:12176338, ECO:0000269|PubMed:12244301, CC ECO:0000269|PubMed:12964941, ECO:0000269|PubMed:14749367, CC ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15118108, CC ECO:0000269|PubMed:16139227, ECO:0000269|PubMed:16417524, CC ECO:0000269|PubMed:16792529, ECO:0000269|PubMed:17726016, CC ECO:0000269|PubMed:17932490, ECO:0000269|PubMed:19592491, CC ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:20086174, CC ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20682768, CC ECO:0000269|PubMed:21329884, ECO:0000269|PubMed:21333377, CC ECO:0000269|PubMed:21775285, ECO:0000269|PubMed:22629392, CC ECO:0000269|PubMed:23251525, ECO:0000269|PubMed:23300339, CC ECO:0000269|PubMed:23676467, ECO:0000269|PubMed:24784001, CC ECO:0000269|PubMed:26440888, ECO:0000269|PubMed:28147277, CC ECO:0000269|PubMed:32228865, ECO:0000269|PubMed:40285646}. CC -!- INTERACTION: CC P31749; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-296087, EBI-10173507; CC P31749; P31749: AKT1; NbExp=4; IntAct=EBI-296087, EBI-296087; CC P31749; P31751: AKT2; NbExp=3; IntAct=EBI-296087, EBI-296058; CC P31749; Q86V81: ALYREF; NbExp=5; IntAct=EBI-296087, EBI-347640; CC P31749; P32121: ARRB2; NbExp=5; IntAct=EBI-296087, EBI-714559; CC P31749; Q8IXJ9: ASXL1; NbExp=3; IntAct=EBI-296087, EBI-1646500; CC P31749; Q13315: ATM; NbExp=5; IntAct=EBI-296087, EBI-495465; CC P31749; P54253: ATXN1; NbExp=6; IntAct=EBI-296087, EBI-930964; CC P31749; Q99728: BARD1; NbExp=3; IntAct=EBI-296087, EBI-473181; CC P31749; O95999: BCL10; NbExp=5; IntAct=EBI-296087, EBI-958922; CC P31749; Q6W2J9: BCOR; NbExp=3; IntAct=EBI-296087, EBI-950027; CC P31749; P15056: BRAF; NbExp=4; IntAct=EBI-296087, EBI-365980; CC P31749; Q9H0C5: BTBD1; NbExp=3; IntAct=EBI-296087, EBI-935503; CC P31749; P62324: BTG1; NbExp=4; IntAct=EBI-296087, EBI-742279; CC P31749; Q9UQM7: CAMK2A; NbExp=3; IntAct=EBI-296087, EBI-1383687; CC P31749; P20248: CCNA2; NbExp=2; IntAct=EBI-296087, EBI-457097; CC P31749; P30281: CCND3; NbExp=3; IntAct=EBI-296087, EBI-375013; CC P31749; Q16543: CDC37; NbExp=5; IntAct=EBI-296087, EBI-295634; CC P31749; P46527: CDKN1B; NbExp=4; IntAct=EBI-296087, EBI-519280; CC P31749; Q8TAP6: CEP76; NbExp=4; IntAct=EBI-296087, EBI-742887; CC P31749; Q92793: CREBBP; NbExp=3; IntAct=EBI-296087, EBI-81215; CC P31749; Q15438: CYTH1; NbExp=3; IntAct=EBI-296087, EBI-997830; CC P31749; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-296087, EBI-742054; CC P31749; P26358: DNMT1; NbExp=6; IntAct=EBI-296087, EBI-719459; CC P31749; P00533: EGFR; NbExp=4; IntAct=EBI-296087, EBI-297353; CC P31749; Q9UJM3: ERRFI1; NbExp=3; IntAct=EBI-296087, EBI-2941912; CC P31749; Q15910: EZH2; NbExp=3; IntAct=EBI-296087, EBI-530054; CC P31749; Q1W6H9: FAM110C; NbExp=2; IntAct=EBI-296087, EBI-3942563; CC P31749; Q00597: FANCC; NbExp=4; IntAct=EBI-296087, EBI-81625; CC P31749; Q9HB96: FANCE; NbExp=4; IntAct=EBI-296087, EBI-396803; CC P31749; Q969H0: FBXW7; NbExp=5; IntAct=EBI-296087, EBI-359574; CC P31749; Q12778: FOXO1; NbExp=2; IntAct=EBI-296087, EBI-1108782; CC P31749; O43524: FOXO3; NbExp=4; IntAct=EBI-296087, EBI-1644164; CC P31749; P06241: FYN; NbExp=3; IntAct=EBI-296087, EBI-515315; CC P31749; P22466: GAL; NbExp=3; IntAct=EBI-296087, EBI-6624768; CC P31749; P49841: GSK3B; NbExp=5; IntAct=EBI-296087, EBI-373586; CC P31749; P68431: H3C12; NbExp=4; IntAct=EBI-296087, EBI-79722; CC P31749; Q96LI6-3: HSFY2; NbExp=3; IntAct=EBI-296087, EBI-25830912; CC P31749; P08238: HSP90AB1; NbExp=3; IntAct=EBI-296087, EBI-352572; CC P31749; P42858: HTT; NbExp=3; IntAct=EBI-296087, EBI-466029; CC P31749; P08476: INHBA; NbExp=3; IntAct=EBI-296087, EBI-8077140; CC P31749; Q8WZ60: KLHL6; NbExp=3; IntAct=EBI-296087, EBI-6426464; CC P31749; Q5S007: LRRK2; NbExp=6; IntAct=EBI-296087, EBI-5323863; CC P31749; Q99683: MAP3K5; NbExp=2; IntAct=EBI-296087, EBI-476263; CC P31749; O15264: MAPK13; NbExp=4; IntAct=EBI-296087, EBI-2116951; CC P31749; Q8TD08: MAPK15; NbExp=3; IntAct=EBI-296087, EBI-1383794; CC P31749; Q9BPZ7: MAPKAP1; NbExp=3; IntAct=EBI-296087, EBI-749938; CC P31749; P10636: MAPT; NbExp=2; IntAct=EBI-296087, EBI-366182; CC P31749; Q07820: MCL1; NbExp=3; IntAct=EBI-296087, EBI-1003422; CC P31749; Q00987: MDM2; NbExp=6; IntAct=EBI-296087, EBI-389668; CC P31749; Q14696: MESD; NbExp=3; IntAct=EBI-296087, EBI-6165891; CC P31749; P42345: MTOR; NbExp=6; IntAct=EBI-296087, EBI-359260; CC P31749; P04198: MYCN; NbExp=3; IntAct=EBI-296087, EBI-878369; CC P31749; P25963: NFKBIA; NbExp=3; IntAct=EBI-296087, EBI-307386; CC P31749; Q9BZQ8: NIBAN1; NbExp=2; IntAct=EBI-296087, EBI-6916466; CC P31749; P04150: NR3C1; NbExp=5; IntAct=EBI-296087, EBI-493507; CC P31749; O15530: PDPK1; NbExp=5; IntAct=EBI-296087, EBI-717097; CC P31749; Q96S96: PEBP4; NbExp=2; IntAct=EBI-296087, EBI-8563667; CC P31749; P19174: PLCG1; NbExp=9; IntAct=EBI-296087, EBI-79387; CC P31749; Q03181: PPARD; NbExp=3; IntAct=EBI-296087, EBI-6426768; CC P31749; O60437: PPL; NbExp=2; IntAct=EBI-296087, EBI-368321; CC P31749; P62136: PPP1CA; NbExp=4; IntAct=EBI-296087, EBI-357253; CC P31749; P67775: PPP2CA; NbExp=4; IntAct=EBI-296087, EBI-712311; CC P31749; P30153: PPP2R1A; NbExp=3; IntAct=EBI-296087, EBI-302388; CC P31749; P54646: PRKAA2; NbExp=3; IntAct=EBI-296087, EBI-1383852; CC P31749; P17612: PRKACA; NbExp=3; IntAct=EBI-296087, EBI-476586; CC P31749; Q05513: PRKCZ; NbExp=2; IntAct=EBI-296087, EBI-295351; CC P31749; Q8WUY3: PRUNE2; NbExp=3; IntAct=EBI-296087, EBI-743880; CC P31749; Q06124: PTPN11; NbExp=3; IntAct=EBI-296087, EBI-297779; CC P31749; P04049: RAF1; NbExp=3; IntAct=EBI-296087, EBI-365996; CC P31749; P10276: RARA; NbExp=3; IntAct=EBI-296087, EBI-413374; CC P31749; Q9NS23: RASSF1; NbExp=3; IntAct=EBI-296087, EBI-367363; CC P31749; Q6R327: RICTOR; NbExp=3; IntAct=EBI-296087, EBI-1387196; CC P31749; P15880: RPS2; NbExp=3; IntAct=EBI-296087, EBI-443446; CC P31749; P23443: RPS6KB1; NbExp=3; IntAct=EBI-296087, EBI-1775921; CC P31749; Q15047: SETDB1; NbExp=10; IntAct=EBI-296087, EBI-79691; CC P31749; Q96EB6: SIRT1; NbExp=5; IntAct=EBI-296087, EBI-1802965; CC P31749; Q13309: SKP2; NbExp=4; IntAct=EBI-296087, EBI-456291; CC P31749; Q13485: SMAD4; NbExp=6; IntAct=EBI-296087, EBI-347263; CC P31749; Q8N3U4: STAG2; NbExp=3; IntAct=EBI-296087, EBI-1057252; CC P31749; Q14849: STARD3; NbExp=3; IntAct=EBI-296087, EBI-9819324; CC P31749; Q13043: STK4; NbExp=13; IntAct=EBI-296087, EBI-367376; CC P31749; Q9UNE7-1: STUB1; NbExp=5; IntAct=EBI-296087, EBI-15687717; CC P31749; P56279: TCL1A; NbExp=8; IntAct=EBI-296087, EBI-749995; CC P31749; Q9NYB0: TERF2IP; NbExp=2; IntAct=EBI-296087, EBI-750109; CC P31749; Q5T1C6: THEM4; NbExp=4; IntAct=EBI-296087, EBI-7684443; CC P31749; Q92547: TOPBP1; NbExp=2; IntAct=EBI-296087, EBI-308302; CC P31749; P53804: TTC3; NbExp=4; IntAct=EBI-296087, EBI-2681313; CC P31749; P10599: TXN; NbExp=3; IntAct=EBI-296087, EBI-594644; CC P31749; P08670: VIM; NbExp=29; IntAct=EBI-296087, EBI-353844; CC P31749; Q6GPH4: XAF1; NbExp=4; IntAct=EBI-296087, EBI-2815120; CC P31749; P17028: ZNF24; NbExp=3; IntAct=EBI-296087, EBI-707773; CC P31749; P29067: Arrb2; Xeno; NbExp=2; IntAct=EBI-296087, EBI-1636616; CC P31749; P06762: Hmox1; Xeno; NbExp=2; IntAct=EBI-296087, EBI-7410266; CC P31749; Q83730: m005R; Xeno; NbExp=3; IntAct=EBI-296087, EBI-6859930; CC P31749; P03165: X; Xeno; NbExp=3; IntAct=EBI-296087, EBI-7683985; CC P31749-1; Q15118-1: PDK1; NbExp=2; IntAct=EBI-12562306, EBI-12562315; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P31750}. Nucleus CC {ECO:0000269|PubMed:20333297}. Cell membrane CC {ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:40285646}. CC Mitochondrion intermembrane space {ECO:0000250|UniProtKB:P31750}. CC Note=Nucleus after activation by integrin-linked protein kinase 1 CC (ILK1). Nuclear translocation is enhanced by interaction with TCL1A. CC Phosphorylation on Tyr-176 by TNK2 results in its localization to the CC cell membrane where it is targeted for further phosphorylations on Thr- CC 308 and Ser-473 leading to its activation and the activated form CC translocates to the nucleus. Colocalizes with WDFY2 in intracellular CC vesicles (PubMed:16792529). Also localizes to mitochondrial CC intermembrane space in response to rapamycin treatment (By similarity). CC {ECO:0000250|UniProtKB:P31750, ECO:0000269|PubMed:16792529}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P31749-1; Sequence=Displayed; CC Name=2; CC IsoId=P31749-2; Sequence=VSP_056180; CC -!- TISSUE SPECIFICITY: Expressed in prostate cancer and levels increase CC from the normal to the malignant state (at protein level). Expressed in CC all human cell types so far analyzed. The Tyr-176 phosphorylated form CC shows a significant increase in expression in breast cancers during the CC progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma CC in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node CC metastatic (LNMM) stages. {ECO:0000269|PubMed:1718748, CC ECO:0000269|PubMed:17932490, ECO:0000269|PubMed:20333297}. CC -!- DOMAIN: Binding of the PH domain to phosphatidylinositol 3,4,5- CC trisphosphate (PI(3,4,5)P3) following phosphatidylinositol 3-kinase CC alpha (PIK3CA) activity results in its targeting to the plasma membrane CC (PubMed:12176338, PubMed:12964941). PI(3,4,5)P3 is also required for CC phosphorylation at Thr-308 and subsequent activation (By similarity). CC The PH domain mediates interaction with TNK2 and Tyr-176 is also CC essential for this interaction (PubMed:20333297). CC {ECO:0000250|UniProtKB:P47196, ECO:0000269|PubMed:12176338, CC ECO:0000269|PubMed:12964941, ECO:0000269|PubMed:20333297}. CC -!- DOMAIN: The AGC-kinase C-terminal mediates interaction with THEM4. CC {ECO:0000269|PubMed:11598301}. CC -!- PTM: O-GlcNAcylation at Thr-305 and Thr-312 inhibits activating CC phosphorylation at Thr-308 via disrupting the interaction between AKT1 CC and PDPK1. O-GlcNAcylation at Ser-473 also probably interferes with CC phosphorylation at this site. {ECO:0000269|PubMed:14761976, CC ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15718470, CC ECO:0000269|PubMed:16266983, ECO:0000269|PubMed:17013611, CC ECO:0000269|PubMed:18456494, ECO:0000269|PubMed:20333297, CC ECO:0000269|PubMed:20481595, ECO:0000269|PubMed:20978158, CC ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:23799035, CC ECO:0000269|PubMed:8978681, ECO:0000269|PubMed:9512493, CC ECO:0000269|PubMed:9736715}. CC -!- PTM: Phosphorylation on Thr-308, Ser-473 and Tyr-474 is required for CC full activity (PubMed:12149249, PubMed:15047712, PubMed:15262962, CC PubMed:16266983, PubMed:18456494, PubMed:20481595, PubMed:20978158, CC PubMed:8978681, PubMed:9512493, PubMed:9736715). Phosphorylation of the CC activation loop at Thr-308 by PDPK1/PDK1 is a prerequisite for full CC activation (PubMed:9512493). Phosphorylation by mTORC2 in response to CC growth factors plays a key role in AKT1 activation: mTORC2 CC phosphorylates different sites depending on the context, such as Thr- CC 450, Ser-473, Ser-477 or Thr-479, thereby facilitating subsequent CC phosphorylation of the activation loop by PDPK1/PDK1 (PubMed:15718470, CC PubMed:24670654). Phosphorylation at Ser-473 by mTORC2 promotes CC ubiquitination and degradation by the proteasome (By similarity). Also CC phosphorylated at Ser-477 and Thr-479 by CDK2, facilitating subsequent CC phosphorylation of the activation loop by PDPK1/PDK1 (PubMed:24670654). CC Activated TNK2 phosphorylates it on Tyr-176 resulting in its binding to CC the anionic plasma membrane phospholipid PA (PubMed:20333297). This CC phosphorylated form localizes to the cell membrane, where it is CC targeted by PDPK1 and PDPK2 for further phosphorylations on Thr-308 and CC Ser-473 leading to its activation (PubMed:20333297). Phosphorylated at CC Thr-308 and Ser-473 by IKBKE and TBK1 (PubMed:21464307). Ser-473 CC phosphorylation is enhanced by interaction with AGAP2 isoform 2 (PIKE- CC A) (PubMed:14761976). Ser-473 phosphorylation is enhanced in focal CC cortical dysplasias with Taylor-type balloon cells (PubMed:17013611). CC Ser-473 phosphorylation is enhanced by signaling through activated FLT3 CC (PubMed:16266983). Ser-473 is dephosphorylated by PHLPP CC (PubMed:28147277). Dephosphorylated at Thr-308 and Ser-473 by PP2A CC phosphatase (PubMed:21329884). The phosphorylated form of PPP2R5B is CC required for bridging AKT1 with PP2A phosphatase (PubMed:21329884). CC Ser-473 is dephosphorylated by CPPED1, leading to termination of CC signaling (PubMed:23799035). AIM2 acts as an inhibitor of AKT1 by CC inhibiting phosphorylation Ser-473: AIM2 acts both by inhibiting the CC activity of PRKDC/DNA-PK kinase and promoting dephosphorylation by PP2A CC phosphatase (By similarity). {ECO:0000250|UniProtKB:P31750, CC ECO:0000269|PubMed:12149249, ECO:0000269|PubMed:14761976, CC ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15262962, CC ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983, CC ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494, CC ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595, CC ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21329884, CC ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:23799035, CC ECO:0000269|PubMed:24670654, ECO:0000269|PubMed:28147277, CC ECO:0000269|PubMed:8978681, ECO:0000269|PubMed:9512493, CC ECO:0000269|PubMed:9736715}. CC -!- PTM: Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked CC polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1 ubiquitination CC is critical for phosphorylation and activation (PubMed:19713527). When CC ubiquitinated, it translocates to the plasma membrane, where it becomes CC phosphorylated (PubMed:20059950). When fully phosphorylated and CC translocated into the nucleus, undergoes 'Lys-48'-polyubiquitination CC catalyzed by TTC3, leading to its degradation by the proteasome CC (PubMed:20059950). Also ubiquitinated by TRIM13 leading to its CC proteasomal degradation (PubMed:21333377). Phosphorylated, undergoes CC 'Lys-48'-linked polyubiquitination preferentially at Lys-284 catalyzed CC by MUL1, leading to its proteasomal degradation (PubMed:22410793). CC Ubiquitinated via 'Lys-48'-linked polyubiquitination by ZNRF1, leading CC to its degradation by the proteasome (By similarity). CC {ECO:0000250|UniProtKB:P31750, ECO:0000269|PubMed:19713527, CC ECO:0000269|PubMed:20059950, ECO:0000269|PubMed:21333377, CC ECO:0000269|PubMed:22410793}. CC -!- PTM: Acetylated on Lys-14 and Lys-20 by the histone acetyltransferases CC EP300 and KAT2B. Acetylation results in reduced phosphorylation and CC inhibition of activity. Deacetylated at Lys-14 and Lys-20 by SIRT1. CC SIRT1-mediated deacetylation relieves the inhibition. CC {ECO:0000269|PubMed:21775285}. CC -!- PTM: Cleavage by caspase-3/CASP3 (By similarity). Cleaved at the CC caspase-3 consensus site Asp-462 during apoptosis, resulting in down- CC regulation of the AKT signaling pathway and decreased cell survival CC (PubMed:23152800). {ECO:0000250|UniProtKB:P31750, CC ECO:0000269|PubMed:23152800}. CC -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy CC originating from breast epithelial tissue. Breast neoplasms can be CC distinguished by their histologic pattern. Invasive ductal carcinoma is CC by far the most common type. Breast cancer is etiologically and CC genetically heterogeneous. Important genetic factors have been CC indicated by familial occurrence and bilateral involvement. Mutations CC at more than one locus can be involved in different families or even in CC the same case. {ECO:0000269|PubMed:17611497}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. Note=The gene represented in this entry may be CC involved in disease pathogenesis. CC -!- DISEASE: Note=Genetic variations in AKT1 may play a role in CC susceptibility to ovarian cancer. CC -!- DISEASE: Proteus syndrome (PROTEUSS) [MIM:176920]: A highly variable, CC severe disorder of asymmetric and disproportionate overgrowth of body CC parts, connective tissue nevi, epidermal nevi, dysregulated adipose CC tissue, and vascular malformations. Many features of Proteus syndrome CC overlap with other overgrowth syndromes. {ECO:0000269|PubMed:18954143, CC ECO:0000269|PubMed:21793738}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cowden syndrome 6 (CWS6) [MIM:615109]: A form of Cowden CC syndrome, a hamartomatous polyposis syndrome with age-related CC penetrance. Cowden syndrome is characterized by hamartomatous lesions CC affecting derivatives of ectodermal, mesodermal and endodermal layers, CC macrocephaly, facial trichilemmomas (benign tumors of the hair follicle CC infundibulum), acral keratoses, papillomatous papules, and elevated CC risk for development of several types of malignancy, particularly CC breast carcinoma in women and thyroid carcinoma in both men and women. CC Colon cancer and renal cell carcinoma have also been reported. CC Hamartomas can be found in virtually every organ, but most commonly in CC the skin, gastrointestinal tract, breast and thyroid. CC {ECO:0000269|PubMed:12176338, ECO:0000269|PubMed:23246288}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. RAC subfamily. {ECO:0000305}. CC -!- CAUTION: PUBMED:20231902 has been retracted because there was evidence CC of data fabrication and/or falsification in multiple figure panels. CC {ECO:0000305|PubMed:20231902, ECO:0000305|PubMed:37490513}. CC -!- CAUTION: PUBMED:19940129 has been retracted because the same data were CC used to represent different experimental conditions. CC {ECO:0000305|PubMed:19940129, ECO:0000305|PubMed:27825096}. CC -!- CAUTION: In light of strong homologies in the primary amino acid CC sequence, the 3 AKT kinases were long surmised to play redundant and CC overlapping roles. More recent studies has brought into question the CC redundancy within AKT kinase isoforms and instead pointed to isoform CC specific functions in different cellular events and diseases. AKT1 is CC more specifically involved in cellular survival pathways, by inhibiting CC apoptotic processes; whereas AKT2 is more specific for the insulin CC receptor signaling pathway. Moreover, while AKT1 and AKT2 are often CC implicated in many aspects of cellular transformation, the 2 isoforms CC act in a complementary opposing manner. The role of AKT3 is less clear, CC though it appears to be predominantly expressed in brain. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/355/AKT1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M63167; AAA36539.1; -; mRNA. DR EMBL; AF283830; AAL55732.1; -; Genomic_DNA. DR EMBL; AF283819; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283820; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283821; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283822; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283823; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283824; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283825; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283826; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283827; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283828; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283829; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AK299310; BAH12997.1; -; mRNA. DR EMBL; AK314256; BAG36922.1; -; mRNA. DR EMBL; AB451242; BAG70056.1; -; mRNA. DR EMBL; AB451367; BAG70181.1; -; mRNA. DR EMBL; AL583722; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL590327; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC000479; AAH00479.1; -; mRNA. DR EMBL; BC084538; AAH84538.1; -; mRNA. DR EMBL; X61037; CAA43372.1; -; mRNA. DR CCDS; CCDS9994.1; -. [P31749-1] DR PIR; A39360; A39360. DR RefSeq; NP_001014431.1; NM_001014431.2. [P31749-1] DR RefSeq; NP_001014432.1; NM_001014432.2. [P31749-1] DR RefSeq; NP_001369359.1; NM_001382430.1. [P31749-1] DR RefSeq; NP_001369360.1; NM_001382431.1. [P31749-1] DR RefSeq; NP_001369361.1; NM_001382432.1. [P31749-1] DR RefSeq; NP_001369362.1; NM_001382433.1. [P31749-1] DR RefSeq; NP_005154.2; NM_005163.2. [P31749-1] DR RefSeq; XP_047287025.1; XM_047431069.1. [P31749-1] DR RefSeq; XP_047287026.1; XM_047431070.1. [P31749-1] DR RefSeq; XP_047287027.1; XM_047431071.1. [P31749-1] DR RefSeq; XP_047287028.1; XM_047431072.1. [P31749-1] DR RefSeq; XP_047287029.1; XM_047431073.1. [P31749-1] DR RefSeq; XP_047287030.1; XM_047431074.1. [P31749-1] DR RefSeq; XP_047287031.1; XM_047431075.1. [P31749-1] DR RefSeq; XP_054231528.1; XM_054375553.1. [P31749-1] DR RefSeq; XP_054231529.1; XM_054375554.1. [P31749-1] DR RefSeq; XP_054231530.1; XM_054375555.1. [P31749-1] DR RefSeq; XP_054231531.1; XM_054375556.1. [P31749-1] DR RefSeq; XP_054231532.1; XM_054375557.1. [P31749-1] DR RefSeq; XP_054231533.1; XM_054375558.1. [P31749-1] DR PDB; 1H10; X-ray; 1.40 A; A=1-123. DR PDB; 1UNP; X-ray; 1.65 A; A=1-121. DR PDB; 1UNQ; X-ray; 0.98 A; A=1-123. DR PDB; 1UNR; X-ray; 1.25 A; A=1-123. DR PDB; 2UVM; X-ray; 1.94 A; A=1-123. DR PDB; 2UZR; X-ray; 1.94 A; A=1-123. DR PDB; 2UZS; X-ray; 2.46 A; A=1-123. DR PDB; 3CQU; X-ray; 2.20 A; A=144-480. DR PDB; 3CQW; X-ray; 2.00 A; A=144-480. DR PDB; 3MV5; X-ray; 2.47 A; A=144-480. DR PDB; 3MVH; X-ray; 2.01 A; A=144-480. DR PDB; 3O96; X-ray; 2.70 A; A=2-443. DR PDB; 3OCB; X-ray; 2.70 A; A/B=144-480. DR PDB; 3OW4; X-ray; 2.60 A; A/B=144-480. DR PDB; 3QKK; X-ray; 2.30 A; A=144-480. DR PDB; 3QKL; X-ray; 1.90 A; A=144-480. DR PDB; 3QKM; X-ray; 2.20 A; A=144-480. DR PDB; 4EJN; X-ray; 2.19 A; A=2-446. DR PDB; 4EKK; X-ray; 2.80 A; A/B=144-480. DR PDB; 4EKL; X-ray; 2.00 A; A=144-480. DR PDB; 4GV1; X-ray; 1.49 A; A=144-480. DR PDB; 5KCV; X-ray; 2.70 A; A=2-446. DR PDB; 6BUU; X-ray; 2.40 A; A/B=144-480. DR PDB; 6CCY; X-ray; 2.18 A; A=144-466. DR PDB; 6HHF; X-ray; 2.90 A; A=2-446. DR PDB; 6HHG; X-ray; 2.30 A; A=2-446. DR PDB; 6HHH; X-ray; 2.70 A; A=2-446. DR PDB; 6HHI; X-ray; 2.70 A; A=2-446. DR PDB; 6HHJ; X-ray; 2.30 A; A=2-446. DR PDB; 6NPZ; X-ray; 2.12 A; A/B=123-480, A/B=144-480. DR PDB; 6S9W; X-ray; 2.30 A; A=2-446. DR PDB; 6S9X; X-ray; 2.60 A; A=2-446. DR PDB; 7APJ; X-ray; 2.05 A; A=1-119, A=136-445. DR PDB; 7MYX; X-ray; 1.39 A; A=1-121. DR PDB; 7NH4; X-ray; 2.30 A; A=2-446. DR PDB; 7NH5; X-ray; 1.90 A; A=2-446. DR PDB; 8JOW; X-ray; 1.40 A; B/D=466-477. DR PDB; 8UVY; X-ray; 2.11 A; A=2-446. DR PDB; 8UW2; X-ray; 2.20 A; A=2-446. DR PDB; 8UW7; X-ray; 1.97 A; A=2-446. DR PDB; 8UW9; X-ray; 1.90 A; A=2-446. DR PDB; 8ZPU; X-ray; 2.80 A; C/D=466-477. DR PDBsum; 1H10; -. DR PDBsum; 1UNP; -. DR PDBsum; 1UNQ; -. DR PDBsum; 1UNR; -. DR PDBsum; 2UVM; -. DR PDBsum; 2UZR; -. DR PDBsum; 2UZS; -. DR PDBsum; 3CQU; -. DR PDBsum; 3CQW; -. DR PDBsum; 3MV5; -. DR PDBsum; 3MVH; -. DR PDBsum; 3O96; -. DR PDBsum; 3OCB; -. DR PDBsum; 3OW4; -. DR PDBsum; 3QKK; -. DR PDBsum; 3QKL; -. DR PDBsum; 3QKM; -. DR PDBsum; 4EJN; -. DR PDBsum; 4EKK; -. DR PDBsum; 4EKL; -. DR PDBsum; 4GV1; -. DR PDBsum; 5KCV; -. DR PDBsum; 6BUU; -. DR PDBsum; 6CCY; -. DR PDBsum; 6HHF; -. DR PDBsum; 6HHG; -. DR PDBsum; 6HHH; -. DR PDBsum; 6HHI; -. DR PDBsum; 6HHJ; -. DR PDBsum; 6NPZ; -. DR PDBsum; 6S9W; -. DR PDBsum; 6S9X; -. DR PDBsum; 7APJ; -. DR PDBsum; 7MYX; -. DR PDBsum; 7NH4; -. DR PDBsum; 7NH5; -. DR PDBsum; 8JOW; -. DR PDBsum; 8UVY; -. DR PDBsum; 8UW2; -. DR PDBsum; 8UW7; -. DR PDBsum; 8UW9; -. DR PDBsum; 8ZPU; -. DR AlphaFoldDB; P31749; -. DR SMR; P31749; -. DR BioGRID; 106710; 600. DR CORUM; P31749; -. DR DIP; DIP-24269N; -. DR ELM; P31749; -. DR FunCoup; P31749; 3098. DR IntAct; P31749; 602. DR MINT; P31749; -. DR STRING; 9606.ENSP00000451828; -. DR BindingDB; P31749; -. DR ChEMBL; CHEMBL4282; -. DR DrugBank; DB08073; (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE. DR DrugBank; DB07585; 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine. DR DrugBank; DB08568; A-674563. DR DrugBank; DB11648; Afuresertib. DR DrugBank; DB05971; Archexin. DR DrugBank; DB01169; Arsenic trioxide. DR DrugBank; DB00171; ATP. DR DrugBank; DB03777; Bisindolylmaleimide I. DR DrugBank; DB15399; BMS-754807. DR DrugBank; DB05424; Canertinib. DR DrugBank; DB12218; Capivasertib. DR DrugBank; DB12429; CI-1040. DR DrugBank; DB12795; CMX-2043. DR DrugBank; DB06486; Enzastaurin. DR DrugBank; DB01645; Genistein. DR DrugBank; DB01863; Inositol 1,3,4,5-Tetrakisphosphate. DR DrugBank; DB11743; Ipatasertib. DR DrugBank; DB15431; M-2698. DR DrugBank; DB14982; Miransertib. DR DrugBank; DB07584; N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine. DR DrugBank; DB06641; Perifosine. DR DrugBank; DB02709; Resveratrol. DR DrugBank; DB04462; Tetrabromo-2-Benzotriazole. DR DrugCentral; P31749; -. DR GuidetoPHARMACOLOGY; 1479; -. DR TCDB; 8.A.104.1.10; the 5'-amp-activated protein kinase (ampk) family. DR GlyCosmos; P31749; 6 sites, 1 glycan. DR GlyGen; P31749; 7 sites, 1 O-linked glycan (6 sites). DR iPTMnet; P31749; -. DR MetOSite; P31749; -. DR PhosphoSitePlus; P31749; -. DR BioMuta; AKT1; -. DR DMDM; 60391226; -. DR CPTAC; CPTAC-3162; -. DR CPTAC; CPTAC-3163; -. DR CPTAC; CPTAC-3164; -. DR CPTAC; CPTAC-3165; -. DR CPTAC; CPTAC-3166; -. DR CPTAC; CPTAC-3167; -. DR CPTAC; CPTAC-5758; -. DR CPTAC; CPTAC-5759; -. DR CPTAC; CPTAC-5805; -. DR CPTAC; CPTAC-5806; -. DR CPTAC; CPTAC-5807; -. DR CPTAC; CPTAC-5808; -. DR CPTAC; CPTAC-783; -. DR CPTAC; CPTAC-784; -. DR CPTAC; non-CPTAC-5328; -. DR CPTAC; non-CPTAC-5329; -. DR CPTAC; non-CPTAC-5332; -. DR CPTAC; non-CPTAC-5527; -. DR CPTAC; non-CPTAC-5528; -. DR CPTAC; non-CPTAC-5719; -. DR CPTAC; non-CPTAC-5720; -. DR jPOST; P31749; -. DR MassIVE; P31749; -. DR PaxDb; 9606-ENSP00000451828; -. DR PeptideAtlas; P31749; -. DR ProteomicsDB; 54800; -. [P31749-1] DR ProteomicsDB; 6712; -. DR Pumba; P31749; -. DR ABCD; P31749; 12 sequenced antibodies. DR Antibodypedia; 135; 5291 antibodies from 58 providers. DR CPTC; P31749; 6 antibodies. DR DNASU; 207; -. DR Ensembl; ENST00000349310.7; ENSP00000270202.4; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000402615.6; ENSP00000385326.2; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000407796.7; ENSP00000384293.2; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000554581.5; ENSP00000451828.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000554848.5; ENSP00000451166.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000555528.5; ENSP00000450688.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000649815.2; ENSP00000497822.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000683722.1; ENSP00000507879.1; ENSG00000142208.20. [P31749-1] DR GeneID; 207; -. DR KEGG; hsa:207; -. DR MANE-Select; ENST00000649815.2; ENSP00000497822.1; NM_001382430.1; NP_001369359.1. DR UCSC; uc001ypk.4; human. [P31749-1] DR AGR; HGNC:391; -. DR CIViC; 207; 18 evidence items across 19 molecular profiles. DR ClinPGx; PA24684; -. DR CTD; 207; -. DR DisGeNET; 207; -. DR GeneCards; AKT1; -. DR GeneReviews; AKT1; -. DR HGNC; HGNC:391; AKT1. DR HPA; ENSG00000142208; Low tissue specificity. DR MalaCards; AKT1; -. DR MIM; 114480; phenotype. DR MIM; 114500; phenotype. DR MIM; 164730; gene. DR MIM; 176920; phenotype. DR MIM; 615109; phenotype. DR OpenTargets; ENSG00000142208; -. DR Orphanet; 201; Cowden syndrome. DR Orphanet; 2495; Meningioma. DR Orphanet; 744; Proteus syndrome. DR VEuPathDB; HostDB:ENSG00000142208; -. DR eggNOG; KOG0690; Eukaryota. DR GeneTree; ENSGT00940000158752; -. DR HOGENOM; CLU_000288_11_0_1; -. DR InParanoid; P31749; -. DR OMA; MDMEIYL; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; P31749; 3 GO annotations based on evolutionary models. DR PhylomeDB; P31749; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P31749; -. DR Reactome; R-HSA-111447; Activation of BAD and translocation to mitochondria. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling. DR Reactome; R-HSA-1445148; Translocation of SLC2A4 (GLUT4) to the plasma membrane. DR Reactome; R-HSA-1474151; Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation. DR Reactome; R-HSA-165159; MTOR signalling. DR Reactome; R-HSA-198323; AKT phosphorylates targets in the cytosol. DR Reactome; R-HSA-198693; AKT phosphorylates targets in the nucleus. DR Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network. DR Reactome; R-HSA-203615; eNOS activation. DR Reactome; R-HSA-211163; AKT-mediated inactivation of FOXO1A. DR Reactome; R-HSA-354192; Integrin signaling. DR Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex. DR Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling. DR Reactome; R-HSA-389513; Co-inhibition by CTLA4. DR Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma. DR Reactome; R-HSA-450385; Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA. DR Reactome; R-HSA-450604; KSRP (KHSRP) binds and destabilizes mRNA. DR Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation. DR Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-69202; Cyclin E associated events during G1/S transition. DR Reactome; R-HSA-69656; Cyclin A:Cdk2-associated events at S phase entry. DR Reactome; R-HSA-8849469; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1. DR Reactome; R-HSA-8876198; RAB GEFs exchange GTP for GDP on RABs. DR Reactome; R-HSA-8941332; RUNX2 regulates genes involved in cell migration. DR Reactome; R-HSA-8948751; Regulation of PTEN stability and activity. DR Reactome; R-HSA-9009391; Extra-nuclear estrogen signaling. DR Reactome; R-HSA-9604323; Negative regulation of NOTCH4 signaling. DR Reactome; R-HSA-9607240; FLT3 Signaling. DR Reactome; R-HSA-9614399; Regulation of localization of FOXO transcription factors. DR Reactome; R-HSA-9634638; Estrogen-dependent nuclear events downstream of ESR-membrane signaling. DR Reactome; R-HSA-9755511; KEAP1-NFE2L2 pathway. DR Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways. DR Reactome; R-HSA-9841251; Mitochondrial unfolded protein response (UPRmt). DR Reactome; R-HSA-9856530; High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells. DR Reactome; R-HSA-9856532; Mechanical load activates signaling by PIEZO1 and integrins in osteocytes. DR SABIO-RK; P31749; -. DR SignaLink; P31749; -. DR SIGNOR; P31749; -. DR Agora; ENSG00000142208; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 207; 54 hits in 1212 CRISPR screens. DR ChiTaRS; AKT1; human. DR EvolutionaryTrace; P31749; -. DR GeneWiki; AKT1; -. DR GenomeRNAi; 207; -. DR Pharos; P31749; Tchem. DR PRO; PR:P31749; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; P31749; protein. DR Bgee; ENSG00000142208; Expressed in stromal cell of endometrium and 189 other cell types or tissues. DR ExpressionAtlas; P31749; baseline and differential. DR GO; GO:0005938; C:cell cortex; NAS:BHF-UCL. DR GO; GO:0005911; C:cell-cell junction; IEA:Ensembl. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0030027; C:lamellipodium; NAS:BHF-UCL. DR GO; GO:0016020; C:membrane; IDA:UniProt. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:HPA. DR GO; GO:0005758; C:mitochondrial intermembrane space; ISS:UniProtKB. DR GO; GO:0005739; C:mitochondrion; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0033011; C:perinuclear theca; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0098794; C:postsynapse; IEA:GOC. DR GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0120238; C:sperm glycocalyx; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0005819; C:spindle; IEA:Ensembl. DR GO; GO:0031982; C:vesicle; IDA:UniProtKB. DR GO; GO:0071889; F:14-3-3 protein binding; IPI:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0005516; F:calmodulin binding; IDA:UniProtKB. DR GO; GO:0019899; F:enzyme binding; ISS:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0016301; F:kinase activity; IDA:MGI. DR GO; GO:0019900; F:kinase binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0030235; F:nitric-oxide synthase regulator activity; IMP:BHF-UCL. DR GO; GO:0005547; F:phosphatidylinositol-3,4,5-trisphosphate binding; IDA:UniProtKB. DR GO; GO:0043325; F:phosphatidylinositol-3,4-bisphosphate binding; IDA:UniProtKB. DR GO; GO:0099104; F:potassium channel activator activity; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IEA:Ensembl. DR GO; GO:0106310; F:protein serine kinase activity; TAS:Reactome. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0030291; F:protein serine/threonine kinase inhibitor activity; ISS:BHF-UCL. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:BHF-UCL. DR GO; GO:1904841; F:TORC2 complex binding; IDA:ParkinsonsUK-UCL. DR GO; GO:0006924; P:activation-induced cell death of T cells; IMP:MGI. DR GO; GO:0043276; P:anoikis; NAS:ParkinsonsUK-UCL. DR GO; GO:0008637; P:apoptotic mitochondrial changes; IEA:Ensembl. DR GO; GO:0048266; P:behavioral response to pain; IEA:Ensembl. DR GO; GO:0160213; P:beta-arrestin-dependent dopamine receptor signaling pathway; NAS:ParkinsonsUK-UCL. DR GO; GO:0030154; P:cell differentiation; TAS:UniProtKB. DR GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; IMP:BHF-UCL. DR GO; GO:0008283; P:cell population proliferation; TAS:UniProtKB. DR GO; GO:0036294; P:cellular response to decreased oxygen levels; IEA:Ensembl. DR GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IDA:UniProtKB. DR GO; GO:0097011; P:cellular response to granulocyte macrophage colony-stimulating factor stimulus; IEA:Ensembl. DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:UniProtKB. DR GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IMP:UniProtKB. DR GO; GO:0140052; P:cellular response to oxidised low-density lipoprotein particle stimulus; IMP:BHF-UCL. DR GO; GO:1901653; P:cellular response to peptide; IEA:Ensembl. DR GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IEA:Ensembl. DR GO; GO:0072752; P:cellular response to rapamycin; ISS:UniProt. DR GO; GO:0033554; P:cellular response to stress; TAS:Reactome. DR GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl. DR GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IEA:Ensembl. DR GO; GO:0002430; P:complement receptor mediated signaling pathway; IDA:BHF-UCL. DR GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0072655; P:establishment of protein localization to mitochondrion; IMP:ParkinsonsUK-UCL. DR GO; GO:0060079; P:excitatory postsynaptic potential; NAS:ParkinsonsUK-UCL. DR GO; GO:0097194; P:execution phase of apoptosis; IEA:Ensembl. DR GO; GO:0010761; P:fibroblast migration; NAS:BHF-UCL. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:ProtInc. DR GO; GO:0010467; P:gene expression; IEA:Ensembl. DR GO; GO:0042593; P:glucose homeostasis; IEA:Ensembl. DR GO; GO:0006006; P:glucose metabolic process; IEA:UniProtKB-KW. DR GO; GO:0005978; P:glycogen biosynthetic process; IEA:UniProtKB-KW. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0008286; P:insulin receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0035655; P:interleukin-18-mediated signaling pathway; IDA:BHF-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IDA:MGI. DR GO; GO:0060716; P:labyrinthine layer blood vessel development; IEA:Ensembl. DR GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0072656; P:maintenance of protein location in mitochondrion; IMP:ParkinsonsUK-UCL. DR GO; GO:0022605; P:mammalian oogenesis stage; IEA:Ensembl. DR GO; GO:0060644; P:mammary gland epithelial cell differentiation; TAS:UniProtKB. DR GO; GO:0001893; P:maternal placenta development; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0010507; P:negative regulation of autophagy; IMP:BHF-UCL. DR GO; GO:0160049; P:negative regulation of cGAS/STING signaling pathway; IDA:UniProt. DR GO; GO:1902018; P:negative regulation of cilium assembly; IDA:UniProtKB. DR GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; TAS:BHF-UCL. DR GO; GO:0031999; P:negative regulation of fatty acid beta-oxidation; IMP:BHF-UCL. DR GO; GO:1903384; P:negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway; IMP:ParkinsonsUK-UCL. DR GO; GO:1903038; P:negative regulation of leukocyte cell-cell adhesion; IMP:BHF-UCL. DR GO; GO:0010748; P:negative regulation of long-chain fatty acid import across plasma membrane; IMP:BHF-UCL. DR GO; GO:2000402; P:negative regulation of lymphocyte migration; IMP:BHF-UCL. DR GO; GO:0016242; P:negative regulation of macroautophagy; NAS:ParkinsonsUK-UCL. DR GO; GO:0045746; P:negative regulation of Notch signaling pathway; TAS:Reactome. DR GO; GO:1902176; P:negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; NAS:BHF-UCL. DR GO; GO:1903898; P:negative regulation of PERK-mediated unfolded protein response; ISS:UniProt. DR GO; GO:0150033; P:negative regulation of protein localization to lysosome; IDA:UniProtKB. DR GO; GO:1903318; P:negative regulation of protein maturation; ISS:UniProt. DR GO; GO:0031397; P:negative regulation of protein ubiquitination; IMP:ARUK-UCL. DR GO; GO:0045861; P:negative regulation of proteolysis; IMP:BHF-UCL. DR GO; GO:0090201; P:negative regulation of release of cytochrome c from mitochondria; ISS:UniProtKB. DR GO; GO:0006809; P:nitric oxide biosynthetic process; TAS:ProtInc. DR GO; GO:0046209; P:nitric oxide metabolic process; TAS:Reactome. DR GO; GO:0001649; P:osteoblast differentiation; IDA:UniProt. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:0032287; P:peripheral nervous system myelin maintenance; IEA:Ensembl. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:BHF-UCL. DR GO; GO:0016310; P:phosphorylation; IDA:UniProtKB. DR GO; GO:1905786; P:positive regulation of anaphase-promoting complex-dependent catabolic process; IDA:UniProt. DR GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:DFLAT. DR GO; GO:0030307; P:positive regulation of cell growth; IDA:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProt. DR GO; GO:0046326; P:positive regulation of D-glucose import; IMP:BHF-UCL. DR GO; GO:0032079; P:positive regulation of endodeoxyribonuclease activity; IDA:UniProtKB. DR GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:BHF-UCL. DR GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB. DR GO; GO:0045600; P:positive regulation of fat cell differentiation; IMP:BHF-UCL. DR GO; GO:0010763; P:positive regulation of fibroblast migration; IEA:Ensembl. DR GO; GO:1900087; P:positive regulation of G1/S transition of mitotic cell cycle; IMP:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0010907; P:positive regulation of glucose metabolic process; IMP:BHF-UCL. DR GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IMP:BHF-UCL. DR GO; GO:0046889; P:positive regulation of lipid biosynthetic process; IDA:UniProtKB. DR GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:BHF-UCL. DR GO; GO:0046622; P:positive regulation of organ growth; IEA:Ensembl. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IDA:UniProt. DR GO; GO:2000010; P:positive regulation of protein localization to cell surface; IEA:Ensembl. DR GO; GO:1905552; P:positive regulation of protein localization to endoplasmic reticulum; IDA:UniProt. DR GO; GO:1900182; P:positive regulation of protein localization to nucleus; IMP:UniProtKB. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IMP:BHF-UCL. DR GO; GO:0051247; P:positive regulation of protein metabolic process; ISS:BHF-UCL. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IDA:BHF-UCL. DR GO; GO:0010765; P:positive regulation of sodium ion transport; IEA:Ensembl. DR GO; GO:1904263; P:positive regulation of TORC1 signaling; IDA:UniProtKB. DR GO; GO:1904515; P:positive regulation of TORC2 signaling; IEA:Ensembl. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB. DR GO; GO:0006606; P:protein import into nucleus; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0016567; P:protein ubiquitination; IEA:Ensembl. DR GO; GO:0042981; P:regulation of apoptotic process; ISS:UniProtKB. DR GO; GO:0030334; P:regulation of cell migration; IMP:UniProtKB. DR GO; GO:0005979; P:regulation of glycogen biosynthetic process; IMP:BHF-UCL. DR GO; GO:0043488; P:regulation of mRNA stability; TAS:Reactome. DR GO; GO:0031641; P:regulation of myelination; IEA:Ensembl. DR GO; GO:0010975; P:regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0099175; P:regulation of postsynapse organization; IEA:Ensembl. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0006417; P:regulation of translation; IEA:UniProtKB-KW. DR GO; GO:0110002; P:regulation of tRNA methylation; IDA:UniProt. DR GO; GO:2000074; P:regulation of type B pancreatic cell development; TAS:Reactome. DR GO; GO:0034405; P:response to fluid shear stress; IMP:BHF-UCL. DR GO; GO:0032094; P:response to food; IEA:Ensembl. DR GO; GO:0070848; P:response to growth factor; IDA:UniProtKB. DR GO; GO:0060416; P:response to growth hormone; ISS:AgBase. DR GO; GO:0009408; P:response to heat; TAS:ProtInc. DR GO; GO:1990418; P:response to insulin-like growth factor stimulus; ISS:AgBase. DR GO; GO:0006979; P:response to oxidative stress; ISS:ParkinsonsUK-UCL. DR GO; GO:0070141; P:response to UV-A; IDA:BHF-UCL. DR GO; GO:0007165; P:signal transduction; TAS:UniProtKB. DR GO; GO:0003376; P:sphingosine-1-phosphate receptor signaling pathway; IMP:BHF-UCL. DR GO; GO:0051146; P:striated muscle cell differentiation; IEA:Ensembl. DR GO; GO:0031295; P:T cell costimulation; TAS:Reactome. DR GO; GO:0031929; P:TOR signaling; NAS:ParkinsonsUK-UCL. DR GO; GO:0097700; P:vascular endothelial cell response to laminar fluid shear stress; TAS:Reactome. DR CDD; cd01241; PH_PKB; 1. DR CDD; cd05594; STKc_PKB_alpha; 1. DR DisProt; DP03300; -. DR FunFam; 1.10.510.10:FF:000033; Non-specific serine/threonine protein kinase; 1. DR FunFam; 2.30.29.30:FF:000027; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:000838; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00412; -. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR034676; Akt1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR001849; PH_domain. DR InterPro; IPR039026; PH_PKB. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00169; PH; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR SMART; SM00233; PH; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50003; PH_DOMAIN; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding; KW Carbohydrate metabolism; Cell membrane; Cytoplasm; Developmental protein; KW Disease variant; Disulfide bond; Glucose metabolism; Glycogen biosynthesis; KW Glycogen metabolism; Glycoprotein; Isopeptide bond; Kinase; Membrane; KW Mitochondrion; Neurogenesis; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Sugar transport; Transferase; KW Translation regulation; Transport; Ubl conjugation. FT CHAIN 1..480 FT /note="RAC-alpha serine/threonine-protein kinase" FT /id="PRO_0000085605" FT DOMAIN 5..108 FT /note="PH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00145" FT DOMAIN 150..408 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 409..480 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 113..138 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 450..480 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 274 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 14..19 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 23..25 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 53 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 86 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 156..164 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 179 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 462 FT /note="Cleavage; by caspase-3" FT /evidence="ECO:0000250|UniProtKB:P31750" FT MOD_RES 14 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:21775285" FT MOD_RES 20 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:21775285" FT MOD_RES 124 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 126 FT /note="Phosphoserine; alternate" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 129 FT /note="Phosphoserine; alternate" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 176 FT /note="Phosphotyrosine; by TNK2" FT /evidence="ECO:0000269|PubMed:20333297" FT MOD_RES 308 FT /note="Phosphothreonine; by IKKE, PDPK1 and TBK1" FT /evidence="ECO:0000269|PubMed:15718470, FT ECO:0000269|PubMed:18456494, ECO:0000269|PubMed:20333297, FT ECO:0000269|PubMed:20481595, ECO:0000269|PubMed:21464307, FT ECO:0000269|PubMed:40285646, ECO:0000269|PubMed:8978681, FT ECO:0000269|PubMed:9512493" FT MOD_RES 448 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 450 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 473 FT /note="Phosphoserine; by IKKE, MTOR, PRKDC and TBK1; FT alternate" FT /evidence="ECO:0000269|PubMed:14761976, FT ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15262962, FT ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983, FT ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:20333297, FT ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307, FT ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:40285646, FT ECO:0000269|PubMed:8978681, ECO:0000269|PubMed:9736715" FT MOD_RES 474 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:12149249" FT MOD_RES 477 FT /note="Phosphoserine; by CDK2 and MTOR" FT /evidence="ECO:0000269|PubMed:24670654" FT MOD_RES 479 FT /note="Phosphothreonine; by CDK2 and MTOR" FT /evidence="ECO:0000269|PubMed:24670654" FT CARBOHYD 126 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 129 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 305 FT /note="O-linked (GlcNAc) threonine" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 312 FT /note="O-linked (GlcNAc) threonine" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 473 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000250|UniProtKB:P31750" FT DISULFID 60..77 FT /evidence="ECO:0000269|PubMed:20886116" FT DISULFID 296..310 FT /evidence="ECO:0000250|UniProtKB:P31751" FT CROSSLNK 284 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:22410793" FT VAR_SEQ 1..62 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_056180" FT VARIANT 17 FT /note="E -> K (in PROTEUSS and breast cancer; also detected FT in colorectal and ovarian cancer; somatic mutation; results FT in increased phosphorylation at T-308 and higher basal FT ubiquitination; the mutant protein is more efficiently FT recruited to the plasma membrane; alters FT phosphatidylinositiol phosphates lipid specificity of the FT AKT1 PH domain; dbSNP:rs121434592)" FT /evidence="ECO:0000269|PubMed:17611497, FT ECO:0000269|PubMed:18954143, ECO:0000269|PubMed:19713527, FT ECO:0000269|PubMed:21793738" FT /id="VAR_055422" FT VARIANT 25 FT /note="R -> C (in CWS6; impairs interaction with FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2; dbSNP:rs397514644)" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:23246288" FT /id="VAR_069791" FT VARIANT 167 FT /note="V -> A (in dbSNP:rs11555433)" FT /id="VAR_051617" FT VARIANT 435 FT /note="T -> P (in CWS6; dbSNP:rs397514645)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069792" FT MUTAGEN 8 FT /note="K->R: Substantial reduction of ubiquitination, FT phosphorylation at T-308 and S-473, AKT activation as well FT as IGF1-induced membrane recruitment. Decrease in FT ubiquitination and phosphorylation at T-308 as well as FT impaired association with the membrane; when associated FT with K-17." FT /evidence="ECO:0000269|PubMed:19713527" FT MUTAGEN 14 FT /note="K->A: Impairs interaction with PtdIns(3,4,5)P3 and FT PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285" FT MUTAGEN 14 FT /note="K->Q: Substantial reduction of phosphorylation at T- FT 308 and S-473, loss of AKT activation, and loss of binding FT to PIP3 as well as IGF1-induced membrane recruitment." FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285" FT MUTAGEN 14 FT /note="K->R: Substantial reduction of ubiquitination, FT phosphorylation at T-308 and S-473, AKT activation, loss of FT binding to PIP3 as well as IGF1-induced membrane FT recruitment." FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285" FT MUTAGEN 17 FT /note="E->K: Loss of membrane localization; when associated FT with Q-20." FT /evidence="ECO:0000269|PubMed:21775285" FT MUTAGEN 20 FT /note="K->Q: Substantial reduction of phosphorylation at T- FT 308 and S-473, reduced AKT activation, and reduced binding FT to PIP3 as well as IGF1-induced membrane recruitment. Loss FT of membrane localization; when associated with K-17." FT /evidence="ECO:0000269|PubMed:21775285" FT MUTAGEN 20 FT /note="K->R: Slight increase of phosphorylation at T-308 FT and S-473." FT /evidence="ECO:0000269|PubMed:21775285" FT MUTAGEN 25 FT /note="R->A: Impairs interaction with PtdIns(3,4,5)P3 and FT PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:12176338" FT MUTAGEN 76..78 FT /note="RCL->ACA: Abolished binding to cyclin-A, preventing FT phosphorylation by CDK2." FT /evidence="ECO:0000269|PubMed:24670654" FT MUTAGEN 86 FT /note="R->A: Impairs interaction with PtdIns(3,4,5)P3 and FT PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:12176338" FT MUTAGEN 176 FT /note="Y->F: Significant loss of interaction with TNK2. FT Loss of membrane localization. Significant reduction in FT phosphorylation on Ser-473." FT /evidence="ECO:0000269|PubMed:20333297" FT MUTAGEN 179 FT /note="K->M: Abolished serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:12172553, FT ECO:0000269|PubMed:33594058" FT MUTAGEN 273..275 FT /note="RDL->ADA: Abolished binding to cyclin-A, preventing FT phosphorylation by CDK2." FT /evidence="ECO:0000269|PubMed:24670654" FT MUTAGEN 305 FT /note="T->A: Reduces O-GlcNAc levels; Reduces O-GlcNAc FT levels even more; when associated with A-312." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 305 FT /note="T->Y: Abolishes phosphorylation at Thr-308." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 308 FT /note="T->D: 5-fold activation and 18-fold activation; when FT associated with D-473." FT /evidence="ECO:0000269|PubMed:12244301, FT ECO:0000269|PubMed:8978681" FT MUTAGEN 312 FT /note="T->A: Reduces O-GlcNAc levels; Reduces O-GlcNAc FT levels even more; when associated with A-305." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 312 FT /note="T->Y: Abolishes phosphorylation at Thr-308." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 473 FT /note="S->D: 7-fold activation and 25-fold activation; when FT associated with D-308." FT /evidence="ECO:0000269|PubMed:12244301, FT ECO:0000269|PubMed:8978681" FT MUTAGEN 474 FT /note="Y->F: 55% inhibition of activation." FT /evidence="ECO:0000269|PubMed:12149249" FT CONFLICT 173..174 FT /note="GR -> A (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 202 FT /note="L -> Q (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 212 FT /note="A -> R (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 246 FT /note="S -> A (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 409 FT /note="A -> T (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 476 FT /note="A -> P (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 478 FT /note="G -> A (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 478 FT /note="G -> S (in Ref. 1; AAA36539, 2; AAL55732, 3; FT BAG36922 and 4; BAG70056/BAG70181)" FT /evidence="ECO:0000305" FT HELIX 2..4 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 6..15 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 17..19 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 22..30 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 33..40 FT /evidence="ECO:0007829|PDB:1UNQ" FT HELIX 42..44 FT /evidence="ECO:0007829|PDB:7APJ" FT HELIX 45..48 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 52..56 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 61..65 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 67..69 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 72..79 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 82..89 FT /evidence="ECO:0007829|PDB:1UNQ" FT HELIX 93..115 FT /evidence="ECO:0007829|PDB:1UNQ" FT HELIX 147..149 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 150..158 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 160..169 FT /evidence="ECO:0007829|PDB:4GV1" FT TURN 170..172 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 175..182 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 183..188 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 192..204 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 213..218 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 220..227 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 235..242 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 247..268 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 277..279 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 280..282 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 284..286 FT /evidence="ECO:0007829|PDB:4EJN" FT STRAND 288..290 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 309..311 FT /evidence="ECO:0007829|PDB:3MVH" FT HELIX 313..315 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 318..322 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 330..344 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 354..363 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 374..383 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 388..390 FT /evidence="ECO:0007829|PDB:4GV1" FT TURN 396..398 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 399..403 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 406..408 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 413..417 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 430..433 FT /evidence="ECO:0007829|PDB:3MVH" FT TURN 436..438 FT /evidence="ECO:0007829|PDB:7NH5" FT HELIX 440..443 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 464..466 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 473..475 FT /evidence="ECO:0007829|PDB:4GV1" SQ SEQUENCE 480 AA; 55686 MW; 6EAFF4F8AD436714 CRC64; MSDVAIVKEG WLHKRGEYIK TWRPRYFLLK NDGTFIGYKE RPQDVDQREA PLNNFSVAQC QLMKTERPRP NTFIIRCLQW TTVIERTFHV ETPEEREEWT TAIQTVADGL KKQEEEEMDF RSGSPSDNSG AEEMEVSLAK PKHRVTMNEF EYLKLLGKGT FGKVILVKEK ATGRYYAMKI LKKEVIVAKD EVAHTLTENR VLQNSRHPFL TALKYSFQTH DRLCFVMEYA NGGELFFHLS RERVFSEDRA RFYGAEIVSA LDYLHSEKNV VYRDLKLENL MLDKDGHIKI TDFGLCKEGI KDGATMKTFC GTPEYLAPEV LEDNDYGRAV DWWGLGVVMY EMMCGRLPFY NQDHEKLFEL ILMEEIRFPR TLGPEAKSLL SGLLKKDPKQ RLGGGSEDAK EIMQHRFFAG IVWQHVYEKK LSPPFKPQVT SETDTRYFDE EFTAQMITIT PPDQDDSMEC VDSERRPHFP QFSYSASGTA // ID ALEX_HUMAN Reviewed; 626 AA. AC P84996; A2A2S4; DT 17-OCT-2006, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 1. DT 28-JAN-2026, entry version 131. DE RecName: Full=Protein ALEX; DE AltName: Full=Alternative gene product encoded by XL-exon; GN Name=GNAS {ECO:0000312|HGNC:HGNC:4392}; GN Synonyms=GNAS1 {ECO:0000312|HGNC:HGNC:4392}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11780052; DOI=10.1038/414865a; RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M., RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D., RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M., RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L., RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 20."; RL Nature 414:865-871(2001). RN [2] {ECO:0000305} RP PUTATIVE FUNCTION, AND VARIANTS THR-374; RP GLN-PRO-ILE-PRO-THR-PRO-GLY-ARG-PRO-LEU-THR-PRO-375 INS AND VAL-397. RX PubMed=12719376; DOI=10.1093/hmg/ddg130; RA Freson K., Jaeken J., Van Helvoirt M., de Zegher F., Wittevrongel C., RA Thys C., Hoylaerts M.F., Vermylen J., Van Geet C.; RT "Functional polymorphisms in the paternally expressed XLalphas and its RT cofactor ALEX decrease their mutual interaction and enhance receptor- RT mediated cAMP formation."; RL Hum. Mol. Genet. 12:1121-1130(2003). RN [3] {ECO:0000305} RP IDENTIFICATION. RX PubMed=15148396; DOI=10.1073/pnas.0308758101; RA Abramowitz J., Grenet D., Birnbaumer M., Torres H.N., Birnbaumer L.; RT "XL alpha-s, the extra-long form of the alpha subunit of the Gs G protein, RT is significantly longer than suspected, and so is its companion Alex."; RL Proc. Natl. Acad. Sci. U.S.A. 101:8366-8371(2004). RN [4] RP INVOLVEMENT IN PHP1B. RX PubMed=11067869; DOI=10.1172/jci10431; RA Liu J., Litman D., Rosenberg M.J., Yu S., Biesecker L.G., Weinstein L.S.; RT "A GNAS1 imprinting defect in pseudohypoparathyroidism type IB."; RL J. Clin. Invest. 106:1167-1174(2000). RN [5] RP INVOLVEMENT IN PHP1B. RX PubMed=11294659; DOI=10.1086/320117; RA Bastepe M., Lane A.H., Jueppner H.; RT "Paternal uniparental isodisomy of chromosome 20q -- and the resulting RT changes in GNAS1 methylation -- as a plausible cause of RT pseudohypoparathyroidism."; RL Am. J. Hum. Genet. 68:1283-1289(2001). RN [6] RP INVOLVEMENT IN PHP1B. RX PubMed=11029463; DOI=10.1074/jbc.m006032200; RA Wu W.-I., Schwindinger W.F., Aparicio L.F., Levine M.A.; RT "Selective resistance to parathyroid hormone caused by a novel uncoupling RT mutation in the carboxyl terminus of G alpha(s). A cause of RT pseudohypoparathyroidism type Ib."; RL J. Biol. Chem. 276:165-171(2001). RN [7] RP INVOLVEMENT IN PHP1B. RX PubMed=12858292; DOI=10.1086/377136; RA Jan de Beur S., Ding C., Germain-Lee E., Cho J., Maret A., Levine M.A.; RT "Discordance between genetic and epigenetic defects in RT pseudohypoparathyroidism type 1b revealed by inconsistent loss of maternal RT imprinting at GNAS1."; RL Am. J. Hum. Genet. 73:314-322(2003). RN [8] RP INVOLVEMENT IN AIMAH1. RX PubMed=12727968; DOI=10.1210/jc.2002-021362; RA Fragoso M.C.B.V., Domenice S., Latronico A.C., Martin R.M., Pereira M.A.A., RA Zerbini M.C.N., Lucon A.M., Mendonca B.B.; RT "Cushing's syndrome secondary to adrenocorticotropin-independent RT macronodular adrenocortical hyperplasia due to activating mutations of RT GNAS1 gene."; RL J. Clin. Endocrinol. Metab. 88:2147-2151(2003). RN [9] RP INVOLVEMENT IN PHP1B. RX PubMed=14561710; DOI=10.1172/jci19159; RA Bastepe M., Froehlich L.F., Hendy G.N., Indridason O.S., Josse R.G., RA Koshiyama H., Koerkkoe J., Nakamoto J.M., Rosenbloom A.L., Slyper A.H., RA Sugimoto T., Tsatsoulis A., Crawford J.D., Jueppner H.; RT "Autosomal dominant pseudohypoparathyroidism type Ib is associated with a RT heterozygous microdeletion that likely disrupts a putative imprinting RT control element of GNAS."; RL J. Clin. Invest. 112:1255-1263(2003). RN [10] RP INVOLVEMENT IN PHP1B. RX PubMed=15800843; DOI=10.1086/429932; RA Linglart A., Gensure R.C., Olney R.C., Jueppner H., Bastepe M.; RT "A novel STX16 deletion in autosomal dominant pseudohypoparathyroidism type RT Ib redefines the boundaries of a cis-acting imprinting control element of RT GNAS."; RL Am. J. Hum. Genet. 76:804-814(2005). RN [11] RP INVOLVEMENT IN PHP1B. RX PubMed=15592469; DOI=10.1038/ng1487; RA Bastepe M., Froehlich L.F., Linglart A., Abu-Zahra H.S., Tojo K., RA Ward L.M., Jueppner H.; RT "Deletion of the NESP55 differentially methylated region causes loss of RT maternal GNAS imprints and pseudohypoparathyroidism type Ib."; RL Nat. Genet. 37:25-27(2005). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-201 AND HIS-201. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). CC -!- FUNCTION: May inhibit the adenylyl cyclase-stimulating activity of CC guanine nucleotide-binding protein G(s) subunit alpha which is produced CC from the same locus in a different open reading frame. CC {ECO:0000269|PubMed:12719376}. CC -!- SUBUNIT: Interacts with the N-terminal region of the XLas isoforms of CC guanine nucleotide-binding protein G(s) subunit alpha. {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: Cell membrane; Peripheral membrane protein. Cell CC projection, ruffle {ECO:0000250}. Note=Predominantly associated with CC cell membrane ruffles. {ECO:0000250}. CC -!- DISEASE: Note=Genetic variation affecting the GNAS locus is associated CC with GNAS hyperfunction, a condition characterized by increased trauma- CC related bleeding tendency, prolonged bleeding time, brachydactyly and CC intellectual disability. Both the XLas isoforms and the ALEX protein CC are mutated which strongly reduces the interaction between them and CC this may allow unimpeded activation of the XLas isoforms. CC {ECO:0000269|PubMed:12719376}. CC -!- DISEASE: ACTH-independent macronodular adrenal hyperplasia 1 (AIMAH1) CC [MIM:219080]: A rare adrenal defect characterized by multiple, CC bilateral, non-pigmented, benign, adrenocortical nodules. It results in CC excessive production of cortisol leading to ACTH-independent Cushing CC syndrome. Clinical manifestations of Cushing syndrome include facial CC and truncal obesity, abdominal striae, muscular weakness, osteoporosis, CC arterial hypertension, diabetes. {ECO:0000269|PubMed:12727968}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Pseudohypoparathyroidism 1B (PHP1B) [MIM:603233]: A disorder CC characterized by end-organ resistance to parathyroid hormone, CC hypocalcemia and hyperphosphatemia. Patients affected with PHP1B lack CC developmental defects characteristic of Albright hereditary CC osteodystrophy, and typically show no other endocrine abnormalities CC besides resistance to PTH. {ECO:0000269|PubMed:11029463, CC ECO:0000269|PubMed:11067869, ECO:0000269|PubMed:11294659, CC ECO:0000269|PubMed:12858292, ECO:0000269|PubMed:14561710, CC ECO:0000269|PubMed:15592469, ECO:0000269|PubMed:15800843}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. Most affected individuals have defects in methylation of the CC gene. In some cases microdeletions involving the STX16 appear to cause CC loss of methylation at exon A/B of GNAS, resulting in PHP1B. Paternal CC uniparental isodisomy have also been observed. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. Note=The disease may be caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: This protein is produced by a bicistronic gene which CC also produces guanine nucleotide-binding protein G(s) subunit alpha CC from an overlapping reading frame. {ECO:0000269|PubMed:15148396}. CC -!- SIMILARITY: Belongs to the ALEX family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AL132655; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR RefSeq; NP_001070958.1; NM_001077490.3. DR RefSeq; NP_001296812.1; NM_001309883.1. DR AlphaFoldDB; P84996; -. DR BioGRID; 109040; 280. DR IntAct; P84996; 9. DR MINT; P84996; -. DR iPTMnet; P84996; -. DR SwissPalm; P84996; -. DR BioMuta; GNAS; -. DR DMDM; 116242967; -. DR MassIVE; P84996; -. DR ProteomicsDB; 57761; -. DR Antibodypedia; 4152; 801 antibodies from 43 providers. DR DNASU; 2778; -. DR GeneID; 2778; -. DR UCSC; uc061ybz.1; human. DR AGR; HGNC:4392; -. DR CIViC; 2778; 15 evidence items across 8 molecular profiles. DR ClinPGx; PA175; -. DR CTD; 2778; -. DR DisGeNET; 2778; -. DR GeneCards; GNAS; -. DR GeneReviews; GNAS; -. DR HGNC; HGNC:4392; GNAS. DR MalaCards; GNAS; -. DR MIM; 114500; phenotype. DR MIM; 139320; gene. DR MIM; 219080; phenotype. DR MIM; 603233; phenotype. DR VEuPathDB; HostDB:ENSG00000087460; -. DR HOGENOM; CLU_437395_0_0_1; -. DR OrthoDB; 9836061at2759; -. DR PathwayCommons; P84996; -. DR SignaLink; P84996; -. DR BioGRID-ORCS; 2778; 33 hits in 1176 CRISPR screens. DR ChiTaRS; GNAS; human. DR GenomeRNAi; 2778; -. DR Pharos; P84996; Tbio. DR Proteomes; UP000005640; Chromosome 20. DR Bgee; ENSG00000087460; Expressed in type B pancreatic cell and 215 other cell types or tissues. DR ExpressionAtlas; P84996; baseline and differential. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell. DR GO; GO:0001726; C:ruffle; IEA:UniProtKB-SubCell. DR GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0060348; P:bone development; IMP:UniProtKB. DR GO; GO:0050890; P:cognition; IMP:UniProtKB. DR GO; GO:0048589; P:developmental growth; IMP:UniProtKB. DR GO; GO:0060789; P:hair follicle placode formation; IMP:UniProtKB. DR GO; GO:0070527; P:platelet aggregation; IMP:UniProtKB. DR GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab. DR GO; GO:0009966; P:regulation of signal transduction; IMP:CACAO. PE 1: Evidence at protein level; KW Cell membrane; Cell projection; Cushing syndrome; Disease variant; KW Membrane; Proteomics identification; Reference proteome. FT CHAIN 1..626 FT /note="Protein ALEX" FT /id="PRO_0000253964" FT REGION 1..29 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 173..223 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 236..473 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 556..612 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 186..195 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 255..270 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 281..312 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 337..346 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 366..399 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 416..435 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 436..445 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 570..579 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 600..611 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VARIANT 201 FT /note="R -> C (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035788" FT VARIANT 201 FT /note="R -> H (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035789" FT VARIANT 374 FT /note="P -> T (found in GNAS hyperfunction; FT dbSNP:rs1376506169)" FT /evidence="ECO:0000269|PubMed:12719376" FT /id="VAR_028774" FT VARIANT 375 FT /note="P -> PQPIPTPGRPLTP (found in GNAS hyperfunction)" FT /id="VAR_028775" FT VARIANT 397 FT /note="L -> V (found in GNAS hyperfunction)" FT /evidence="ECO:0000269|PubMed:12719376" FT /id="VAR_028776" SQ SEQUENCE 626 AA; 67948 MW; F4CEFA7FA5917EEC CRC64; MMARPVDPQR SPDPTFRSST RHSGKLEPME ATAHLLRKQC PSRLNSPAWE ASGLHWSSLD SPVGSMQALR PSAQHSWSPE PSVVPDQAWE DTALHQKKLC PLSLTSLPRE AAVNFSYRSQ TLLQEAQVLQ GSPELLPRSP KPSGLQRLAP EEATALPLRR LCHLSLMEKD LGTTAHPRGF PELSHKSTAA ASSRQSRPRV RSASLPPRTR LPSGSQAPSA AHPKRLSDLL LTSRAAAPGW RSPDPRSRLA APPLGSTTLP STWTAPQSRL TARPSRSPEP QIRESEQRDP QLRRKQQRWK EPLMPRREEK YPLRGTDPLP PGQPQRIPLP GQPLQPQPIL TPGQPQKIPT PGQHQPILTP GHSQPIPTPG QPLPPQPIPT PGRPLTPQPI PTPGRPLTPQ PIQMPGRPLR LPPPLRLLRP GQPMSPQLRQ TQGLPLPQPL LPPGQPKSAG RPLQPLPPGP DARSISDPPA PRSRLPIRLL RGLLARLPGG ASPRAAAAAA CTTMKGWPAA TMTPAETSPT MGPPDASAGF SIGEIAAAES PSATYSATFS CKPSGAASVD LRVPSPKPRA LSRSRRYPWR RSADRCAKKP WRSGPRSAQR RNAVSSSTNN SRTKRWATCV RTACCF // ID AMGO2_HUMAN Reviewed; 522 AA. AC Q86SJ2; Q4VBP6; Q7Z4A0; Q96CN8; DT 21-JUN-2005, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-2003, sequence version 1. DT 28-JAN-2026, entry version 187. DE RecName: Full=Amphoterin-induced protein 2; DE AltName: Full=AMIGO-2; DE AltName: Full=Alivin-1; DE AltName: Full=Differentially expressed in gastric adenocarcinomas; DE Short=DEGA; DE Flags: Precursor; GN Name=AMIGO2 {ECO:0000312|EMBL:AAH47595.1}; GN Synonyms=ALI1 {ECO:0000312|EMBL:BAC81189.1}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000312|EMBL:AAO48946.1} RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Fibrosarcoma {ECO:0000269|PubMed:12629050}; RX PubMed=12629050; DOI=10.1083/jcb.200209074; RA Kuja-Panula J., Kiiltomaeki M., Yamashiro T., Rouhiainen A., Rauvala H.; RT "AMIGO, a transmembrane protein implicated in axon tract development, RT defines a novel protein family with leucine-rich repeats."; RL J. Cell Biol. 160:963-973(2003). RN [2] {ECO:0000312|EMBL:BAC81189.1} RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Brain {ECO:0000312|EMBL:BAC81189.1}; RX PubMed=12843293; DOI=10.1523/jneurosci.23-13-05887.2003; RA Ono T., Sekino-Suzuki N., Kikkawa Y., Yonekawa H., Kawashima S.; RT "Alivin 1, a novel neuronal activity-dependent gene, inhibits apoptosis and RT promotes survival of cerebellar granule neurons."; RL J. Neurosci. 23:5887-5896(2003). RN [3] {ECO:0000305, ECO:0000312|EMBL:AAR83271.1} RP NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY. RX PubMed=15107827; DOI=10.1038/sj.onc.1207681; RA Rabenau K.E., O'Toole J.M., Bassi R., Kotanides H., Witte L., Ludwig D.L., RA Pereira D.S.; RT "DEGA/AMIGO-2, a leucine-rich repeat family member, differentially RT expressed in human gastric adenocarcinoma: effects on ploidy, chromosomal RT stability, cell adhesion/migration and tumorigenicity."; RL Oncogene 23:5056-5067(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Stomach; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [5] {ECO:0000312|EMBL:AAH47595.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Testis {ECO:0000312|EMBL:AAH47595.1}, and RC Uterus {ECO:0000312|EMBL:AAH14103.2}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). CC -!- FUNCTION: Required for depolarization-dependent survival of cultured CC cerebellar granule neurons. May mediate homophilic as well as CC heterophilic cell-cell interaction with AMIGO1 or AMIGO3. May CC contribute to signal transduction through its intracellular domain. May CC be required for tumorigenesis of a subset of gastric adenocarcinomas. CC -!- SUBUNIT: Binds itself as well as AMIGO1 and AMIGO3. {ECO:0000250}. CC -!- INTERACTION: CC Q86SJ2; O00555: CACNA1A; NbExp=2; IntAct=EBI-3866830, EBI-766279; CC Q86SJ2; Q6PL24: TMED8; NbExp=3; IntAct=EBI-3866830, EBI-11603430; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Single-pass type I CC membrane protein {ECO:0000250}. Nucleus {ECO:0000250}. Note=Associated CC with nucleus as well as plasma membrane. Restricted to somata of CC cerebellar as well as hippocampal neurons (By similarity). CC {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Highest levels in breast, ovary, cervix, and CC uterus. Lower levels in lung, colon, and rectum. Differentially CC expressed in 56% of thyroid, 57% of pancreatic and 45% of stomach CC cancers. {ECO:0000269|PubMed:15107827}. CC -!- SIMILARITY: Belongs to the immunoglobulin superfamily. AMIGO family. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY237005; AAO48946.1; -; mRNA. DR EMBL; AB079074; BAC81188.1; -; mRNA. DR EMBL; AB080610; BAC81189.1; -; mRNA. DR EMBL; AY454159; AAR83271.1; -; mRNA. DR EMBL; AL833007; CAH56293.1; -; mRNA. DR EMBL; BC014103; AAH14103.2; -; mRNA. DR EMBL; BC047595; AAH47595.1; -; mRNA. DR EMBL; BC095477; AAH95477.1; -; mRNA. DR CCDS; CCDS8751.1; -. DR RefSeq; NP_001137140.1; NM_001143668.1. DR RefSeq; NP_001357228.1; NM_001370299.1. DR RefSeq; NP_862830.1; NM_181847.4. DR RefSeq; XP_047284741.1; XM_047428785.1. DR AlphaFoldDB; Q86SJ2; -. DR SMR; Q86SJ2; -. DR BioGRID; 131497; 48. DR FunCoup; Q86SJ2; 22. DR IntAct; Q86SJ2; 9. DR STRING; 9606.ENSP00000266581; -. DR GlyConnect; 1007; 4 N-Linked glycans (1 site). DR GlyCosmos; Q86SJ2; 8 sites, 4 glycans. DR GlyGen; Q86SJ2; 10 sites, 6 N-linked glycans (3 sites). DR iPTMnet; Q86SJ2; -. DR PhosphoSitePlus; Q86SJ2; -. DR SwissPalm; Q86SJ2; -. DR BioMuta; AMIGO2; -. DR DMDM; 68052338; -. DR jPOST; Q86SJ2; -. DR MassIVE; Q86SJ2; -. DR PaxDb; 9606-ENSP00000266581; -. DR PeptideAtlas; Q86SJ2; -. DR ProteomicsDB; 69596; -. DR Pumba; Q86SJ2; -. DR Antibodypedia; 13397; 235 antibodies from 31 providers. DR DNASU; 347902; -. DR Ensembl; ENST00000266581.4; ENSP00000266581.4; ENSG00000139211.8. DR Ensembl; ENST00000429635.1; ENSP00000406020.1; ENSG00000139211.8. DR Ensembl; ENST00000550413.2; ENSP00000449034.1; ENSG00000139211.8. DR GeneID; 347902; -. DR KEGG; hsa:347902; -. DR MANE-Select; ENST00000550413.2; ENSP00000449034.1; NM_001370299.1; NP_001357228.1. DR UCSC; uc001rpk.4; human. DR AGR; HGNC:24073; -. DR ClinPGx; PA142672626; -. DR CTD; 347902; -. DR DisGeNET; 347902; -. DR GeneCards; AMIGO2; -. DR HGNC; HGNC:24073; AMIGO2. DR HPA; ENSG00000139211; Low tissue specificity. DR MIM; 615690; gene. DR OpenTargets; ENSG00000139211; -. DR VEuPathDB; HostDB:ENSG00000139211; -. DR eggNOG; ENOG502R009; Eukaryota. DR GeneTree; ENSGT00950000183146; -. DR HOGENOM; CLU_030478_0_0_1; -. DR InParanoid; Q86SJ2; -. DR OMA; DFVWVGP; -. DR OrthoDB; 676979at2759; -. DR PAN-GO; Q86SJ2; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q86SJ2; -. DR PathwayCommons; Q86SJ2; -. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR Reactome; R-HSA-9013423; RAC3 GTPase cycle. DR SignaLink; Q86SJ2; -. DR Agora; ENSG00000139211; -. DR BioGRID-ORCS; 347902; 22 hits in 1166 CRISPR screens. DR GenomeRNAi; 347902; -. DR Pharos; Q86SJ2; Tbio. DR PRO; PR:Q86SJ2; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q86SJ2; protein. DR Bgee; ENSG00000139211; Expressed in blood vessel layer and 190 other cell types or tissues. DR ExpressionAtlas; Q86SJ2; baseline and differential. DR GO; GO:0016020; C:membrane; IBA:GO_Central. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell. DR GO; GO:0007420; P:brain development; IBA:GO_Central. DR GO; GO:0007157; P:heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules; ISS:UniProtKB. DR GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; ISS:UniProtKB. DR GO; GO:0043069; P:negative regulation of programmed cell death; ISS:UniProtKB. DR GO; GO:0051965; P:positive regulation of synapse assembly; IBA:GO_Central. DR FunFam; 2.60.40.10:FF:001047; amphoterin-induced protein 2 isoform X1; 1. DR FunFam; 3.80.10.10:FF:000170; amphoterin-induced protein 2 isoform X1; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 1. DR Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1. DR InterPro; IPR031283; AMIGO. DR InterPro; IPR000483; Cys-rich_flank_reg_C. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR001611; Leu-rich_rpt. DR InterPro; IPR003591; Leu-rich_rpt_typical-subtyp. DR InterPro; IPR032675; LRR_dom_sf. DR PANTHER; PTHR24368; AMPHOTERIN-INDUCED PROTEIN; 1. DR PANTHER; PTHR24368:SF209; AMPHOTERIN-INDUCED PROTEIN 2; 1. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF13855; LRR_8; 1. DR SMART; SM00409; IG; 1. DR SMART; SM00369; LRR_TYP; 5. DR SMART; SM00082; LRRCT; 1. DR SUPFAM; SSF48726; Immunoglobulin; 1. DR SUPFAM; SSF52058; L domain-like; 1. DR PROSITE; PS50835; IG_LIKE; 1. DR PROSITE; PS51450; LRR; 7. PE 1: Evidence at protein level; KW Cell adhesion; Cell membrane; Disulfide bond; Glycoprotein; KW Immunoglobulin domain; Leucine-rich repeat; Membrane; Nucleus; KW Proteomics identification; Reference proteome; Repeat; Signal; KW Transmembrane; Transmembrane helix. FT SIGNAL 1..39 FT /evidence="ECO:0000255" FT CHAIN 40..522 FT /note="Amphoterin-induced protein 2" FT /evidence="ECO:0000255" FT /id="PRO_0000014509" FT TOPO_DOM 40..398 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 399..419 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 420..522 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 40..68 FT /note="LRRNT" FT REPEAT 69..90 FT /note="LRR 1" FT REPEAT 94..115 FT /note="LRR 2" FT REPEAT 118..139 FT /note="LRR 3" FT REPEAT 142..163 FT /note="LRR 4" FT REPEAT 166..187 FT /note="LRR 5" FT REPEAT 193..214 FT /note="LRR 6" FT DOMAIN 228..284 FT /note="LRRCT" FT DOMAIN 289..379 FT /note="Ig-like C2-type" FT /evidence="ECO:0000255" FT REGION 501..522 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT CARBOHYD 58 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 104 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 281 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 288 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 345 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 373 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 381 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 384 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 41..47 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 45..54 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 232..260 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 234..282 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 310..363 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" SQ SEQUENCE 522 AA; 57934 MW; 20A86E3D82C05B9B CRC64; MSLRVHTLPT LLGAVVRPGC RELLCLLMIT VTVGPGASGV CPTACICATD IVSCTNKNLS KVPGNLFRLI KRLDLSYNRI GLLDSEWIPV SFAKLNTLIL RHNNITSIST GSFSTTPNLK CLDLSSNKLK TVKNAVFQEL KVLEVLLLYN NHISYLDPSA FGGLSQLQKL YLSGNFLTQF PMDLYVGRFK LAELMFLDVS YNRIPSMPMH HINLVPGKQL RGIYLHGNPF VCDCSLYSLL VFWYRRHFSS VMDFKNDYTC RLWSDSRHSR QVLLLQDSFM NCSDSIINGS FRALGFIHEA QVGERLMVHC DSKTGNANTD FIWVGPDNRL LEPDKEMENF YVFHNGSLVI ESPRFEDAGV YSCIAMNKQR LLNETVDVTI NVSNFTVSRS HAHEAFNTAF TTLAACVASI VLVLLYLYLT PCPCKCKTKR QKNMLHQSNA HSSILSPGPA SDASADERKA GAGKRVVFLE PLKDTAAGQN GKVRLFPSEA VIAEGILKST RGKSDSDSVN SVFSDTPFVA ST // ID ERBB4_HUMAN Reviewed; 1308 AA. AC Q15303; B7ZLD7; B7ZLE2; B7ZLE3; Q2M1W1; Q59EW4; DT 15-DEC-1998, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 251. DE RecName: Full=Receptor tyrosine-protein kinase erbB-4; DE EC=2.7.10.1; DE AltName: Full=Proto-oncogene-like protein c-ErbB-4; DE AltName: Full=Tyrosine kinase-type cell surface receptor HER4; DE AltName: Full=p180erbB4; DE Contains: DE RecName: Full=ERBB4 intracellular domain; DE Short=4ICD; DE Short=E4ICD; DE AltName: Full=s80HER4; DE Flags: Precursor; GN Name=ERBB4; Synonyms=HER4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM JM-A CYT-1), FUNCTION AS CELL SURFACE RP RECEPTOR, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RC TISSUE=Mammary carcinoma; RX PubMed=8383326; DOI=10.1073/pnas.90.5.1746; RA Plowman G.D., Culouscou J.-M., Whitney G.S., Green J.M., Carlton G.W., RA Foy L., Neubauer M.G., Shoyab M.; RT "Ligand-specific activation of HER4/p180erbB4, a fourth member of the RT epidermal growth factor receptor family."; RL Proc. Natl. Acad. Sci. U.S.A. 90:1746-1750(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS JM-A CYT-1 AND JM-B CYT-1), TISSUE RP SPECIFICITY, FUNCTION AS CELL SURFACE RECEPTOR FOR NRG1 AND BTC, RP SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND PROTEOLYTIC PROCESSING. RC TISSUE=Fetal brain; RX PubMed=9334263; DOI=10.1074/jbc.272.42.26761; RA Elenius K., Corfas G., Paul S., Choi C.J., Rio C., Plowman G.D., RA Klagsbrun M.; RT "A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific RT tissue distribution and differential processing in response to phorbol RT ester."; RL J. Biol. Chem. 272:26761-26768(1997). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS JM-A CYT-1; JM-B CYT-1; RP JM-A CYT-2 AND JM-B CYT-2). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 401-1308 (ISOFORM JM-A CYT-2). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP INTERACTION WITH NRG1, AND AUTOPHOSPHORYLATION. RX PubMed=7689552; DOI=10.1016/s0021-9258(17)46636-1; RA Culouscou J.-M., Plowman G.D., Carlton G.W., Green J.M., Shoyab M.; RT "Characterization of a breast cancer cell differentiation factor that RT specifically activates the HER4/p180erbB4 receptor."; RL J. Biol. Chem. 268:18407-18410(1993). RN [6] RP INTERACTION WITH NRG1, AND AUTOPHOSPHORYLATION. RX PubMed=7902537; DOI=10.1038/366473a0; RA Plowman G.D., Green J.M., Culouscou J.M., Carlton G.W., Rothwell V.M., RA Buckley S.; RT "Heregulin induces tyrosine phosphorylation of HER4/p180erbB4."; RL Nature 366:473-475(1993). RN [7] RP FUNCTION AS NRG1 RECEPTOR IN REGULATION OF CELL PROLIFERATION, CATALYTIC RP ACTIVITY, ACTIVITY REGULATION, AUTOPHOSPHORYLATION, PHOSPHORYLATION AT RP TYR-1056; TYR-1188 AND TYR-1242, AND INTERACTION WITH EGFR; SHC1 AND RP PIK3R1. RX PubMed=8617750; DOI=10.1074/jbc.271.9.4813; RA Cohen B.D., Green J.M., Foy L., Fell H.P.; RT "HER4-mediated biological and biochemical properties in NIH 3T3 cells. RT Evidence for HER1-HER4 heterodimers."; RL J. Biol. Chem. 271:4813-4818(1996). RN [8] RP INTERACTION WITH BTC, AND AUTOPHOSPHORYLATION. RX PubMed=8570211; RA Riese D.J. II, Bermingham Y., van Raaij T.M., Buckley S., Plowman G.D., RA Stern D.F.; RT "Betacellulin activates the epidermal growth factor receptor and erbB-4, RT and induces cellular response patterns distinct from those stimulated by RT epidermal growth factor or neuregulin-beta."; RL Oncogene 12:345-353(1996). RN [9] RP FUNCTION AS HBEGF RECEPTOR; IN CELL MIGRATION; CELL PROLIFERATION AND IN RP ACTIVATION OF PIK3R1, INTERACTION WITH HBEGF AND PIK3R1, AND RP AUTOPHOSPHORYLATION. RX PubMed=9135143; DOI=10.1093/emboj/16.6.1268; RA Elenius K., Paul S., Allison G., Sun J., Klagsbrun M.; RT "Activation of HER4 by heparin-binding EGF-like growth factor stimulates RT chemotaxis but not proliferation."; RL EMBO J. 16:1268-1278(1997). RN [10] RP INTERACTION WITH NRG2, FUNCTION AS NRG2 RECEPTOR, AND PHOSPHORYLATION. RX PubMed=9168115; DOI=10.1038/387512a0; RA Carraway K.L. III, Weber J.L., Unger M.J., Ledesma J., Yu N., Gassmann M., RA Lai C.; RT "Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases."; RL Nature 387:512-516(1997). RN [11] RP INTERACTION WITH EREG, AND AUTOPHOSPHORYLATION. RX PubMed=9419975; DOI=10.1038/sj.onc.1201458; RA Komurasaki T., Toyoda H., Uchida D., Morimoto S.; RT "Epiregulin binds to epidermal growth factor receptor and ErbB-4 and RT induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB- RT 2, ErbB-3 and ErbB-4."; RL Oncogene 15:2841-2848(1997). RN [12] RP INTERACTION WITH NRG3, AND AUTOPHOSPHORYLATION. RX PubMed=9275162; DOI=10.1073/pnas.94.18.9562; RA Zhang D., Sliwkowski M.X., Mark M., Frantz G., Akita R., Sun Y., Hillan K., RA Crowley C., Brush J., Godowski P.J.; RT "Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and RT activates ErbB4."; RL Proc. Natl. Acad. Sci. U.S.A. 94:9562-9567(1997). RN [13] RP INTERACTION WITH GRB7. RX PubMed=9516479; DOI=10.1074/jbc.273.13.7717; RA Fiddes R.J., Campbell D.H., Janes P.W., Sivertsen S.P., Sasaki H., RA Wallasch C., Daly R.J.; RT "Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals RT a novel target selectivity for erbB3."; RL J. Biol. Chem. 273:7717-7724(1998). RN [14] RP INTERACTION WITH ERBB2, AND FUNCTION IN ACTIVATION OF STAT5A. RX PubMed=10358079; DOI=10.1074/jbc.274.24.17209; RA Olayioye M.A., Beuvink I., Horsch K., Daly J.M., Hynes N.E.; RT "ErbB receptor-induced activation of stat transcription factors is mediated RT by Src tyrosine kinases."; RL J. Biol. Chem. 274:17209-17218(1999). RN [15] RP ALTERNATIVE SPLICING, FUNCTION IN PHOSPHORYLATION AND ACTIVATION OF PIK3R1, RP INTERACTION WITH NRG1 AND PIKR3R1, AUTOPHOSPHORYLATION, AND TISSUE RP SPECIFICITY. RX PubMed=10353604; DOI=10.1038/sj.onc.1202612; RA Elenius K., Choi C.J., Paul S., Santiestevan E., Nishi E., Klagsbrun M.; RT "Characterization of a naturally occurring ErbB4 isoform that does not bind RT or activate phosphatidyl inositol 3-kinase."; RL Oncogene 18:2607-2615(1999). RN [16] RP FUNCTION AS NRG4 RECEPTOR IN ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1 AND IN RP CELL PROLIFERATION, INTERACTION WITH NRG4, AND SUBCELLULAR LOCATION. RX PubMed=10348342; DOI=10.1038/sj.onc.1202631; RA Harari D., Tzahar E., Romano J., Shelly M., Pierce J.H., Andrews G.C., RA Yarden Y.; RT "Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor RT tyrosine kinase."; RL Oncogene 18:2681-2689(1999). RN [17] RP FUNCTION AS NRG1 RECEPTOR IN CELL PROLIFERATION; MIGRATION; SURVIVAL AND IN RP PHOSPHORYLATION OF SHC1; ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1, AND RP ALTERNATIVE SPLICING. RX PubMed=10722704; DOI=10.1074/jbc.275.12.8641; RA Kainulainen V., Sundvall M., Maatta J.A., Santiestevan E., Klagsbrun M., RA Elenius K.; RT "A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase RT mediates proliferation but not survival or chemotaxis."; RL J. Biol. Chem. 275:8641-8649(2000). RN [18] RP PROTEOLYTIC PROCESSING. RX PubMed=10744726; DOI=10.1074/jbc.275.14.10379; RA Rio C., Buxbaum J.D., Peschon J.J., Corfas G.; RT "Tumor necrosis factor-alpha-converting enzyme is required for cleavage of RT erbB4/HER4."; RL J. Biol. Chem. 275:10379-10387(2000). RN [19] RP FUNCTION IN ACTIVATION OF AKT1; MAPK1/ERK2 AND MAPK3/ERK1, INTERACTION WITH RP PIK3R1; GRB2; SHC1; BTC; NRG1; NRG2 AND NRG3, AND LIGAND-SPECIFIC RP AUTOPHOSPHORYLATION. RX PubMed=10867024; DOI=10.1074/jbc.c901015199; RA Sweeney C., Lai C., Riese D.J. II, Diamonti A.J., Cantley L.C., RA Carraway K.L. III; RT "Ligand discrimination in signaling through an ErbB4 receptor homodimer."; RL J. Biol. Chem. 275:19803-19807(2000). RN [20] RP INTERACTION WITH DLG2; DLG3; DLG4 AND SNTB2. RX PubMed=10725395; DOI=10.1073/pnas.97.7.3596; RA Garcia R.A., Vasudevan K., Buonanno A.; RT "The neuregulin receptor ErbB-4 interacts with PDZ-containing proteins at RT neuronal synapses."; RL Proc. Natl. Acad. Sci. U.S.A. 97:3596-3601(2000). RN [21] RP FUNCTION AS NRG1 RECEPTOR AND IN ACTIVATION OF MAP KINASES, RP AUTOPHOSPHORYLATION, AND ACTIVITY REGULATION. RX PubMed=11178955; DOI=10.1006/bbrc.2001.4302; RA Egeblad M., Mortensen O.H., van Kempen L.C., Jaattela M.; RT "BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at RT different concentrations in intact cells."; RL Biochem. Biophys. Res. Commun. 281:25-31(2001). RN [22] RP MUTAGENESIS OF LYS-751, AND FUNCTION IN PROMOTING CELL DIFFERENTIATION AND RP INHIBITING CELL PROLIFERATION. RX PubMed=11390655; DOI=10.1128/mcb.21.13.4265-4275.2001; RA Sartor C.I., Zhou H., Kozlowska E., Guttridge K., Kawata E., Caskey L., RA Harrelson J., Hynes N., Ethier S., Calvo B., Earp H.S. III; RT "Her4 mediates ligand-dependent antiproliferative and differentiation RT responses in human breast cancer cells."; RL Mol. Cell. Biol. 21:4265-4275(2001). RN [23] RP FUNCTION, PROTEOLYTIC PROCESSING, SUBCELLULAR LOCATION, INTERACTION WITH RP YAP1, AND MUTAGENESIS OF TYR-1301. RX PubMed=12807903; DOI=10.1074/jbc.m305597200; RA Komuro A., Nagai M., Navin N.E., Sudol M.; RT "WW domain-containing protein YAP associates with ErbB-4 and acts as a co- RT transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that RT translocates to the nucleus."; RL J. Biol. Chem. 278:33334-33341(2003). RN [24] RP INTERACTION WITH MUC1. RX PubMed=12939402; RA Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M., Kufe D.; RT "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent RT on the DF3/MUC1 oncoprotein."; RL Mol. Cancer Res. 1:765-775(2003). RN [25] RP INTERACTION WITH STAT5A, SUBCELLULAR LOCATION, FUNCTION IN NUCLEAR RP LOCALIZATION OF STAT5A, DNA-BINDING, AND MUTAGENESIS OF 681-LYS--ARG-684. RX PubMed=15534001; DOI=10.1083/jcb.200403155; RA Williams C.C., Allison J.G., Vidal G.A., Burow M.E., Beckman B.S., RA Marrero L., Jones F.E.; RT "The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by RT functioning as a STAT5A nuclear chaperone."; RL J. Cell Biol. 167:469-478(2004). RN [26] RP INTERACTION WITH WWOX, DOMAIN, AND MUTAGENESIS OF TYR-1035 AND TYR-1301. RX PubMed=16061658; DOI=10.1158/0008-5472.can-05-1150; RA Aqeilan R.I., Donati V., Palamarchuk A., Trapasso F., Kaou M., Pekarsky Y., RA Sudol M., Croce C.M.; RT "WW domain-containing proteins, WWOX and YAP, compete for interaction with RT ErbB-4 and modulate its transcriptional function."; RL Cancer Res. 65:6764-6772(2005). RN [27] RP FUNCTION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF VAL-675. RX PubMed=15746097; DOI=10.1074/jbc.m412457200; RA Vidal G.A., Naresh A., Marrero L., Jones F.E.; RT "Presenilin-dependent gamma-secretase processing regulates multiple RT ERBB4/HER4 activities."; RL J. Biol. Chem. 280:19777-19783(2005). RN [28] RP FUNCTION IN PROMOTING APOPTOSIS, SUBCELLULAR LOCATION, AND INTERACTION WITH RP BCL2. RX PubMed=16778220; DOI=10.1158/0008-5472.can-05-2368; RA Naresh A., Long W., Vidal G.A., Wimley W.C., Marrero L., Sartor C.I., RA Tovey S., Cooke T.G., Bartlett J.M., Jones F.E.; RT "The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting RT apoptosis of breast cancer cells."; RL Cancer Res. 66:6412-6420(2006). RN [29] RP INTERACTION WITH CBFA2T3. RX PubMed=16815842; DOI=10.1074/jbc.m603998200; RA Linggi B., Carpenter G.; RT "ErbB-4 s80 intracellular domain abrogates ETO2-dependent transcriptional RT repression."; RL J. Biol. Chem. 281:25373-25380(2006). RN [30] RP FUNCTION, PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=16251361; DOI=10.1091/mbc.e05-05-0402; RA Maatta J.A., Sundvall M., Junttila T.T., Peri L., Laine V.J., Isola J., RA Egeblad M., Elenius K.; RT "Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 RT isoform promote ligand-independent survival and cancer cell growth."; RL Mol. Biol. Cell 17:67-79(2006). RN [31] RP FUNCTION IN DIFFERENTIATION OF MAMMARY EPITHELIUM, PROTEOLYTIC PROCESSING, RP AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND INTERACTION WITH STAT5A. RX PubMed=16837552; DOI=10.1091/mbc.e06-02-0101; RA Muraoka-Cook R.S., Sandahl M., Husted C., Hunter D., Miraglia L., RA Feng S.M., Elenius K., Earp H.S. III; RT "The intracellular domain of ErbB4 induces differentiation of mammary RT epithelial cells."; RL Mol. Biol. Cell 17:4118-4129(2006). RN [32] RP MUTAGENESIS OF GLN-646, AND PHOSPHORYLATION AT TYR-1056. RX PubMed=17120616; DOI=10.3727/000000006783981134; RA Pitfield S.E., Bryant I., Penington D.J., Park G., Riese D.J. II; RT "Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling RT to inhibition of colony formation by human mammary cell lines."; RL Oncol. Res. 16:179-193(2006). RN [33] RP FUNCTION OF ERBB4 INTRACELLULAR DOMAIN, PROTEOLYTIC PROCESSING, SUBCELLULAR RP LOCATION, UBIQUITINATION OF ERBB4 INTRACELLULAR DOMAIN, AND MUTAGENESIS OF RP VAL-675; LYS-751; ARG-992; LEU-995 AND ASP-1000. RX PubMed=17638867; DOI=10.1158/0008-5472.can-06-4145; RA Strunk K.E., Husted C., Miraglia L.C., Sandahl M., Rearick W.A., RA Hunter D.M., Earp H.S. III, Muraoka-Cook R.S.; RT "HER4 D-box sequences regulate mitotic progression and degradation of the RT nuclear HER4 cleavage product s80HER4."; RL Cancer Res. 67:6582-6590(2007). RN [34] RP INTERACTION WITH ERBB2, MUTAGENESIS OF ASP-843, AND AUTOPHOSPHORYLATION IN RP TRANS. RX PubMed=16978839; DOI=10.1016/j.cellsig.2006.07.020; RA Li Z., Mei Y., Liu X., Zhou M.; RT "Neuregulin-1 only induces trans-phosphorylation between ErbB receptor RT heterodimer partners."; RL Cell. Signal. 19:466-471(2007). RN [35] RP FUNCTION OF E4ICD, PHOSPHORYLATION, SUBCELLULAR LOCATION OF E4ICD, AND RP MUTAGENESIS OF LYS-751. RX PubMed=17486069; DOI=10.1038/sj.onc.1210501; RA Sundvall M., Peri L., Maatta J.A., Tvorogov D., Paatero I., Savisalo M., RA Silvennoinen O., Yarden Y., Elenius K.; RT "Differential nuclear localization and kinase activity of alternative ErbB4 RT intracellular domains."; RL Oncogene 26:6905-6914(2007). RN [36] RP PHOSPHORYLATION AT TYR-875; TYR-1035; TYR-1056; TYR-1150; TYR-1162; RP TYR-1188; TYR-1202; TYR-1242; TYR-1258 AND TYR-1284, INTERACTION WITH RP PIK3R1 AND STAT1, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=18721752; DOI=10.1016/j.chembiol.2008.07.006; RA Kaushansky A., Gordus A., Budnik B.A., Lane W.S., Rush J., MacBeath G.; RT "System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation RT that are unusually selective in their recruitment properties."; RL Chem. Biol. 15:808-817(2008). RN [37] RP INTERACTION WITH NEDD4, SUBCELLULAR LOCATION, AND UBIQUITINATION OF E4ICD1. RX PubMed=19193720; DOI=10.1096/fj.08-121947; RA Zeng F., Xu J., Harris R.C.; RT "Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK RT II cells."; RL FASEB J. 23:1935-1945(2009). RN [38] RP FUNCTION IN ACTIVATION OF SIGNALING PATHWAYS, INTERACTION WITH ERBB2, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, PHOSPHORYLATION BY ERBB2, ACTIVITY RP REGULATION, AND MUTAGENESIS OF VAL-721; ALA-773; ARG-782; GLU-810; PRO-854; RP ASP-861; GLU-872 AND THR-926. RX PubMed=19098003; DOI=10.1074/jbc.m805438200; RA Tvorogov D., Sundvall M., Kurppa K., Hollmen M., Repo S., Johnson M.S., RA Elenius K.; RT "Somatic mutations of ErbB4: selective loss-of-function phenotype affecting RT signal transduction pathways in cancer."; RL J. Biol. Chem. 284:5582-5591(2009). RN [39] RP INTERACTION WITH WWP1, AND MUTAGENESIS OF TYR-1056 AND TYR-1301. RX PubMed=19561640; DOI=10.1038/onc.2009.162; RA Li Y., Zhou Z., Alimandi M., Chen C.; RT "WW domain containing E3 ubiquitin protein ligase 1 targets the full-length RT ErbB4 for ubiquitin-mediated degradation in breast cancer."; RL Oncogene 28:2948-2958(2009). RN [40] RP INTERACTION WITH TXNL4A; DDX23; MATR3; RBM15; ILF3; TRIM28; U5S1; U2SURP; RP ITCH; HNRNPU; AP2A1; NULC; LEO1; WWP2; MDM2; HXK1 AND SRRT, FUNCTION, RP SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=20858735; DOI=10.1158/1541-7786.mcr-10-0042; RA Gilmore-Hebert M., Ramabhadran R., Stern D.F.; RT "Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage RT response pathways."; RL Mol. Cancer Res. 8:1388-1398(2010). RN [41] RP ACTIVITY REGULATION. RX PubMed=21439954; DOI=10.1016/j.yexcr.2011.03.015; RA Carrasco-Garcia E., Saceda M., Grasso S., Rocamora-Reverte L., Conde M., RA Gomez-Martinez A., Garcia-Morales P., Ferragut J.A., Martinez-Lacaci I.; RT "Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting RT with erbB3 and erbB4 in glioblastoma cell lines."; RL Exp. Cell Res. 317:1476-1489(2011). RN [42] RP REVIEW ON ROLE IN BREAST AND NEURAL DEVELOPMENT. RX PubMed=14504474; RA Jones F.E., Golding J.P., Gassmann M.; RT "ErbB4 signaling during breast and neural development: novel genetic models RT reveal unique ErbB4 activities."; RL Cell Cycle 2:555-559(2003). RN [43] RP REVIEW. RX PubMed=15944951; DOI=10.14670/hh-20.1005; RA Zaczek A., Brandt B., Bielawski K.P.; RT "The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase RT receptors and the consequences for therapeutic approaches."; RL Histol. Histopathol. 20:1005-1015(2005). RN [44] RP REVIEW ON ROLE IN MAMMARY GLAND DEVELOPMENT. RX PubMed=18437540; DOI=10.1007/s10911-008-9080-x; RA Muraoka-Cook R.S., Feng S.M., Strunk K.E., Earp H.S. III; RT "ErbB4/HER4: role in mammary gland development, differentiation and growth RT inhibition."; RL J. Mammary Gland Biol. Neoplasia 13:235-246(2008). RN [45] RP REVIEW ON ROLE OF THE ERBB4 INTRACELLULAR DOMAIN. RX PubMed=18473151; DOI=10.1007/s10911-008-9076-6; RA Jones F.E.; RT "HER4 intracellular domain (4ICD) activity in the developing mammary gland RT and breast cancer."; RL J. Mammary Gland Biol. Neoplasia 13:247-258(2008). RN [46] RP REVIEW ON LIGAND SPECIFICITY AND SIGNALING. RX PubMed=18454307; DOI=10.1007/s10911-008-9079-3; RA Sundvall M., Iljin K., Kilpinen S., Sara H., Kallioniemi O.P., Elenius K.; RT "Role of ErbB4 in breast cancer."; RL J. Mammary Gland Biol. Neoplasia 13:259-268(2008). RN [47] RP REVIEW ON ROLE IN NRG1 SIGNALING AND CARDIOVASCULAR HEALTH. RX PubMed=20933198; DOI=10.1016/s1054-3589(10)59002-1; RA Xu Y., Li X., Liu X., Zhou M.; RT "Neuregulin-1/ErbB signaling and chronic heart failure."; RL Adv. Pharmacol. 59:31-51(2010). RN [48] RP REVIEW ON ALTERNATIVE SPLICING AND PROTEOLYTIC PROCESSING; TISSUE RP SPECIFICITY; SIGNALING AND ROLE IN DISEASE. RX PubMed=21811097; DOI=10.4161/cc.10.16.17194; RA Veikkolainen V., Vaparanta K., Halkilahti K., Iljin K., Sundvall M., RA Elenius K.; RT "Function of ERBB4 is determined by alternative splicing."; RL Cell Cycle 10:2647-2657(2011). RN [49] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 26-641, DISULFIDE BONDS, AND RP GLYCOSYLATION AT ASN-138; ASN-174; ASN-253; ASN-358; ASN-410; ASN-473; RP ASN-495 AND ASN-576. RX PubMed=16203964; DOI=10.1073/pnas.0507591102; RA Bouyain S., Longo P.A., Li S., Ferguson K.M., Leahy D.J.; RT "The extracellular region of ErbB4 adopts a tethered conformation in the RT absence of ligand."; RL Proc. Natl. Acad. Sci. U.S.A. 102:15024-15029(2005). RN [50] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 690-999 IN COMPLEX WITH INHIBITOR, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF LEU-710; RP MET-766; LEU-864 AND ILE-947. RX PubMed=18287036; DOI=10.1073/pnas.0708281105; RA Wood E.R., Shewchuk L.M., Ellis B., Brignola P., Brashear R.L., RA Caferro T.R., Dickerson S.H., Dickson H.D., Donaldson K.H., Gaul M., RA Griffin R.J., Hassell A.M., Keith B., Mullin R., Petrov K.G., Reno M.J., RA Rusnak D.W., Tadepalli S.M., Ulrich J.C., Wagner C.D., Vanderwall D.E., RA Waterson A.G., Williams J.D., White W.L., Uehling D.E.; RT "6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as RT tunable covalent modifiers of ErbB kinases."; RL Proc. Natl. Acad. Sci. U.S.A. 105:2773-2778(2008). RN [51] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 702-1029 OF APOPROTEIN AND IN RP COMPLEX WITH LAPATINIB, CATALYTIC ACTIVITY, ACTIVITY REGULATION, RP AUTOPHOSPHORYLATION, AND SUBUNIT. RX PubMed=18334220; DOI=10.1016/j.str.2007.12.016; RA Qiu C., Tarrant M.K., Choi S.H., Sathyamurthy A., Bose R., Banjade S., RA Pal A., Bornmann W.G., Lemmon M.A., Cole P.A., Leahy D.J.; RT "Mechanism of activation and inhibition of the HER4/ErbB4 kinase."; RL Structure 16:460-467(2008). RN [52] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-140 AND TYR-303. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [53] RP VARIANTS ALS19 GLN-927 AND TRP-1275, AND CHARACTERIZATION OF VARIANTS ASL19 RP GLN-927 AND TRP-1275. RX PubMed=24119685; DOI=10.1016/j.ajhg.2013.09.008; RA Takahashi Y., Fukuda Y., Yoshimura J., Toyoda A., Kurppa K., Moritoyo H., RA Belzil V.V., Dion P.A., Higasa K., Doi K., Ishiura H., Mitsui J., Date H., RA Ahsan B., Matsukawa T., Ichikawa Y., Moritoyo T., Ikoma M., Hashimoto T., RA Kimura F., Murayama S., Onodera O., Nishizawa M., Yoshida M., Atsuta N., RA Sobue G., Fifita J.A., Williams K.L., Blair I.P., Nicholson G.A., RA Gonzalez-Perez P., Brown R.H. Jr., Nomoto M., Elenius K., Rouleau G.A., RA Fujiyama A., Morishita S., Goto J., Tsuji S., Nakamura R., Watanabe H., RA Izumi Y., Kaji R., Morita M., Ogaki K., Taniguchi A., Aiba I., RA Mizoguchi K., Okamoto K., Hasegawa K., Aoki M., Kawata A., Nakano I., RA Abe K., Oda M., Konagaya M., Imai T., Nakagawa M., Fujita T., Sasaki H., RA Nishizawa M.; RT "ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause RT amyotrophic lateral sclerosis type 19."; RL Am. J. Hum. Genet. 93:900-905(2013). CC -!- FUNCTION: Tyrosine-protein kinase that plays an essential role as cell CC surface receptor for neuregulins and EGF family members and regulates CC development of the heart, the central nervous system and the mammary CC gland, gene transcription, cell proliferation, differentiation, CC migration and apoptosis. Required for normal cardiac muscle CC differentiation during embryonic development, and for postnatal CC cardiomyocyte proliferation. Required for normal development of the CC embryonic central nervous system, especially for normal neural crest CC cell migration and normal axon guidance. Required for mammary gland CC differentiation, induction of milk proteins and lactation. Acts as CC cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and CC the EGF family members BTC, EREG and HBEGF. Ligand binding triggers CC receptor dimerization and autophosphorylation at specific tyrosine CC residues that then serve as binding sites for scaffold proteins and CC effectors. Ligand specificity and signaling is modulated by alternative CC splicing, proteolytic processing, and by the formation of heterodimers CC with other ERBB family members, thereby creating multiple combinations CC of intracellular phosphotyrosines that trigger ligand- and context- CC specific cellular responses. Mediates phosphorylation of SHC1 and CC activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A CC CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the CC activation of phosphatidylinositol 3-kinase and AKT1 and protect cells CC against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate CC reorganization of the actin cytoskeleton and promote cell migration in CC response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the CC phosphotyrosine that mediates interaction with PIK3R1, and hence do not CC phosphorylate PIK3R1, do not protect cells against apoptosis, and do CC not promote reorganization of the actin cytoskeleton and cell CC migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM- CC A CYT-2 gives rise to the corresponding soluble intracellular domains CC (4ICD) that translocate to the nucleus, promote nuclear import of CC STAT5A, activation of STAT5A, mammary epithelium differentiation, cell CC proliferation and activation of gene expression. The ERBB4 soluble CC intracellular domains (4ICD) colocalize with STAT5A at the CSN2 CC promoter to regulate transcription of milk proteins during lactation. CC The ERBB4 soluble intracellular domains can also translocate to CC mitochondria and promote apoptosis. {ECO:0000269|PubMed:10348342, CC ECO:0000269|PubMed:10353604, ECO:0000269|PubMed:10358079, CC ECO:0000269|PubMed:10722704, ECO:0000269|PubMed:10867024, CC ECO:0000269|PubMed:11178955, ECO:0000269|PubMed:11390655, CC ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15534001, CC ECO:0000269|PubMed:15746097, ECO:0000269|PubMed:16251361, CC ECO:0000269|PubMed:16778220, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:20858735, CC ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:8617750, CC ECO:0000269|PubMed:9135143, ECO:0000269|PubMed:9168115, CC ECO:0000269|PubMed:9334263}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:18287036, ECO:0000269|PubMed:18334220, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:8617750}; CC -!- ACTIVITY REGULATION: Binding of a cognate ligand leads to dimerization CC and activation by autophosphorylation on tyrosine residues. In vitro CC kinase activity is increased by Mg(2+). Inhibited by PD153035, CC lapatinib, gefitinib (iressa, ZD1839), AG1478 and BIBX1382BS. CC {ECO:0000269|PubMed:11178955, ECO:0000269|PubMed:18334220, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:21439954, CC ECO:0000269|PubMed:8617750}. CC -!- SUBUNIT: Monomer in the absence of bound ligand. Homodimer or CC heterodimer with another ERBB family member upon ligand binding, thus CC forming heterotetramers. Interacts with EGFR and ERBB2. Interacts with CC CBFA2T3 (By similarity). Interacts with DLG2 (via its PDZ domain), DLG3 CC (via its PDZ domain), DLG4 (via its PDZ domain) and SNTB2 (via its PDZ CC domain). Interacts with MUC1. Interacts (via its PPxy motifs) with CC WWOX. Interacts (via the PPxY motif 3 of isoform JM-A CYT-2) with YAP1 CC (via the WW domain 1 of isoform 1). Interacts (isoform JM-A CYT-1 and CC isoform JM-B CYT-1) with WWP1. Interacts (via its intracellular domain) CC with TRIM28. Interacts (via the intracellular domains of both CYT-1 and CC CYT-2 isoforms) with KAP1; the interaction does not phosphorylate KAP1 CC but represses ERBB4-mediated transcriptional activity. Interacts with CC PRPU, DDX23, MATR3, RBM15, ILF3, KAP1, U5S1, U2SURP, ITCH, HNRNPU, CC AP2A1, NULC, LEO1, WWP2, IGHG1, HXK1, GRB7 and SRRT. Interacts CC (phosphorylated isoform JM-A CYT-1 and isoform JM-B CYT-1) with PIK3R1. CC Interacts with SHC1. Interacts with GRB2. Interacts (soluble CC intracellular domain) with STAT5A. Interacts (soluble intracellular CC domain) with BCL2. Interacts (phosphorylated) with STAT1. {ECO:0000250, CC ECO:0000269|PubMed:10348342, ECO:0000269|PubMed:10353604, CC ECO:0000269|PubMed:10358079, ECO:0000269|PubMed:10725395, CC ECO:0000269|PubMed:10867024, ECO:0000269|PubMed:12807903, CC ECO:0000269|PubMed:12939402, ECO:0000269|PubMed:15534001, CC ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:16778220, CC ECO:0000269|PubMed:16815842, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:16978839, ECO:0000269|PubMed:18287036, CC ECO:0000269|PubMed:18334220, ECO:0000269|PubMed:18721752, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:19193720, CC ECO:0000269|PubMed:19561640, ECO:0000269|PubMed:20858735, CC ECO:0000269|PubMed:7689552, ECO:0000269|PubMed:7902537, CC ECO:0000269|PubMed:8570211, ECO:0000269|PubMed:8617750, CC ECO:0000269|PubMed:9135143, ECO:0000269|PubMed:9168115, CC ECO:0000269|PubMed:9275162, ECO:0000269|PubMed:9419975, CC ECO:0000269|PubMed:9516479}. CC -!- INTERACTION: CC Q15303; P42684: ABL2; NbExp=4; IntAct=EBI-80371, EBI-1102694; CC Q15303; Q13895: BYSL; NbExp=3; IntAct=EBI-80371, EBI-358049; CC Q15303; Q12959: DLG1; NbExp=4; IntAct=EBI-80371, EBI-357481; CC Q15303; Q15700: DLG2; NbExp=3; IntAct=EBI-80371, EBI-80426; CC Q15303; Q92796: DLG3; NbExp=4; IntAct=EBI-80371, EBI-80440; CC Q15303; P78352: DLG4; NbExp=9; IntAct=EBI-80371, EBI-80389; CC Q15303; P00533: EGFR; NbExp=4; IntAct=EBI-80371, EBI-297353; CC Q15303; P04626: ERBB2; NbExp=5; IntAct=EBI-80371, EBI-641062; CC Q15303; P21860: ERBB3; NbExp=4; IntAct=EBI-80371, EBI-720706; CC Q15303; P62993: GRB2; NbExp=7; IntAct=EBI-80371, EBI-401755; CC Q15303; Q99075: HBEGF; NbExp=2; IntAct=EBI-80371, EBI-7211558; CC Q15303; P08238: HSP90AB1; NbExp=2; IntAct=EBI-80371, EBI-352572; CC Q15303; Q96J02-2: ITCH; NbExp=3; IntAct=EBI-80371, EBI-6672198; CC Q15303; Q96JA1: LRIG1; NbExp=3; IntAct=EBI-80371, EBI-2865191; CC Q15303; Q86UL8: MAGI2; NbExp=2; IntAct=EBI-80371, EBI-311035; CC Q15303; Q02297-6: NRG1; NbExp=3; IntAct=EBI-80371, EBI-15651799; CC Q15303; Q06124: PTPN11; NbExp=2; IntAct=EBI-80371, EBI-297779; CC Q15303; P26447: S100A4; NbExp=4; IntAct=EBI-80371, EBI-717058; CC Q15303; P29353: SHC1; NbExp=6; IntAct=EBI-80371, EBI-78835; CC Q15303; Q12815: TROAP; NbExp=3; IntAct=EBI-80371, EBI-2349743; CC Q15303; P46937: YAP1; NbExp=3; IntAct=EBI-80371, EBI-1044059; CC Q15303; P62258: YWHAE; NbExp=2; IntAct=EBI-80371, EBI-356498; CC Q15303-3; Q96J02-2: ITCH; NbExp=2; IntAct=EBI-15692884, EBI-6672198; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10348342, CC ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15534001, CC ECO:0000269|PubMed:16251361, ECO:0000269|PubMed:16778220, CC ECO:0000269|PubMed:16837552, ECO:0000269|PubMed:17486069, CC ECO:0000269|PubMed:17638867, ECO:0000269|PubMed:19193720, CC ECO:0000269|PubMed:20858735, ECO:0000269|PubMed:8383326, CC ECO:0000269|PubMed:9334263}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:10348342, ECO:0000269|PubMed:12807903, CC ECO:0000269|PubMed:15534001, ECO:0000269|PubMed:16251361, CC ECO:0000269|PubMed:16778220, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867, CC ECO:0000269|PubMed:19193720, ECO:0000269|PubMed:20858735, CC ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:9334263}. Note=In CC response to NRG1 treatment, the activated receptor is internalized. CC -!- SUBCELLULAR LOCATION: [ERBB4 intracellular domain]: Nucleus CC {ECO:0000269|PubMed:17486069}. Mitochondrion CC {ECO:0000269|PubMed:17486069}. Note=Following proteolytical processing CC E4ICD (E4ICD1 or E4ICD2 generated from the respective isoforms) is CC translocated to the nucleus. Significantly more E4ICD2 than E4ICD1 is CC found in the nucleus. E4ICD2 colocalizes with YAP1 in the nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=JM-A CYT-1; CC IsoId=Q15303-1; Sequence=Displayed; CC Name=JM-B CYT-1; CC IsoId=Q15303-2; Sequence=VSP_002895; CC Name=JM-A CYT-2; CC IsoId=Q15303-3; Sequence=VSP_022148; CC Name=JM-B CYT-2; CC IsoId=Q15303-4; Sequence=VSP_002895, VSP_022148; CC -!- TISSUE SPECIFICITY: Expressed at highest levels in brain, heart, CC kidney, in addition to skeletal muscle, parathyroid, cerebellum, CC pituitary, spleen, testis and breast. Lower levels in thymus, lung, CC salivary gland, and pancreas. Isoform JM-A CYT-1 and isoform JM-B CYT-1 CC are expressed in cerebellum, but only the isoform JM-B is expressed in CC the heart. {ECO:0000269|PubMed:10353604, ECO:0000269|PubMed:8383326, CC ECO:0000269|PubMed:9334263}. CC -!- PTM: Isoform JM-A CYT-1 and isoform JM-A CYT-2 are processed by ADAM17. CC Proteolytic processing in response to ligand or 12-O- CC tetradecanoylphorbol-13-acetate stimulation results in the production CC of 120 kDa soluble receptor forms and intermediate membrane-anchored 80 CC kDa fragments (m80HER4), which are further processed by a presenilin- CC dependent gamma-secretase to release a cytoplasmic intracellular domain CC (E4ICD; E4ICD1/s80Cyt1 or E4ICD2/s80Cyt2, depending on the isoform). CC Membrane-anchored 80 kDa fragments of the processed isoform JM-A CYT-1 CC are more readily degraded by the proteasome than fragments of isoform CC JM-A CYT-2, suggesting a prevalence of E4ICD2 over E4ICD1. Isoform JM-B CC CYT-1 and isoform JM-B CYT-2 lack the ADAM17 cleavage site and are not CC processed by ADAM17, precluding further processing by gamma-secretase. CC {ECO:0000269|PubMed:10744726, ECO:0000269|PubMed:12807903, CC ECO:0000269|PubMed:15746097, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:17638867, ECO:0000269|PubMed:9334263}. CC -!- PTM: Autophosphorylated on tyrosine residues in response to ligand CC binding. Autophosphorylation occurs in trans, i.e. one subunit of the CC dimeric receptor phosphorylates tyrosine residues on the other subunit. CC Ligands trigger phosphorylation at specific tyrosine residues, thereby CC creating binding sites for scaffold proteins and effectors. CC Constitutively phosphorylated at a basal level when overexpressed in CC heterologous systems; ligand binding leads to increased CC phosphorylation. Phosphorylation at Tyr-1035 is important for CC interaction with STAT1. Phosphorylation at Tyr-1056 is important for CC interaction with PIK3R1. Phosphorylation at Tyr-1242 is important for CC interaction with SHC1. Phosphorylation at Tyr-1188 may also contribute CC to the interaction with SHC1. Isoform JM-A CYT-2 is constitutively CC phosphorylated on tyrosine residues in a ligand-independent manner. CC E4ICD2 but not E4ICD1 is phosphorylated on tyrosine residues. CC {ECO:0000269|PubMed:16251361, ECO:0000269|PubMed:17120616, CC ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:18721752, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:8617750, CC ECO:0000269|PubMed:9168115}. CC -!- PTM: Ubiquitinated. During mitosis, the ERBB4 intracellular domain is CC ubiquitinated by the APC/C complex and targeted to proteasomal CC degradation. Isoform JM-A CYT-1 and isoform JM-B CYT-1 are CC ubiquitinated by WWP1. The ERBB4 intracellular domain (E4ICD1) is CC ubiquitinated, and this involves NEDD4. {ECO:0000269|PubMed:17638867, CC ECO:0000269|PubMed:19193720}. CC -!- DISEASE: Amyotrophic lateral sclerosis 19 (ALS19) [MIM:615515]: A CC neurodegenerative disorder affecting upper motor neurons in the brain CC and lower motor neurons in the brain stem and spinal cord, resulting in CC fatal paralysis. Sensory abnormalities are absent. The pathologic CC hallmarks of the disease include pallor of the corticospinal tract due CC to loss of motor neurons, presence of ubiquitin-positive inclusions CC within surviving motor neurons, and deposition of pathologic CC aggregates. The etiology of amyotrophic lateral sclerosis is likely to CC be multifactorial, involving both genetic and environmental factors. CC The disease is inherited in 5-10% of the cases. CC {ECO:0000269|PubMed:24119685}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform JM-A CYT-1]: Proteolytical processing generates CC E4ICD1 (s80Cyt1). CC -!- MISCELLANEOUS: [Isoform JM-A CYT-2]: Proteolytical processing generates CC E4ICD2 (s80Cyt2). {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- CAUTION: Conflicting reports about the role of ERBB4 in mediating CC apoptosis, differentiation, or tumor cell proliferation may be CC explained by the opposite functions of the different isoforms and their CC intracellular fragments, and by the formation of heterodimers with CC other EGF receptor family members (PubMed:18454307, PubMed:21811097). CC Thus, heterodimer formation of a kinase-dead ERBB4 mutant with ERBB2 is CC sufficient for the activation of AKT1, MAPK1/ERK2 and MAPK3/ERK1 CC (PubMed:19098003). {ECO:0000305|PubMed:19098003}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L07868; AAB59446.1; -; mRNA. DR EMBL; BC112199; AAI12200.1; -; mRNA. DR EMBL; BC143741; AAI43742.1; -; mRNA. DR EMBL; BC143747; AAI43748.1; -; mRNA. DR EMBL; BC143749; AAI43750.1; -; mRNA. DR EMBL; AB209697; BAD92934.1; -; mRNA. DR CCDS; CCDS2394.1; -. [Q15303-1] DR CCDS; CCDS42811.1; -. [Q15303-3] DR PIR; A47253; A47253. DR RefSeq; NP_001036064.1; NM_001042599.2. [Q15303-3] DR RefSeq; NP_001425934.1; NM_001439005.1. [Q15303-2] DR RefSeq; NP_001425935.1; NM_001439006.1. [Q15303-4] DR RefSeq; NP_005226.1; NM_005235.3. [Q15303-1] DR PDB; 2AHX; X-ray; 2.40 A; A/B=26-641. DR PDB; 2L2T; NMR; -; A/B=642-685. DR PDB; 2LCX; NMR; -; A/B=642-685. DR PDB; 2R4B; X-ray; 2.40 A; A/B=690-999. DR PDB; 3BBT; X-ray; 2.80 A; B/D=702-1029. DR PDB; 3BBW; X-ray; 4.00 A; A/B=702-1029. DR PDB; 3BCE; X-ray; 2.50 A; A/B/C=702-1029. DR PDB; 3U2P; X-ray; 2.57 A; A=26-522. DR PDB; 3U7U; X-ray; 3.03 A; A/B/C/D/E/F=26-640. DR PDB; 3U9U; X-ray; 3.42 A; E/F=26-650. DR PDB; 8U4I; EM; 3.38 A; A/B=26-635. DR PDB; 8U4J; EM; 3.70 A; A/B=26-635. DR PDB; 8U4K; EM; 4.27 A; A=26-634. DR PDB; 8U4L; EM; 3.31 A; A=26-634. DR PDBsum; 2AHX; -. DR PDBsum; 2L2T; -. DR PDBsum; 2LCX; -. DR PDBsum; 2R4B; -. DR PDBsum; 3BBT; -. DR PDBsum; 3BBW; -. DR PDBsum; 3BCE; -. DR PDBsum; 3U2P; -. DR PDBsum; 3U7U; -. DR PDBsum; 3U9U; -. DR PDBsum; 8U4I; -. DR PDBsum; 8U4J; -. DR PDBsum; 8U4K; -. DR PDBsum; 8U4L; -. DR AlphaFoldDB; Q15303; -. DR EMDB; EMD-41883; -. DR EMDB; EMD-41884; -. DR EMDB; EMD-41885; -. DR EMDB; EMD-41886; -. DR SMR; Q15303; -. DR BioGRID; 108378; 183. DR CORUM; Q15303; -. DR DIP; DIP-29650N; -. DR ELM; Q15303; -. DR FunCoup; Q15303; 1593. DR IntAct; Q15303; 146. DR MINT; Q15303; -. DR STRING; 9606.ENSP00000342235; -. DR BindingDB; Q15303; -. DR ChEMBL; CHEMBL3009; -. DR DrugBank; DB08916; Afatinib. DR DrugBank; DB12267; Brigatinib. DR DrugBank; DB05424; Canertinib. DR DrugBank; DB12744; CGI-1842. DR DrugBank; DB11963; Dacomitinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB12325; Idasanutlin. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; Q15303; -. DR GuidetoPHARMACOLOGY; 1799; -. DR TCDB; 8.A.23.1.17; the basigin (basigin) family. DR GlyCosmos; Q15303; 11 sites, No reported glycans. DR GlyGen; Q15303; 11 sites, 6 N-linked glycans (4 sites). DR iPTMnet; Q15303; -. DR PhosphoSitePlus; Q15303; -. DR BioMuta; ERBB4; -. DR DMDM; 3913590; -. DR jPOST; Q15303; -. DR MassIVE; Q15303; -. DR PaxDb; 9606-ENSP00000342235; -. DR PeptideAtlas; Q15303; -. DR ProteomicsDB; 60520; -. [Q15303-1] DR ProteomicsDB; 60521; -. [Q15303-2] DR ProteomicsDB; 60522; -. [Q15303-3] DR ProteomicsDB; 60523; -. [Q15303-4] DR Pumba; Q15303; -. DR ABCD; Q15303; 1 sequenced antibody. DR Antibodypedia; 1602; 1464 antibodies from 47 providers. DR DNASU; 2066; -. DR Ensembl; ENST00000260943.11; ENSP00000260943.7; ENSG00000178568.16. [Q15303-4] DR Ensembl; ENST00000342788.9; ENSP00000342235.4; ENSG00000178568.16. [Q15303-1] DR Ensembl; ENST00000436443.5; ENSP00000403204.1; ENSG00000178568.16. [Q15303-3] DR GeneID; 2066; -. DR KEGG; hsa:2066; -. DR MANE-Select; ENST00000342788.9; ENSP00000342235.4; NM_005235.3; NP_005226.1. DR UCSC; uc002veg.2; human. [Q15303-1] DR AGR; HGNC:3432; -. DR CIViC; 2066; 9 evidence items across 8 molecular profiles. DR ClinPGx; PA27847; -. DR CTD; 2066; -. DR DisGeNET; 2066; -. DR GeneCards; ERBB4; -. DR HGNC; HGNC:3432; ERBB4. DR HPA; ENSG00000178568; Tissue enhanced (brain, fallopian tube). DR MalaCards; ERBB4; -. DR MIM; 600543; gene. DR MIM; 615515; phenotype. DR OpenTargets; ENSG00000178568; -. DR Orphanet; 803; Amyotrophic lateral sclerosis. DR Orphanet; 178469; Autosomal dominant non-syndromic intellectual disability. DR VEuPathDB; HostDB:ENSG00000178568; -. DR eggNOG; KOG1025; Eukaryota. DR GeneTree; ENSGT00940000154695; -. DR InParanoid; Q15303; -. DR OMA; VCHSECL; -. DR OrthoDB; 6219513at2759; -. DR PAN-GO; Q15303; 9 GO annotations based on evolutionary models. DR PhylomeDB; Q15303; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q15303; -. DR Reactome; R-HSA-1227986; Signaling by ERBB2. DR Reactome; R-HSA-1236394; Signaling by ERBB4. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1250342; PI3K events in ERBB4 signaling. DR Reactome; R-HSA-1250347; SHC1 events in ERBB4 signaling. DR Reactome; R-HSA-1251985; Nuclear signaling by ERBB4. DR Reactome; R-HSA-1253288; Downregulation of ERBB4 signaling. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling. DR Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling. DR Reactome; R-HSA-9018519; Estrogen-dependent gene expression. DR Reactome; R-HSA-9620244; Long-term potentiation. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR SignaLink; Q15303; -. DR SIGNOR; Q15303; -. DR Agora; ENSG00000178568; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 2066; 33 hits in 1186 CRISPR screens. DR ChiTaRS; ERBB4; human. DR EvolutionaryTrace; Q15303; -. DR GeneWiki; ERBB4; -. DR GenomeRNAi; 2066; -. DR Pharos; Q15303; Tclin. DR PRO; PR:Q15303; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q15303; protein. DR Bgee; ENSG00000178568; Expressed in endothelial cell and 154 other cell types or tissues. DR ExpressionAtlas; Q15303; baseline and differential. DR GO; GO:0009925; C:basal plasma membrane; IBA:GO_Central. DR GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0098982; C:GABA-ergic synapse; IEA:Ensembl. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:MGI. DR GO; GO:0098839; C:postsynaptic density membrane; IEA:Ensembl. DR GO; GO:0045211; C:postsynaptic membrane; ISS:UniProtKB. DR GO; GO:0042734; C:presynaptic membrane; IEA:Ensembl. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005006; F:epidermal growth factor receptor activity; IEA:Ensembl. DR GO; GO:0005154; F:epidermal growth factor receptor binding; IPI:UniProtKB. DR GO; GO:0050811; F:GABA receptor binding; IEA:Ensembl. DR GO; GO:0038131; F:neuregulin receptor activity; IDA:MGI. DR GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IMP:UniProtKB. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0061026; P:cardiac muscle tissue regeneration; ISS:UniProtKB. DR GO; GO:0045165; P:cell fate commitment; IEA:Ensembl. DR GO; GO:0016477; P:cell migration; IDA:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IDA:UniProtKB. DR GO; GO:0007259; P:cell surface receptor signaling pathway via JAK-STAT; IEA:Ensembl. DR GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IEA:Ensembl. DR GO; GO:0021551; P:central nervous system morphogenesis; ISS:UniProtKB. DR GO; GO:0009880; P:embryonic pattern specification; ISS:UniProtKB. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central. DR GO; GO:0038135; P:ERBB2-ERBB4 signaling pathway; IEA:Ensembl. DR GO; GO:0038130; P:ERBB4 signaling pathway; IDA:MGI. DR GO; GO:0038138; P:ERBB4-ERBB4 signaling pathway; IDA:MGI. DR GO; GO:0072046; P:establishment of planar polarity involved in nephron morphogenesis; IEA:Ensembl. DR GO; GO:0007507; P:heart development; ISS:UniProtKB. DR GO; GO:0007595; P:lactation; IMP:UniProtKB. DR GO; GO:0060749; P:mammary gland alveolus development; ISS:UniProtKB. DR GO; GO:0060644; P:mammary gland epithelial cell differentiation; ISS:UniProtKB. DR GO; GO:0043653; P:mitochondrial fragmentation involved in apoptotic process; IMP:UniProtKB. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:2001223; P:negative regulation of neuron migration; IEA:Ensembl. DR GO; GO:0007399; P:nervous system development; ISS:UniProtKB. DR GO; GO:0001755; P:neural crest cell migration; ISS:UniProtKB. DR GO; GO:0030182; P:neuron differentiation; IBA:GO_Central. DR GO; GO:0099645; P:neurotransmitter receptor localization to postsynaptic specialization membrane; IEA:Ensembl. DR GO; GO:0021889; P:olfactory bulb interneuron differentiation; ISS:UniProtKB. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IBA:GO_Central. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IBA:GO_Central. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IEA:Ensembl. DR GO; GO:2000010; P:positive regulation of protein localization to cell surface; IEA:Ensembl. DR GO; GO:0001934; P:positive regulation of protein phosphorylation; TAS:UniProtKB. DR GO; GO:0046427; P:positive regulation of receptor signaling pathway via JAK-STAT; IMP:UniProtKB. DR GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0030334; P:regulation of cell migration; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IDA:UniProtKB. DR GO; GO:0007416; P:synapse assembly; IEA:Ensembl. DR CDD; cd00064; FU; 3. DR CDD; cd05110; PTKc_HER4; 1. DR CDD; cd12092; TM_ErbB4; 1. DR FunFam; 2.10.220.10:FF:000001; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000004; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.30.200.20:FF:000044; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000003; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000004; Receptor protein-tyrosine kinase; 1. DR FunFam; 1.10.510.10:FF:002828; Receptor tyrosine-protein kinase erbB-2; 1. DR Gene3D; 6.10.250.880; -; 1. DR Gene3D; 2.10.220.10; Hormone Receptor, Insulin-like Growth Factor Receptor 1, Chain A, domain 2; 3. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.20.20; Receptor L-domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR006211; Furin-like_Cys-rich_dom. DR InterPro; IPR006212; Furin_repeat. DR InterPro; IPR032778; GF_recep_IV. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR000494; Rcpt_L-dom. DR InterPro; IPR036941; Rcpt_L-dom_sf. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR049328; TM_ErbB1. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt. DR PANTHER; PTHR24416:SF90; RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00757; Furin-like; 1. DR Pfam; PF14843; GF_recep_IV; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF01030; Recep_L_domain; 2. DR Pfam; PF21314; TM_ErbB1; 1. DR PIRSF; PIRSF000619; TyrPK_EGF-R; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00261; FU; 5. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 2. DR SUPFAM; SSF52058; L domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; KW Amyotrophic lateral sclerosis; Apoptosis; ATP-binding; Cell membrane; KW Developmental protein; Disease variant; Disulfide bond; Glycoprotein; KW Kinase; Lactation; Membrane; Mitochondrion; Neurodegeneration; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Receptor; Reference proteome; Repeat; Signal; Transcription; KW Transcription regulation; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..25 FT /evidence="ECO:0000255" FT CHAIN 26..1308 FT /note="Receptor tyrosine-protein kinase erbB-4" FT /id="PRO_0000016674" FT CHAIN 676..1308 FT /note="ERBB4 intracellular domain" FT /evidence="ECO:0000250" FT /id="PRO_0000396797" FT TOPO_DOM 26..651 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 652..675 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 676..1308 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 718..985 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1117..1150 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 676..684 FT /note="Nuclear localization signal" FT MOTIF 1032..1035 FT /note="PPxY motif 1" FT MOTIF 1053..1056 FT /note="PPxY motif 2" FT MOTIF 1298..1301 FT /note="PPxY motif 3" FT MOTIF 1306..1308 FT /note="PDZ-binding" FT ACT_SITE 843 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 724..732 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 751 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 797..799 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 843..848 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 875 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1035 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1056 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17120616, FT ECO:0000269|PubMed:18721752, ECO:0000269|PubMed:8617750" FT MOD_RES 1150 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1162 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1188 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752, FT ECO:0000269|PubMed:8617750" FT MOD_RES 1202 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1242 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752, FT ECO:0000269|PubMed:8617750" FT MOD_RES 1258 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1284 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT CARBOHYD 138 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 174 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 181 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 253 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 358 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 410 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 473 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 495 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 548 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 576 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 620 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 29..56 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 156..186 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 189..197 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 193..205 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 213..221 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 217..229 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 230..238 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 234..246 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 249..258 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 262..289 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 293..304 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 308..323 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 326..330 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 503..512 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 507..520 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 523..532 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 536..552 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 555..569 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 559..577 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 580..589 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 593..614 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 617..625 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 621..633 FT /evidence="ECO:0000269|PubMed:16203964" FT VAR_SEQ 626..648 FT /note="NGPTSHDCIYYPWTGHSTLPQHA -> IGSSIEDCIGLMD (in isoform FT JM-B CYT-1 and isoform JM-B CYT-2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:9334263" FT /id="VSP_002895" FT VAR_SEQ 1046..1061 FT /note="Missing (in isoform JM-A CYT-2 and isoform JM-B CYT- FT 2)" FT /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.4" FT /id="VSP_022148" FT VARIANT 140 FT /note="T -> I (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042113" FT VARIANT 303 FT /note="S -> Y (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs1484791833)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042114" FT VARIANT 927 FT /note="R -> Q (in ALS19; reduces autophosphorylation upon FT NRG1 stimulation; dbSNP:rs397514262)" FT /evidence="ECO:0000269|PubMed:24119685" FT /id="VAR_070810" FT VARIANT 1275 FT /note="R -> W (in ALS19; reduces autophosphorylation upon FT NRG1 stimulation; dbSNP:rs397514263)" FT /evidence="ECO:0000269|PubMed:24119685" FT /id="VAR_070811" FT MUTAGEN 646 FT /note="Q->C: Constitutively activated kinase." FT /evidence="ECO:0000269|PubMed:17120616" FT MUTAGEN 675 FT /note="V->A: Abolishes proteolytic processing and nuclear FT localization." FT /evidence="ECO:0000269|PubMed:15746097, FT ECO:0000269|PubMed:17638867" FT MUTAGEN 681..684 FT /note="KKKR->EIMG: Abolishes nuclear localization of the FT ERBB4 intracellular domain." FT /evidence="ECO:0000269|PubMed:15534001" FT MUTAGEN 710 FT /note="L->N: Strongly reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 721 FT /note="V->I: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 751 FT /note="K->R: Abolishes kinase activity. Abolishes FT phosphorylation, proteolytic processing and nuclear FT localization." FT /evidence="ECO:0000269|PubMed:11390655, FT ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867" FT MUTAGEN 766 FT /note="M->R: Strongly reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 773 FT /note="A->S: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 782 FT /note="R->Q: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 810 FT /note="E->K: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 843 FT /note="D->N: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:16978839" FT MUTAGEN 854 FT /note="P->Q: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 861 FT /note="D->Y: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 864 FT /note="L->R: Strongly reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 872 FT /note="E->K: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 926 FT /note="T->M: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 947 FT /note="I->R: Constitutively autophosphorylated." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 992 FT /note="R->A: Abolishes APC/C-mediated degradation; when FT associated with A-995 and A-1000." FT /evidence="ECO:0000269|PubMed:17638867" FT MUTAGEN 995 FT /note="L->A: Abolishes APC/C-mediated degradation; when FT associated with A-992 and A-1000." FT /evidence="ECO:0000269|PubMed:17638867" FT MUTAGEN 1000 FT /note="D->A: Abolishes APC/C-mediated degradation; when FT associated with A-992 and A-995." FT /evidence="ECO:0000269|PubMed:17638867" FT MUTAGEN 1035 FT /note="Y->A: No effect on interaction with WWOX. Abolishes FT interaction with WWOX; when associated with A-1301." FT /evidence="ECO:0000269|PubMed:16061658" FT MUTAGEN 1056 FT /note="Y->A: Abolishes interaction with NEDD4 and impairs FT ubiquitination. Promotes nuclear translocation of ERBB4 FT intracellular domain E4ICD1." FT /evidence="ECO:0000269|PubMed:19561640" FT MUTAGEN 1056 FT /note="Y->F: Abolishes interaction with WWP1; when FT associated with F-1301." FT /evidence="ECO:0000269|PubMed:19561640" FT MUTAGEN 1301 FT /note="Y->A: Abolishes interaction with NEDD4 and impairs FT ubiquitination." FT /evidence="ECO:0000269|PubMed:12807903, FT ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640" FT MUTAGEN 1301 FT /note="Y->A: No effect on interaction with WWOX. Abolishes FT interaction with WWOX; when associated with A-1035. Loss of FT interaction with YAP1 and stimulation of transcription." FT /evidence="ECO:0000269|PubMed:12807903, FT ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640" FT MUTAGEN 1301 FT /note="Y->F: Abolishes interaction with WWP1; when FT associated with F-1056." FT /evidence="ECO:0000269|PubMed:12807903, FT ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640" FT STRAND 28..30 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 38..41 FT /evidence="ECO:0007829|PDB:3U7U" FT HELIX 42..53 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 57..61 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 63..67 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 75..79 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 82..85 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 87..91 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 95..98 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 112..114 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 115..120 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 125..128 FT /evidence="ECO:0007829|PDB:3U2P" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 144..150 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 158..160 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 163..165 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 167..169 FT /evidence="ECO:0007829|PDB:8U4L" FT HELIX 173..175 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 176..178 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 191..193 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 197..201 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 202..204 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 209..213 FT /evidence="ECO:0007829|PDB:8U4L" FT STRAND 221..225 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 226..228 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 234..242 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 245..254 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 257..261 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 265..269 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 270..273 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 274..277 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 283..285 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 288..292 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 298..300 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 303..307 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 312..317 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 320..325 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 327..329 FT /evidence="ECO:0007829|PDB:3U2P" FT STRAND 333..335 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 340..342 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 350..352 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 353..356 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 360..364 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 366..368 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 370..374 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 377..379 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 386..394 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 397..400 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 402..405 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 415..417 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 425..427 FT /evidence="ECO:0007829|PDB:8U4L" FT STRAND 432..438 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 455..461 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 469..471 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 474..476 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 479..482 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 485..487 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 489..491 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 493..497 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 498..500 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 512..516 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 519..528 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 531..534 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 537..543 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 545..548 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 551..554 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 568..573 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 576..585 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 588..592 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 595..608 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 612..616 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 625..629 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 630..632 FT /evidence="ECO:0007829|PDB:8U4L" FT HELIX 651..676 FT /evidence="ECO:0007829|PDB:2L2T" FT HELIX 715..717 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 718..729 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 731..737 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 740..743 FT /evidence="ECO:0007829|PDB:3BBT" FT STRAND 746..752 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 762..773 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 778..780 FT /evidence="ECO:0007829|PDB:3BBT" FT STRAND 783..787 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 789..791 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 793..797 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 804..810 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 812..814 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 817..836 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 846..848 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 849..853 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 856..859 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 864..869 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 884..886 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 889..893 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 899..914 FT /evidence="ECO:0007829|PDB:2R4B" FT TURN 920..923 FT /evidence="ECO:0007829|PDB:2R4B" FT TURN 926..928 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 929..934 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 947..955 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 961..963 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 967..977 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 981..983 FT /evidence="ECO:0007829|PDB:2R4B" SQ SEQUENCE 1308 AA; 146808 MW; 5E4AE80985D88761 CRC64; MKPATGLWVW VSLLVAAGTV QPSDSQSVCA GTENKLSSLS DLEQQYRALR KYYENCEVVM GNLEITSIEH NRDLSFLRSV REVTGYVLVA LNQFRYLPLE NLRIIRGTKL YEDRYALAIF LNYRKDGNFG LQELGLKNLT EILNGGVYVD QNKFLCYADT IHWQDIVRNP WPSNLTLVST NGSSGCGRCH KSCTGRCWGP TENHCQTLTR TVCAEQCDGR CYGPYVSDCC HRECAGGCSG PKDTDCFACM NFNDSGACVT QCPQTFVYNP TTFQLEHNFN AKYTYGAFCV KKCPHNFVVD SSSCVRACPS SKMEVEENGI KMCKPCTDIC PKACDGIGTG SLMSAQTVDS SNIDKFINCT KINGNLIFLV TGIHGDPYNA IEAIDPEKLN VFRTVREITG FLNIQSWPPN MTDFSVFSNL VTIGGRVLYS GLSLLILKQQ GITSLQFQSL KEISAGNIYI TDNSNLCYYH TINWTTLFST INQRIVIRDN RKAENCTAEG MVCNHLCSSD GCWGPGPDQC LSCRRFSRGR ICIESCNLYD GEFREFENGS ICVECDPQCE KMEDGLLTCH GPGPDNCTKC SHFKDGPNCV EKCPDGLQGA NSFIFKYADP DRECHPCHPN CTQGCNGPTS HDCIYYPWTG HSTLPQHART PLIAAGVIGG LFILVIVGLT FAVYVRRKSI KKKRALRRFL ETELVEPLTP SGTAPNQAQL RILKETELKR VKVLGSGAFG TVYKGIWVPE GETVKIPVAI KILNETTGPK ANVEFMDEAL IMASMDHPHL VRLLGVCLSP TIQLVTQLMP HGCLLEYVHE HKDNIGSQLL LNWCVQIAKG MMYLEERRLV HRDLAARNVL VKSPNHVKIT DFGLARLLEG DEKEYNADGG KMPIKWMALE CIHYRKFTHQ SDVWSYGVTI WELMTFGGKP YDGIPTREIP DLLEKGERLP QPPICTIDVY MVMVKCWMID ADSRPKFKEL AAEFSRMARD PQRYLVIQGD DRMKLPSPND SKFFQNLLDE EDLEDMMDAE EYLVPQAFNI PPPIYTSRAR IDSNRSEIGH SPPPAYTPMS GNQFVYRDGG FAAEQGVSVP YRAPTSTIPE APVAQGATAE IFDDSCCNGT LRKPVAPHVQ EDSSTQRYSA DPTVFAPERS PRGELDEEGY MTPMRDKPKQ EYLNPVEENP FVSRRKNGDL QALDNPEYHN ASNGPPKAED EYVNEPLYLN TFANTLGKAE YLKNNILSMP EKAKKAFDNP DYWNHSLPPR STLQHPDYLQ EYSTKYFYKQ NGRIRPIVAE NPEYLSEFSL KPGTVLPPPP YRHRNTVV // ID GLT12_HUMAN Reviewed; 581 AA. AC Q8IXK2; Q5TCF7; Q8NG54; Q96CT9; Q9H771; DT 16-AUG-2004, integrated into UniProtKB/Swiss-Prot. DT 20-DEC-2005, sequence version 3. DT 28-JAN-2026, entry version 192. DE RecName: Full=Polypeptide N-acetylgalactosaminyltransferase 12; DE EC=2.4.1.41; DE AltName: Full=Polypeptide GalNAc transferase 12; DE Short=GalNAc-T12; DE Short=pp-GaNTase 12; DE AltName: Full=Protein-UDP acetylgalactosaminyltransferase 12; DE AltName: Full=UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 12; GN Name=GALNT12; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ENZYME ACTIVITY, TISSUE RP SPECIFICITY, AND VARIANT VAL-119. RC TISSUE=Lung; RX PubMed=12135769; DOI=10.1016/s0014-5793(02)03007-7; RA Guo J.-M., Zhang Y., Cheng L., Iwasaki H., Wang H., Kubota T., RA Tachibana K., Narimatsu H.; RT "Molecular cloning and characterization of a novel member of the UDP- RT GalNAc:polypeptide N-acetylgalactosaminyltransferase family, pp-GalNAc- RT T12(1)."; RL FEBS Lett. 524:211-218(2002). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Bennett E.P.; RL Submitted (JAN-1999) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Bone marrow; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 144-581 (ISOFORM 1). RC TISSUE=Colon; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP VARIANTS CRCS1 TRP-297; ASN-303; ASP-341; HIS-373; HIS-382; PHE-479 AND RP MET-491, CHARACTERIZATION OF VARIANTS CRCS1 TRP-297; ASN-303; ASP-341; RP HIS-373; HIS-382; PHE-479 AND MET-491, AND VARIANTS GLU-3; ARG-46; VAL-119; RP ASN-261; ARG-272 AND LYS-552. RX PubMed=19617566; DOI=10.1073/pnas.0901454106; RA Guda K., Moinova H., He J., Jamison O., Ravi L., Natale L., Lutterbaugh J., RA Lawrence E., Lewis S., Willson J.K., Lowe J.B., Wiesner G.L., RA Parmigiani G., Barnholtz-Sloan J., Dawson D.W., Velculescu V.E., RA Kinzler K.W., Papadopoulos N., Vogelstein B., Willis J., Gerken T.A., RA Markowitz S.D.; RT "Inactivating germ-line and somatic mutations in polypeptide N- RT acetylgalactosaminyltransferase 12 in human colon cancers."; RL Proc. Natl. Acad. Sci. U.S.A. 106:12921-12925(2009). RN [7] RP VARIANTS CRCS1 ASN-303 AND CYS-396. RX PubMed=22461326; DOI=10.1002/humu.22088; RA Clarke E., Green R.C., Green J.S., Mahoney K., Parfrey P.S., RA Younghusband H.B., Woods M.O.; RT "Inherited deleterious variants in GALNT12 are associated with CRC RT susceptibility."; RL Hum. Mutat. 33:1056-1058(2012). RN [8] RP INVOLVEMENT IN CRCS1. RX PubMed=24115450; DOI=10.1002/humu.22454; RA Segui N., Pineda M., Navarro M., Lazaro C., Brunet J., Infante M., RA Duran M., Soto J.L., Blanco I., Capella G., Valle L.; RT "GALNT12 is not a major contributor of familial colorectal cancer type X."; RL Hum. Mutat. 35:50-52(2014). CC -!- FUNCTION: Catalyzes the initial reaction in O-linked oligosaccharide CC biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a CC serine or threonine residue on the protein receptor. Has activity CC toward non-glycosylated peptides such as Muc5AC, Muc1a and EA2, and no CC detectable activity with Muc2 and Muc7. Displays enzymatic activity CC toward the Gal-NAc-Muc5AC glycopeptide, but no detectable activity to CC mono-GalNAc-glycosylated Muc1a, Muc2, Muc7 and EA2. May play an CC important role in the initial step of mucin-type oligosaccharide CC biosynthesis in digestive organs. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + UDP-N-acetyl-alpha-D-galactosamine = a 3- CC O-[N-acetyl-alpha-D-galactosaminyl]-L-seryl-[protein] + UDP + H(+); CC Xref=Rhea:RHEA:23956, Rhea:RHEA-COMP:9863, Rhea:RHEA-COMP:12788, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:53604, CC ChEBI:CHEBI:58223, ChEBI:CHEBI:67138; EC=2.4.1.41; CC Evidence={ECO:0000269|PubMed:12135769}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + UDP-N-acetyl-alpha-D-galactosamine = a CC 3-O-[N-acetyl-alpha-D-galactosaminyl]-L-threonyl-[protein] + UDP + CC H(+); Xref=Rhea:RHEA:52424, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11689, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:58223, CC ChEBI:CHEBI:67138, ChEBI:CHEBI:87075; EC=2.4.1.41; CC Evidence={ECO:0000269|PubMed:12135769}; CC -!- COFACTOR: CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250}; CC -!- PATHWAY: Protein modification; protein glycosylation. CC -!- INTERACTION: CC Q8IXK2; P02790: HPX; NbExp=3; IntAct=EBI-8995375, EBI-1223791; CC -!- SUBCELLULAR LOCATION: Golgi apparatus membrane {ECO:0000250}; Single- CC pass type II membrane protein {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q8IXK2-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8IXK2-2; Sequence=VSP_011217; CC -!- TISSUE SPECIFICITY: Widely expressed at different levels of expression. CC Highly expressed in digestive organs such as small intestine, stomach, CC pancreas and colon. Expressed at intermediate level in testis, thyroid CC gland and spleen. Weakly expressed in whole brain, cerebral cortex, CC cerebellum, fetal brain, bone marrow, thymus, leukocytes, heart, CC skeletal muscle, liver, lung, esophagus, kidney, adrenal gland, mammary CC gland, uterus, placenta, ovary and prostate. CC {ECO:0000269|PubMed:12135769}. CC -!- DOMAIN: There are two conserved domains in the glycosyltransferase CC region: the N-terminal domain (domain A, also called GT1 motif), which CC is probably involved in manganese coordination and substrate binding CC and the C-terminal domain (domain B, also called Gal/GalNAc-T motif), CC which is probably involved in catalytic reaction and UDP-Gal binding. CC {ECO:0000250}. CC -!- DOMAIN: The ricin B-type lectin domain binds to GalNAc and contributes CC to the glycopeptide specificity. {ECO:0000250}. CC -!- DISEASE: Colorectal cancer 1 (CRCS1) [MIM:608812]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:19617566, CC ECO:0000269|PubMed:22461326, ECO:0000269|PubMed:24115450}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. The role of GALNT12 in colon cancer CC susceptibility is however subject to discussion: studies on 103 CC probants with colorectal cancer 1 (CRCS1) suggest that it does not act CC as a major contributor of CRCS1 (PubMed:24115450). CC {ECO:0000269|PubMed:24115450}. CC -!- SIMILARITY: Belongs to the glycosyltransferase 2 family. GalNAc-T CC subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAB15027.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Functional Glycomics Gateway - GTase; CC Note=Polypeptide N-acetylgalactosaminyltransferase 12; CC URL="http://www.functionalglycomics.org/glycomics/molecule/jsp/glycoEnzyme/viewGlycoEnzyme.jsp?gbpId=gt_hum_495"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB078146; BAC07181.1; -; mRNA. DR EMBL; AJ132365; CAC80100.2; -; mRNA. DR EMBL; AL136084; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC013945; AAH13945.1; -; mRNA. DR EMBL; AK024865; BAB15027.1; ALT_INIT; mRNA. DR CCDS; CCDS6737.1; -. [Q8IXK2-1] DR RefSeq; NP_078918.3; NM_024642.4. [Q8IXK2-1] DR RefSeq; XP_006717350.1; XM_006717287.1. DR PDB; 6PXU; X-ray; 2.01 A; A/B=39-581. DR PDBsum; 6PXU; -. DR AlphaFoldDB; Q8IXK2; -. DR SMR; Q8IXK2; -. DR BioGRID; 122816; 129. DR FunCoup; Q8IXK2; 763. DR IntAct; Q8IXK2; 92. DR MINT; Q8IXK2; -. DR STRING; 9606.ENSP00000364150; -. DR CAZy; CBM13; Carbohydrate-Binding Module Family 13. DR CAZy; GT27; Glycosyltransferase Family 27. DR UniLectin; Q8IXK2; -. DR GlyGen; Q8IXK2; 3 sites, 1 O-linked glycan (3 sites). DR iPTMnet; Q8IXK2; -. DR PhosphoSitePlus; Q8IXK2; -. DR SwissPalm; Q8IXK2; -. DR BioMuta; GALNT12; -. DR DMDM; 84028209; -. DR jPOST; Q8IXK2; -. DR MassIVE; Q8IXK2; -. DR PaxDb; 9606-ENSP00000364150; -. DR PeptideAtlas; Q8IXK2; -. DR ProteomicsDB; 71019; -. [Q8IXK2-1] DR ProteomicsDB; 71020; -. [Q8IXK2-2] DR Pumba; Q8IXK2; -. DR Antibodypedia; 29005; 88 antibodies from 14 providers. DR DNASU; 79695; -. DR Ensembl; ENST00000375011.4; ENSP00000364150.3; ENSG00000119514.8. [Q8IXK2-1] DR GeneID; 79695; -. DR KEGG; hsa:79695; -. DR MANE-Select; ENST00000375011.4; ENSP00000364150.3; NM_024642.5; NP_078918.3. DR UCSC; uc004ayz.3; human. [Q8IXK2-1] DR AGR; HGNC:19877; -. DR ClinPGx; PA134929192; -. DR CTD; 79695; -. DR DisGeNET; 79695; -. DR GeneCards; GALNT12; -. DR HGNC; HGNC:19877; GALNT12. DR HPA; ENSG00000119514; Tissue enhanced (epididymis, intestine, stomach). DR MalaCards; GALNT12; -. DR MIM; 608812; phenotype. DR MIM; 610290; gene. DR OpenTargets; ENSG00000119514; -. DR VEuPathDB; HostDB:ENSG00000119514; -. DR eggNOG; KOG3736; Eukaryota. DR GeneTree; ENSGT00940000157173; -. DR HOGENOM; CLU_013477_0_3_1; -. DR InParanoid; Q8IXK2; -. DR OMA; SKSYFHY; -. DR OrthoDB; 416652at2759; -. DR PAN-GO; Q8IXK2; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q8IXK2; -. DR BRENDA; 2.4.1.41; 2681. DR PathwayCommons; Q8IXK2; -. DR Reactome; R-HSA-5083636; Defective GALNT12 causes CRCS1. DR Reactome; R-HSA-913709; O-linked glycosylation of mucins. DR SignaLink; Q8IXK2; -. DR UniPathway; UPA00378; -. DR Agora; ENSG00000119514; -. DR BioGRID-ORCS; 79695; 10 hits in 1155 CRISPR screens. DR ChiTaRS; GALNT12; human. DR GenomeRNAi; 79695; -. DR Pharos; Q8IXK2; Tbio. DR PRO; PR:Q8IXK2; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q8IXK2; protein. DR Bgee; ENSG00000119514; Expressed in palpebral conjunctiva and 153 other cell types or tissues. DR ExpressionAtlas; Q8IXK2; baseline and differential. DR GO; GO:0005794; C:Golgi apparatus; IBA:GO_Central. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004653; F:polypeptide N-acetylgalactosaminyltransferase activity; IBA:GO_Central. DR GO; GO:0006493; P:protein O-linked glycosylation; IBA:GO_Central. DR GO; GO:0016266; P:protein O-linked glycosylation via N-acetyl-galactosamine; TAS:Reactome. DR CDD; cd23471; beta-trefoil_Ricin_GALNT12; 1. DR CDD; cd02510; pp-GalNAc-T; 1. DR FunFam; 2.80.10.50:FF:000057; Polypeptide N-acetylgalactosaminyltransferase; 1. DR FunFam; 3.90.550.10:FF:000021; Polypeptide N-acetylgalactosaminyltransferase; 1. DR Gene3D; 2.80.10.50; -; 1. DR Gene3D; 3.90.550.10; Spore Coat Polysaccharide Biosynthesis Protein SpsA, Chain A; 1. DR InterPro; IPR045885; GalNAc-T. DR InterPro; IPR001173; Glyco_trans_2-like. DR InterPro; IPR029044; Nucleotide-diphossugar_trans. DR InterPro; IPR035992; Ricin_B-like_lectins. DR InterPro; IPR000772; Ricin_B_lectin. DR PANTHER; PTHR11675; N-ACETYLGALACTOSAMINYLTRANSFERASE; 1. DR PANTHER; PTHR11675:SF18; POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 12; 1. DR Pfam; PF00535; Glycos_transf_2; 1. DR Pfam; PF00652; Ricin_B_lectin; 1. DR SMART; SM00458; RICIN; 1. DR SUPFAM; SSF53448; Nucleotide-diphospho-sugar transferases; 1. DR SUPFAM; SSF50370; Ricin B-like lectins; 1. DR PROSITE; PS50231; RICIN_B_LECTIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Disease variant; Disulfide bond; KW Glycosyltransferase; Golgi apparatus; Lectin; Manganese; Membrane; KW Metal-binding; Proteomics identification; Reference proteome; KW Signal-anchor; Transferase; Transmembrane; Transmembrane helix. FT CHAIN 1..581 FT /note="Polypeptide N-acetylgalactosaminyltransferase 12" FT /id="PRO_0000059128" FT TOPO_DOM 1..19 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 20..37 FT /note="Helical; Signal-anchor for type II membrane protein" FT /evidence="ECO:0000255" FT TOPO_DOM 38..581 FT /note="Lumenal" FT /evidence="ECO:0000255" FT DOMAIN 445..577 FT /note="Ricin B-type lectin" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00174" FT REGION 43..67 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 135..244 FT /note="Catalytic subdomain A" FT REGION 304..366 FT /note="Catalytic subdomain B" FT BINDING 176 FT /ligand="substrate" FT /evidence="ECO:0000250" FT BINDING 205 FT /ligand="substrate" FT /evidence="ECO:0000250" FT BINDING 228 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /evidence="ECO:0000250" FT BINDING 230 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /evidence="ECO:0000250" FT BINDING 335 FT /ligand="substrate" FT /evidence="ECO:0000250" FT BINDING 363 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /evidence="ECO:0000250" FT BINDING 371 FT /ligand="substrate" FT /evidence="ECO:0000250" FT DISULFID 125..358 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00174" FT DISULFID 349..422 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00174" FT DISULFID 458..479 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00174" FT DISULFID 506..521 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00174" FT DISULFID 547..566 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00174" FT VAR_SEQ 1..309 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_011217" FT VARIANT 3 FT /note="G -> E (in dbSNP:rs1356894484)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064352" FT VARIANT 46 FT /note="G -> R (in dbSNP:rs10987768)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064353" FT VARIANT 119 FT /note="E -> V (in dbSNP:rs1137654)" FT /evidence="ECO:0000269|PubMed:12135769, FT ECO:0000269|PubMed:19617566" FT /id="VAR_064354" FT VARIANT 261 FT /note="D -> N (in dbSNP:rs41306504)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064355" FT VARIANT 272 FT /note="G -> R (in dbSNP:rs367645298)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064356" FT VARIANT 297 FT /note="R -> W (in CRCS1; germline mutation; partial loss of FT activity; dbSNP:rs149726976)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064357" FT VARIANT 303 FT /note="D -> N (in CRCS1; germline mutation; reduction of FT activity; dbSNP:rs145236923)" FT /evidence="ECO:0000269|PubMed:19617566, FT ECO:0000269|PubMed:22461326" FT /id="VAR_064358" FT VARIANT 341 FT /note="E -> D (in CRCS1; somatic mutation; loss of FT activity)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064359" FT VARIANT 373 FT /note="R -> H (in CRCS1; germline mutation; partial loss of FT activity; dbSNP:rs920049418)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064360" FT VARIANT 382 FT /note="R -> H (in CRCS1; germline mutation; loss of FT activity; dbSNP:rs868590153)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064361" FT VARIANT 396 FT /note="Y -> C (in CRCS1; dbSNP:rs1272530441)" FT /evidence="ECO:0000269|PubMed:22461326" FT /id="VAR_068509" FT VARIANT 479 FT /note="C -> F (in CRCS1; somatic mutation; loss of FT activity)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064362" FT VARIANT 491 FT /note="T -> M (in CRCS1; germline mutation; loss of FT activity; dbSNP:rs267606840)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064363" FT VARIANT 552 FT /note="R -> K (in dbSNP:rs1285871027)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064364" FT STRAND 61..65 FT /evidence="ECO:0007829|PDB:6PXU" FT TURN 75..78 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 88..101 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 105..108 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 123..127 FT /evidence="ECO:0007829|PDB:6PXU" FT TURN 132..134 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 138..146 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 149..162 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 165..167 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 168..175 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 181..183 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 185..191 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 197..201 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 207..218 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 221..226 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 229..233 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 238..247 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 251..260 FT /evidence="ECO:0007829|PDB:6PXU" FT TURN 262..264 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 276..279 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 285..288 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 292..297 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 315..318 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 319..324 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 334..337 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 338..348 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 352..364 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 376..387 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 389..391 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 392..398 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 400..404 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 411..419 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 425..431 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 445..454 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 457..460 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 464..467 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 475..478 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 484..486 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 488..490 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 496..498 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 500..503 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 505..508 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 517..520 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 527..529 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 531..533 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 537..541 FT /evidence="ECO:0007829|PDB:6PXU" FT TURN 542..545 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 546..551 FT /evidence="ECO:0007829|PDB:6PXU" FT TURN 554..556 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 560..564 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 570..572 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 573..579 FT /evidence="ECO:0007829|PDB:6PXU" SQ SEQUENCE 581 AA; 66938 MW; 8C001D58E103A523 CRC64; MWGRTARRRC PRELRRGREA LLVLLALLAL AGLGSVLRAQ RGAGAGAAEP GPPRTPRPGR REPVMPRPPV PANALGARGE AVRLQLQGEE LRLQEESVRL HQINIYLSDR ISLHRRLPER WNPLCKEKKY DYDNLPRTSV IIAFYNEAWS TLLRTVYSVL ETSPDILLEE VILVDDYSDR EHLKERLANE LSGLPKVRLI RANKREGLVR ARLLGASAAR GDVLTFLDCH CECHEGWLEP LLQRIHEEES AVVCPVIDVI DWNTFEYLGN SGEPQIGGFD WRLVFTWHTV PERERIRMQS PVDVIRSPTM AGGLFAVSKK YFEYLGSYDT GMEVWGGENL EFSFRIWQCG GVLETHPCSH VGHVFPKQAP YSRNKALANS VRAAEVWMDE FKELYYHRNP RARLEPFGDV TERKQLRDKL QCKDFKWFLE TVYPELHVPE DRPGFFGMLQ NKGLTDYCFD YNPPDENQIV GHQVILYLCH GMGQNQFFEY TSQKEIRYNT HQPEGCIAVE AGMDTLIMHL CEETAPENQK FILQEDGSLF HEQSKKCVQA ARKESSDSFV PLLRDCTNSD HQKWFFKERM L // ID INSR_HUMAN Reviewed; 1382 AA. AC P06213; Q17RW0; Q59H98; Q9UCB7; Q9UCB8; Q9UCB9; DT 01-JAN-1988, integrated into UniProtKB/Swiss-Prot. DT 05-OCT-2010, sequence version 4. DT 28-JAN-2026, entry version 294. DE RecName: Full=Insulin receptor; DE Short=IR; DE EC=2.7.10.1; DE AltName: CD_antigen=CD220; DE Contains: DE RecName: Full=Insulin receptor subunit alpha; DE Contains: DE RecName: Full=Insulin receptor subunit beta; DE Flags: Precursor; GN Name=INSR; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANTS GLY-2; HIS-171; RP THR-448 AND LYS-492. RX PubMed=2859121; DOI=10.1016/0092-8674(85)90334-4; RA Ebina Y., Ellis L., Jarnagin K., Edery M., Graf L., Clauser E., Ou J.-H., RA Masiarz F., Kan Y.W., Goldfine I.D., Roth R.A., Rutter W.J.; RT "The human insulin receptor cDNA: the structural basis for hormone- RT activated transmembrane signalling."; RL Cell 40:747-758(1985). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), PROTEIN SEQUENCE OF 28-49 AND RP 763-782, GLYCOSYLATION AT ASN-43 AND ASN-769, AND VARIANT GLY-2. RX PubMed=2983222; DOI=10.1038/313756a0; RA Ullrich A., Bell J.R., Chen E.Y., Herrera R., Petruzzelli L.M., Dull T.J., RA Gray A., Coussens L., Liao Y.-C., Tsubokawa M., Mason A., Seeburg P.H., RA Grunfeld C., Rosen O.M., Ramachandran J.; RT "Human insulin receptor and its relationship to the tyrosine kinase family RT of oncogenes."; RL Nature 313:756-761(1985). RN [3] RP SEQUENCE REVISION TO 899-900. RA Chen E.Y.; RL Submitted (JUL-1985) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLY-2. RC TISSUE=Fetal liver; RX PubMed=2210055; DOI=10.2337/diacare.39.1.123; RA Seino S., Seino M., Bell G.I.; RT "Human insulin-receptor gene. Partial sequence and amplification of exons RT by polymerase chain reaction."; RL Diabetes 39:123-128(1990). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SHORT), AND VARIANT GLY-2. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2. RX PubMed=3680248; DOI=10.1016/s0021-9258(18)47714-9; RA Araki E., Shimada F., Uzawa H., Mori M., Ebina Y.; RT "Characterization of the promoter region of the human insulin receptor RT gene. Evidence for promoter activity."; RL J. Biol. Chem. 262:16186-16191(1987). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2. RX PubMed=2806055; DOI=10.1016/0168-8227(89)90085-5; RA Araki E., Shimada F., Fukushima H., Mori M., Shichiri M., Ebina Y.; RT "Characterization of the promoter region of the human insulin receptor RT gene."; RL Diabetes Res. Clin. Pract. 7:S31-S33(1989). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2. RX PubMed=2777789; DOI=10.1016/s0021-9258(18)71612-8; RA Tewari D.S., Cook D.M., Taub R.; RT "Characterization of the promoter region and 3' end of the human insulin RT receptor gene."; RL J. Biol. Chem. 264:16238-16245(1989). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2. RC TISSUE=Skin fibroblast; RX PubMed=2280779; DOI=10.1210/mend-4-4-647; RA McKeon C., Moncada V., Pham T., Salvatore P., Kadowaki T., Accili D., RA Taylor S.I.; RT "Structural and functional analysis of the insulin receptor promoter."; RL Mol. Endocrinol. 4:647-656(1990). RN [11] RP PROTEIN SEQUENCE OF 28-44; 192-205; 299-314; 610-627 AND 763-780, ACTIVITY RP REGULATION, AND SUBUNIT. RC TISSUE=Placenta; RX PubMed=2211730; DOI=10.1016/s0021-9258(17)44805-8; RA Xu Q.-Y., Paxton R.J., Fujita-Yamaguchi Y.; RT "Substructural analysis of the insulin receptor by microsequence analyses RT of limited tryptic fragments isolated by sodium dodecyl sulfate- RT polyacrylamide gel electrophoresis in the absence or presence of RT dithiothreitol."; RL J. Biol. Chem. 265:18673-18681(1990). RN [12] RP PROTEIN SEQUENCE OF 28-45 AND 763-782, FUNCTION, AND FORMATION OF A HYBRID RP RECEPTOR WITH IGF1R. RC TISSUE=Placenta; RX PubMed=8257688; DOI=10.1021/bi00212a019; RA Kasuya J., Paz I.B., Maddux B.A., Goldfine I.D., Hefta S.A., RA Fujita-Yamaguchi Y.; RT "Characterization of human placental insulin-like growth factor-I/insulin RT hybrid receptors by protein microsequencing and purification."; RL Biochemistry 32:13531-13536(1993). RN [13] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 538-1382 (ISOFORM SHORT). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] OF 728-772 (ISOFORM LONG), AND ALTERNATIVE RP SPLICING. RX PubMed=2538124; DOI=10.1016/0006-291x(89)92439-x; RA Seino S., Bell G.I.; RT "Alternative splicing of human insulin receptor messenger RNA."; RL Biochem. Biophys. Res. Commun. 159:312-316(1989). RN [15] RP NUCLEOTIDE SEQUENCE [MRNA] OF 744-823 (ISOFORM LONG), TISSUE SPECIFICITY, RP LIGAND-BINDING, AND AUTOPHOSPHORYLATION. RX PubMed=2369896; DOI=10.1002/j.1460-2075.1990.tb07416.x; RA Mosthaf L., Grako K., Dull T.J., Coussens L., Ullrich A., McClain D.A.; RT "Functionally distinct insulin receptors generated by tissue-specific RT alternative splicing."; RL EMBO J. 9:2409-2413(1990). RN [16] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 895-1085. RX PubMed=2566545; DOI=10.2337/diab.38.6.737; RA Elbein S.C.; RT "Molecular and clinical characterization of an insertional polymorphism of RT the insulin-receptor gene."; RL Diabetes 38:737-743(1989). RN [17] RP PROTEIN SEQUENCE OF 927-956; 981-1019; 1182-1194 AND 1352-1369, AND RP PHOSPHORYLATION AT TYR-999; TYR-1355 AND TYR-1361. RC TISSUE=Placenta; RX PubMed=3166375; DOI=10.1042/bj2520607; RA Tavare J.M., Denton R.M.; RT "Studies on the autophosphorylation of the insulin receptor from human RT placenta. Analysis of the sites phosphorylated by two-dimensional peptide RT mapping."; RL Biochem. J. 252:607-615(1988). RN [18] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1006-1123. RX PubMed=2544997; DOI=10.1126/science.2544997; RA Taira M., Taira M., Hashimoto N., Shimada F., Suzuki Y., Kanatsuka A., RA Nakamura F., Ebina Y., Tatibana M., Makino H.; RT "Human diabetes associated with a deletion of the tyrosine kinase domain of RT the insulin receptor."; RL Science 245:63-66(1989). RN [19] RP PARTIAL PROTEIN SEQUENCE. RX PubMed=3447155; RA Fujita-Yamaguchi Y., Hawke D., Shively J.E., Choi S.; RT "Partial amino acid sequence analyses of human placental insulin RT receptor."; RL Protein Seq. Data Anal. 1:3-6(1987). RN [20] RP MUTAGENESIS OF LYS-1057. RX PubMed=3101064; DOI=10.1073/pnas.84.3.704; RA Ebina Y., Araki E., Taira M., Shimada F., Mori M., Craik C.S., Siddle K., RA Pierce S.B., Roth R.A., Rutter W.J.; RT "Replacement of lysine residue 1030 in the putative ATP-binding region of RT the insulin receptor abolishes insulin- and antibody-stimulated glucose RT uptake and receptor kinase activity."; RL Proc. Natl. Acad. Sci. U.S.A. 84:704-708(1987). RN [21] RP MUTAGENESIS OF TYR-999. RX PubMed=2842060; DOI=10.1016/s0092-8674(88)80008-4; RA White M.F., Livingston J.N., Backer J.M., Lauris V., Dull T.J., Ullrich A., RA Kahn C.R.; RT "Mutation of the insulin receptor at tyrosine 960 inhibits signal RT transmission but does not affect its tyrosine kinase activity."; RL Cell 54:641-649(1988). RN [22] RP AUTOPHOSPHORYLATION. RX PubMed=1321605; DOI=10.1016/s0006-291x(05)80799-5; RA Dickens M., Tavare J.M.; RT "Analysis of the order of autophosphorylation of human insulin receptor RT tyrosines 1158, 1162 and 1163."; RL Biochem. Biophys. Res. Commun. 186:244-250(1992). RN [23] RP DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-541. RX PubMed=1472036; DOI=10.1016/0006-291x(92)92250-2; RA Schaeffer L., Ljungqvist L.; RT "Identification of a disulfide bridge connecting the alpha-subunits of the RT extracellular domain of the insulin receptor."; RL Biochem. Biophys. Res. Commun. 189:650-653(1992). RN [24] RP FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R. RX PubMed=8452530; DOI=10.1042/bj2900419; RA Soos M.A., Field C.E., Siddle K.; RT "Purified hybrid insulin/insulin-like growth factor-I receptors bind RT insulin-like growth factor-I, but not insulin, with high affinity."; RL Biochem. J. 290:419-426(1993). RN [25] RP FUNCTION, AND INTERACTION WITH PIK3R1. RX PubMed=8276809; DOI=10.1016/s0021-9258(17)42304-0; RA Van Horn D.J., Myers M.G. Jr., Backer J.M.; RT "Direct activation of the phosphatidylinositol 3'-kinase by the insulin RT receptor."; RL J. Biol. Chem. 269:29-32(1994). RN [26] RP INTERACTION WITH IRS1 AND SHC1, AND MUTAGENESIS OF LEU-991; TYR-992; RP ASN-996; 996-ASN-PRO-997; PRO-997; TYR-999; LEU-1000 AND ALA-1002. RX PubMed=7559478; DOI=10.1074/jbc.270.40.23258; RA He W., O'Neill T.J., Gustafson T.A.; RT "Distinct modes of interaction of SHC and insulin receptor substrate-1 with RT the insulin receptor NPEY region via non-SH2 domains."; RL J. Biol. Chem. 270:23258-23262(1995). RN [27] RP INTERACTION WITH IRS1; SHC1 AND PIK3R1, AND MUTAGENESIS OF ASN-996; RP PRO-997; GLU-998; TYR-999 AND LYS-1057. RX PubMed=7537849; DOI=10.1128/mcb.15.5.2500; RA Gustafson T.A., He W., Craparo A., Schaub C.D., O'Neill T.J.; RT "Phosphotyrosine-dependent interaction of SHC and insulin receptor RT substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 RT domain."; RL Mol. Cell. Biol. 15:2500-2508(1995). RN [28] RP FORMATION OF A HYBRID RECEPTOR WITH IGF1R, AND TISSUE SPECIFICITY. RX PubMed=9355755; DOI=10.1042/bj3270209; RA Bailyes E.M., Nave B.T., Soos M.A., Orr S.R., Hayward A.C., Siddle K.; RT "Insulin receptor/IGF-I receptor hybrids are widely distributed in RT mammalian tissues: quantification of individual receptor species by RT selective immunoprecipitation and immunoblotting."; RL Biochem. J. 327:209-215(1997). RN [29] RP FUNCTION IN PHOSPHORYLATION OF STAT5B, MUTAGENESIS OF TYR-999, AND RP INTERACTION WITH STAT5B; IRS1 AND IRS2. RX PubMed=9428692; DOI=10.1111/j.1432-1033.1997.0411a.x; RA Sawka-Verhelle D., Filloux C., Tartare-Deckert S., Mothe I., RA Van Obberghen E.; RT "Identification of Stat 5B as a substrate of the insulin receptor."; RL Eur. J. Biochem. 250:411-417(1997). RN [30] RP INTERACTION WITH PTPRF. RX PubMed=8995282; DOI=10.1074/jbc.272.11.7519; RA Ahmad F., Goldstein B.J.; RT "Functional association between the insulin receptor and the transmembrane RT protein-tyrosine phosphatase LAR in intact cells."; RL J. Biol. Chem. 272:448-457(1997). RN [31] RP INTERACTION WITH PTPRE, AND DEPHOSPHORYLATION BY PTPRE. RX PubMed=8999839; DOI=10.1074/jbc.272.3.1639; RA Bandyopadhyay D., Kusari A., Kenner K.A., Liu F., Chernoff J., RA Gustafson T.A., Kusari J.; RT "Protein-tyrosine phosphatase 1B complexes with the insulin receptor in RT vivo and is tyrosine-phosphorylated in the presence of insulin."; RL J. Biol. Chem. 272:1639-1645(1997). RN [32] RP FORMATION OF A HYBRID RECEPTOR WITH IGF1R, AND TISSUE SPECIFICITY. RX PubMed=9202395; DOI=10.1016/s0303-7207(97)04050-1; RA Federici M., Porzio O., Zucaro L., Fusco A., Borboni P., Lauro D., RA Sesti G.; RT "Distribution of insulin/insulin-like growth factor-I hybrid receptors in RT human tissues."; RL Mol. Cell. Endocrinol. 129:121-126(1997). RN [33] RP TISSUE SPECIFICITY, AND FUNCTION AS RECEPTOR FOR IGFII (ISOFORM SHORT). RX PubMed=10207053; DOI=10.1128/mcb.19.5.3278; RA Frasca F., Pandini G., Scalia P., Sciacca L., Mineo R., Costantino A., RA Goldfine I.D., Belfiore A., Vigneri R.; RT "Insulin receptor isoform A, a newly recognized, high-affinity insulin-like RT growth factor II receptor in fetal and cancer cells."; RL Mol. Cell. Biol. 19:3278-3288(1999). RN [34] RP INTERACTION WITH ENPP1, AND ACTIVITY REGULATION. RX PubMed=10615944; DOI=10.2337/diabetes.49.1.13; RA Maddux B.A., Goldfine I.D.; RT "Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs RT via direct interaction with the receptor alpha-subunit."; RL Diabetes 49:13-19(2000). RN [35] RP PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN1 AND PTPN2. RX PubMed=10734133; DOI=10.1074/jbc.275.13.9792; RA Waelchli S., Curchod M.L., Gobert R.P., Arkinstall S., RA Hooft van Huijsduijnen R.; RT "Identification of tyrosine phosphatases that dephosphorylate the insulin RT receptor. A brute force approach based on 'substrate-trapping' mutants."; RL J. Biol. Chem. 275:9792-9796(2000). RN [36] RP INTERACTION WITH GRB7, AND MUTAGENESIS OF LYS-1057; TYR-1189 AND TYR-1190. RX PubMed=10803466; DOI=10.1038/sj.onc.1203469; RA Kasus-Jacobi A., Bereziat V., Perdereau D., Girard J., Burnol A.F.; RT "Evidence for an interaction between the insulin receptor and Grb7. A role RT for two of its binding domains, PIR and SH2."; RL Oncogene 19:2052-2059(2000). RN [37] RP INTERACTION WITH SORBS1. RX PubMed=11374898; DOI=10.1006/geno.2001.6541; RA Lin W.-H., Huang C.-J., Liu M.-W., Chang H.-M., Chen Y.-J., Tai T.-Y., RA Chuang L.-M.; RT "Cloning, mapping, and characterization of the human sorbin and SH3 domain RT containing 1 (SORBS1) gene: a protein associated with c-Abl during insulin RT signaling in the hepatoma cell line Hep3B."; RL Genomics 74:12-20(2001). RN [38] RP CATALYTIC ACTIVITY, MUTAGENESIS OF ASP-1159 AND ARG-1163, AND ACTIVITY RP REGULATION. RX PubMed=11598120; DOI=10.1074/jbc.m107236200; RA Ablooglu A.J., Frankel M., Rusinova E., Ross J.B., Kohanski R.A.; RT "Multiple activation loop conformations and their regulatory properties in RT the insulin receptor's kinase domain."; RL J. Biol. Chem. 276:46933-46940(2001). RN [39] RP INTERACTION WITH GRB14, AND ACTIVITY REGULATION. RX PubMed=11726652; DOI=10.1074/jbc.m106574200; RA Bereziat V., Kasus-Jacobi A., Perdereau D., Cariou B., Girard J., RA Burnol A.F.; RT "Inhibition of insulin receptor catalytic activity by the molecular adapter RT Grb14."; RL J. Biol. Chem. 277:4845-4852(2002). RN [40] RP FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R. RX PubMed=12138094; DOI=10.1074/jbc.m202766200; RA Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., Belfiore A.; RT "Insulin/insulin-like growth factor I hybrid receptors have different RT biological characteristics depending on the insulin receptor isoform RT involved."; RL J. Biol. Chem. 277:39684-39695(2002). RN [41] RP INTERACTION WITH GRB10, AND ACTIVITY REGULATION. RX PubMed=12493740; DOI=10.1074/jbc.m208518200; RA Wick K.R., Werner E.D., Langlais P., Ramos F.J., Dong L.Q., Shoelson S.E., RA Liu F.; RT "Grb10 inhibits insulin-stimulated insulin receptor substrate (IRS)- RT phosphatidylinositol 3-kinase/Akt signaling pathway by disrupting the RT association of IRS-1/IRS-2 with the insulin receptor."; RL J. Biol. Chem. 278:8460-8467(2003). RN [42] RP PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN2. RX PubMed=12612081; DOI=10.1128/mcb.23.6.2096-2108.2003; RA Galic S., Klingler-Hoffmann M., Fodero-Tavoletti M.T., Puryer M.A., RA Meng T.C., Tonks N.K., Tiganis T.; RT "Regulation of insulin receptor signaling by the protein tyrosine RT phosphatase TCPTP."; RL Mol. Cell. Biol. 23:2096-2108(2003). RN [43] RP INTERACTION WITH SOCS7. RX PubMed=16127460; DOI=10.1172/jci23853; RA Banks A.S., Li J., McKeag L., Hribal M.L., Kashiwada M., Accili D., RA Rothman P.B.; RT "Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of RT Langerhans."; RL J. Clin. Invest. 115:2462-2471(2005). RN [44] RP FUNCTION IN PHOSPHORYLATION OF PDPK1, AND INTERACTION WITH PDPK1. RX PubMed=16314505; DOI=10.1128/mcb.25.24.10803-10814.2005; RA Fiory F., Alberobello A.T., Miele C., Oriente F., Esposito I., Corbo V., RA Ruvo M., Tizzano B., Rasmussen T.E., Gammeltoft S., Formisano P., RA Beguinot F.; RT "Tyrosine phosphorylation of phosphoinositide-dependent kinase 1 by the RT insulin receptor is necessary for insulin metabolic signaling."; RL Mol. Cell. Biol. 25:10803-10814(2005). RN [45] RP DEPHOSPHORYLATION BY PTPRE. RX PubMed=15738637; DOI=10.2108/zsj.22.169; RA Nakagawa Y., Aoki N., Aoyama K., Shimizu H., Shimano H., Yamada N., RA Miyazaki H.; RT "Receptor-type protein tyrosine phosphatase epsilon (PTPepsilonM) is a RT negative regulator of insulin signaling in primary hepatocytes and liver."; RL Zool. Sci. 22:169-175(2005). RN [46] RP FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R. RX PubMed=16831875; DOI=10.1074/jbc.m605189200; RA Slaaby R., Schaeffer L., Lautrup-Larsen I., Andersen A.S., Shaw A.C., RA Mathiasen I.S., Brandt J.; RT "Hybrid receptors formed by insulin receptor (IR) and insulin-like growth RT factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity RT irrespective of the IR splice variant."; RL J. Biol. Chem. 281:25869-25874(2006). RN [47] RP REVIEW ON SIGNALING PATHWAYS. RX PubMed=16493415; DOI=10.1038/nrm1837; RA Taniguchi C.M., Emanuelli B., Kahn C.R.; RT "Critical nodes in signalling pathways: insights into insulin action."; RL Nat. Rev. Mol. Cell Biol. 7:85-96(2006). RN [48] RP REVIEW ON REGULATION OF INSR FUNCTION. RX PubMed=17347799; DOI=10.1007/s00018-007-6359-9; RA Youngren J.F.; RT "Regulation of insulin receptor function."; RL Cell. Mol. Life Sci. 64:873-891(2007). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-400; TYR-401 AND SER-407, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [50] RP DOMAIN, AND INSULIN-BINDING SITE. RX PubMed=19459609; DOI=10.1021/bi900261q; RA Menting J.G., Ward C.W., Margetts M.B., Lawrence M.C.; RT "A thermodynamic study of ligand binding to the first three domains of the RT human insulin receptor: relationship between the receptor alpha-chain C- RT terminal peptide and the site 1 insulin mimetic peptides."; RL Biochemistry 48:5492-5500(2009). RN [51] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-242 AND ASN-541. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [52] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [53] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-445 AND ASN-920. RC TISSUE=Leukemic T-cell; RX PubMed=19349973; DOI=10.1038/nbt.1532; RA Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M., RA Schiess R., Aebersold R., Watts J.D.; RT "Mass-spectrometric identification and relative quantification of N-linked RT cell surface glycoproteins."; RL Nat. Biotechnol. 27:378-386(2009). RN [54] RP INTERACTION WITH NCK1, AND PHOSPHORYLATION AT TYR-1189 AND TYR-1190. RX PubMed=21707536; DOI=10.1042/bj20110799; RA Wu C.L., Buszard B., Teng C.H., Chen W.L., Warr C.G., Tiganis T., RA Meng T.C.; RT "Dock/Nck facilitates PTP61F/PTP1B regulation of insulin signalling."; RL Biochem. J. 439:151-159(2011). RN [55] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [56] RP INTERACTION WITH CCDC88A AND GNAI3. RX PubMed=25187647; DOI=10.1091/mbc.e14-05-0978; RA Lin C., Ear J., Midde K., Lopez-Sanchez I., Aznar N., Garcia-Marcos M., RA Kufareva I., Abagyan R., Ghosh P.; RT "Structural basis for activation of trimeric Gi proteins by multiple growth RT factor receptors via GIV/Girdin."; RL Mol. Biol. Cell 25:3654-3671(2014). RN [57] RP PHOSPHORYLATION AT TYR-1185 AND TYR-1190. RX PubMed=26584640; DOI=10.1038/cr.2015.133; RA Yin Y., Hua H., Li M., Liu S., Kong Q., Shao T., Wang J., Luo Y., Wang Q., RA Luo T., Jiang Y.; RT "mTORC2 promotes type I insulin-like growth factor receptor and insulin RT receptor activation through the tyrosine kinase activity of mTOR."; RL Cell Res. 26:46-65(2016). RN [58] RP MUTAGENESIS OF LYS-1079, AND UBIQUITINATION AT LYS-1079. RX PubMed=27577745; DOI=10.1038/ncomms12639; RA Nagarajan A., Petersen M.C., Nasiri A.R., Butrico G., Fung A., Ruan H.B., RA Kursawe R., Caprio S., Thibodeau J., Bourgeois-Daigneault M.C., Sun L., RA Gao G., Bhanot S., Jurczak M.J., Green M.R., Shulman G.I., Wajapeyee N.; RT "MARCH1 regulates insulin sensitivity by controlling cell surface insulin RT receptor levels."; RL Nat. Commun. 7:12639-12639(2016). RN [59] RP INTERACTION WITH SORL1. RX PubMed=27322061; DOI=10.1172/jci84708; RA Schmidt V., Schulz N., Yan X., Schuermann A., Kempa S., Kern M., RA Blueher M., Poy M.N., Olivecrona G., Willnow T.E.; RT "SORLA facilitates insulin receptor signaling in adipocytes and exacerbates RT obesity."; RL J. Clin. Invest. 126:2706-2720(2016). RN [60] RP SUBUNIT. RX PubMed=27617429; DOI=10.1038/nsmb.3292; RA Menting J.G., Gajewiak J., MacRaild C.A., Chou D.H., Disotuar M.M., RA Smith N.A., Miller C., Erchegyi J., Rivier J.E., Olivera B.M., Forbes B.E., RA Smith B.J., Norton R.S., Safavi-Hemami H., Lawrence M.C.; RT "A minimized human insulin-receptor-binding motif revealed in a Conus RT geographus venom insulin."; RL Nat. Struct. Mol. Biol. 23:916-920(2016). RN [61] RP S-NITROSYLATION AT CYS-1083, AND MUTAGENESIS OF CYS-462; CYS-825; CYS-834 RP AND CYS-1083. RX PubMed=38056462; DOI=10.1016/j.cell.2023.11.009; RA Zhou H.L., Grimmett Z.W., Venetos N.M., Stomberski C.T., Qian Z., RA McLaughlin P.J., Bansal P.K., Zhang R., Reynolds J.D., Premont R.T., RA Stamler J.S.; RT "An enzyme that selectively S-nitrosylates proteins to regulate insulin RT signaling."; RL Cell 0:0-0(2023). RN [62] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1005-1310. RX PubMed=7997262; DOI=10.1038/372746a0; RA Hubbard S.R., Wei L., Ellis L., Hendrickson W.A.; RT "Crystal structure of the tyrosine kinase domain of the human insulin RT receptor."; RL Nature 372:746-754(1994). RN [63] RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP RP ANALOG AND IRS1 PEPTIDE, CATALYTIC ACTIVITY, ACTIVE SITE, RP AUTOPHOSPHORYLATION, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND RP TYR-1190. RX PubMed=9312016; DOI=10.1093/emboj/16.18.5572; RA Hubbard S.R.; RT "Crystal structure of the activated insulin receptor tyrosine kinase in RT complex with peptide substrate and ATP analog."; RL EMBO J. 16:5572-5581(1997). RN [64] RP X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP RP ANALOG, AND CATALYTIC ACTIVITY. RX PubMed=11124964; DOI=10.1074/jbc.m010161200; RA Till J.H., Ablooglu A.J., Frankel M., Bishop S.M., Kohanski R.A., RA Hubbard S.R.; RT "Crystallographic and solution studies of an activation loop mutant of the RT insulin receptor tyrosine kinase: insights into kinase mechanism."; RL J. Biol. Chem. 276:10049-10055(2001). RN [65] RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1005-1298 OF MUTANT ASN-1159, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF TYR-1011. RX PubMed=12707268; DOI=10.1074/jbc.m302425200; RA Li S., Covino N.D., Stein E.G., Till J.H., Hubbard S.R.; RT "Structural and biochemical evidence for an autoinhibitory role for RT tyrosine 984 in the juxtamembrane region of the insulin receptor."; RL J. Biol. Chem. 278:26007-26014(2003). RN [66] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP RP ANALOG AND SH2B2, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190. RX PubMed=14690593; DOI=10.1016/s1097-2765(03)00487-8; RA Hu J., Liu J., Ghirlando R., Saltiel A.R., Hubbard S.R.; RT "Structural basis for recruitment of the adaptor protein APS to the RT activated insulin receptor."; RL Mol. Cell 12:1379-1389(2003). RN [67] RP X-RAY CRYSTALLOGRAPHY (3.20 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH GRB14, RP INTERACTION WITH GRB14, AUTOPHOSPHORYLATION, AND PHOSPHORYLATION AT RP TYR-1185; TYR-1189 AND TYR-1190. RX PubMed=16246733; DOI=10.1016/j.molcel.2005.09.001; RA Depetris R.S., Hu J., Gimpelevich I., Holt L.J., Daly R.J., Hubbard S.R.; RT "Structural basis for inhibition of the insulin receptor by the adaptor RT protein Grb14."; RL Mol. Cell 20:325-333(2005). RN [68] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH PTPN1, RP AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190. RX PubMed=16271887; DOI=10.1016/j.str.2005.07.019; RA Li S., Depetris R.S., Barford D., Chernoff J., Hubbard S.R.; RT "Crystal structure of a complex between protein tyrosine phosphatase 1B and RT the insulin receptor tyrosine kinase."; RL Structure 13:1643-1651(2005). RN [69] RP X-RAY CRYSTALLOGRAPHY (3.8 ANGSTROMS) OF 28-943 IN COMPLEX WITH INSULIN RP ANALOG, DOMAIN, AND DISULFIDE BONDS. RX PubMed=16957736; DOI=10.1038/nature05106; RA McKern N.M., Lawrence M.C., Streltsov V.A., Lou M.Z., Adams T.E., RA Lovrecz G.O., Elleman T.C., Richards K.M., Bentley J.D., Pilling P.A., RA Hoyne P.A., Cartledge K.A., Pham T.M., Lewis J.L., Sankovich S.E., RA Stoichevska V., Da Silva E., Robinson C.P., Frenkel M.J., Sparrow L.G., RA Fernley R.T., Epa V.C., Ward C.W.; RT "Structure of the insulin receptor ectodomain reveals a folded-over RT conformation."; RL Nature 443:218-221(2006). RN [70] RP X-RAY CRYSTALLOGRAPHY (2.32 ANGSTROMS) OF 28-512, GLYCOSYLATION AT ASN-43; RP ASN-52; ASN-138; ASN-242; ASN-282; ASN-364; ASN-424 AND ASN-445, AND RP DISULFIDE BONDS. RX PubMed=16894147; DOI=10.1073/pnas.0605395103; RA Lou M., Garrett T.P., McKern N.M., Hoyne P.A., Epa V.C., Bentley J.D., RA Lovrecz G.O., Cosgrove L.J., Frenkel M.J., Ward C.W.; RT "The first three domains of the insulin receptor differ structurally from RT the insulin-like growth factor 1 receptor in the regions governing ligand RT specificity."; RL Proc. Natl. Acad. Sci. U.S.A. 103:12429-12434(2006). RN [71] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP AND RP IRS2, CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-1185; TYR-1189 AND RP TYR-1190, AND INTERACTION WITH IRS2. RX PubMed=18278056; DOI=10.1038/nsmb.1388; RA Wu J., Tseng Y.D., Xu C.F., Neubert T.A., White M.F., Hubbard S.R.; RT "Structural and biochemical characterization of the KRLB region in insulin RT receptor substrate-2."; RL Nat. Struct. Mol. Biol. 15:251-258(2008). RN [72] RP X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 1009-1310 IN COMPLEX WITH RP INHIBITORY PEPTIDE, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190. RX PubMed=18767165; DOI=10.1002/prot.22207; RA Katayama N., Orita M., Yamaguchi T., Hisamichi H., Kuromitsu S., RA Kurihara H., Sakashita H., Matsumoto Y., Fujita S., Niimi T.; RT "Identification of a key element for hydrogen-bonding patterns between RT protein kinases and their inhibitors."; RL Proteins 73:795-801(2008). RN [73] RP X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH RP SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19071018; DOI=10.1016/j.bmcl.2008.11.077; RA Chamberlain S.D., Redman A.M., Wilson J.W., Deanda F., Shotwell J.B., RA Gerding R., Lei H., Yang B., Stevens K.L., Hassell A.M., Shewchuk L.M., RA Leesnitzer M.A., Smith J.L., Sabbatini P., Atkins C., Groy A., Rowand J.L., RA Kumar R., Mook R.A. Jr., Moorthy G., Patnaik S.; RT "Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R RT tyrosine kinase inhibitors towards JNK selectivity."; RL Bioorg. Med. Chem. Lett. 19:360-364(2009). RN [74] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH RP SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19056263; DOI=10.1016/j.bmcl.2008.11.046; RA Chamberlain S.D., Wilson J.W., Deanda F., Patnaik S., Redman A.M., Yang B., RA Shewchuk L., Sabbatini P., Leesnitzer M.A., Groy A., Atkins C., Gerding R., RA Hassell A.M., Lei H., Mook R.A. Jr., Moorthy G., Rowand J.L., Stevens K.L., RA Kumar R., Shotwell J.B.; RT "Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent RT inhibitors of the IGF-1R receptor tyrosine kinase."; RL Bioorg. Med. Chem. Lett. 19:469-473(2009). RN [75] RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 1017-1322 IN COMPLEX WITH RP SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19394223; DOI=10.1016/j.bmcl.2008.12.110; RA Patnaik S., Stevens K.L., Gerding R., Deanda F., Shotwell J.B., Tang J., RA Hamajima T., Nakamura H., Leesnitzer M.A., Hassell A.M., Shewchuck L.M., RA Kumar R., Lei H., Chamberlain S.D.; RT "Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent RT inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine RT kinase."; RL Bioorg. Med. Chem. Lett. 19:3136-3140(2009). RN [76] RP X-RAY CRYSTALLOGRAPHY (3.80 ANGSTROMS) OF 28-956, INSULIN-BINDING REGION, RP AND DISULFIDE BONDS. RX PubMed=20348418; DOI=10.1073/pnas.1001813107; RA Smith B.J., Huang K., Kong G., Chan S.J., Nakagawa S., Menting J.G., RA Hu S.Q., Whittaker J., Steiner D.F., Katsoyannis P.G., Ward C.W., RA Weiss M.A., Lawrence M.C.; RT "Structural resolution of a tandem hormone-binding element in the insulin RT receptor and its implications for design of peptide agonists."; RL Proc. Natl. Acad. Sci. U.S.A. 107:6771-6776(2010). RN [77] RP X-RAY CRYSTALLOGRAPHY (3.9 ANGSTROMS) OF 28-620 IN COMPLEX WITH INSULIN, RP DOMAIN, GLYCOSYLATION AT ASN-43; ASN-52; ASN-138; ASN-242 AND ASN-282, AND RP DISULFIDE BONDS. RX PubMed=23302862; DOI=10.1038/nature11781; RA Menting J.G., Whittaker J., Margetts M.B., Whittaker L.J., Kong G.K., RA Smith B.J., Watson C.J., Zakova L., Kletvikova E., Jiracek J., Chan S.J., RA Steiner D.F., Dodson G.G., Brzozowski A.M., Weiss M.A., Ward C.W., RA Lawrence M.C.; RT "How insulin engages its primary binding site on the insulin receptor."; RL Nature 493:241-245(2013). RN [78] RP VARIANT IRAN TYPE A SER-762. RX PubMed=3283938; DOI=10.1126/science.3283938; RA Yoshimasa Y., Seino S., Whittaker J., Kakehi T., Kosaki A., Kuzuya H., RA Imura H., Bell G.I., Steiner D.F.; RT "Insulin-resistant diabetes due to a point mutation that prevents insulin RT proreceptor processing."; RL Science 240:784-787(1988). RN [79] RP VARIANT LEPRCH GLU-487. RX PubMed=2834824; DOI=10.1126/science.2834824; RA Kadowaki T., Bevins C., Cama A., Ojamaa K., Marcus-Samuels B., Kadowaki H., RA Beitz L., McKeon C., Taylor S.I.; RT "Two mutant alleles of the insulin receptor gene in a patient with extreme RT insulin resistance."; RL Science 240:787-790(1988). RN [80] RP VARIANT LEPRCH PRO-260. RX PubMed=2479553; DOI=10.1002/j.1460-2075.1989.tb08387.x; RA Klinkhamer M.P., Groen N.A., van der Zon G.C.M., Lindhout D., RA Sandkuyl L.A., Krans H.M.J., Moeller W., Maassen J.A.; RT "A leucine-to-proline mutation in the insulin receptor in a family with RT insulin resistance."; RL EMBO J. 8:2503-2507(1989). RN [81] RP VARIANT IRAN TYPE A VAL-1035. RX PubMed=2544998; DOI=10.1126/science.2544998; RA Odawara M., Kadowaki T., Yamamoto R., Shibasaki Y., Tobe K., Accili D., RA Bevins C., Mikami Y., Matsuura N., Akanuma Y., Takaku F., Taylor S.I., RA Kasuga M.; RT "Human diabetes associated with a mutation in the tyrosine kinase domain of RT the insulin receptor."; RL Science 245:66-68(1989). RN [82] RP VARIANT IRAN TYPE A THR-1161. RX PubMed=2168397; DOI=10.1016/s0021-9258(18)77212-8; RA Moller D.E., Yokota A., White M.F., Pazianos A.G., Flier J.S.; RT "A naturally occurring mutation of insulin receptor alanine 1134 impairs RT tyrosine kinase function and is associated with dominantly inherited RT insulin resistance."; RL J. Biol. Chem. 265:14979-14985(1990). RN [83] RP CHARACTERIZATION OF VARIANT RMS LYS-42. RX PubMed=2121734; DOI=10.1016/s0021-9258(17)30636-1; RA Kadowaki T., Kadowaki H., Accili D., Taylor S.I.; RT "Substitution of lysine for asparagine at position 15 in the alpha-subunit RT of the human insulin receptor. A mutation that impairs transport of RT receptors to the cell surface and decreases the affinity of insulin RT binding."; RL J. Biol. Chem. 265:19143-19150(1990). RN [84] RP VARIANT RMS LYS-42, VARIANT LEPRCH ARG-236, AND VARIANT IRAN TYPE A RP SER-489. RX PubMed=2365819; DOI=10.1172/jci114693; RA Kadowaki T., Kadowaki H., Rechler M.M., Serrano-Rios M., Roth J., RA Gorden P., Taylor S.I.; RT "Five mutant alleles of the insulin receptor gene in patients with genetic RT forms of insulin resistance."; RL J. Clin. Invest. 86:254-264(1990). RN [85] RP VARIANT IRAN TYPE A SER-1227. RX PubMed=1963473; DOI=10.1210/mend-4-8-1183; RA Moller D.E., Yokota A., Ginsberg-Fellner F., Flier J.S.; RT "Functional properties of a naturally occurring Trp1200-->Ser1200 mutation RT of the insulin receptor."; RL Mol. Endocrinol. 4:1183-1191(1990). RN [86] RP VARIANT GLU-1095. RX PubMed=2040394; DOI=10.2337/diab.40.6.777; RA O'Rahilly S., Choi W.H., Patel P., Turner R.C., Flier J.S., Moller D.E.; RT "Detection of mutations in insulin-receptor gene in NIDDM patients by RT analysis of single-stranded conformation polymorphisms."; RL Diabetes 40:777-782(1991). RN [87] RP VARIANT IRAN TYPE A GLN-1020. RX PubMed=2002058; DOI=10.1016/s0021-9258(19)67781-1; RA Kusari J., Takata Y., Hatada E., Freidenberg G., Kolterman O., RA Olefsky J.M.; RT "Insulin resistance and diabetes due to different mutations in the tyrosine RT kinase domain of both insulin receptor gene alleles."; RL J. Biol. Chem. 266:5260-5267(1991). RN [88] RP VARIANT INS RESISTANCE ILE-1180. RX PubMed=1890161; DOI=10.1210/jcem-73-4-894; RA Cama A., de la Luz Sierra M., Ottini L., Kadowaki T., Gorden P., RA Imperato-Mcginley J., Taylor S.I.; RT "A mutation in the tyrosine kinase domain of the insulin receptor RT associated with insulin resistance in an obese woman."; RL J. Clin. Endocrinol. Metab. 73:894-901(1991). RN [89] RP VARIANTS LEPRCH ALA-55 AND ARG-393. RX PubMed=1607067; DOI=10.2337/diab.41.4.408; RA Barbetti F., Gejman P.V., Taylor S.I., Raben N., Cama A., Bonora E., RA Pizzo P., Moghetti P., Muggeo M., Roth J.; RT "Detection of mutations in insulin receptor gene by denaturing gradient gel RT electrophoresis."; RL Diabetes 41:408-415(1992). RN [90] RP VARIANT T2D GLN-1191. RX PubMed=1607076; DOI=10.2337/diab.41.4.521; RA Cocozza S., Porcellini A., Riccardi G., Monticelli A., Condorelli G., RA Ferrara A., Pianese L., Miele C., Capaldo B., Beguinot F., Varrone S.; RT "NIDDM associated with mutation in tyrosine kinase domain of insulin RT receptor gene."; RL Diabetes 41:521-526(1992). RN [91] RP VARIANT IRAN TYPE A LEU-1205. RX PubMed=1563582; DOI=10.1007/bf00400927; RA Kim H., Kadowaki H., Sakura H., Odawara M., Momomura K., Takahashi Y., RA Miyazaki Y., Ohtani T., Akanuma Y., Yazaki Y., Kasuga M., Taylor S.I., RA Kadowaki T.; RT "Detection of mutations in the insulin receptor gene in patients with RT insulin resistance by analysis of single-stranded conformational RT polymorphisms."; RL Diabetologia 35:261-266(1992). RN [92] RP VARIANT LEPRCH ARG-58. RX PubMed=1730625; DOI=10.1016/s0021-9258(18)48459-1; RA van der Vorm E.R., van der Zon G.C.M., Moeller W., Krans H.M.J., RA Lindhout D., Maassen J.A.; RT "An Arg for Gly substitution at position 31 in the insulin receptor, linked RT to insulin resistance, inhibits receptor processing and transport."; RL J. Biol. Chem. 267:66-71(1992). RN [93] RP VARIANT T2D GLN-1158. RX PubMed=1470163; RA Kasuga M., Kishimoto M., Hashiramoto M., Yonezawa K., Kazumi T., Hagino H., RA Shii K.; RT "Insulin receptor Arg1131-->Gln: a novel mutation in the catalytic loop of RT insulin receptor observed in insulin resistant diabetes."; RL Nihon Geka Gakkai Zasshi 93:968-971(1992). RN [94] RP VARIANT MET-1012. RX PubMed=8432414; DOI=10.2337/diab.42.3.429; RA Elbein S.C., Sorensen L.K., Schumacher M.C.; RT "Methionine for valine substitution in exon 17 of the insulin receptor gene RT in a pedigree with familial NIDDM."; RL Diabetes 42:429-434(1993). RN [95] RP VARIANT IRAN TYPE A ASP-1075. RX PubMed=8243830; DOI=10.2337/diab.42.12.1837; RA Haruta T., Takata Y., Iwanishi M., Maegawa H., Imamura T., Egawa K., RA Itazu T., Kobayashi M.; RT "Ala1048-->Asp mutation in the kinase domain of insulin receptor causes RT defective kinase activity and insulin resistance."; RL Diabetes 42:1837-1844(1993). RN [96] RP VARIANT MET-1012. RX PubMed=8458533; DOI=10.1007/bf00400701; RA van der Vorm E.R., Kuipers A., Bonenkamp J.W., Kleijer W.J., RA van Maldergem L., Herwig J., Maassen J.A.; RT "Patients with lipodystrophic diabetes mellitus of the Seip-Berardinelli RT type, express normal insulin receptors."; RL Diabetologia 36:172-174(1993). RN [97] RP VARIANT INS RESISTANCE LEU-1220. RX PubMed=8390949; DOI=10.1007/bf00402277; RA Iwanishi M., Haruta T., Takata Y., Ishibashi O., Sasaoka T., Egawa K., RA Imamura T., Naitou K., Itazu T., Kobayashi M.; RT "A mutation (Trp1193-->Leu1193) in the tyrosine kinase domain of the RT insulin receptor associated with type A syndrome of insulin resistance."; RL Diabetologia 36:414-422(1993). RN [98] RP VARIANT INS RESISTANCE LEU-220. RX PubMed=8242067; DOI=10.1093/hmg/2.9.1437; RA Carrera P., Cordera R., Ferrari M., Cremonesi L., Taramelli R., RA Andraghetti G., Carducci C., Dozio N., Pozza G., Taylor S.I., Micossi P., RA Barbetti F.; RT "Substitution of Leu for Pro-193 in the insulin receptor in a patient with RT a genetic form of severe insulin resistance."; RL Hum. Mol. Genet. 2:1437-1441(1993). RN [99] RP CHARACTERIZATION OF VARIANT IRAN TYPE A GLU-1162. RX PubMed=8096518; DOI=10.1016/s0021-9258(18)53063-5; RA Cama A., de la Luz Sierra M., Quon M.J., Ottini L., Gorden P., Taylor S.I.; RT "Substitution of glutamic acid for alanine 1135 in the putative 'catalytic RT loop' of the tyrosine kinase domain of the human insulin receptor. A RT mutation that impairs proteolytic processing into subunits and inhibits RT receptor tyrosine kinase activity."; RL J. Biol. Chem. 268:8060-8069(1993). RN [100] RP VARIANT IRAN TYPE A VAL-409. RX PubMed=8388389; DOI=10.1016/s0021-9258(18)82120-2; RA Lebrun C., Baron V., Kaliman P., Gautier N., Dolais-Kitabgi J., RA Taylor S.I., Accili D., van Obberghen E.; RT "Antibodies to the extracellular receptor domain restore the hormone- RT insensitive kinase and conformation of the mutant insulin receptor valine RT 382."; RL J. Biol. Chem. 268:11272-11277(1993). RN [101] RP VARIANT LEPRCH MET-146. RX PubMed=8326490; DOI=10.1136/jmg.30.6.470; RA Al-Gazali L.I., Khalil M., Devadas K.; RT "A syndrome of insulin resistance resembling leprechaunism in five sibs of RT consanguineous parents."; RL J. Med. Genet. 30:470-475(1993). RN [102] RP VARIANT LEPRCH PRO-113. RX PubMed=8419945; DOI=10.1073/pnas.90.1.60; RA Longo N., Langley S.D., Griffin L.D., Elsas L.J.; RT "Activation of glucose transport by a natural mutation in the human insulin RT receptor."; RL Proc. Natl. Acad. Sci. U.S.A. 90:60-64(1993). RN [103] RP VARIANT IRAN TYPE A GLN-1201. RX PubMed=8288049; DOI=10.2337/diab.43.2.247; RA Moller D.E., Cohen O., Yamaguchi Y., Assiz R., Grigorescu F., Eberle A., RA Morrow L.A., Moses A.C., Flier J.S.; RT "Prevalence of mutations in the insulin receptor gene in subjects with RT features of the type A syndrome of insulin resistance."; RL Diabetes 43:247-255(1994). RN [104] RP VARIANT RMS SYNDROME LEU-350, VARIANTS IRAN TYPE A LEU-1205 AND GLN-1378, RP AND VARIANT MET-1012. RX PubMed=8314008; DOI=10.2337/diab.43.3.357; RA Krook A., Kumar S., Laing I., Boulton A.J., Wass J.A., O'Rahilly S.; RT "Molecular scanning of the insulin receptor gene in syndromes of insulin RT resistance."; RL Diabetes 43:357-368(1994). RN [105] RP CHARACTERIZATION OF VARIANT IRAN TYPE A GLN-1201. RX PubMed=8082780; DOI=10.1016/0014-5793(94)00876-0; RA Moritz W., Froesch E.R., Boeni-Schnetzler M.; RT "Functional properties of a heterozygous mutation (Arg1174-->Gln) in the RT tyrosine kinase domain of the insulin receptor from a type A insulin RT resistant patient."; RL FEBS Lett. 351:276-280(1994). RN [106] RP VARIANT LEPRCH SER-439. RX PubMed=8188715; DOI=10.1016/s0021-9258(17)36788-1; RA van der Vorm E.R., Kuipers A., Kielkopf-Renner S., Krans H.M.J., Moller W., RA Maassen J.A.; RT "A mutation in the insulin receptor that impairs proreceptor processing but RT not insulin binding."; RL J. Biol. Chem. 269:14297-14302(1994). RN [107] RP CHARACTERIZATION OF VARIANTS IRAN TYPE A ASP-1206 AND LEU-1220. RX PubMed=7983039; DOI=10.1016/s0021-9258(18)47384-x; RA Imamura T., Takata Y., Sasaoka T., Takada Y., Morioka H., Haruta T., RA Sawa T., Iwanishi M., Hu Y.G., Suzuki Y., Hamada J., Kobayashi M.; RT "Two naturally occurring mutations in the kinase domain of insulin receptor RT accelerate degradation of the insulin receptor and impair the kinase RT activity."; RL J. Biol. Chem. 269:31019-31027(1994). RN [108] RP VARIANT LEPRCH MET-146. RX PubMed=7815442; DOI=10.1136/jmg.31.9.715; RA Hone J., Accili D., al-Gazali L.I., Lestringant G., Orban T., Taylor S.I.; RT "Homozygosity for a new mutation (Ile119-->Met) in the insulin receptor RT gene in five sibs with familial insulin resistance."; RL J. Med. Genet. 31:715-716(1994). RN [109] RP VARIANT T2D ALA-858, AND VARIANT CYS-1361. RX PubMed=7657032; DOI=10.2337/diab.44.9.1081; RA Kan M., Kanai F., Iida M., Jinnouchi H., Todaka M., Imanaka T., Ito K., RA Nishioka Y., Ohnishi T., Kamohara S., Hayashi H., Murakami T., Kagawa S., RA Sano H., Hashimoto N., Yoshida S., Makino H., Ebina Y.; RT "Frequency of mutations of insulin receptor gene in Japanese patients with RT NIDDM."; RL Diabetes 44:1081-1086(1995). RN [110] RP VARIANT LEPRCH ASN-308 DEL. RX PubMed=7538143; DOI=10.1210/jcem.80.5.7538143; RA Longo N., Langley S.D., Griffin L.D., Elsas L.J.; RT "Two mutations in the insulin receptor gene of a patient with RT leprechaunism: application to prenatal diagnosis."; RL J. Clin. Endocrinol. Metab. 80:1496-1501(1995). RN [111] RP VARIANT PHE-1023. RX PubMed=8890729; DOI=10.1530/eje.0.1350357; RA Moritz W., Boeni-Schnetzler M., Stevens W., Froesch E.R., Levy J.R.; RT "In-frame exon 2 deletion in insulin receptor RNA in a family with extreme RT insulin resistance in association with defective insulin binding: a case RT report."; RL Eur. J. Endocrinol. 135:357-363(1996). RN [112] RP VARIANT LEPRCH ASN-308 DEL. RX PubMed=8636294; DOI=10.1210/jcem.81.2.8636294; RA Desbois-Mouthon C., Sert-Langeron C., Magre J., Oreal E., Blivet M.J., RA Flori E., Besmond C., Capeau J., Caron M.; RT "Deletion of Asn281 in the alpha-subunit of the human insulin receptor RT causes constitutive activation of the receptor and insulin RT desensitization."; RL J. Clin. Endocrinol. Metab. 81:719-727(1996). RN [113] RP VARIANT MET-1012. RX PubMed=9199575; DOI=10.1086/515464; RA Hansen L., Hansen T., Clausen J.O., Echwald S.M., Urhammer S.A., RA Rasmussen S.K., Pedersen O.; RT "The Val985Met insulin-receptor variant in the Danish Caucasian population: RT lack of associations with non-insulin-dependent diabetes mellitus or RT insulin resistance."; RL Am. J. Hum. Genet. 60:1532-1535(1997). RN [114] RP VARIANTS IRAN TYPE A GLY-86 AND PRO-89. RX PubMed=9175790; DOI=10.1006/bbrc.1997.6695; RA Rouard M., Macari F., Bouix O., Lautier C., Brun J.F., Lefebvre P., RA Renard E., Bringer J., Jaffiol C., Grigorescu F.; RT "Identification of two novel insulin receptor mutations, Asp59Gly and RT Leu62Pro, in type A syndrome of extreme insulin resistance."; RL Biochem. Biophys. Res. Commun. 234:764-768(1997). RN [115] RP CHARACTERIZATION OF VARIANT LEPRCH MET-937. RX PubMed=9299395; DOI=10.1006/bbrc.1997.7181; RA Kadowaki H., Takahashi Y., Ando A., Momomura K., Kaburagi Y., Quin J.D., RA MacCuish A.C., Koda N., Fukushima Y., Taylor S.I., Akanuma Y., Yazaki Y., RA Kadowaki T.; RT "Four mutant alleles of the insulin receptor gene associated with genetic RT syndromes of extreme insulin resistance."; RL Biochem. Biophys. Res. Commun. 237:516-520(1997). RN [116] RP VARIANTS LEPRCH TRP-1119 AND LYS-1206. RX PubMed=9249867; RX DOI=10.1002/(sici)1097-0223(199707)17:7<657::aid-pd132>3.3.co;2-#; RA Desbois-Mouthon C., Girodon E., Ghanem N., Caron M., Pennerath A., RA Conteville P., Magre J., Besmond C., Goossens M., Capeau J., Amselem S.; RT "Molecular analysis of the insulin receptor gene for prenatal diagnosis of RT leprechaunism in two families."; RL Prenat. Diagn. 17:657-663(1997). RN [117] RP VARIANTS LEPRCH TYR-301 AND TRP-1201. RX PubMed=9703342; DOI=10.2337/diab.47.8.1362; RA Whitehead J.P., Soos M.A., Jackson R., Tasic V., Kocova M., O'Rahilly S.; RT "Multiple molecular mechanisms of insulin receptor dysfunction in a patient RT with Donohue syndrome."; RL Diabetes 47:1362-1364(1998). RN [118] RP VARIANTS RMS THR-1143 AND TRP-1158. RX PubMed=10443650; DOI=10.1210/jcem.84.8.5902; RA Longo N., Wang Y., Pasquali M.; RT "Progressive decline in insulin levels in Rabson-Mendenhall syndrome."; RL J. Clin. Endocrinol. Metab. 84:2623-2629(1999). RN [119] RP VARIANTS IRAN TYPE A LEU-167 AND VAL-1055. RX PubMed=10733238; DOI=10.1034/j.1399-0004.2000.570110.x; RA Rique S., Nogues C., Ibanez L., Marcos M.V., Ferragut J., Carrascosa A., RA Potau N.; RT "Identification of three novel mutations in the insulin receptor gene in RT type A insulin resistant patients."; RL Clin. Genet. 57:67-69(2000). RN [120] RP VARIANT IRAN TYPE A TYR-280. RX PubMed=11260230; DOI=10.1034/j.1399-0004.2001.590309.x; RA Osawa H., Nishimiya T., Ochi M., Niiya T., Onuma H., Kitamuro F., Kaino Y., RA Kida K., Makino H.; RT "Identification of novel C253Y missense and Y864X nonsense mutations in the RT insulin receptor gene in type A insulin-resistant patients."; RL Clin. Genet. 59:194-197(2001). RN [121] RP VARIANT IRAN TYPE A CYS-279. RX PubMed=12107746; DOI=10.1007/s00125-002-0798-5; RA Hamer I., Foti M., Emkey R., Cordier-Bussat M., Philippe J., De Meyts P., RA Maeder C., Kahn C.R., Carpentier J.-L.; RT "An arginine to cysteine(252) mutation in insulin receptors from a patient RT with severe insulin resistance inhibits receptor internalisation but RT preserves signalling events."; RL Diabetologia 45:657-667(2002). RN [122] RP CHARACTERIZATION OF VARIANTS LEPRCH PRO-113; VAL-119; ASN-308 DEL; THR-925 RP AND TRP-926, AND VARIANTS RMS THR-997; THR-1143; TRP-1158 AND TRP-1201. RX PubMed=12023989; DOI=10.1093/hmg/11.12.1465; RA Longo N., Wang Y., Smith S.A., Langley S.D., DiMeglio L.A., RA Giannella-Neto D.; RT "Genotype-phenotype correlation in inherited severe insulin resistance."; RL Hum. Mol. Genet. 11:1465-1475(2002). RN [123] RP VARIANT LEPRCH VAL-362 DEL. RX PubMed=12538626; DOI=10.1210/en.2002-220815; RA George S., Johansen A., Soos M.A., Mortensen H., Gammeltoft S., Saudek V., RA Siddle K., Hansen L., O'Rahilly S.; RT "Deletion of V335 from the L2 domain of the insulin receptor results in a RT conformationally abnormal receptor that is unable to bind insulin and RT causes Donohue's syndrome in a human subject."; RL Endocrinology 144:631-637(2003). RN [124] RP VARIANT IRAN TYPE A HIS-279, VARIANTS LEPRCH GLN-120; LEU-350; ASP-458 AND RP TRP-1119, CHARACTERIZATION OF VARIANT IRAN TYPE A HIS-279, AND RP CHARACTERIZATION OF VARIANTS LEPRCH GLN-120 AND ASP-458. RX PubMed=12970295; DOI=10.1210/jc.2003-030034; RA Maassen J.A., Tobias E.S., Kayserilli H., Tukel T., Yuksel-Apak M., RA D'Haens E., Kleijer W.J., Fery F., van der Zon G.C.M.; RT "Identification and functional assessment of novel and known insulin RT receptor mutations in five patients with syndromes of severe insulin RT resistance."; RL J. Clin. Endocrinol. Metab. 88:4251-4257(2003). RN [125] RP VARIANT HHF5 GLN-1201. RX PubMed=15161766; DOI=10.2337/diabetes.53.6.1592; RA Hoejlund K., Hansen T., Lajer M., Henriksen J.E., Levin K., Lindholm J., RA Pedersen O., Bech-Nielsen H.; RT "A novel syndrome of autosomal-dominant hyperinsulinemic hypoglycemia RT linked to a mutation in the human insulin receptor gene."; RL Diabetes 53:1592-1598(2004). RN [126] RP VARIANTS RMS ARG-236 AND SER-386, AND CHARACTERIZATION OF VARIANTS RMS RP ARG-236 AND SER-386. RX PubMed=17201797; DOI=10.1111/j.1365-2265.2006.02678.x; RA Tuthill A., Semple R.K., Day R., Soos M.A., Sweeney E., Seymour P.J., RA Didi M., O'Rahilly S.; RT "Functional characterization of a novel insulin receptor mutation RT contributing to Rabson-Mendenhall syndrome."; RL Clin. Endocrinol. (Oxf.) 66:21-26(2007). RN [127] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-228; ARG-695; SER-811; MET-1012; RP VAL-1065 AND ALA-1282. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [128] RP VARIANTS LEPRCH CYS-818 AND 890-ARG--SER-1382 DEL. RX PubMed=22768670; DOI=10.1515/jpem-2011-0448; RA Nobile S., Semple R.K., Carnielli V.P.; RT "A novel mutation of the insulin receptor gene in a preterm infant with RT Donohue syndrome and heart failure."; RL J. Pediatr. Endocrinol. Metab. 25:363-366(2012). RN [129] RP VARIANTS LEPRCH THR-56 AND TYR-286, AND CHARACTERIZATION OF VARIANTS LEPRCH RP THR-56 AND TYR-286. RX PubMed=24498630; DOI=10.1002/mgg3.43; RA Falik Zaccai T.C., Kalfon L., Klar A., Elisha M.B., Hurvitz H., RA Weingarten G., Chechik E., Fleisher Sheffer V., Haj Yahya R., Meidan G., RA Gross-Kieselstein E., Bauman D., Hershkovitz S., Yaron Y., Orr-Urtreger A., RA Wertheimer E.; RT "Two novel mutations identified in familial cases with Donohue syndrome."; RL Mol. Genet. Genomic Med. 2:64-72(2014). RN [130] RP VARIANTS RMS CYS-256; LEU-635; ILE-835; VAL-842; LEU-874; SER-878 AND RP 999-TYR--SER-1382 DEL, VARIANTS IRAN TYPE A ASP-489 AND MET-1054, VARIANTS RP LEPRCH PHE-657; ARG-659 AND CYS-818, CHARACTERIZATION OF VARIANTS LEPRCH RP PHE-657; ARG-659; CYS-818; THR-925; TRP-926 AND MET-937, AND RP CHARACTERIZATION OF VARIANTS RMS LEU-635; ILE-835; VAL-842; LEU-874 AND RP SER-878. RX PubMed=28765322; DOI=10.2337/db17-0301; RA Hosoe J., Kadowaki H., Miya F., Aizu K., Kawamura T., Miyata I., RA Satomura K., Ito T., Hara K., Tanaka M., Ishiura H., Tsuji S., Suzuki K., RA Takakura M., Boroevich K.A., Tsunoda T., Yamauchi T., Shojima N., RA Kadowaki T.; RT "Structural Basis and Genotype-Phenotype Correlations of INSR Mutations RT Causing Severe Insulin Resistance."; RL Diabetes 66:2713-2723(2017). CC -!- FUNCTION: Receptor tyrosine kinase which mediates the pleiotropic CC actions of insulin. Binding of insulin leads to phosphorylation of CC several intracellular substrates, including, insulin receptor CC substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling CC intermediates. Each of these phosphorylated proteins serve as docking CC proteins for other signaling proteins that contain Src-homology-2 CC domains (SH2 domain) that specifically recognize different CC phosphotyrosine residues, including the p85 regulatory subunit of PI3K CC and SHP2. Phosphorylation of IRSs proteins lead to the activation of CC two main signaling pathways: the PI3K-AKT/PKB pathway, which is CC responsible for most of the metabolic actions of insulin, and the Ras- CC MAPK pathway, which regulates expression of some genes and cooperates CC with the PI3K pathway to control cell growth and differentiation. CC Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to CC the activation of PI3K and the generation of phosphatidylinositol-(3, CC 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates CC several PIP3-dependent serine/threonine kinases, such as PDPK1 and CC subsequently AKT/PKB. The net effect of this pathway is to produce a CC translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic CC vesicles to the cell membrane to facilitate glucose transport. CC Moreover, upon insulin stimulation, activated AKT/PKB is responsible CC for: anti-apoptotic effect of insulin by inducing phosphorylation of CC BAD; regulates the expression of gluconeogenic and lipogenic enzymes by CC controlling the activity of the winged helix or forkhead (FOX) class of CC transcription factors. Another pathway regulated by PI3K-AKT/PKB CC activation is mTORC1 signaling pathway which regulates cell growth and CC metabolism and integrates signals from insulin. AKT mediates insulin- CC stimulated protein synthesis by phosphorylating TSC2 thereby activating CC mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in CC mediating cell growth, survival and cellular differentiation of CC insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers CC the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to CC binding insulin, the insulin receptor can bind insulin-like growth CC factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII CC binding. When present in a hybrid receptor with IGF1R, binds IGF1. CC PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR CC isoform Long are activated with a high affinity by IGF1, with low CC affinity by IGF2 and not significantly activated by insulin, and that CC hybrid receptors composed of IGF1R and INSR isoform Short are activated CC by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that CC hybrid receptors composed of IGF1R and INSR isoform Long and hybrid CC receptors composed of IGF1R and INSR isoform Short have similar binding CC characteristics, both bind IGF1 and have a low affinity for insulin. In CC adipocytes, inhibits lipolysis (By similarity). CC {ECO:0000250|UniProtKB:P15208, ECO:0000269|PubMed:12138094, CC ECO:0000269|PubMed:16314505, ECO:0000269|PubMed:16831875, CC ECO:0000269|PubMed:8257688, ECO:0000269|PubMed:8276809, CC ECO:0000269|PubMed:8452530, ECO:0000269|PubMed:9428692}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:11124964, ECO:0000269|PubMed:11598120, CC ECO:0000269|PubMed:12707268, ECO:0000269|PubMed:18278056, CC ECO:0000269|PubMed:19056263, ECO:0000269|PubMed:19071018, CC ECO:0000269|PubMed:19394223, ECO:0000269|PubMed:9312016}; CC -!- ACTIVITY REGULATION: Activated in response to insulin. CC Autophosphorylation activates the kinase activity. PTPN1, PTPRE and CC PTPRF dephosphorylate important tyrosine residues, thereby reducing CC INSR activity. Inhibited by ENPP1. GRB10 and GRB14 inhibit the CC catalytic activity of the INSR, they block access of substrates to the CC activated receptor. SOCS1 and SOCS3 act as negative regulators of INSR CC activity, they bind to the activated INRS and interfere with the CC phosphorylation of INSR substrates. {ECO:0000269|PubMed:10615944, CC ECO:0000269|PubMed:11598120, ECO:0000269|PubMed:11726652, CC ECO:0000269|PubMed:12493740, ECO:0000269|PubMed:2211730}. CC -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide CC bonds. The alpha chains carry the insulin-binding regions, while the CC beta chains carry the kinase domain. Forms a hybrid receptor with CC IGF1R, the hybrid is a tetramer consisting of 1 alpha chain and 1 beta CC chain of INSR and 1 alpha chain and 1 beta chain of IGF1R. Interacts CC with SORBS1 but dissociates from it following insulin stimulation. CC Binds SH2B2. Activated form of INSR interacts (via Tyr-999) with the CC PTB/PID domains of IRS1 and SHC1. The sequences surrounding the CC phosphorylated NPXY motif contribute differentially to either IRS1 or CC SHC1 recognition. Interacts (via tyrosines in the C-terminus) with IRS2 CC (via PTB domain and 591-786 AA); the 591-786 would be the primary CC anchor of IRS2 to INSR while the PTB domain would have a stabilizing CC action on the interaction with INSR. Interacts with the SH2 domains of CC the 85 kDa regulatory subunit of PI3K (PIK3R1) in vitro, when CC autophosphorylated on tyrosine residues. Interacts with SOCS7. CC Interacts (via the phosphorylated Tyr-999), with SOCS3. Interacts (via CC the phosphorylated Tyr-1185, Tyr-1189, Tyr-1190) with SOCS1. Interacts CC with CAV2 (tyrosine-phosphorylated form); the interaction is increased CC with 'Tyr-27'phosphorylation of CAV2 (By similarity). Interacts with CC ARRB2 (By similarity). Interacts with GRB10; this interaction blocks CC the association between IRS1/IRS2 and INSR, significantly reduces CC insulin-stimulated tyrosine phosphorylation of IRS1 and IRS2 and thus CC decreases insulin signaling. Interacts with GRB7. Interacts with PDPK1. CC Interacts (via Tyr-1190) with GRB14 (via BPS domain); this interaction CC protects the tyrosines in the activation loop from dephosphorylation, CC but promotes dephosphorylation of Tyr-999, this results in decreased CC interaction with, and phosphorylation of, IRS1. Interacts (via subunit CC alpha) with ENPP1 (via 485-599 AA); this interaction blocks CC autophosphorylation. Interacts with PTPRE; this interaction is CC dependent of Tyr-1185, Tyr-1189 and Tyr-1190 of the INSR. Interacts CC with STAT5B (via SH2 domain). Interacts with PTPRF. Interacts with CC ATIC; ATIC together with PRKAA2/AMPK2 and HACD3/PTPLAD1 is proposed to CC be part of a signaling netwok regulating INSR autophosphorylation and CC endocytosis (By similarity). Interacts with the cone snail venom CC insulin Con-Ins G1 (PubMed:27617429). Interacts with the insulin CC receptor SORL1; this interaction strongly increases its surface CC exposure, hence strengthens insulin signal reception (PubMed:27322061). CC Interacts (tyrosine phosphorylated) with CCDC88A/GIV (via SH2-like CC region); binding requires autophosphorylation of the INSR C-terminal CC region (PubMed:25187647). Interacts with GNAI3; the interaction is CC probably mediated by CCDC88A/GIV (PubMed:25187647). Interacts with CC LMBRD1 (By similarity). Interacts (in response to insulin stimulation) CC with NCK1; this interaction may recruit PTPN1 to mediate INSR CC dephosphorylation (PubMed:21707536). Interacts with CD248; this CC interaction diminishes INSR autophosphorylation (By similarity). CC {ECO:0000250|UniProtKB:P15127, ECO:0000250|UniProtKB:P15208, CC ECO:0000269|PubMed:10615944, ECO:0000269|PubMed:10803466, CC ECO:0000269|PubMed:11124964, ECO:0000269|PubMed:11374898, CC ECO:0000269|PubMed:11726652, ECO:0000269|PubMed:12493740, CC ECO:0000269|PubMed:14690593, ECO:0000269|PubMed:16127460, CC ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, CC ECO:0000269|PubMed:16314505, ECO:0000269|PubMed:16957736, CC ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, CC ECO:0000269|PubMed:19056263, ECO:0000269|PubMed:19071018, CC ECO:0000269|PubMed:19394223, ECO:0000269|PubMed:21707536, CC ECO:0000269|PubMed:2211730, ECO:0000269|PubMed:23302862, CC ECO:0000269|PubMed:25187647, ECO:0000269|PubMed:27322061, CC ECO:0000269|PubMed:27617429, ECO:0000269|PubMed:7537849, CC ECO:0000269|PubMed:7559478, ECO:0000269|PubMed:8276809, CC ECO:0000269|PubMed:8995282, ECO:0000269|PubMed:8999839, CC ECO:0000269|PubMed:9312016, ECO:0000269|PubMed:9428692}. CC -!- INTERACTION: CC P06213; Q99490: AGAP2; NbExp=2; IntAct=EBI-475899, EBI-2361824; CC P06213; Q8NEJ0: DUSP18; NbExp=2; IntAct=EBI-475899, EBI-10698945; CC P06213; Q13322: GRB10; NbExp=4; IntAct=EBI-475899, EBI-80275; CC P06213; P05019: IGF1; NbExp=4; IntAct=EBI-475899, EBI-7902275; CC P06213; P08069: IGF1R; NbExp=5; IntAct=EBI-475899, EBI-475981; CC P06213; P14616: INSRR; NbExp=6; IntAct=EBI-475899, EBI-6424336; CC P06213; P35568: IRS1; NbExp=5; IntAct=EBI-475899, EBI-517592; CC P06213; Q9Y4H2: IRS2; NbExp=4; IntAct=EBI-475899, EBI-1049582; CC P06213; Q15323: KRT31; NbExp=3; IntAct=EBI-475899, EBI-948001; CC P06213; Q13257: MAD2L1; NbExp=4; IntAct=EBI-475899, EBI-78203; CC P06213; P27986: PIK3R1; NbExp=9; IntAct=EBI-475899, EBI-79464; CC P06213; P19174: PLCG1; NbExp=9; IntAct=EBI-475899, EBI-79387; CC P06213; P18031: PTPN1; NbExp=33; IntAct=EBI-475899, EBI-968788; CC P06213; Q06124: PTPN11; NbExp=3; IntAct=EBI-475899, EBI-297779; CC P06213; Q15262: PTPRK; NbExp=2; IntAct=EBI-475899, EBI-474052; CC P06213; Q15256: PTPRR; NbExp=2; IntAct=EBI-475899, EBI-2265659; CC P06213; Q9NRF2: SH2B1; NbExp=6; IntAct=EBI-475899, EBI-310491; CC P06213; P29353: SHC1; NbExp=2; IntAct=EBI-475899, EBI-78835; CC P06213; P01317: INS; Xeno; NbExp=5; IntAct=EBI-475899, EBI-3989070; CC P06213; P35570: Irs1; Xeno; NbExp=5; IntAct=EBI-475899, EBI-520230; CC P06213-1; P32121: ARRB2; NbExp=2; IntAct=EBI-15558981, EBI-714559; CC P06213-1; P06213-1: INSR; NbExp=4; IntAct=EBI-15558981, EBI-15558981; CC P06213-1; P18031: PTPN1; NbExp=2; IntAct=EBI-15558981, EBI-968788; CC P06213-1; Q92485-2: SMPDL3B; NbExp=2; IntAct=EBI-15558981, EBI-21501656; CC P06213-1; P81122: Irs2; Xeno; NbExp=8; IntAct=EBI-15558981, EBI-1369862; CC P06213-1; Q1XH17: Trim72; Xeno; NbExp=2; IntAct=EBI-15558981, EBI-16034016; CC P06213-2; P01308: INS; NbExp=6; IntAct=EBI-9984921, EBI-7090529; CC P06213-2; Q13257: MAD2L1; NbExp=3; IntAct=EBI-9984921, EBI-78203; CC P06213-2; Q92485-2: SMPDL3B; NbExp=2; IntAct=EBI-9984921, EBI-21501656; CC P06213-2; P01317: INS; Xeno; NbExp=2; IntAct=EBI-9984921, EBI-3989070; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:P15208}; CC Single-pass type I membrane protein {ECO:0000305}. Late endosome CC {ECO:0000250|UniProtKB:P15208}. Lysosome CC {ECO:0000250|UniProtKB:P15208}. Note=Binding of insulin to INSR induces CC internalization and lysosomal degradation of the receptor, a means for CC down-regulating this signaling pathway after stimulation. In the CC presence of SORL1, internalized INSR molecules are redirected back to CC the cell surface, thereby preventing their lysosomal catabolism and CC strengthening insulin signal reception. {ECO:0000250|UniProtKB:P15208}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=Long; Synonyms=HIR-B; CC IsoId=P06213-1; Sequence=Displayed; CC Name=Short; Synonyms=HIR-A; CC IsoId=P06213-2; Sequence=VSP_002898; CC -!- TISSUE SPECIFICITY: Isoform Long and isoform Short are predominantly CC expressed in tissue targets of insulin metabolic effects: liver, CC adipose tissue and skeletal muscle but are also expressed in the CC peripheral nerve, kidney, pulmonary alveoli, pancreatic acini, placenta CC vascular endothelium, fibroblasts, monocytes, granulocytes, CC erythrocytes and skin. Isoform Short is preferentially expressed in CC fetal cells such as fetal fibroblasts, muscle, liver and kidney. Found CC as a hybrid receptor with IGF1R in muscle, heart, kidney, adipose CC tissue, skeletal muscle, hepatoma, fibroblasts, spleen and placenta (at CC protein level). Overexpressed in several tumors, including breast, CC colon, lung, ovary, and thyroid carcinomas. CC {ECO:0000269|PubMed:10207053, ECO:0000269|PubMed:2369896, CC ECO:0000269|PubMed:9202395, ECO:0000269|PubMed:9355755}. CC -!- DOMAIN: The tetrameric insulin receptor binds insulin via non-identical CC regions from two alpha chains, primarily via the C-terminal region of CC the first INSR alpha chain. Residues from the leucine-rich N-terminus CC of the other INSR alpha chain also contribute to this insulin binding CC site. A secondary insulin-binding site is formed by residues at the CC junction of fibronectin type-III domain 1 and 2. CC {ECO:0000269|PubMed:16957736, ECO:0000269|PubMed:19459609, CC ECO:0000269|PubMed:23302862}. CC -!- PTM: After being transported from the endoplasmic reticulum to the CC Golgi apparatus, the single glycosylated precursor is further CC glycosylated and then cleaved, followed by its transport to the plasma CC membrane. {ECO:0000269|PubMed:1472036, ECO:0000269|PubMed:16894147, CC ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:19349973, CC ECO:0000269|PubMed:23302862, ECO:0000269|PubMed:2983222}. CC -!- PTM: Autophosphorylated on tyrosine residues in response to insulin CC (PubMed:14690593, PubMed:16246733, PubMed:16271887, PubMed:18278056, CC PubMed:18767165, PubMed:3166375, PubMed:9312016). Phosphorylation of CC Tyr-999 is required for binding to IRS1, SHC1 and STAT5B CC (PubMed:14690593, PubMed:16246733, PubMed:16271887, PubMed:18278056, CC PubMed:18767165, PubMed:3166375, PubMed:9312016). Dephosphorylated by CC PTPRE at Tyr-999, Tyr-1185, Tyr-1189 and Tyr-1190 (PubMed:14690593, CC PubMed:16246733, PubMed:16271887, PubMed:18278056, PubMed:18767165, CC PubMed:3166375, PubMed:9312016). May also be phosphorylated at Tyr-1185 CC and Tyr-1190 by mTORC2 (PubMed:26584640). Dephosphorylated by PTPRF and CC PTPN1 (PubMed:8995282). Dephosphorylated by PTPN2; down-regulates CC insulin-induced signaling (PubMed:10734133, PubMed:12612081). CC Dephosphorylation at Tyr-1189 and Tyr-1190 requires the SH2/SH3 adapter CC protein NCK1, probably to recruit its interaction partner PTPN1 CC (PubMed:21707536). {ECO:0000269|PubMed:10734133, CC ECO:0000269|PubMed:12612081, ECO:0000269|PubMed:14690593, CC ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, CC ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, CC ECO:0000269|PubMed:21707536, ECO:0000269|PubMed:26584640, CC ECO:0000269|PubMed:3166375, ECO:0000269|PubMed:8995282, CC ECO:0000269|PubMed:9312016}. CC -!- PTM: S-nitrosylation at Cys-1083 by BLVRB inhibits the receptor CC tyrosine kinase, thereby inhibiting insulin signaling. CC {ECO:0000269|PubMed:38056462}. CC -!- PTM: Ubiquitinated by MARCHF1; leading to degradation thereby reducing CC surface INSR expression. {ECO:0000269|PubMed:27577745}. CC -!- DISEASE: Rabson-Mendenhall syndrome (RMS) [MIM:262190]: Severe insulin CC resistance syndrome characterized by insulin-resistant diabetes CC mellitus with pineal hyperplasia and somatic abnormalities. Typical CC features include coarse, senile-appearing facies, dental and skin CC abnormalities, abdominal distension, and phallic enlargement. CC Inheritance is autosomal recessive. {ECO:0000269|PubMed:10443650, CC ECO:0000269|PubMed:12023989, ECO:0000269|PubMed:17201797, CC ECO:0000269|PubMed:2121734, ECO:0000269|PubMed:2365819, CC ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:8314008}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Leprechaunism (LEPRCH) [MIM:246200]: Represents the most CC severe form of insulin resistance syndrome, characterized by CC intrauterine and postnatal growth retardation and death in early CC infancy. Inheritance is autosomal recessive. CC {ECO:0000269|PubMed:12023989, ECO:0000269|PubMed:12538626, CC ECO:0000269|PubMed:12970295, ECO:0000269|PubMed:1607067, CC ECO:0000269|PubMed:1730625, ECO:0000269|PubMed:22768670, CC ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:24498630, CC ECO:0000269|PubMed:2479553, ECO:0000269|PubMed:2834824, CC ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:7538143, CC ECO:0000269|PubMed:7815442, ECO:0000269|PubMed:8188715, CC ECO:0000269|PubMed:8326490, ECO:0000269|PubMed:8419945, CC ECO:0000269|PubMed:8636294, ECO:0000269|PubMed:9249867, CC ECO:0000269|PubMed:9299395, ECO:0000269|PubMed:9703342}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Type 2 diabetes mellitus (T2D) [MIM:125853]: A multifactorial CC disorder of glucose homeostasis caused by a lack of sensitivity to CC insulin. Affected individuals usually have an obese body habitus and CC manifestations of a metabolic syndrome characterized by diabetes, CC insulin resistance, hypertension and hypertriglyceridemia. The disease CC results in long-term complications that affect the eyes, kidneys, CC nerves, and blood vessels. {ECO:0000269|PubMed:1470163, CC ECO:0000269|PubMed:1607076, ECO:0000269|PubMed:7657032}. Note=The gene CC represented in this entry may be involved in disease pathogenesis. CC -!- DISEASE: Hyperinsulinemic hypoglycemia, familial, 5 (HHF5) CC [MIM:609968]: A form of hyperinsulinemic hypoglycemia, a clinically and CC genetically heterogeneous disorder characterized by inappropriate CC insulin secretion from the pancreatic beta-cells in the presence of low CC blood glucose levels. HHF5 clinical features include loss of CC consciousness due to hypoglycemia and hypoglycemic seizures. HHF5 CC inheritance is autosomal dominant. {ECO:0000269|PubMed:15161766}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Insulin-resistant diabetes mellitus with acanthosis nigricans CC type A (IRAN type A) [MIM:610549]: Characterized by the association of CC severe insulin resistance (manifested by marked hyperinsulinemia and a CC failure to respond to exogenous insulin) with the skin lesion CC acanthosis nigricans and ovarian hyperandrogenism in adolescent female CC subjects. Women frequently present with hirsutism, acne, amenorrhea or CC oligomenorrhea, and virilization. This syndrome is different from the CC type B that has been demonstrated to be secondary to the presence of CC circulating autoantibodies against the insulin receptor. CC {ECO:0000269|PubMed:10733238, ECO:0000269|PubMed:11260230, CC ECO:0000269|PubMed:12107746, ECO:0000269|PubMed:12970295, CC ECO:0000269|PubMed:1563582, ECO:0000269|PubMed:1963473, CC ECO:0000269|PubMed:2002058, ECO:0000269|PubMed:2168397, CC ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:2544998, CC ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:3283938, CC ECO:0000269|PubMed:8243830, ECO:0000269|PubMed:8288049, CC ECO:0000269|PubMed:8314008, ECO:0000269|PubMed:8388389, CC ECO:0000269|PubMed:9175790}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Wikipedia; Note=Insulin receptor entry; CC URL="https://en.wikipedia.org/wiki/Insulin_receptor"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M10051; AAA59174.1; -; mRNA. DR EMBL; X02160; CAA26096.1; -; mRNA. DR EMBL; M32972; AAA59452.1; -; Genomic_DNA. DR EMBL; M23100; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32823; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32824; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32825; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32826; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32827; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32828; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32829; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32830; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32831; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32832; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32833; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32834; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32835; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32836; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32837; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32838; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32839; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32840; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32841; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32842; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; AC010311; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC010526; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC010606; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC125387; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC117172; AAI17173.1; -; mRNA. DR EMBL; J03466; AAA59175.1; -; Genomic_DNA. DR EMBL; J05043; AAA59190.1; -; Genomic_DNA. DR EMBL; M76592; AAC37604.1; -; Genomic_DNA. DR EMBL; AB208861; BAD92098.1; -; mRNA. DR EMBL; M24555; AAA59178.1; -; mRNA. DR EMBL; M29929; AAA59176.1; -; Genomic_DNA. DR EMBL; M29930; AAA59177.1; -; Genomic_DNA. DR EMBL; M27197; AAA86791.1; -; Genomic_DNA. DR EMBL; M27195; AAA86791.1; JOINED; Genomic_DNA. DR CCDS; CCDS12176.1; -. [P06213-1] DR CCDS; CCDS42487.1; -. [P06213-2] DR PIR; A37348; INHUR. DR RefSeq; NP_000199.2; NM_000208.4. [P06213-1] DR RefSeq; NP_001073285.1; NM_001079817.3. [P06213-2] DR PDB; 1GAG; X-ray; 2.70 A; A=1005-1310. DR PDB; 1I44; X-ray; 2.40 A; A=1005-1310. DR PDB; 1IR3; X-ray; 1.90 A; A=1005-1310. DR PDB; 1IRK; X-ray; 2.10 A; A=1005-1310. DR PDB; 1P14; X-ray; 1.90 A; A=1005-1310. DR PDB; 1RQQ; X-ray; 2.60 A; A/B=1005-1310. DR PDB; 2AUH; X-ray; 3.20 A; A=1005-1310. DR PDB; 2B4S; X-ray; 2.30 A; B/D=1005-1310. DR PDB; 2HR7; X-ray; 2.32 A; A/B=28-512. DR PDB; 2MFR; NMR; -; A=940-988. DR PDB; 2Z8C; X-ray; 3.25 A; A=1008-1310. DR PDB; 3BU3; X-ray; 1.65 A; A=1005-1310. DR PDB; 3BU5; X-ray; 2.10 A; A=1005-1310. DR PDB; 3BU6; X-ray; 1.95 A; A=1005-1310. DR PDB; 3EKK; X-ray; 2.10 A; A=1005-1310. DR PDB; 3EKN; X-ray; 2.20 A; A=1005-1310. DR PDB; 3ETA; X-ray; 2.60 A; A/B=1017-1322. DR PDB; 3W11; X-ray; 3.90 A; E=28-337, F=731-744. DR PDB; 3W12; X-ray; 4.30 A; E=28-337, F=731-744. DR PDB; 3W13; X-ray; 4.30 A; E=28-337, F=724-744. DR PDB; 4IBM; X-ray; 1.80 A; A/B=1005-1310. DR PDB; 4OGA; X-ray; 3.50 A; E=28-337, F=731-744. DR PDB; 4XLV; X-ray; 2.30 A; A=983-1310. DR PDB; 4XSS; X-ray; 3.00 A; E=28-337. DR PDB; 4XST; X-ray; 3.00 A; E=28-337. DR PDB; 4ZXB; X-ray; 3.30 A; E=28-956. DR PDB; 5E1S; X-ray; 2.26 A; A=1005-1310. DR PDB; 5HHW; X-ray; 1.79 A; A=1005-1310. DR PDB; 5J3H; X-ray; 3.27 A; E=28-337. DR PDB; 5KQV; X-ray; 4.40 A; E/F=28-746. DR PDB; 5U1M; X-ray; 1.80 A; B=991-999. DR PDB; 6HN4; EM; 4.20 A; E/F=28-955. DR PDB; 6HN5; EM; 3.20 A; E/F=28-955. DR PDB; 6PXV; EM; 3.20 A; A/C=28-1382. DR PDB; 6PXW; EM; 3.10 A; A/B=28-1382. DR PDB; 6SOF; EM; 4.30 A; A/C=28-746, B/D=795-956. DR PDB; 6VEP; X-ray; 2.90 A; E/K/Q/W=28-337, F/L/R/X=731-746. DR PDB; 6VEQ; X-ray; 3.25 A; E/K=28-337, F/L=731-746. DR PDB; 7BW7; EM; 4.10 A; A/C=28-1382. DR PDB; 7BW8; EM; 3.80 A; A/C=28-1382. DR PDB; 7BWA; EM; 4.90 A; A/C=28-1382. DR PDB; 7KD6; X-ray; 2.60 A; E/K/Q/W=28-337. DR PDB; 7MQO; EM; 3.40 A; E/F=28-956. DR PDB; 7MQR; EM; 4.10 A; E/F=28-955. DR PDB; 7MQS; EM; 4.40 A; E/F=28-955. DR PDB; 7PG0; EM; 7.60 A; A/B=1-1382. DR PDB; 7PG2; EM; 6.70 A; A/B=1-1382. DR PDB; 7PG3; EM; 7.30 A; A/B=1-1382. DR PDB; 7PG4; EM; 9.10 A; A/B=1-1382. DR PDB; 7PHT; NMR; -; A=953-982. DR PDB; 7QID; EM; 5.00 A; A/C=28-746, B/D=763-956. DR PDB; 7S0Q; EM; 3.70 A; B=28-955. DR PDB; 7S8V; EM; 3.73 A; B=28-955. DR PDB; 7U6D; EM; 5.03 A; B/C=28-955. DR PDB; 7U6E; EM; 3.00 A; E/F=28-955. DR PDB; 7YQ3; EM; 3.60 A; E/F=28-946. DR PDB; 7YQ4; EM; 3.95 A; E/F=28-946. DR PDB; 7YQ5; EM; 4.27 A; E/F=28-946. DR PDB; 7YQ6; EM; 4.18 A; E/F=28-946. DR PDB; 8DWN; X-ray; 2.15 A; A=1005-1310. DR PDB; 8GUY; EM; 4.18 A; E/F=28-946. DR PDB; 8U4B; EM; 3.90 A; A/B=1-1382. DR PDB; 8U4C; EM; 3.60 A; A/B=1-1382. DR PDB; 8U4E; EM; 4.20 A; A/B=1-1382. DR PDB; 8VJB; EM; 3.60 A; A/B=1-1382. DR PDB; 8VJC; EM; 3.80 A; A/B=1-1382. DR PDB; 8X06; EM; 3.24 A; A/B=1-1382. DR PDB; 8X2M; EM; 3.31 A; A/B=1-1382. DR PDB; 8XJS; EM; 3.24 A; A/B=1-1382. DR PDB; 8XK1; EM; 3.31 A; A/B=1-1382. DR PDB; 8XKM; EM; 5.00 A; A/B=1-1382. DR PDB; 8XKR; EM; 3.53 A; A/B=1-1382. DR PDB; 8YSZ; EM; 3.38 A; A/B=1-1382. DR PDB; 8YYL; EM; 4.01 A; A/B=1-1382. DR PDB; 8YYS; EM; 4.14 A; A/B=1-1382. DR PDB; 8YYT; EM; 3.60 A; A/B=1-1382. DR PDBsum; 1GAG; -. DR PDBsum; 1I44; -. DR PDBsum; 1IR3; -. DR PDBsum; 1IRK; -. DR PDBsum; 1P14; -. DR PDBsum; 1RQQ; -. DR PDBsum; 2AUH; -. DR PDBsum; 2B4S; -. DR PDBsum; 2HR7; -. DR PDBsum; 2MFR; -. DR PDBsum; 2Z8C; -. DR PDBsum; 3BU3; -. DR PDBsum; 3BU5; -. DR PDBsum; 3BU6; -. DR PDBsum; 3EKK; -. DR PDBsum; 3EKN; -. DR PDBsum; 3ETA; -. DR PDBsum; 3W11; -. DR PDBsum; 3W12; -. DR PDBsum; 3W13; -. DR PDBsum; 4IBM; -. DR PDBsum; 4OGA; -. DR PDBsum; 4XLV; -. DR PDBsum; 4XSS; -. DR PDBsum; 4XST; -. DR PDBsum; 4ZXB; -. DR PDBsum; 5E1S; -. DR PDBsum; 5HHW; -. DR PDBsum; 5J3H; -. DR PDBsum; 5KQV; -. DR PDBsum; 5U1M; -. DR PDBsum; 6HN4; -. DR PDBsum; 6HN5; -. DR PDBsum; 6PXV; -. DR PDBsum; 6PXW; -. DR PDBsum; 6SOF; -. DR PDBsum; 6VEP; -. DR PDBsum; 6VEQ; -. DR PDBsum; 7BW7; -. DR PDBsum; 7BW8; -. DR PDBsum; 7BWA; -. DR PDBsum; 7KD6; -. DR PDBsum; 7MQO; -. DR PDBsum; 7MQR; -. DR PDBsum; 7MQS; -. DR PDBsum; 7PG0; -. DR PDBsum; 7PG2; -. DR PDBsum; 7PG3; -. DR PDBsum; 7PG4; -. DR PDBsum; 7PHT; -. DR PDBsum; 7QID; -. DR PDBsum; 7S0Q; -. DR PDBsum; 7S8V; -. DR PDBsum; 7U6D; -. DR PDBsum; 7U6E; -. DR PDBsum; 7YQ3; -. DR PDBsum; 7YQ4; -. DR PDBsum; 7YQ5; -. DR PDBsum; 7YQ6; -. DR PDBsum; 8DWN; -. DR PDBsum; 8GUY; -. DR PDBsum; 8U4B; -. DR PDBsum; 8U4C; -. DR PDBsum; 8U4E; -. DR PDBsum; 8VJB; -. DR PDBsum; 8VJC; -. DR PDBsum; 8X06; -. DR PDBsum; 8X2M; -. DR PDBsum; 8XJS; -. DR PDBsum; 8XK1; -. DR PDBsum; 8XKM; -. DR PDBsum; 8XKR; -. DR PDBsum; 8YSZ; -. DR PDBsum; 8YYL; -. DR PDBsum; 8YYS; -. DR PDBsum; 8YYT; -. DR AlphaFoldDB; P06213; -. DR BMRB; P06213; -. DR EMDB; EMD-10273; -. DR EMDB; EMD-10311; -. DR EMDB; EMD-13385; -. DR EMDB; EMD-13386; -. DR EMDB; EMD-13387; -. DR EMDB; EMD-13388; -. DR EMDB; EMD-20522; -. DR EMDB; EMD-20523; -. DR EMDB; EMD-23766; -. DR EMDB; EMD-23767; -. DR EMDB; EMD-23949; -. DR EMDB; EMD-23950; -. DR EMDB; EMD-24791; -. DR EMDB; EMD-24927; -. DR EMDB; EMD-26363; -. DR EMDB; EMD-30225; -. DR EMDB; EMD-30227; -. DR EMDB; EMD-30229; -. DR EMDB; EMD-30230; -. DR EMDB; EMD-30231; -. DR EMDB; EMD-34018; -. DR EMDB; EMD-34019; -. DR EMDB; EMD-34021; -. DR EMDB; EMD-34281; -. DR EMDB; EMD-37970; -. DR EMDB; EMD-38017; -. DR EMDB; EMD-38404; -. DR EMDB; EMD-38413; -. DR EMDB; EMD-38420; -. DR EMDB; EMD-38423; -. DR EMDB; EMD-39566; -. DR EMDB; EMD-39675; -. DR EMDB; EMD-39677; -. DR EMDB; EMD-39678; -. DR EMDB; EMD-41877; -. DR EMDB; EMD-41878; -. DR EMDB; EMD-41880; -. DR EMDB; EMD-43279; -. DR EMDB; EMD-43280; -. DR EMDB; EMD-61431; -. DR EMDB; EMD-61432; -. DR EMDB; EMD-61490; -. DR EMDB; EMD-7461; -. DR EMDB; EMD-7462; -. DR EMDB; EMD-7463; -. DR SASBDB; P06213; -. DR SMR; P06213; -. DR BioGRID; 109854; 380. DR DIP; DIP-480N; -. DR ELM; P06213; -. DR FunCoup; P06213; 1946. DR IntAct; P06213; 709. DR MINT; P06213; -. DR STRING; 9606.ENSP00000303830; -. DR BindingDB; P06213; -. DR ChEMBL; CHEMBL1981; -. DR DrugBank; DB08513; [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID. DR DrugBank; DB03909; Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate. DR DrugBank; DB05120; AT1391. DR DrugBank; DB16028; Azemiglitazone. DR DrugBank; DB15399; BMS-754807. DR DrugBank; DB12267; Brigatinib. DR DrugBank; DB09129; Chromic chloride. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB11564; Insulin argine. DR DrugBank; DB01306; Insulin aspart. DR DrugBank; DB09456; Insulin beef. DR DrugBank; DB09564; Insulin degludec. DR DrugBank; DB01307; Insulin detemir. DR DrugBank; DB00047; Insulin glargine. DR DrugBank; DB01309; Insulin glulisine. DR DrugBank; DB00030; Insulin human. DR DrugBank; DB16693; Insulin icodec. DR DrugBank; DB00046; Insulin lispro. DR DrugBank; DB11567; Insulin peglispro. DR DrugBank; DB00071; Insulin pork. DR DrugBank; DB11568; Insulin tregopil. DR DrugBank; DB16637; KW-2450 free base. DR DrugBank; DB06075; Linsitinib. DR DrugBank; DB01277; Mecasermin. DR DrugBank; DB14751; Mecasermin rinfabate. DR DrugBank; DB11721; Mitoglitazone. DR DrugBank; DB05115; NN344. DR DrugBank; DB12518; Raclopride. DR DrugBank; DB06156; Tesofensine. DR DrugCentral; P06213; -. DR GuidetoPHARMACOLOGY; 1800; -. DR GlyConnect; 1402; 8 N-Linked glycans (6 sites). DR GlyCosmos; P06213; 21 sites, 11 glycans. DR GlyGen; P06213; 25 sites, 79 N-linked glycans (13 sites), 4 O-linked glycans (6 sites). DR iPTMnet; P06213; -. DR PhosphoSitePlus; P06213; -. DR SwissPalm; P06213; -. DR BioMuta; INSR; -. DR DMDM; 308153655; -. DR CPTAC; CPTAC-1771; -. DR CPTAC; CPTAC-1772; -. DR CPTAC; CPTAC-2814; -. DR CPTAC; CPTAC-3053; -. DR jPOST; P06213; -. DR MassIVE; P06213; -. DR PaxDb; 9606-ENSP00000303830; -. DR PeptideAtlas; P06213; -. DR ProteomicsDB; 51872; -. [P06213-1] DR ProteomicsDB; 51873; -. [P06213-2] DR Pumba; P06213; -. DR ABCD; P06213; 3 sequenced antibodies. DR Antibodypedia; 3403; 2189 antibodies from 53 providers. DR DNASU; 3643; -. DR Ensembl; ENST00000302850.10; ENSP00000303830.4; ENSG00000171105.15. [P06213-1] DR Ensembl; ENST00000341500.9; ENSP00000342838.4; ENSG00000171105.15. [P06213-2] DR GeneID; 3643; -. DR KEGG; hsa:3643; -. DR MANE-Select; ENST00000302850.10; ENSP00000303830.4; NM_000208.4; NP_000199.2. DR UCSC; uc002mgd.2; human. [P06213-1] DR AGR; HGNC:6091; -. DR ClinPGx; PA202; -. DR CTD; 3643; -. DR DisGeNET; 3643; -. DR GeneCards; INSR; -. DR GeneReviews; INSR; -. DR HGNC; HGNC:6091; INSR. DR HPA; ENSG00000171105; Low tissue specificity. DR MalaCards; INSR; -. DR MIM; 125853; phenotype. DR MIM; 147670; gene. DR MIM; 246200; phenotype. DR MIM; 262190; phenotype. DR MIM; 609968; phenotype. DR MIM; 610549; phenotype. DR OpenTargets; ENSG00000171105; -. DR Orphanet; 508; Donohue syndrome. DR Orphanet; 263458; Hyperinsulinism due to INSR deficiency. DR Orphanet; 2297; Insulin-resistance syndrome type A. DR Orphanet; 769; Rabson-Mendenhall syndrome. DR VEuPathDB; HostDB:ENSG00000171105; -. DR eggNOG; KOG4258; Eukaryota. DR GeneTree; ENSGT00940000155404; -. DR HOGENOM; CLU_000288_166_0_1; -. DR InParanoid; P06213; -. DR OMA; AVESNTW; -. DR OrthoDB; 5809444at2759; -. DR PAN-GO; P06213; 12 GO annotations based on evolutionary models. DR PhylomeDB; P06213; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P06213; -. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-74713; IRS activation. DR Reactome; R-HSA-74749; Signal attenuation. DR Reactome; R-HSA-74751; Insulin receptor signalling cascade. DR Reactome; R-HSA-74752; Signaling by Insulin receptor. DR Reactome; R-HSA-77387; Insulin receptor recycling. DR SABIO-RK; P06213; -. DR SignaLink; P06213; -. DR SIGNOR; P06213; -. DR Agora; ENSG00000171105; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 3643; 15 hits in 1203 CRISPR screens. DR ChiTaRS; INSR; human. DR EvolutionaryTrace; P06213; -. DR GeneWiki; Insulin_receptor; -. DR GenomeRNAi; 3643; -. DR Pharos; P06213; Tclin. DR PRO; PR:P06213; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; P06213; protein. DR Bgee; ENSG00000171105; Expressed in buccal mucosa cell and 209 other cell types or tissues. DR ExpressionAtlas; P06213; baseline and differential. DR GO; GO:0030424; C:axon; IBA:GO_Central. DR GO; GO:0005901; C:caveola; IDA:BHF-UCL. DR GO; GO:0032590; C:dendrite membrane; ISS:ARUK-UCL. DR GO; GO:0010008; C:endosome membrane; TAS:Reactome. DR GO; GO:0009897; C:external side of plasma membrane; ISS:ARUK-UCL. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005899; C:insulin receptor complex; IDA:UniProtKB. DR GO; GO:0005770; C:late endosome; IEA:UniProtKB-SubCell. DR GO; GO:0005764; C:lysosome; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; IDA:BHF-UCL. DR GO; GO:0032809; C:neuronal cell body membrane; ISS:ARUK-UCL. DR GO; GO:0005886; C:plasma membrane; IDA:ARUK-UCL. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0001540; F:amyloid-beta binding; IPI:ARUK-UCL. DR GO; GO:0005524; F:ATP binding; IDA:BHF-UCL. DR GO; GO:0038024; F:cargo receptor activity; ISS:ARUK-UCL. DR GO; GO:0005525; F:GTP binding; IDA:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0043559; F:insulin binding; IDA:UniProtKB. DR GO; GO:0005009; F:insulin receptor activity; IDA:UniProtKB. DR GO; GO:0043560; F:insulin receptor substrate binding; IPI:UniProtKB. DR GO; GO:0031994; F:insulin-like growth factor I binding; IPI:BHF-UCL. DR GO; GO:0031995; F:insulin-like growth factor II binding; IPI:BHF-UCL. DR GO; GO:0005159; F:insulin-like growth factor receptor binding; IDA:BHF-UCL. DR GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IPI:UniProtKB. DR GO; GO:0019904; F:protein domain specific binding; IPI:CAFA. DR GO; GO:0030295; F:protein kinase activator activity; IMP:BHF-UCL. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; IPI:ARUK-UCL. DR GO; GO:0051425; F:PTB domain binding; IPI:UniProtKB. DR GO; GO:0030325; P:adrenal gland development; IEA:Ensembl. DR GO; GO:0097242; P:amyloid-beta clearance; ISS:ARUK-UCL. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl. DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:BHF-UCL. DR GO; GO:0097062; P:dendritic spine maintenance; ISS:ARUK-UCL. DR GO; GO:0008544; P:epidermis development; IEA:Ensembl. DR GO; GO:0031017; P:exocrine pancreas development; IEA:Ensembl. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0042593; P:glucose homeostasis; IMP:BHF-UCL. DR GO; GO:0003007; P:heart morphogenesis; IMP:BHF-UCL. DR GO; GO:0008286; P:insulin receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0007612; P:learning; TAS:ARUK-UCL. DR GO; GO:0008584; P:male gonad development; IEA:Ensembl. DR GO; GO:0030238; P:male sex determination; IEA:Ensembl. DR GO; GO:0007613; P:memory; TAS:ARUK-UCL. DR GO; GO:1990535; P:neuron projection maintenance; ISS:ARUK-UCL. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IGI:BHF-UCL. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0046326; P:positive regulation of D-glucose import; IDA:BHF-UCL. DR GO; GO:0048639; P:positive regulation of developmental growth; IMP:BHF-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IEA:Ensembl. DR GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IDA:BHF-UCL. DR GO; GO:0045821; P:positive regulation of glycolytic process; IMP:BHF-UCL. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL. DR GO; GO:0051446; P:positive regulation of meiotic cell cycle; IEA:Ensembl. DR GO; GO:0045840; P:positive regulation of mitotic nuclear division; IMP:BHF-UCL. DR GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:BHF-UCL. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:BHF-UCL. DR GO; GO:0043243; P:positive regulation of protein-containing complex disassembly; ISS:ARUK-UCL. DR GO; GO:0002092; P:positive regulation of receptor internalization; IDA:CACAO. DR GO; GO:0060267; P:positive regulation of respiratory burst; IDA:BHF-UCL. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR GO; GO:0031623; P:receptor internalization; IEA:Ensembl. DR GO; GO:0006898; P:receptor-mediated endocytosis; ISS:ARUK-UCL. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IMP:BHF-UCL. DR GO; GO:0045995; P:regulation of embryonic development; IMP:BHF-UCL. DR GO; GO:2000194; P:regulation of female gonad development; IEA:Ensembl. DR GO; GO:0046718; P:symbiont entry into host cell; IMP:BHF-UCL. DR GO; GO:0150104; P:transport across blood-brain barrier; NAS:ARUK-UCL. DR CDD; cd00063; FN3; 2. DR CDD; cd00064; FU; 1. DR CDD; cd05061; PTKc_InsR; 1. DR FunFam; 1.10.510.10:FF:000050; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.10.220.10:FF:000005; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000087; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000108; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:001010; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.30.200.20:FF:000026; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.80.20.20:FF:000001; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.80.20.20:FF:000002; Tyrosine-protein kinase receptor; 1. DR Gene3D; 2.10.220.10; Hormone Receptor, Insulin-like Growth Factor Receptor 1, Chain A, domain 2; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 4. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.20.20; Receptor L-domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR006211; Furin-like_Cys-rich_dom. DR InterPro; IPR006212; Furin_repeat. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR040969; Insulin_TMD. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR000494; Rcpt_L-dom. DR InterPro; IPR036941; Rcpt_L-dom_sf. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt. DR InterPro; IPR002011; Tyr_kinase_rcpt_2_CS. DR PANTHER; PTHR24416:SF535; INSULIN RECEPTOR; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00757; Furin-like; 1. DR Pfam; PF17870; Insulin_TMD; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF01030; Recep_L_domain; 2. DR PIRSF; PIRSF000620; Insulin_receptor; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00060; FN3; 3. DR SMART; SM00261; FU; 2. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 3. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF52058; L domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Carbohydrate metabolism; KW Cell membrane; Cleavage on pair of basic residues; Diabetes mellitus; KW Direct protein sequencing; Disease variant; Disulfide bond; Endosome; KW Glycoprotein; Isopeptide bond; Kinase; Lysosome; Membrane; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; Receptor; KW Reference proteome; Repeat; S-nitrosylation; Signal; Transferase; KW Transmembrane; Transmembrane helix; Tyrosine-protein kinase; KW Ubl conjugation. FT SIGNAL 1..27 FT /evidence="ECO:0000269|PubMed:2211730, FT ECO:0000269|PubMed:2983222, ECO:0000269|PubMed:8257688" FT CHAIN 28..758 FT /note="Insulin receptor subunit alpha" FT /id="PRO_0000016687" FT CHAIN 763..1382 FT /note="Insulin receptor subunit beta" FT /id="PRO_0000016689" FT TOPO_DOM 28..758 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TOPO_DOM 763..956 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 957..979 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 980..1382 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT DOMAIN 624..726 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 757..842 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 853..947 FT /note="Fibronectin type-III 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 1023..1298 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 686..708 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 733..741 FT /note="Insulin-binding" FT REGION 746..766 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 999 FT /note="Important for interaction with IRS1, SHC1 and FT STAT5B" FT /evidence="ECO:0000269|PubMed:9428692" FT REGION 1360..1382 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1361..1364 FT /note="PIK3R1-binding" FT ACT_SITE 1159 FT /note="Proton donor/acceptor" FT /evidence="ECO:0000269|PubMed:9312016" FT BINDING 1033 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT BINDING 1057 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT BINDING 1104..1110 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT BINDING 1163..1164 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT BINDING 1177 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT SITE 66 FT /note="Insulin-binding" FT /evidence="ECO:0000305" FT MOD_RES 400 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 401 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 407 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 992 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305" FT MOD_RES 999 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:3166375" FT MOD_RES 1011 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305" FT MOD_RES 1083 FT /note="S-nitrosocysteine" FT /evidence="ECO:0000269|PubMed:38056462" FT MOD_RES 1185 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14690593, FT ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, FT ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, FT ECO:0000269|PubMed:26584640, ECO:0000269|PubMed:3166375, FT ECO:0000269|PubMed:9312016" FT MOD_RES 1189 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14690593, FT ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, FT ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, FT ECO:0000269|PubMed:3166375, ECO:0000269|PubMed:9312016" FT MOD_RES 1190 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14690593, FT ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, FT ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, FT ECO:0000269|PubMed:26584640, ECO:0000269|PubMed:3166375, FT ECO:0000269|PubMed:9312016" FT MOD_RES 1355 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:3166375" FT MOD_RES 1361 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:3166375" FT CARBOHYD 43 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:23302862, ECO:0000269|PubMed:2983222" FT CARBOHYD 52 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:23302862" FT CARBOHYD 105 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 138 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:23302862" FT CARBOHYD 242 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23302862" FT CARBOHYD 282 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:23302862" FT CARBOHYD 322 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 364 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147" FT CARBOHYD 424 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147" FT CARBOHYD 445 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:19349973" FT CARBOHYD 541 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:1472036, FT ECO:0000269|PubMed:19159218" FT CARBOHYD 633 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 651 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 698 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 769 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:2983222" FT CARBOHYD 782 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 920 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 933 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 35..53 FT DISULFID 153..182 FT DISULFID 186..209 FT DISULFID 196..215 FT DISULFID 219..228 FT DISULFID 223..234 FT DISULFID 235..243 FT DISULFID 239..252 FT DISULFID 255..264 FT DISULFID 268..280 FT DISULFID 286..311 FT DISULFID 293..301 FT DISULFID 315..328 FT DISULFID 331..335 FT DISULFID 339..360 FT DISULFID 462..495 FT /evidence="ECO:0000269|PubMed:1472036" FT DISULFID 551 FT /note="Interchain" FT /evidence="ECO:0000269|PubMed:1472036" FT DISULFID 674..899 FT DISULFID 825..834 FT CROSSLNK 1079 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:27577745" FT VAR_SEQ 745..756 FT /note="Missing (in isoform Short)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:2983222, ECO:0000303|Ref.13" FT /id="VSP_002898" FT VARIANT 2 FT /note="A -> G (in dbSNP:rs7508518)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:2210055, ECO:0000269|PubMed:2280779, FT ECO:0000269|PubMed:2777789, ECO:0000269|PubMed:2806055, FT ECO:0000269|PubMed:2859121, ECO:0000269|PubMed:2983222, FT ECO:0000269|PubMed:3680248" FT /id="VAR_058395" FT VARIANT 42 FT /note="N -> K (in RMS; impairs transport to the plasma FT membrane and reduces the affinity to bind insulin; FT dbSNP:rs121913143)" FT /evidence="ECO:0000269|PubMed:2121734, FT ECO:0000269|PubMed:2365819" FT /id="VAR_004079" FT VARIANT 55 FT /note="V -> A (in LEPRCH; Verona-1; dbSNP:rs121913152)" FT /evidence="ECO:0000269|PubMed:1607067" FT /id="VAR_004080" FT VARIANT 56 FT /note="I -> T (in LEPRCH; abolishes post-translational FT processing; dbSNP:rs1555689937)" FT /evidence="ECO:0000269|PubMed:24498630" FT /id="VAR_079535" FT VARIANT 58 FT /note="G -> R (in LEPRCH; Helmond; inhibits processing and FT transport; dbSNP:rs52836744)" FT /evidence="ECO:0000269|PubMed:1730625" FT /id="VAR_004081" FT VARIANT 86 FT /note="D -> G (in IRAN type A)" FT /evidence="ECO:0000269|PubMed:9175790" FT /id="VAR_015907" FT VARIANT 89 FT /note="L -> P (in IRAN type A)" FT /evidence="ECO:0000269|PubMed:9175790" FT /id="VAR_015908" FT VARIANT 113 FT /note="R -> P (in LEPRCH; Atlanta-1; abolishes insulin FT binding; dbSNP:rs121913153)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:8419945" FT /id="VAR_004082" FT VARIANT 119 FT /note="A -> V (in LEPRCH; markedly impairs insulin binding; FT dbSNP:rs1347473020)" FT /evidence="ECO:0000269|PubMed:12023989" FT /id="VAR_015909" FT VARIANT 120 FT /note="L -> Q (in LEPRCH; inhibits receptor processing)" FT /evidence="ECO:0000269|PubMed:12970295" FT /id="VAR_031518" FT VARIANT 146 FT /note="I -> M (in LEPRCH; mild; dbSNP:rs121913159)" FT /evidence="ECO:0000269|PubMed:7815442, FT ECO:0000269|PubMed:8326490" FT /id="VAR_015539" FT VARIANT 167 FT /note="V -> L (in IRAN type A; dbSNP:rs938519025)" FT /evidence="ECO:0000269|PubMed:10733238" FT /id="VAR_015910" FT VARIANT 171 FT /note="Y -> H (in dbSNP:rs1051692)" FT /evidence="ECO:0000269|PubMed:2859121" FT /id="VAR_058396" FT VARIANT 220 FT /note="P -> L (in Ins resistance; severe; FT dbSNP:rs749094324)" FT /evidence="ECO:0000269|PubMed:8242067" FT /id="VAR_004083" FT VARIANT 228 FT /note="C -> R (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041429" FT VARIANT 236 FT /note="H -> R (in RMS and LEPRCH; Winnipeg; may impair FT receptor processing; dbSNP:rs121913145)" FT /evidence="ECO:0000269|PubMed:17201797, FT ECO:0000269|PubMed:2365819" FT /id="VAR_004084" FT VARIANT 256 FT /note="R -> C (in RMS; dbSNP:rs781007453)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079536" FT VARIANT 260 FT /note="L -> P (in LEPRCH; Geldeimalsen; dbSNP:rs121913141)" FT /evidence="ECO:0000269|PubMed:2479553" FT /id="VAR_004085" FT VARIANT 279 FT /note="R -> C (in IRAN type A; inhibits receptor FT internalization; dbSNP:rs1568470274)" FT /evidence="ECO:0000269|PubMed:12107746" FT /id="VAR_015540" FT VARIANT 279 FT /note="R -> H (in IRAN type A; interferes with receptor FT processing; dbSNP:rs1329693158)" FT /evidence="ECO:0000269|PubMed:12970295" FT /id="VAR_031519" FT VARIANT 280 FT /note="C -> Y (in IRAN type A)" FT /evidence="ECO:0000269|PubMed:11260230" FT /id="VAR_015911" FT VARIANT 286 FT /note="C -> Y (in LEPRCH; abolishes post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:24498630" FT /id="VAR_079537" FT VARIANT 301 FT /note="C -> Y (in LEPRCH)" FT /evidence="ECO:0000269|PubMed:9703342" FT /id="VAR_015912" FT VARIANT 308 FT /note="Missing (in LEPRCH; abolishes insulin binding)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:7538143, ECO:0000269|PubMed:8636294" FT /id="VAR_015913" FT VARIANT 350 FT /note="S -> L (in RMS and LEPRCH; dbSNP:rs1974095413)" FT /evidence="ECO:0000269|PubMed:12970295, FT ECO:0000269|PubMed:8314008" FT /id="VAR_015914" FT VARIANT 362 FT /note="Missing (in LEPRCH)" FT /evidence="ECO:0000269|PubMed:12538626" FT /id="VAR_015541" FT VARIANT 386 FT /note="G -> S (in RMS; may impair receptor processing; FT dbSNP:rs764221583)" FT /evidence="ECO:0000269|PubMed:17201797" FT /id="VAR_031520" FT VARIANT 393 FT /note="G -> R (in LEPRCH; Verona-1; dbSNP:rs267607184)" FT /evidence="ECO:0000269|PubMed:1607067" FT /id="VAR_004086" FT VARIANT 409 FT /note="F -> V (in IRAN type A; dbSNP:rs121913142)" FT /evidence="ECO:0000269|PubMed:8388389" FT /id="VAR_004087" FT VARIANT 439 FT /note="W -> S (in LEPRCH; impairs transport of the receptor FT to the cell surface; dbSNP:rs121913158)" FT /evidence="ECO:0000269|PubMed:8188715" FT /id="VAR_015542" FT VARIANT 448 FT /note="I -> T (in dbSNP:rs1051691)" FT /evidence="ECO:0000269|PubMed:2859121" FT /id="VAR_015915" FT VARIANT 458 FT /note="N -> D (in LEPRCH; partially inhibits receptor FT processing and autophosphorylation; strongly impairs ERK FT phosphorylation; induces wild-type levels of IRS-1 FT phosphorylation; dbSNP:rs121913160)" FT /evidence="ECO:0000269|PubMed:12970295" FT /id="VAR_031521" FT VARIANT 487 FT /note="K -> E (in LEPRCH; ARK-1; dbSNP:rs121913136)" FT /evidence="ECO:0000269|PubMed:2834824" FT /id="VAR_004088" FT VARIANT 489 FT /note="N -> D (in IRAN type A; uncertain significance; FT dbSNP:rs1135401742)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079538" FT VARIANT 489 FT /note="N -> S (in IRAN type A; dbSNP:rs121913147)" FT /evidence="ECO:0000269|PubMed:2365819" FT /id="VAR_004089" FT VARIANT 492 FT /note="Q -> K" FT /evidence="ECO:0000269|PubMed:2859121" FT /id="VAR_015916" FT VARIANT 635 FT /note="S -> L (in RMS; decreases post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079539" FT VARIANT 657 FT /note="V -> F (in LEPRCH; impairs post-translational FT processing; dbSNP:rs1135401737)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079540" FT VARIANT 659 FT /note="W -> R (in LEPRCH; impairs post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079541" FT VARIANT 695 FT /note="Q -> R (in dbSNP:rs55906835)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041430" FT VARIANT 762 FT /note="R -> S (in IRAN type A; dbSNP:rs121913138)" FT /evidence="ECO:0000269|PubMed:3283938" FT /id="VAR_004090" FT VARIANT 811 FT /note="G -> S (in dbSNP:rs35045353)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041431" FT VARIANT 818 FT /note="Y -> C (in LEPRCH; abolishes post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:22768670, FT ECO:0000269|PubMed:28765322" FT /id="VAR_079542" FT VARIANT 830 FT /note="P -> L (in dbSNP:rs2162771)" FT /id="VAR_055986" FT VARIANT 835 FT /note="S -> I (in RMS; impairs post-translational FT processing; dbSNP:rs1135401739)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079543" FT VARIANT 842 FT /note="A -> V (in RMS; decreases post-translational FT processing; dbSNP:rs1135401738)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079544" FT VARIANT 858 FT /note="T -> A (in T2D; dbSNP:rs182552223)" FT /evidence="ECO:0000269|PubMed:7657032" FT /id="VAR_015917" FT VARIANT 874 FT /note="P -> L (in RMS; impairs post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079545" FT VARIANT 878 FT /note="N -> S (in RMS; impairs post-translational FT processing; dbSNP:rs887190835)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079546" FT VARIANT 890..1382 FT /note="Missing (in LEPRCH)" FT /evidence="ECO:0000269|PubMed:22768670" FT /id="VAR_079547" FT VARIANT 925 FT /note="I -> T (in LEPRCH; abolishes post-translational FT processing; abolishes insulin binding; dbSNP:rs1599881881)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:28765322" FT /id="VAR_015918" FT VARIANT 926 FT /note="R -> W (in LEPRCH; markedly impairs insulin FT binding;impairs post-translational processing; FT dbSNP:rs911929963)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:28765322" FT /id="VAR_015919" FT VARIANT 937 FT /note="T -> M (in LEPRCH; impaired receptor processing; FT impairs post-translational processing; dbSNP:rs1972802448)" FT /evidence="ECO:0000269|PubMed:28765322, FT ECO:0000269|PubMed:9299395" FT /id="VAR_015920" FT VARIANT 997 FT /note="P -> T (in RMS; reduces insulin binding)" FT /evidence="ECO:0000269|PubMed:12023989" FT /id="VAR_015921" FT VARIANT 999..1382 FT /note="Missing (in RMS)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079548" FT VARIANT 1012 FT /note="V -> M (in dbSNP:rs1799816)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:8314008, ECO:0000269|PubMed:8432414, FT ECO:0000269|PubMed:8458533, ECO:0000269|PubMed:9199575" FT /id="VAR_004091" FT VARIANT 1020 FT /note="R -> Q (in IRAN type A; dbSNP:rs121913148)" FT /evidence="ECO:0000269|PubMed:2002058" FT /id="VAR_004092" FT VARIANT 1023 FT /note="I -> F" FT /evidence="ECO:0000269|PubMed:8890729" FT /id="VAR_015922" FT VARIANT 1035 FT /note="G -> V (in IRAN type A; dbSNP:rs121913135)" FT /evidence="ECO:0000269|PubMed:2544998" FT /id="VAR_004093" FT VARIANT 1054 FT /note="V -> M (in IRAN type A; uncertain significance; FT dbSNP:rs1135401741)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079549" FT VARIANT 1055 FT /note="A -> V (in IRAN type A; dbSNP:rs1599874183)" FT /evidence="ECO:0000269|PubMed:10733238" FT /id="VAR_015923" FT VARIANT 1065 FT /note="L -> V (in dbSNP:rs56395521)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041432" FT VARIANT 1075 FT /note="A -> D (in IRAN type A)" FT /evidence="ECO:0000269|PubMed:8243830" FT /id="VAR_004094" FT VARIANT 1095 FT /note="K -> E (in a subject with non-insulin dependent FT diabetes mellitus; dbSNP:rs909008899)" FT /evidence="ECO:0000269|PubMed:2040394" FT /id="VAR_015924" FT VARIANT 1119 FT /note="R -> W (in LEPRCH; dbSNP:rs1229730671)" FT /evidence="ECO:0000269|PubMed:12970295, FT ECO:0000269|PubMed:9249867" FT /id="VAR_015925" FT VARIANT 1143 FT /note="I -> T (in RMS; reduces insulin binding)" FT /evidence="ECO:0000269|PubMed:10443650, FT ECO:0000269|PubMed:12023989" FT /id="VAR_015926" FT VARIANT 1158 FT /note="R -> Q (in T2D)" FT /evidence="ECO:0000269|PubMed:1470163" FT /id="VAR_015927" FT VARIANT 1158 FT /note="R -> W (in RMS; abolishes insulin binding; FT dbSNP:rs111993466)" FT /evidence="ECO:0000269|PubMed:10443650, FT ECO:0000269|PubMed:12023989" FT /id="VAR_015928" FT VARIANT 1161 FT /note="A -> T (in IRAN type A; dbSNP:rs121913139)" FT /evidence="ECO:0000269|PubMed:2168397" FT /id="VAR_004095" FT VARIANT 1162 FT /note="A -> E (in IRAN type A; impairs proteolytic FT processing; dbSNP:rs121913154)" FT /evidence="ECO:0000269|PubMed:8096518" FT /id="VAR_004096" FT VARIANT 1180 FT /note="M -> I (in a patient with insulin resistance; FT dbSNP:rs121913157)" FT /evidence="ECO:0000269|PubMed:1890161" FT /id="VAR_004097" FT VARIANT 1191 FT /note="R -> Q (in T2D; dbSNP:rs121913150)" FT /evidence="ECO:0000269|PubMed:1607076" FT /id="VAR_004098" FT VARIANT 1201 FT /note="R -> Q (in HHF5 and IRAN type A; interferes with FT kinase activation by insulin; dbSNP:rs121913156)" FT /evidence="ECO:0000269|PubMed:15161766, FT ECO:0000269|PubMed:8082780, ECO:0000269|PubMed:8288049" FT /id="VAR_015929" FT VARIANT 1201 FT /note="R -> W (in LEPRCH and RMS; reduces insulin binding FT possibly due to reduced receptor levels on the cell FT surface; dbSNP:rs1568426700)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:9703342" FT /id="VAR_015930" FT VARIANT 1205 FT /note="P -> L (in IRAN type A; moderate; FT dbSNP:rs1295645322)" FT /evidence="ECO:0000269|PubMed:1563582, FT ECO:0000269|PubMed:8314008" FT /id="VAR_004099" FT VARIANT 1206 FT /note="E -> D (in IRAN type A; accelerates degradation of FT the protein and impairs kinase activity)" FT /evidence="ECO:0000269|PubMed:7983039" FT /id="VAR_015931" FT VARIANT 1206 FT /note="E -> K (in LEPRCH)" FT /evidence="ECO:0000269|PubMed:9249867" FT /id="VAR_015932" FT VARIANT 1220 FT /note="W -> L (in IRAN type A; accelerates degradation of FT the protein and impairs kinase activity; dbSNP:rs52800171)" FT /evidence="ECO:0000269|PubMed:7983039, FT ECO:0000269|PubMed:8390949" FT /id="VAR_004100" FT VARIANT 1227 FT /note="W -> S (in IRAN type A; dbSNP:rs121913140)" FT /evidence="ECO:0000269|PubMed:1963473" FT /id="VAR_004101" FT VARIANT 1282 FT /note="T -> A (in dbSNP:rs55875349)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041433" FT VARIANT 1361 FT /note="Y -> C (in dbSNP:rs13306449)" FT /evidence="ECO:0000269|PubMed:7657032" FT /id="VAR_015933" FT VARIANT 1378 FT /note="R -> Q (in IRAN type A; dbSNP:rs52826008)" FT /evidence="ECO:0000269|PubMed:8314008" FT /id="VAR_015934" FT MUTAGEN 462 FT /note="C->A: Does not affect S-nitrosylation." FT /evidence="ECO:0000269|PubMed:38056462" FT MUTAGEN 825 FT /note="C->A: Does not affect S-nitrosylation." FT /evidence="ECO:0000269|PubMed:38056462" FT MUTAGEN 834 FT /note="C->A: Does not affect S-nitrosylation." FT /evidence="ECO:0000269|PubMed:38056462" FT MUTAGEN 991 FT /note="L->A: Reduces interaction with IRS1 but has no FT effect on interaction with SHC1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 992 FT /note="Y->A: Reduces interaction with IRS1 but has no FT effect on interaction with SHC1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 996..997 FT /note="NP->AA: Abolishes interaction with IRS1. Severely FT disrupts, but does not abolish interaction with SHC1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 996 FT /note="N->A: Abolishes interaction with IRS1 and FT significantly reduces interaction with SHC1. Has no effect FT on interaction with PIK3R1." FT /evidence="ECO:0000269|PubMed:7537849, FT ECO:0000269|PubMed:7559478" FT MUTAGEN 997 FT /note="P->A: Abolishes interaction with IRS1 and FT significantly reduces interaction with SHC1. Has no effect FT on interaction with PIK3R1." FT /evidence="ECO:0000269|PubMed:7537849, FT ECO:0000269|PubMed:7559478" FT MUTAGEN 998 FT /note="E->A: Does not affect interaction with IRS1, SHC1 or FT PIK3R1." FT /evidence="ECO:0000269|PubMed:7537849" FT MUTAGEN 999 FT /note="Y->E: Abolishes interaction with IRS1 and SHC1." FT /evidence="ECO:0000269|PubMed:2842060, FT ECO:0000269|PubMed:7537849, ECO:0000269|PubMed:7559478, FT ECO:0000269|PubMed:9428692" FT MUTAGEN 999 FT /note="Y->F: Has no effect on insulin-stimulated FT autophosphorylation, but inhibits the biological activity FT of the receptor. Abolishes interaction with IRS1 and almost FT completely prevents interaction with SHC1. Has no effect on FT interaction with PIK3R1. Abolishes interaction with FT STAT5B." FT /evidence="ECO:0000269|PubMed:2842060, FT ECO:0000269|PubMed:7537849, ECO:0000269|PubMed:7559478, FT ECO:0000269|PubMed:9428692" FT MUTAGEN 1000 FT /note="L->A,R: Severely reduces interaction with SHC1. Has FT no effect on interaction with IRS1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 1002 FT /note="A->D: Reduces interaction with IRS1 but has no FT effect on interaction with SHC1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 1011 FT /note="Y->A: Increases kinase activity." FT /evidence="ECO:0000269|PubMed:12707268" FT MUTAGEN 1057 FT /note="K->A: Abolishes the kinase activity and abolishes FT interaction with IRS1, SHC1, GRB7 and PIK3R1." FT /evidence="ECO:0000269|PubMed:10803466, FT ECO:0000269|PubMed:3101064, ECO:0000269|PubMed:7537849" FT MUTAGEN 1057 FT /note="K->M,R: Abolishes the kinase activity." FT /evidence="ECO:0000269|PubMed:10803466, FT ECO:0000269|PubMed:3101064, ECO:0000269|PubMed:7537849" FT MUTAGEN 1079 FT /note="K->R: Increased cell surface stability." FT /evidence="ECO:0000269|PubMed:27577745" FT MUTAGEN 1083 FT /note="C->A: Reduced S-nitrosylation by BLVRB, leading to FT increased receptor tyrosine kinase activity." FT /evidence="ECO:0000269|PubMed:38056462" FT MUTAGEN 1159 FT /note="D->N: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:11598120" FT MUTAGEN 1163 FT /note="R->Q: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:11598120" FT MUTAGEN 1189 FT /note="Y->F: Reduced interaction with GRB7." FT /evidence="ECO:0000269|PubMed:10803466" FT MUTAGEN 1190 FT /note="Y->F: Strongly reduced interaction with GRB7." FT /evidence="ECO:0000269|PubMed:10803466" FT CONFLICT 601 FT /note="D -> N (in Ref. 19; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 830 FT /note="P -> E (in Ref. 19; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 1278 FT /note="K -> N (in Ref. 2; CAA26096)" FT /evidence="ECO:0000305" FT STRAND 33..42 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 45..50 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 53..65 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 70..72 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 73..75 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 83..86 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 88..93 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 100..102 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 103..105 FT /evidence="ECO:0007829|PDB:8X2M" FT STRAND 115..117 FT /evidence="ECO:0007829|PDB:6PXW" FT STRAND 118..124 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 141..149 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 155..158 FT /evidence="ECO:0007829|PDB:7U6E" FT HELIX 160..162 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 167..169 FT /evidence="ECO:0007829|PDB:7KD6" FT STRAND 171..175 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 176..178 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 187..192 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 199..201 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 204..206 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 209..211 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 221..223 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 224..226 FT /evidence="ECO:0007829|PDB:8X06" FT STRAND 230..232 FT /evidence="ECO:0007829|PDB:7MQO" FT STRAND 243..247 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 251..260 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 263..267 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 273..275 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 276..278 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 279..281 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 283..295 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 298..300 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 305..307 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 310..314 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 319..321 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 323..325 FT /evidence="ECO:0007829|PDB:7KD6" FT STRAND 327..330 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 332..334 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 338..348 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 351..355 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 356..359 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 361..369 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 373..375 FT /evidence="ECO:0007829|PDB:7U6E" FT HELIX 377..385 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 390..393 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 395..399 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 404..406 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 414..416 FT /evidence="ECO:0007829|PDB:8X06" FT TURN 422..424 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 425..430 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 437..439 FT /evidence="ECO:0007829|PDB:7U6E" FT TURN 441..443 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 447..450 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 452..458 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 463..472 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 476..478 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 481..483 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 486..490 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 498..500 FT /evidence="ECO:0007829|PDB:6PXW" FT STRAND 504..507 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 512..515 FT /evidence="ECO:0007829|PDB:7U6E" FT HELIX 524..526 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 527..536 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 538..540 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 552..554 FT /evidence="ECO:0007829|PDB:6HN5" FT STRAND 557..561 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 570..573 FT /evidence="ECO:0007829|PDB:6HN5" FT STRAND 577..580 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 588..597 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 601..603 FT /evidence="ECO:0007829|PDB:6PXW" FT STRAND 608..610 FT /evidence="ECO:0007829|PDB:4ZXB" FT STRAND 613..616 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 626..631 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 633..636 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 638..643 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 654..658 FT /evidence="ECO:0007829|PDB:6PXV" FT HELIX 666..669 FT /evidence="ECO:0007829|PDB:6PXV" FT HELIX 732..740 FT /evidence="ECO:0007829|PDB:7KD6" FT STRAND 798..803 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 805..809 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 817..827 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 838..843 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 858..861 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 867..870 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 881..890 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 896..901 FT /evidence="ECO:0007829|PDB:6PXV" FT HELIX 902..908 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 910..913 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 918..931 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 940..944 FT /evidence="ECO:0007829|PDB:6PXV" FT HELIX 953..979 FT /evidence="ECO:0007829|PDB:2MFR" FT STRAND 992..995 FT /evidence="ECO:0007829|PDB:5U1M" FT TURN 1003..1005 FT /evidence="ECO:0007829|PDB:4XLV" FT HELIX 1009..1011 FT /evidence="ECO:0007829|PDB:1IR3" FT HELIX 1014..1016 FT /evidence="ECO:0007829|PDB:1IRK" FT HELIX 1020..1022 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1023..1031 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1033..1043 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1046..1048 FT /evidence="ECO:0007829|PDB:2Z8C" FT STRAND 1050..1057 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1065..1078 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1089..1093 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1095..1098 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1100..1104 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1111..1117 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1119..1121 FT /evidence="ECO:0007829|PDB:3ETA" FT HELIX 1133..1152 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1154..1156 FT /evidence="ECO:0007829|PDB:2AUH" FT HELIX 1162..1164 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1165..1167 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1173..1175 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1181..1183 FT /evidence="ECO:0007829|PDB:1IRK" FT TURN 1185..1187 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1190..1192 FT /evidence="ECO:0007829|PDB:5HHW" FT STRAND 1194..1198 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1200..1202 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1205..1210 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1215..1230 FT /evidence="ECO:0007829|PDB:3BU3" FT TURN 1236..1239 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1242..1250 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1263..1272 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1277..1279 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1283..1290 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1291..1293 FT /evidence="ECO:0007829|PDB:5HHW" FT HELIX 1298..1301 FT /evidence="ECO:0007829|PDB:3BU3" FT TURN 1303..1305 FT /evidence="ECO:0007829|PDB:4XLV" FT HELIX 1307..1309 FT /evidence="ECO:0007829|PDB:8DWN" SQ SEQUENCE 1382 AA; 156333 MW; 709A955660739066 CRC64; MATGGRRGAA AAPLLVAVAA LLLGAAGHLY PGEVCPGMDI RNNLTRLHEL ENCSVIEGHL QILLMFKTRP EDFRDLSFPK LIMITDYLLL FRVYGLESLK DLFPNLTVIR GSRLFFNYAL VIFEMVHLKE LGLYNLMNIT RGSVRIEKNN ELCYLATIDW SRILDSVEDN YIVLNKDDNE ECGDICPGTA KGKTNCPATV INGQFVERCW THSHCQKVCP TICKSHGCTA EGLCCHSECL GNCSQPDDPT KCVACRNFYL DGRCVETCPP PYYHFQDWRC VNFSFCQDLH HKCKNSRRQG CHQYVIHNNK CIPECPSGYT MNSSNLLCTP CLGPCPKVCH LLEGEKTIDS VTSAQELRGC TVINGSLIIN IRGGNNLAAE LEANLGLIEE ISGYLKIRRS YALVSLSFFR KLRLIRGETL EIGNYSFYAL DNQNLRQLWD WSKHNLTITQ GKLFFHYNPK LCLSEIHKME EVSGTKGRQE RNDIALKTNG DQASCENELL KFSYIRTSFD KILLRWEPYW PPDFRDLLGF MLFYKEAPYQ NVTEFDGQDA CGSNSWTVVD IDPPLRSNDP KSQNHPGWLM RGLKPWTQYA IFVKTLVTFS DERRTYGAKS DIIYVQTDAT NPSVPLDPIS VSNSSSQIIL KWKPPSDPNG NITHYLVFWE RQAEDSELFE LDYCLKGLKL PSRTWSPPFE SEDSQKHNQS EYEDSAGECC SCPKTDSQIL KELEESSFRK TFEDYLHNVV FVPRKTSSGT GAEDPRPSRK RRSLGDVGNV TVAVPTVAAF PNTSSTSVPT SPEEHRPFEK VVNKESLVIS GLRHFTGYRI ELQACNQDTP EERCSVAAYV SARTMPEAKA DDIVGPVTHE IFENNVVHLM WQEPKEPNGL IVLYEVSYRR YGDEELHLCV SRKHFALERG CRLRGLSPGN YSVRIRATSL AGNGSWTEPT YFYVTDYLDV PSNIAKIIIG PLIFVFLFSV VIGSIYLFLR KRQPDGPLGP LYASSNPEYL SASDVFPCSV YVPDEWEVSR EKITLLRELG QGSFGMVYEG NARDIIKGEA ETRVAVKTVN ESASLRERIE FLNEASVMKG FTCHHVVRLL GVVSKGQPTL VVMELMAHGD LKSYLRSLRP EAENNPGRPP PTLQEMIQMA AEIADGMAYL NAKKFVHRDL AARNCMVAHD FTVKIGDFGM TRDIYETDYY RKGGKGLLPV RWMAPESLKD GVFTTSSDMW SFGVVLWEIT SLAEQPYQGL SNEQVLKFVM DGGYLDQPDN CPERVTDLMR MCWQFNPKMR PTFLEIVNLL KDDLHPSFPE VSFFHSEENK APESEELEME FEDMENVPLD RSSHCQREEA GGRDGGSSLG FKRSYEEHIP YTHMNGGKKN GRILTLPRSN PS // ID KKCC2_HUMAN Reviewed; 588 AA. AC Q96RR4; A8K7Q7; O94883; Q8IUG2; Q8IUG3; Q8N3I4; Q8WY03; Q8WY04; Q8WY05; AC Q8WY06; Q96RP1; Q96RP2; Q96RR3; Q9BWE9; Q9UER3; Q9UES2; Q9Y5N2; DT 07-DEC-2004, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2011, sequence version 2. DT 28-JAN-2026, entry version 201. DE RecName: Full=Calcium/calmodulin-dependent protein kinase kinase 2; DE Short=CaM-KK 2; DE Short=CaM-kinase kinase 2; DE Short=CaMKK 2; DE EC=2.7.11.17; DE AltName: Full=Calcium/calmodulin-dependent protein kinase kinase beta; DE Short=CaM-KK beta; DE Short=CaM-kinase kinase beta; DE Short=CaMKK beta; GN Name=CAMKK2; Synonyms=CAMKKB, KIAA0787; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1; 2; 3; 4; 5 AND 6), RP FUNCTION, AND VARIANT SER-85. RX PubMed=11395482; DOI=10.1074/jbc.m011720200; RA Hsu L.-S., Chen G.-D., Lee L.-S., Chi C.-W., Cheng J.-F., Chen J.-Y.; RT "Human Ca2+/calmodulin-dependent protein kinase kinase beta gene encodes RT multiple isoforms that display distinct kinase activity."; RL J. Biol. Chem. 276:31113-31123(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Brain cortex; RX PubMed=9822657; DOI=10.1074/jbc.273.48.31880; RA Anderson K.A., Means R.L., Huang Q.-H., Kemp B.E., Goldstein E.G., RA Selbert M.A., Edelman A.M., Fremeau R.T., Means A.R.; RT "Components of a calmodulin-dependent protein kinase cascade. Molecular RT cloning, functional characterization and cellular localization of RT Ca2+/calmodulin-dependent protein kinase kinase beta."; RL J. Biol. Chem. 273:31880-31889(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND FUNCTION IN PHOSPHORYLATION OF RP CAMK1D. RX PubMed=12935886; DOI=10.1016/s0014-5793(03)00817-2; RA Ishikawa Y., Tokumitsu H., Inuzuka H., Murata-Hori M., Hosoya H., RA Kobayashi R.; RT "Identification and characterization of novel components of a RT Ca2+/calmodulin-dependent protein kinase cascade in HeLa cells."; RL FEBS Lett. 550:57-63(2003). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 7), AND VARIANT SER-85. RC TISSUE=Brain; RX PubMed=9872452; DOI=10.1093/dnares/5.5.277; RA Nagase T., Ishikawa K., Suyama M., Kikuno R., Miyajima N., Tanaka A., RA Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XI. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 5:277-286(1998). RN [5] RP SEQUENCE REVISION. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Stomach; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16541075; DOI=10.1038/nature04569; RA Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y., RA Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., RA Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C., RA Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., RA Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E., RA Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., RA Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., RA Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., RA Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., RA Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., RA Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., RA Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., RA Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., RA Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., RA Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K., RA Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D., RA Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R., RA David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E., RA D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N., RA Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N., RA Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R., RA Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S., RA LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H., RA Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P., RA Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G., RA Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E., RA Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S., RA Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., RA Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J., RA Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A., RA Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M., RA Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I., RA Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A., RA Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y., RA Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A., RA Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F., RA Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L., RA Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G., RA Gibbs R.A.; RT "The finished DNA sequence of human chromosome 12."; RL Nature 440:346-351(2006). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 233-588 (ISOFORM 5), AND VARIANT SER-85. RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 117-588 (ISOFORM 2), FUNCTION IN RP PHOSPHORYLATION OF CAMK1, AND TISSUE SPECIFICITY. RX PubMed=9662074; DOI=10.1007/bf02258368; RA Hsu L.-S., Tsou A.-P., Chi C.-W., Lee C.-H., Chen J.-Y.; RT "Cloning, expression and chromosomal localization of human Ca2+/calmodulin- RT dependent protein kinase kinase."; RL J. Biomed. Sci. 5:141-149(1998). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 254-588 (ISOFORM 7). RC TISSUE=Amygdala; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 338-533 (ISOFORM 2). RA Barrow I.K.-P., Boguski M.S., Touchman J.W., Spencer F.; RT "Full-insert sequence of mapped XREF EST."; RL Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases. RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-495, PHOSPHORYLATION [LARGE RP SCALE ANALYSIS] AT SER-522 (ISOFORM 3), PHOSPHORYLATION [LARGE SCALE RP ANALYSIS] AT SER-479 (ISOFORM 5), AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [14] RP FUNCTION, SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, PHOSPHORYLATION BY RP PKA, AND INDUCTION OF ISOFORM 1. RX PubMed=21957496; DOI=10.4161/rna.8.6.16691; RA Cao W., Sohail M., Liu G., Koumbadinga G.A., Lobo V.G., Xie J.; RT "Differential effects of PKA-controlled CaMKK2 variants on neuronal RT differentiation."; RL RNA Biol. 8:1061-1072(2011). RN [15] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-114; SER-129; SER-495 AND RP SER-511, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-495, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [18] RP VARIANTS [LARGE SCALE ANALYSIS] ASN-10; SER-85; TYR-123; LEU-127; THR-182 RP AND HIS-492. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium/calmodulin-dependent protein kinase belonging to a CC proposed calcium-triggered signaling cascade involved in a number of CC cellular processes. Isoform 1, isoform 2 and isoform 3 phosphorylate CC CAMK1 and CAMK4. Isoform 3 phosphorylates CAMK1D. Isoform 4, isoform 5 CC and isoform 6 lacking part of the calmodulin-binding domain are CC inactive. Efficiently phosphorylates 5'-AMP-activated protein kinase CC (AMPK) trimer, including that consisting of PRKAA1, PRKAB1 and PRKAG1. CC This phosphorylation is stimulated in response to Ca(2+) signals (By CC similarity). Seems to be involved in hippocampal activation of CREB1 CC (By similarity). May play a role in neurite growth. Isoform 3 may CC promote neurite elongation, while isoform 1 may promoter neurite CC branching. {ECO:0000250, ECO:0000269|PubMed:11395482, CC ECO:0000269|PubMed:12935886, ECO:0000269|PubMed:21957496, CC ECO:0000269|PubMed:9662074}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.17; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.17; CC -!- ACTIVITY REGULATION: Activated by Ca(2+)/calmodulin. Binding of CC calmodulin may relieve intrasteric autoinhibition. Autophosphorylation CC does not alter activity or regulation by Ca(2+)/calmodulin. In part, CC activity is independent on Ca(2+)/calmodulin (By similarity). CC {ECO:0000250}. CC -!- SUBUNIT: Interacts with calmodulin. {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:21957496}. Cytoplasm CC {ECO:0000269|PubMed:21957496}. Cell projection, neuron projection CC {ECO:0000269|PubMed:21957496}. Note=Predominantly nuclear in CC unstimulated cells, relocalizes into cytoplasm and neurites after CC forskolin induction. {ECO:0000269|PubMed:21957496}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Name=1; Synonyms=Beta1, CAMKK2+E16; CC IsoId=Q96RR4-1; Sequence=Displayed; CC Name=2; Synonyms=Beta2; CC IsoId=Q96RR4-2; Sequence=VSP_012146, VSP_012147, VSP_012149; CC Name=3; Synonyms=Beta1delta16, CAMKK2-E16; CC IsoId=Q96RR4-3; Sequence=VSP_012143, VSP_012144, VSP_012145, CC VSP_012149; CC Name=4; Synonyms=Beta1delta14; CC IsoId=Q96RR4-4; Sequence=VSP_012142; CC Name=5; Synonyms=Beta1delta14/16, beta-3x; CC IsoId=Q96RR4-5; Sequence=VSP_012142, VSP_012143, VSP_012144, CC VSP_012145, VSP_012149; CC Name=6; Synonyms=Beta2delta14; CC IsoId=Q96RR4-6; Sequence=VSP_012142, VSP_012146, VSP_012147, CC VSP_012149; CC Name=7; CC IsoId=Q96RR4-7; Sequence=VSP_012148, VSP_012149; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed with higher levels in the CC brain. Intermediate levels are detected in spleen, prostate, thyroid CC and leukocytes. The lowest level is in lung. CC {ECO:0000269|PubMed:9662074}. CC -!- INDUCTION: [Isoform 1]: Up-regulated by PKA pathway. CC {ECO:0000269|PubMed:21957496}. CC -!- DOMAIN: The autoinhibitory domain overlaps with the calmodulin binding CC region and may be involved in intrasteric autoinhibition. CC -!- DOMAIN: The RP domain (arginine/proline-rich) is involved in the CC recognition of CAMKI and CAMK4 as substrates. {ECO:0000250}. CC -!- PTM: Autophosphorylated and phosphorylated by PKA. Each isoform may CC show a different pattern of phosphorylation. CC {ECO:0000269|PubMed:21957496}. CC -!- MISCELLANEOUS: [Isoform 1]: Major isoform. CC -!- MISCELLANEOUS: [Isoform 2]: Major isoform. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 5]: Inactive. Does not activate CAMK1 and CC CAMK4. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 6]: Inactive. Does not activate CAMK1 and CC CAMK4. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC72943.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAA34507.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAD38990.1; Type=Miscellaneous discrepancy; Note=Intron retention.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB081337; BAC19841.1; -; mRNA. DR EMBL; AF287630; AAK64600.1; -; mRNA. DR EMBL; AF287631; AAK64601.1; -; mRNA. DR EMBL; AF321385; AAL37215.1; -; mRNA. DR EMBL; AF321386; AAL37216.1; -; mRNA. DR EMBL; AF321387; AAL37217.1; -; mRNA. DR EMBL; AF321388; AAL37218.1; -; mRNA. DR EMBL; AF321401; AAK91830.1; -; Genomic_DNA. DR EMBL; AF321390; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321391; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321392; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321393; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321394; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321395; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321396; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321397; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321398; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321399; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321400; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321575; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321576; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321577; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321578; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321402; AAK91829.1; -; Genomic_DNA. DR EMBL; AF321390; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321391; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321392; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321393; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321394; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321395; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321396; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321397; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321398; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321399; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321400; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321575; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321576; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321577; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321578; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF140507; AAD31507.1; -; mRNA. DR EMBL; AB081336; BAC19840.1; -; mRNA. DR EMBL; AB018330; BAA34507.2; ALT_INIT; mRNA. DR EMBL; AK292072; BAF84761.1; -; mRNA. DR EMBL; AC069209; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC000318; AAH00318.2; -; mRNA. DR EMBL; BC026060; AAH26060.1; -; mRNA. DR EMBL; AF101264; AAD04566.1; -; mRNA. DR EMBL; AL834322; CAD38990.1; ALT_SEQ; mRNA. DR EMBL; AF091074; AAC72943.1; ALT_INIT; mRNA. DR CCDS; CCDS44999.1; -. [Q96RR4-2] DR CCDS; CCDS53837.1; -. [Q96RR4-6] DR CCDS; CCDS58283.1; -. [Q96RR4-7] DR CCDS; CCDS9216.1; -. [Q96RR4-1] DR CCDS; CCDS9217.1; -. [Q96RR4-4] DR CCDS; CCDS9218.1; -. [Q96RR4-3] DR CCDS; CCDS9219.1; -. [Q96RR4-5] DR PIR; JE0191; JE0191. DR RefSeq; NP_001257414.1; NM_001270485.2. [Q96RR4-1] DR RefSeq; NP_001257415.1; NM_001270486.1. [Q96RR4-7] DR RefSeq; NP_006540.3; NM_006549.3. [Q96RR4-1] DR RefSeq; NP_705719.2; NM_153499.2. [Q96RR4-3] DR RefSeq; NP_705720.1; NM_153500.2. [Q96RR4-5] DR RefSeq; NP_757363.1; NM_172214.3. [Q96RR4-2] DR RefSeq; NP_757364.1; NM_172215.3. [Q96RR4-6] DR RefSeq; NP_757365.1; NM_172216.2. [Q96RR4-4] DR RefSeq; NP_757380.1; NM_172226.3. [Q96RR4-3] DR RefSeq; XP_005253879.1; XM_005253822.3. [Q96RR4-4] DR RefSeq; XP_005253880.1; XM_005253823.1. [Q96RR4-2] DR RefSeq; XP_005253881.1; XM_005253824.3. [Q96RR4-5] DR RefSeq; XP_011536065.1; XM_011537763.1. [Q96RR4-7] DR RefSeq; XP_016874191.1; XM_017018702.3. [Q96RR4-7] DR RefSeq; XP_047284057.1; XM_047428101.1. [Q96RR4-1] DR RefSeq; XP_047284058.1; XM_047428102.1. [Q96RR4-7] DR RefSeq; XP_047284059.1; XM_047428103.1. [Q96RR4-3] DR RefSeq; XP_047284060.1; XM_047428104.1. [Q96RR4-2] DR RefSeq; XP_047284063.1; XM_047428107.1. [Q96RR4-5] DR RefSeq; XP_047284064.1; XM_047428108.1. [Q96RR4-6] DR RefSeq; XP_054226771.1; XM_054370796.1. [Q96RR4-1] DR RefSeq; XP_054226772.1; XM_054370797.1. [Q96RR4-7] DR RefSeq; XP_054226773.1; XM_054370798.1. [Q96RR4-7] DR RefSeq; XP_054226774.1; XM_054370799.1. [Q96RR4-7] DR RefSeq; XP_054226775.1; XM_054370800.1. [Q96RR4-4] DR RefSeq; XP_054226776.1; XM_054370801.1. [Q96RR4-3] DR RefSeq; XP_054226777.1; XM_054370802.1. [Q96RR4-2] DR RefSeq; XP_054226778.1; XM_054370803.1. [Q96RR4-2] DR RefSeq; XP_054226781.1; XM_054370806.1. [Q96RR4-5] DR RefSeq; XP_054226782.1; XM_054370807.1. [Q96RR4-5] DR RefSeq; XP_054226783.1; XM_054370808.1. [Q96RR4-6] DR PDB; 2ZV2; X-ray; 2.40 A; A=158-448. DR PDB; 5UY6; X-ray; 1.70 A; A=161-449. DR PDB; 5UYJ; X-ray; 1.60 A; A=161-449. DR PDB; 5VT1; X-ray; 1.90 A; A=161-449. DR PDB; 5YV8; X-ray; 1.93 A; A=158-448. DR PDB; 5YV9; X-ray; 2.53 A; A=158-448. DR PDB; 5YVA; X-ray; 2.57 A; A=158-448. DR PDB; 5YVB; X-ray; 2.02 A; A=158-448. DR PDB; 5YVC; X-ray; 2.02 A; A=158-448. DR PDB; 6BKU; X-ray; 2.00 A; A=162-449. DR PDB; 6BLE; X-ray; 1.90 A; A=161-449. DR PDB; 6BQL; X-ray; 2.00 A; A=161-449. DR PDB; 6BQP; X-ray; 1.95 A; A=161-449. DR PDB; 6BQQ; X-ray; 1.80 A; A=161-449. DR PDB; 6BRC; X-ray; 2.20 A; A/B=161-449. DR PDB; 6CMJ; X-ray; 2.40 A; A/B=149-465. DR PDB; 6EF5; X-ray; 2.44 A; Q/S=508-514. DR PDB; 6EWW; X-ray; 2.68 A; E/F/G/H=97-104. DR PDB; 6FEL; X-ray; 2.84 A; E/F/G/H=508-515. DR PDB; 6Y3O; X-ray; 1.50 A; P=97-104. DR PDB; 6Y4K; X-ray; 3.00 A; E/F=97-104. DR PDB; 6Y6B; X-ray; 3.08 A; C/D=97-104. DR PDB; 6Y8A; X-ray; 1.50 A; P=508-515. DR PDB; 8TUC; X-ray; 1.50 A; A=161-449. DR PDBsum; 2ZV2; -. DR PDBsum; 5UY6; -. DR PDBsum; 5UYJ; -. DR PDBsum; 5VT1; -. DR PDBsum; 5YV8; -. DR PDBsum; 5YV9; -. DR PDBsum; 5YVA; -. DR PDBsum; 5YVB; -. DR PDBsum; 5YVC; -. DR PDBsum; 6BKU; -. DR PDBsum; 6BLE; -. DR PDBsum; 6BQL; -. DR PDBsum; 6BQP; -. DR PDBsum; 6BQQ; -. DR PDBsum; 6BRC; -. DR PDBsum; 6CMJ; -. DR PDBsum; 6EF5; -. DR PDBsum; 6EWW; -. DR PDBsum; 6FEL; -. DR PDBsum; 6Y3O; -. DR PDBsum; 6Y4K; -. DR PDBsum; 6Y6B; -. DR PDBsum; 6Y8A; -. DR PDBsum; 8TUC; -. DR AlphaFoldDB; Q96RR4; -. DR SASBDB; Q96RR4; -. DR SMR; Q96RR4; -. DR BioGRID; 115889; 77. DR FunCoup; Q96RR4; 2743. DR IntAct; Q96RR4; 51. DR STRING; 9606.ENSP00000312741; -. DR BindingDB; Q96RR4; -. DR ChEMBL; CHEMBL5284; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q96RR4; -. DR GuidetoPHARMACOLOGY; 1957; -. DR GlyCosmos; Q96RR4; 1 site, 1 glycan. DR GlyGen; Q96RR4; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q96RR4; -. DR PhosphoSitePlus; Q96RR4; -. DR SwissPalm; Q96RR4; -. DR BioMuta; CAMKK2; -. DR DMDM; 317373374; -. DR jPOST; Q96RR4; -. DR MassIVE; Q96RR4; -. DR PaxDb; 9606-ENSP00000312741; -. DR PeptideAtlas; Q96RR4; -. DR ProteomicsDB; 78009; -. [Q96RR4-1] DR ProteomicsDB; 78010; -. [Q96RR4-2] DR ProteomicsDB; 78011; -. [Q96RR4-3] DR ProteomicsDB; 78012; -. [Q96RR4-4] DR ProteomicsDB; 78013; -. [Q96RR4-5] DR ProteomicsDB; 78014; -. [Q96RR4-6] DR ProteomicsDB; 78015; -. [Q96RR4-7] DR Pumba; Q96RR4; -. DR Antibodypedia; 19059; 384 antibodies from 36 providers. DR DNASU; 10645; -. DR Ensembl; ENST00000324774.9; ENSP00000312741.5; ENSG00000110931.20. [Q96RR4-1] DR Ensembl; ENST00000337174.7; ENSP00000336634.3; ENSG00000110931.20. [Q96RR4-3] DR Ensembl; ENST00000347034.6; ENSP00000321230.3; ENSG00000110931.20. [Q96RR4-4] DR Ensembl; ENST00000392473.2; ENSP00000376265.2; ENSG00000110931.20. [Q96RR4-2] DR Ensembl; ENST00000392474.6; ENSP00000376266.2; ENSG00000110931.20. [Q96RR4-7] DR Ensembl; ENST00000402834.8; ENSP00000384591.4; ENSG00000110931.20. [Q96RR4-1] DR Ensembl; ENST00000404169.8; ENSP00000384600.3; ENSG00000110931.20. [Q96RR4-1] DR Ensembl; ENST00000412367.6; ENSP00000388368.2; ENSG00000110931.20. [Q96RR4-3] DR Ensembl; ENST00000446440.6; ENSP00000388273.2; ENSG00000110931.20. [Q96RR4-6] DR Ensembl; ENST00000538733.5; ENSP00000445944.1; ENSG00000110931.20. [Q96RR4-5] DR Ensembl; ENST00000652382.1; ENSP00000498824.1; ENSG00000110931.20. [Q96RR4-1] DR GeneID; 10645; -. DR KEGG; hsa:10645; -. DR MANE-Select; ENST00000404169.8; ENSP00000384600.3; NM_001270485.2; NP_001257414.1. DR UCSC; uc001tzt.4; human. [Q96RR4-1] DR AGR; HGNC:1470; -. DR ClinPGx; PA26052; -. DR CTD; 10645; -. DR DisGeNET; 10645; -. DR GeneCards; CAMKK2; -. DR HGNC; HGNC:1470; CAMKK2. DR HPA; ENSG00000110931; Tissue enriched (brain). DR MIM; 615002; gene. DR OpenTargets; ENSG00000110931; -. DR VEuPathDB; HostDB:ENSG00000110931; -. DR eggNOG; KOG0585; Eukaryota. DR GeneTree; ENSGT00940000161828; -. DR HOGENOM; CLU_000288_63_0_1; -. DR InParanoid; Q96RR4; -. DR OMA; EPRSECR; -. DR OrthoDB; 68483at2759; -. DR PAN-GO; Q96RR4; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q96RR4; -. DR BRENDA; 2.7.11.17; 2681. DR PathwayCommons; Q96RR4; -. DR Reactome; R-HSA-111932; CaMK IV-mediated phosphorylation of CREB. DR Reactome; R-HSA-442729; CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde. DR Reactome; R-HSA-9619229; Activation of RAC1 downstream of NMDARs. DR Reactome; R-HSA-9619483; Activation of AMPK downstream of NMDARs. DR SignaLink; Q96RR4; -. DR SIGNOR; Q96RR4; -. DR Agora; ENSG00000110931; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 10645; 17 hits in 1185 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; CAMKK2; human. DR EvolutionaryTrace; Q96RR4; -. DR GeneWiki; CAMKK2; -. DR GenomeRNAi; 10645; -. DR Pharos; Q96RR4; Tchem. DR PRO; PR:Q96RR4; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q96RR4; protein. DR Bgee; ENSG00000110931; Expressed in cerebellar cortex and 202 other cell types or tissues. DR ExpressionAtlas; Q96RR4; baseline and differential. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0043005; C:neuron projection; IEA:UniProtKB-SubCell. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB. DR GO; GO:0004683; F:calcium/calmodulin-dependent protein kinase activity; IEA:UniProtKB-EC. DR GO; GO:0005516; F:calmodulin binding; TAS:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0004713; F:protein tyrosine kinase activity; TAS:UniProtKB. DR GO; GO:0019722; P:calcium-mediated signaling; TAS:UniProtKB. DR GO; GO:0061762; P:CAMKK-AMPK signaling cascade; IMP:ParkinsonsUK-UCL. DR GO; GO:0034614; P:cellular response to reactive oxygen species; TAS:ParkinsonsUK-UCL. DR GO; GO:0000165; P:MAPK cascade; TAS:UniProtKB. DR GO; GO:1903599; P:positive regulation of autophagy of mitochondrion; IMP:ParkinsonsUK-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; TAS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0045859; P:regulation of protein kinase activity; TAS:UniProtKB. DR CDD; cd14199; STKc_CaMKK2; 1. DR FunFam; 3.30.200.20:FF:000429; Calcium/calmodulin-dependent protein kinase kinase; 1. DR FunFam; 1.10.510.10:FF:000091; Calcium/calmodulin-dependent protein kinase kinase 2 isoform 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR43895; CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE-RELATED; 1. DR PANTHER; PTHR43895:SF39; CALCIUM_CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; KW Calmodulin-binding; Cell projection; Cytoplasm; Kinase; Nucleotide-binding; KW Nucleus; Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..588 FT /note="Calcium/calmodulin-dependent protein kinase kinase FT 2" FT /id="PRO_0000086144" FT DOMAIN 165..446 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..33 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 78..100 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 128..149 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 204..226 FT /note="RP domain" FT REGION 205..225 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 472..477 FT /note="Autoinhibitory domain" FT /evidence="ECO:0000250" FT REGION 475..500 FT /note="Calmodulin-binding" FT /evidence="ECO:0000250" FT REGION 497..588 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..14 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 128..139 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 521..536 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 579..588 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 312 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 171..179 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 194 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 100 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8C078" FT MOD_RES 114 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 129 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 133 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8C078" FT MOD_RES 137 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8C078" FT MOD_RES 495 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 511 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 572 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8C078" FT VAR_SEQ 442..484 FT /note="Missing (in isoform 4, isoform 5 and isoform 6)" FT /evidence="ECO:0000303|PubMed:11395482, FT ECO:0000303|PubMed:15489334" FT /id="VSP_012142" FT VAR_SEQ 520..532 FT /note="KPTRECESLSELK -> QGSEDNLQGTDPP (in isoform 3 and FT isoform 5)" FT /evidence="ECO:0000303|PubMed:11395482, FT ECO:0000303|PubMed:12935886, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_012143" FT VAR_SEQ 533..554 FT /note="EARQRRQPPGHRPAPRGGGGSA -> GTKKKKGLDSMTSTVAAGWLDRRV FT (in isoform 7)" FT /evidence="ECO:0000303|PubMed:17974005, FT ECO:0000303|PubMed:9872452" FT /id="VSP_012148" FT VAR_SEQ 533..541 FT /note="EARQRRQPP -> PVGEEEVLL (in isoform 3 and isoform 5)" FT /evidence="ECO:0000303|PubMed:11395482, FT ECO:0000303|PubMed:12935886, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_012144" FT VAR_SEQ 533 FT /note="E -> T (in isoform 2 and isoform 6)" FT /evidence="ECO:0000303|PubMed:11395482, FT ECO:0000303|PubMed:9662074, ECO:0000303|Ref.11" FT /id="VSP_012146" FT VAR_SEQ 534..554 FT /note="Missing (in isoform 2 and isoform 6)" FT /evidence="ECO:0000303|PubMed:11395482, FT ECO:0000303|PubMed:9662074, ECO:0000303|Ref.11" FT /id="VSP_012147" FT VAR_SEQ 542..554 FT /note="Missing (in isoform 3 and isoform 5)" FT /evidence="ECO:0000303|PubMed:11395482, FT ECO:0000303|PubMed:12935886, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_012145" FT VAR_SEQ 555..588 FT /note="Missing (in isoform 2, isoform 3, isoform 5, isoform FT 6 and isoform 7)" FT /evidence="ECO:0000303|PubMed:11395482, FT ECO:0000303|PubMed:12935886, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:17974005, FT ECO:0000303|PubMed:9662074, ECO:0000303|PubMed:9872452, FT ECO:0000303|Ref.11" FT /id="VSP_012149" FT VARIANT 10 FT /note="S -> N (in dbSNP:rs28360477)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032788" FT VARIANT 85 FT /note="T -> S (in dbSNP:rs3817190)" FT /evidence="ECO:0000269|PubMed:11395482, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9872452" FT /id="VAR_020532" FT VARIANT 123 FT /note="C -> Y (in dbSNP:rs35403710)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040610" FT VARIANT 127 FT /note="P -> L (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040611" FT VARIANT 182 FT /note="A -> T (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs1207121718)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040612" FT VARIANT 363 FT /note="R -> C (in dbSNP:rs1132780)" FT /id="VAR_020533" FT VARIANT 492 FT /note="R -> H (in dbSNP:rs34129994)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040613" FT CONFLICT 206 FT /note="G -> A (in Ref. 2; AAD31507)" FT /evidence="ECO:0000305" FT CONFLICT 331 FT /note="F -> I (in Ref. 6; BAF84761)" FT /evidence="ECO:0000305" FT CONFLICT 347 FT /note="T -> Y (in Ref. 2; AAD31507)" FT /evidence="ECO:0000305" FT CONFLICT 371 FT /note="L -> K (in Ref. 2; AAD31507)" FT /evidence="ECO:0000305" FT CONFLICT 554 FT /note="A -> H (in Ref. 1; AAK91829)" FT /evidence="ECO:0000305" FT CONFLICT 557 FT /note="R -> N (in Ref. 1; AAK91829)" FT /evidence="ECO:0000305" FT STRAND 165..172 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 175..184 FT /evidence="ECO:0007829|PDB:8TUC" FT TURN 185..188 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 189..197 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 198..204 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 231..242 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 251..255 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 260..268 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 273..275 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 286..305 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 315..317 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 318..320 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 326..328 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 338..341 FT /evidence="ECO:0007829|PDB:5UY6" FT STRAND 343..346 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 351..353 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 356..358 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 364..367 FT /evidence="ECO:0007829|PDB:6CMJ" FT HELIX 368..385 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 395..404 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 411..413 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 417..426 FT /evidence="ECO:0007829|PDB:8TUC" FT TURN 431..433 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 437..440 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 444..447 FT /evidence="ECO:0007829|PDB:8TUC" FT TURN 448..451 FT /evidence="ECO:0007829|PDB:6CMJ" FT HELIX 457..461 FT /evidence="ECO:0007829|PDB:6CMJ" FT MOD_RES Q96RR4-3:522 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES Q96RR4-5:479 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" SQ SEQUENCE 588 AA; 64746 MW; 04E3583561341167 CRC64; MSSCVSSQPS SNRAAPQDEL GGRGSSSSES QKPCEALRGL SSLSIHLGME SFIVVTECEP GCAVDLGLAR DRPLEADGQE VPLDTSGSQA RPHLSGRKLS LQERSQGGLA AGGSLDMNGR CICPSLPYSP VSSPQSSPRL PRRPTVESHH VSITGMQDCV QLNQYTLKDE IGKGSYGVVK LAYNENDNTY YAMKVLSKKK LIRQAGFPRR PPPRGTRPAP GGCIQPRGPI EQVYQEIAIL KKLDHPNVVK LVEVLDDPNE DHLYMVFELV NQGPVMEVPT LKPLSEDQAR FYFQDLIKGI EYLHYQKIIH RDIKPSNLLV GEDGHIKIAD FGVSNEFKGS DALLSNTVGT PAFMAPESLS ETRKIFSGKA LDVWAMGVTL YCFVFGQCPF MDERIMCLHS KIKSQALEFP DQPDIAEDLK DLITRMLDKN PESRIVVPEI KLHPWVTRHG AEPLPSEDEN CTLVEVTEEE VENSVKHIPS LATVILVKTM IRKRSFGNPF EGSRREERSL SAPGNLLTKK PTRECESLSE LKEARQRRQP PGHRPAPRGG GGSALVRGSP CVESCWAPAP GSPARMHPLR PEEAMEPE // ID KS6A2_HUMAN Reviewed; 733 AA. AC Q15349; B3KTK9; Q15419; Q59GJ3; Q5TI68; Q96J38; Q9UJN5; DT 15-DEC-1998, integrated into UniProtKB/Swiss-Prot. DT 21-MAR-2006, sequence version 2. DT 28-JAN-2026, entry version 230. DE RecName: Full=Ribosomal protein S6 kinase alpha-2; DE Short=S6K-alpha-2; DE EC=2.7.11.1; DE AltName: Full=90 kDa ribosomal protein S6 kinase 2; DE Short=p90-RSK 2; DE Short=p90RSK2; DE AltName: Full=MAP kinase-activated protein kinase 1c; DE Short=MAPK-activated protein kinase 1c; DE Short=MAPKAP kinase 1c; DE Short=MAPKAPK-1c; DE AltName: Full=Ribosomal S6 kinase 3; DE Short=RSK-3; DE AltName: Full=pp90RSK3; GN Name=RPS6KA2; Synonyms=MAPKAPK1C, RSK3; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY, AND RP SUBCELLULAR LOCATION. RX PubMed=7623830; DOI=10.1128/mcb.15.8.4353; RA Zhao Y., Bjoerbaek C., Weremowicz S., Morton C.C., Moller D.E.; RT "RSK3 encodes a novel pp90rsk isoform with a unique N-terminal sequence: RT growth factor-stimulated kinase function and nuclear translocation."; RL Mol. Cell. Biol. 15:4353-4363(1995). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-540 (ISOFORM 1). RX PubMed=8141249; DOI=10.1152/ajpcell.1994.266.2.c351; RA Moller D.E., Xia C.-H., Tang W., Zhu A.X., Jakubowski M.; RT "Human rsk isoforms: cloning and characterization of tissue-specific RT expression."; RL Am. J. Physiol. 266:C351-C359(1994). RN [7] RP ACTIVITY REGULATION, AND PHOSPHORYLATION AT SER-218. RX PubMed=10480933; DOI=10.1074/jbc.274.38.27168; RA Jensen C.J., Buch M.-B., Krag T.O., Hemmings B.A., Gammeltoft S., RA Froedin M.; RT "90-kDa ribosomal S6 kinase is phosphorylated and activated by 3- RT phosphoinositide-dependent protein kinase-1."; RL J. Biol. Chem. 274:27168-27176(1999). RN [8] RP FUNCTION IN TUMORIGENESIS, AND TISSUE SPECIFICITY. RX PubMed=16878154; DOI=10.1038/sj.onc.1209827; RA Bignone P.A., Lee K.Y., Liu Y., Emilion G., Finch J., Soosay A.E., RA Charnock F.M., Beck S., Dunham I., Mungall A.J., Ganesan T.S.; RT "RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial RT ovarian cancer."; RL Oncogene 26:683-700(2007). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [10] RP REVIEW ON FUNCTION. RX PubMed=18813292; DOI=10.1038/nrm2509; RA Anjum R., Blenis J.; RT "The RSK family of kinases: emerging roles in cellular signalling."; RL Nat. Rev. Mol. Cell Biol. 9:747-758(2008). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] LYS-311 AND GLN-732. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase that acts downstream of ERK CC (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and CC stress-induced activation of transcription factors, regulates CC translation, and mediates cellular proliferation, survival, and CC differentiation. May function as tumor suppressor in epithelial ovarian CC cancer cells. {ECO:0000269|PubMed:16878154, CC ECO:0000269|PubMed:7623830}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Upon extracellular signal or mitogen stimulation, CC phosphorylated at Thr-570 in the C-terminal kinase domain (CTKD) by CC MAPK1/ERK2 and MAPK3/ERK1. The activated CTKD then autophosphorylates CC Ser-377, allowing binding of PDPK1, which in turn phosphorylates Ser- CC 218 in the N-terminal kinase domain (NTDK) leading to the full CC activation of the protein and subsequent phosphorylation of the CC substrates by the NTKD. {ECO:0000269|PubMed:10480933}. CC -!- SUBUNIT: Forms a complex with either MAPK1/ERK2 or MAPK3/ERK1 in CC quiescent cells. Transiently dissociates following mitogenic CC stimulation (By similarity). Interacts with FBXO5; cooperate to induce CC the metaphase arrest of early blastomeres; increases and stabilizes CC interaction of FBXO5 with CDC20 (By similarity). {ECO:0000250, CC ECO:0000250|UniProtKB:Q9WUT3}. CC -!- INTERACTION: CC Q15349; P05067: APP; NbExp=3; IntAct=EBI-1384149, EBI-77613; CC Q15349; P15056: BRAF; NbExp=2; IntAct=EBI-1384149, EBI-365980; CC Q15349; P67870: CSNK2B; NbExp=4; IntAct=EBI-1384149, EBI-348169; CC Q15349; O14901: KLF11; NbExp=3; IntAct=EBI-1384149, EBI-948266; CC Q15349; P28482: MAPK1; NbExp=12; IntAct=EBI-1384149, EBI-959949; CC Q15349; Q02156: PRKCE; NbExp=2; IntAct=EBI-1384149, EBI-706254; CC Q15349; Q14160: SCRIB; NbExp=9; IntAct=EBI-1384149, EBI-357345; CC Q15349; Q9Y566: SHANK1; NbExp=2; IntAct=EBI-1384149, EBI-3442234; CC Q15349; P62258: YWHAE; NbExp=2; IntAct=EBI-1384149, EBI-356498; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:7623830}. Cytoplasm CC {ECO:0000269|PubMed:7623830}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q15349-1; Sequence=Displayed; CC Name=2; CC IsoId=Q15349-2; Sequence=VSP_017732; CC Name=3; CC IsoId=Q15349-3; Sequence=VSP_041836; CC -!- TISSUE SPECIFICITY: Widely expressed with higher expression in lung, CC skeletal muscle, brain, uterus, ovary, thyroid and prostate. CC {ECO:0000269|PubMed:16878154, ECO:0000269|PubMed:7623830}. CC -!- PTM: Activated by phosphorylation at Ser-218 by PDPK1. CC Autophosphorylated on Ser-377, as part of the activation process. May CC be phosphorylated at Thr-356 and Ser-360 by MAPK1/ERK2 and MAPK3/ERK1 CC (By similarity). {ECO:0000250}. CC -!- PTM: N-terminal myristoylation results in an activated kinase in the CC absence of added growth factors. {ECO:0000250}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. S6 kinase subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC82496.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAD92353.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAG53121.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X85106; CAA59427.1; -; mRNA. DR EMBL; AB209116; BAD92353.1; ALT_INIT; mRNA. DR EMBL; AK095751; BAG53121.1; ALT_FRAME; mRNA. DR EMBL; AL022069; CAI19651.1; -; Genomic_DNA. DR EMBL; Z98049; CAI19651.1; JOINED; Genomic_DNA. DR EMBL; AL023775; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL159163; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z98049; CAI20579.1; -; Genomic_DNA. DR EMBL; AL022069; CAI20579.1; JOINED; Genomic_DNA. DR EMBL; BC002363; AAH02363.1; -; mRNA. DR EMBL; L07598; AAC82496.1; ALT_INIT; mRNA. DR CCDS; CCDS34570.1; -. [Q15349-3] DR CCDS; CCDS5294.1; -. [Q15349-1] DR CCDS; CCDS83148.1; -. [Q15349-2] DR PIR; A57459; A57459. DR RefSeq; NP_001006933.3; NM_001006932.3. [Q15349-3] DR RefSeq; NP_001305865.2; NM_001318936.2. DR RefSeq; NP_001305866.1; NM_001318937.1. DR RefSeq; NP_001305867.1; NM_001318938.1. DR RefSeq; NP_066958.2; NM_021135.5. [Q15349-1] DR AlphaFoldDB; Q15349; -. DR SMR; Q15349; -. DR BioGRID; 112110; 201. DR DIP; DIP-295N; -. DR FunCoup; Q15349; 3133. DR IntAct; Q15349; 62. DR MINT; Q15349; -. DR STRING; 9606.ENSP00000422435; -. DR BindingDB; Q15349; -. DR ChEMBL; CHEMBL3906; -. DR DrugCentral; Q15349; -. DR GuidetoPHARMACOLOGY; 1529; -. DR iPTMnet; Q15349; -. DR PhosphoSitePlus; Q15349; -. DR BioMuta; RPS6KA2; -. DR DMDM; 90110031; -. DR REPRODUCTION-2DPAGE; Q15349; -. DR CPTAC; CPTAC-2945; -. DR jPOST; Q15349; -. DR MassIVE; Q15349; -. DR PaxDb; 9606-ENSP00000427015; -. DR PeptideAtlas; Q15349; -. DR ProteomicsDB; 60536; -. [Q15349-1] DR ProteomicsDB; 60537; -. [Q15349-2] DR ProteomicsDB; 60538; -. [Q15349-3] DR Antibodypedia; 33522; 564 antibodies from 43 providers. DR DNASU; 6196; -. DR Ensembl; ENST00000265678.9; ENSP00000265678.4; ENSG00000071242.14. [Q15349-1] DR Ensembl; ENST00000503859.5; ENSP00000427015.1; ENSG00000071242.14. [Q15349-3] DR GeneID; 6196; -. DR KEGG; hsa:6196; -. DR MANE-Select; ENST00000265678.9; ENSP00000265678.4; NM_021135.6; NP_066958.2. DR UCSC; uc003qvb.2; human. [Q15349-1] DR AGR; HGNC:10431; -. DR ClinPGx; PA34846; -. DR CTD; 6196; -. DR DisGeNET; 6196; -. DR GeneCards; RPS6KA2; -. DR HGNC; HGNC:10431; RPS6KA2. DR HPA; ENSG00000071242; Low tissue specificity. DR MIM; 601685; gene. DR OpenTargets; ENSG00000071242; -. DR VEuPathDB; HostDB:ENSG00000071242; -. DR eggNOG; KOG0603; Eukaryota. DR GeneTree; ENSGT00940000159956; -. DR InParanoid; Q15349; -. DR OMA; GAMKATY; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; Q15349; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q15349; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q15349; -. DR Reactome; R-HSA-198753; ERK/MAPK targets. DR Reactome; R-HSA-199920; CREB phosphorylation. DR Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP). DR Reactome; R-HSA-437239; Recycling pathway of L1. DR Reactome; R-HSA-442742; CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling. DR Reactome; R-HSA-444257; RSK activation. DR Reactome; R-HSA-881907; Gastrin-CREB signalling pathway via PKC and MAPK. DR SignaLink; Q15349; -. DR SIGNOR; Q15349; -. DR Agora; ENSG00000071242; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 6196; 19 hits in 1179 CRISPR screens. DR ChiTaRS; RPS6KA2; human. DR GeneWiki; RPS6KA2; -. DR GenomeRNAi; 6196; -. DR Pharos; Q15349; Tchem. DR PRO; PR:Q15349; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q15349; protein. DR Bgee; ENSG00000071242; Expressed in inferior olivary complex and 215 other cell types or tissues. DR ExpressionAtlas; Q15349; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0072687; C:meiotic spindle; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0045202; C:synapse; IEA:GOC. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0000287; F:magnesium ion binding; IEA:InterPro. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:MGI. DR GO; GO:0004711; F:ribosomal protein S6 kinase activity; IBA:GO_Central. DR GO; GO:0002035; P:brain renin-angiotensin system; IEA:Ensembl. DR GO; GO:0010659; P:cardiac muscle cell apoptotic process; IEA:Ensembl. DR GO; GO:0071322; P:cellular response to carbohydrate stimulus; IEA:Ensembl. DR GO; GO:0007268; P:chemical synaptic transmission; TAS:Reactome. DR GO; GO:0060047; P:heart contraction; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; TAS:ProtInc. DR GO; GO:0045786; P:negative regulation of cell cycle; IDA:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:0045835; P:negative regulation of meiotic nuclear division; IEA:Ensembl. DR GO; GO:0001556; P:oocyte maturation; IEA:Ensembl. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl. DR GO; GO:0070613; P:regulation of protein processing; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; NAS:ProtInc. DR GO; GO:0038202; P:TORC1 signaling; IBA:GO_Central. DR CDD; cd14178; STKc_RSK3_C; 1. DR CDD; cd05582; STKc_RSK_N; 1. DR FunFam; 1.10.510.10:FF:000010; Ribosomal protein S6 kinase; 1. DR FunFam; 1.10.510.10:FF:000041; Ribosomal protein S6 kinase; 1. DR FunFam; 3.30.200.20:FF:000013; Ribosomal protein S6 kinase; 1. DR FunFam; 3.30.200.20:FF:000121; Ribosomal protein S6 kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 2. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR016239; Ribosomal_S6_kinase_II. DR InterPro; IPR042766; RSK3_STKc. DR InterPro; IPR041906; RSK_N. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00069; Pkinase; 2. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000606; Ribsml_S6_kin_2; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 2. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 2. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 2. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 2. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cytoplasm; Kinase; Magnesium; KW Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase; Tumor suppressor. FT CHAIN 1..733 FT /note="Ribosomal protein S6 kinase alpha-2" FT /id="PRO_0000086201" FT DOMAIN 59..318 FT /note="Protein kinase 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 319..388 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT DOMAIN 415..672 FT /note="Protein kinase 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ACT_SITE 184 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT ACT_SITE 532 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 65..73 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 91 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 421..429 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 444 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 218 FT /note="Phosphoserine; by PDPK1" FT /evidence="ECO:0000269|PubMed:10480933" FT MOD_RES 377 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT VAR_SEQ 1..32 FT /note="MDLSMKKFAVRRFFSVYLRRKSRSKSSSLSRL -> MPIAQLLELWKKIEVE FT PMEIETTEEDLNLDVGPATEDTAEEGKSDSAACKTKVAGSV (in isoform 2)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017732" FT VAR_SEQ 1..32 FT /note="MDLSMKKFAVRRFFSVYLRRKSRSKSSSLSRL -> MPIAQLLELWKKIEVE FT PMEIETTEEDLNLDVEPTTEDTAE (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_041836" FT VARIANT 311 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs267600891)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040627" FT VARIANT 732 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs376029388)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040628" FT CONFLICT 256 FT /note="S -> A (in Ref. 6; AAC82496)" FT /evidence="ECO:0000305" FT CONFLICT 269 FT /note="A -> S (in Ref. 6; AAC82496)" FT /evidence="ECO:0000305" FT CONFLICT 339 FT /note="V -> L (in Ref. 1; CAA59427 and 6; AAC82496)" FT /evidence="ECO:0000305" FT CONFLICT 447 FT /note="D -> G (in Ref. 6; AAC82496)" FT /evidence="ECO:0000305" FT CONFLICT Q15349-3:32 FT /note="E -> G (in Ref. 3; BAG53121)" FT /evidence="ECO:0000305" FT CONFLICT Q15349-3:34 FT /note="T -> A (in Ref. 3; BAG53121)" FT /evidence="ECO:0000305" SQ SEQUENCE 733 AA; 83239 MW; 087CFB819A313760 CRC64; MDLSMKKFAV RRFFSVYLRR KSRSKSSSLS RLEEEGVVKE IDISHHVKEG FEKADPSQFE LLKVLGQGSY GKVFLVRKVK GSDAGQLYAM KVLKKATLKV RDRVRSKMER DILAEVNHPF IVKLHYAFQT EGKLYLILDF LRGGDLFTRL SKEVMFTEED VKFYLAELAL ALDHLHSLGI IYRDLKPENI LLDEEGHIKI TDFGLSKEAI DHDKRAYSFC GTIEYMAPEV VNRRGHTQSA DWWSFGVLMF EMLTGSLPFQ GKDRKETMAL ILKAKLGMPQ FLSGEAQSLL RALFKRNPCN RLGAGIDGVE EIKRHPFFVT IDWNTLYRKE IKPPFKPAVG RPEDTFHFDP EFTARTPTDS PGVPPSANAH HLFRGFSFVA SSLIQEPSQQ DLHKVPVHPI VQQLHGNNIH FTDGYEIKED IGVGSYSVCK RCVHKATDTE YAVKIIDKSK RDPSEEIEIL LRYGQHPNII TLKDVYDDGK FVYLVMELMR GGELLDRILR QRYFSEREAS DVLCTITKTM DYLHSQGVVH RDLKPSNILY RDESGSPESI RVCDFGFAKQ LRAGNGLLMT PCYTANFVAP EVLKRQGYDA ACDIWSLGIL LYTMLAGFTP FANGPDDTPE EILARIGSGK YALSGGNWDS ISDAAKDVVS KMLHVDPHQR LTAMQVLKHP WVVNREYLSP NQLSRQDVHL VKGAMAATYF ALNRTPQAPR LEPVLSSNLA QRRGMKRLTS TRL // ID LN28B_HUMAN Reviewed; 250 AA. AC Q6ZN17; A1L165; B2RPN6; Q5TCM4; DT 17-OCT-2006, integrated into UniProtKB/Swiss-Prot. DT 05-JUL-2004, sequence version 1. DT 28-JAN-2026, entry version 181. DE RecName: Full=Protein lin-28 homolog B; DE Short=Lin-28B; GN Name=LIN28B; Synonyms=CSDD2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Moss E.G., Kemper K.; RT "Expression of Lin28A and Lin28B in post-implantation mouse embryos."; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Teratocarcinoma; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP ALTERNATIVE SPLICING (ISOFORMS 1 AND 2), SUBCELLULAR LOCATION, TISSUE RP SPECIFICITY, AND INDUCTION. RX PubMed=16971064; DOI=10.1016/j.gene.2006.07.011; RA Guo Y., Chen Y., Ito H., Watanabe A., Ge X., Kodama T., Aburatani H.; RT "Identification and characterization of lin-28 homolog B (LIN28B) in human RT hepatocellular carcinoma."; RL Gene 384:51-61(2006). RN [7] RP FUNCTION, SUBCELLULAR LOCATION, AND RNA-BINDING. RX PubMed=18951094; DOI=10.1016/j.molcel.2008.09.014; RA Heo I., Joo C., Cho J., Ha M., Han J., Kim V.N.; RT "Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA."; RL Mol. Cell 32:276-284(2008). RN [8] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [9] RP FUNCTION, AND RNA-BINDING. RX PubMed=19703396; DOI=10.1016/j.cell.2009.08.002; RA Heo I., Joo C., Kim Y.-K., Ha M., Yoon M.-J., Cho J., Yeom K.-H., Han J., RA Kim V.N.; RT "TUT4 in concert with Lin28 suppresses MicroRNA biogenesis through pre- RT microRNA uridylation."; RL Cell 138:696-708(2009). RN [10] RP POSSIBLE INVOLVEMENT IN CANCERS. RX PubMed=19483683; DOI=10.1038/ng.392; RA Viswanathan S.R., Powers J.T., Einhorn W., Hoshida Y., Ng T.L., RA Toffanin S., O'Sullivan M., Lu J., Phillips L.A., Lockhart V.L., Shah S.P., RA Tanwar P.S., Mermel C.H., Beroukhim R., Azam M., Teixeira J., Meyerson M., RA Hughes T.P., Llovet J.M., Radich J., Mullighan C.G., Golub T.R., RA Sorensen P.H., Daley G.Q.; RT "Lin28 promotes transformation and is associated with advanced human RT malignancies."; RL Nat. Genet. 41:843-848(2009). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [12] RP FUNCTION IN PRE-LET-7 REPRESSION, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=22118463; DOI=10.1016/j.cell.2011.10.039; RA Piskounova E., Polytarchou C., Thornton J.E., LaPierre R.J., RA Pothoulakis C., Hagan J.P., Iliopoulos D., Gregory R.I.; RT "Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct RT mechanisms."; RL Cell 147:1066-1079(2011). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-54; SER-96; SER-105; SER-110 RP AND SER-203, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [15] RP X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 24-111, AND ZINC KNUCKLE DOMAIN. RX PubMed=22570413; DOI=10.1093/nar/gks355; RA Mayr F., Schutz A., Doge N., Heinemann U.; RT "The Lin28 cold-shock domain remodels pre-let-7 microRNA."; RL Nucleic Acids Res. 40:7492-7506(2012). CC -!- FUNCTION: Suppressor of microRNA (miRNA) biogenesis, including that of CC let-7 and possibly of miR107, miR-143 and miR-200c. Binds primary let-7 CC transcripts (pri-let-7), including pri-let-7g and pri-let-7a-1, and CC sequester them in the nucleolus, away from the microprocessor complex, CC hence preventing their processing into mature miRNA (PubMed:22118463). CC Does not act on pri-miR21 (PubMed:22118463). The repression of let-7 CC expression is required for normal development and contributes to CC maintain the pluripotent state of embryonic stem cells by preventing CC let-7-mediated differentiation. When overexpressed, recruits CC ZCCHC11/TUT4 uridylyltransferase to pre-let-7 transcripts, leading to CC their terminal uridylation and degradation (PubMed:19703396). This CC activity might not be relevant in vivo, as LIN28B-mediated inhibition CC of let-7 miRNA maturation appears to be ZCCHC11-independent CC (PubMed:22118463). Interaction with target pre-miRNAs occurs via an 5'- CC GGAG-3' motif in the pre-miRNA terminal loop. Mediates MYC-induced let- CC 7 repression (By similarity). When overexpressed, isoform 1 stimulates CC growth of the breast adenocarcinoma cell line MCF-7. Isoform 2 has no CC effect on cell growth. {ECO:0000250|UniProtKB:Q45KJ6, CC ECO:0000269|PubMed:16971064, ECO:0000269|PubMed:18951094, CC ECO:0000269|PubMed:19703396, ECO:0000269|PubMed:22118463}. CC -!- SUBCELLULAR LOCATION: Nucleus. Nucleus, nucleolus CC {ECO:0000269|PubMed:22118463}. Cytoplasm {ECO:0000269|PubMed:16971064}. CC Note=Predominantly nucleolar (PubMed:22118463). In Huh7 cells, CC predominantly cytoplasmic, with only a subset of cells exhibiting CC strong nuclear staining; however, the specificity of the polyclonal CC antibody used in these experiments has not been not documented CC (PubMed:16971064). {ECO:0000269|PubMed:16971064, CC ECO:0000269|PubMed:22118463}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q6ZN17-1; Sequence=Displayed; CC Name=2; Synonyms=LIN28BS; CC IsoId=Q6ZN17-2; Sequence=VSP_027207; CC -!- TISSUE SPECIFICITY: Expressed at high levels in the placenta and, at CC mucher lower, in testis and fetal liver (PubMed:16971064). Isoform 1 is CC only detected in placenta and in moderately and poorly differentiated CC hepatocellular carcinoma cells (at protein level). Isoform 2 is CC detected in fetal liver, non-tumor liver tissues, as well as well- CC differentiated tumor tissues (at protein level). Tends to be up- CC regulated in triple-negative (ER-,PR-,HER2-) breast tumors, as well as CC in liver, ovarian, and thyroid carcinomas (PubMed:22118463). CC {ECO:0000269|PubMed:16971064, ECO:0000269|PubMed:22118463}. CC -!- INDUCTION: Might be negatively regulated by the microRNA let-7b. CC {ECO:0000269|PubMed:16971064}. CC -!- DOMAIN: The tandem zinc fingers, also referred as zinc knuckle domain CC (ZKD), mediate specific binding to the GGAG/GGUG motif while the CSD CC shows only limited pyrimidine-rich sequence specificity. Both domains CC bind single-stranded nucleic acids. CC -!- SIMILARITY: Belongs to the lin-28 family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/45723/LIN28B"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; DQ127228; AAZ38897.1; -; mRNA. DR EMBL; AK131411; BAD18558.1; -; mRNA. DR EMBL; AL135911; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z95329; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471051; EAW48434.1; -; Genomic_DNA. DR EMBL; BC127712; AAI27713.1; -; mRNA. DR EMBL; BC127713; AAI27714.1; -; mRNA. DR EMBL; BC137526; AAI37527.1; -; mRNA. DR EMBL; BC137527; AAI37528.1; -; mRNA. DR EMBL; BC141960; AAI41961.1; -; mRNA. DR CCDS; CCDS34504.1; -. [Q6ZN17-1] DR RefSeq; NP_001004317.1; NM_001004317.4. [Q6ZN17-1] DR PDB; 4A4I; X-ray; 1.95 A; A/B=24-111. DR PDBsum; 4A4I; -. DR AlphaFoldDB; Q6ZN17; -. DR SMR; Q6ZN17; -. DR BioGRID; 133142; 363. DR FunCoup; Q6ZN17; 1779. DR IntAct; Q6ZN17; 813. DR MINT; Q6ZN17; -. DR STRING; 9606.ENSP00000344401; -. DR ChEMBL; CHEMBL4295873; -. DR GlyGen; Q6ZN17; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q6ZN17; -. DR PhosphoSitePlus; Q6ZN17; -. DR BioMuta; LIN28B; -. DR DMDM; 74758701; -. DR jPOST; Q6ZN17; -. DR MassIVE; Q6ZN17; -. DR PaxDb; 9606-ENSP00000344401; -. DR PeptideAtlas; Q6ZN17; -. DR ProteomicsDB; 67959; -. [Q6ZN17-1] DR ProteomicsDB; 67960; -. [Q6ZN17-2] DR Pumba; Q6ZN17; -. DR Antibodypedia; 32105; 310 antibodies from 36 providers. DR DNASU; 389421; -. DR Ensembl; ENST00000345080.5; ENSP00000344401.4; ENSG00000187772.8. [Q6ZN17-1] DR GeneID; 389421; -. DR KEGG; hsa:389421; -. DR MANE-Select; ENST00000345080.5; ENSP00000344401.4; NM_001004317.4; NP_001004317.1. DR UCSC; uc003pqv.2; human. [Q6ZN17-1] DR AGR; HGNC:32207; -. DR ClinPGx; PA142671543; -. DR CTD; 389421; -. DR DisGeNET; 389421; -. DR GeneCards; LIN28B; -. DR HGNC; HGNC:32207; LIN28B. DR HPA; ENSG00000187772; Tissue enriched (placenta). DR MalaCards; LIN28B; -. DR MIM; 611044; gene. DR OpenTargets; ENSG00000187772; -. DR Orphanet; 635; Neuroblastoma. DR VEuPathDB; HostDB:ENSG00000187772; -. DR eggNOG; KOG3070; Eukaryota. DR GeneTree; ENSGT00940000153295; -. DR HOGENOM; CLU_089169_1_1_1; -. DR InParanoid; Q6ZN17; -. DR OMA; WGNMAEG; -. DR OrthoDB; 422005at2759; -. DR PAN-GO; Q6ZN17; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q6ZN17; -. DR PathwayCommons; Q6ZN17; -. DR SignaLink; Q6ZN17; -. DR SIGNOR; Q6ZN17; -. DR Agora; ENSG00000187772; -. DR BioGRID-ORCS; 389421; 55 hits in 1180 CRISPR screens. DR CD-CODE; 232F8A39; P-body. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; LIN28B; human. DR EvolutionaryTrace; Q6ZN17; -. DR GenomeRNAi; 389421; -. DR Pharos; Q6ZN17; Tbio. DR PRO; PR:Q6ZN17; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q6ZN17; protein. DR Bgee; ENSG00000187772; Expressed in placenta and 37 other cell types or tissues. DR ExpressionAtlas; Q6ZN17; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0003729; F:mRNA binding; IBA:GO_Central. DR GO; GO:0003723; F:RNA binding; IDA:UniProtKB. DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0010587; P:miRNA catabolic process; IMP:UniProtKB. DR GO; GO:2000632; P:negative regulation of pre-miRNA processing; IDA:CACAO. DR GO; GO:2000635; P:negative regulation of primary miRNA processing; IDA:CACAO. DR GO; GO:2000627; P:positive regulation of miRNA catabolic process; IMP:CACAO. DR GO; GO:0031054; P:pre-miRNA processing; IMP:UniProtKB. DR GO; GO:0031123; P:RNA 3'-end processing; IMP:UniProtKB. DR GO; GO:0050779; P:RNA destabilization; IDA:CACAO. DR CDD; cd04458; CSP_CDS; 1. DR FunFam; 4.10.60.10:FF:000007; Protein lin-28 homolog A; 1. DR FunFam; 2.40.50.140:FF:000087; Protein lin-28 homolog B; 1. DR Gene3D; 2.40.50.140; Nucleic acid-binding proteins; 1. DR Gene3D; 4.10.60.10; Zinc finger, CCHC-type; 1. DR InterPro; IPR011129; CSD. DR InterPro; IPR002059; CSP_DNA-bd. DR InterPro; IPR051373; Lin-28_RNA-binding. DR InterPro; IPR054081; Lin-28A-like_Znf-CCHC_2. DR InterPro; IPR012340; NA-bd_OB-fold. DR InterPro; IPR001878; Znf_CCHC. DR InterPro; IPR036875; Znf_CCHC_sf. DR PANTHER; PTHR46109; PROTEIN LIN-28; 1. DR PANTHER; PTHR46109:SF3; PROTEIN LIN-28 HOMOLOG B; 1. DR Pfam; PF00313; CSD; 1. DR Pfam; PF21890; Lin-28A-like_zf-CCHC_2; 1. DR Pfam; PF00098; zf-CCHC; 1. DR PRINTS; PR00050; COLDSHOCK. DR SMART; SM00357; CSP; 1. DR SMART; SM00343; ZnF_C2HC; 2. DR SUPFAM; SSF50249; Nucleic acid-binding proteins; 1. DR SUPFAM; SSF57756; Retrovirus zinc finger-like domains; 1. DR PROSITE; PS51857; CSD_2; 1. DR PROSITE; PS50158; ZF_CCHC; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cytoplasm; Metal-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW RNA-binding; RNA-mediated gene silencing; Zinc; Zinc-finger. FT CHAIN 1..250 FT /note="Protein lin-28 homolog B" FT /id="PRO_0000253793" FT DOMAIN 29..102 FT /note="CSD" FT ZN_FING 127..144 FT /note="CCHC-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00047" FT ZN_FING 149..166 FT /note="CCHC-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00047" FT REGION 1..26 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 98..126 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 169..250 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 112..125 FT /note="Bipartite nuclear localization signal" FT /evidence="ECO:0000269|PubMed:22118463" FT MOTIF 239..250 FT /note="Nucleolar localization signal" FT /evidence="ECO:0000269|PubMed:22118463" FT COMPBIAS 114..125 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 173..191 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 210..219 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 220..231 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 129 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 132 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 137 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 142 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 151 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 154 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 159 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 164 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT MOD_RES 54 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 96 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 105 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 110 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 203 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..70 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_027207" FT STRAND 28..38 FT /evidence="ECO:0007829|PDB:4A4I" FT TURN 39..42 FT /evidence="ECO:0007829|PDB:4A4I" FT STRAND 43..51 FT /evidence="ECO:0007829|PDB:4A4I" FT STRAND 54..65 FT /evidence="ECO:0007829|PDB:4A4I" FT HELIX 66..68 FT /evidence="ECO:0007829|PDB:4A4I" FT STRAND 71..74 FT /evidence="ECO:0007829|PDB:4A4I" FT STRAND 82..88 FT /evidence="ECO:0007829|PDB:4A4I" FT STRAND 95..101 FT /evidence="ECO:0007829|PDB:4A4I" FT HELIX 102..104 FT /evidence="ECO:0007829|PDB:4A4I" SQ SEQUENCE 250 AA; 27084 MW; DEF2920C5F1D0BBD CRC64; MAEGGASKGG GEEPGKLPEP AEEESQVLRG TGHCKWFNVR MGFGFISMIN REGSPLDIPV DVFVHQSKLF MEGFRSLKEG EPVEFTFKKS SKGLESIRVT GPGGSPCLGS ERRPKGKTLQ KRKPKGDRCY NCGGLDHHAK ECSLPPQPKK CHYCQSIMHM VANCPHKNVA QPPASSQGRQ EAESQPCTST LPREVGGGHG CTSPPFPQEA RAEISERSGR SPQEASSTKS SIAPEEQSKK GPSVQKRKKT // ID MLH1_HUMAN Reviewed; 756 AA. AC P40692; B4DI13; B4DQ11; E9PCU2; DT 01-FEB-1995, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1995, sequence version 1. DT 28-JAN-2026, entry version 252. DE RecName: Full=DNA mismatch repair protein Mlh1; DE AltName: Full=MutL protein homolog 1; GN Name=MLH1; Synonyms=COCA2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8145827; DOI=10.1038/368258a0; RA Bronner C.E., Baker S.M., Morrison P.T., Warren G., Smith L.G., RA Lescoe M.K., Kane M.F., Earibino C., Lipford J., Lindblom A., RA Tannergaard P., Bollag R.J., Godwin A.R., Ward D.C., Nordenskjoeld M., RA Fishel R., Kolodner R.D., Liskay R.M.; RT "Mutation in the DNA mismatch repair gene homologue hMLH1 is associated RT with hereditary non-polyposis colon cancer."; RL Nature 368:258-261(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Gall bladder; RX PubMed=8128251; DOI=10.1126/science.8128251; RA Papadopoulos N., Nicolaides N.C., Wei Y.-F., Ruben S.M., Carter K.C., RA Rosen C.A., Haseltine W.A., Fleischmann R.D., Fraser C.M., Adams M.D., RA Venter J.C., Hamilton S.R., Petersen G.M., Watson P., Lynch H.T., RA Peltomaeki P., Mecklin J.-P., de la Chapelle A., Kinzler K.W., RA Vogelstein B.; RT "Mutation of a mutL homolog in hereditary colon cancer."; RL Science 263:1625-1629(1994). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=7812952; RA Kolodner R.D., Hall N.R., Lipford J.R., Kane M.F., Morrison P., Finan P.J., RA Burn J., Chapman P., Earabino C., Merchant E., Bishop D.T.; RT "Structure of the human MLH1 locus and analysis of a large hereditary RT nonpolyposis colorectal carcinoma kindred for mlh1 mutations."; RL Cancer Res. 55:242-248(1995). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LYNCH2 LEU-542; PRO-574; RP VAL-582 AND THR-618. RX PubMed=7757073; DOI=10.1093/hmg/4.2.237; RA Han H.-J., Maruyama M., Baba S., Park J.-G., Nakamura Y.; RT "Genomic structure of human mismatch repair gene, hMLH1, and its mutation RT analysis in patients with hereditary non-polyposis colorectal cancer RT (HNPCC)."; RL Hum. Mol. Genet. 4:237-242(1995). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-32; MET-213 AND RP VAL-219. RG NIEHS SNPs program; RL Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3). RC TISSUE=Brain, Corpus callosum, Kidney, and Substantia nigra; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP IDENTIFICATION OF MLH1 AS MEMBER OF BASC. RX PubMed=10783165; RA Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.; RT "BASC, a super complex of BRCA1-associated proteins involved in the RT recognition and repair of aberrant DNA structures."; RL Genes Dev. 14:927-939(2000). RN [11] RP INTERACTION WITH MBD4. RX PubMed=10097147; DOI=10.1073/pnas.96.7.3969; RA Bellacosa A., Cicchillitti L., Schepis F., Riccio A., Yeung A.T., RA Matsumoto Y., Golemis E.A., Genuardi M., Neri G.; RT "MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA RT mismatch repair protein MLH1."; RL Proc. Natl. Acad. Sci. U.S.A. 96:3969-3974(1999). RN [12] RP INTERACTION WITH EXO1 AND PMS2, CHARACTERIZATION OF VARIANTS LYNCH2 RP PRO-574; LYS-616 DEL; LEU-659 AND THR-681, AND CHARACTERIZATION OF VARIANT RP MMRCS1 LYS-616 DEL. RX PubMed=11427529; DOI=10.1074/jbc.m102670200; RA Schmutte C., Sadoff M.M., Shim K.-S., Acharya S., Fishel R.; RT "The interaction of DNA mismatch repair proteins with human exonuclease RT I."; RL J. Biol. Chem. 276:33011-33018(2001). RN [13] RP INTERACTION WITH EXO1, SUBCELLULAR LOCATION, AND CHARACTERIZATION OF RP VARIANT MET-117. RX PubMed=11429708; DOI=10.1038/sj.onc.1204467; RA Jaeger A.C., Rasmussen M., Bisgaard H.C., Singh K.K., Nielsen F.C., RA Rasmussen L.J.; RT "HNPCC mutations in the human DNA mismatch repair gene hMLH1 influence RT assembly of hMutLalpha and hMLH1-hEXO1 complexes."; RL Oncogene 20:3590-3595(2001). RN [14] RP INTERACTION WITH EXO1. RX PubMed=12414623; RA Sun X., Zheng L., Shen B.; RT "Functional alterations of human exonuclease 1 mutants identified in RT atypical hereditary nonpolyposis colorectal cancer syndrome."; RL Cancer Res. 62:6026-6030(2002). RN [15] RP INTERACTION WITH EXO1, AND SUBCELLULAR LOCATION. RX PubMed=14676842; DOI=10.1038/sj.onc.1207265; RA Nielsen F.C., Jaeger A.C., Luetzen A., Bundgaard J.R., Rasmussen L.J.; RT "Characterization of human exonuclease 1 in complex with mismatch repair RT proteins, subcellular localization and association with PCNA."; RL Oncogene 23:1457-1468(2004). RN [16] RP INVOLVEMENT IN MRTES. RX PubMed=8751876; RA Bapat B., Xia L., Madlensky L., Mitri A., Tonin P., Narod S.A., RA Gallinger S.; RT "The genetic basis of Muir-Torre syndrome includes the hMLH1 locus."; RL Am. J. Hum. Genet. 59:736-739(1996). RN [17] RP FUNCTION. RX PubMed=16873062; DOI=10.1016/j.cell.2006.05.039; RA Kadyrov F.A., Dzantiev L., Constantin N., Modrich P.; RT "Endonucleolytic function of MutLalpha in human mismatch repair."; RL Cell 126:297-308(2006). RN [18] RP FUNCTION. RX PubMed=18206974; DOI=10.1016/j.molcel.2007.10.030; RA Sacho E.J., Kadyrov F.A., Modrich P., Kunkel T.A., Erie D.A.; RT "Direct visualization of asymmetric adenine nucleotide-induced RT conformational changes in MutL alpha."; RL Mol. Cell 29:112-121(2008). RN [19] RP REVIEW. RX PubMed=16188885; DOI=10.1074/jbc.m509701200; RA Constantin N., Dzantiev L., Kadyrov F.A., Modrich P.; RT "Human mismatch repair: reconstitution of a nick-directed bidirectional RT reaction."; RL J. Biol. Chem. 280:39752-39761(2005). RN [20] RP REVIEW. RX PubMed=16873053; DOI=10.1016/j.cell.2006.07.003; RA Jiricny J.; RT "MutLalpha: at the cutting edge of mismatch repair."; RL Cell 126:239-241(2006). RN [21] RP REVIEW. RX PubMed=18157157; DOI=10.1038/cr.2007.115; RA Li G.M.; RT "Mechanisms and functions of DNA mismatch repair."; RL Cell Res. 18:85-98(2008). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [24] RP INTERACTION WITH MTMR15. RX PubMed=20603073; DOI=10.1016/j.molcel.2010.06.023; RA Smogorzewska A., Desetty R., Saito T.T., Schlabach M., Lach F.P., RA Sowa M.E., Clark A.B., Kunkel T.A., Harper J.W., Colaiacovo M.P., RA Elledge S.J.; RT "A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease RT necessary for DNA interstrand crosslink repair."; RL Mol. Cell 39:36-47(2010). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [27] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [30] RP IDENTIFICATION IN THE MMR COMPLEX, INTERACTION WITH MCM9 AND MCM8, AND RP SUBCELLULAR LOCATION. RX PubMed=26300262; DOI=10.1016/j.molcel.2015.07.010; RA Traver S., Coulombe P., Peiffer I., Hutchins J.R., Kitzmann M., RA Latreille D., Mechali M.; RT "MCM9 Is Required for Mammalian DNA Mismatch Repair."; RL Mol. Cell 59:831-839(2015). RN [31] RP SUBCELLULAR LOCATION, ACETYLATION AT LYS-33; LYS-241; LYS-361 AND LYS-377, RP DEACETYLATION BY HDAC6, AND MUTAGENESIS OF LYS-33; LYS-241; LYS-361 AND RP LYS-377. RX PubMed=30770470; DOI=10.1074/jbc.ra118.006374; RA Zhang M., Hu C., Moses N., Haakenson J., Xiang S., Quan D., Fang B., RA Yang Z., Bai W., Bepler G., Li G.M., Zhang X.M.; RT "HDAC6 regulates DNA damage response via deacetylating MLH1."; RL J. Biol. Chem. 294:5813-5826(2019). RN [32] RP FUNCTION, UBIQUITINATION BY UBR4, DEUBIQUITINATION BY USP5, INTERACTION RP WITH PSM2, AND CHARACTERIZATION OF VARIANT LEU-574 AND ALA-589. RX PubMed=39032648; DOI=10.1016/j.jbc.2024.107592; RA Mao C., Li S., Che J., Liu D., Mao X., Rao H.; RT "The ubiquitin ligase UBR4 and the deubiquitylase USP5 modulate the RT stability of DNA mismatch repair protein MLH1."; RL J. Biol. Chem. 300:107592-107592(2024). RN [33] RP X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 486-751. RA Dombrovsky L., Dong A., Wernimont A., Loppnau P., Bountra C., Weigelt J., RA Arrowsmith C.H., Edwards A.M., Min J., Wu H.; RT "Crystal structure of MutL protein homolog 1 isoform 1."; RL Submitted (MAR-2011) to the PDB data bank. RN [34] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 3-196 IN COMPLEX WITH ADP AND RP MAGNESIUM IONS. RX PubMed=26249686; DOI=10.1107/s2053230x15010183; RA Wu H., Zeng H., Lam R., Tempel W., Kerr I.D., Min J.; RT "Structure of the human MLH1 N-terminus: implications for predisposition to RT Lynch syndrome."; RL Acta Crystallogr. F 71:981-985(2015). RN [35] {ECO:0007744|PDB:5U5P} RP X-RAY CRYSTALLOGRAPHY (2.17 ANGSTROMS) OF 467-476, NUCLEAR LOCALIZATION RP SIGNAL, AND MUTAGENESIS OF LYS-471 AND ARG-472. RX PubMed=29175432; DOI=10.1016/j.biochi.2017.11.013; RA de Barros A.C., Takeda A.A.S., Dreyer T.R., Velazquez-Campoy A., Kobe B., RA Fontes M.R.M.; RT "DNA mismatch repair proteins MLH1 and PMS2 can be imported to the nucleus RT by a classical nuclear import pathway."; RL Biochimie 146:87-96(2018). RN [36] RP CHARACTERIZATION OF VARIANTS LYNCH2 CYS-31; LYS-37; HIS-38; LYS-38; PHE-44; RP ARG-67; PRO-109; PRO-111; MET-117; CYS-265; SER-265; GLN-443; PRO-550; RP GLY-578; PHE-582; ASP-589; ALA-618; CYS-646; LEU-648; LEU-654 AND PRO-659, RP CHARACTERIZATION OF VARIANTS GLY-93; VAL-219; SER-403; ASN-406 AND MET-716, RP AND FUNCTION. RX PubMed=20020535; DOI=10.1002/humu.21180; RA Drost M., Zonneveld J.B., van Dijk L., Morreau H., Tops C.M., Vasen H.F., RA Wijnen J.T., de Wind N.; RT "A cell-free assay for the functional analysis of variants of the mismatch RT repair protein MLH1."; RL Hum. Mutat. 31:247-253(2010). RN [37] RP CHARACTERIZATION OF VARIANTS LYNCH2 LEU-28; SER-29; 45-THR--ILE-47 DELINS RP CYS-PHE; GLU-63; ARG-67; GLU-71 DEL; ARG-77; VAL-80; GLU-84; ARG-107; RP ARG-155; GLY-185; PRO-247; PRO-329; ILE-330 DEL; GLN-443; ALA-460; PRO-550; RP 578-GLU--GLU-632 DEL; ASP-589; VAL-612 DEL; LYS-616 DEL; ALA-618; THR-618; RP 633-GLU--GLU-663 DEL; CYS-646; LEU-648; SER-648; LEU-654; GLN-659; PRO-659; RP THR-681 AND TRP-687, CHARACTERIZATION OF VARIANTS GLY-93; MET-213; VAL-219 RP AND MET-716, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=21120944; DOI=10.1002/humu.21409; RA Kansikas M., Kariola R., Nystroem M.; RT "Verification of the three-step model in assessing the pathogenicity of RT mismatch repair gene variants."; RL Hum. Mutat. 32:107-115(2011). RN [38] RP VARIANT LYNCH2 ARG-35. RX PubMed=8521398; RA Tannergaard P., Lipford J.R., Kolodner R., Froedin J.E., Nordenskjoeld M., RA Lindblom A.; RT "Mutation screening in the hMLH1 gene in Swedish hereditary nonpolyposis RT colon cancer families."; RL Cancer Res. 55:6092-6096(1995). RN [39] RP VARIANT MMRCS1 LYS-616 DEL. RX PubMed=7661930; DOI=10.1056/nejm199503303321302; RA Hamilton S.R., Liu B., Parsons R.E., Papadopoulos N., Jen J., Powell S.M., RA Krush A.J., Berk T., Cohen Z., Tetu B., Burger P.C., Wood P.A., Taqi F., RA Booker S.V., Petersen G.M., Offerhaus G.J.A., Tersmette A.C., RA Giardiello F.M., Vogelstein B., Kinzler K.W.; RT "The molecular basis of Turcot's syndrome."; RL N. Engl. J. Med. 332:839-847(1995). RN [40] RP VARIANT LYNCH2 LYS-616 DEL. RX PubMed=8571956; RA Wijnen J., Khan P.M., Vasen H., Menko F., van der Klift H., RA van den Broek M., van Leeuwen-Cornelisse I., Nagengast F., RA Meijers-Heijboer E.J., Lindhout D., Griffioen G., Cats A., Kleibeuker J., RA Varesco L., Bertario L., Bisgaard M.-L., Mohr J., Kolodner R.D., Fodde R.; RT "Majority of hMLH1 mutations responsible for hereditary nonpolyposis RT colorectal cancer cluster at the exonic region 15-16."; RL Am. J. Hum. Genet. 58:300-307(1996). RN [41] RP VARIANTS LYNCH2 MET-117 AND LEU-226. RX PubMed=8566964; DOI=10.1007/bf02265276; RA Maliaka Y.K., Chudina A.P., Belev N.F., Alday P., Bochkov N.P., RA Buerstedde J.-M.; RT "CpG dinucleotides in the hMSH2 and hMLH1 genes are hotspots for HNPCC RT mutations."; RL Hum. Genet. 97:251-255(1996). RN [42] RP VARIANTS LYNCH2 LYS-616 DEL AND THR-618, AND VARIANT CRC THR-492. RX PubMed=8872463; DOI=10.1093/hmg/5.9.1245; RA Moslein G., Tester D.J., Lindor N.M., Honchel R., Cunningham J.M., RA French A.J., Halling K.C., Schwab M., Goretzki P., Thibodeau S.N.; RT "Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in RT patients with sporadic, familial and hereditary colorectal cancer."; RL Hum. Mol. Genet. 5:1245-1252(1996). RN [43] RP VARIANTS LYNCH2 CYS-217; LEU-542; PRO-549 AND PRO-574. RX PubMed=8797773; DOI=10.1093/jnci/88.18.1317; RA Han H.-J., Yuan Y., Ku J.-L., Oh J.-H., Won Y.-J., Kang K.J., Kim K.Y., RA Kim S., Kim C.Y., Kim J.-P., Oh N.-G., Lee K.H., Choe K.J., Nakamura Y., RA Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in Korean hereditary RT nonpolyposis colorectal cancer."; RL J. Natl. Cancer Inst. 88:1317-1319(1996). RN [44] RP VARIANTS LEU-ASN-HIS-37 INS AND ASP-384. RX PubMed=8609062; DOI=10.1111/j.1349-7006.1996.tb03151.x; RA Kobayashi K., Matsushima M., Koi S., Saito H., Sagae S., Kudo R., RA Nakamura Y.; RT "Mutational analysis of mismatch repair genes, hMLH1 and hMSH2, in sporadic RT endometrial carcinomas with microsatellite instability."; RL Jpn. J. Cancer Res. 87:141-145(1996). RN [45] RP VARIANT LYNCH2 ALA-506. RX PubMed=8574961; DOI=10.1038/nm0296-169; RA Liu B., Parsons R., Papadopoulos N., Nicolaides N.C., Lynch H.T., RA Watson P., Jass J.R., Dunlop M., Wyllie A., Peltomaeki P., RA de la Chapelle A., Hamilton S.R., Vogelstein B., Kinzler K.W.; RT "Analysis of mismatch repair genes in hereditary non-polyposis colorectal RT cancer patients."; RL Nat. Med. 2:169-174(1996). RN [46] RP VARIANTS LYNCH2 LYS-62; SER-64; LYS-616 DEL; ALA-618 AND PRO-659, RP CHARACTERIZATION OF VARIANT LYNCH2 LYS-62, AND FUNCTION. RX PubMed=9311737; DOI=10.1086/514847; RA Wijnen J., Khan P.M., Vasen H., van der Klift H., Mulder A., RA van Leeuwen-Cornelisse I., Bakker B., Losekoot M., Moeller P., Fodde R.; RT "Hereditary nonpolyposis colorectal cancer families not complying with the RT Amsterdam criteria show extremely low frequency of mismatch-repair-gene RT mutations."; RL Am. J. Hum. Genet. 61:329-335(1997). RN [47] RP VARIANT LYNCH2 LYS-616 DEL, AND VARIANT HIS-265. RX PubMed=8993976; RX DOI=10.1002/(sici)1098-2264(199701)18:1<8::aid-gcc2>3.0.co;2-7; RA Viel A., Genuardi M., Capozzi E., Leonardi F., Bellacosa A., RA Paravatou-Petsotas M., Pomponi M.G., Fornasarig M., Percesepe A., RA Roncucci L., Tamassia M.G., Benatti P., Ponz de Leon M., Valenti A., RA Covino M., Anti M., Foletto M., Boiocchi M., Neri G.; RT "Characterization of MSH2 and MLH1 mutations in Italian families with RT hereditary nonpolyposis colorectal cancer."; RL Genes Chromosomes Cancer 18:8-18(1997). RN [48] RP VARIANTS CRC GLU-54 AND VAL-244, AND VARIANTS VAL-219; GLN-325 AND ASN-406. RX PubMed=9087566; RX DOI=10.1002/(sici)1098-2264(199704)18:4<269::aid-gcc4>3.3.co;2-9; RA Wu Y., Nystroem-Lahti M., Osinga J., Looman M.W.G., Peltomaeki P., RA Aaltonen L.A., de la Chapelle A., Hofstra R.M.W., Buys C.H.C.M.; RT "MSH2 and MLH1 mutations in sporadic replication error-positive colorectal RT carcinoma as assessed by two-dimensional DNA electrophoresis."; RL Genes Chromosomes Cancer 18:269-278(1997). RN [49] RP VARIANTS LYNCH2 PRO-128 AND ASP-244, AND VARIANT VAL-219. RX PubMed=9218993; RX DOI=10.1002/(sici)1098-2264(199707)19:3<135::aid-gcc1>3.3.co;2-x; RA Pensotti V., Radice P., Presciuttini S., Calistri D., Gazzoli I., RA Grimalt Perez A.P., Mondini P., Buonsanti G., Sala P., Rossetti C., RA Ranzani G.N., Bertario L., Pierotti M.A.; RT "Mean age of tumor onset in hereditary nonpolyposis colorectal cancer RT (HNPCC) families correlates with the presence of mutations in DNA mismatch RT repair genes."; RL Genes Chromosomes Cancer 19:135-142(1997). RN [50] RP VARIANT LYNCH2 626-PHE-SER-627 DELINS SER-THR. RX PubMed=9048925; DOI=10.1007/s004390050343; RA Beck N.E., Tomlinson I.P.M., Homfray T., Frayling I., Hodgson S.V., RA Harocopos C.J., Bodmer W.F.; RT "Use of SSCP analysis to identify germline mutations in HNPCC families RT fulfilling the Amsterdam criteria."; RL Hum. Genet. 99:219-224(1997). RN [51] RP VARIANT LYNCH2 PRO-329. RX PubMed=9272156; DOI=10.1007/s004390050517; RA Wang Y., Friedl W., Lamberti C., Ruelfs C., Kruse R., Propping P.; RT "Hereditary nonpolyposis colorectal cancer: causative role of a germline RT missense mutation in the hMLH1 gene confirmed by the independent occurrence RT of the same somatic mutation in tumour tissue."; RL Hum. Genet. 100:362-364(1997). RN [52] RP VARIANT LYNCH2 ARG-67, AND VARIANT VAL-219. RX PubMed=9067757; RX DOI=10.1002/(sici)1098-1004(1997)9:2<164::aid-humu9>3.0.co;2-9; RA Sasaki S., Tokino T., Miyatsu T., Muto T., Nakamura Y.; RT "Mutational analysis of the hMLH1 gene using an automated two-dimensional RT DNA typing system."; RL Hum. Mutat. 9:164-171(1997). RN [53] RP REVIEW ON VARIANTS. RX PubMed=9259192; RX DOI=10.1002/(sici)1098-1004(1997)10:2<89::aid-humu1>3.0.co;2-h; RA Papadopoulos N., Lindblom A.; RT "Molecular basis of HNPCC: mutations of MMR genes."; RL Hum. Mutat. 10:89-99(1997). RN [54] RP VARIANT LYNCH2 LEU-28. RX PubMed=9298827; RX DOI=10.1002/(sici)1098-1004(1997)10:3<241::aid-humu12>3.0.co;2-#; RA Wehner M., Buschhausen L., Lamberti C., Kruse R., Caspari R., Propping P., RA Friedl W.; RT "Hereditary nonpolyposis colorectal cancer (HNPCC): eight novel germline RT mutations in hMSH2 or hMLH1 genes."; RL Hum. Mutat. 10:241-244(1997). RN [55] RP VARIANTS LYNCH2 GLY-182; THR-295 AND THR-551. RX PubMed=9399661; RX DOI=10.1002/(sici)1097-0215(19971210)73:6<831::aid-ijc11>3.0.co;2-7; RA Wang Q., Desseigne F., Lasset C., Saurin J.-C., Navarro C., Yagci T., RA Keser I., Bagci H., Luleci G., Gelen T., Chayvialle J.-A., Puisieux A., RA Ozturk M.; RT "Germline hMSH2 and hMLH1 gene mutations in incomplete HNPCC families."; RL Int. J. Cancer 73:831-836(1997). RN [56] RP VARIANT CRC TYR-77, AND VARIANT VAL-219. RX PubMed=9032648; DOI=10.1136/jmg.34.1.39; RA Tomlinson I.P.M., Beck N.E., Homfray T., Harocopos C.J., Bodmer W.F.; RT "Germline HNPCC gene variants have little influence on the risk for RT sporadic colorectal cancer."; RL J. Med. Genet. 34:39-42(1997). RN [57] RP VARIANTS LYNCH2 PHE-44 AND THR-441. RX PubMed=9326924; DOI=10.1038/ng1097-135; RA Hackman P., Tannergaerd P., Osei-Mensa S., Chen J., Kane M.F., RA Kolodner R.D., Lambert B., Hellgren D., Lindblom A.; RT "A human compound heterozygote for two MLH1 missense mutations."; RL Nat. Genet. 17:135-136(1997). RN [58] RP VARIANTS LYNCH2, AND VARIANTS. RX PubMed=9718327; DOI=10.1086/301996; RA Farrington S.M., Lin-Goerke J., Ling J., Wang Y., Burczak J.D., RA Robbins D.J., Dunlop M.G.; RT "Systematic analysis of hMSH2 and hMLH1 in young colon cancer patients and RT controls."; RL Am. J. Hum. Genet. 63:749-759(1998). RN [59] RP VARIANT CRC GLY-268. RX PubMed=9611074; DOI=10.1111/j.1399-0004.1998.tb02660.x; RA Liu T., Wahlberg S., Rubio C., Holmberg E., Groenberg H., Lindblom A.; RT "DGGE screening of mutations in mismatch repair genes (hMSH2 and hMLH1) in RT 34 Swedish families with colorectal cancer."; RL Clin. Genet. 53:131-135(1998). RN [60] RP VARIANT LYNCH2 CYS-217. RX PubMed=9559627; DOI=10.1007/bf02235756; RA Yuan Y., Han H.-J., Zheng S., Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in patients with suspected RT hereditary nonpolyposis colorectal cancer and sporadic early-onset RT colorectal cancer."; RL Dis. Colon Rectum 41:434-440(1998). RN [61] RP VARIANT ASP-384, AND ASSOCIATION WITH HNPCC. RX PubMed=9526167; DOI=10.1159/000022786; RA Wang Y., Friedl W., Lamberti C., Noethen M.M., Kruse R., Propping P.; RT "A novel missense mutation in the DNA mismatch repair gene hMLH1 present RT among East Asians but not among Europeans."; RL Hum. Hered. 48:87-91(1998). RN [62] RP VARIANT LYNCH2 LYS-69. RX PubMed=10627141; RX DOI=10.1002/(sici)1098-1004(1998)12:1<73::aid-humu20>3.0.co;2-f; RA Herfarth K.K.-F., Ogunbiyi O.A., Moley J.F., Kodner I.J., Wells S.A. Jr., RA Goodfellow P.J.; RT "Four new mutations in the DNA mismatch repair gene MLH1 in colorectal RT cancers with microsatellite instability."; RL Hum. Mutat. 12:73-73(1998). RN [63] RP VARIANTS LYNCH2 ARG-77 AND PRO-193. RX PubMed=10660333; RA Panariello L., Scarano M.I., de Rosa M., Capasso L., Renda A., Riegler G., RA Rossi G.B., Salvatore F., Izzo P.; RT "hMLH1 mutations in hereditary nonpolyposis colorectal cancer kindreds."; RL Hum. Mutat. 12:216-217(1998). RN [64] RP VARIANT GLY-93. RX PubMed=10671064; RX DOI=10.1002/(sici)1098-1004(1998)12:6<433::aid-humu13>3.0.co;2-j; RA Quaresima B., Grandinetti C., Baudi F., Tassone P., Barbieri V., RA Conforti S., Avvedimento E.V., Costanzo F., Venuta S.; RT "Hereditary nonpolyposis colorectal cancer: identification of novel RT germline mutations in two kindreds not fulfilling the Amsterdam criteria."; RL Hum. Mutat. 12:433-433(1998). RN [65] RP VARIANTS LYNCH2 ARG-67; ILE-262 DEL; THR-551 AND PHE-565, AND VARIANTS RP VAL-219 AND MET-716. RX PubMed=9833759; RX DOI=10.1002/(sici)1097-0215(19981209)78:6<680::aid-ijc3>3.0.co;2-u; RA Hutter P., Couturier A., Membrez V., Joris F., Sappino A.-P., RA Chappuis P.O.; RT "Excess of hMLH1 germline mutations in Swiss families with hereditary non- RT polyposis colorectal cancer."; RL Int. J. Cancer 78:680-684(1998). RN [66] RP VARIANTS LYNCH2 ARG-67; ARG-117 AND GLU-485, AND VARIANT VAL-219. RX PubMed=10375096; RX DOI=10.1002/(sici)1097-0142(19990615)85:12<2512::aid-cncr4>3.0.co;2-g; RA Heinimann K., Scott R.J., Buerstedde J.-M., Weber W., Siebold K., RA Attenhofer M., Mueller H., Dobbie Z.; RT "Influence of selection criteria on mutation detection in patients with RT hereditary nonpolyposis colorectal cancer."; RL Cancer 85:2512-2518(1999). RN [67] RP VARIANT LYNCH2 TRP-67. RX PubMed=9927034; RA Wang Q., Lasset C., Desseigne F., Frappaz D., Bergeron C., Navarro C., RA Ruano E., Puisieux A.; RT "Neurofibromatosis and early onset of cancers in hMLH1-deficient RT children."; RL Cancer Res. 59:294-297(1999). RN [68] RP VARIANTS HIS-265; ALA-326; PRO-385; ASN-406; THR-618 AND MET-716. RX PubMed=10573010; DOI=10.1038/sj.ejhg.5200363; RA Genuardi M., Carrara S., Anti M., Ponz de Leon M., Viel A.; RT "Assessment of pathogenicity criteria for constitutional missense mutations RT of the hereditary nonpolyposis colorectal cancer genes MLH1 and MSH2."; RL Eur. J. Hum. Genet. 7:778-782(1999). RN [69] RP VARIANTS LYNCH2 LEU-28; GLU-84 AND PRO-329. RX PubMed=10323887; DOI=10.1136/gut.44.6.839; RA Lamberti C., Kruse R., Ruelfs C., Caspari R., Wang Y., Jungck M., RA Mathiak M., Malayeri H.R.H., Friedl W., Sauerbruch T., Propping P.; RT "Microsatellite instability, a useful diagnostic tool to select patients at RT high risk for hereditary non-polyposis colorectal cancer: a study in RT different groups of patients with colorectal cancer."; RL Gut 44:839-843(1999). RN [70] RP VARIANTS LYNCH2 TRP-67; MET-117; GLY-182 AND LYS-616 DEL, AND VARIANT HNPCC RP TRP-755. RX PubMed=10480359; DOI=10.1007/s004399900064; RA Wang Q., Lasset C., Desseigne F., Saurin J.-C., Maugard C., Navarro C., RA Ruano E., Descos L., Trillet-Lenoir V., Bosset J.-F., Puisieux A.; RT "Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 RT genes in 75 French kindreds with nonpolyposis colorectal cancer."; RL Hum. Genet. 105:79-85(1999). RN [71] RP VARIANT CRC GLY-578, AND VARIANT LYNCH2 ALA-618. RX PubMed=10598809; DOI=10.1007/s004390051127; RA Liu T., Tannergaerd P., Hackman P., Rubio C., Kressner U., Lindmark G., RA Hellgren D., Lambert B., Lindblom A.; RT "Missense mutations in hMLH1 associated with colorectal cancer."; RL Hum. Genet. 105:437-441(1999). RN [72] RP VARIANT LYNCH2 PHE-25, AND VARIANT TYR-718. RX PubMed=10386556; DOI=10.1001/jama.281.24.2316; RA Weber T.K., Chin H.-M., Rodriguez-Bigas M., Keitz B., Gilligan R., RA O'Malley L., Urf E., Diba N., Pazik J., Petrelli N.J.; RT "Novel hMLH1 and hMSH2 germline mutations in African Americans with RT colorectal cancer."; RL JAMA 281:2316-2320(1999). RN [73] RP VARIANT LYNCH2 TYR-264. RX PubMed=10413423; DOI=10.1093/jnci/91.14.1221; RA Chan T.L., Yuen S.T., Chung L.P., Ho J.W.C., Kwan K.Y.M., Chan A.S.Y., RA Ho J.C.Y., Leung S.Y., Wyllie A.H.; RT "Frequent microsatellite instability and mismatch repair gene mutations in RT young Chinese patients with colorectal cancer."; RL J. Natl. Cancer Inst. 91:1221-1226(1999). RN [74] RP VARIANTS LYNCH2 VAL-111 AND PRO-588, AND VARIANTS VAL-219 AND ASP-384. RX PubMed=10777691; DOI=10.1006/bbrc.2000.2547; RA Nomura S., Sugano K., Kashiwabara H., Taniguchi T., Fukayama N., Fujita S., RA Akasu T., Moriya Y., Ohhigashi S., Kakizoe T., Sekiya T.; RT "Enhanced detection of deleterious and other germline mutations of hMSH2 RT and hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds."; RL Biochem. Biophys. Res. Commun. 271:120-129(2000). RN [75] RP VARIANTS LYNCH2 HIS-607; ALA-618 AND LEU-659, AND VARIANT MET-213. RX PubMed=10713887; DOI=10.1038/sj.ejhg.5200393; RA Fidalgo P., Almeida M.R., West S., Gaspar C., Maia L., Wijnen J., RA Albuquerque C., Curtis A., Cravo M., Fodde R., Leitao C.N., Burn J.; RT "Detection of mutations in mismatch repair genes in Portuguese families RT with hereditary non-polyposis colorectal cancer (HNPCC) by a multi-method RT approach."; RL Eur. J. Hum. Genet. 8:49-53(2000). RN [76] RP VARIANT CRC ARG-260, AND VARIANT LYNCH2 VAL-304. RX PubMed=10882759; DOI=10.1136/jmg.37.7.e7; RA Montera M., Resta N., Simone C., Guanti G., Marchese C., Civitelli S., RA Mancini A., Pozzi S., De Salvo L., Bruzzone D., Donadini A., Romio L., RA Mareni C.; RT "Mutational germline analysis of hMSH2 and hMLH1 genes in early onset RT colorectal cancer patients."; RL J. Med. Genet. 37:E7-E7(2000). RN [77] RP ERRATUM OF PUBMED:10882759. RA Montera M., Resta N., Simone C., Guanti G., Marchese C., Civitelli S., RA Mancini A., Pozzi S., De Salvo L., Bruzzone D., Donadini A., Romio L., RA Mareni C.; RL J. Med. Genet. 40:472-472(2003). RN [78] RP VARIANTS GASTRIC CANCER ARG-106; GLN-109 AND LYS-635, VARIANTS LYNCH2 RP GLY-234; ILE-321; HIS-485 AND ALA-631, AND VARIANT CRC ILE-472. RX PubMed=12132870; RA Kim J.C., Kim H.C., Roh S.A., Koo K.H., Lee D.H., Yu C.S., Lee J.H., RA Kim T.W., Lee H.I., Beck N.E., Bodmer W.F.; RT "hMLH1 and hMSH2 mutations in families with familial clustering of gastric RT cancer and hereditary non-polyposis colorectal cancer."; RL Cancer Detect. Prev. 25:503-510(2001). RN [79] RP VARIANT HIS-607. RX PubMed=11369138; DOI=10.1016/s0304-3835(01)00448-7; RA Stone J.G., Coleman G., Gusterson B., Marossy A., Lakhani S.R., Ward A., RA Nash A., McKinna A., A'Hern R., Stratton M.R., Houlston R.S.; RT "Contribution of germline MLH1 and MSH2 mutations to lobular carcinoma in RT situ of the breast."; RL Cancer Lett. 167:171-174(2001). RN [80] RP INVOLVEMENT IN TUMORIGENESIS. RX PubMed=11389087; RA Vilkki S., Tsao J.-L., Loukola A., Poyhonen M., Vierimaa O., Herva R., RA Aaltonen L.A., Shibata D.; RT "Extensive somatic microsatellite mutations in normal human tissue."; RL Cancer Res. 61:4541-4544(2001). RN [81] RP VARIANTS LYNCH2 VAL-80; PRO-329; ARG-603; ALA-618; LEU-648; PRO-662 AND RP ARG-689. RX PubMed=11726306; RA Mueller-Koch Y., Kopp R., Lohse P., Baretton G., Stoetzer A., Aust D., RA Daum J., Kerker B., Gross M., Dietmeier W., Holinski-Feder E.; RT "Sixteen rare sequence variants of the hMLH1 and hMSH2 genes found in a RT cohort of 254 suspected HNPCC (hereditary non-polyposis colorectal cancer) RT patients: mutations or polymorphisms?"; RL Eur. J. Med. Res. 6:473-482(2001). RN [82] RP CHARACTERIZATION OF VARIANTS. RX PubMed=11555625; DOI=10.1093/hmg/10.18.1889; RA Ellison A.R., Lofing J., Bitter G.A.; RT "Functional analysis of human MLH1 and MSH2 missense variants and hybrid RT human-yeast MLH1 proteins in Saccharomyces cerevisiae."; RL Hum. Mol. Genet. 10:1889-1900(2001). RN [83] RP VARIANT LYNCH2 ARG-751. RX PubMed=11139242; DOI=10.1002/1098-1004(2001)17:1<52::aid-humu6>3.0.co;2-e; RA Jakubowska A., Gorski B., Kurzawski G., Debniak T., Hadaczek P., RA Cybulski C., Kladny J., Oszurek O., Scott R.J., Lubinski J.; RT "Optimization of experimental conditions for RNA-based sequencing of MLH1 RT and MSH2 genes."; RL Hum. Mutat. 17:52-60(2001). RN [84] RP VARIANTS LYNCH2 HIS-622 AND TRP-687. RX PubMed=11748856; DOI=10.1002/humu.1240; RA Godino J., de La Hoya M., Diaz-Rubio E., Benito M., Caldes T.; RT "Eight novel germline MLH1 and MSH2 mutations in hereditary non-polyposis RT colorectal cancer families from Spain."; RL Hum. Mutat. 18:549-549(2001). RN [85] RP VARIANTS LYNCH2 SER-338; ARG-603; THR-618 AND TYR-718. RX PubMed=12095971; DOI=10.1007/bf02573891; RA Rossi B.M., Lopes A., Oliveira Ferreira F., Nakagawa W.T., RA Napoli Ferreira C.C., Casali Da Rocha J.C., Simpson C.C., Simpson A.J.G.; RT "hMLH1 and hMSH2 gene mutation in Brazilian families with suspected RT hereditary nonpolyposis colorectal cancer."; RL Ann. Surg. Oncol. 9:555-561(2002). RN [86] RP VARIANTS LYNCH2 ASN-35; HIS-38; MET-117 AND ALA-618. RX PubMed=12373605; DOI=10.1038/sj.bjc.6600565; RA Gille J.J.P., Hogervorst F.B.L., Pals G., Wijnen J.T., van Schooten R.J., RA Dommering C.J., Meijer G.A., Craanen M.E., Nederlof P.M., de Jong D., RA McElgunn C.J., Schouten J.P., Menko F.H.; RT "Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected RT by a novel mutation detection approach."; RL Br. J. Cancer 87:892-897(2002). RN [87] RP VARIANTS VAL-219 AND VAL-655. RX PubMed=12115348; DOI=10.1002/cncr.10606; RA Baldinu P., Cossu A., Manca A., Satta M.P., Pisano M., Casula M., RA Dessole S., Pintus A., Tanda F., Palmieri G.; RT "Microsatellite instability and mutation analysis of candidate genes in RT unselected Sardinian patients with endometrial carcinoma."; RL Cancer 94:3157-3168(2002). RN [88] RP CHARACTERIZATION OF VARIANTS LYNCH2 MET-117; GLY-185; CYS-217; ASP-244 AND RP ALA-326, AND CHARACTERIZATION OF VARIANTS VAL-219 AND HIS-265. RX PubMed=11781295; DOI=10.1053/gast.2002.30296; RA Trojan J., Zeuzem S., Randolph A., Hemmerle C., Brieger A., Raedle J., RA Plotz G., Jiricny J., Marra G.; RT "Functional analysis of hMLH1 variants and HNPCC-related mutations using a RT human expression system."; RL Gastroenterology 122:211-219(2002). RN [89] RP VARIANTS LYNCH2 CYS-385; HIS-607; THR-618 AND SER-648, AND VARIANT MET-213. RX PubMed=11839723; DOI=10.1136/gut.50.3.405; RA Cravo M., Afonso A.J., Lage P., Albuquerque C., Maia L., Lacerda C., RA Fidalgo P., Chaves P., Cruz C., Nobre-Leitao C.; RT "Pathogenicity of missense and splice site mutations in hMSH2 and hMLH1 RT mismatch repair genes: implications for genetic testing."; RL Gut 50:405-412(2002). RN [90] RP CHARACTERIZATION OF VARIANTS LYNCH2 ARG-77; ARG-107 AND PRO-659, AND RP CHARACTERIZATION OF VARIANT GLY-93. RX PubMed=11793442; DOI=10.1002/gcc.1225.abs; RA Nystroem-Lahti M., Perrera C., Raeschle M., Panyushkina-Seiler E., RA Marra G., Curci A., Quaresima B., Costanzo F., D'Urso M., Venuta S., RA Jiricny J.; RT "Functional analysis of MLH1 mutations linked to hereditary nonpolyposis RT colon cancer."; RL Genes Chromosomes Cancer 33:160-167(2002). RN [91] RP VARIANT LYNCH2 PRO-662, AND VARIANT VAL-219. RX PubMed=11754112; DOI=10.1002/humu.9004; RA Krueger S., Plaschke J., Pistorius S., Jeske B., Haas S., Kraemer H., RA Hinterseher I., Bier A., Kreuz F.R., Theissig F., Saeger H.D., RA Schackert H.K.; RT "Seven novel MLH1 and MSH2 germline mutations in hereditary nonpolyposis RT colorectal cancer."; RL Hum. Mutat. 19:82-82(2002). RN [92] RP VARIANTS LYNCH2 MET-117 AND PRO-247, AND VARIANTS VAL-219; ALA-618 AND RP MET-716. RX PubMed=12200596; DOI=10.1007/s00432-002-0361-2; RA Ward R., Meldrum C., Williams R., Mokany E., Scott R., Turner J., RA Hawkins N., Burgess B., Groombridge C., Spigelman A.; RT "Impact of microsatellite testing and mismatch repair protein expression on RT the clinical interpretation of genetic testing in hereditary non-polyposis RT colorectal cancer."; RL J. Cancer Res. Clin. Oncol. 128:403-411(2002). RN [93] RP VARIANT LYNCH2 CYS-646, AND VARIANT ALA-618. RX PubMed=11870161; DOI=10.1200/jco.2002.20.5.1203; RA Scartozzi M., Bianchi F., Rosati S., Galizia E., Antolini A., Loretelli C., RA Piga A., Bearzi I., Cellerino R., Porfiri E.; RT "Mutations of hMLH1 and hMSH2 in patients with suspected hereditary RT nonpolyposis colorectal cancer: correlation with microsatellite instability RT and abnormalities of mismatch repair protein expression."; RL J. Clin. Oncol. 20:1203-1208(2002). RN [94] RP VARIANTS LYNCH2 PHE-19; LEU-28; MET-117; PRO-292; THR-681 AND TRP-687, AND RP VARIANT VAL-219. RX PubMed=12362047; DOI=10.1136/jmg.39.10.e65; RA Kurzawski G., Suchy J., Kladny J., Safranow K., Jakubowska A., Elsakov P., RA Kucinskas V., Gardovski J., Irmejs A., Sibul H., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Clark J., Gozdz S., RA Niepsuj S., Slomski R., Plawski A., Lacka-Wojciechowska A., Rozmiarek A., RA Fiszer-Maliszewska L., Bebenek M., Sorokin D., Stawicka M., Godlewski D., RA Richter P., Brozek I., Wysocka B., Jawien A., Banaszkiewicz Z., RA Kowalczyk J., Czudowska D., Goretzki P.E., Moeslein G., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland RT and the Baltic States."; RL J. Med. Genet. 39:E65-E65(2002). RN [95] RP VARIANTS LYNCH2 SER-29; ARG-67; LEU-185 AND ASP-244. RX PubMed=12658575; DOI=10.1086/373963; RA Wagner A., Barrows A., Wijnen J.T., van der Klift H., Franken P.F., RA Verkuijlen P., Nakagawa H., Geugien M., Jaghmohan-Changur S., Breukel C., RA Meijers-Heijboer H., Morreau H., van Puijenbroek M., Burn J., Coronel S., RA Kinarski Y., Okimoto R., Watson P., Lynch J.F., de la Chapelle A., RA Lynch H.T., Fodde R.; RT "Molecular analysis of hereditary nonpolyposis colorectal cancer in the RT United States: high mutation detection rate among clinically selected RT families and characterization of an American founder genomic deletion of RT the MSH2 gene."; RL Am. J. Hum. Genet. 72:1088-1100(2003). RN [96] RP VARIANTS CRC 325-ARG--GLN-327 DEL; ARG-618 AND PRO-749. RX PubMed=14504054; DOI=10.1093/annonc/mdg402; RA Colombino M., Cossu A., Arba A., Manca A., Curci A., Avallone A., RA Comella G., Botti G., Scintu F., Amoruso M., D'Abbicco D., d'Agnessa M.R., RA Spanu A., Tanda F., Palmieri G.; RT "Microsatellite instability and mutation analysis among southern Italian RT patients with colorectal carcinoma: detection of different alterations RT accounting for MLH1 and MSH2 inactivation in familial cases."; RL Ann. Oncol. 14:1530-1536(2003). RN [97] RP VARIANT LYNCH2 PRO-586. RX PubMed=12655562; DOI=10.1002/humu.9121; RA Kruger S., Plaschke J., Jeske B., Gorgens H., Pistorius S.R., Bier A., RA Kreuz F.R., Theissig F., Aust D.E., Saeger H.D., Schackert H.K.; RT "Identification of six novel MSH2 and MLH1 germline mutations in HNPCC."; RL Hum. Mutat. 21:445-446(2003). RN [98] RP VARIANT CRC GLY-601. RX PubMed=12655564; DOI=10.1002/humu.9123; RA Chen-Shtoyerman R., Theodor L., Harmati E., Friedman E., Dacka S., RA Kopelman Y., Sternberg A., Zarivach R., Bar-Meir S., Fireman Z.; RT "Genetic analysis of familial colorectal cancer in Israeli Arabs."; RL Hum. Mutat. 21:446-447(2003). RN [99] RP VARIANTS LYNCH2 CYS-18; ASP-101; LYS-182; CYS-379; ARG-559 AND LYS-616 DEL. RX PubMed=14635101; DOI=10.1002/humu.10291; RA Taylor C.F., Charlton R.S., Burn J., Sheridan E., Taylor G.R.; RT "Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non- RT polyposis colorectal cancer: identification of novel and recurrent RT deletions by MLPA."; RL Hum. Mutat. 22:428-433(2003). RN [100] RP VARIANT LYNCH2 SER-648. RX PubMed=15139004; DOI=10.1002/gcc.20040; RA Raevaara T.E., Gerdes A.-M., Loennqvist K.E., Tybjaerg-Hansen A., RA Abdel-Rahman W.M., Kariola R., Peltomaeki P., Nystroem-Lahti M.; RT "HNPCC mutation MLH1 P648S makes the functional protein unstable, and RT homozygosity predisposes to mild neurofibromatosis type 1."; RL Genes Chromosomes Cancer 40:261-265(2004). RN [101] RP VARIANTS LYNCH2 CYS-217; GLY-282; LEU-542; PRO-542; PRO-549; PRO-574; RP PRO-636; SER-640 AND MET-724. RX PubMed=15365995; DOI=10.1002/humu.9277; RA Shin Y.-K., Heo S.-C., Shin J.-H., Hong S.-H., Ku J.-L., Yoo B.-C., RA Kim I.-J., Park J.-G.; RT "Germline mutations in MLH1, MSH2 and MSH6 in Korean hereditary non- RT polyposis colorectal cancer families."; RL Hum. Mutat. 24:351-351(2004). RN [102] RP ERRATUM OF PUBMED:15365995. RA Shin Y.K., Heo S.C., Shin J.H., Hong S.H., Ku J.L., Yoo B.C., Kim I.J., RA Park J.G.; RL Hum. Mutat. 25:224-224(2005). RN [103] RP VARIANTS LYNCH2 GLY-41 AND ASN-VAL-PHE-HIS-ILE-719 INS. RX PubMed=15365996; DOI=10.1002/humu.9278; RA Krueger S., Bier A., Plaschke J., Hoehl R., Aust D.E., Kreuz F.R., RA Pistorius S.R., Saeger H.D., Rothhammer V., Al-Taie O., Schackert H.K.; RT "Ten novel MSH2 and MLH1 germline mutations in families with HNPCC."; RL Hum. Mutat. 24:351-352(2004). RN [104] RP VARIANTS LYNCH2 VAL-21; ARG-67; ASN-68 AND LYS-616 DEL. RX PubMed=14961575; DOI=10.1002/ijc.11718; RA Cederquist K., Emanuelsson M., Goeransson I., Holinski-Feder E., RA Mueller-Koch Y., Golovleva I., Groenberg H.; RT "Mutation analysis of the MLH1, MSH2 and MSH6 genes in patients with double RT primary cancers of the colorectum and the endometrium: a population-based RT study in northern Sweden."; RL Int. J. Cancer 109:370-376(2004). RN [105] RP ERRATUM OF PUBMED:14961575. RA Cederquist K., Emanuelsson M., Goransson I., Holinski-Feder E., RA Muller-Koch Y., Golovleva I., Gronberg H.; RL Int. J. Cancer 115:1011-1011(2005). RN [106] RP INVOLVEMENT IN LYNCH2 BY EPIGENETIC INHERITANCE. RX PubMed=15064764; DOI=10.1038/ng1342; RA Suter C.M., Martin D.I.K., Ward R.L.; RT "Germline epimutation of MLH1 in individuals with multiple cancers."; RL Nat. Genet. 36:497-501(2004). RN [107] RP VARIANT HIS-132. RX PubMed=15184898; DOI=10.1038/ng1374; RA Lipkin S.M., Rozek L.S., Rennert G., Yang W., Chen P.-C., Hacia J., RA Hunt N., Shin B., Fodor S., Kokoris M., Greenson J.K., Fearon E., Lynch H., RA Collins F., Gruber S.B.; RT "The MLH1 D132H variant is associated with susceptibility to sporadic RT colorectal cancer."; RL Nat. Genet. 36:694-699(2004). RN [108] RP VARIANTS LYNCH2 LEU-28; 45-THR--PHE-47 DELINS CYS-PHE; GLU-63; ARG-67; RP GLU-71 DEL; ARG-77; VAL-80; GLU-84; ARG-107; ARG-155; GLY-185; PRO-247; RP PRO-329; ILE-330 DEL; PRO-550; ASP-589; VAL-612 DEL; LYS-616 DEL; LEU-648; RP SER-648; LEU-654 AND PRO-659, VARIANTS SER-29; GLY-93; GLN-443; ALA-618; RP CYS-646; GLN-659; THR-681 AND MET-716, CHARACTERIZATION OF VARIANTS LYNCH2 RP LEU-28; 45-THR--PHE-47 DELINS CYS-PHE; GLU-63; ARG-67; GLU-71 DEL; ARG-77; RP VAL-80; GLU-84; ARG-107; ARG-155; GLY-185; PRO-247; PRO-329; ILE-330 DEL; RP PRO-550; ASP-589; VAL-612 DEL; LYS-616 DEL; THR-618; LEU-648; SER-648; RP LEU-654 AND PRO-659, AND CHARACTERIZATION OF VARIANTS SER-29; GLY-93; RP MET-213; VAL-219; GLN-443; ALA-618; CYS-646; GLN-659; THR-681 AND MET-716. RX PubMed=16083711; DOI=10.1016/j.gastro.2005.06.005; RA Raevaara T.E., Korhonen M.K., Lohi H., Hampel H., Lynch E., RA Loennqvist K.E., Holinski-Feder E., Sutter C., McKinnon W., Duraisamy S., RA Gerdes A.-M., Peltomaeki P., Kohonen-Corish M., Mangold E., Macrae F., RA Greenblatt M., de la Chapelle A., Nystroem M.; RT "Functional significance and clinical phenotype of nontruncating mismatch RT repair variants of MLH1."; RL Gastroenterology 129:537-549(2005). RN [109] RP VARIANTS LYNCH2 LEU-28; LYS-35; ARG-67; VAL-111; MET-117; PRO-292; THR-441; RP LYS-618 DEL; PRO-623; ILE-657 DEL; THR-681; TRP-687 AND ARG-751. RX PubMed=16451135; DOI=10.1111/j.1399-0004.2006.00550.x; RA Kurzawski G., Suchy J., Lener M., Klujszo-Grabowska E., Kladny J., RA Safranow K., Jakubowska K., Jakubowska A., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Oszutowska D., RA Kowalska E., Gozdz S., Niepsuj S., Slomski R., Plawski A., RA Lacka-Wojciechowska A., Rozmiarek A., Fiszer-Maliszewska L., Bebenek M., RA Sorokin D., Sasiadek M.M., Stembalska A., Grzebieniak Z., Kilar E., RA Stawicka M., Godlewski D., Richter P., Brozek I., Wysocka B., Limon J., RA Jawien A., Banaszkiewicz Z., Janiszewska H., Kowalczyk J., Czudowska D., RA Scott R.J., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum including large rearrangements RT in HNPCC families from Poland (update study)."; RL Clin. Genet. 69:40-47(2006). RN [110] RP VARIANT MMRCS1 ASN-35. RX PubMed=17440981; DOI=10.1002/cncr.22697; RG Rotterdam initiative on gastrointestinal hereditary tumors; RA Poley J.-W., Wagner A., Hoogmans M.M.C.P., Menko F.H., Tops C., Kros J.M., RA Reddingius R.E., Meijers-Heijboer H., Kuipers E.J., Dinjens W.N.M.; RT "Biallelic germline mutations of mismatch-repair genes: a possible cause RT for multiple pediatric malignancies."; RL Cancer 109:2349-2356(2007). RN [111] RP VARIANTS LYNCH2 LYS-102 AND GLN-474. RX PubMed=17510385; DOI=10.1158/0008-5472.can-06-3509; RA Takahashi M., Shimodaira H., Andreutti-Zaugg C., Iggo R., Kolodner R.D., RA Ishioka C.; RT "Functional analysis of human MLH1 variants using yeast and in vitro RT mismatch repair assays."; RL Cancer Res. 67:4595-4604(2007). RN [112] RP INVOLVEMENT IN LYNCH2 BY GERMLINE EPIMUTATION. RX PubMed=17301300; DOI=10.1056/nejmoa064522; RA Hitchins M.P., Wong J.J.L., Suthers G., Suter C.M., Martin D.I.K., RA Hawkins N.J., Ward R.L.; RT "Inheritance of a cancer-associated MLH1 germ-line epimutation."; RL N. Engl. J. Med. 356:697-705(2007). RN [113] RP VARIANTS CRC GLU-67 AND THR-681, AND VARIANTS ALA-22; GLY-93; SER-309; RP ASN-406; HIS-607; ALA-618; ARG-689; MET-716; TYR-718 AND ARG-751. RX PubMed=18033691; DOI=10.1002/humu.20635; RA Barnetson R.A., Cartwright N., van Vliet A., Haq N., Drew K., RA Farrington S., Williams N., Warner J., Campbell H., Porteous M.E., RA Dunlop M.G.; RT "Classification of ambiguous mutations in DNA mismatch repair genes RT identified in a population-based study of colorectal cancer."; RL Hum. Mutat. 29:367-374(2008). RN [114] RP VARIANTS LYNCH2 HIS-41; SER-101; ILE-330 DEL; PRO-619 AND ARG-689, AND RP VARIANTS ARG-67; ARG-77; SER-98; ASP-101; LYS-116; MET-117; ASN-126; RP MET-213; SER-215; SER-216; PHE-260; CYS-265; HIS-265; ASP-320; ALA-326; RP ILE-330 DEL; TRP-474; GLN-474; ASP-539; PRO-549; THR-551; ARG-585; ARG-603; RP HIS-607; SER-640; LEU-640; VAL-655; SER-656; ARG-666 AND THR-681. RX PubMed=18561205; DOI=10.1002/humu.20796; RA Tournier I., Vezain M., Martins A., Charbonnier F., Baert-Desurmont S., RA Olschwang S., Wang Q., Buisine M.P., Soret J., Tazi J., Frebourg T., RA Tosi M.; RT "A large fraction of unclassified variants of the mismatch repair genes RT MLH1 and MSH2 is associated with splicing defects."; RL Hum. Mutat. 29:1412-1424(2008). RN [115] RP VARIANTS LYNCH2 CYS-233 DEL AND TRP-389, CHARACTERIZATION OF VARIANTS RP LYNCH2 LEU-28; LYS-37; HIS-38; LYS-38; PHE-44; ARG-67; PRO-109; PRO-111; RP MET-117; CYS-233 DEL; CYS-265; TRP-389; GLN-443; PRO-550; GLY-578; PHE-582; RP ASP-589; ALA-618; CYS-646; LEU-648; LEU-654; PRO-659 AND VAL-716 DEL, RP CHARACTERIZATION OF VARIANTS GLY-93; VAL-219; SER-403; ASN-406 AND MET-716, RP INTERACTION WITH PMS2, INTERACTION WITH EXO1, AND SUBCELLULAR LOCATION. RX PubMed=22753075; DOI=10.1002/humu.22153; RA Andersen S.D., Liberti S.E., Luetzen A., Drost M., Bernstein I., RA Nilbert M., Dominguez M., Nystroem M., Hansen T.V., Christoffersen J.W., RA Jaeger A.C., de Wind N., Nielsen F.C., Toerring P.M., Rasmussen L.J.; RT "Functional characterization of MLH1 missense variants identified in Lynch RT syndrome patients."; RL Hum. Mutat. 33:1647-1655(2012). RN [116] RP VARIANTS ARG-116; LEU-213; LEU-264; THR-423 AND HIS-725, AND RP CHARACTERIZATION OF VARIANTS ARG-116; LEU-213; LEU-264; THR-423 AND RP HIS-725. RX PubMed=28494185; DOI=10.1080/15384047.2017.1326439; RA Arora S., Huwe P.J., Sikder R., Shah M., Browne A.J., Lesh R., Nicolas E., RA Deshpande S., Hall M.J., Dunbrack R.L. Jr., Golemis E.A.; RT "Functional analysis of rare variants in mismatch repair proteins augments RT results from computation-based predictive methods."; RL Cancer Biol. Ther. 18:519-533(2017). CC -!- FUNCTION: Heterodimerizes with PMS2 to form MutL alpha, a component of CC the post-replicative DNA mismatch repair system (MMR). DNA repair is CC initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to CC a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. CC Assembly of the MutL-MutS-heteroduplex ternary complex in presence of CC RFC and PCNA is sufficient to activate endonuclease activity of PMS2. CC It introduces single-strand breaks near the mismatch and thus generates CC new entry points for the exonuclease EXO1 to degrade the strand CC containing the mismatch. DNA methylation would prevent cleavage and CC therefore assure that only the newly mutated DNA strand is going to be CC corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp CC loader subunits of DNA polymerase III, suggesting that it may play a CC role to recruit the DNA polymerase III to the site of the MMR. Also CC implicated in DNA damage signaling, a process which induces cell cycle CC arrest and can lead to apoptosis in case of major DNA damages. CC Heterodimerizes with MLH3 to form MutL gamma which plays a role in CC meiosis. {ECO:0000269|PubMed:16873062, ECO:0000269|PubMed:18206974, CC ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, CC ECO:0000269|PubMed:39032648, ECO:0000269|PubMed:9311737}. CC -!- SUBUNIT: Component of the DNA mismatch repair (MMR) complex composed at CC least of MSH2, MSH3, MSH6, PMS1 and MLH1 (PubMed:26300262). Heterodimer CC of MLH1 and PMS2 (MutL alpha), MLH1 and PMS1 (MutL beta) or MLH1 and CC MLH3 (MutL gamma). Forms a ternary complex with MutS alpha (MSH2-MSH6) CC or MutS beta (MSH2-MSH3). Part of the BRCA1-associated genome CC surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, CC ATM, BLM, PMS2 and the RAD50-MRE11-NBS1 protein complex CC (PubMed:10783165). This association could be a dynamic process changing CC throughout the cell cycle and within subnuclear domains CC (PubMed:10097147). Interacts with MCM9; the interaction recruits MLH1 CC to chromatin (PubMed:26300262). Interacts with MCM8 (PubMed:26300262). CC Interacts with PMS2; this interaction promotes MLH1 stability CC (PubMed:11427529, PubMed:22753075, PubMed:39032648). Interacts with CC MBD4 (PubMed:10097147). Interacts with EXO1 (PubMed:11427529, CC PubMed:11429708, PubMed:12414623, PubMed:14676842, PubMed:22753075). CC Interacts with MTMR15/FAN1 (PubMed:20603073). CC {ECO:0000269|PubMed:10097147, ECO:0000269|PubMed:10783165, CC ECO:0000269|PubMed:11427529, ECO:0000269|PubMed:11429708, CC ECO:0000269|PubMed:12414623, ECO:0000269|PubMed:14676842, CC ECO:0000269|PubMed:20603073, ECO:0000269|PubMed:22753075, CC ECO:0000269|PubMed:26300262, ECO:0000269|PubMed:39032648}. CC -!- INTERACTION: CC P40692; P63261: ACTG1; NbExp=6; IntAct=EBI-744248, EBI-351292; CC P40692; P07355: ANXA2; NbExp=6; IntAct=EBI-744248, EBI-352622; CC P40692; Q10567-3: AP1B1; NbExp=3; IntAct=EBI-744248, EBI-11978055; CC P40692; P63010-2: AP2B1; NbExp=8; IntAct=EBI-744248, EBI-11529439; CC P40692; Q9BX63: BRIP1; NbExp=21; IntAct=EBI-744248, EBI-3509650; CC P40692; Q9BX70: BTBD2; NbExp=3; IntAct=EBI-744248, EBI-710091; CC P40692; Q5JTZ5: C9orf152; NbExp=3; IntAct=EBI-744248, EBI-18560658; CC P40692; Q8NA61: CBY2; NbExp=6; IntAct=EBI-744248, EBI-741724; CC P40692; Q8NA61-2: CBY2; NbExp=11; IntAct=EBI-744248, EBI-11524851; CC P40692; Q8N5R6: CCDC33; NbExp=4; IntAct=EBI-744248, EBI-740841; CC P40692; Q96LY2-2: CCDC74B; NbExp=3; IntAct=EBI-744248, EBI-17967022; CC P40692; Q96GN5: CDCA7L; NbExp=4; IntAct=EBI-744248, EBI-5278764; CC P40692; O76039: CDKL5; NbExp=4; IntAct=EBI-744248, EBI-1752465; CC P40692; P07858: CTSB; NbExp=6; IntAct=EBI-744248, EBI-715062; CC P40692; P17661: DES; NbExp=6; IntAct=EBI-744248, EBI-1055572; CC P40692; Q9H0I2: ENKD1; NbExp=3; IntAct=EBI-744248, EBI-744099; CC P40692; Q86W67: FAM228A; NbExp=3; IntAct=EBI-744248, EBI-12958227; CC P40692; Q9Y247: FAM50B; NbExp=3; IntAct=EBI-744248, EBI-742802; CC P40692; Q86YD7: FAM90A1; NbExp=3; IntAct=EBI-744248, EBI-6658203; CC P40692; Q96NE9: FRMD6; NbExp=3; IntAct=EBI-744248, EBI-741729; CC P40692; Q96NE9-2: FRMD6; NbExp=4; IntAct=EBI-744248, EBI-13213391; CC P40692; Q16658: FSCN1; NbExp=7; IntAct=EBI-744248, EBI-351076; CC P40692; P11142: HSPA8; NbExp=2; IntAct=EBI-744248, EBI-351896; CC P40692; Q9ULR0: ISY1; NbExp=3; IntAct=EBI-744248, EBI-2557660; CC P40692; P52292: KPNA2; NbExp=9; IntAct=EBI-744248, EBI-349938; CC P40692; O15131: KPNA5; NbExp=3; IntAct=EBI-744248, EBI-540602; CC P40692; Q5T749: KPRP; NbExp=3; IntAct=EBI-744248, EBI-10981970; CC P40692; O95232-2: LUC7L3; NbExp=3; IntAct=EBI-744248, EBI-19157865; CC P40692; P43361: MAGEA8; NbExp=7; IntAct=EBI-744248, EBI-10182930; CC P40692; Q8WWY6: MBD3L1; NbExp=3; IntAct=EBI-744248, EBI-12516603; CC P40692; O95243-2: MBD4; NbExp=3; IntAct=EBI-744248, EBI-6448717; CC P40692; Q9UJA3: MCM8; NbExp=2; IntAct=EBI-744248, EBI-8756095; CC P40692; Q9NXL9: MCM9; NbExp=5; IntAct=EBI-744248, EBI-2804985; CC P40692; Q9UHC1: MLH3; NbExp=7; IntAct=EBI-744248, EBI-3893094; CC P40692; Q6PF18: MORN3; NbExp=3; IntAct=EBI-744248, EBI-9675802; CC P40692; P29372-4: MPG; NbExp=3; IntAct=EBI-744248, EBI-10695618; CC P40692; P20585: MSH3; NbExp=5; IntAct=EBI-744248, EBI-1164205; CC P40692; P15173: MYOG; NbExp=12; IntAct=EBI-744248, EBI-3906629; CC P40692; P60323-2: NANOS3; NbExp=3; IntAct=EBI-744248, EBI-18012223; CC P40692; Q9H3P2: NELFA; NbExp=3; IntAct=EBI-744248, EBI-5461341; CC P40692; Q14938-5: NFIX; NbExp=3; IntAct=EBI-744248, EBI-12024662; CC P40692; O00746: NME4; NbExp=3; IntAct=EBI-744248, EBI-744871; CC P40692; O15055: PER2; NbExp=3; IntAct=EBI-744248, EBI-1054296; CC P40692; P78356-2: PIP4K2B; NbExp=3; IntAct=EBI-744248, EBI-11532361; CC P40692; P54277: PMS1; NbExp=8; IntAct=EBI-744248, EBI-2893308; CC P40692; P54278: PMS2; NbExp=24; IntAct=EBI-744248, EBI-1162561; CC P40692; Q96KQ4: PPP1R13B; NbExp=3; IntAct=EBI-744248, EBI-1105153; CC P40692; Q6MZQ0: PRR5L; NbExp=3; IntAct=EBI-744248, EBI-1567866; CC P40692; P25786: PSMA1; NbExp=5; IntAct=EBI-744248, EBI-359352; CC P40692; P26045: PTPN3; NbExp=3; IntAct=EBI-744248, EBI-1047946; CC P40692; Q6NSI4: RADX; NbExp=9; IntAct=EBI-744248, EBI-8634209; CC P40692; Q5RL73: RBM48; NbExp=3; IntAct=EBI-744248, EBI-473821; CC P40692; Q86UC2: RSPH3; NbExp=3; IntAct=EBI-744248, EBI-6873025; CC P40692; Q6RVD6: SPATA8; NbExp=3; IntAct=EBI-744248, EBI-8635958; CC P40692; Q13813: SPTAN1; NbExp=6; IntAct=EBI-744248, EBI-351450; CC P40692; O95926: SYF2; NbExp=3; IntAct=EBI-744248, EBI-2557644; CC P40692; Q5VWN6: TASOR2; NbExp=6; IntAct=EBI-744248, EBI-745958; CC P40692; Q7Z6R9: TFAP2D; NbExp=5; IntAct=EBI-744248, EBI-11952651; CC P40692; Q08117-2: TLE5; NbExp=3; IntAct=EBI-744248, EBI-11741437; CC P40692; P62328: TMSB4X; NbExp=15; IntAct=EBI-744248, EBI-712598; CC P40692; Q96PP4: TSGA13; NbExp=3; IntAct=EBI-744248, EBI-12390276; CC P40692; Q01081: U2AF1; NbExp=3; IntAct=EBI-744248, EBI-632461; CC P40692; O94941: UBOX5; NbExp=7; IntAct=EBI-744248, EBI-751901; CC P40692; O75152: ZC3H11A; NbExp=8; IntAct=EBI-744248, EBI-748480; CC P40692; Q9NU63-3: ZFP57; NbExp=3; IntAct=EBI-744248, EBI-12879708; CC P40692; Q8TF47: ZFP90; NbExp=3; IntAct=EBI-744248, EBI-11419867; CC P40692; Q9UDW3: ZMAT5; NbExp=3; IntAct=EBI-744248, EBI-7850213; CC P40692; Q13360-2: ZNF177; NbExp=3; IntAct=EBI-744248, EBI-12272076; CC P40692; Q9UDV6: ZNF212; NbExp=3; IntAct=EBI-744248, EBI-1640204; CC P40692; Q6S9Z5: ZNF474; NbExp=3; IntAct=EBI-744248, EBI-17269964; CC P40692; Q6NX45: ZNF774; NbExp=3; IntAct=EBI-744248, EBI-10251462; CC P40692; P42843: SKP2; Xeno; NbExp=3; IntAct=EBI-744248, EBI-28370; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11429708, CC ECO:0000269|PubMed:14676842, ECO:0000269|PubMed:21120944, CC ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:30770470}. Chromosome CC {ECO:0000269|PubMed:26300262}. Note=Recruited to chromatin in a MCM9- CC dependent manner. {ECO:0000269|PubMed:26300262}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=P40692-1; Sequence=Displayed; CC Name=2; CC IsoId=P40692-2; Sequence=VSP_045201; CC Name=3; CC IsoId=P40692-3; Sequence=VSP_047023; CC -!- TISSUE SPECIFICITY: Colon, lymphocytes, breast, lung, spleen, testis, CC prostate, thyroid, gall bladder and heart. CC -!- PTM: Acetylated (PubMed:30770470). Deacetylated by HDAC6 which prevents CC the MutL alpha complex, formed by the MLH1-PMS2 heterodimer, from being CC recruited to the MutS alpha complex, formed by the MSH2-MSH6 CC heterodimer, leading to tolerance of DNA damage (PubMed:30770470). CC {ECO:0000269|PubMed:30770470}. CC -!- PTM: Ubiquitinated by UBR4; leading to proteasomal degradation. This CC ubiquitination is counteracted by the deubiquitinase USP5. CC {ECO:0000269|PubMed:39032648}. CC -!- DISEASE: Lynch syndrome 2 (LYNCH2) [MIM:609310]: A form of Lynch CC syndrome, an autosomal dominant disease associated with marked increase CC in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. Lynch syndrome is reported to be the most common CC form of inherited colorectal cancer in the Western world. Clinically, CC it is often divided into two subgroups. Type I is characterized by CC hereditary predisposition to colorectal cancer, a young age of onset, CC and carcinoma observed in the proximal colon. Type II is characterized CC by increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical Lynch syndrome is based on the CC Amsterdam criteria: 3 or more relatives affected by colorectal cancer, CC one a first degree relative of the other two; 2 or more generation CC affected; 1 or more colorectal cancers presenting before 50 years of CC age; exclusion of hereditary polyposis syndromes. The term 'suspected CC Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe CC families who do not or only partially fulfill the Amsterdam criteria, CC but in whom a genetic basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:10323887, ECO:0000269|PubMed:10375096, CC ECO:0000269|PubMed:10386556, ECO:0000269|PubMed:10413423, CC ECO:0000269|PubMed:10480359, ECO:0000269|PubMed:10598809, CC ECO:0000269|PubMed:10627141, ECO:0000269|PubMed:10660333, CC ECO:0000269|PubMed:10671064, ECO:0000269|PubMed:10713887, CC ECO:0000269|PubMed:10777691, ECO:0000269|PubMed:10882759, CC ECO:0000269|PubMed:11139242, ECO:0000269|PubMed:11427529, CC ECO:0000269|PubMed:11726306, ECO:0000269|PubMed:11748856, CC ECO:0000269|PubMed:11754112, ECO:0000269|PubMed:11781295, CC ECO:0000269|PubMed:11793442, ECO:0000269|PubMed:11839723, CC ECO:0000269|PubMed:11870161, ECO:0000269|PubMed:12095971, CC ECO:0000269|PubMed:12132870, ECO:0000269|PubMed:12200596, CC ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:12373605, CC ECO:0000269|PubMed:12655562, ECO:0000269|PubMed:12658575, CC ECO:0000269|PubMed:14635101, ECO:0000269|PubMed:14961575, CC ECO:0000269|PubMed:15064764, ECO:0000269|PubMed:15139004, CC ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:15365996, CC ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:16451135, CC ECO:0000269|PubMed:17301300, ECO:0000269|PubMed:17510385, CC ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:20020535, CC ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, CC ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8521398, CC ECO:0000269|PubMed:8566964, ECO:0000269|PubMed:8571956, CC ECO:0000269|PubMed:8574961, ECO:0000269|PubMed:8797773, CC ECO:0000269|PubMed:8872463, ECO:0000269|PubMed:8993976, CC ECO:0000269|PubMed:9048925, ECO:0000269|PubMed:9067757, CC ECO:0000269|PubMed:9218993, ECO:0000269|PubMed:9272156, CC ECO:0000269|PubMed:9298827, ECO:0000269|PubMed:9311737, CC ECO:0000269|PubMed:9326924, ECO:0000269|PubMed:9399661, CC ECO:0000269|PubMed:9559627, ECO:0000269|PubMed:9718327, CC ECO:0000269|PubMed:9833759, ECO:0000269|PubMed:9927034, CC ECO:0000269|Ref.5}. Note=The disease is caused by variants affecting CC the gene represented in this entry. CC -!- DISEASE: Mismatch repair cancer syndrome 1 (MMRCS1) [MIM:276300]: An CC autosomal recessive form of mismatch repair cancer syndrome, a CC childhood cancer predisposition syndrome encompassing a broad tumor CC spectrum. This includes hematological malignancies, central nervous CC system tumors, Lynch syndrome-associated malignancies such as CC colorectal tumors as well as multiple intestinal polyps, embryonic CC tumors and rhabdomyosarcoma. Multiple cafe-au-lait macules, a feature CC reminiscent of neurofibromatosis type 1, are often found as first CC manifestation of the underlying cancer. {ECO:0000269|PubMed:11427529, CC ECO:0000269|PubMed:17440981, ECO:0000269|PubMed:7661930}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Muir-Torre syndrome (MRTES) [MIM:158320]: Rare autosomal CC dominant disorder characterized by sebaceous neoplasms and visceral CC malignancy. {ECO:0000269|PubMed:8751876}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Note=Defects in MLH1 may contribute to lobular carcinoma in CC situ (LCIS), a non-invasive neoplastic disease of the breast. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. Note=Disease susceptibility is associated with CC variants affecting the gene represented in this entry. CC -!- DISEASE: Note=Some epigenetic changes can be transmitted unchanged CC through the germline (termed 'epigenetic inheritance'). Evidence that CC this mechanism occurs in humans is provided by the identification of CC individuals in whom 1 allele of the MLH1 gene is epigenetically CC silenced throughout the soma (implying a germline event). These CC individuals are affected by Lynch syndrome but does not have CC identifiable mutations in MLH1, even though it is silenced, which CC demonstrates that an epimutation can phenocopy a genetic disease. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:10598809, CC ECO:0000269|PubMed:10882759, ECO:0000269|PubMed:12132870, CC ECO:0000269|PubMed:12655564, ECO:0000269|PubMed:14504054, CC ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:8872463, CC ECO:0000269|PubMed:9032648, ECO:0000269|PubMed:9087566, CC ECO:0000269|PubMed:9611074}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the DNA mismatch repair MutL/HexB family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/149/MLH1"; CC -!- WEB RESOURCE: Name=Colon cancer gene variant databases MutL homolog 1 CC (E.coli) (MLH1); Note=Leiden Open Variation Database (LOVD); CC URL="https://databases.lovd.nl/shared/genes/MLH1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U07343; AAC50285.1; -; mRNA. DR EMBL; U07418; AAA17374.1; -; mRNA. DR EMBL; U40978; AAA82079.1; -; Genomic_DNA. DR EMBL; U40960; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40961; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40962; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40963; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40964; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40965; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40966; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40967; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40968; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40969; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40970; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40971; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40972; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40973; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40974; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40975; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40976; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40977; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U17857; AAA85687.1; -; Genomic_DNA. DR EMBL; U17839; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17840; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17841; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17842; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17843; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17844; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17845; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17846; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17847; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17848; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17849; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17851; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17852; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17853; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17854; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17855; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17856; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; AY217549; AAO22994.1; -; Genomic_DNA. DR EMBL; AK295359; BAG58325.1; -; mRNA. DR EMBL; AK298324; BAG60576.1; -; mRNA. DR EMBL; AK298583; BAG60773.1; -; mRNA. DR EMBL; AK316074; BAH14445.1; -; mRNA. DR EMBL; AK316264; BAH14635.1; -; mRNA. DR EMBL; AC006583; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC011816; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471055; EAW64483.1; -; Genomic_DNA. DR EMBL; BC006850; AAH06850.1; -; mRNA. DR CCDS; CCDS2663.1; -. [P40692-1] DR CCDS; CCDS54562.1; -. [P40692-3] DR CCDS; CCDS54563.1; -. [P40692-2] DR PIR; S43085; S43085. DR RefSeq; NP_000240.1; NM_000249.4. [P40692-1] DR RefSeq; NP_001161089.1; NM_001167617.3. [P40692-3] DR RefSeq; NP_001161090.1; NM_001167618.3. [P40692-2] DR RefSeq; NP_001161091.1; NM_001167619.3. [P40692-2] DR RefSeq; NP_001245200.1; NM_001258271.1. DR RefSeq; NP_001245202.1; NM_001258273.2. [P40692-2] DR RefSeq; NP_001245203.1; NM_001258274.3. [P40692-2] DR RefSeq; NP_001341544.1; NM_001354615.2. [P40692-2] DR RefSeq; NP_001341545.1; NM_001354616.2. [P40692-2] DR RefSeq; NP_001341546.1; NM_001354617.2. [P40692-2] DR RefSeq; NP_001341547.1; NM_001354618.2. [P40692-2] DR RefSeq; NP_001341548.1; NM_001354619.2. [P40692-2] DR RefSeq; NP_001341549.1; NM_001354620.2. [P40692-3] DR RefSeq; XP_047304109.1; XM_047448153.1. [P40692-2] DR RefSeq; XP_047304110.1; XM_047448154.1. [P40692-2] DR RefSeq; XP_047304111.1; XM_047448155.1. [P40692-2] DR RefSeq; XP_054202541.1; XM_054346566.1. [P40692-2] DR RefSeq; XP_054202542.1; XM_054346567.1. [P40692-2] DR RefSeq; XP_054202543.1; XM_054346568.1. [P40692-2] DR PDB; 3RBN; X-ray; 2.16 A; A/B=486-751. DR PDB; 4P7A; X-ray; 2.30 A; A=1-347. DR PDB; 5U5P; X-ray; 2.17 A; B/C=467-476. DR PDB; 6WBA; X-ray; 2.15 A; B/C=466-476. DR PDB; 6WBB; X-ray; 2.66 A; B/C=466-476. DR PDB; 6WBC; X-ray; 2.15 A; B=466-476. DR PDB; 7M60; X-ray; 2.30 A; B/C=466-476. DR PDBsum; 3RBN; -. DR PDBsum; 4P7A; -. DR PDBsum; 5U5P; -. DR PDBsum; 6WBA; -. DR PDBsum; 6WBB; -. DR PDBsum; 6WBC; -. DR PDBsum; 7M60; -. DR AlphaFoldDB; P40692; -. DR SMR; P40692; -. DR BioGRID; 110438; 261. DR ComplexPortal; CPX-9901; MutLalpha endonuclease complex. DR ComplexPortal; CPX-9941; MutLabeta endonuclease complex. DR ComplexPortal; CPX-9961; MutLgamma endonuclease complex. DR CORUM; P40692; -. DR DIP; DIP-27601N; -. DR FunCoup; P40692; 2633. DR IntAct; P40692; 232. DR MINT; P40692; -. DR STRING; 9606.ENSP00000231790; -. DR GlyCosmos; P40692; 1 site, 1 glycan. DR GlyGen; P40692; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P40692; -. DR MetOSite; P40692; -. DR PhosphoSitePlus; P40692; -. DR BioMuta; MLH1; -. DR DMDM; 730028; -. DR jPOST; P40692; -. DR MassIVE; P40692; -. DR PaxDb; 9606-ENSP00000231790; -. DR PeptideAtlas; P40692; -. DR ProteomicsDB; 19516; -. DR ProteomicsDB; 4266; -. DR ProteomicsDB; 55377; -. [P40692-1] DR Pumba; P40692; -. DR Antibodypedia; 4599; 923 antibodies from 47 providers. DR CPTC; P40692; 3 antibodies. DR DNASU; 4292; -. DR Ensembl; ENST00000231790.8; ENSP00000231790.3; ENSG00000076242.19. [P40692-1] DR Ensembl; ENST00000429117.6; ENSP00000407019.2; ENSG00000076242.19. [P40692-3] DR Ensembl; ENST00000435176.5; ENSP00000402564.1; ENSG00000076242.19. [P40692-3] DR Ensembl; ENST00000455445.6; ENSP00000398272.2; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000458205.6; ENSP00000402667.2; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000466900.6; ENSP00000519069.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000485889.2; ENSP00000518946.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000492474.6; ENSP00000518393.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000536378.5; ENSP00000444286.2; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000539477.6; ENSP00000443665.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000674019.1; ENSP00000501081.1; ENSG00000076242.19. [P40692-2] DR GeneID; 4292; -. DR KEGG; hsa:4292; -. DR MANE-Select; ENST00000231790.8; ENSP00000231790.3; NM_000249.4; NP_000240.1. DR UCSC; uc003cgl.4; human. [P40692-1] DR AGR; HGNC:7127; -. DR CIViC; 4292; 30 evidence items across 33 molecular profiles. DR ClinPGx; PA240; -. DR CTD; 4292; -. DR DisGeNET; 4292; -. DR GeneCards; MLH1; -. DR GeneReviews; MLH1; -. DR HGNC; HGNC:7127; MLH1. DR HPA; ENSG00000076242; Low tissue specificity. DR MalaCards; MLH1; -. DR MIM; 114500; phenotype. DR MIM; 120436; gene. DR MIM; 158320; phenotype. DR MIM; 276300; phenotype. DR MIM; 608089; phenotype. DR MIM; 609310; phenotype. DR OpenTargets; ENSG00000076242; -. DR Orphanet; 252202; Constitutional mismatch repair deficiency syndrome. DR Orphanet; 144; Lynch syndrome. DR VEuPathDB; HostDB:ENSG00000076242; -. DR eggNOG; KOG1979; Eukaryota. DR GeneTree; ENSGT00800000124177; -. DR InParanoid; P40692; -. DR OMA; ANYHVKK; -. DR OrthoDB; 10263226at2759; -. DR PAN-GO; P40692; 4 GO annotations based on evolutionary models. DR PhylomeDB; P40692; -. DR PathwayCommons; P40692; -. DR Reactome; R-HSA-5358565; Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha). DR Reactome; R-HSA-5358606; Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta). DR Reactome; R-HSA-5545483; Defective Mismatch Repair Associated With MLH1. DR Reactome; R-HSA-5632987; Defective Mismatch Repair Associated With PMS2. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-912446; Meiotic recombination. DR SignaLink; P40692; -. DR SIGNOR; P40692; -. DR Agora; ENSG00000076242; -. DR BioGRID-ORCS; 4292; 15 hits in 1172 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; MLH1; human. DR EvolutionaryTrace; P40692; -. DR GeneWiki; MLH1; -. DR GenomeRNAi; 4292; -. DR Pharos; P40692; Tbio. DR PRO; PR:P40692; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P40692; protein. DR Bgee; ENSG00000076242; Expressed in tibialis anterior and 210 other cell types or tissues. DR ExpressionAtlas; P40692; baseline and differential. DR GO; GO:0005712; C:chiasma; IEA:Ensembl. DR GO; GO:0005694; C:chromosome; ISS:UniProtKB. DR GO; GO:0005715; C:late recombination nodule; IEA:Ensembl. DR GO; GO:0001673; C:male germ cell nucleus; IEA:Ensembl. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0032389; C:MutLalpha complex; IBA:GO_Central. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0000795; C:synaptonemal complex; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016887; F:ATP hydrolysis activity; IBA:GO_Central. DR GO; GO:0140664; F:ATP-dependent DNA damage sensor activity; IEA:InterPro. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0008047; F:enzyme activator activity; IDA:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0032137; F:guanine/thymine mispair binding; IEA:Ensembl. DR GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; IEA:Ensembl. DR GO; GO:0016321; P:female meiosis chromosome segregation; IEA:Ensembl. DR GO; GO:0007129; P:homologous chromosome pairing at meiosis; IEA:Ensembl. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IEA:Ensembl. DR GO; GO:0045190; P:isotype switching; IEA:Ensembl. DR GO; GO:0007060; P:male meiosis chromosome segregation; IEA:Ensembl. DR GO; GO:0043060; P:meiotic metaphase I homologous chromosome alignment; IEA:Ensembl. DR GO; GO:0051257; P:meiotic spindle midzone assembly; IEA:Ensembl. DR GO; GO:0045141; P:meiotic telomere clustering; IEA:Ensembl. DR GO; GO:0006298; P:mismatch repair; IGI:MGI. DR GO; GO:0045950; P:negative regulation of mitotic recombination; IEA:Ensembl. DR GO; GO:0000289; P:nuclear-transcribed mRNA poly(A) tail shortening; IEA:Ensembl. DR GO; GO:0048477; P:oogenesis; IEA:Ensembl. DR GO; GO:0048298; P:positive regulation of isotype switching to IgA isotypes; IEA:Ensembl. DR GO; GO:0048304; P:positive regulation of isotype switching to IgG isotypes; IEA:Ensembl. DR GO; GO:0000712; P:resolution of meiotic recombination intermediates; IEA:Ensembl. DR GO; GO:0009617; P:response to bacterium; IEA:Ensembl. DR GO; GO:0016446; P:somatic hypermutation of immunoglobulin genes; IBA:GO_Central. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR CDD; cd16926; HATPase_MutL-MLH-PMS-like; 1. DR CDD; cd03483; MutL_Trans_MLH1; 1. DR DisProt; DP03062; -. DR FunFam; 3.30.230.10:FF:000014; DNA mismatch repair protein Mlh1; 1. DR FunFam; 3.30.565.10:FF:000034; DNA mismatch repair protein mlh1, putative; 1. DR Gene3D; 3.30.230.10; -; 1. DR Gene3D; 3.30.565.10; Histidine kinase-like ATPase, C-terminal domain; 1. DR InterPro; IPR014762; DNA_mismatch_repair_CS. DR InterPro; IPR013507; DNA_mismatch_S5_2-like. DR InterPro; IPR036890; HATPase_C_sf. DR InterPro; IPR032189; Mlh1_C. DR InterPro; IPR002099; MutL/Mlh/PMS. DR InterPro; IPR038973; MutL/Mlh/Pms-like. DR InterPro; IPR020568; Ribosomal_Su5_D2-typ_SF. DR InterPro; IPR014721; Ribsml_uS5_D2-typ_fold_subgr. DR NCBIfam; TIGR00585; mutl; 1. DR PANTHER; PTHR10073; DNA MISMATCH REPAIR PROTEIN MLH, PMS, MUTL; 1. DR PANTHER; PTHR10073:SF12; DNA MISMATCH REPAIR PROTEIN MLH1; 1. DR Pfam; PF01119; DNA_mis_repair; 1. DR Pfam; PF13589; HATPase_c_3; 1. DR Pfam; PF16413; Mlh1_C; 1. DR SMART; SM01340; DNA_mis_repair; 1. DR SUPFAM; SSF55874; ATPase domain of HSP90 chaperone/DNA topoisomerase II/histidine kinase; 1. DR SUPFAM; SSF54211; Ribosomal protein S5 domain 2-like; 1. DR PROSITE; PS00058; DNA_MISMATCH_REPAIR_1; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; Cell cycle; KW Chromosome; Disease variant; DNA damage; DNA repair; KW Hereditary nonpolyposis colorectal cancer; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22223895" FT CHAIN 2..756 FT /note="DNA mismatch repair protein Mlh1" FT /id="PRO_0000178000" FT REGION 355..378 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 400..491 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 410..650 FT /note="Interaction with EXO1" FT /evidence="ECO:0000269|PubMed:11427529, FT ECO:0000269|PubMed:11429708, ECO:0000269|PubMed:12414623, FT ECO:0000269|PubMed:14676842, ECO:0000269|PubMed:22753075" FT MOTIF 471..474 FT /note="Nuclear localization signal" FT /evidence="ECO:0000269|PubMed:29175432" FT COMPBIAS 362..375 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 443..457 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 38 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT BINDING 63 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT BINDING 82..84 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT BINDING 100..104 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:22223895" FT MOD_RES 33 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 241 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 361 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 377 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 477 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT VAR_SEQ 1..241 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045201" FT VAR_SEQ 1..101 FT /note="MSFVAGVIRRLDETVVNRIAAGEVIQRPANAIKEMIENCLDAKSTSIQVIVK FT EGGLKLIQIQDNGTGIRKEDLDIVCERFTTSKLQSFEDLASISTYGFRG -> MAF FT (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_047023" FT VARIANT 18 FT /note="R -> C (in LYNCH2; dbSNP:rs367654552)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022663" FT VARIANT 19 FT /note="I -> F (in LYNCH2; dbSNP:rs63750648)" FT /evidence="ECO:0000269|PubMed:12362047" FT /id="VAR_043383" FT VARIANT 21 FT /note="A -> V (in LYNCH2; dbSNP:rs63750706)" FT /evidence="ECO:0000269|PubMed:14961575" FT /id="VAR_043384" FT VARIANT 22 FT /note="G -> A (in dbSNP:rs41295280)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038023" FT VARIANT 25 FT /note="I -> F (in LYNCH2; dbSNP:rs63749838)" FT /evidence="ECO:0000269|PubMed:10386556" FT /id="VAR_043385" FT VARIANT 28 FT /note="P -> L (in LYNCH2; loss of protein expression; FT normal interaction with PMS2 and EXO1; decreased mismatch FT repair activity; no effect on nuclear localization; FT dbSNP:rs63750792)" FT /evidence="ECO:0000269|PubMed:10323887, FT ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9298827" FT /id="VAR_004433" FT VARIANT 29 FT /note="A -> S (in LYNCH2; uncertain significance; acts FT functionally like the wild-type protein; dbSNP:rs63750656)" FT /evidence="ECO:0000269|PubMed:12658575, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_043386" FT VARIANT 31 FT /note="A -> C (in LYNCH2; decreased mismatch repair FT activity; requires 2 nucleotide substitutions; FT dbSNP:rs63749994)" FT /evidence="ECO:0000269|PubMed:20020535" FT /id="VAR_076338" FT VARIANT 32 FT /note="I -> V (in dbSNP:rs2020872)" FT /evidence="ECO:0000269|Ref.5" FT /id="VAR_014876" FT VARIANT 35 FT /note="M -> K (in LYNCH2; uncertain significance; FT dbSNP:rs63749906)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043387" FT VARIANT 35 FT /note="M -> N (in MMRCS1; requires 2 nucleotide FT substitutions; dbSNP:rs121912965)" FT /evidence="ECO:0000269|PubMed:12373605, FT ECO:0000269|PubMed:17440981" FT /id="VAR_043388" FT VARIANT 35 FT /note="M -> R (in LYNCH2; dbSNP:rs63749906)" FT /evidence="ECO:0000269|PubMed:8521398" FT /id="VAR_004434" FT VARIANT 37 FT /note="E -> ELNH (found in an endometrial cancer sample; FT somatic mutation)" FT /id="VAR_004435" FT VARIANT 37 FT /note="E -> K (in LYNCH2; decreased mismatch repair FT activity; loss of nuclear localization; dbSNP:rs63751012)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076339" FT VARIANT 38 FT /note="N -> H (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs63750580)" FT /evidence="ECO:0000269|PubMed:12373605, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:22753075" FT /id="VAR_043389" FT VARIANT 38 FT /note="N -> K (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs267607706)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076340" FT VARIANT 41 FT /note="D -> G (in LYNCH2; dbSNP:rs63751094)" FT /evidence="ECO:0000269|PubMed:15365996" FT /id="VAR_043390" FT VARIANT 41 FT /note="D -> H (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607713)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054522" FT VARIANT 44 FT /note="S -> F (in LYNCH2; no effect on MLH1 splicing; loss FT of mismatch repair activity; dbSNP:rs63751109)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9326924" FT /id="VAR_004436" FT VARIANT 45..47 FT /note="TSI -> CF (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_043391" FT VARIANT 54 FT /note="G -> E (in CRC; sporadic; somatic mutation; FT uncertain significance; dbSNP:rs63751267)" FT /evidence="ECO:0000269|PubMed:9087566" FT /id="VAR_012902" FT VARIANT 62 FT /note="Q -> K (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63751428)" FT /evidence="ECO:0000269|PubMed:9311737" FT /id="VAR_004437" FT VARIANT 63 FT /note="D -> E (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; dbSNP:rs587778955)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043392" FT VARIANT 64 FT /note="N -> S (in LYNCH2; dbSNP:rs63750952)" FT /evidence="ECO:0000269|PubMed:9311737" FT /id="VAR_004438" FT VARIANT 67 FT /note="G -> E (in CRC; dbSNP:rs63749939)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038024" FT VARIANT 67 FT /note="G -> R (in LYNCH2; no effect on MLH1 splicing; FT decreased mismatch repair activity; loss of protein FT expression; loss of nuclear localization; FT dbSNP:rs63750206)" FT /evidence="ECO:0000269|PubMed:10375096, FT ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:14961575, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9067757, ECO:0000269|PubMed:9833759" FT /id="VAR_004439" FT VARIANT 67 FT /note="G -> W (in LYNCH2; dbSNP:rs63750206)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:9927034" FT /id="VAR_012903" FT VARIANT 68 FT /note="I -> N (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750281)" FT /evidence="ECO:0000269|PubMed:14961575" FT /id="VAR_004440" FT VARIANT 69 FT /note="R -> K (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63751661)" FT /evidence="ECO:0000269|PubMed:10627141" FT /id="VAR_004441" FT VARIANT 71 FT /note="Missing (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043393" FT VARIANT 77 FT /note="C -> R (in LYNCH2; decreased mismatch repair FT activity; loss of nuclear localization; normal interaction FT with PMS2; dbSNP:rs63749859)" FT /evidence="ECO:0000269|PubMed:10660333, FT ECO:0000269|PubMed:11793442, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944" FT /id="VAR_004442" FT VARIANT 77 FT /note="C -> Y (in CRC; sporadic; early onset; FT dbSNP:rs63750437)" FT /evidence="ECO:0000269|PubMed:9032648" FT /id="VAR_012904" FT VARIANT 80 FT /note="F -> V (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63749990)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_012905" FT VARIANT 84 FT /note="K -> E (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750641)" FT /evidence="ECO:0000269|PubMed:10323887, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_012906" FT VARIANT 93 FT /note="S -> G (normal interaction with PMS2; no decrease in FT mismatch repair activity; no effect on nuclear FT localization; dbSNP:rs41295282)" FT /evidence="ECO:0000269|PubMed:10671064, FT ECO:0000269|PubMed:11793442, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075" FT /id="VAR_004443" FT VARIANT 98 FT /note="G -> S (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607725)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054523" FT VARIANT 101 FT /note="G -> D (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607727)" FT /evidence="ECO:0000269|PubMed:14635101, FT ECO:0000269|PubMed:18561205" FT /id="VAR_022664" FT VARIANT 101 FT /note="G -> S (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607726)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054524" FT VARIANT 102 FT /note="E -> K (in LYNCH2; dbSNP:rs63750453)" FT /evidence="ECO:0000269|PubMed:17510385" FT /id="VAR_043394" FT VARIANT 106 FT /note="S -> R (in gastric cancer; uncertain significance; FT dbSNP:rs63750297)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043395" FT VARIANT 107 FT /note="I -> R (in LYNCH2; decreased mismatch repair FT activity; normal interaction with PMS2; loss of protein FT expression; loss of nuclear localization; FT dbSNP:rs63750507)" FT /evidence="ECO:0000269|PubMed:11793442, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_004444" FT VARIANT 109 FT /note="H -> P (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs587779004)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076341" FT VARIANT 109 FT /note="H -> Q (in gastric cancer; uncertain significance; FT dbSNP:rs63749803)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043396" FT VARIANT 111 FT /note="A -> P (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs587779005)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076342" FT VARIANT 111 FT /note="A -> V (in LYNCH2; dbSNP:rs63750539)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:16451135" FT /id="VAR_012907" FT VARIANT 116 FT /note="T -> K (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs63750465)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054525" FT VARIANT 116 FT /note="T -> R (no effect on protein expression; FT dbSNP:rs63750465)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079812" FT VARIANT 117 FT /note="T -> M (in LYNCH2; decreased mismatch repair FT activity; no effect on MLH1 splicing; fails to interact FT with PMS2 and EXO1; loss of nuclear localization; FT dbSNP:rs63750781)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:11429708, ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:12200596, ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:12373605, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:8566964" FT /id="VAR_004445" FT VARIANT 117 FT /note="T -> R (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750781)" FT /evidence="ECO:0000269|PubMed:10375096" FT /id="VAR_004446" FT VARIANT 126 FT /note="Y -> N (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs200076893)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054526" FT VARIANT 128 FT /note="A -> P (in LYNCH2; dbSNP:rs63750866)" FT /evidence="ECO:0000269|PubMed:9218993" FT /id="VAR_012908" FT VARIANT 132 FT /note="D -> H (decreased but not abolished ATPase activity; FT dbSNP:rs28930073)" FT /evidence="ECO:0000269|PubMed:15184898" FT /id="VAR_022665" FT VARIANT 155 FT /note="L -> R (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; dbSNP:rs63750891)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043397" FT VARIANT 182 FT /note="R -> G (in LYNCH2; incomplete; dbSNP:rs63750211)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:9399661" FT /id="VAR_012909" FT VARIANT 182 FT /note="R -> K (in LYNCH2; dbSNP:rs587779021)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022666" FT VARIANT 185 FT /note="V -> G (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; no effect on MLH1 splicing; FT dbSNP:rs63750515)" FT /evidence="ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_004447" FT VARIANT 185 FT /note="V -> L (in LYNCH2; uncertain significance; FT dbSNP:rs63750012)" FT /evidence="ECO:0000269|PubMed:12658575" FT /id="VAR_043398" FT VARIANT 193 FT /note="S -> P (in LYNCH2; dbSNP:rs63751021)" FT /evidence="ECO:0000269|PubMed:10660333" FT /id="VAR_004448" FT VARIANT 213 FT /note="V -> L (no effect on protein expression; FT dbSNP:rs2308317)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079813" FT VARIANT 213 FT /note="V -> M (no effect on MLH1 splicing; FT dbSNP:rs2308317)" FT /evidence="ECO:0000269|PubMed:10713887, FT ECO:0000269|PubMed:11839723, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944, FT ECO:0000269|Ref.5" FT /id="VAR_012910" FT VARIANT 215 FT /note="N -> S (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607775)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054527" FT VARIANT 216 FT /note="I -> S (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607776)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054528" FT VARIANT 217 FT /note="R -> C (in LYNCH2; uncertain significance; no FT decrease in mismatch repair activity; dbSNP:rs4986984)" FT /evidence="ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:8797773, FT ECO:0000269|PubMed:9559627" FT /id="VAR_004449" FT VARIANT 217 FT /note="R -> G (in dbSNP:rs4986984)" FT /id="VAR_020469" FT VARIANT 219 FT /note="I -> V (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs1799977)" FT /evidence="ECO:0000269|PubMed:10375096, FT ECO:0000269|PubMed:10777691, ECO:0000269|PubMed:11754112, FT ECO:0000269|PubMed:11781295, ECO:0000269|PubMed:12115348, FT ECO:0000269|PubMed:12200596, ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9032648, ECO:0000269|PubMed:9067757, FT ECO:0000269|PubMed:9087566, ECO:0000269|PubMed:9218993, FT ECO:0000269|PubMed:9833759, ECO:0000269|Ref.5" FT /id="VAR_004450" FT VARIANT 226..295 FT /note="Missing (in LYNCH2)" FT /id="VAR_004452" FT VARIANT 226 FT /note="R -> L (in LYNCH2; dbSNP:rs63751711)" FT /evidence="ECO:0000269|PubMed:8566964" FT /id="VAR_004451" FT VARIANT 233 FT /note="Missing (in LYNCH2; loss of nuclear localization)" FT /evidence="ECO:0000269|PubMed:22753075" FT /id="VAR_076343" FT VARIANT 234 FT /note="E -> G (in LYNCH2; uncertain significance; FT dbSNP:rs63750696)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043399" FT VARIANT 244 FT /note="G -> D (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750303)" FT /evidence="ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:9218993" FT /id="VAR_012911" FT VARIANT 244 FT /note="G -> V (in CRC; sporadic; somatic mutation; FT uncertain significance; dbSNP:rs63750303)" FT /evidence="ECO:0000269|PubMed:9087566" FT /id="VAR_012912" FT VARIANT 247 FT /note="S -> P (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; dbSNP:rs63750948)" FT /evidence="ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_043400" FT VARIANT 260 FT /note="L -> F (in LYNCH2; uncertain significance; no effect FT on MLH1 splicing; dbSNP:rs63750642)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054529" FT VARIANT 260 FT /note="L -> R (in CRC; dbSNP:rs63751283)" FT /evidence="ECO:0000269|PubMed:10882759" FT /id="VAR_043401" FT VARIANT 262 FT /note="Missing (in LYNCH2)" FT /evidence="ECO:0000269|PubMed:9833759" FT /id="VAR_012913" FT VARIANT 264 FT /note="H -> L (no effect on protein expression; FT dbSNP:rs63751664)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079814" FT VARIANT 264 FT /note="H -> Y (in LYNCH2; dbSNP:rs63751597)" FT /evidence="ECO:0000269|PubMed:10413423" FT /id="VAR_043402" FT VARIANT 265 FT /note="R -> C (in LYNCH2; results in partial MLH1 exon 10 FT skipping on ex vivo splicing assay; decreased mismatch FT repair activity; no effect on nuclear localization; FT dbSNP:rs63751194)" FT /evidence="ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:22753075" FT /id="VAR_054530" FT VARIANT 265 FT /note="R -> H (risk factor for LYNCH2; results in partial FT MLH1 exon 10 skipping on ex vivo splicing assay; decreased FT mismatch repair activity; dbSNP:rs63751448)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11781295, ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:8993976" FT /id="VAR_012914" FT VARIANT 265 FT /note="R -> S (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63751194)" FT /evidence="ECO:0000269|PubMed:20020535" FT /id="VAR_076344" FT VARIANT 268 FT /note="E -> G (in CRC; benign; dbSNP:rs63750650)" FT /evidence="ECO:0000269|PubMed:9611074" FT /id="VAR_012915" FT VARIANT 282 FT /note="A -> G (in LYNCH2; likely benign; dbSNP:rs63750360)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043403" FT VARIANT 292 FT /note="L -> P (in LYNCH2; uncertain significance; FT dbSNP:rs63750517)" FT /evidence="ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16451135" FT /id="VAR_043404" FT VARIANT 295 FT /note="S -> T (in LYNCH2; uncertain significance; FT dbSNP:rs63750144)" FT /evidence="ECO:0000269|PubMed:9399661" FT /id="VAR_012916" FT VARIANT 304 FT /note="D -> V (in LYNCH2; dbSNP:rs63750993)" FT /evidence="ECO:0000269|PubMed:10882759" FT /id="VAR_043405" FT VARIANT 309 FT /note="P -> S (in dbSNP:rs267607808)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038025" FT VARIANT 320 FT /note="E -> D (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607811)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054531" FT VARIANT 321 FT /note="S -> I (in LYNCH2; uncertain significance; FT dbSNP:rs63750286)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043406" FT VARIANT 325..327 FT /note="Missing (in CRC)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043407" FT VARIANT 325 FT /note="R -> Q (in dbSNP:rs63750268)" FT /evidence="ECO:0000269|PubMed:9087566" FT /id="VAR_012917" FT VARIANT 326 FT /note="V -> A (in LYNCH2; benign; no decrease in mismatch FT repair activity; dbSNP:rs63751049)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11781295, ECO:0000269|PubMed:18561205" FT /id="VAR_004453" FT VARIANT 329 FT /note="H -> P (in LYNCH2; loss of protein expression; loss FT of nuclear localization; dbSNP:rs63750710)" FT /evidence="ECO:0000269|PubMed:10323887, FT ECO:0000269|PubMed:11726306, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:9272156" FT /id="VAR_012918" FT VARIANT 330 FT /note="Missing (in LYNCH2; results in weak MLH1 exon 11 FT skipping on ex vivo splicing assay; decreased mismatch FT repair activity; loss of protein expression; loss of FT nuclear localization; dbSNP:rs63751197)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944" FT /id="VAR_043408" FT VARIANT 338 FT /note="N -> S (in LYNCH2; dbSNP:rs63751467)" FT /evidence="ECO:0000269|PubMed:12095971" FT /id="VAR_043409" FT VARIANT 379 FT /note="Y -> C (in LYNCH2; dbSNP:rs143009528)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022667" FT VARIANT 384 FT /note="V -> D (probable risk factor for HNPCC in some FT populations; dbSNP:rs63750447)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:8609062, ECO:0000269|PubMed:9526167" FT /id="VAR_004454" FT VARIANT 385 FT /note="R -> C (in LYNCH2; uncertain significance; FT dbSNP:rs63750760)" FT /evidence="ECO:0000269|PubMed:11839723" FT /id="VAR_043410" FT VARIANT 385 FT /note="R -> P (in LYNCH2; uncertain significance; FT dbSNP:rs63750430)" FT /evidence="ECO:0000269|PubMed:10573010" FT /id="VAR_043411" FT VARIANT 389 FT /note="R -> W (in LYNCH2; uncertain significance; no effect FT on nuclear localization; normal interaction with PMS2 and FT EXO1; dbSNP:rs61751644)" FT /evidence="ECO:0000269|PubMed:22753075" FT /id="VAR_076345" FT VARIANT 403 FT /note="P -> S (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs587778897)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076346" FT VARIANT 406 FT /note="S -> N (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs41294980)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9087566" FT /id="VAR_012919" FT VARIANT 423 FT /note="R -> T (no effect on protein expression; FT dbSNP:rs370687064)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079815" FT VARIANT 441 FT /note="A -> T (in LYNCH2; benign; dbSNP:rs63750365)" FT /evidence="ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:9326924" FT /id="VAR_012920" FT VARIANT 443 FT /note="K -> Q (in LYNCH2; uncertain significance; no FT decrease in mismatch repair activity; no effect on nuclear FT localization; dbSNP:rs34213726)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075" FT /id="VAR_043412" FT VARIANT 460 FT /note="E -> A (in LYNCH2; uncertain significance; FT dbSNP:rs202038499)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076347" FT VARIANT 472 FT /note="R -> I (in CRC; uncertain significance; FT dbSNP:rs63750498)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043413" FT VARIANT 474 FT /note="R -> Q (in LYNCH2; uncertain significance; FT dbSNP:rs63751083)" FT /evidence="ECO:0000269|PubMed:17510385, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043414" FT VARIANT 474 FT /note="R -> W (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs147939838)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054532" FT VARIANT 485 FT /note="D -> E (in LYNCH2; dbSNP:rs63750956)" FT /evidence="ECO:0000269|PubMed:10375096" FT /id="VAR_043415" FT VARIANT 485 FT /note="D -> H (in LYNCH2; uncertain significance; FT dbSNP:rs63750314)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043416" FT VARIANT 492 FT /note="A -> T (in LYNCH2; also found in sporadic colorectal FT cancer; dbSNP:rs63751145)" FT /evidence="ECO:0000269|PubMed:8872463" FT /id="VAR_004455" FT VARIANT 506 FT /note="V -> A (in LYNCH2; dbSNP:rs63749909)" FT /evidence="ECO:0000269|PubMed:8574961" FT /id="VAR_004456" FT VARIANT 539 FT /note="A -> D (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607843)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054533" FT VARIANT 542 FT /note="Q -> L (in LYNCH2; type II; decreased mismatch FT repair activity; dbSNP:rs63750511)" FT /evidence="ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8797773" FT /id="VAR_004457" FT VARIANT 542 FT /note="Q -> P (in LYNCH2; dbSNP:rs63750511)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043417" FT VARIANT 549 FT /note="L -> P (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs63750289)" FT /evidence="ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:8797773" FT /id="VAR_012921" FT VARIANT 550 FT /note="L -> P (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2 and EXO1; loss FT of protein expression; may lose nuclear localization; FT dbSNP:rs63750193)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075" FT /id="VAR_043418" FT VARIANT 551 FT /note="N -> T (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs63750271)" FT /evidence="ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:9399661, ECO:0000269|PubMed:9833759" FT /id="VAR_012922" FT VARIANT 559 FT /note="L -> R (in LYNCH2; uncertain significance; FT dbSNP:rs63750059)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022668" FT VARIANT 565 FT /note="I -> F (in LYNCH2; dbSNP:rs63750062)" FT /evidence="ECO:0000269|PubMed:9833759" FT /id="VAR_012923" FT VARIANT 574 FT /note="L -> P (in LYNCH2; type I; abrogates interaction FT with EXO1; loss of protein expression; dbSNP:rs63751608)" FT /evidence="ECO:0000269|PubMed:11427529, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:39032648, FT ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8797773" FT /id="VAR_004458" FT VARIANT 578..632 FT /note="Missing (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076348" FT VARIANT 578 FT /note="E -> G (in LYNCH2 and CRC; benign; no decrease in FT mismatch repair activity; no effect on nuclear FT localization; dbSNP:rs63751612)" FT /evidence="ECO:0000269|PubMed:10598809, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:22753075" FT /id="VAR_004459" FT VARIANT 582 FT /note="L -> F (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs63751713)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076349" FT VARIANT 582 FT /note="L -> V (in LYNCH2; type II; dbSNP:rs63751713)" FT /evidence="ECO:0000269|PubMed:7757073" FT /id="VAR_004460" FT VARIANT 585 FT /note="L -> R (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607865)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054534" FT VARIANT 586 FT /note="A -> P (in LYNCH2; dbSNP:rs63751176)" FT /evidence="ECO:0000269|PubMed:12655562" FT /id="VAR_015689" FT VARIANT 588 FT /note="L -> P (in LYNCH2; dbSNP:rs63750575)" FT /evidence="ECO:0000269|PubMed:10777691" FT /id="VAR_012924" FT VARIANT 589 FT /note="A -> D (in LYNCH2; decreased mismatch repair FT activity; loss of interaction with PMS2 and EXO1; loss of FT protein expression; may lose nuclear localization; FT dbSNP:rs63750016)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:39032648" FT /id="VAR_043419" FT VARIANT 596 FT /note="Missing (in LYNCH2)" FT /id="VAR_043420" FT VARIANT 601 FT /note="D -> G (in CRC; uncertain significance; FT dbSNP:rs63750718)" FT /evidence="ECO:0000269|PubMed:12655564" FT /id="VAR_043421" FT VARIANT 603 FT /note="P -> R (in LYNCH2; likely benign; no effect on MLH1 FT splicing; dbSNP:rs63750876)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:12095971, ECO:0000269|PubMed:18561205" FT /id="VAR_012925" FT VARIANT 607 FT /note="L -> H (in LYNCH2; likely benign; no effect on MLH1 FT splicing; dbSNP:rs41295284)" FT /evidence="ECO:0000269|PubMed:10713887, FT ECO:0000269|PubMed:11369138, ECO:0000269|PubMed:11839723, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:18561205" FT /id="VAR_012926" FT VARIANT 612 FT /note="Missing (in LYNCH2; loss of protein expression; loss FT of nuclear localization)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043422" FT VARIANT 616 FT /note="Missing (in LYNCH2 and MMRCS1; abrogates interaction FT with EXO1; loss of protein expression; loss of nuclear FT localization; no effect on MLH1 splicing)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:11427529, ECO:0000269|PubMed:14635101, FT ECO:0000269|PubMed:14961575, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:7661930, FT ECO:0000269|PubMed:8571956, ECO:0000269|PubMed:8872463, FT ECO:0000269|PubMed:8993976, ECO:0000269|PubMed:9311737" FT /id="VAR_004461" FT VARIANT 618 FT /note="K -> A (in LYNCH2; benign; interacts weakly with FT PMS2; no decrease in mismatch repair activity; no effect on FT nuclear localization; requires 2 nucleotide substitutions; FT dbSNP:rs35502531)" FT /evidence="ECO:0000269|PubMed:10598809, FT ECO:0000269|PubMed:10713887, ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:11870161, ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:12373605, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004462" FT VARIANT 618 FT /note="K -> R (in CRC; likely benign; dbSNP:rs63750449)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043424" FT VARIANT 618 FT /note="K -> T (in LYNCH2; benign; type II; loss of nuclear FT localization; dbSNP:rs63750449)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11839723, ECO:0000269|PubMed:12095971, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8872463" FT /id="VAR_004463" FT VARIANT 618 FT /note="Missing (in LYNCH2; dbSNP:rs63751247)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043423" FT VARIANT 619 FT /note="A -> P (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607866)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054535" FT VARIANT 622 FT /note="L -> H (in LYNCH2; dbSNP:rs63750693)" FT /evidence="ECO:0000269|PubMed:11748856" FT /id="VAR_012927" FT VARIANT 623 FT /note="A -> P (in LYNCH2; uncertain significance; FT dbSNP:rs587778951)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043425" FT VARIANT 626..627 FT /note="FS -> ST (in LYNCH2)" FT /evidence="ECO:0000269|PubMed:9048925" FT /id="VAR_004464" FT VARIANT 631 FT /note="D -> A (in LYNCH2; uncertain significance; FT dbSNP:rs63750240)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043426" FT VARIANT 633..663 FT /note="Missing (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2; loss of FT protein expression; loss of nuclear localization)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076350" FT VARIANT 635 FT /note="N -> K (in gastric cancer; uncertain significance; FT dbSNP:rs63751047)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043427" FT VARIANT 636 FT /note="L -> P (in LYNCH2; dbSNP:rs63750825)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043428" FT VARIANT 640 FT /note="P -> L (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607875)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054536" FT VARIANT 640 FT /note="P -> S (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs63749792)" FT /evidence="ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043429" FT VARIANT 646 FT /note="Y -> C (in LYNCH2; defective in interaction with FT PMS2 and EXO1; no decrease in mismatch repair activity; FT dbSNP:rs35045067)" FT /evidence="ECO:0000269|PubMed:11870161, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075" FT /id="VAR_043430" FT VARIANT 648 FT /note="P -> L (in LYNCH2; defective in interaction with FT PMS2 and EXO1; may lose nuclear localization; loss of FT protein expression; no decrease in mismatch repair FT activity; dbSNP:rs63750610)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075" FT /id="VAR_012928" FT VARIANT 648 FT /note="P -> S (in LYNCH2; the protein is unstable; loss of FT nuclear localization; loss of protein expression; no FT decrease in mismatch repair activity; dbSNP:rs63750899)" FT /evidence="ECO:0000269|PubMed:11839723, FT ECO:0000269|PubMed:15139004, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_022669" FT VARIANT 654 FT /note="P -> L (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2 and EXO1; loss FT of protein expression; may lose nuclear localization; FT dbSNP:rs63750726)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075" FT /id="VAR_043431" FT VARIANT 655 FT /note="I -> V (in LYNCH2; likely benign; also found in an FT endometrial cancer sample; no effect on MLH1 splicing; FT dbSNP:rs55907433)" FT /evidence="ECO:0000269|PubMed:12115348, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043432" FT VARIANT 656 FT /note="F -> S (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607876)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054537" FT VARIANT 657 FT /note="Missing (in LYNCH2; uncertain significance)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043433" FT VARIANT 659 FT /note="R -> L (in LYNCH2; dbSNP:rs63749900)" FT /evidence="ECO:0000269|PubMed:10713887, FT ECO:0000269|PubMed:11427529" FT /id="VAR_012929" FT VARIANT 659 FT /note="R -> P (in LYNCH2; interacts only very weakly with FT PMS2; abrogates interaction with EXO1; decreased mismatch FT repair activity; may lose nuclear localization; FT dbSNP:rs63749900)" FT /evidence="ECO:0000269|PubMed:11793442, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004465" FT VARIANT 659 FT /note="R -> Q (in LYNCH2; uncertain significance; FT dbSNP:rs63749900)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043434" FT VARIANT 662 FT /note="T -> P (in LYNCH2; dbSNP:rs587778964)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:11754112" FT /id="VAR_012930" FT VARIANT 666 FT /note="W -> R (in LYNCH2; uncertain significance; no effect FT on MLH1 splicing; dbSNP:rs267607887)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054538" FT VARIANT 681 FT /note="A -> T (in LYNCH2 and CRC; abrogates interaction FT with EXO1; no decrease in mismatch repair activity; FT dbSNP:rs63750217)" FT /evidence="ECO:0000269|PubMed:11427529, FT ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944" FT /id="VAR_004466" FT VARIANT 687 FT /note="R -> W (in LYNCH2; dbSNP:rs63751275)" FT /evidence="ECO:0000269|PubMed:11748856, FT ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:21120944" FT /id="VAR_012931" FT VARIANT 689 FT /note="Q -> R (in LYNCH2; benign; dbSNP:rs63750702)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:18561205" FT /id="VAR_012932" FT VARIANT 716 FT /note="V -> M (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs35831931)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11726306, ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9833759" FT /id="VAR_012933" FT VARIANT 718 FT /note="H -> Y (in LYNCH2; benign; dbSNP:rs2020873)" FT /evidence="ECO:0000269|PubMed:10386556, FT ECO:0000269|PubMed:12095971, ECO:0000269|PubMed:18033691" FT /id="VAR_004467" FT VARIANT 719 FT /note="I -> INVFHI (in LYNCH2)" FT /id="VAR_043435" FT VARIANT 724 FT /note="L -> M (in LYNCH2; dbSNP:rs63749875)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043436" FT VARIANT 725 FT /note="R -> H (reduces by 60% protein expression; FT dbSNP:rs566928243)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079816" FT VARIANT 729 FT /note="L -> V (in dbSNP:rs1800149)" FT /id="VAR_004468" FT VARIANT 749 FT /note="L -> P (in CRC; dbSNP:rs267607894)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043437" FT VARIANT 751 FT /note="K -> R (in LYNCH2; likely benign; FT dbSNP:rs140195825)" FT /evidence="ECO:0000269|PubMed:11139242, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:18033691" FT /id="VAR_012934" FT VARIANT 755 FT /note="R -> W (in HNPCC; incomplete; dbSNP:rs267607900)" FT /evidence="ECO:0000269|PubMed:10480359" FT /id="VAR_012935" FT MUTAGEN 33 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 241, Q-361 and Q-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 33 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-241, R-361 and R- FT 377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 241 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 33, Q-361 and Q-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 241 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-33, R-361 and R-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 361 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 33, Q-241 and Q-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 361 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-33, R-241 and R-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 377 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 33, Q-241 and Q-361." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 377 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-33, R-241 and R-361." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 471 FT /note="K->N: Affects binding to importins alpha, including FT KPNA2, hence may affect import to the nucleus." FT /evidence="ECO:0000269|PubMed:29175432" FT MUTAGEN 472 FT /note="R->N: Affects binding to importins alpha, including FT KPNA2, hence may affect import to the nucleus." FT /evidence="ECO:0000269|PubMed:29175432" FT CONFLICT 352 FT /note="L -> H (in Ref. 6; BAG60773)" FT /evidence="ECO:0000305" FT CONFLICT 708..711 FT /note="Missing (in Ref. 4; AAA85687)" FT /evidence="ECO:0000305" FT HELIX 13..25 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 28..41 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 45..52 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 53..56 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 57..63 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 70..72 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 73..77 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 103..109 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 110..118 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 122..131 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 134..137 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 140..142 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 146..154 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 155..158 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 160..165 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 169..186 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 187..189 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 190..196 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 203..205 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 212..220 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 222..225 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 228..235 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 236..239 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 240..247 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 253..255 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 257..262 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 270..281 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 291..298 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 322..335 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 504..516 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 519..526 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 529..543 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 546..551 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 552..566 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 572..581 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 582..590 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 593..595 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 604..626 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 634..641 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 650..652 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 653..662 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 669..684 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 688..690 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 712..718 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 720..724 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 732..735 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 737..745 FT /evidence="ECO:0007829|PDB:3RBN" SQ SEQUENCE 756 AA; 84601 MW; C9231FC406C2CA20 CRC64; MSFVAGVIRR LDETVVNRIA AGEVIQRPAN AIKEMIENCL DAKSTSIQVI VKEGGLKLIQ IQDNGTGIRK EDLDIVCERF TTSKLQSFED LASISTYGFR GEALASISHV AHVTITTKTA DGKCAYRASY SDGKLKAPPK PCAGNQGTQI TVEDLFYNIA TRRKALKNPS EEYGKILEVV GRYSVHNAGI SFSVKKQGET VADVRTLPNA STVDNIRSIF GNAVSRELIE IGCEDKTLAF KMNGYISNAN YSVKKCIFLL FINHRLVEST SLRKAIETVY AAYLPKNTHP FLYLSLEISP QNVDVNVHPT KHEVHFLHEE SILERVQQHI ESKLLGSNSS RMYFTQTLLP GLAGPSGEMV KSTTSLTSSS TSGSSDKVYA HQMVRTDSRE QKLDAFLQPL SKPLSSQPQA IVTEDKTDIS SGRARQQDEE MLELPAPAEV AAKNQSLEGD TTKGTSEMSE KRGPTSSNPR KRHREDSDVE MVEDDSRKEM TAACTPRRRI INLTSVLSLQ EEINEQGHEV LREMLHNHSF VGCVNPQWAL AQHQTKLYLL NTTKLSEELF YQILIYDFAN FGVLRLSEPA PLFDLAMLAL DSPESGWTEE DGPKEGLAEY IVEFLKKKAE MLADYFSLEI DEEGNLIGLP LLIDNYVPPL EGLPIFILRL ATEVNWDEEK ECFESLSKEC AMFYSIRKQY ISEESTLSGQ QSEVPGSIPN SWKWTVEHIV YKALRSHILP PKHFTEDGNI LQLANLPDLY KVFERC // ID MUC24_HUMAN Reviewed; 197 AA. AC Q04900; B4DQ85; E1P5E7; E1P5E8; E1P5E9; O95413; Q5JSU6; Q9BPV0; Q9NR26; DT 01-JUN-1994, integrated into UniProtKB/Swiss-Prot. DT 01-SEP-2009, sequence version 2. DT 28-JAN-2026, entry version 178. DE RecName: Full=Sialomucin core protein 24; DE Short=MUC-24; DE AltName: Full=Endolyn; DE AltName: Full=Multi-glycosylated core protein 24; DE Short=MGC-24; DE Short=MGC-24v; DE AltName: CD_antigen=CD164; DE Flags: Precursor; GN Name=CD164; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, AND RP GLYCOSYLATION. RC TISSUE=Gastric carcinoma; RX PubMed=1478919; DOI=10.1093/oxfordjournals.jbchem.a123948; RA Masuzawa Y., Miyauchi T., Hamanoue M., Ando S., Yoshida J., Takao S., RA Shimazu H., Adachi M., Muramatsu T.; RT "A novel core protein as well as polymorphic epithelial mucin carry peanut RT agglutinin binding sites in human gastric carcinoma cells: sequence RT analysis and examination of gene expression."; RL J. Biochem. 112:609-615(1992). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), FUNCTION, SUBUNIT, AND TISSUE RP SPECIFICITY. RC TISSUE=Bone marrow; RX PubMed=9763543; RA Zannettino A.C.W., Buehring H.-J., Niutta S., Watt S.M., Benton M.A., RA Simmons P.J.; RT "The sialomucin CD164 (MGC-24v) is an adhesive glycoprotein expressed by RT human hematopoietic progenitors and bone marrow stromal cells that serves RT as a potent negative regulator of hematopoiesis."; RL Blood 92:2613-2628(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY. RX PubMed=10878358; DOI=10.4049/jimmunol.165.2.840; RA Doyonnas R., Chan J.Y.-H., Butler L.H., Rappold I., Lee-Prudhoe J.E., RA Zannettino A.C.W., Simmons P.J., Buehring H.-J., Levesque J.-P., Watt S.M.; RT "CD164 monoclonal antibodies that block hemopoietic progenitor cell RT adhesion and proliferation interact with the first mucin domain of the RT CD164 receptor."; RL J. Immunol. 165:840-851(2000). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1; 3 AND 4), ALTERNATIVE RP SPLICING, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=11027692; DOI=10.1074/jbc.m007965200; RA Chan J.Y.-H., Lee-Prudhoe J.E., Jorgensen B., Ihrke G., Doyonnas R., RA Zannettino A.C.W., Buckle V.J., Ward C.J., Simmons P.J., Watt S.M.; RT "Relationship between novel isoforms, functionally important domains, and RT subcellular distribution of CD164/endolyn."; RL J. Biol. Chem. 276:2139-2152(2001). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 3; 4 AND 5). RC TISSUE=Amygdala, Astrocyte, Neutrophil, and Thymus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Colon; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP FUNCTION, INDUCTION, AND TISSUE SPECIFICITY. RX PubMed=16859559; DOI=10.1186/1471-2407-6-195; RA Havens A.M., Jung Y., Sun Y.X., Wang J., Shah R.B., Buehring H.J., RA Pienta K.J., Taichman R.S.; RT "The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer RT metastasis."; RL BMC Cancer 6:195-195(2006). RN [10] RP FUNCTION, AND INTERACTION WITH CXCR4. RX PubMed=17077324; DOI=10.1182/blood-2006-05-023028; RA Forde S., Tye B.J., Newey S.E., Roubelakis M., Smythe J., McGuckin C.P., RA Pettengell R., Watt S.M.; RT "Endolyn (CD164) modulates the CXCL12-mediated migration of umbilical cord RT blood CD133+ cells."; RL Blood 109:1825-1833(2007). RN [11] RP SUBCELLULAR LOCATION, AND INVOLVEMENT IN DFNA66. RX PubMed=26197441; DOI=10.1371/journal.pgen.1005386; RA Nyegaard M., Rendtorff N.D., Nielsen M.S., Corydon T.J., Demontis D., RA Starnawska A., Hedemand A., Buniello A., Niola F., Overgaard M.T., RA Leal S.M., Ahmad W., Wikman F.P., Petersen K.B., Crueger D.G., Oostrik J., RA Kremer H., Tommerup N., Froedin M., Steel K.P., Tranebjaerg L., RA Boerglum A.D.; RT "A novel locus harbouring a functional CD164 nonsense mutation identified RT in a large Danish family with nonsyndromic hearing impairment."; RL PLoS Genet. 11:E1005386-E1005386(2015). CC -!- FUNCTION: Sialomucin that may play a key role in hematopoiesis by CC facilitating the adhesion of CD34(+) cells to the stroma and by CC negatively regulating CD34(+)CD38(lo/-) cell proliferation. Modulates CC the migration of umbilical cord blood CD133+ cells and this is mediated CC through the CXCL12/CXCR4 axis. May play an important role in prostate CC cancer metastasis and the infiltration of bone marrow by cancer cells. CC Promotes myogenesis by enhancing CXCR4-dependent cell motility. CC Positively regulates myoblast migration and promotes myoblast fusion CC into myotubes (By similarity). {ECO:0000250|UniProtKB:Q9R0L9, CC ECO:0000269|PubMed:16859559, ECO:0000269|PubMed:17077324, CC ECO:0000269|PubMed:9763543}. CC -!- SUBUNIT: Homodimer (isoform 4). Interacts with CXCR4. CC {ECO:0000269|PubMed:17077324, ECO:0000269|PubMed:9763543}. CC -!- INTERACTION: CC Q04900; P61073: CXCR4; NbExp=2; IntAct=EBI-2115896, EBI-489411; CC Q04900; P49639: HOXA1; NbExp=3; IntAct=EBI-2115896, EBI-740785; CC Q04900; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-2115896, EBI-945833; CC Q04900; P0DPK4: NOTCH2NLC; NbExp=3; IntAct=EBI-2115896, EBI-22310682; CC -!- SUBCELLULAR LOCATION: Lysosome membrane {ECO:0000269|PubMed:11027692}; CC Single-pass type I membrane protein {ECO:0000269|PubMed:11027692}. CC Endosome membrane {ECO:0000269|PubMed:11027692}; Single-pass type I CC membrane protein {ECO:0000269|PubMed:11027692}. Cell membrane CC {ECO:0000269|PubMed:11027692, ECO:0000269|PubMed:26197441}; Single-pass CC type I membrane protein {ECO:0000269|PubMed:11027692}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Name=1; Synonyms=CD164(E1-6); CC IsoId=Q04900-1; Sequence=Displayed; CC Name=2; CC IsoId=Q04900-2; Sequence=VSP_037974; CC Name=3; Synonyms=CD164(Delta 4); CC IsoId=Q04900-3; Sequence=VSP_037972; CC Name=4; Synonyms=CD164(Delta 5); CC IsoId=Q04900-4; Sequence=VSP_037973; CC Name=5; CC IsoId=Q04900-5; Sequence=VSP_038018, VSP_038019; CC -!- TISSUE SPECIFICITY: Isoform 1 and isoform 3 are expressed in CC hematopoietic and non-hematopoietic tissues. Isoform 1 is expressed by CC prostate cancer tumors and prostate cancer cell lines. The expression CC is greater in bone metastases than in primary tumors. Expression in CC osseous metastasis is greater than that in soft tissue metastasis. CC Isoform 2 is expressed in the small intestine, colon, lung, thyroid and CC in colorectal and pancreatic adenocarcinoma. Isoform 4 is expressed by CC both hematopoietic progenitor cells and bone marrow stromal cells. CC {ECO:0000269|PubMed:10878358, ECO:0000269|PubMed:11027692, CC ECO:0000269|PubMed:1478919, ECO:0000269|PubMed:16859559, CC ECO:0000269|PubMed:9763543}. CC -!- INDUCTION: Up-regulated by CXCL12 in prostate cancer cell lines. CC {ECO:0000269|PubMed:16859559}. CC -!- PTM: Highly N- and O-glycosylated; contains sialic acid. CC {ECO:0000269|PubMed:1478919}. CC -!- PTM: The motif Ser-Gly may serve as the site of attachment of a CC glycosaminoglycan side chain. CC -!- DISEASE: Deafness, autosomal dominant, 66 (DFNA66) [MIM:616969]: A form CC of non-syndromic sensorineural hearing loss. Sensorineural deafness CC results from damage to the neural receptors of the inner ear, the nerve CC pathways to the brain, or the area of the brain that receives sound CC information. {ECO:0000269|PubMed:26197441}. Note=The disease is caused CC by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the CD164 family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D14043; BAA03130.1; -; mRNA. DR EMBL; AF106518; AAC82473.1; -; mRNA. DR EMBL; AF263279; AAF85965.1; -; mRNA. DR EMBL; AF299341; AAG53906.1; -; mRNA. DR EMBL; AF299342; AAG53907.1; -; mRNA. DR EMBL; AF299343; AAG53908.1; -; mRNA. DR EMBL; AF299340; AAG53903.1; -; Genomic_DNA. DR EMBL; AF299340; AAG53904.1; -; Genomic_DNA. DR EMBL; AF299340; AAG53905.1; -; Genomic_DNA. DR EMBL; AK298684; BAG60847.1; -; mRNA. DR EMBL; AK303525; BAG64553.1; -; mRNA. DR EMBL; AK312357; BAG35275.1; -; mRNA. DR EMBL; AK315908; BAH14279.1; -; mRNA. DR EMBL; AL359711; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471051; EAW48348.1; -; Genomic_DNA. DR EMBL; CH471051; EAW48352.1; -; Genomic_DNA. DR EMBL; CH471051; EAW48349.1; -; Genomic_DNA. DR EMBL; CH471051; EAW48353.1; -; Genomic_DNA. DR EMBL; CH471051; EAW48354.1; -; Genomic_DNA. DR EMBL; CH471051; EAW48355.1; -; Genomic_DNA. DR EMBL; BC011522; AAH11522.1; -; mRNA. DR CCDS; CCDS47462.1; -. [Q04900-5] DR CCDS; CCDS47463.1; -. [Q04900-2] DR CCDS; CCDS47464.1; -. [Q04900-3] DR CCDS; CCDS47465.1; -. [Q04900-4] DR CCDS; CCDS5073.1; -. [Q04900-1] DR PIR; JX0235; JX0235. DR RefSeq; NP_001135873.1; NM_001142401.3. [Q04900-3] DR RefSeq; NP_001135874.1; NM_001142402.3. [Q04900-4] DR RefSeq; NP_001135875.1; NM_001142403.3. [Q04900-2] DR RefSeq; NP_001135876.1; NM_001142404.3. [Q04900-5] DR RefSeq; NP_001333429.1; NM_001346500.1. DR RefSeq; NP_006007.2; NM_006016.5. [Q04900-1] DR AlphaFoldDB; Q04900; -. DR SMR; Q04900; -. DR BioGRID; 114297; 8. DR DIP; DIP-43970N; -. DR FunCoup; Q04900; 915. DR IntAct; Q04900; 13. DR MINT; Q04900; -. DR STRING; 9606.ENSP00000309376; -. DR GlyConnect; 1744; 5 N-Linked glycans (2 sites). DR GlyCosmos; Q04900; 12 sites, 8 glycans. DR GlyGen; Q04900; 16 sites, 32 N-linked glycans (5 sites), 4 O-linked glycans (5 sites). DR iPTMnet; Q04900; -. DR PhosphoSitePlus; Q04900; -. DR SwissPalm; Q04900; -. DR BioMuta; CD164; -. DR DMDM; 257051036; -. DR CPTAC; CPTAC-1481; -. DR MassIVE; Q04900; -. DR PaxDb; 9606-ENSP00000309376; -. DR PeptideAtlas; Q04900; -. DR ProteomicsDB; 58289; -. [Q04900-1] DR ProteomicsDB; 58290; -. [Q04900-2] DR ProteomicsDB; 58291; -. [Q04900-3] DR ProteomicsDB; 58292; -. [Q04900-4] DR ProteomicsDB; 58293; -. [Q04900-5] DR Pumba; Q04900; -. DR Antibodypedia; 2460; 288 antibodies from 29 providers. DR DNASU; 8763; -. DR Ensembl; ENST00000275080.11; ENSP00000275080.7; ENSG00000135535.18. [Q04900-3] DR Ensembl; ENST00000310786.10; ENSP00000309376.4; ENSG00000135535.18. [Q04900-1] DR Ensembl; ENST00000324953.9; ENSP00000314177.5; ENSG00000135535.18. [Q04900-4] DR Ensembl; ENST00000413644.6; ENSP00000402237.2; ENSG00000135535.18. [Q04900-2] DR Ensembl; ENST00000512821.5; ENSP00000427546.1; ENSG00000135535.18. [Q04900-5] DR GeneID; 8763; -. DR KEGG; hsa:8763; -. DR MANE-Select; ENST00000310786.10; ENSP00000309376.4; NM_006016.6; NP_006007.2. DR UCSC; uc003ptd.4; human. [Q04900-1] DR AGR; HGNC:1632; -. DR ClinPGx; PA26191; -. DR CTD; 8763; -. DR DisGeNET; 8763; -. DR GeneCards; CD164; -. DR HGNC; HGNC:1632; CD164. DR HPA; ENSG00000135535; Low tissue specificity. DR MalaCards; CD164; -. DR MIM; 603356; gene. DR MIM; 616969; phenotype. DR OpenTargets; ENSG00000135535; -. DR Orphanet; 90635; Rare autosomal dominant non-syndromic sensorineural deafness type DFNA. DR VEuPathDB; HostDB:ENSG00000135535; -. DR eggNOG; ENOG502S7HA; Eukaryota. DR GeneTree; ENSGT00530000063929; -. DR HOGENOM; CLU_101414_0_0_1; -. DR InParanoid; Q04900; -. DR OrthoDB; 6160056at2759; -. DR PAN-GO; Q04900; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q04900; -. DR PathwayCommons; Q04900; -. DR SignaLink; Q04900; -. DR Agora; ENSG00000135535; -. DR BioGRID-ORCS; 8763; 21 hits in 1158 CRISPR screens. DR ChiTaRS; CD164; human. DR GeneWiki; CD164; -. DR GenomeRNAi; 8763; -. DR Pharos; Q04900; Tbio. DR PRO; PR:Q04900; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q04900; protein. DR Bgee; ENSG00000135535; Expressed in mucosa of sigmoid colon and 215 other cell types or tissues. DR ExpressionAtlas; Q04900; baseline and differential. DR GO; GO:0005768; C:endosome; IDA:UniProtKB. DR GO; GO:0010008; C:endosome membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0005765; C:lysosomal membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005764; C:lysosome; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0007155; P:cell adhesion; IDA:MGI. DR GO; GO:0030097; P:hemopoiesis; NAS:UniProtKB. DR GO; GO:0007157; P:heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules; IDA:MGI. DR GO; GO:0006955; P:immune response; TAS:ProtInc. DR GO; GO:0007517; P:muscle organ development; IEA:UniProtKB-KW. DR GO; GO:0007162; P:negative regulation of cell adhesion; NAS:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR InterPro; IPR007947; CD164_MGC24. DR PANTHER; PTHR11337; MUCIN/PORIMIN; 1. DR PANTHER; PTHR11337:SF12; SIALOMUCIN CORE PROTEIN 24; 1. DR Pfam; PF05283; MGC-24; 1. DR PRINTS; PR01701; CD164ANTIGEN. PE 1: Evidence at protein level; KW Alternative splicing; Cell adhesion; Cell membrane; Deafness; Endosome; KW Glycoprotein; Lysosome; Membrane; Myogenesis; Non-syndromic deafness; KW Proteoglycan; Proteomics identification; Reference proteome; Secreted; KW Signal; Transmembrane; Transmembrane helix. FT SIGNAL 1..23 FT /evidence="ECO:0000255" FT CHAIN 24..197 FT /note="Sialomucin core protein 24" FT /id="PRO_0000019292" FT TOPO_DOM 24..162 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 163..183 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 184..197 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT REGION 118..154 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 191..197 FT /note="Required for endosomal and lysosomal localization" FT /evidence="ECO:0000250" FT COMPBIAS 125..154 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT CARBOHYD 26 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 32 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 41 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 72 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 77 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 94 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 104 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 121 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 142 FT /note="O-linked (Xyl...) (glycosaminoglycan) serine" FT /evidence="ECO:0000255" FT CARBOHYD 146 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 111..123 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:11027692, FT ECO:0000303|PubMed:14702039" FT /id="VSP_037972" FT VAR_SEQ 124..142 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:11027692, FT ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:9763543" FT /id="VSP_037973" FT VAR_SEQ 143..157 FT /note="GTTNNTVTPTSQPVR -> EIRCHTRNYIPDLKK (in isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_038018" FT VAR_SEQ 158..197 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_038019" FT VAR_SEQ 175..197 FT /note="GVQAVIFFLYKFCKSKERNYHTL -> EIRCHTRNYIPDLKK (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:1478919" FT /id="VSP_037974" SQ SEQUENCE 197 AA; 20917 MW; 4855E02646F4CB35 CRC64; MSRLSRSLLW AATCLGVLCV LSADKNTTQH PNVTTLAPIS NVTSAPVTSL PLVTTPAPET CEGRNSCVSC FNVSVVNTTC FWIECKDESY CSHNSTVSDC QVGNTTDFCS VSTATPVPTA NSTAKPTVQP SPSTTSKTVT TSGTTNNTVT PTSQPVRKST FDAASFIGGI VLVLGVQAVI FFLYKFCKSK ERNYHTL // ID NEK8_HUMAN Reviewed; 692 AA. AC Q86SG6; A6NIC5; Q14CL7; Q2M1S6; Q8NDH1; DT 15-AUG-2003, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-2003, sequence version 1. DT 28-JAN-2026, entry version 190. DE RecName: Full=Serine/threonine-protein kinase Nek8; DE EC=2.7.11.1; DE AltName: Full=Never in mitosis A-related kinase 8; DE Short=NimA-related protein kinase 8; DE AltName: Full=Nima-related protein kinase 12a; GN Name=NEK8; Synonyms=JCK, NEK12A; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RA Huang C.Q., Wu S.L., Yu L.; RL Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RA Nedwidek M.N., Roig J., Lenz G., Avruch J.; RT "NIMA-family kinase Nek8 complete human coding region."; RL Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 445-692. RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [7] RP TISSUE SPECIFICITY. RX PubMed=15019993; DOI=10.1016/j.gene.2003.12.002; RA Bowers A.J., Boylan J.F.; RT "Nek8, a NIMA family kinase member, is overexpressed in primary human RT breast tumors."; RL Gene 328:135-142(2004). RN [8] RP INVOLVEMENT IN RHPD2, FUNCTION, AND INTERACTION WITH NPHP3. RX PubMed=23418306; DOI=10.1093/hmg/ddt070; RA Frank V., Habbig S., Bartram M.P., Eisenberger T., Veenstra-Knol H.E., RA Decker C., Boorsma R.A., Goebel H., Nuernberg G., Griessmann A., Franke M., RA Borgal L., Kohli P., Voelker L.A., Doetsch J., Nuernberg P., Benzing T., RA Bolz H.J., Johnson C., Gerkes E.H., Schermer B., Bergmann C.; RT "Mutations in NEK8 link multiple organ dysplasia with altered Hippo RT signalling and increased c-MYC expression."; RL Hum. Mol. Genet. 22:2177-2185(2013). RN [9] RP INTERACTION WITH ANKS6; INVS AND NPHP3. RX PubMed=23793029; DOI=10.1038/ng.2681; RA Hoff S., Halbritter J., Epting D., Frank V., Nguyen T.M., van Reeuwijk J., RA Boehlke C., Schell C., Yasunaga T., Helmstadter M., Mergen M., Filhol E., RA Boldt K., Horn N., Ueffing M., Otto E.A., Eisenberger T., Elting M.W., RA van Wijk J.A., Bockenhauer D., Sebire N.J., Rittig S., Vyberg M., Ring T., RA Pohl M., Pape L., Neuhaus T.J., Elshakhs N.A., Koon S.J., Harris P.C., RA Grahammer F., Huber T.B., Kuehn E.W., Kramer-Zucker A., Bolz H.J., RA Roepman R., Saunier S., Walz G., Hildebrandt F., Bergmann C., RA Lienkamp S.S.; RT "ANKS6 is a central component of a nephronophthisis module linking NEK8 to RT INVS and NPHP3."; RL Nat. Genet. 45:951-956(2013). RN [10] RP INTERACTION WITH ANKS3. RX PubMed=26188091; DOI=10.1016/j.bbrc.2015.07.063; RA Ramachandran H., Engel C., Mueller B., Dengjel J., Walz G., Yakulov T.A.; RT "Anks3 alters the sub-cellular localization of the Nek7 kinase."; RL Biochem. Biophys. Res. Commun. 464:901-907(2015). RN [11] RP VARIANTS NPHP9 PHE-330; TYR-425 AND PRO-497, CHARACTERIZATION OF VARIANTS RP NPHP9 PHE-330; TYR-425 AND PRO-497, AND SUBCELLULAR LOCATION. RX PubMed=18199800; DOI=10.1681/asn.2007040490; RA Otto E.A., Trapp M.L., Schultheiss U.T., Helou J., Quarmby L.M., RA Hildebrandt F.; RT "NEK8 mutations affect ciliary and centrosomal localization and may cause RT nephronophthisis."; RL J. Am. Soc. Nephrol. 19:587-592(2008). RN [12] RP VARIANTS RHPD2 ALA-87; 127-ARG--PRO-692 DEL; SER-416; 462-ARG--PRO-692 DEL; RP SER-580 AND TRP-602, CHARACTERIZATION OF VARIANTS RHPD2 ALA-87; RP 127-ARG--PRO-692 DEL; 462-ARG--PRO-692 DEL; SER-580 AND TRP-602, RP CHARACTERIZATION OF VARIANT NPHP9 TYR-425, INTERACTION WITH ANKS6, RP SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=26967905; DOI=10.1371/journal.pgen.1005894; RA Grampa V., Delous M., Zaidan M., Odye G., Thomas S., Elkhartoufi N., RA Filhol E., Niel O., Silbermann F., Lebreton C., Collardeau-Frachon S., RA Rouvet I., Alessandri J.L., Devisme L., Dieux-Coeslier A., Cordier M.P., RA Capri Y., Khung-Savatovsky S., Sigaudy S., Salomon R., Antignac C., RA Gubler M.C., Benmerah A., Terzi F., Attie-Bitach T., Jeanpierre C., RA Saunier S.; RT "Novel NEK8 Mutations Cause Severe Syndromic Renal Cystic Dysplasia through RT YAP Dysregulation."; RL PLoS Genet. 12:e1005894-e1005894(2016). RN [13] RP VARIANTS PKD8 TRP-45; MET-150 AND GLN-157, CHARACTERIZATION OF VARIANTS RP PKD8 TRP-45; MET-150 AND GLN-157, INVOLVEMENT IN PKD8, AND FUNCTION. RX PubMed=37598857; DOI=10.1016/j.kint.2023.07.021; RG Genomics England Research Consortium; RA Claus L.R., Chen C., Stallworth J., Turner J.L., Slaats G.G., Hawks A.L., RA Mabillard H., Senum S.R., Srikanth S., Flanagan-Steet H., Louie R.J., RA Silver J., Lerner-Ellis J., Morel C., Mighton C., Sleutels F., RA van Slegtenhorst M., van Ham T., Brooks A.S., Dorresteijn E.M., RA Barakat T.S., Dahan K., Demoulin N., Goffin E.J., Olinger E., Larsen M., RA Hertz J.M., Lilien M.R., Obeidova L., Seeman T., Stone H.K., Kerecuk L., RA Gurgu M., Yousef Yengej F.A., Ammerlaan C.M.E., Rookmaaker M.B., Hanna C., RA Rogers R.C., Duran K., Peters E., Sayer J.A., van Haaften G., Harris P.C., RA Ling K., Mason J.M., van Eerde A.M., Steet R.; RT "Certain heterozygous variants in the kinase domain of the serine/threonine RT kinase NEK8 can cause an autosomal dominant form of polycystic kidney RT disease."; RL Kidney Int. 104:995-1007(2023). RN [14] RP VARIANT PKD8 TRP-45, AND INVOLVEMENT IN PKD8. RX PubMed=36215968; DOI=10.1159/000526841; RA Mehawej C., Chouery E., Ghabril R., Tokajian S., Megarbane A.; RT "NEK8-Associated Nephropathies: Do Autosomal Dominant Forms Exist?"; RL Nephron 147:229-233(2023). CC -!- FUNCTION: Required for renal tubular integrity. May regulate local CC cytoskeletal structure in kidney tubule epithelial cells. May regulate CC ciliary biogenesis through targeting of proteins to the cilia CC (PubMed:37598857). Plays a role in organogenesis, and is involved in CC the regulation of the Hippo signaling pathway (PubMed:26967905). CC {ECO:0000269|PubMed:23418306, ECO:0000269|PubMed:26967905, CC ECO:0000269|PubMed:37598857}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC -!- SUBUNIT: Interacts with PKD2; may regulate PKD2 targeting to the cilium CC (By similarity). Interacts with ANKS6 (PubMed:26967905). Component of a CC complex containing at least ANKS6, INVS, NEK8 and NPHP3 CC (PubMed:23418306, PubMed:23793029). ANKS6 may organize complex assembly CC by linking INVS and NPHP3 to NEK8 and INVS may target the complex to CC the proximal ciliary axoneme (PubMed:23418306, PubMed:23793029). CC Interacts with ANKS3 (PubMed:26188091). {ECO:0000250|UniProtKB:Q91ZR4, CC ECO:0000269|PubMed:23418306, ECO:0000269|PubMed:23793029, CC ECO:0000269|PubMed:26188091}. CC -!- INTERACTION: CC Q86SG6; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-1752987, EBI-10173507; CC Q86SG6; Q6ZW76: ANKS3; NbExp=3; IntAct=EBI-1752987, EBI-949601; CC Q86SG6; Q68DC2: ANKS6; NbExp=5; IntAct=EBI-1752987, EBI-7054139; CC Q86SG6; P54253: ATXN1; NbExp=3; IntAct=EBI-1752987, EBI-930964; CC Q86SG6; P08238: HSP90AB1; NbExp=2; IntAct=EBI-1752987, EBI-352572; CC Q86SG6; P42858: HTT; NbExp=3; IntAct=EBI-1752987, EBI-466029; CC Q86SG6; Q52LG2: KRTAP13-2; NbExp=3; IntAct=EBI-1752987, EBI-11953846; CC Q86SG6; Q8TDX7: NEK7; NbExp=3; IntAct=EBI-1752987, EBI-1055945; CC Q86SG6; Q8WVJ2: NUDCD2; NbExp=3; IntAct=EBI-1752987, EBI-1052153; CC Q86SG6; Q8TDS5: OXER1; NbExp=3; IntAct=EBI-1752987, EBI-12813389; CC Q86SG6; O76081-6: RGS20; NbExp=3; IntAct=EBI-1752987, EBI-10178530; CC Q86SG6; P15884: TCF4; NbExp=3; IntAct=EBI-1752987, EBI-533224; CC Q86SG6; Q8IWZ5: TRIM42; NbExp=3; IntAct=EBI-1752987, EBI-5235829; CC Q86SG6; Q86WT6: TRIM69; NbExp=3; IntAct=EBI-1752987, EBI-749955; CC Q86SG6; Q86WT6-2: TRIM69; NbExp=3; IntAct=EBI-1752987, EBI-11525489; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:18199800}. CC Cytoplasm, cytoskeleton {ECO:0000250|UniProtKB:Q91ZR4}. Cell CC projection, cilium {ECO:0000269|PubMed:18199800}. Cytoplasm, CC cytoskeleton, microtubule organizing center, centrosome CC {ECO:0000269|PubMed:18199800}. Cytoplasm, cytoskeleton, cilium axoneme CC {ECO:0000269|PubMed:26967905}. Note=Predominantly cytoplasmic. CC Localizes to the proximal region of the primary cilium and is not CC observed in dividing cells. {ECO:0000250|UniProtKB:Q91ZR4}. CC -!- TISSUE SPECIFICITY: Highest expression in thyroid, adrenal gland and CC skin. Low levels in spleen, colon and uterus. Overexpressed in breast CC tumors, with highest expression in infiltrating ductal carcinomas and CC moderate levels in mucinous adenocarcinoma. CC {ECO:0000269|PubMed:15019993}. CC -!- DISEASE: Nephronophthisis 9 (NPHP9) [MIM:613824]: An autosomal CC recessive disorder resulting in end-stage renal disease. It is a CC progressive tubulo-interstitial kidney disorder histologically CC characterized by modifications of the tubules with thickening of the CC basement membrane, interstitial fibrosis and, in the advanced stages, CC medullary cysts. {ECO:0000269|PubMed:18199800, CC ECO:0000269|PubMed:26967905}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Renal-hepatic-pancreatic dysplasia 2 (RHPD2) [MIM:615415]: A CC form of renal-hepatic-pancreatic dysplasia, a disease characterized by CC cystic malformations of the kidneys, liver, and pancreas. The CC pathological findings consist of multicystic dysplastic kidneys, CC dilated and dysgenetic bile ducts, a dysplastic pancreas with dilated CC ducts, cysts, fibrosis and inflammatory infiltrates. CC {ECO:0000269|PubMed:23418306, ECO:0000269|PubMed:26967905}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Polycystic kidney disease 8 (PKD8) [MIM:620903]: A form of CC polycystic kidney disease, a disorder characterized by progressive CC formation and enlargement of cysts in both kidneys, typically leading CC to end-stage renal disease in adult life. Cysts may also occur in other CC organs, particularly the liver. PKD8 inheritance is autosomal dominant. CC {ECO:0000269|PubMed:36215968, ECO:0000269|PubMed:37598857}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. NEK Ser/Thr CC protein kinase family. NIMA subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY242354; AAO88243.1; -; mRNA. DR EMBL; AY267371; AAP04006.1; -; mRNA. DR EMBL; AC010761; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471159; EAW51136.1; -; Genomic_DNA. DR EMBL; BC112240; AAI12241.1; -; mRNA. DR EMBL; BC113705; AAI13706.1; -; mRNA. DR EMBL; AL833909; CAD38765.1; -; mRNA. DR CCDS; CCDS32597.1; -. DR RefSeq; NP_835464.1; NM_178170.3. DR AlphaFoldDB; Q86SG6; -. DR SMR; Q86SG6; -. DR BioGRID; 129755; 63. DR CORUM; Q86SG6; -. DR FunCoup; Q86SG6; 177. DR IntAct; Q86SG6; 64. DR STRING; 9606.ENSP00000268766; -. DR BindingDB; Q86SG6; -. DR ChEMBL; CHEMBL2417353; -. DR iPTMnet; Q86SG6; -. DR PhosphoSitePlus; Q86SG6; -. DR BioMuta; NEK8; -. DR DMDM; 34098463; -. DR jPOST; Q86SG6; -. DR MassIVE; Q86SG6; -. DR PaxDb; 9606-ENSP00000268766; -. DR PeptideAtlas; Q86SG6; -. DR ProteomicsDB; 69588; -. DR Pumba; Q86SG6; -. DR Antibodypedia; 26547; 285 antibodies from 26 providers. DR DNASU; 284086; -. DR Ensembl; ENST00000268766.11; ENSP00000268766.6; ENSG00000160602.15. DR GeneID; 284086; -. DR KEGG; hsa:284086; -. DR MANE-Select; ENST00000268766.11; ENSP00000268766.6; NM_178170.3; NP_835464.1. DR UCSC; uc002hcp.4; human. DR AGR; HGNC:13387; -. DR ClinPGx; PA38361; -. DR CTD; 284086; -. DR DisGeNET; 284086; -. DR GeneCards; NEK8; -. DR GeneReviews; NEK8; -. DR HGNC; HGNC:13387; NEK8. DR HPA; ENSG00000160602; Low tissue specificity. DR MalaCards; NEK8; -. DR MIM; 609799; gene. DR MIM; 613824; phenotype. DR MIM; 615415; phenotype. DR MIM; 620903; phenotype. DR OpenTargets; ENSG00000160602; -. DR Orphanet; 730; Autosomal dominant polycystic kidney disease. DR Orphanet; 93591; Infantile nephronophthisis. DR Orphanet; 294415; Renal-hepatic-pancreatic dysplasia. DR VEuPathDB; HostDB:ENSG00000160602; -. DR eggNOG; KOG0589; Eukaryota. DR GeneTree; ENSGT00940000159297; -. DR HOGENOM; CLU_000288_123_1_1; -. DR InParanoid; Q86SG6; -. DR OrthoDB; 248923at2759; -. DR PAN-GO; Q86SG6; 7 GO annotations based on evolutionary models. DR PhylomeDB; Q86SG6; -. DR PathwayCommons; Q86SG6; -. DR SignaLink; Q86SG6; -. DR SIGNOR; Q86SG6; -. DR Agora; ENSG00000160602; -. DR BioGRID-ORCS; 284086; 18 hits in 1190 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR GeneWiki; NEK8; -. DR GenomeRNAi; 284086; -. DR Pharos; Q86SG6; Tchem. DR PRO; PR:Q86SG6; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q86SG6; protein. DR Bgee; ENSG00000160602; Expressed in buccal mucosa cell and 133 other cell types or tissues. DR ExpressionAtlas; Q86SG6; baseline and differential. DR GO; GO:0005930; C:axoneme; IEA:UniProtKB-SubCell. DR GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell. DR GO; GO:0097546; C:ciliary base; IEA:Ensembl. DR GO; GO:0097543; C:ciliary inversin compartment; IEA:Ensembl. DR GO; GO:0005929; C:cilium; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0009887; P:animal organ morphogenesis; IMP:UniProtKB. DR GO; GO:0007368; P:determination of left/right symmetry; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0035330; P:regulation of hippo signaling; IDA:UniProtKB. DR CDD; cd08220; STKc_Nek8; 1. DR FunFam; 1.10.510.10:FF:000262; Serine/threonine-protein kinase Nek8; 1. DR FunFam; 2.130.10.30:FF:000017; Serine/threonine-protein kinase Nek8; 1. DR FunFam; 2.130.10.30:FF:000020; serine/threonine-protein kinase Nek8; 1. DR FunFam; 3.30.200.20:FF:000243; serine/threonine-protein kinase Nek8; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.130.10.30; Regulator of chromosome condensation 1/beta-lactamase-inhibitor protein II; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR058923; RCC1-like_dom. DR InterPro; IPR009091; RCC1/BLIP-II. DR InterPro; IPR000408; Reg_chr_condens. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051997; STK_NEK. DR InterPro; IPR044120; STKc_Nek8. DR PANTHER; PTHR44535; PROTEIN CBG16200; 1. DR PANTHER; PTHR44535:SF4; SERINE_THREONINE-PROTEIN KINASE NEK8; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF25390; WD40_RLD; 1. DR PRINTS; PR00633; RCCNDNSATION. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF50985; RCC1/BLIP-II; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50012; RCC1_3; 5. PE 1: Evidence at protein level; KW ATP-binding; Cell projection; Ciliopathy; Cilium; Cytoplasm; Cytoskeleton; KW Disease variant; Kinase; Magnesium; Metal-binding; Nephronophthisis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Serine/threonine-protein kinase; Transferase. FT CHAIN 1..692 FT /note="Serine/threonine-protein kinase Nek8" FT /id="PRO_0000086432" FT DOMAIN 4..258 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REPEAT 312..350 FT /note="RCC1 1" FT REPEAT 410..461 FT /note="RCC1 2" FT REPEAT 462..513 FT /note="RCC1 3" FT REPEAT 580..631 FT /note="RCC1 4" FT REPEAT 632..684 FT /note="RCC1 5" FT REGION 277..301 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 282..293 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 128 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 10..18 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 33 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 162 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250" FT VARIANT 45 FT /note="R -> W (in PKD8; pathogenic; fails to rescue FT defective PKD2 targeting to cilia in NEK8-deficient FT epithelial renal cells; decreased autophosphorylation; FT dbSNP:rs1567759130)" FT /evidence="ECO:0000269|PubMed:36215968, FT ECO:0000269|PubMed:37598857" FT /id="VAR_089841" FT VARIANT 87 FT /note="T -> A (in RHPD2; likely pathogenic; contrary to the FT wild type, it fails to rescue body curvature defects in FT zebrafish morphants; decreased localization to cilia; FT decreased interaction with ANKS6; dbSNP:rs1555563787)" FT /evidence="ECO:0000269|PubMed:26967905" FT /id="VAR_089842" FT VARIANT 127..692 FT /note="Missing (in RHPD2; likely pathogenic; loss of FT protein expression)" FT /evidence="ECO:0000269|PubMed:26967905" FT /id="VAR_089843" FT VARIANT 150 FT /note="I -> M (in PKD8; uncertain significance; it rescues FT ciliary defects when transfected in NEK8-deficient FT epithelial renal cells)" FT /evidence="ECO:0000269|PubMed:37598857" FT /id="VAR_089844" FT VARIANT 157 FT /note="K -> Q (in PKD8; likely pathogenic; contrary to the FT wild type, it does not rescue ciliary defects when FT transfected in NEK8-deficient epithelial renal cells)" FT /evidence="ECO:0000269|PubMed:37598857" FT /id="VAR_089845" FT VARIANT 330 FT /note="L -> F (in NPHP9; a full-length mouse NEK8 construct FT containing the mutation shows a defect in ciliary FT localization with no apparent effect on ciliation, mitosis FT or centriole number; dbSNP:rs199962228)" FT /evidence="ECO:0000269|PubMed:18199800" FT /id="VAR_065769" FT VARIANT 416 FT /note="G -> S (in RHPD2; uncertain significance; FT dbSNP:rs199823733)" FT /evidence="ECO:0000269|PubMed:26967905" FT /id="VAR_089846" FT VARIANT 425 FT /note="H -> Y (in NPHP9; loss of ciliary localization; a FT full-length mouse NEK8 construct containing the mutation FT shows a defect in ciliary localization with no apparent FT effect on ciliation, mitosis or centriole number; no effect FT on interaction with ANKS6; dbSNP:rs118204032)" FT /evidence="ECO:0000269|PubMed:18199800" FT /id="VAR_065770" FT VARIANT 462..692 FT /note="Missing (in RHPD2; likely pathogenic; loss of FT protein expression)" FT /evidence="ECO:0000269|PubMed:26967905" FT /id="VAR_089847" FT VARIANT 497 FT /note="A -> P (in NPHP9; a full-length mouse NEK8 construct FT containing the mutation shows a defect in ciliary FT localization with no apparent effect on ciliation, mitosis FT or centriole number; dbSNP:rs146326420)" FT /evidence="ECO:0000269|PubMed:18199800" FT /id="VAR_065771" FT VARIANT 580 FT /note="G -> S (in RHPD2; likely pathogenic; loss of ciliary FT localization; no effect on interaction with ANKS6; FT dbSNP:rs751440831)" FT /evidence="ECO:0000269|PubMed:26967905" FT /id="VAR_089848" FT VARIANT 602 FT /note="R -> W (in RHPD2; likely pathogenic; contrary to the FT wild type, it fails to rescue body curvature defects in FT zebrafish morphants; loss of ciliary localization; no FT effect on interaction with ANKS6; dbSNP:rs773883764)" FT /evidence="ECO:0000269|PubMed:26967905" FT /id="VAR_089849" SQ SEQUENCE 692 AA; 74806 MW; 9E09820DFB3D5CA1 CRC64; MEKYERIRVV GRGAFGIVHL CLRKADQKLV IIKQIPVEQM TKEERQAAQN ECQVLKLLNH PNVIEYYENF LEDKALMIAM EYAPGGTLAE FIQKRCNSLL EEETILHFFV QILLALHHVH THLILHRDLK TQNILLDKHR MVVKIGDFGI SKILSSKSKA YTVVGTPCYI SPELCEGKPY NQKSDIWALG CVLYELASLK RAFEAANLPA LVLKIMSGTF APISDRYSPE LRQLVLSLLS LEPAQRPPLS HIMAQPLCIR ALLNLHTDVG SVRMRRAEKS VAPSNTGSRT TSVRCRGIPR GPVRPAIPPP LSSVYAWGGG LGTPLRLPML NTEVVQVAAG RTQKAGVTRS GRLILWEAPP LGAGGGSLLP GAVEQPQPQF ISRFLEGQSG VTIKHVACGD FFTACLTDRG IIMTFGSGSN GCLGHGSLTD ISQPTIVEAL LGYEMVQVAC GASHVLALST ERELFAWGRG DSGRLGLGTR ESHSCPQQVP MPPGQEAQRV VCGIDSSMIL TVPGQALACG SNRFNKLGLD HLSLGEEPVP HQQVEEALSF TLLGSAPLDQ EPLLSIDLGT AHSAAVTASG DCYTFGSNQH GQLGTNTRRG SRAPCKVQGL EGIKMAMVAC GDAFTVAIGA ESEVYSWGKG ARGRLGRRDE DAGLPRPVQL DETHPYTVTS VSCCHGNTLL AVRSVTDEPV PP // ID PGFRB_HUMAN Reviewed; 1106 AA. AC P09619; B5A957; Q8N5L4; DT 01-JUL-1989, integrated into UniProtKB/Swiss-Prot. DT 01-JUL-1989, sequence version 1. DT 28-JAN-2026, entry version 269. DE RecName: Full=Platelet-derived growth factor receptor beta; DE Short=PDGF-R-beta; DE Short=PDGFR-beta; DE EC=2.7.10.1; DE AltName: Full=Beta platelet-derived growth factor receptor; DE AltName: Full=Beta-type platelet-derived growth factor receptor; DE AltName: Full=CD140 antigen-like family member B; DE AltName: Full=Platelet-derived growth factor receptor 1; DE Short=PDGFR-1; DE AltName: CD_antigen=CD140b; DE Flags: Precursor; GN Name=PDGFRB; Synonyms=PDGFR, PDGFR1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION AS PDGFB RECEPTOR, RP SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND INTERACTION WITH PDGFB. RX PubMed=2835772; DOI=10.1073/pnas.85.10.3435; RA Gronwald R.G.K., Grant F.J., Haldeman B.A., Hart C.E., O'Hara P.J., RA Hagen F.S., Ross R., Bowen-Pope D.F., Murray M.J.; RT "Cloning and expression of a cDNA coding for the human platelet-derived RT growth factor receptor: evidence for more than one receptor class."; RL Proc. Natl. Acad. Sci. U.S.A. 85:3435-3439(1988). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION AS PDGFB RECEPTOR, RP SUBCELLULAR LOCATION, GLYCOSYLATION, AUTOPHOSPHORYLATION, AND INTERACTION RP WITH PDGFA AND PDGFB. RX PubMed=2850496; DOI=10.1128/mcb.8.8.3476-3486.1988; RA Claesson-Welsh L., Eriksson A., Moren A., Severinsson L., Ek B., RA Oestman A., Betsholtz C., Heldin C.-H.; RT "cDNA cloning and expression of a human platelet-derived growth factor RT (PDGF) receptor specific for B-chain-containing PDGF molecules."; RL Mol. Cell. Biol. 8:3476-3486(1988). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING. RX PubMed=18593464; DOI=10.1186/ar2447; RA Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D., RA Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.; RT "Novel splice variants derived from the receptor tyrosine kinase RT superfamily are potential therapeutics for rheumatoid arthritis."; RL Arthritis Res. Ther. 10:R73-R73(2008). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT PHE-180. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 548-569. RX PubMed=9285559; DOI=10.1038/sj.onc.1201267; RA Chi K.D., McPhee R.A., Wagner A.S., Dietz J.J., Pantazis P., Goustin A.S.; RT "Integration of proviral DNA into the PDGF beta-receptor gene in HTLV-I- RT infected T-cells results in a novel tyrosine kinase product with RT transforming activity."; RL Oncogene 15:1051-1057(1997). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 559-1106 (ISOFORM 1), AND CHROMOSOMAL RP TRANSLOCATION WITH CEP85L. RX PubMed=21938754; DOI=10.1002/gcc.20930; RA Chmielecki J., Peifer M., Viale A., Hutchinson K., Giltnane J., Socci N.D., RA Hollis C.J., Dean R.S., Yenamandra A., Jagasia M., Kim A.S., Dave U.P., RA Thomas R.K., Pao W.; RT "Systematic screen for tyrosine kinase rearrangements identifies a novel RT C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated RT myeloproliferative neoplasm."; RL Genes Chromosomes Cancer 51:54-65(2012). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1046-1106. RX PubMed=2846185; DOI=10.1016/0092-8674(88)90224-3; RA Roberts W.M., Look A.T., Roussel M.F., Sherr C.J.; RT "Tandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor genes."; RL Cell 55:655-661(1988). RN [9] RP PROTEIN SEQUENCE OF 33-47. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [10] RP PHOSPHORYLATION AT TYR-751 AND TYR-857. RX PubMed=2550144; DOI=10.1016/0092-8674(89)90510-2; RA Kazlauskas A., Cooper J.A.; RT "Autophosphorylation of the PDGF receptor in the kinase insert region RT regulates interactions with cell proteins."; RL Cell 58:1121-1133(1989). RN [11] RP FUNCTION AS PDGFB RECEPTOR IN CELL PROLIFERATION AND CHEMOTAXIS, AND RP SUBCELLULAR LOCATION. RX PubMed=2554309; DOI=10.1073/pnas.86.21.8314; RA Matsui T., Pierce J.H., Fleming T.P., Greenberger J.S., LaRochelle W.J., RA Ruggiero M., Aaronson S.A.; RT "Independent expression of human alpha or beta platelet-derived growth RT factor receptor cDNAs in a naive hematopoietic cell leads to functional RT coupling with mitogenic and chemotactic signaling pathways."; RL Proc. Natl. Acad. Sci. U.S.A. 86:8314-8318(1989). RN [12] RP FUNCTION IN CELL PROLIFERATION; ACTIVATION OF PLCG1 AND IN PHOSPHORYLATION RP OF PLCG1 AND RASA1/GAP, AND MUTAGENESIS OF TYR-751 AND TYR-857. RX PubMed=1653029; DOI=10.1091/mbc.2.6.413; RA Kazlauskas A., Durden D.L., Cooper J.A.; RT "Functions of the major tyrosine phosphorylation site of the PDGF receptor RT beta subunit."; RL Cell Regul. 2:413-425(1991). RN [13] RP INTERACTION WITH PDGFRA; PDGFA AND PDGFB, FUNCTION AS RECEPTOR FOR PDGFA RP AND PDGFB, AND PHOSPHORYLATION AT TYR-857 AND TYR-751. RX PubMed=1709159; DOI=10.1016/s0021-9258(18)31541-2; RA Kelly J.D., Haldeman B.A., Grant F.J., Murray M.J., Seifert R.A., RA Bowen-Pope D.F., Cooper J.A., Kazlauskas A.; RT "Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit RT dimerization and intersubunit trans-phosphorylation."; RL J. Biol. Chem. 266:8987-8992(1991). RN [14] RP FUNCTION AS RECEPTOR FOR PDGFA AND PDGFB, SUBCELLULAR LOCATION, CATALYTIC RP ACTIVITY, AND MUTAGENESIS OF LYS-634. RX PubMed=1846866; DOI=10.1083/jcb.112.3.469; RA Sorkin A., Westermark B., Heldin C.H., Claesson-Welsh L.; RT "Effect of receptor kinase inactivation on the rate of internalization and RT degradation of PDGF and the PDGF beta-receptor."; RL J. Cell Biol. 112:469-478(1991). RN [15] RP FUNCTION IN ACTIVATION OF PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY, RP INTERACTION WITH PIK3R1 AND RASA1, PHOSPHORYLATION AT TYR-740; TYR-751; RP TYR-771 AND TYR-857, AND MUTAGENESIS OF LYS-634; TYR-716; TYR-740; TYR-751; RP TYR-763; TYR-771; TYR-775; TYR-778 AND TYR-857. RX PubMed=1314164; DOI=10.1002/j.1460-2075.1992.tb05182.x; RA Kashishian A., Kazlauskas A., Cooper J.A.; RT "Phosphorylation sites in the PDGF receptor with different specificities RT for binding GAP and PI3 kinase in vivo."; RL EMBO J. 11:1373-1382(1992). RN [16] RP FUNCTION AS PDGFB RECEPTOR IN CELL PROLIFERATION AND PHOSPHORYLATION OF RP PLCG1, INTERACTION WITH PLCG1, PHOSPHORYLATION AT TYR-1009 AND TYR-1021, RP AND MUTAGENESIS OF TYR-1009 AND TYR-1021. RX PubMed=1396585; DOI=10.1002/j.1460-2075.1992.tb05484.x; RA Ronnstrand L., Mori S., Arridsson A.K., Eriksson A., Wernstedt C., RA Hellman U., Claesson-Welsh L., Heldin C.H.; RT "Identification of two C-terminal autophosphorylation sites in the PDGF RT beta-receptor: involvement in the interaction with phospholipase C-gamma."; RL EMBO J. 11:3911-3919(1992). RN [17] RP UBIQUITINATION, AND DEGRADATION. RX PubMed=1313434; DOI=10.1016/s0021-9258(18)42714-7; RA Mori S., Heldin C.H., Claesson-Welsh L.; RT "Ligand-induced polyubiquitination of the platelet-derived growth factor RT beta-receptor."; RL J. Biol. Chem. 267:6429-6434(1992). RN [18] RP INTERACTION WITH PIK3R1 AND RASA1, AND MUTAGENESIS OF TYR-740; TYR-751 AND RP TYR-771. RX PubMed=1375321; DOI=10.1128/mcb.12.6.2534-2544.1992; RA Kazlauskas A., Kashishian A., Cooper J.A., Valius M.; RT "GTPase-activating protein and phosphatidylinositol 3-kinase bind to RT distinct regions of the platelet-derived growth factor receptor beta RT subunit."; RL Mol. Cell. Biol. 12:2534-2544(1992). RN [19] RP FUNCTION AS PDGFB RECEPTOR IN CELL PROLIFERATION, PHOSPHORYLATION AT RP TYR-579 AND TYR-581; INTERACTION WITH SRC, CATALYTIC ACTIVITY, AND RP MUTAGENESIS OF TYR-579 AND TYR-581. RX PubMed=7685273; DOI=10.1002/j.1460-2075.1993.tb05879.x; RA Mori S., Ronnstrand L., Yokote K., Engstrom A., Courtneidge S.A., RA Claesson-Welsh L., Heldin C.H.; RT "Identification of two juxtamembrane autophosphorylation sites in the PDGF RT beta-receptor; involvement in the interaction with Src family tyrosine RT kinases."; RL EMBO J. 12:2257-2264(1993). RN [20] RP INTERACTION WITH DGFA AND PDGFB. RX PubMed=7679113; DOI=10.1016/s0021-9258(18)53739-x; RA Fretto L.J., Snape A.J., Tomlinson J.E., Seroogy J.J., Wolf D.L., RA LaRochelle W.J., Giese N.A.; RT "Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB binding RT to alpha and beta PDGF receptor."; RL J. Biol. Chem. 268:3625-3631(1993). RN [21] RP FUNCTION IN PHOSPHORYLATION AND ACTIVATION OF PTPN11, INTERACTION WITH RP PTPN11; PIK3R1; PLCG1 AND RASA1, AND MUTAGENESIS OF TYR-1009. RX PubMed=7691811; DOI=10.1016/s0021-9258(20)80562-6; RA Lechleider R.J., Sugimoto S., Bennett A.M., Kashishian A.S., Cooper J.A., RA Shoelson S.E., Walsh C.T., Neel B.G.; RT "Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by RT its binding site, phosphotyrosine 1009, on the human platelet-derived RT growth factor receptor."; RL J. Biol. Chem. 268:21478-21481(1993). RN [22] RP INTERACTION WITH NCK1 AND PIK3R1, FUNCTION IN PHOSPHORYLATION OF NCK1, AND RP MUTAGENESIS OF TYR-751. RX PubMed=7692233; DOI=10.1128/mcb.13.11.6889-6896.1993; RA Nishimura R., Li W., Kashishian A., Mondino A., Zhou M., Cooper J., RA Schlessinger J.; RT "Two signaling molecules share a phosphotyrosine-containing binding site in RT the platelet-derived growth factor receptor."; RL Mol. Cell. Biol. 13:6889-6896(1993). RN [23] RP INTERACTION WITH SHB. RX PubMed=8302579; RA Welsh M., Mares J., Karlsson T., Lavergne C., Breant B., Claesson-Welsh L.; RT "Shb is a ubiquitously expressed Src homology 2 protein."; RL Oncogene 9:19-27(1994). RN [24] RP INTERACTION WITH GRB7. RX PubMed=8940081; DOI=10.1074/jbc.271.48.30942; RA Yokote K., Margolis B., Heldin C.H., Claesson-Welsh L.; RT "Grb7 is a downstream signaling component of platelet-derived growth factor RT alpha- and beta-receptors."; RL J. Biol. Chem. 271:30942-30949(1996). RN [25] RP CHROMOSOMAL TRANSLOCATION WITH TRIP11. RX PubMed=9373237; RA Abe A., Emi N., Tanimoto M., Terasaki H., Marunouchi T., Saito H.; RT "Fusion of the platelet-derived growth factor receptor beta to a novel gene RT CEV14 in acute myelogenous leukemia after clonal evolution."; RL Blood 90:4271-4277(1997). RN [26] RP INTERACTION WITH GRB10, AND MUTAGENESIS OF TYR-579; TYR-581; TYR-716; RP TYR-740; TYR-751; TYR-771; TYR-857; TYR-1009 AND TYR-1021. RX PubMed=10454568; DOI=10.1128/mcb.19.9.6217; RA Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A., RA Swamy O.R., Leone M.E., Riedel H.; RT "Grb10, a positive, stimulatory signaling adapter in platelet-derived RT growth factor BB-, insulin-like growth factor I-, and insulin-mediated RT mitogenesis."; RL Mol. Cell. Biol. 19:6217-6228(1999). RN [27] RP INTERACTION WITH SH2B2/APS. RX PubMed=9989826; DOI=10.1038/sj.onc.1202326; RA Yokouchi M., Wakioka T., Sakamoto H., Yasukawa H., Ohtsuka S., Sasaki A., RA Ohtsubo M., Valius M., Inoue A., Komiya S., Yoshimura A.; RT "APS, an adaptor protein containing PH and SH2 domains, is associated with RT the PDGF receptor and c-Cbl and inhibits PDGF-induced mitogenesis."; RL Oncogene 18:759-767(1999). RN [28] RP PHOSPHORYLATION AT TYR-562; TYR-751; TYR-763; TYR-771; TYR-775; TYR-778; RP TYR-857; TYR-1009 AND TYR-1021, AND DEPHOSPHORYLATION AT TYR-751; TYR-857; RP TYR-1009 AND TYR-1021 BY PTPRJ. RX PubMed=10821867; DOI=10.1074/jbc.275.21.16219; RA Kovalenko M., Denner K., Sandstrom J., Persson C., Gross S., Jandt E., RA Vilella R., Bohmer F., Ostman A.; RT "Site-selective dephosphorylation of the platelet-derived growth factor RT beta-receptor by the receptor-like protein-tyrosine phosphatase DEP-1."; RL J. Biol. Chem. 275:16219-16226(2000). RN [29] RP INTERACTION WITH PIK3C2B. RX PubMed=10805725; DOI=10.1128/mcb.20.11.3817-3830.2000; RA Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D., RA Domin J.; RT "Class II phosphoinositide 3-kinases are downstream targets of activated RT polypeptide growth factor receptors."; RL Mol. Cell. Biol. 20:3817-3830(2000). RN [30] RP FUNCTION AS A RECEPTOR FOR PDGFC, AND INTERACTION WITH PDGFC. RX PubMed=11297552; DOI=10.1074/jbc.m101056200; RA Gilbertson D.G., Duff M.E., West J.W., Kelly J.D., Sheppard P.O., RA Hofstrand P.D., Gao Z., Shoemaker K., Bukowski T.R., Moore M., RA Feldhaus A.L., Humes J.M., Palmer T.E., Hart C.E.; RT "Platelet-derived growth factor C (PDGF-C), a novel growth factor that RT binds to PDGF alpha and beta receptor."; RL J. Biol. Chem. 276:27406-27414(2001). RN [31] RP FUNCTION AS A RECEPTOR FOR PDGFD. RX PubMed=11331881; DOI=10.1038/35074588; RA Bergsten E., Uutela M., Li X., Pietras K., Oestman A., Heldin C.-H., RA Alitalo K., Eriksson U.; RT "PDGF-D is a specific, protease-activated ligand for the PDGF beta- RT receptor."; RL Nat. Cell Biol. 3:512-516(2001). RN [32] RP CHROMOSOMAL TRANSLOCATION WITH ETV6. RX PubMed=12181402; DOI=10.1056/nejmoa020150; RA Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., RA Baxter E.J., Chase A., Chessells J.M., Colombat M., Dearden C.E., RA Dimitrijevic S., Mahon F.-X., Marin D., Nikolova Z., Olavarria E., RA Silberman S., Schultheis B., Cross N.C.P., Goldman J.M.; RT "Response to imatinib mesylate in patients with chronic myeloproliferative RT diseases with rearrangements of the platelet-derived growth factor receptor RT beta."; RL N. Engl. J. Med. 347:481-487(2002). RN [33] RP CHROMOSOMAL TRANSLOCATION WITH PDE4DIP. RX PubMed=12907457; DOI=10.1182/blood-2003-04-1150; RA Wilkinson K., Velloso E.R.P., Lopes L.F., Lee C., Aster J.C., Shipp M.A., RA Aguiar R.C.T.; RT "Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated RT with eosinophilia: involvement of PDGFRB and response to imatinib."; RL Blood 102:4187-4190(2003). RN [34] RP CHROMOSOMAL TRANSLOCATION WITH SPECC1. RX PubMed=15087372; DOI=10.1158/0008-5472.can-03-4026; RA Morerio C., Acquila M., Rosanda C., Rapella A., Dufour C., Locatelli F., RA Maserati E., Pasquali F., Panarello C.; RT "HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic RT leukemia with t(5;17)(q33;p11.2)."; RL Cancer Res. 64:2649-2651(2004). RN [35] RP CHROMOSOMAL TRANSLOCATION WITH TP53BP1, AND ACTIVITY REGULATION. RX PubMed=15492236; DOI=10.1158/0008-5472.can-04-2005; RA Grand F.H., Burgstaller S., Kuhr T., Baxter E.J., Webersinke G., Thaler J., RA Chase A.J., Cross N.C.; RT "p53-Binding protein 1 is fused to the platelet-derived growth factor RT receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib- RT responsive eosinophilic myeloproliferative disorder."; RL Cancer Res. 64:7216-7219(2004). RN [36] RP PHOSPHORYLATION AT TYR-579; TYR-751; TYR-771 AND TYR-1021, AND RP DEPHOSPHORYLATION AT TYR-579 AND TYR-1021 BY PTPN2. RX PubMed=14966296; DOI=10.1128/mcb.24.5.2190-2201.2004; RA Persson C., Saevenhed C., Bourdeau A., Tremblay M.L., Markova B., RA Boehmer F.D., Haj F.G., Neel B.G., Elson A., Heldin C.H., Roennstrand L., RA Ostman A., Hellberg C.; RT "Site-selective regulation of platelet-derived growth factor beta receptor RT tyrosine phosphorylation by T-cell protein tyrosine phosphatase."; RL Mol. Cell. Biol. 24:2190-2201(2004). RN [37] RP PHOSPHORYLATION AT TYR-579; TYR-581; TYR-716; TYR-740; TYR-771; TYR-857; RP TYR-1009 AND TYR-1021. RX PubMed=15902258; DOI=10.1038/nature03587; RA Choi M.H., Lee I.K., Kim G.W., Kim B.U., Han Y.H., Yu D.Y., Park H.S., RA Kim K.Y., Lee J.S., Choi C., Bae Y.S., Lee B.I., Rhee S.G., Kang S.W.; RT "Regulation of PDGF signalling and vascular remodelling by peroxiredoxin RT II."; RL Nature 435:347-353(2005). RN [38] RP INTERACTION WITH CBL, SUBCELLULAR LOCATION, MUTAGENESIS OF TYR-1021, AND RP UBIQUITINATION. RX PubMed=17620338; DOI=10.1074/jbc.m701797200; RA Reddi A.L., Ying G., Duan L., Chen G., Dimri M., Douillard P., Druker B.J., RA Naramura M., Band V., Band H.; RT "Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-derived RT growth factor receptor beta provides a dual mechanism of negative RT regulation."; RL J. Biol. Chem. 282:29336-29347(2007). RN [39] RP FUNCTION AS PDGFD RECEPTOR. RX PubMed=21098708; DOI=10.1158/0008-5472.can-10-0511; RA Ustach C.V., Huang W., Conley-LaComb M.K., Lin C.Y., Che M., Abrams J., RA Kim H.R.; RT "A novel signaling axis of matriptase/PDGF-D/ss-PDGFR in human prostate RT cancer."; RL Cancer Res. 70:9631-9640(2010). RN [40] RP FUNCTION IN PHOSPHORYLATION OF CBL; STAM; PDCD6IP/ALIX; PLCG1 AND PTPN11, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND RP MUTAGENESIS OF LYS-634 AND TYR-857. RX PubMed=20494825; DOI=10.1016/j.cellsig.2010.05.004; RA Wardega P., Heldin C.H., Lennartsson J.; RT "Mutation of tyrosine residue 857 in the PDGF beta-receptor affects cell RT proliferation but not migration."; RL Cell. Signal. 22:1363-1368(2010). RN [41] RP FUNCTION. RX PubMed=20529858; DOI=10.1074/jbc.m110.102566; RA Mendelson K., Swendeman S., Saftig P., Blobel C.P.; RT "Stimulation of platelet-derived growth factor receptor beta (PDGFRbeta) RT activates ADAM17 and promotes metalloproteinase-dependent cross-talk RT between the PDGFRbeta and epidermal growth factor receptor (EGFR) signaling RT pathways."; RL J. Biol. Chem. 285:25024-25032(2010). RN [42] RP FUNCTION IN SMOOTH MUSCLE CELL PROLIFERATION AND MIGRATION. RX PubMed=21733313; DOI=10.1017/s0007114511002571; RA Kim H.J., Cha B.Y., Choi B., Lim J.S., Woo J.T., Kim J.S.; RT "Glyceollins inhibit platelet-derived growth factor-mediated human arterial RT smooth muscle cell proliferation and migration."; RL Br. J. Nutr. 107:24-35(2012). RN [43] RP INTERACTION WITH SHC1 AND GRB2, AND FUNCTION IN PHOSPHORYLATION OF SHC1. RX PubMed=8195171; DOI=10.1016/s0021-9258(17)36611-5; RA Yokote K., Mori S., Hansen K., McGlade J., Pawson T., Heldin C.H., RA Claesson-Welsh L.; RT "Direct interaction between Shc and the platelet-derived growth factor RT beta-receptor."; RL J. Biol. Chem. 269:15337-15343(1994). RN [44] RP FUNCTION IN SMOOTH MUSCLE CELL MIGRATION AND NEOINTIMA FORMATION AFTER RP BLOOD VESSEL INJURY, AND MUTAGENESIS OF TYR-740; TYR-751 AND TYR-1021. RX PubMed=21679854; DOI=10.1016/j.jacc.2011.02.037; RA Caglayan E., Vantler M., Leppanen O., Gerhardt F., Mustafov L., RA Ten Freyhaus H., Kappert K., Odenthal M., Zimmermann W.H., Tallquist M.D., RA Rosenkranz S.; RT "Disruption of platelet-derived growth factor-dependent RT phosphatidylinositol 3-kinase and phospholipase Cgamma 1 activity abolishes RT vascular smooth muscle cell proliferation and migration and attenuates RT neointima formation in vivo."; RL J. Am. Coll. Cardiol. 57:2527-2538(2011). RN [45] RP INVOLVEMENT IN PENTT, VARIANT PENTT ALA-665, AND CHARACTERIZATION OF RP VARIANT PENTT ALA-665. RX PubMed=26279204; DOI=10.1016/j.ajhg.2015.07.009; RA Johnston J.J., Sanchez-Contreras M.Y., Keppler-Noreuil K.M., Sapp J., RA Crenshaw M., Finch N.A., Cormier-Daire V., Rademakers R., Sybert V.P., RA Biesecker L.G.; RT "A point mutation in PDGFRB causes autosomal-dominant Penttinen syndrome."; RL Am. J. Hum. Genet. 97:465-474(2015). RN [46] RP INVOLVEMENT IN KOGS, AND VARIANT KOGS ARG-584. RX PubMed=25454926; DOI=10.1016/j.jpeds.2014.10.015; RA Takenouchi T., Yamaguchi Y., Tanikawa A., Kosaki R., Okano H., Kosaki K.; RT "Novel overgrowth syndrome phenotype due to recurrent de novo PDGFRB RT mutation."; RL J. Pediatr. 166:483-486(2015). RN [47] RP CHARACTERIZATION OF VARIANTS IBGC4 PRO-658; TRP-987 AND VAL-1071, AND RP FUNCTION. RX PubMed=26599395; DOI=10.1371/journal.pone.0143407; RA Vanlandewijck M., Lebouvier T., Andaloussi Maee M., Nahar K., Hornemann S., RA Kenkel D., Cunha S.I., Lennartsson J., Boss A., Heldin C.H., Keller A., RA Betsholtz C.; RT "Functional characterization of germline mutations in PDGFB and PDGFRB in RT primary familial brain calcification."; RL PLoS ONE 10:E0143407-E0143407(2015). RN [48] RP REVIEW ON SIGNALING AND AUTOPHOSPHORYLATION. RX PubMed=9739761; DOI=10.1016/s0304-419x(98)00015-8; RA Heldin C.H., Ostman A., Ronnstrand L.; RT "Signal transduction via platelet-derived growth factor receptors."; RL Biochim. Biophys. Acta 1378:F79-113(1998). RN [49] RP REVIEW. RX PubMed=15207817; DOI=10.1016/j.cytogfr.2004.03.002; RA Ostman A.; RT "PDGF receptors-mediators of autocrine tumor growth and regulators of tumor RT vasculature and stroma."; RL Cytokine Growth Factor Rev. 15:275-286(2004). RN [50] RP REVIEW. RX PubMed=17419949; DOI=10.1016/s0065-230x(06)97011-0; RA Ostman A., Heldin C.H.; RT "PDGF receptors as targets in tumor treatment."; RL Adv. Cancer Res. 97:247-274(2007). RN [51] RP REVIEW ON FUNCTION; LIGANDS; ROLE IN DEVELOPMENT AND DISEASE AND ACTIVATION RP OF SIGNALING PATHWAYS. RX PubMed=18483217; DOI=10.1101/gad.1653708; RA Andrae J., Gallini R., Betsholtz C.; RT "Role of platelet-derived growth factors in physiology and medicine."; RL Genes Dev. 22:1276-1312(2008). RN [52] RP X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 751-755 IN COMPLEX WITH PIK3R1, RP AND COMPARISON WITH NMR ANALYSIS. RX PubMed=11567151; DOI=10.1107/s0907444901012434; RA Pauptit R.A., Dennis C.A., Derbyshire D.J., Breeze A.L., Weston S.A., RA Rowsell S., Murshudov G.N.; RT "NMR trial models: experiences with the colicin immunity protein Im7 and RT the p85alpha C-terminal SH2-peptide complex."; RL Acta Crystallogr. D 57:1397-1404(2001). RN [53] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1102-1106 IN COMPLEX WITH NHERF1, RP AND INTERACTION WITH NHERF1. RX PubMed=11882663; DOI=10.1074/jbc.m201507200; RA Karthikeyan S., Leung T., Ladias J.A.A.; RT "Structural determinants of the Na+/H+ exchanger regulatory factor RT interaction with the beta 2 adrenergic and platelet-derived growth factor RT receptors."; RL J. Biol. Chem. 277:18973-18978(2002). RN [54] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 33-314 IN COMPLEX WITH PDGFB, RP SUBUNIT, GLYCOSYLATION AT ASN-45; ASN-89; ASN-103; ASN-215; ASN-230; RP ASN-292 AND ASN-307, AND DISULFIDE BONDS. RX PubMed=20534510; DOI=10.1073/pnas.1000806107; RA Shim A.H., Liu H., Focia P.J., Chen X., Lin P.C., He X.; RT "Structures of a platelet-derived growth factor/propeptide complex and a RT platelet-derived growth factor/receptor complex."; RL Proc. Natl. Acad. Sci. U.S.A. 107:11307-11312(2010). RN [55] RP VARIANTS [LARGE SCALE ANALYSIS] PHE-29; LYS-282; LYS-485; HIS-589; TYR-718 RP AND ILE-882. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [56] RP VARIANT IMF1 THR-660, AND INVOLVEMENT IN IMF1. RX PubMed=23731542; DOI=10.1016/j.ajhg.2013.04.024; RA Martignetti J.A., Tian L., Li D., Ramirez M.C., Camacho-Vanegas O., RA Camacho S.C., Guo Y., Zand D.J., Bernstein A.M., Masur S.K., Kim C.E., RA Otieno F.G., Hou C., Abdel-Magid N., Tweddale B., Metry D., Fournet J.C., RA Papp E., McPherson E.W., Zabel C., Vaksmann G., Morisot C., Keating B., RA Sleiman P.M., Cleveland J.A., Everman D.B., Zackai E., Hakonarson H.; RT "Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis."; RL Am. J. Hum. Genet. 92:1001-1007(2013). RN [57] RP VARIANT IMF1 CYS-561, AND INVOLVEMENT IN IMF1. RX PubMed=23731537; DOI=10.1016/j.ajhg.2013.04.026; RA Cheung Y.H., Gayden T., Campeau P.M., Leduc C.A., Russo D., Nguyen V.H., RA Guo J., Qi M., Guan Y., Albrecht S., Moroz B., Eldin K.W., Lu J.T., RA Schwartzentruber J., Malkin D., Berghuis A.M., Emil S., Gibbs R.A., RA Burk D.L., Vanstone M., Lee B.H., Orchard D., Boycott K.M., Chung W.K., RA Jabado N.; RT "A recurrent PDGFRB mutation causes familial infantile myofibromatosis."; RL Am. J. Hum. Genet. 92:996-1000(2013). RN [58] RP VARIANTS IBGC4 PRO-658; TRP-987 AND VAL-1071, AND INVOLVEMENT IN IBGC4. RX PubMed=24065723; DOI=10.1093/brain/awt255; RG French IBGC Study Group; RA Nicolas G., Pottier C., Charbonnier C., Guyant-Marechal L., Le Ber I., RA Pariente J., Labauge P., Ayrignac X., Defebvre L., Maltete D., RA Martinaud O., Lefaucheur R., Guillin O., Wallon D., Chaumette B., RA Rondepierre P., Derache N., Fromager G., Schaeffer S., Krystkowiak P., RA Verny C., Jurici S., Sauvee M., Verin M., Lebouvier T., Rouaud O., RA Thauvin-Robinet C., Rousseau S., Rovelet-Lecrux A., Frebourg T., RA Campion D., Hannequin D.; RT "Phenotypic spectrum of probable and genetically-confirmed idiopathic basal RT ganglia calcification."; RL Brain 136:3395-3407(2013). RN [59] RP VARIANTS IBGC4 PRO-658 AND TRP-987, AND INVOLVEMENT IN IBGC4. RX PubMed=23255827; DOI=10.1212/wnl.0b013e31827ccf34; RA Nicolas G., Pottier C., Maltete D., Coutant S., Rovelet-Lecrux A., RA Legallic S., Rousseau S., Vaschalde Y., Guyant-Marechal L., Augustin J., RA Martinaud O., Defebvre L., Krystkowiak P., Pariente J., Clanet M., RA Labauge P., Ayrignac X., Lefaucheur R., Le Ber I., Frebourg T., RA Hannequin D., Campion D.; RT "Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia RT calcification."; RL Neurology 80:181-187(2013). RN [60] RP VARIANT PENTT SER-666, CHARACTERIZATION OF VARIANT PENTT SER-666, AND RP INVOLVEMENT IN PENTT. RX PubMed=30573803; DOI=10.1038/s41431-018-0323-z; RA Bredrup C., Stokowy T., McGaughran J., Lee S., Sapkota D., Cristea I., RA Xu L., Tveit K.S., Hoevding G., Steen V.M., Roedahl E., Bruland O., RA Houge G.; RT "A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a RT progeria-like condition in the severe end of Penttinen syndrome."; RL Eur. J. Hum. Genet. 27:574-581(2019). RN [61] RP VARIANT OPDKD TYR-666, CHARACTERIZATION OF VARIANT OPDKD TYR-666, AND RP INVOLVEMENT IN OPDKD. RX PubMed=33450762; DOI=10.1093/hmg/ddab014; RA Bredrup C., Cristea I., Safieh L.A., Di Maria E., Gjertsen B.T., RA Tveit K.S., Thu F., Bull N., Edward D.P., Hennekam R.C.M., Hoevding G., RA Haugen O.H., Houge G., Roedahl E., Bruland O.; RT "Temperature-dependent autoactivation associated with clinical variability RT of PDGFRB Asn666 substitutions."; RL Hum. Mol. Genet. 30:72-77(2021). CC -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor CC for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA CC and PDGFB, and plays an essential role in the regulation of embryonic CC development, cell proliferation, survival, differentiation, chemotaxis CC and migration. Plays an essential role in blood vessel development by CC promoting proliferation, migration and recruitment of pericytes and CC smooth muscle cells to endothelial cells. Plays a role in the migration CC of vascular smooth muscle cells and the formation of neointima at CC vascular injury sites. Required for normal development of the CC cardiovascular system. Required for normal recruitment of pericytes CC (mesangial cells) in the kidney glomerulus, and for normal formation of CC a branched network of capillaries in kidney glomeruli. Promotes CC rearrangement of the actin cytoskeleton and the formation of membrane CC ruffles. Binding of its cognate ligands - homodimeric PDGFB, CC heterodimers formed by PDGFA and PDGFB or homodimeric PDGFD -leads to CC the activation of several signaling cascades; the response depends on CC the nature of the bound ligand and is modulated by the formation of CC heterodimers between PDGFRA and PDGFRB. Phosphorylates PLCG1, PIK3R1, CC PTPN11, RASA1/GAP, CBL, SHC1 and NCK1. Activation of PLCG1 leads to the CC production of the cellular signaling molecules diacylglycerol and CC inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the CC activation of protein kinase C. Phosphorylation of PIK3R1, the CC regulatory subunit of phosphatidylinositol 3-kinase, leads to the CC activation of the AKT1 signaling pathway. Phosphorylation of SHC1, or CC of the C-terminus of PTPN11, creates a binding site for GRB2, resulting CC in the activation of HRAS, RAF1 and down-stream MAP kinases, including CC MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation and activation CC of SRC family kinases. Promotes phosphorylation of PDCD6IP/ALIX and CC STAM. Receptor signaling is down-regulated by protein phosphatases that CC dephosphorylate the receptor and its down-stream effectors, and by CC rapid internalization of the activated receptor. CC {ECO:0000269|PubMed:11297552, ECO:0000269|PubMed:11331881, CC ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1396585, CC ECO:0000269|PubMed:1653029, ECO:0000269|PubMed:1709159, CC ECO:0000269|PubMed:1846866, ECO:0000269|PubMed:20494825, CC ECO:0000269|PubMed:20529858, ECO:0000269|PubMed:21098708, CC ECO:0000269|PubMed:21679854, ECO:0000269|PubMed:21733313, CC ECO:0000269|PubMed:2554309, ECO:0000269|PubMed:26599395, CC ECO:0000269|PubMed:2835772, ECO:0000269|PubMed:2850496, CC ECO:0000269|PubMed:7685273, ECO:0000269|PubMed:7691811, CC ECO:0000269|PubMed:7692233, ECO:0000269|PubMed:8195171}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:1846866, ECO:0000269|PubMed:20494825, CC ECO:0000269|PubMed:7685273}; CC -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence CC of bound ligand. Binding of PDGFB and/or PDGFD leads to dimerization CC and activation by autophosphorylation on tyrosine residues. Inhibited CC by imatinib. {ECO:0000269|PubMed:15492236}. CC -!- SUBUNIT: Interacts with homodimeric PDGFB and PDGFD, and with CC heterodimers formed by PDGFA and PDGFB. May also interact with CC homodimeric PDGFC. Monomer in the absence of bound ligand. Interaction CC with homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or CC homodimeric PDGFD, leads to receptor dimerization, where both PDGFRA CC homodimers and heterodimers with PDGFRB are observed. Interacts with CC SH2B2/APS. Interacts directly (tyrosine phosphorylated) with SHB. CC Interacts (tyrosine phosphorylated) with PIK3R1 and RASA1. Interacts CC (tyrosine phosphorylated) with CBL. Interacts (tyrosine phosphorylated) CC with SRC and SRC family kinases. Interacts (tyrosine phosphorylated) CC with PIK3C2B, maybe indirectly. Interacts (tyrosine phosphorylated) CC with SHC1, GRB7, GRB10 and NCK1. Interaction with GRB2 is mediated by CC SHC1. Interacts (via C-terminus) with NHERF1. CC {ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:10805725, CC ECO:0000269|PubMed:11297552, ECO:0000269|PubMed:11567151, CC ECO:0000269|PubMed:11882663, ECO:0000269|PubMed:1314164, CC ECO:0000269|PubMed:1375321, ECO:0000269|PubMed:1396585, CC ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:17620338, CC ECO:0000269|PubMed:20534510, ECO:0000269|PubMed:2835772, CC ECO:0000269|PubMed:2850496, ECO:0000269|PubMed:7679113, CC ECO:0000269|PubMed:7691811, ECO:0000269|PubMed:7692233, CC ECO:0000269|PubMed:8195171, ECO:0000269|PubMed:8302579, CC ECO:0000269|PubMed:8940081, ECO:0000269|PubMed:9989826}. CC -!- INTERACTION: CC P09619; P05067: APP; NbExp=3; IntAct=EBI-641237, EBI-77613; CC P09619; Q8TAP6: CEP76; NbExp=3; IntAct=EBI-641237, EBI-742887; CC P09619; P06241: FYN; NbExp=3; IntAct=EBI-641237, EBI-515315; CC P09619; Q14451: GRB7; NbExp=4; IntAct=EBI-641237, EBI-970191; CC P09619; P14778: IL1R1; NbExp=2; IntAct=EBI-641237, EBI-525905; CC P09619; P35968: KDR; NbExp=2; IntAct=EBI-641237, EBI-1005487; CC P09619; Q53G59: KLHL12; NbExp=6; IntAct=EBI-641237, EBI-740929; CC P09619; Q5T749: KPRP; NbExp=3; IntAct=EBI-641237, EBI-10981970; CC P09619; Q15323: KRT31; NbExp=3; IntAct=EBI-641237, EBI-948001; CC P09619; O76011: KRT34; NbExp=3; IntAct=EBI-641237, EBI-1047093; CC P09619; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-641237, EBI-10172052; CC P09619; P60328: KRTAP12-3; NbExp=3; IntAct=EBI-641237, EBI-11953334; CC P09619; O94898: LRIG2; NbExp=3; IntAct=EBI-641237, EBI-2830372; CC P09619; O75581: LRP6; NbExp=3; IntAct=EBI-641237, EBI-910915; CC P09619; O14745: NHERF1; NbExp=5; IntAct=EBI-641237, EBI-349787; CC P09619; Q15599: NHERF2; NbExp=2; IntAct=EBI-641237, EBI-1149760; CC P09619; P01127: PDGFB; NbExp=16; IntAct=EBI-641237, EBI-1554925; CC P09619; P27986: PIK3R1; NbExp=21; IntAct=EBI-641237, EBI-79464; CC P09619; O00459: PIK3R2; NbExp=3; IntAct=EBI-641237, EBI-346930; CC P09619; P19174: PLCG1; NbExp=7; IntAct=EBI-641237, EBI-79387; CC P09619; P60484: PTEN; NbExp=3; IntAct=EBI-641237, EBI-696162; CC P09619; P18031: PTPN1; NbExp=3; IntAct=EBI-641237, EBI-968788; CC P09619; Q06124: PTPN11; NbExp=8; IntAct=EBI-641237, EBI-297779; CC P09619; Q05209: PTPN12; NbExp=3; IntAct=EBI-641237, EBI-2266035; CC P09619; P23470: PTPRG; NbExp=2; IntAct=EBI-641237, EBI-2258115; CC P09619; Q12913: PTPRJ; NbExp=4; IntAct=EBI-641237, EBI-2264500; CC P09619; P20936: RASA1; NbExp=3; IntAct=EBI-641237, EBI-1026476; CC P09619; Q13239: SLA; NbExp=4; IntAct=EBI-641237, EBI-726214; CC P09619; Q15654: TRIP6; NbExp=3; IntAct=EBI-641237, EBI-742327; CC P09619; P07947: YES1; NbExp=3; IntAct=EBI-641237, EBI-515331; CC P09619; P0CK45: E5; Xeno; NbExp=2; IntAct=EBI-641237, EBI-7015490; CC P09619; P35918: Kdr; Xeno; NbExp=4; IntAct=EBI-641237, EBI-1555005; CC P09619; Q28619: NHERF1; Xeno; NbExp=3; IntAct=EBI-641237, EBI-7073613; CC P09619; P23727: PIK3R1; Xeno; NbExp=6; IntAct=EBI-641237, EBI-520244; CC P09619; P08487: PLCG1; Xeno; NbExp=3; IntAct=EBI-641237, EBI-8013886; CC P09619; P41499: Ptpn11; Xeno; NbExp=4; IntAct=EBI-641237, EBI-7180604; CC P09619; P25020: V-SRC; Xeno; NbExp=4; IntAct=EBI-641237, EBI-8636140; CC -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane CC protein. Cytoplasmic vesicle. Lysosome lumen. Note=After ligand CC binding, the autophosphorylated receptor is ubiquitinated and CC internalized, leading to its degradation. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P09619-1; Sequence=Displayed; CC Name=2; CC IsoId=P09619-2; Sequence=VSP_056008, VSP_056009; CC -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding. CC Autophosphorylation occurs in trans, i.e. one subunit of the dimeric CC receptor phosphorylates tyrosine residues on the other subunit. CC Phosphorylation at Tyr-579, and to a lesser degree, at Tyr-581, is CC important for interaction with SRC family kinases. Phosphorylation at CC Tyr-740 and Tyr-751 is important for interaction with PIK3R1. CC Phosphorylation at Tyr-751 is important for interaction with NCK1. CC Phosphorylation at Tyr-771 and Tyr-857 is important for interaction CC with RASA1/GAP. Phosphorylation at Tyr-857 is important for efficient CC phosphorylation of PLCG1 and PTPN11, resulting in increased CC phosphorylation of AKT1, MAPK1/ERK2 and/or MAPK3/ERK1, PDCD6IP/ALIX and CC STAM, and in increased cell proliferation. Phosphorylation at Tyr-1009 CC is important for interaction with PTPN11. Phosphorylation at Tyr-1009 CC and Tyr-1021 is important for interaction with PLCG1. Phosphorylation CC at Tyr-1021 is important for interaction with CBL; PLCG1 and CBL CC compete for the same binding site. Dephosphorylated by PTPRJ at Tyr- CC 751, Tyr-857, Tyr-1009 and Tyr-1021. Dephosphorylated by PTPN2 at Tyr- CC 579 and Tyr-1021. {ECO:0000269|PubMed:10821867, CC ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1396585, CC ECO:0000269|PubMed:14966296, ECO:0000269|PubMed:15902258, CC ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:2550144, CC ECO:0000269|PubMed:7685273}. CC -!- PTM: N-glycosylated. {ECO:0000269|PubMed:20534510, CC ECO:0000269|PubMed:2850496}. CC -!- PTM: Ubiquitinated. After autophosphorylation, the receptor is CC polyubiquitinated, leading to its degradation. CC {ECO:0000269|PubMed:1313434, ECO:0000269|PubMed:17620338}. CC -!- DISEASE: Note=A chromosomal aberration involving PDGFRB is found in a CC form of chronic myelomonocytic leukemia (CMML). Translocation CC t(5;12)(q33;p13) with EVT6/TEL. It is characterized by abnormal clonal CC myeloid proliferation and by progression to acute myelogenous leukemia CC (AML). CC -!- DISEASE: Myeloproliferative disorder chronic with eosinophilia (MPE) CC [MIM:131440]: A hematologic disorder characterized by malignant CC eosinophils proliferation. Note=The gene represented in this entry may CC be involved in disease pathogenesis. Chromosomal aberrations involving CC PDGFRB have been found in many instances of chronic myeloproliferative CC disorder with eosinophilia. Translocation t(5;12) with ETV6 on CC chromosome 12 creating an PDGFRB-ETV6 fusion protein (PubMed:12181402). CC Translocation t(5;15)(q33;q22) with TP53BP1 creating a PDGFRB-TP53BP1 CC fusion protein (PubMed:15492236). Translocation t(1;5)(q23;q33) that CC forms a PDE4DIP-PDGFRB fusion protein (PubMed:12907457). Translocation CC t(5;6)(q33-34;q23) with CEP85L that fuses the 5'-end of CEP85L (isoform CC 4) to the 3'-end of PDGFRB (PubMed:21938754). CC {ECO:0000269|PubMed:12181402, ECO:0000269|PubMed:12907457, CC ECO:0000269|PubMed:15492236, ECO:0000269|PubMed:21938754}. CC -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of CC acute leukemia, a cancer of the white blood cells. AML is a malignant CC disease of bone marrow characterized by maturational arrest of CC hematopoietic precursors at an early stage of development. Clonal CC expansion of myeloid blasts occurs in bone marrow, blood, and other CC tissue. Myelogenous leukemias develop from changes in cells that CC normally produce neutrophils, basophils, eosinophils and monocytes. CC Note=The gene represented in this entry may be involved in disease CC pathogenesis. A chromosomal aberration involving PDGFRB has been found CC in a patient with AML. Translocation t(5;14)(q33;q32) with TRIP11 CC (PubMed:9373237). {ECO:0000269|PubMed:9373237}. CC -!- DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An CC aggressive pediatric myelodysplastic syndrome/myeloproliferative CC disorder characterized by malignant transformation in the hematopoietic CC stem cell compartment with proliferation of differentiated progeny. CC Patients have splenomegaly, enlarged lymph nodes, rashes, and CC hemorrhages. Note=The gene represented in this entry may be involved in CC disease pathogenesis. A chromosomal aberration involving PDGFRB has CC been found in a patient with JMML. Translocation t(5;17)(q33;p11.2) CC with SPECC1 (PubMed:15087372). {ECO:0000269|PubMed:15087372}. CC -!- DISEASE: Basal ganglia calcification, idiopathic, 4 (IBGC4) CC [MIM:615007]: A form of basal ganglia calcification, an autosomal CC dominant condition characterized by symmetric calcification in the CC basal ganglia and other brain regions. Affected individuals can either CC be asymptomatic or show a wide spectrum of neuropsychiatric symptoms, CC including parkinsonism, dystonia, tremor, ataxia, dementia, psychosis, CC seizures, and chronic headache. Serum levels of calcium, phosphate, CC alkaline phosphatase and parathyroid hormone are normal. The CC neuropathological hallmark of the disease is vascular and pericapillary CC calcification, mainly of calcium phosphate, in the affected brain CC areas. {ECO:0000269|PubMed:23255827, ECO:0000269|PubMed:24065723, CC ECO:0000269|PubMed:26599395}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Myofibromatosis, infantile 1 (IMF1) [MIM:228550]: A rare CC mesenchymal disorder characterized by the development of benign tumors CC in the skin, striated muscles, bones, and, more rarely, visceral CC organs. Subcutaneous or soft tissue nodules commonly involve the skin CC of the head, neck, and trunk. Skeletal and muscular lesions occur in CC about half of the patients. Lesions may be solitary or multicentric, CC and they may be present at birth or become apparent in early infancy or CC occasionally in adult life. Visceral lesions are associated with high CC morbidity and mortality. {ECO:0000269|PubMed:23731537, CC ECO:0000269|PubMed:23731542}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Kosaki overgrowth syndrome (KOGS) [MIM:616592]: A syndrome CC characterized by somatic overgrowth, distinctive facial features, CC hyperelastic and fragile skin, and progressive neurologic deterioration CC with white matter lesions on brain imaging. CC {ECO:0000269|PubMed:25454926}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Premature aging syndrome, Penttinen type (PENTT) [MIM:601812]: CC An autosomal dominant syndrome characterized by a prematurely aged CC appearance with lipoatrophy, epidermal and dermal atrophy along with CC hypertrophic lesions that resemble scars, thin hair, proptosis, CC underdeveloped cheekbones, and marked acro-osteolysis. CC {ECO:0000269|PubMed:26279204, ECO:0000269|PubMed:30573803}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Ocular pterygium-digital keloid dysplasia syndrome (OPDKD) CC [MIM:621091]: An autosomal dominant disorder that presents in childhood CC with aggressive ingrowth of vascularized connective tissue on the CC cornea, ultimately leading to loss of vision. Later, affected CC individuals develop keloids on digits after minor trauma, but are CC otherwise healthy. {ECO:0000269|PubMed:33450762}. Note=The disease may CC be caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. CSF-1/PDGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/21/PDGFRB"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; J03278; AAA60049.1; -; mRNA. DR EMBL; M21616; AAA36427.1; -; mRNA. DR EMBL; EU826595; ACF47631.1; -; mRNA. DR EMBL; AC005895; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC011382; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC032224; AAH32224.1; -; mRNA. DR EMBL; U33172; AAC51675.1; -; Genomic_DNA. DR CCDS; CCDS4303.1; -. [P09619-1] DR PIR; A28206; PFHUGB. DR RefSeq; NP_002600.1; NM_002609.4. [P09619-1] DR PDB; 1GQ5; X-ray; 2.20 A; A=1102-1106. DR PDB; 1H9O; X-ray; 1.79 A; B=751-755. DR PDB; 1SHA; X-ray; 1.50 A; B=751-755. DR PDB; 2IUI; X-ray; 2.40 A; C/D=748-758. DR PDB; 2L6W; NMR; -; A/B=526-563. DR PDB; 2PLD; NMR; -; B=1018-1029. DR PDB; 2PLE; NMR; -; B=1018-1029. DR PDB; 3MJG; X-ray; 2.30 A; X/Y=33-314. DR PDBsum; 1GQ5; -. DR PDBsum; 1H9O; -. DR PDBsum; 1SHA; -. DR PDBsum; 2IUI; -. DR PDBsum; 2L6W; -. DR PDBsum; 2PLD; -. DR PDBsum; 2PLE; -. DR PDBsum; 3MJG; -. DR AlphaFoldDB; P09619; -. DR BMRB; P09619; -. DR EMDB; EMD-6426; -. DR SMR; P09619; -. DR BioGRID; 111185; 211. DR ComplexPortal; CPX-2882; PDGF receptor beta - PDGF-BB complex. DR ComplexPortal; CPX-2883; PDGF receptor alpha-beta - PDGF-BB complex. DR ComplexPortal; CPX-2886; PDGF receptor beta - PDGF-AB complex. DR ComplexPortal; CPX-2888; PDGF receptor alpha-beta - PDGF-CC complex. DR ComplexPortal; CPX-2889; PDGF receptor beta - PDGF-DD complex. DR ComplexPortal; CPX-2890; PDGF receptor alpha-beta - PDGF-DD complex. DR ComplexPortal; CPX-2891; PDGF receptor beta - PDGF-CC complex. DR ComplexPortal; CPX-2892; PDGF receptor alpha-beta - PDGF-AB complex. DR CORUM; P09619; -. DR DIP; DIP-558N; -. DR FunCoup; P09619; 1764. DR IntAct; P09619; 390. DR MINT; P09619; -. DR STRING; 9606.ENSP00000261799; -. DR BindingDB; P09619; -. DR ChEMBL; CHEMBL1913; -. DR DrugBank; DB00102; Becaplermin. DR DrugBank; DB01254; Dasatinib. DR DrugBank; DB12147; Erdafitinib. DR DrugBank; DB11741; Famitinib. DR DrugBank; DB10770; Foreskin fibroblast (neonatal). DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB00619; Imatinib. DR DrugBank; DB11845; Lucitanib. DR DrugBank; DB06595; Midostaurin. DR DrugBank; DB09079; Nintedanib. DR DrugBank; DB06589; Pazopanib. DR DrugBank; DB08339; PD-166326. DR DrugBank; DB17041; PD-173952. DR DrugBank; DB02567; PD173955. DR DrugBank; DB12978; Pexidartinib. DR DrugBank; DB09221; Polaprezinc. DR DrugBank; DB15822; Pralsetinib. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB14840; Ripretinib. DR DrugBank; DB06436; Semaxanib. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB08009; SU-11652. DR DrugBank; DB01268; Sunitinib. DR DrugBank; DB13093; TAK-593. DR DrugBank; DB11800; Tivozanib. DR DrugBank; DB09283; Trapidil. DR DrugBank; DB05146; XL820. DR DrugBank; DB05014; XL999. DR DrugCentral; P09619; -. DR GuidetoPHARMACOLOGY; 1804; -. DR TCDB; 8.A.23.1.37; the basigin (basigin) family. DR GlyConnect; 1967; 4 N-Linked glycans (3 sites). DR GlyCosmos; P09619; 11 sites, 4 glycans. DR GlyGen; P09619; 13 sites, 4 N-linked glycans (3 sites), 1 O-linked glycan (1 site). DR iPTMnet; P09619; -. DR PhosphoSitePlus; P09619; -. DR BioMuta; PDGFRB; -. DR DMDM; 129890; -. DR CPTAC; CPTAC-1630; -. DR CPTAC; CPTAC-3063; -. DR jPOST; P09619; -. DR MassIVE; P09619; -. DR PaxDb; 9606-ENSP00000261799; -. DR PeptideAtlas; P09619; -. DR ProteomicsDB; 52253; -. [P09619-1] DR Pumba; P09619; -. DR ABCD; P09619; 7 sequenced antibodies. DR Antibodypedia; 3424; 2244 antibodies from 49 providers. DR DNASU; 5159; -. DR Ensembl; ENST00000261799.9; ENSP00000261799.4; ENSG00000113721.15. [P09619-1] DR GeneID; 5159; -. DR KEGG; hsa:5159; -. DR MANE-Select; ENST00000261799.9; ENSP00000261799.4; NM_002609.4; NP_002600.1. DR UCSC; uc003lro.4; human. [P09619-1] DR AGR; HGNC:8804; -. DR CIViC; 5159; 2 evidence items across 3 molecular profiles. DR ClinPGx; PA33148; -. DR CTD; 5159; -. DR DisGeNET; 5159; -. DR GeneCards; PDGFRB; -. DR GeneReviews; PDGFRB; -. DR HGNC; HGNC:8804; PDGFRB. DR HPA; ENSG00000113721; Low tissue specificity. DR MalaCards; PDGFRB; -. DR MIM; 131440; phenotype. DR MIM; 173410; gene. DR MIM; 228550; phenotype. DR MIM; 601626; phenotype. DR MIM; 601812; phenotype. DR MIM; 607785; phenotype. DR MIM; 615007; phenotype. DR MIM; 616592; phenotype. DR MIM; 621091; phenotype. DR OpenTargets; ENSG00000113721; -. DR Orphanet; 363665; Acroosteolysis-keloid-like lesions-premature aging syndrome. DR Orphanet; 1980; Bilateral striopallidodentate calcinosis. DR Orphanet; 86830; Chronic myeloproliferative disease, unclassifiable. DR Orphanet; 2591; Infantile myofibromatosis. DR Orphanet; 477831; Kosaki overgrowth syndrome. DR Orphanet; 168950; Myeloid/lymphoid neoplasm associated with PDGFRB rearrangement. DR Orphanet; 314950; Primary hypereosinophilic syndrome. DR VEuPathDB; HostDB:ENSG00000113721; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00940000157138; -. DR HOGENOM; CLU_000288_49_0_1; -. DR InParanoid; P09619; -. DR OMA; WPEDQEF; -. DR OrthoDB; 9936425at2759; -. DR PAN-GO; P09619; 10 GO annotations based on evolutionary models. DR PhylomeDB; P09619; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P09619; -. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-186763; Downstream signal transduction. DR Reactome; R-HSA-186797; Signaling by PDGF. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR SignaLink; P09619; -. DR SIGNOR; P09619; -. DR Agora; ENSG00000113721; -. DR BioGRID-ORCS; 5159; 18 hits in 1194 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; PDGFRB; human. DR EvolutionaryTrace; P09619; -. DR GeneWiki; PDGFRB; -. DR GenomeRNAi; 5159; -. DR Pharos; P09619; Tclin. DR PRO; PR:P09619; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P09619; protein. DR Bgee; ENSG00000113721; Expressed in stromal cell of endometrium and 182 other cell types or tissues. DR ExpressionAtlas; P09619; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; ISS:UniProtKB. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-SubCell. DR GO; GO:0005925; C:focal adhesion; HDA:UniProtKB. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0043202; C:lysosomal lumen; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; IDA:BHF-UCL. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0005096; F:GTPase activator activity; IMP:UniProtKB. DR GO; GO:0160185; F:phospholipase C activator activity; IMP:UniProtKB. DR GO; GO:0004992; F:platelet activating factor receptor activity; TAS:ProtInc. DR GO; GO:0005019; F:platelet-derived growth factor beta-receptor activity; IDA:UniProtKB. DR GO; GO:0048407; F:platelet-derived growth factor binding; IDA:UniProtKB. DR GO; GO:0005017; F:platelet-derived growth factor receptor activity; TAS:ProtInc. DR GO; GO:0005161; F:platelet-derived growth factor receptor binding; IPI:BHF-UCL. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0005102; F:signaling receptor binding; IPI:UniProtKB. DR GO; GO:0038085; F:vascular endothelial growth factor binding; IPI:BHF-UCL. DR GO; GO:0001525; P:angiogenesis; IBA:GO_Central. DR GO; GO:0035909; P:aorta morphogenesis; ISS:BHF-UCL. DR GO; GO:0055003; P:cardiac myofibril assembly; ISS:UniProtKB. DR GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB. DR GO; GO:0060981; P:cell migration involved in coronary angiogenesis; ISS:UniProtKB. DR GO; GO:0035441; P:cell migration involved in vasculogenesis; ISS:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0072277; P:metanephric glomerular capillary formation; ISS:UniProtKB. DR GO; GO:0072262; P:metanephric glomerular mesangial cell proliferation involved in metanephros development; ISS:UniProtKB. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0035791; P:platelet-derived growth factor receptor-beta signaling pathway; IMP:UniProtKB. DR GO; GO:0090280; P:positive regulation of calcium ion import; ISS:UniProtKB. DR GO; GO:0050850; P:positive regulation of calcium-mediated signaling; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0038091; P:positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0050921; P:positive regulation of chemotaxis; ISS:UniProtKB. DR GO; GO:2000573; P:positive regulation of DNA biosynthetic process; ISS:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0043406; P:positive regulation of MAP kinase activity; ISS:UniProtKB. DR GO; GO:0035793; P:positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway; ISS:UniProtKB. DR GO; GO:0045840; P:positive regulation of mitotic nuclear division; ISS:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProtKB. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; ISS:UniProtKB. DR GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IMP:UniProtKB. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0032956; P:regulation of actin cytoskeleton organization; ISS:BHF-UCL. DR GO; GO:0061298; P:retina vasculature development in camera-type eye; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IDA:UniProtKB. DR GO; GO:0014805; P:smooth muscle adaptation; NAS:BHF-UCL. DR GO; GO:0071670; P:smooth muscle cell chemotaxis; ISS:BHF-UCL. DR CDD; cd00096; Ig; 1. DR CDD; cd05859; Ig4_PDGFR; 1. DR CDD; cd05861; IgI_PDGFR-alphabeta; 1. DR CDD; cd05107; PTKc_PDGFR_beta; 1. DR FunFam; 3.30.200.20:FF:000025; Platelet-derived growth factor receptor alpha; 1. DR FunFam; 1.10.510.10:FF:000140; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000223; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000572; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000715; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000814; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000982; Platelet-derived growth factor receptor beta; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 5. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR013151; Immunoglobulin_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR027288; PGFRB. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR001824; Tyr_kinase_rcpt_3_CS. DR PANTHER; PTHR24416:SF53; PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00047; ig; 1. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF25305; Ig_PDGFR_d4; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF500948; Beta-PDGF_receptor; 1. DR PIRSF; PIRSF000615; TyrPK_CSF1-R; 1. DR PRINTS; PR01832; VEGFRECEPTOR. DR SMART; SM00409; IG; 3. DR SMART; SM00408; IGc2; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; Chemotaxis; KW Chromosomal rearrangement; Cytoplasmic vesicle; Developmental protein; KW Direct protein sequencing; Disease variant; Disulfide bond; Glycoprotein; KW Immunoglobulin domain; Kinase; Lysosome; Membrane; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Proto-oncogene; Receptor; KW Reference proteome; Repeat; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..32 FT /evidence="ECO:0000269|PubMed:15340161" FT CHAIN 33..1106 FT /note="Platelet-derived growth factor receptor beta" FT /id="PRO_0000016757" FT TOPO_DOM 33..532 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 533..553 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 554..1106 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 33..120 FT /note="Ig-like C2-type 1" FT DOMAIN 129..210 FT /note="Ig-like C2-type 2" FT DOMAIN 214..309 FT /note="Ig-like C2-type 3" FT DOMAIN 331..403 FT /note="Ig-like C2-type 4" FT DOMAIN 416..524 FT /note="Ig-like C2-type 5" FT DOMAIN 600..962 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1019..1106 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1043..1060 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1066..1088 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 826 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 606..614 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 634 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT SITE 527..528 FT /note="Breakpoint for insertion to form PDE4DIP-PDGFRB FT fusion protein" FT SITE 527..528 FT /note="Breakpoint for translocation to form TRIP11-PDGFRB" FT SITE 558..559 FT /note="Breakpoint for translocation to form the CEP85L- FT PDGFRB fusion protein" FT MOD_RES 562 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867" FT MOD_RES 579 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14966296, FT ECO:0000269|PubMed:15902258, ECO:0000269|PubMed:7685273" FT MOD_RES 581 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15902258, FT ECO:0000269|PubMed:7685273" FT MOD_RES 686 FT /note="Phosphotyrosine; by ABL1 and ABL2" FT /evidence="ECO:0000250|UniProtKB:P05622" FT MOD_RES 716 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15902258" FT MOD_RES 740 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:1314164, FT ECO:0000269|PubMed:15902258" FT MOD_RES 751 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:14966296, FT ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:2550144" FT MOD_RES 763 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867" FT MOD_RES 771 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:14966296, FT ECO:0000269|PubMed:15902258" FT MOD_RES 775 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867" FT MOD_RES 778 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867" FT MOD_RES 857 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:15902258, FT ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:2550144" FT MOD_RES 934 FT /note="Phosphotyrosine; by ABL1 and ABL2" FT /evidence="ECO:0000250|UniProtKB:P05622" FT MOD_RES 970 FT /note="Phosphotyrosine; by ABL1 and ABL2" FT /evidence="ECO:0000250|UniProtKB:P05622" FT MOD_RES 1009 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:15902258" FT MOD_RES 1021 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:14966296, FT ECO:0000269|PubMed:15902258" FT CARBOHYD 45 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 89 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 103 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 215 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 230 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 292 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 307 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 354 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 371 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 468 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 479 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 54..100 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:20534510" FT DISULFID 149..190 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:20534510" FT DISULFID 235..291 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:20534510" FT DISULFID 436..508 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 311..336 FT /note="VESGYVRLLGEVGTLQFAELHRSRTL -> RAATCGSWERWAHYNLLSCIGA FT GHCR (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056008" FT VAR_SEQ 337..1106 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056009" FT VARIANT 29 FT /note="I -> F (in dbSNP:rs17110944)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_034377" FT VARIANT 180 FT /note="S -> F (in dbSNP:rs17853027)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_035125" FT VARIANT 282 FT /note="E -> K (in dbSNP:rs34586048)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042027" FT VARIANT 345 FT /note="P -> S (in dbSNP:rs2229558)" FT /id="VAR_049717" FT VARIANT 485 FT /note="E -> K (in dbSNP:rs41287110)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042028" FT VARIANT 561 FT /note="R -> C (in IMF1; dbSNP:rs367543286)" FT /evidence="ECO:0000269|PubMed:23731537" FT /id="VAR_069925" FT VARIANT 584 FT /note="P -> R (in KOGS; dbSNP:rs863224946)" FT /evidence="ECO:0000269|PubMed:25454926" FT /id="VAR_075865" FT VARIANT 589 FT /note="Y -> H (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042029" FT VARIANT 658 FT /note="L -> P (in IBGC4; no effect on protein abundance; FT loss of PDGF beta receptor activity; dbSNP:rs397509381)" FT /evidence="ECO:0000269|PubMed:23255827, FT ECO:0000269|PubMed:24065723, ECO:0000269|PubMed:26599395" FT /id="VAR_069320" FT VARIANT 660 FT /note="P -> T (in IMF1; dbSNP:rs144050370)" FT /evidence="ECO:0000269|PubMed:23731542" FT /id="VAR_069926" FT VARIANT 665 FT /note="V -> A (in PENTT; gain of function in protein FT tyrosine kinase activity; shows ligand-independent FT constitutive signaling; dbSNP:rs1554108211)" FT /evidence="ECO:0000269|PubMed:26279204" FT /id="VAR_075866" FT VARIANT 666 FT /note="N -> S (in PENTT; likely pathogenic; gain-of- FT function variant resulting in constitutive FT autophosphorylation and increased phosphorylation of FT downstream signaling proteins; levels of protein FT phosphorylation are similar at 32 and 37 degrees Celsius; FT dbSNP:rs2113894766)" FT /evidence="ECO:0000269|PubMed:30573803" FT /id="VAR_090402" FT VARIANT 666 FT /note="N -> Y (in OPDKD; likely pathogenic; gain-of- FT function variant resulting in temperature-dependent FT constitutive autophosphorylation and increased FT phosphorylation of downstream signaling proteins; levels of FT protein phosphorylation at 32 degrees Celsius are higher FT than at 37 degrees; dbSNP:rs797044887)" FT /evidence="ECO:0000269|PubMed:33450762" FT /id="VAR_090403" FT VARIANT 718 FT /note="N -> Y (in dbSNP:rs35322465)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042030" FT VARIANT 882 FT /note="T -> I (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042031" FT VARIANT 987 FT /note="R -> W (in IBGC4; decreased protein abundance; no FT effect on receptor activity; decreased PDGF signaling FT pathway; dbSNP:rs397509382)" FT /evidence="ECO:0000269|PubMed:23255827, FT ECO:0000269|PubMed:24065723, ECO:0000269|PubMed:26599395" FT /id="VAR_069321" FT VARIANT 1071 FT /note="E -> V (in IBGC4; no effect on protein abundance; no FT effect on receptor activity; decreased PDGF signaling FT pathway)" FT /evidence="ECO:0000269|PubMed:24065723, FT ECO:0000269|PubMed:26599395" FT /id="VAR_075395" FT MUTAGEN 579 FT /note="Y->F: Loss of kinase activity; when associated with FT F-581. Strongly reduces interaction with SRC family FT kinases. No effect on interaction with GRB10." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:7685273" FT MUTAGEN 581 FT /note="Y->F: Loss of kinase activity; when associated with FT F-579. No effect on interaction with GRB10." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:7685273" FT MUTAGEN 634 FT /note="K->A,R: Loss of kinase activity. Abolishes FT interaction with RASA1. No effect on phosphatidylinositol FT 3-kinase activity." FT /evidence="ECO:0000269|PubMed:1314164, FT ECO:0000269|PubMed:1846866, ECO:0000269|PubMed:20494825" FT MUTAGEN 716 FT /note="Y->F: No effect neither on interaction with GRB10 FT and RASA1 nor on phosphatidylinositol 3-kinase activity." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164" FT MUTAGEN 740 FT /note="Y->F: Strongly reduces up-regulation of cell FT proliferation; when associated with F-751. Strongly FT decreases phosphatidylinositol 3-kinase activity. No effect FT on interaction with GRB10 and RASA1." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1375321, FT ECO:0000269|PubMed:21679854" FT MUTAGEN 751 FT /note="Y->F: Strongly reduces up-regulation of cell FT proliferation; when associated with F-740. Abolishes FT phosphatidylinositol 3-kinase activity and interaction with FT NCK1, and slightly reduces interaction with RASA1. No FT effect on interaction with GRB10." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1375321, FT ECO:0000269|PubMed:1653029, ECO:0000269|PubMed:21679854, FT ECO:0000269|PubMed:7692233" FT MUTAGEN 763 FT /note="Y->F: No effect on interaction with RASA1 and on FT phosphatidylinositol 3-kinase activity." FT /evidence="ECO:0000269|PubMed:1314164" FT MUTAGEN 771 FT /note="Y->F: Loss of interaction with GRB10. Abolishes FT interaction with RASA1. No effect on phosphatidylinositol FT 3-kinase activity." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1375321" FT MUTAGEN 775 FT /note="Y->F: No effect on interaction with RASA1 and on FT phosphatidylinositol 3-kinase activity." FT /evidence="ECO:0000269|PubMed:1314164" FT MUTAGEN 778 FT /note="Y->F: Strongly reduces expression levels." FT /evidence="ECO:0000269|PubMed:1314164" FT MUTAGEN 857 FT /note="Y->F: Reduces kinase activity. No effect on FT interaction with GRB10. Abolishes interaction with RASA1. FT No effect on phosphatidylinositol 3-kinase activity." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1653029, FT ECO:0000269|PubMed:20494825" FT MUTAGEN 1009 FT /note="Y->F: No effect on interaction with GRB10. Abolishes FT interaction with PLCG1; when associated with F-1021." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:7691811" FT MUTAGEN 1021 FT /note="Y->F: Strongly reduces up-regulation of cell FT proliferation. Abolishes interaction with PLCG1; when FT associated with F-1009. No effect on interaction with FT GRB10." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:17620338, FT ECO:0000269|PubMed:21679854" FT CONFLICT 241 FT /note="E -> D (in Ref. 2; AAA36427)" FT /evidence="ECO:0000305" FT STRAND 40..43 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 50..58 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 61..64 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 70..75 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 81..87 FT /evidence="ECO:0007829|PDB:3MJG" FT HELIX 92..94 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 96..101 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 114..119 FT /evidence="ECO:0007829|PDB:3MJG" FT HELIX 132..135 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 136..141 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 145..147 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 158..164 FT /evidence="ECO:0007829|PDB:3MJG" FT TURN 175..177 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 178..181 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 185..194 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 197..200 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 204..208 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 217..221 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 223..226 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 231..239 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 241..248 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 252..255 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 261..265 FT /evidence="ECO:0007829|PDB:3MJG" FT TURN 267..270 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 271..280 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 287..295 FT /evidence="ECO:0007829|PDB:3MJG" FT TURN 296..299 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 300..311 FT /evidence="ECO:0007829|PDB:3MJG" FT HELIX 530..556 FT /evidence="ECO:0007829|PDB:2L6W" SQ SEQUENCE 1106 AA; 123968 MW; 038C15E531D6E89D CRC64; MRLPGAMPAL ALKGELLLLS LLLLLEPQIS QGLVVTPPGP ELVLNVSSTF VLTCSGSAPV VWERMSQEPP QEMAKAQDGT FSSVLTLTNL TGLDTGEYFC THNDSRGLET DERKRLYIFV PDPTVGFLPN DAEELFIFLT EITEITIPCR VTDPQLVVTL HEKKGDVALP VPYDHQRGFS GIFEDRSYIC KTTIGDREVD SDAYYVYRLQ VSSINVSVNA VQTVVRQGEN ITLMCIVIGN EVVNFEWTYP RKESGRLVEP VTDFLLDMPY HIRSILHIPS AELEDSGTYT CNVTESVNDH QDEKAINITV VESGYVRLLG EVGTLQFAEL HRSRTLQVVF EAYPPPTVLW FKDNRTLGDS SAGEIALSTR NVSETRYVSE LTLVRVKVAE AGHYTMRAFH EDAEVQLSFQ LQINVPVRVL ELSESHPDSG EQTVRCRGRG MPQPNIIWSA CRDLKRCPRE LPPTLLGNSS EEESQLETNV TYWEEEQEFE VVSTLRLQHV DRPLSVRCTL RNAVGQDTQE VIVVPHSLPF KVVVISAILA LVVLTIISLI ILIMLWQKKP RYEIRWKVIE SVSSDGHEYI YVDPMQLPYD STWELPRDQL VLGRTLGSGA FGQVVEATAH GLSHSQATMK VAVKMLKSTA RSSEKQALMS ELKIMSHLGP HLNVVNLLGA CTKGGPIYII TEYCRYGDLV DYLHRNKHTF LQHHSDKRRP PSAELYSNAL PVGLPLPSHV SLTGESDGGY MDMSKDESVD YVPMLDMKGD VKYADIESSN YMAPYDNYVP SAPERTCRAT LINESPVLSY MDLVGFSYQV ANGMEFLASK NCVHRDLAAR NVLICEGKLV KICDFGLARD IMRDSNYISK GSTFLPLKWM APESIFNSLY TTLSDVWSFG ILLWEIFTLG GTPYPELPMN EQFYNAIKRG YRMAQPAHAS DEIYEIMQKC WEEKFEIRPP FSQLVLLLER LLGEGYKKKY QQVDEEFLRS DHPAILRSQA RLPGFHGLRS PLDTSSVLYT AVQPNEGDND YIIPLPDPKP EVADEGPLEG SPSLASSTLN EVNTSSTISC DSPLEPQDEP EPEPQLELQV EPEPELEQLP DSGCPAPRAE AEDSFL // ID PK3CA_HUMAN Reviewed; 1068 AA. AC P42336; Q14CW1; Q99762; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 20-FEB-2007, sequence version 2. DT 28-JAN-2026, entry version 242. DE RecName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; DE Short=PI3-kinase subunit alpha; DE Short=PI3K-alpha; DE Short=PI3Kalpha {ECO:0000303|PubMed:28676499}; DE Short=PtdIns-3-kinase subunit alpha; DE EC=2.7.1.137 {ECO:0000269|PubMed:23936502}; DE EC=2.7.1.153 {ECO:0000269|PubMed:15135396, ECO:0000269|PubMed:28676499}; DE AltName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha; DE Short=PtdIns-3-kinase subunit p110-alpha; DE Short=p110alpha {ECO:0000303|PubMed:15135396}; DE AltName: Full=Phosphoinositide 3-kinase alpha {ECO:0000303|PubMed:28676499}; DE AltName: Full=Phosphoinositide-3-kinase catalytic alpha polypeptide; DE AltName: Full=Serine/threonine protein kinase PIK3CA; DE EC=2.7.11.1 {ECO:0000269|PubMed:23936502, ECO:0000269|PubMed:28676499}; GN Name=PIK3CA; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS VAL-43 AND ARG-332. RX PubMed=7713498; DOI=10.1006/geno.1994.1655; RA Volinia S., Hiles I., Ormondroyd E., Nizetic D., Antonacci R., Rocchi M., RA Waterfield M.; RT "Molecular cloning, cDNA sequence, and chromosomal localization of the RT human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene."; RL Genomics 24:472-477(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9043658; DOI=10.1016/s0968-0896(96)00196-4; RA Stirdivant S.M., Ahern J., Conroy R.R., Barnett S.F., Ledder L.M., RA Oliff A., Heimbrook D.C.; RT "Cloning and mutagenesis of the p110 alpha subunit of human RT phosphoinositide 3'-hydroxykinase."; RL Bioorg. Med. Chem. 5:65-74(1997). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP INTERACTION WITH APPL1. RX PubMed=10490823; DOI=10.1038/sj.onc.1203080; RA Mitsuuchi Y., Johnson S.W., Sonoda G., Tanno S., Golemis E.A., Testa J.R.; RT "Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor RT molecule that interacts with the oncoprotein-serine/threonine kinase RT AKT2."; RL Oncogene 18:4891-4898(1999). RN [5] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15135396; DOI=10.1016/j.pep.2003.12.010; RA Meier T.I., Cook J.A., Thomas J.E., Radding J.A., Horn C., Lingaraj T., RA Smith M.C.; RT "Cloning, expression, purification, and characterization of the human Class RT Ia phosphoinositide 3-kinase isoforms."; RL Protein Expr. Purif. 35:218-224(2004). RN [6] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=23936502; DOI=10.1371/journal.pone.0071337; RA Buchanan C.M., Dickson J.M., Lee W.J., Guthridge M.A., Kendall J.D., RA Shepherd P.R.; RT "Oncogenic mutations of p110alpha isoform of PI 3-kinase upregulate its RT protein kinase activity."; RL PLoS ONE 8:e71337-e71337(2013). RN [7] RP FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=28676499; DOI=10.1074/jbc.m116.772426; RA Maheshwari S., Miller M.S., O'Meally R., Cole R.N., Amzel L.M., RA Gabelli S.B.; RT "Kinetic and structural analyses reveal residues in phosphoinositide 3- RT kinase alpha that are critical for catalysis and substrate recognition."; RL J. Biol. Chem. 292:13541-13550(2017). RN [8] RP FUNCTION IN INVADOPODIA FORMATION, AND CHARACTERIZATION OF VARIANTS LYS-545 RP AND ARG-1047. RX PubMed=21708979; DOI=10.1083/jcb.201009126; RA Yamaguchi H., Yoshida S., Muroi E., Yoshida N., Kawamura M., Kouchi Z., RA Nakamura Y., Sakai R., Fukami K.; RT "Phosphoinositide 3-kinase signaling pathway mediated by p110{alpha} RT regulates invadopodia formation."; RL J. Cell Biol. 193:1275-1288(2011). RN [9] RP INVOLVEMENT IN MADAC, AND VARIANTS MADAC PRO-115; LYS-542; ARG-1047 AND RP LEU-1047. RX PubMed=23100325; DOI=10.1093/hmg/dds440; RA Rios J.J., Paria N., Burns D.K., Israel B.A., Cornelia R., Wise C.A., RA Ezaki M.; RT "Somatic gain-of-function mutations in PIK3CA in patients with RT macrodactyly."; RL Hum. Mol. Genet. 22:444-451(2013). RN [10] RP INTERACTION WITH FAM83B. RX PubMed=23676467; DOI=10.18632/oncotarget.1027; RA Cipriano R., Miskimen K.L., Bryson B.L., Foy C.R., Bartel C.A., RA Jackson M.W.; RT "FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to RT promote epithelial cell transformation and resistance to targeted RT therapies."; RL Oncotarget 4:729-738(2013). RN [11] RP REVIEW ON CANCER. RX PubMed=18418043; DOI=10.4161/cc.7.9.5817; RA Huang C.-H., Mandelker D., Gabelli S.B., Amzel L.M.; RT "Insights into the oncogenic effects of PIK3CA mutations from the structure RT of p110alpha/p85alpha."; RL Cell Cycle 7:1151-1156(2008). RN [12] RP REVIEW ON FUNCTION, AND REVIEW ON CANCER. RX PubMed=18794883; DOI=10.1038/onc.2008.244; RA Zhao L., Vogt P.K.; RT "Class I PI3K in oncogenic cellular transformation."; RL Oncogene 27:5486-5496(2008). RN [13] RP REVIEW ON FUNCTION. RX PubMed=19200708; DOI=10.1016/j.ceb.2008.12.007; RA Jia S., Roberts T.M., Zhao J.J.; RT "Should individual PI3 kinase isoforms be targeted in cancer?"; RL Curr. Opin. Cell Biol. 21:199-208(2009). RN [14] RP INVOLVEMENT IN CLAPO, AND VARIANTS CLAPO SER-83; PRO-115; ARG-420; LYS-542 RP AND LEU-1047. RX PubMed=29446767; DOI=10.1038/gim.2017.200; RA Rodriguez-Laguna L., Ibanez K., Gordo G., Garcia-Minaur S., RA Santos-Simarro F., Agra N., Vallespin E., Fernandez-Montano V.E., RA Martin-Arenas R., Del Pozo A., Gonzalez-Pecellin H., Mena R., RA Rueda-Arenas I., Gomez M.V., Villaverde C., Bustamante A., Ayuso C., RA Ruiz-Perez V.L., Nevado J., Lapunzina P., Lopez-Gutierrez J.C., RA Martinez-Glez V.; RT "CLAPO syndrome: identification of somatic activating PIK3CA mutations and RT delineation of the natural history and phenotype."; RL Genet. Med. 20:882-889(2018). RN [15] RP INVOLVEMENT IN CCM4, AND VARIANTS CCM4 LYS-542; ARG-1047 AND LEU-1047. RX PubMed=34496175; DOI=10.1056/nejmoa2100440; RA Peyre M., Miyagishima D., Bielle F., Chapon F., Sierant M., Venot Q., RA Lerond J., Marijon P., Abi-Jaoude S., Le Van T., Labreche K., Houlston R., RA Faisant M., Clemenceau S., Boch A.L., Nouet A., Carpentier A., Boetto J., RA Louvi A., Kalamarides M.; RT "Somatic PIK3CA mutations in sporadic cerebral cavernous malformations."; RL N. Engl. J. Med. 385:996-996(2021). RN [16] RP INVOLVEMENT IN HFMH, VARIANTS HFMH LYS-542; LYS-545 AND ARG-1047, AND RP CHARACTERIZATION OF VARIANTS HFMH LYS-542; LYS-545 AND ARG-1047. RX PubMed=37712948; DOI=10.1084/jem.20230926; RA Bayard C., Segna E., Taverne M., Fraissenon A., Hennocq Q., Periou B., RA Zerbib L., Ladraa S., Chapelle C., Hoguin C., Kaltenbach S., Villarese P., RA Asnafi V., Broissand C., Nemazanyy I., Autret G., Goudin N., Legendre C., RA Authier F.J., Viel T., Tavitian B., Gitiaux C., Fraitag S., Duong J.P., RA Delcros C., Sergent B., Picard A., Dussiot M., Guibaud L., Khonsari R., RA Canaud G.; RT "Hemifacial myohyperplasia is due to somatic muscular PIK3CA gain-of- RT function mutations and responds to pharmacological inhibition."; RL J. Exp. Med. 220:0-0(2023). RN [17] RP X-RAY CRYSTALLOGRAPHY (3 ANGSTROMS) IN A COMPLEX WITH PIK3R1, AND DOMAINS. RX PubMed=18079394; DOI=10.1126/science.1150799; RA Huang C.-H., Mandelker D., Schmidt-Kittler O., Samuels Y., Velculescu V.E., RA Kinzler K.W., Vogelstein B., Gabelli S.B., Amzel L.M.; RT "The structure of a human p110alpha/p85alpha complex elucidates the effects RT of oncogenic PI3Kalpha mutations."; RL Science 318:1744-1748(2007). RN [18] RP STRUCTURE BY NMR OF 331-481. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the C2 domain from human PI3-kinase p110 subunit RT alpha."; RL Submitted (APR-2008) to the PDB data bank. RN [19] RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF MUTANT HIS-1047 IN COMPLEX WITH RP WORTMANNIN AND PIK3R1, INTERACTION WITH PIK3R1, CHARACTERIZATION OF VARIANT RP ARG-1047, AND DOMAINS. RX PubMed=19805105; DOI=10.1073/pnas.0908444106; RA Mandelker D., Gabelli S.B., Schmidt-Kittler O., Zhu J., Cheong I., RA Huang C.H., Kinzler K.W., Vogelstein B., Amzel L.M.; RT "A frequent kinase domain mutation that changes the interaction between RT PI3Kalpha and the membrane."; RL Proc. Natl. Acad. Sci. U.S.A. 106:16996-17001(2009). RN [20] RP VARIANTS CANCER LYS-542; LYS-545; PRO-546; ASN-1021; ARG-1047; LEU-1047 AND RP TYR-1065. RX PubMed=15289301; DOI=10.1158/0008-5472.can-04-1170; RA Broderick D.K., Di C., Parrett T.J., Samuels Y.R., Cummins J.M., RA McLendon R.E., Fults D.W., Velculescu V.E., Bigner D.D., Yan H.; RT "Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade RT astrocytomas, and medulloblastomas."; RL Cancer Res. 64:5048-5050(2004). RN [21] RP INVOLVEMENT IN OC, AND VARIANTS CANCER GLY-545; LYS-545; LYS-546; GLU-546; RP ARG-1047 AND LEU-1047. RX PubMed=15520168; DOI=10.1158/0008-5472.can-04-2933; RA Campbell I.G., Russell S.E., Choong D.Y.H., Montgomery K.G., RA Ciavarella M.L., Hooi C.S.F., Cristiano B.E., Pearson R.B., Phillips W.A.; RT "Mutation of the PIK3CA gene in ovarian and breast cancer."; RL Cancer Res. 64:7678-7681(2004). RN [22] RP VARIANT CANCER ARG-1047. RX PubMed=15016963; DOI=10.1126/science.1096502; RA Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., RA Gazdar A., Powell S.M., Riggins G.J., Willson J.K.V., Markowitz S., RA Kinzler K.W., Vogelstein B., Velculescu V.E.; RT "High frequency of mutations of the PIK3CA gene in human cancers."; RL Science 304:554-554(2004). RN [23] RP VARIANTS CANCER GLN-88; LYS-542; ALA-545 AND ASN-1025. RX PubMed=15924253; DOI=10.1007/s00401-005-1000-1; RA Hartmann C., Bartels G., Gehlhaar C., Holtkamp N., von Deimling A.; RT "PIK3CA mutations in glioblastoma multiforme."; RL Acta Neuropathol. 109:639-642(2005). RN [24] RP VARIANTS CANCER LYS-542; LYS-545 AND ARG-1047. RX PubMed=15784156; DOI=10.1186/1471-2407-5-29; RA Li V.S.W., Wong C.W., Chan T.L., Chan A.S.W., Zhao W., Chu K.-M., So S., RA Chen X., Yuen S.T., Leung S.Y.; RT "Mutations of PIK3CA in gastric adenocarcinoma."; RL BMC Cancer 5:29-29(2005). RN [25] RP INVOLVEMENT IN CRC, AND CHARACTERIZATION OF VARIANTS CRC HIS-38; VAL-106; RP ARG-420; GLN-453; LYS-542; LYS-545; ILE-1043 AND ARG-1047. RX PubMed=15930273; DOI=10.1158/0008-5472.can-04-4114; RA Ikenoue T., Kanai F., Hikiba Y., Obata T., Tanaka Y., Imamura J., Ohta M., RA Jazag A., Guleng B., Tateishi K., Asaoka Y., Matsumura M., Kawabe T., RA Omata M.; RT "Functional analysis of PIK3CA gene mutations in human colorectal cancer."; RL Cancer Res. 65:4562-4567(2005). RN [26] RP VARIANTS CANCER GLN-542; LYS-542; GLY-545; LYS-545; ARG-1007; HIS-1021; RP CYS-1021; VAL-1035; ILE-1043; TYR-1047; ARG-1047; ASP-1050; LYS-1052 AND RP LEU-1065. RX PubMed=16322209; DOI=10.1158/0008-5472.can-05-2620; RA Oda K., Stokoe D., Taketani Y., McCormick F.; RT "High frequency of coexistent mutations of PIK3CA and PTEN genes in RT endometrial carcinoma."; RL Cancer Res. 65:10669-10673(2005). RN [27] RP INVOLVEMENT IN CRC, AND VARIANTS CANCER LYS-542; GLY-545; LYS-545; RP GLN-1023; ARG-1047 AND LEU-1047. RX PubMed=15994075; DOI=10.1016/j.ejca.2005.04.022; RA Velho S., Oliveira C., Ferreira A., Ferreira A.C., Suriano G., RA Schwartz S. Jr., Duval A., Carneiro F., Machado J.C., Hamelin R., RA Seruca R.; RT "The prevalence of PIK3CA mutations in gastric and colon cancer."; RL Eur. J. Cancer 41:1649-1654(2005). RN [28] RP VARIANTS CANCER LYS-545 AND ARG-1047. RX PubMed=15712344; DOI=10.1002/humu.9316; RA Wang Y., Helland A., Holm R., Kristensen G.B., Boerresen-Dale A.-L.; RT "PIK3CA mutations in advanced ovarian carcinomas."; RL Hum. Mutat. 25:322-322(2005). RN [29] RP VARIANT HCC ALA-545. RX PubMed=15608678; DOI=10.1038/sj.onc.1208304; RA Lee J.W., Soung Y.H., Kim S.Y., Lee H.W., Park W.S., Nam S.W., Kim S.H., RA Lee J.Y., Yoo N.J., Lee S.H.; RT "PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular RT carcinomas."; RL Oncogene 24:1477-1480(2005). RN [30] RP VARIANTS CANCER CYS-343; LYS-542; LYS-545 AND ARG-1047, AND VARIANT RP MET-391. RX PubMed=16533766; DOI=10.1158/1078-0432.ccr-05-2173; RA Qiu W., Schoenleben F., Li X., Ho D.J., Close L.G., Manolidis S., RA Bennett B.P., Su G.H.; RT "PIK3CA mutations in head and neck squamous cell carcinoma."; RL Clin. Cancer Res. 12:1441-1446(2006). RN [31] RP VARIANT CANCER ARG-1047. RX PubMed=16114017; DOI=10.1002/ijc.21444; RA Or Y.Y.-Y., Hui A.B.-Y., To K.-F., Lam C.N.-Y., Lo K.-W.; RT "PIK3CA mutations in nasopharyngeal carcinoma."; RL Int. J. Cancer 118:1065-1067(2006). RN [32] RP VARIANTS BC LYS-542; VAL-542; LYS-545; ARG-546; ARG-1047 AND LEU-1047. RX PubMed=16353168; DOI=10.1002/path.1908; RA Buttitta F., Felicioni L., Barassi F., Martella C., Paolizzi D., Fresu G., RA Salvatore S., Cuccurullo F., Mezzetti A., Campani D., Marchetti A.; RT "PIK3CA mutation and histological type in breast carcinoma: high frequency RT of mutations in lobular carcinoma."; RL J. Pathol. 208:350-355(2006). RN [33] RP CHARACTERIZATION OF VARIANTS CANCER LYS-542; LYS-545 AND ARG-1047. RX PubMed=16432179; DOI=10.1073/pnas.0510857103; RA Bader A.G., Kang S., Vogt P.K.; RT "Cancer-specific mutations in PIK3CA are oncogenic in vivo."; RL Proc. Natl. Acad. Sci. U.S.A. 103:1475-1479(2006). RN [34] RP VARIANTS KERSEB LYS-542; LYS-545; GLY-545 AND ARG-1047. RX PubMed=17673550; DOI=10.1073/pnas.0705218104; RA Hafner C., Lopez-Knowles E., Luis N.M., Toll A., Baselga E., RA Fernandez-Casado A., Hernandez S., Ribe A., Mentzel T., Stoehr R., RA Hofstaedter F., Landthaler M., Vogt T., Pujol R.M., Hartmann A., Real F.X.; RT "Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic RT keratoses with a characteristic mutation pattern."; RL Proc. Natl. Acad. Sci. U.S.A. 104:13450-13454(2007). RN [35] RP VARIANTS CLOVE ARG-420; LYS-542 AND ARG-1047. RX PubMed=22658544; DOI=10.1016/j.ajhg.2012.05.006; RA Kurek K.C., Luks V.L., Ayturk U.M., Alomari A.I., Fishman S.J., RA Spencer S.A., Mulliken J.B., Bowen M.E., Yamamoto G.L., Kozakewich H.P., RA Warman M.L.; RT "Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome."; RL Am. J. Hum. Genet. 90:1108-1115(2012). RN [36] RP VARIANTS MCAP LYS-81; GLN-88; ARG-364; LYS-365; TYR-378; GLU-453 DEL; RP LYS-545; LYS-726; ARG-914; CYS-1021; ALA-1025; VAL-1035; ILE-1043; TYR-1047 RP AND SER-1049. RX PubMed=22729224; DOI=10.1038/ng.2331; RA Riviere J.B., Mirzaa G.M., O'Roak B.J., Beddaoui M., Alcantara D., RA Conway R.L., St-Onge J., Schwartzentruber J.A., Gripp K.W., Nikkel S.M., RA Worthylake T., Sullivan C.T., Ward T.R., Butler H.E., Kramer N.A., RA Albrecht B., Armour C.M., Armstrong L., Caluseriu O., Cytrynbaum C., RA Drolet B.A., Innes A.M., Lauzon J.L., Lin A.E., Mancini G.M., RA Meschino W.S., Reggin J.D., Saggar A.K., Lerman-Sagie T., Uyanik G., RA Weksberg R., Zirn B., Beaulieu C.L., Majewski J., Bulman D.E., RA O'Driscoll M., Shendure J., Graham J.M. Jr., Boycott K.M., Dobyns W.B.; RT "De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA RT cause a spectrum of related megalencephaly syndromes."; RL Nat. Genet. 44:934-940(2012). RN [37] RP VARIANTS CWS5 ASP-118; LYS-135; LYS-218; ILE-356; LYS-382 AND ALA-545. RX PubMed=23246288; DOI=10.1016/j.ajhg.2012.10.021; RA Orloff M.S., He X., Peterson C., Chen F., Chen J.L., Mester J.L., Eng C.; RT "Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes."; RL Am. J. Hum. Genet. 92:76-80(2013). RN [38] RP VARIANT MCAP ASN-112, CHARACTERIZATION OF VARIANT MCAP ASN-112, FUNCTION, RP AND SUBUNIT. RX PubMed=26593112; DOI=10.1002/humu.22933; RA Donato N.D., Rump A., Mirzaa G.M., Alcantara D., Oliver A., Schrock E., RA Dobyns W.B., O'Driscoll M.; RT "Identification and characterisation of a novel constitutional PIK3CA RT mutation in a child lacking the typical segmental overgrowth of 'PIK3CA- RT related overgrowth spectrum' (PROS)."; RL Hum. Mutat. 37:242-245(2016). CC -!- FUNCTION: Phosphoinositide-3-kinase (PI3K) phosphorylates CC phosphatidylinositol (PI) and its phosphorylated derivatives at CC position 3 of the inositol ring to produce 3-phosphoinositides CC (PubMed:15135396, PubMed:23936502, PubMed:28676499). Uses ATP and CC PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate CC phosphatidylinositol 3,4,5-trisphosphate (PIP3) (PubMed:15135396, CC PubMed:28676499). PIP3 plays a key role by recruiting PH domain- CC containing proteins to the membrane, including AKT1 and PDPK1, CC activating signaling cascades involved in cell growth, survival, CC proliferation, motility and morphology. Participates in cellular CC signaling in response to various growth factors. Involved in the CC activation of AKT1 upon stimulation by receptor tyrosine kinases CC ligands such as EGF, insulin, IGF1, VEGFA and PDGF. Involved in CC signaling via insulin-receptor substrate (IRS) proteins. Essential in CC endothelial cell migration during vascular development through VEGFA CC signaling, possibly by regulating RhoA activity. Required for lymphatic CC vasculature development, possibly by binding to RAS and by activation CC by EGF and FGF2, but not by PDGF. Regulates invadopodia formation CC through the PDPK1-AKT1 pathway. Participates in cardiomyogenesis in CC embryonic stem cells through a AKT1 pathway. Participates in CC vasculogenesis in embryonic stem cells through PDK1 and protein kinase CC C pathway. In addition to its lipid kinase activity, it displays a CC serine-protein kinase activity that results in the autophosphorylation CC of the p85alpha regulatory subunit as well as phosphorylation of other CC proteins such as 4EBP1, H-Ras, the IL-3 beta c receptor and possibly CC others (PubMed:23936502, PubMed:28676499). Plays a role in the positive CC regulation of phagocytosis and pinocytosis (By similarity). CC {ECO:0000250|UniProtKB:P42337, ECO:0000269|PubMed:15135396, CC ECO:0000269|PubMed:21708979, ECO:0000269|PubMed:23936502, CC ECO:0000269|PubMed:26593112, ECO:0000269|PubMed:28676499}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5- CC bisphosphate) + ATP = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- CC inositol-3,4,5-trisphosphate) + ADP + H(+); Xref=Rhea:RHEA:21292, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:57836, CC ChEBI:CHEBI:58456, ChEBI:CHEBI:456216; EC=2.7.1.153; CC Evidence={ECO:0000269|PubMed:15135396, ECO:0000269|PubMed:28676499}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:21293; CC Evidence={ECO:0000305|PubMed:15135396, ECO:0000305|PubMed:28676499}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + ATP = a CC 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3-phosphate) + ADP + CC H(+); Xref=Rhea:RHEA:12709, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:57880, ChEBI:CHEBI:58088, ChEBI:CHEBI:456216; CC EC=2.7.1.137; Evidence={ECO:0000269|PubMed:23936502}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:12710; CC Evidence={ECO:0000305|PubMed:23936502}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:23936502, ECO:0000269|PubMed:28676499}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000305|PubMed:23936502, ECO:0000305|PubMed:28676499}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5- CC bisphosphate) + ATP = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo- CC inositol-3,4,5-trisphosphate) + ADP + H(+); Xref=Rhea:RHEA:55632, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:83416, CC ChEBI:CHEBI:83419, ChEBI:CHEBI:456216; CC Evidence={ECO:0000269|PubMed:28676499}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:55633; CC Evidence={ECO:0000305|PubMed:28676499}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1-octadecanoyl-2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero- CC 3-phospho-1D-myo-inositol 4,5-bisphosphate + ATP = 1-octadecanoyl-2- CC (5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phospho-(1D-myo- CC inositol 3,4,5-triphosphate) + ADP + H(+); Xref=Rhea:RHEA:43396, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:77137, CC ChEBI:CHEBI:83243, ChEBI:CHEBI:456216; CC Evidence={ECO:0000305|PubMed:15135396}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43397; CC Evidence={ECO:0000305|PubMed:15135396}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=1.77 uM for PIP2 (1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo- CC inositol-4,5-bisphosphate)) {ECO:0000269|PubMed:28676499}; CC KM=2.00 uM for ATP {ECO:0000269|PubMed:28676499}; CC Vmax=1.70 pmol/min/ng enzyme for the phosphorylation of PIP2 (1,2- CC dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-bisphosphate)) CC {ECO:0000269|PubMed:28676499}; CC -!- PATHWAY: Phospholipid metabolism; phosphatidylinositol phosphate CC biosynthesis. {ECO:0000305|PubMed:15135396, CC ECO:0000305|PubMed:28676499}. CC -!- SUBUNIT: Heterodimer of a catalytic subunit PIK3CA and a p85 regulatory CC subunit (PIK3R1, PIK3R2 or PIK3R3) (PubMed:26593112). Interacts with CC IRS1 in nuclear extracts (By similarity). Interacts with RUFY3 (By CC similarity). Interacts with RASD2 (By similarity). Interacts with CC APPL1. Interacts with HRAS and KRAS (By similarity). Interaction with CC HRAS/KRAS is required for PI3K pathway signaling and cell proliferation CC stimulated by EGF and FGF2 (By similarity). Interacts with FAM83B; CC activates the PI3K/AKT signaling cascade (PubMed:23676467). CC {ECO:0000250|UniProtKB:P42337, ECO:0000269|PubMed:23676467, CC ECO:0000269|PubMed:26593112}. CC -!- INTERACTION: CC P42336; P54253: ATXN1; NbExp=3; IntAct=EBI-2116585, EBI-930964; CC P42336; P54252: ATXN3; NbExp=3; IntAct=EBI-2116585, EBI-946046; CC P42336; P21860: ERBB3; NbExp=18; IntAct=EBI-2116585, EBI-720706; CC P42336; P01100: FOS; NbExp=3; IntAct=EBI-2116585, EBI-852851; CC P42336; P62993: GRB2; NbExp=6; IntAct=EBI-2116585, EBI-401755; CC P42336; P42858: HTT; NbExp=3; IntAct=EBI-2116585, EBI-466029; CC P42336; P35568: IRS1; NbExp=42; IntAct=EBI-2116585, EBI-517592; CC P42336; P27986: PIK3R1; NbExp=63; IntAct=EBI-2116585, EBI-79464; CC P42336; P27986-2: PIK3R1; NbExp=3; IntAct=EBI-2116585, EBI-9090282; CC P42336; O00459: PIK3R2; NbExp=49; IntAct=EBI-2116585, EBI-346930; CC P42336; Q92569: PIK3R3; NbExp=48; IntAct=EBI-2116585, EBI-79893; CC P42336; O43791: SPOP; NbExp=4; IntAct=EBI-2116585, EBI-743549; CC -!- DOMAIN: The PI3K-ABD domain and the PI3K-RBD domain interact with the CC PI3K/PI4K kinase domain. The C2 PI3K-type domain may facilitate the CC recruitment to the plasma membrane. The inhibitory interactions with CC PIK3R1 are mediated by the PI3K-ABD domain and the C2 PI3K-type domain CC with the iSH2 (inter-SH2) region of PIK3R1, and the C2 PI3K-type CC domain, the PI3K helical domain, and the PI3K/PI4K kinase domain with CC the nSH2 (N-terminal SH2) region of PIK3R1. CC {ECO:0000269|PubMed:18079394, ECO:0000269|PubMed:19805105}. CC -!- DISEASE: Note=PIK3CA mutations are involved in various type of cancer. CC Most of the cancer-associated mutations are missense mutations and map CC to one of the three hotspots: Glu-542; Glu-545 and His-1047. Mutated CC isoforms participate in cellular transformation and tumorigenesis CC induced by oncogenic receptor tyrosine kinases (RTKs) and HRAS/KRAS. CC Interaction with HRAS/KRAS is required for Ras-driven tumor formation. CC Mutations increasing the lipid kinase activity are required for CC oncogenic signaling. The protein kinase activity may not be required CC for tumorigenesis. {ECO:0000269|PubMed:15016963, CC ECO:0000269|PubMed:15289301, ECO:0000269|PubMed:15520168, CC ECO:0000269|PubMed:15712344, ECO:0000269|PubMed:15784156, CC ECO:0000269|PubMed:15924253, ECO:0000269|PubMed:15930273, CC ECO:0000269|PubMed:15994075, ECO:0000269|PubMed:16114017, CC ECO:0000269|PubMed:16322209, ECO:0000269|PubMed:16353168, CC ECO:0000269|PubMed:16432179, ECO:0000269|PubMed:16533766, CC ECO:0000269|PubMed:17673550, ECO:0000269|PubMed:19805105, CC ECO:0000269|PubMed:21708979, ECO:0000269|PubMed:22658544, CC ECO:0000269|PubMed:22729224}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:15930273, CC ECO:0000269|PubMed:15994075}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy CC originating from breast epithelial tissue. Breast neoplasms can be CC distinguished by their histologic pattern. Invasive ductal carcinoma is CC by far the most common type. Breast cancer is etiologically and CC genetically heterogeneous. Important genetic factors have been CC indicated by familial occurrence and bilateral involvement. Mutations CC at more than one locus can be involved in different families or even in CC the same case. {ECO:0000269|PubMed:16353168}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer CC defines malignancies originating from ovarian tissue. Although many CC histologic types of ovarian tumors have been described, epithelial CC ovarian carcinoma is the most common form. Ovarian cancers are often CC asymptomatic and the recognized signs and symptoms, even of late-stage CC disease, are vague. Consequently, most patients are diagnosed with CC advanced disease. {ECO:0000269|PubMed:15520168}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Hepatocellular carcinoma (HCC) [MIM:114550]: A primary CC malignant neoplasm of epithelial liver cells. The major risk factors CC for HCC are chronic hepatitis B virus (HBV) infection, chronic CC hepatitis C virus (HCV) infection, prolonged dietary aflatoxin CC exposure, alcoholic cirrhosis, and cirrhosis due to other causes. CC {ECO:0000269|PubMed:15608678}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Keratosis, seborrheic (KERSEB) [MIM:182000]: A common benign CC skin tumor. Seborrheic keratoses usually begin with the appearance of CC one or more sharply defined, light brown, flat macules. The lesions may CC be sparse or numerous. As they initially grow, they develop a velvety CC to finely verrucous surface, followed by an uneven warty surface with CC multiple plugged follicles and a dull or lackluster appearance. CC {ECO:0000269|PubMed:17673550}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Megalencephaly-capillary malformation-polymicrogyria syndrome CC (MCAP) [MIM:602501]: A syndrome characterized by a spectrum of CC anomalies including primary megalencephaly, prenatal overgrowth, brain CC and body asymmetry, cutaneous vascular malformations, digital anomalies CC consisting of syndactyly with or without postaxial polydactyly, CC connective tissue dysplasia involving the skin, subcutaneous tissue, CC and joints, and cortical brain malformations, most distinctively CC polymicrogyria. {ECO:0000269|PubMed:22729224, CC ECO:0000269|PubMed:26593112}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Congenital lipomatous overgrowth, vascular malformations, and CC epidermal nevi (CLOVE) [MIM:612918]: A sporadically occurring, non- CC hereditary disorder characterized by asymmetric somatic hypertrophy and CC anomalies in multiple organs. It is defined by four main clinical CC findings: congenital lipomatous overgrowth, vascular malformations, CC epidermal nevi, and skeletal/spinal abnormalities. The presence of CC truncal overgrowth and characteristic patterned macrodactyly at birth CC differentiates CLOVE from other syndromic forms of overgrowth. CC {ECO:0000269|PubMed:22658544}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cowden syndrome 5 (CWS5) [MIM:615108]: A form of Cowden CC syndrome, a hamartomatous polyposis syndrome with age-related CC penetrance. Cowden syndrome is characterized by hamartomatous lesions CC affecting derivatives of ectodermal, mesodermal and endodermal layers, CC macrocephaly, facial trichilemmomas (benign tumors of the hair follicle CC infundibulum), acral keratoses, papillomatous papules, and elevated CC risk for development of several types of malignancy, particularly CC breast carcinoma in women and thyroid carcinoma in both men and women. CC Colon cancer and renal cell carcinoma have also been reported. CC Hamartomas can be found in virtually every organ, but most commonly in CC the skin, gastrointestinal tract, breast and thyroid. CC {ECO:0000269|PubMed:23246288}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: CLAPO syndrome (CLAPO) [MIM:613089]: A syndrome characterized CC by capillary malformation of the lower lip, lymphatic malformation of CC the face and neck, asymmetry of face and limbs and partial or CC generalised overgrowth. {ECO:0000269|PubMed:29446767}. Note=The disease CC may be caused by variants affecting the gene represented in this entry. CC The tissue distribution of the clinical manifestations in CLAPO seems CC to follow a pattern of somatic mosaicism. CC {ECO:0000269|PubMed:29446767}. CC -!- DISEASE: Macrodactyly (MADAC) [MIM:155500]: A congenital anomaly CC characterized by fibrofatty tissue enlargement and bony overgrowth CC affecting the digits or the entire hand or foot. CC {ECO:0000269|PubMed:23100325}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. The tissue CC distribution of the clinical manifestations in MADAC seems to follow a CC pattern of somatic mosaicism. {ECO:0000269|PubMed:23100325}. CC -!- DISEASE: Cerebral cavernous malformations 4 (CCM4) [MIM:619538]: A form CC of cerebral cavernous malformations, a congenital vascular anomaly of CC the central nervous system that can result in hemorrhagic stroke, CC seizures, recurrent headaches, and focal neurologic deficits. The CC lesions are characterized by grossly enlarged blood vessels consisting CC of a single layer of endothelium and without any intervening neural CC tissue, ranging in diameter from a few millimeters to several CC centimeters. CCM4 cases occur sporadically. CC {ECO:0000269|PubMed:34496175}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Hemifacial myohyperplasia (HFMH) [MIM:606773]: A rare disease CC characterized by facial asymmetry due to unilateral muscular CC hypertrophy mimicking spasm and orofacial dystonia. CC {ECO:0000269|PubMed:37712948}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: The avian sarcoma virus 16 genome encodes an oncogene CC derived from PIK3CA. {ECO:0000305|PubMed:18418043}. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. {ECO:0000255|PROSITE- CC ProRule:PRU00877, ECO:0000255|PROSITE-ProRule:PRU00879, CC ECO:0000255|PROSITE-ProRule:PRU00880}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/415/PIK3CA"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Z29090; CAA82333.1; -; mRNA. DR EMBL; U79143; AAB39753.1; -; mRNA. DR EMBL; BC113601; AAI13602.1; -; mRNA. DR EMBL; BC113603; AAI13604.1; -; mRNA. DR CCDS; CCDS43171.1; -. DR PIR; I38110; I38110. DR RefSeq; NP_006209.2; NM_006218.4. DR RefSeq; XP_006713721.1; XM_006713658.5. DR RefSeq; XP_054202817.1; XM_054346842.1. DR RefSeq; XP_054202818.1; XM_054346843.1. DR RefSeq; XP_054202819.1; XM_054346844.1. DR RefSeq; XP_054202820.1; XM_054346845.1. DR RefSeq; XP_054202821.1; XM_054346846.1. DR RefSeq; XP_054202822.1; XM_054346847.1. DR RefSeq; XP_054202823.1; XM_054346848.1. DR PDB; 2ENQ; NMR; -; A=331-481. DR PDB; 2RD0; X-ray; 3.05 A; A=1-1068. DR PDB; 3HHM; X-ray; 2.80 A; A=1-1068. DR PDB; 3HIZ; X-ray; 3.30 A; A=1-1068. DR PDB; 3ZIM; X-ray; 2.85 A; A=107-1046. DR PDB; 4JPS; X-ray; 2.20 A; A=1-1068. DR PDB; 4L1B; X-ray; 2.59 A; A=1-1068. DR PDB; 4L23; X-ray; 2.50 A; A=1-1068. DR PDB; 4L2Y; X-ray; 2.80 A; A=1-1068. DR PDB; 4OVU; X-ray; 2.96 A; A=1-1068. DR PDB; 4OVV; X-ray; 3.50 A; A=1-1068. DR PDB; 4TUU; X-ray; 2.64 A; A=105-1048. DR PDB; 4TV3; X-ray; 2.85 A; A=105-1048. DR PDB; 4WAF; X-ray; 2.39 A; A=2-1068. DR PDB; 4YKN; X-ray; 2.90 A; A=2-1068. DR PDB; 4ZOP; X-ray; 2.62 A; A=1-1068. DR PDB; 5DXH; X-ray; 3.00 A; A/D=2-1068. DR PDB; 5DXT; X-ray; 2.25 A; A=107-1068. DR PDB; 5FI4; X-ray; 2.50 A; A=1-1068. DR PDB; 5ITD; X-ray; 3.02 A; A=1-1068. DR PDB; 5SW8; X-ray; 3.30 A; A=1-1068. DR PDB; 5SWG; X-ray; 3.11 A; A=1-1068. DR PDB; 5SWO; X-ray; 3.50 A; A=1-1068. DR PDB; 5SWP; X-ray; 3.41 A; A=1-1068. DR PDB; 5SWR; X-ray; 3.31 A; A=1-1068. DR PDB; 5SWT; X-ray; 3.49 A; A=1-1068. DR PDB; 5SX8; X-ray; 3.47 A; A=1-1068. DR PDB; 5SX9; X-ray; 3.52 A; A=1-1068. DR PDB; 5SXA; X-ray; 3.35 A; A=1-1068. DR PDB; 5SXB; X-ray; 3.30 A; A=1-1068. DR PDB; 5SXC; X-ray; 3.55 A; A=1-1068. DR PDB; 5SXD; X-ray; 3.50 A; A=1-1068. DR PDB; 5SXE; X-ray; 3.51 A; A=1-1068. DR PDB; 5SXF; X-ray; 3.46 A; A=1-1068. DR PDB; 5SXI; X-ray; 3.40 A; A=1-1068. DR PDB; 5SXJ; X-ray; 3.42 A; A=1-1068. DR PDB; 5SXK; X-ray; 3.55 A; A=1-1068. DR PDB; 5UBR; X-ray; 2.40 A; A=107-1050. DR PDB; 5UK8; X-ray; 2.50 A; A=1-1068. DR PDB; 5UKJ; X-ray; 2.80 A; A=1-1068. DR PDB; 5UL1; X-ray; 3.00 A; A=1-1068. DR PDB; 5XGH; X-ray; 2.97 A; A=8-1055. DR PDB; 5XGI; X-ray; 2.56 A; A=8-1059. DR PDB; 5XGJ; X-ray; 2.97 A; A=8-1055. DR PDB; 6GVF; X-ray; 2.50 A; A=107-1051. DR PDB; 6GVG; X-ray; 3.00 A; A=107-1068. DR PDB; 6GVH; X-ray; 2.74 A; A=107-1068. DR PDB; 6GVI; X-ray; 2.90 A; A=107-1068. DR PDB; 6NCT; X-ray; 3.35 A; A=1-1068. DR PDB; 6OAC; X-ray; 3.15 A; A=105-1048. DR PDB; 6PYS; X-ray; 2.19 A; A=107-1051. DR PDB; 6VO7; X-ray; 2.31 A; A=157-300. DR PDB; 7JIU; X-ray; 2.12 A; A=107-1052. DR PDB; 7K6M; X-ray; 2.41 A; A=105-1048. DR PDB; 7K6N; X-ray; 2.77 A; A=105-1048. DR PDB; 7K6O; X-ray; 2.74 A; A=105-1048. DR PDB; 7K71; X-ray; 2.90 A; A=105-1048. DR PDB; 7L1B; X-ray; 2.04 A; C=1046-1054. DR PDB; 7L1C; X-ray; 1.96 A; C=1046-1054. DR PDB; 7L1D; X-ray; 3.11 A; C=1046-1054. DR PDB; 7MLK; X-ray; 2.91 A; A=105-1048. DR PDB; 7MYN; EM; 2.79 A; A=1-1068. DR PDB; 7MYO; EM; 2.92 A; A=1-1068. DR PDB; 7PG5; X-ray; 2.20 A; A=1-1068. DR PDB; 7PG6; X-ray; 2.50 A; A=1-1068. DR PDB; 7R9V; X-ray; 2.69 A; A=105-1048. DR PDB; 7R9Y; X-ray; 2.85 A; A=105-1048. DR PDB; 7RRG; X-ray; 2.12 A; C=1046-1054. DR PDB; 7TZ7; X-ray; 2.41 A; A=1-1068. DR PDB; 8AM0; X-ray; 2.82 A; A=1-1068. DR PDB; 8BFU; X-ray; 2.41 A; A=105-1048. DR PDB; 8DCP; EM; 2.41 A; A=1-1068. DR PDB; 8DCX; EM; 2.80 A; A=1-1068. DR PDB; 8DD4; EM; 3.10 A; A=1-1068. DR PDB; 8DD8; EM; 3.40 A; A=1-1068. DR PDB; 8EXL; X-ray; 1.99 A; A=7-1052. DR PDB; 8EXO; X-ray; 2.46 A; A=7-1052. DR PDB; 8EXU; X-ray; 2.68 A; A=7-1052. DR PDB; 8EXV; X-ray; 2.48 A; A=7-1052. DR PDB; 8GUA; EM; 2.77 A; A=1-1068. DR PDB; 8GUB; EM; 2.73 A; A=1-1068. DR PDB; 8GUD; EM; 2.62 A; A=1-1068. DR PDB; 8ILR; EM; 3.05 A; A=1-1068. DR PDB; 8ILS; EM; 3.10 A; A=1-1068. DR PDB; 8ILV; EM; 3.19 A; A=1-1068. DR PDB; 8OW2; X-ray; 2.57 A; A=105-1048. DR PDB; 8SBC; X-ray; 2.30 A; A=1-1068. DR PDB; 8SBJ; X-ray; 3.10 A; A=1-1068. DR PDB; 8TDU; X-ray; 3.11 A; A/C=1-1068. DR PDB; 8TGD; X-ray; 2.93 A; A/C=1-1068. DR PDB; 8TS7; X-ray; 2.71 A; A=2-1053. DR PDB; 8TS8; X-ray; 2.72 A; A=2-1053. DR PDB; 8TS9; X-ray; 2.83 A; A=2-1050. DR PDB; 8TSA; X-ray; 2.51 A; A=2-1050. DR PDB; 8TSB; X-ray; 3.53 A; A=2-1053. DR PDB; 8TSC; X-ray; 3.62 A; A=2-1050. DR PDB; 8TSD; X-ray; 2.70 A; A=2-1053. DR PDB; 8TU6; EM; 3.12 A; A=2-1068. DR PDB; 8TWY; X-ray; 2.67 A; A=105-1048. DR PDB; 8V8H; X-ray; 3.58 A; A/C=1-1068. DR PDB; 8V8I; X-ray; 3.20 A; A/C=1-1068. DR PDB; 8V8J; X-ray; 3.35 A; A/C=1-1068. DR PDB; 8V8U; X-ray; 2.93 A; A/C=1-1068. DR PDB; 8V8V; X-ray; 2.61 A; A/C=1-1068. DR PDB; 8VCL; X-ray; 2.40 A; C=1046-1054. DR PDB; 8W9A; EM; 2.70 A; A=1-1068. DR PDB; 8W9B; EM; 3.00 A; A=1-1068. DR PDB; 9ASF; X-ray; 1.77 A; C=1046-1054. DR PDB; 9ASG; X-ray; 2.03 A; C=1046-1054. DR PDB; 9B4S; X-ray; 3.10 A; A=105-1068. DR PDB; 9B4T; X-ray; 2.75 A; A=105-1068. DR PDB; 9B4U; X-ray; 2.21 A; A/B=157-300. DR PDB; 9C15; X-ray; 2.81 A; A=105-1068. DR PDB; 9CMK; X-ray; 1.75 A; A/B=160-300. DR PDB; 9CML; X-ray; 2.01 A; A/B=160-300. DR PDB; 9CMV; X-ray; 3.01 A; A=105-1068. DR PDB; 9E8M; X-ray; 2.83 A; A/B=157-300. DR PDBsum; 2ENQ; -. DR PDBsum; 2RD0; -. DR PDBsum; 3HHM; -. DR PDBsum; 3HIZ; -. DR PDBsum; 3ZIM; -. DR PDBsum; 4JPS; -. DR PDBsum; 4L1B; -. DR PDBsum; 4L23; -. DR PDBsum; 4L2Y; -. DR PDBsum; 4OVU; -. DR PDBsum; 4OVV; -. DR PDBsum; 4TUU; -. DR PDBsum; 4TV3; -. DR PDBsum; 4WAF; -. DR PDBsum; 4YKN; -. DR PDBsum; 4ZOP; -. DR PDBsum; 5DXH; -. DR PDBsum; 5DXT; -. DR PDBsum; 5FI4; -. DR PDBsum; 5ITD; -. DR PDBsum; 5SW8; -. DR PDBsum; 5SWG; -. DR PDBsum; 5SWO; -. DR PDBsum; 5SWP; -. DR PDBsum; 5SWR; -. DR PDBsum; 5SWT; -. DR PDBsum; 5SX8; -. DR PDBsum; 5SX9; -. DR PDBsum; 5SXA; -. DR PDBsum; 5SXB; -. DR PDBsum; 5SXC; -. DR PDBsum; 5SXD; -. DR PDBsum; 5SXE; -. DR PDBsum; 5SXF; -. DR PDBsum; 5SXI; -. DR PDBsum; 5SXJ; -. DR PDBsum; 5SXK; -. DR PDBsum; 5UBR; -. DR PDBsum; 5UK8; -. DR PDBsum; 5UKJ; -. DR PDBsum; 5UL1; -. DR PDBsum; 5XGH; -. DR PDBsum; 5XGI; -. DR PDBsum; 5XGJ; -. DR PDBsum; 6GVF; -. DR PDBsum; 6GVG; -. DR PDBsum; 6GVH; -. DR PDBsum; 6GVI; -. DR PDBsum; 6NCT; -. DR PDBsum; 6OAC; -. DR PDBsum; 6PYS; -. DR PDBsum; 6VO7; -. DR PDBsum; 7JIU; -. DR PDBsum; 7K6M; -. DR PDBsum; 7K6N; -. DR PDBsum; 7K6O; -. DR PDBsum; 7K71; -. DR PDBsum; 7L1B; -. DR PDBsum; 7L1C; -. DR PDBsum; 7L1D; -. DR PDBsum; 7MLK; -. DR PDBsum; 7MYN; -. DR PDBsum; 7MYO; -. DR PDBsum; 7PG5; -. DR PDBsum; 7PG6; -. DR PDBsum; 7R9V; -. DR PDBsum; 7R9Y; -. DR PDBsum; 7RRG; -. DR PDBsum; 7TZ7; -. DR PDBsum; 8AM0; -. DR PDBsum; 8BFU; -. DR PDBsum; 8DCP; -. DR PDBsum; 8DCX; -. DR PDBsum; 8DD4; -. DR PDBsum; 8DD8; -. DR PDBsum; 8EXL; -. DR PDBsum; 8EXO; -. DR PDBsum; 8EXU; -. DR PDBsum; 8EXV; -. DR PDBsum; 8GUA; -. DR PDBsum; 8GUB; -. DR PDBsum; 8GUD; -. DR PDBsum; 8ILR; -. DR PDBsum; 8ILS; -. DR PDBsum; 8ILV; -. DR PDBsum; 8OW2; -. DR PDBsum; 8SBC; -. DR PDBsum; 8SBJ; -. DR PDBsum; 8TDU; -. DR PDBsum; 8TGD; -. DR PDBsum; 8TS7; -. DR PDBsum; 8TS8; -. DR PDBsum; 8TS9; -. DR PDBsum; 8TSA; -. DR PDBsum; 8TSB; -. DR PDBsum; 8TSC; -. DR PDBsum; 8TSD; -. DR PDBsum; 8TU6; -. DR PDBsum; 8TWY; -. DR PDBsum; 8V8H; -. DR PDBsum; 8V8I; -. DR PDBsum; 8V8J; -. DR PDBsum; 8V8U; -. DR PDBsum; 8V8V; -. DR PDBsum; 8VCL; -. DR PDBsum; 8W9A; -. DR PDBsum; 8W9B; -. DR PDBsum; 9ASF; -. DR PDBsum; 9ASG; -. DR PDBsum; 9B4S; -. DR PDBsum; 9B4T; -. DR PDBsum; 9B4U; -. DR PDBsum; 9C15; -. DR PDBsum; 9CMK; -. DR PDBsum; 9CML; -. DR PDBsum; 9CMV; -. DR PDBsum; 9E8M; -. DR AlphaFoldDB; P42336; -. DR EMDB; EMD-24081; -. DR EMDB; EMD-24082; -. DR EMDB; EMD-27327; -. DR EMDB; EMD-27330; -. DR EMDB; EMD-27334; -. DR EMDB; EMD-27336; -. DR EMDB; EMD-34271; -. DR EMDB; EMD-34272; -. DR EMDB; EMD-34273; -. DR EMDB; EMD-35543; -. DR EMDB; EMD-35545; -. DR EMDB; EMD-35547; -. DR EMDB; EMD-37362; -. DR EMDB; EMD-37363; -. DR EMDB; EMD-41617; -. DR SMR; P42336; -. DR BioGRID; 111308; 178. DR ComplexPortal; CPX-1917; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p85beta. DR ComplexPortal; CPX-1918; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p55gamma. DR ComplexPortal; CPX-2384; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p85alpha. DR ComplexPortal; CPX-5970; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p55alpha. DR ComplexPortal; CPX-5971; Phosphatidylinositol 3-kinase complex class IA, p110alpha/p50alpha. DR CORUM; P42336; -. DR DIP; DIP-42728N; -. DR FunCoup; P42336; 3134. DR IntAct; P42336; 216. DR MINT; P42336; -. DR STRING; 9606.ENSP00000263967; -. DR BindingDB; P42336; -. DR ChEMBL; CHEMBL4005; -. DR DrugBank; DB12015; Alpelisib. DR DrugBank; DB00171; ATP. DR DrugBank; DB11666; Buparlisib. DR DrugBank; DB00201; Caffeine. DR DrugBank; DB13051; CH-5132799. DR DrugBank; DB12483; Copanlisib. DR DrugBank; DB15275; Inavolisib. DR DrugBank; DB12167; LY-3023414. DR DrugBank; DB11772; Pilaralisib. DR DrugBank; DB14935; Serabelisib. DR DrugBank; DB12108; Taselisib. DR DrugBank; DB08059; Wortmannin. DR DrugBank; DB05241; XL765. DR DrugCentral; P42336; -. DR GuidetoPHARMACOLOGY; 2153; -. DR iPTMnet; P42336; -. DR MetOSite; P42336; -. DR PhosphoSitePlus; P42336; -. DR BioMuta; PIK3CA; -. DR DMDM; 126302584; -. DR CPTAC; CPTAC-1631; -. DR CPTAC; CPTAC-3127; -. DR CPTAC; CPTAC-3128; -. DR CPTAC; CPTAC-3129; -. DR jPOST; P42336; -. DR MassIVE; P42336; -. DR PaxDb; 9606-ENSP00000263967; -. DR PeptideAtlas; P42336; -. DR ProteomicsDB; 55509; -. DR Pumba; P42336; -. DR Antibodypedia; 1374; 746 antibodies from 44 providers. DR CPTC; P42336; 1 antibody. DR DNASU; 5290; -. DR Ensembl; ENST00000263967.4; ENSP00000263967.3; ENSG00000121879.7. DR GeneID; 5290; -. DR KEGG; hsa:5290; -. DR MANE-Select; ENST00000263967.4; ENSP00000263967.3; NM_006218.4; NP_006209.2. DR UCSC; uc003fjk.4; human. DR AGR; HGNC:8975; -. DR CIViC; 5290; 319 evidence items across 211 molecular profiles. DR ClinPGx; PA33308; -. DR CTD; 5290; -. DR DisGeNET; 5290; -. DR GeneCards; PIK3CA; -. DR GeneReviews; PIK3CA; -. DR HGNC; HGNC:8975; PIK3CA. DR HPA; ENSG00000121879; Low tissue specificity. DR MalaCards; PIK3CA; -. DR MIM; 114480; phenotype. DR MIM; 114500; phenotype. DR MIM; 114550; phenotype. DR MIM; 155500; phenotype. DR MIM; 167000; phenotype. DR MIM; 171834; gene. DR MIM; 182000; phenotype. DR MIM; 602501; phenotype. DR MIM; 606773; phenotype. DR MIM; 612918; phenotype. DR MIM; 613089; phenotype. DR MIM; 615108; phenotype. DR MIM; 619538; phenotype. DR OpenTargets; ENSG00000121879; -. DR Orphanet; 210159; Adult hepatocellular carcinoma. DR Orphanet; 90308; Capillary-lymphatic-venous malformation with segmental distribution. DR Orphanet; 168984; CLAPO syndrome. DR Orphanet; 140944; CLOVES syndrome. DR Orphanet; 201; Cowden syndrome. DR Orphanet; 221061; Familial cerebral cavernous malformation. DR Orphanet; 276280; Hemihyperplasia-multiple lipomatosis syndrome. DR Orphanet; 99802; Hemimegalencephaly. DR Orphanet; 144; Lynch syndrome. DR Orphanet; 295239; Macrodactyly of fingers, unilateral. DR Orphanet; 295243; Macrodactyly of toes, unilateral. DR Orphanet; 60040; Megalencephaly-capillary malformation-polymicrogyria syndrome. DR Orphanet; 2495; Meningioma. DR Orphanet; 314662; Segmental progressive overgrowth syndrome with fibroadipose hyperplasia. DR VEuPathDB; HostDB:ENSG00000121879; -. DR eggNOG; KOG0904; Eukaryota. DR GeneTree; ENSGT00940000155531; -. DR HOGENOM; CLU_002191_1_1_1; -. DR InParanoid; P42336; -. DR OMA; RWSEWLN; -. DR OrthoDB; 67688at2759; -. DR PAN-GO; P42336; 9 GO annotations based on evolutionary models. DR PhylomeDB; P42336; -. DR BioCyc; MetaCyc:HS04527-MONOMER; -. DR BRENDA; 2.7.1.137; 2681. DR BRENDA; 2.7.1.153; 2681. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P42336; -. DR Reactome; R-HSA-109704; PI3K Cascade. DR Reactome; R-HSA-112399; IRS-mediated signalling. DR Reactome; R-HSA-114604; GPVI-mediated activation cascade. DR Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants. DR Reactome; R-HSA-1250342; PI3K events in ERBB4 signaling. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1433557; Signaling by SCF-KIT. DR Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane. DR Reactome; R-HSA-180292; GAB1 signalosome. DR Reactome; R-HSA-1839117; Signaling by cytosolic FGFR1 fusion mutants. DR Reactome; R-HSA-186763; Downstream signal transduction. DR Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling. DR Reactome; R-HSA-198203; PI3K/AKT activation. DR Reactome; R-HSA-201556; Signaling by ALK. DR Reactome; R-HSA-202424; Downstream TCR signaling. DR Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis. DR Reactome; R-HSA-210993; Tie2 Signaling. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-2424491; DAP12 signaling. DR Reactome; R-HSA-2730905; Role of LAT2/NTAL/LAB on calcium mobilization. DR Reactome; R-HSA-373753; Nephrin family interactions. DR Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling. DR Reactome; R-HSA-416476; G alpha (q) signalling events. DR Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway. DR Reactome; R-HSA-512988; Interleukin-3, Interleukin-5 and GM-CSF signaling. DR Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII. DR Reactome; R-HSA-5654689; PI-3K cascade:FGFR1. DR Reactome; R-HSA-5654695; PI-3K cascade:FGFR2. DR Reactome; R-HSA-5654710; PI-3K cascade:FGFR3. DR Reactome; R-HSA-5654720; PI-3K cascade:FGFR4. DR Reactome; R-HSA-5655253; Signaling by FGFR2 in disease. DR Reactome; R-HSA-5655291; Signaling by FGFR4 in disease. DR Reactome; R-HSA-5655302; Signaling by FGFR1 in disease. DR Reactome; R-HSA-5655332; Signaling by FGFR3 in disease. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8851907; MET activates PI3K/AKT signaling. DR Reactome; R-HSA-8853659; RET signaling. DR Reactome; R-HSA-9009391; Extra-nuclear estrogen signaling. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR Reactome; R-HSA-9013404; RAC2 GTPase cycle. DR Reactome; R-HSA-9027276; Erythropoietin activates Phosphoinositide-3-kinase (PI3K). DR Reactome; R-HSA-9028335; Activated NTRK2 signals through PI3K. DR Reactome; R-HSA-912526; Interleukin receptor SHC signaling. DR Reactome; R-HSA-912631; Regulation of signaling by CBL. DR Reactome; R-HSA-9603381; Activated NTRK3 signals through PI3K. DR Reactome; R-HSA-9607240; FLT3 Signaling. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants. DR Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants. DR Reactome; R-HSA-9673767; Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants. DR Reactome; R-HSA-9673770; Signaling by PDGFRA extracellular domain mutants. DR Reactome; R-HSA-9680350; Signaling by CSF1 (M-CSF) in myeloid cells. DR Reactome; R-HSA-9703465; Signaling by FLT3 fusion proteins. DR Reactome; R-HSA-9703648; Signaling by FLT3 ITD and TKD mutants. DR Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants. DR Reactome; R-HSA-9842640; Signaling by LTK in cancer. DR Reactome; R-HSA-9842663; Signaling by LTK. DR Reactome; R-HSA-9856530; High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells. DR Reactome; R-HSA-9927354; Co-stimulation by ICOS. DR SABIO-RK; P42336; -. DR SignaLink; P42336; -. DR SIGNOR; P42336; -. DR UniPathway; UPA00220; -. DR Agora; ENSG00000121879; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 5290; 275 hits in 1174 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; PIK3CA; human. DR EvolutionaryTrace; P42336; -. DR GeneWiki; P110%CE%B1; -. DR GenomeRNAi; 5290; -. DR Pharos; P42336; Tclin. DR PRO; PR:P42336; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P42336; protein. DR Bgee; ENSG00000121879; Expressed in calcaneal tendon and 201 other cell types or tissues. DR ExpressionAtlas; P42336; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0014704; C:intercalated disc; ISS:BHF-UCL. DR GO; GO:0030027; C:lamellipodium; IEA:Ensembl. DR GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:BHF-UCL. DR GO; GO:0005942; C:phosphatidylinositol 3-kinase complex; ISS:BHF-UCL. DR GO; GO:0005943; C:phosphatidylinositol 3-kinase complex, class IA; IDA:UniProtKB. DR GO; GO:0005944; C:phosphatidylinositol 3-kinase complex, class IB; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; IDA:UniProtKB. DR GO; GO:0046934; F:1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity; IDA:UniProt. DR GO; GO:0035005; F:1-phosphatidylinositol-4-phosphate 3-kinase activity; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0043560; F:insulin receptor substrate binding; IEA:Ensembl. DR GO; GO:0030295; F:protein kinase activator activity; IEA:Ensembl. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0030036; P:actin cytoskeleton organization; ISS:BHF-UCL. DR GO; GO:0060612; P:adipose tissue development; IEA:Ensembl. DR GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW. DR GO; GO:0043276; P:anoikis; NAS:ParkinsonsUK-UCL. DR GO; GO:0141068; P:autosome genomic imprinting; IEA:Ensembl. DR GO; GO:0086003; P:cardiac muscle cell contraction; ISS:BHF-UCL. DR GO; GO:0060048; P:cardiac muscle contraction; TAS:UniProtKB. DR GO; GO:0016477; P:cell migration; IBA:GO_Central. DR GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl. DR GO; GO:0071464; P:cellular response to hydrostatic pressure; ISS:BHF-UCL. DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:UniProt. DR GO; GO:0043542; P:endothelial cell migration; TAS:UniProtKB. DR GO; GO:0097009; P:energy homeostasis; IEA:Ensembl. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome. DR GO; GO:0006006; P:glucose metabolic process; IEA:Ensembl. DR GO; GO:0008286; P:insulin receptor signaling pathway; TAS:UniProtKB. DR GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0001889; P:liver development; IEA:Ensembl. DR GO; GO:0030835; P:negative regulation of actin filament depolymerization; ISS:BHF-UCL. DR GO; GO:2000811; P:negative regulation of anoikis; IMP:UniProtKB. DR GO; GO:2000270; P:negative regulation of fibroblast apoptotic process; IEA:Ensembl. DR GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl. DR GO; GO:0016242; P:negative regulation of macroautophagy; NAS:ParkinsonsUK-UCL. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0006909; P:phagocytosis; IEA:UniProtKB-KW. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IGI:BHF-UCL. DR GO; GO:0046854; P:phosphatidylinositol phosphate biosynthetic process; ISS:BHF-UCL. DR GO; GO:0036092; P:phosphatidylinositol-3-phosphate biosynthetic process; IBA:GO_Central. DR GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IBA:GO_Central. DR GO; GO:0030168; P:platelet activation; TAS:UniProtKB. DR GO; GO:0010592; P:positive regulation of lamellipodium assembly; ISS:BHF-UCL. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IGI:BHF-UCL. DR GO; GO:1905477; P:positive regulation of protein localization to membrane; IDA:UniProt. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl. DR GO; GO:0032008; P:positive regulation of TOR signaling; NAS:ParkinsonsUK-UCL. DR GO; GO:0110053; P:regulation of actin filament organization; ISS:BHF-UCL. DR GO; GO:0043457; P:regulation of cellular respiration; IEA:Ensembl. DR GO; GO:0040014; P:regulation of multicellular organism growth; IEA:Ensembl. DR GO; GO:0055119; P:relaxation of cardiac muscle; ISS:BHF-UCL. DR GO; GO:0014823; P:response to activity; IEA:Ensembl. DR GO; GO:1903544; P:response to butyrate; IEA:Ensembl. DR GO; GO:0071548; P:response to dexamethasone; IEA:Ensembl. DR GO; GO:0043201; P:response to L-leucine; IEA:Ensembl. DR GO; GO:0014870; P:response to muscle inactivity; IEA:Ensembl. DR GO; GO:0035994; P:response to muscle stretch; ISS:BHF-UCL. DR GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome. DR GO; GO:0038203; P:TORC2 signaling; IMP:MGI. DR GO; GO:0038084; P:vascular endothelial growth factor signaling pathway; IGI:BHF-UCL. DR GO; GO:0001944; P:vasculature development; TAS:UniProtKB. DR CDD; cd08398; C2_PI3K_class_I_alpha; 1. DR CDD; cd00872; PI3Ka_I; 1. DR CDD; cd05175; PI3Kc_IA_alpha; 1. DR FunFam; 1.10.1070.11:FF:000006; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 1.25.40.70:FF:000001; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 2.60.40.150:FF:000041; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 3.10.20.90:FF:000055; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 3.10.20.90:FF:000074; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR FunFam; 3.30.1010.10:FF:000007; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1. DR Gene3D; 2.60.40.150; C2 domain; 1. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 2. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR Gene3D; 1.25.40.70; Phosphatidylinositol 3-kinase, accessory domain (PIK); 1. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR037704; PI3-kinase_alpha_cat. DR InterPro; IPR015433; PI3/4_kinase. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR002420; PI3K-type_C2_dom. DR InterPro; IPR003113; PI3K_ABD. DR InterPro; IPR001263; PI3K_accessory_dom. DR InterPro; IPR042236; PI3K_accessory_sf. DR InterPro; IPR000341; PI3K_Ras-bd_dom. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR PANTHER; PTHR10048:SF107; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT ALPHA ISOFORM; 1. DR PANTHER; PTHR10048; PHOSPHATIDYLINOSITOL KINASE; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR Pfam; PF00792; PI3K_C2; 1. DR Pfam; PF02192; PI3K_p85B; 1. DR Pfam; PF00794; PI3K_rbd; 1. DR Pfam; PF00613; PI3Ka; 1. DR SMART; SM00142; PI3K_C2; 1. DR SMART; SM00143; PI3K_p85B; 1. DR SMART; SM00144; PI3K_rbd; 1. DR SMART; SM00145; PI3Ka; 1. DR SMART; SM00146; PI3Kc; 1. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS51547; C2_PI3K; 1. DR PROSITE; PS00915; PI3_4_KINASE_1; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. DR PROSITE; PS51544; PI3K_ABD; 1. DR PROSITE; PS51546; PI3K_RBD; 1. DR PROSITE; PS51545; PIK_HELICAL; 1. PE 1: Evidence at protein level; KW 3D-structure; Angiogenesis; ATP-binding; Disease variant; Kinase; KW Lipid metabolism; Nucleotide-binding; Phagocytosis; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..1068 FT /note="Phosphatidylinositol 4,5-bisphosphate 3-kinase FT catalytic subunit alpha isoform" FT /id="PRO_0000088785" FT DOMAIN 16..105 FT /note="PI3K-ABD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00877" FT DOMAIN 187..289 FT /note="PI3K-RBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00879" FT DOMAIN 330..487 FT /note="C2 PI3K-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00880" FT DOMAIN 517..694 FT /note="PIK helical" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00878" FT DOMAIN 765..1051 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 771..777 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 912..920 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 931..957 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT SITE 776 FT /note="Implicated in the recognition of ATP as well as FT PIP2. Also crucial for autophosphorylation of the p85alpha FT subunit" FT /evidence="ECO:0000305|PubMed:23936502" FT VARIANT 38 FT /note="R -> H (in CRC; likely involved in disease FT pathogenesis; shows an increase in lipid kinase activity; FT may disrupt the interaction between the PI3K-ABD domain and FT the N-terminal lobe of PI3K/PI4K kinase domain possibly FT affecting the conformation of the kinase domain; FT dbSNP:rs772110575)" FT /evidence="ECO:0000269|PubMed:15930273" FT /id="VAR_026166" FT VARIANT 43 FT /note="I -> V (in dbSNP:rs1051399)" FT /evidence="ECO:0000269|PubMed:7713498" FT /id="VAR_042942" FT VARIANT 81 FT /note="E -> K (in MCAP; dbSNP:rs1057519929)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069251" FT VARIANT 83 FT /note="F -> S (in CLAPO; uncertain significance; somatic FT mutation; dbSNP:rs1560137208)" FT /evidence="ECO:0000269|PubMed:29446767" FT /id="VAR_081475" FT VARIANT 88 FT /note="R -> Q (in MCAP; also found in a glioblastoma FT multiforme sample; dbSNP:rs121913287)" FT /evidence="ECO:0000269|PubMed:15924253, FT ECO:0000269|PubMed:22729224" FT /id="VAR_026167" FT VARIANT 106 FT /note="G -> V (in CRC; likely involved in disease FT pathogenesis; shows an increase in lipid kinase activity; FT dbSNP:rs1057519930)" FT /evidence="ECO:0000269|PubMed:15930273" FT /id="VAR_026168" FT VARIANT 112 FT /note="I -> N (in MCAP; increased phosphatidylinositol 3- FT kinase signaling; decreased interaction with p85 regulatory FT subunit; no effect on protein abundance; FT dbSNP:rs863225460)" FT /evidence="ECO:0000269|PubMed:26593112" FT /id="VAR_075634" FT VARIANT 115 FT /note="R -> P (in CLAPO and MADAC; uncertain significance; FT somatic mutation in CLAPO and MADAC patients; FT dbSNP:rs200018596)" FT /evidence="ECO:0000269|PubMed:23100325, FT ECO:0000269|PubMed:29446767" FT /id="VAR_081476" FT VARIANT 118 FT /note="G -> D (in CWS5; dbSNP:rs587777790)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069786" FT VARIANT 135 FT /note="E -> K (in CWS5; dbSNP:rs587777791)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069787" FT VARIANT 218 FT /note="E -> K (in CWS5; dbSNP:rs587777792)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069788" FT VARIANT 332 FT /note="S -> R (in dbSNP:rs1051407)" FT /evidence="ECO:0000269|PubMed:7713498" FT /id="VAR_042943" FT VARIANT 343 FT /note="Y -> C (found in a cancer sample; uncertain FT significance; dbSNP:rs2108393253)" FT /evidence="ECO:0000269|PubMed:16533766" FT /id="VAR_026169" FT VARIANT 356 FT /note="V -> I (in CWS5; dbSNP:rs587777793)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069789" FT VARIANT 364 FT /note="G -> R (in MCAP; dbSNP:rs1576935161)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069252" FT VARIANT 365 FT /note="E -> K (in MCAP; dbSNP:rs1064793732)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069253" FT VARIANT 378 FT /note="C -> Y (in MCAP; dbSNP:rs397514565)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069254" FT VARIANT 382 FT /note="R -> K (in CWS5; dbSNP:rs587777794)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069790" FT VARIANT 391 FT /note="I -> M (in dbSNP:rs2230461)" FT /evidence="ECO:0000269|PubMed:16533766" FT /id="VAR_026170" FT VARIANT 420 FT /note="C -> R (in CLOVE, CRC and CLAPO; uncertain FT significance; somatic mutation in CLAPO patients; shows an FT increase in lipid kinase activity; may increase the FT affinity for lipid membranes; dbSNP:rs121913272)" FT /evidence="ECO:0000269|PubMed:15930273, FT ECO:0000269|PubMed:22658544, ECO:0000269|PubMed:29446767" FT /id="VAR_026171" FT VARIANT 453 FT /note="E -> Q (in CRC; likely involved in disease FT pathogenesis; shows an increase in lipid kinase activity; FT may disrupt the interaction of the C2 PI3K-type domain with FT the iSH2 region of the p85 regulatory subunit; FT dbSNP:rs1057519925)" FT /evidence="ECO:0000269|PubMed:15930273" FT /id="VAR_026172" FT VARIANT 453 FT /note="Missing (in MCAP)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069255" FT VARIANT 542 FT /note="E -> K (in CLOVE, KERSEB, CRC, BC, CLAPO, MADAC, FT CCM4 and HFMH; somatic mutation; also found in glioblastoma FT multiforme and endometrial carcinoma; somatic mutation; FT shows an increase in lipid kinase activity; oncogenic in FT vivo; occurs in the interface between the PI3K helical FT domain and the nSH2 (N-terminal SH2) region of the p85 FT regulatory subunit and may reduce the inhibitory effect of FT p85; requires interaction with RAS to induce cellular FT transformation; increased AKT and RPS6 phosphorylation in FT HFMH patient's cells; dbSNP:rs121913273)" FT /evidence="ECO:0000269|PubMed:15289301, FT ECO:0000269|PubMed:15784156, ECO:0000269|PubMed:15924253, FT ECO:0000269|PubMed:15930273, ECO:0000269|PubMed:15994075, FT ECO:0000269|PubMed:16322209, ECO:0000269|PubMed:16353168, FT ECO:0000269|PubMed:16432179, ECO:0000269|PubMed:16533766, FT ECO:0000269|PubMed:17673550, ECO:0000269|PubMed:22658544, FT ECO:0000269|PubMed:23100325, ECO:0000269|PubMed:29446767, FT ECO:0000269|PubMed:34496175, ECO:0000269|PubMed:37712948" FT /id="VAR_026173" FT VARIANT 542 FT /note="E -> Q (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs121913273)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026174" FT VARIANT 542 FT /note="E -> V (in BC; uncertain significance; FT dbSNP:rs1057519927)" FT /evidence="ECO:0000269|PubMed:16353168" FT /id="VAR_026175" FT VARIANT 545 FT /note="E -> A (in CWS5 and HCC; also found in a FT glioblastoma multiforme sample; dbSNP:rs121913274)" FT /evidence="ECO:0000269|PubMed:15608678, FT ECO:0000269|PubMed:15924253, ECO:0000269|PubMed:23246288" FT /id="VAR_026176" FT VARIANT 545 FT /note="E -> G (in KERSEB; also found in an endometrial FT carcinoma sample; dbSNP:rs121913274)" FT /evidence="ECO:0000269|PubMed:15520168, FT ECO:0000269|PubMed:15994075, ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:17673550" FT /id="VAR_026177" FT VARIANT 545 FT /note="E -> K (in MCAP, KERSEB, CRC, BC and HFMH; somatic FT mutation; shows an increase in lipid kinase activity; FT oncogenic in vivo; occurs in the interface between the PI3K FT helical domain and the nSH2 (N-terminal SH2) region of the FT p85 regulatory subunit and may reduce the inhibitory effect FT of p85; requires interaction with RAS to induce cellular FT transformation; enhances invadopodia-mediated extracellular FT matrix degradation and invasion in breast cancer cells; FT increased AKT and RPS6 phosphorylation in HFMH patient's FT cells; dbSNP:rs104886003)" FT /evidence="ECO:0000269|PubMed:15289301, FT ECO:0000269|PubMed:15520168, ECO:0000269|PubMed:15712344, FT ECO:0000269|PubMed:15784156, ECO:0000269|PubMed:15930273, FT ECO:0000269|PubMed:15994075, ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:16353168, ECO:0000269|PubMed:16432179, FT ECO:0000269|PubMed:16533766, ECO:0000269|PubMed:17673550, FT ECO:0000269|PubMed:21708979, ECO:0000269|PubMed:22729224, FT ECO:0000269|PubMed:37712948" FT /id="VAR_026178" FT VARIANT 546 FT /note="Q -> E (in BC; uncertain significance; FT dbSNP:rs121913286)" FT /evidence="ECO:0000269|PubMed:15520168" FT /id="VAR_026179" FT VARIANT 546 FT /note="Q -> K (in OC; uncertain significance; FT dbSNP:rs121913286)" FT /evidence="ECO:0000269|PubMed:15520168" FT /id="VAR_026180" FT VARIANT 546 FT /note="Q -> P (found in an anaplastic astrocytoma sample; FT uncertain significance; dbSNP:rs397517201)" FT /evidence="ECO:0000269|PubMed:15289301" FT /id="VAR_026181" FT VARIANT 546 FT /note="Q -> R (in BC; uncertain significance; FT dbSNP:rs397517201)" FT /evidence="ECO:0000269|PubMed:16353168" FT /id="VAR_026182" FT VARIANT 726 FT /note="E -> K (in MCAP; dbSNP:rs867262025)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069256" FT VARIANT 914 FT /note="G -> R (in MCAP; dbSNP:rs587776932)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069257" FT VARIANT 1007 FT /note="G -> R (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs1448660730)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026183" FT VARIANT 1021 FT /note="Y -> C (in MCAP; also found in an endometrial FT carcinoma sample; dbSNP:rs121913288)" FT /evidence="ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:22729224" FT /id="VAR_026184" FT VARIANT 1021 FT /note="Y -> H (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs2108429509)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026185" FT VARIANT 1021 FT /note="Y -> N (found in a glioblastoma multiforme sample; FT uncertain significance; dbSNP:rs2108429509)" FT /evidence="ECO:0000269|PubMed:15289301" FT /id="VAR_026186" FT VARIANT 1023 FT /note="R -> Q (in CRC; uncertain significance; FT dbSNP:rs2108429549)" FT /evidence="ECO:0000269|PubMed:15994075" FT /id="VAR_026187" FT VARIANT 1025 FT /note="T -> A (in MCAP; dbSNP:rs397517202)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069258" FT VARIANT 1025 FT /note="T -> N (found in a glioblastoma multiforme sample; FT uncertain significance; dbSNP:rs1553826166)" FT /evidence="ECO:0000269|PubMed:15924253" FT /id="VAR_026188" FT VARIANT 1035 FT /note="A -> V (in MCAP; also found in an endometrial FT carcinoma sample; dbSNP:rs1242945375)" FT /evidence="ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:22729224" FT /id="VAR_026189" FT VARIANT 1043 FT /note="M -> I (in MCAP and CRC; also found in an FT endometrial carcinoma sample; shows an increase in lipid FT kinase activity; dbSNP:rs121913283)" FT /evidence="ECO:0000269|PubMed:15930273, FT ECO:0000269|PubMed:16322209, ECO:0000269|PubMed:22729224" FT /id="VAR_026190" FT VARIANT 1047 FT /note="H -> L (in BC, CLAPO, MADAC and CCM4; somatic FT mutation; dbSNP:rs121913279)" FT /evidence="ECO:0000269|PubMed:15289301, FT ECO:0000269|PubMed:15520168, ECO:0000269|PubMed:15994075, FT ECO:0000269|PubMed:16353168, ECO:0000269|PubMed:23100325, FT ECO:0000269|PubMed:29446767, ECO:0000269|PubMed:34496175" FT /id="VAR_026191" FT VARIANT 1047 FT /note="H -> R (in CLOVE, KERSEB, CRC, BC, OC, MADAC, CCM4 FT and HFMH; also found in an endometrial carcinoma sample; FT somatic mutation; shows an increase in lipid kinase FT activity; oncogenic in vivo; requires binding to p85 FT regulatory subunit to induce cellular transformation but FT not interaction with RAS; may mimic the conformatitonal FT change triggered by the interaction with RAS; enhances FT invadopodia-mediated extracellular matrix degradation and FT invasion in breast cancer cells; may alter the interaction FT of the PI3K/PI4K kinase domain with the cell membrane; FT increased AKT and RPS6 phosphorylation in HFMH patient's FT cell; dbSNP:rs121913279)" FT /evidence="ECO:0000269|PubMed:15016963, FT ECO:0000269|PubMed:15289301, ECO:0000269|PubMed:15520168, FT ECO:0000269|PubMed:15712344, ECO:0000269|PubMed:15784156, FT ECO:0000269|PubMed:15930273, ECO:0000269|PubMed:15994075, FT ECO:0000269|PubMed:16114017, ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:16353168, ECO:0000269|PubMed:16432179, FT ECO:0000269|PubMed:16533766, ECO:0000269|PubMed:17673550, FT ECO:0000269|PubMed:19805105, ECO:0000269|PubMed:21708979, FT ECO:0000269|PubMed:22658544, ECO:0000269|PubMed:23100325, FT ECO:0000269|PubMed:34496175, ECO:0000269|PubMed:37712948" FT /id="VAR_026192" FT VARIANT 1047 FT /note="H -> Y (in MCAP; also found in an endometrial FT carcinoma sample; dbSNP:rs121913281)" FT /evidence="ECO:0000269|PubMed:16322209, FT ECO:0000269|PubMed:22729224" FT /id="VAR_026193" FT VARIANT 1049 FT /note="G -> S (in MCAP; dbSNP:rs121913277)" FT /evidence="ECO:0000269|PubMed:22729224" FT /id="VAR_069259" FT VARIANT 1050 FT /note="G -> D (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs2108429937)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026194" FT VARIANT 1052 FT /note="T -> K (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs2108429956)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026195" FT VARIANT 1065 FT /note="H -> L (found in an endometrial carcinoma sample; FT uncertain significance; dbSNP:rs1560150596)" FT /evidence="ECO:0000269|PubMed:16322209" FT /id="VAR_026196" FT VARIANT 1065 FT /note="H -> Y (found in brain tumors; uncertain FT significance; dbSNP:rs2108430115)" FT /evidence="ECO:0000269|PubMed:15289301" FT /id="VAR_026197" FT CONFLICT 170 FT /note="N -> H (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 187 FT /note="K -> R (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 286..287 FT /note="ML -> KM (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 346 FT /note="V -> L (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 723 FT /note="K -> R (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 751 FT /note="F -> L (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT CONFLICT 767 FT /note="E -> K (in Ref. 1; CAA82333)" FT /evidence="ECO:0000305" FT STRAND 5..10 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 13..15 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 18..25 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 27..29 FT /evidence="ECO:0007829|PDB:8TSA" FT STRAND 31..37 FT /evidence="ECO:0007829|PDB:4JPS" FT HELIX 42..52 FT /evidence="ECO:0007829|PDB:4JPS" FT HELIX 53..55 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 56..58 FT /evidence="ECO:0007829|PDB:8DCX" FT HELIX 59..61 FT /evidence="ECO:0007829|PDB:4JPS" FT HELIX 65..67 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 69..74 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 75..77 FT /evidence="ECO:0007829|PDB:4OVU" FT STRAND 79..82 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 85..87 FT /evidence="ECO:0007829|PDB:8DCX" FT HELIX 89..91 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 94..102 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:5SXA" FT HELIX 108..121 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 126..129 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 134..142 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 144..154 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 155..159 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 160..166 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 179..182 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 183..185 FT /evidence="ECO:0007829|PDB:3HHM" FT HELIX 186..188 FT /evidence="ECO:0007829|PDB:8BFU" FT STRAND 189..197 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 199..202 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 204..212 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 217..230 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 231..233 FT /evidence="ECO:0007829|PDB:8V8V" FT HELIX 236..246 FT /evidence="ECO:0007829|PDB:7PG5" FT HELIX 247..249 FT /evidence="ECO:0007829|PDB:7JIU" FT STRAND 250..254 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 255..257 FT /evidence="ECO:0007829|PDB:8W9A" FT STRAND 259..261 FT /evidence="ECO:0007829|PDB:8W9B" FT STRAND 263..265 FT /evidence="ECO:0007829|PDB:8DCX" FT HELIX 267..269 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 271..279 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 284..289 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 290..294 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 306..308 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 319..321 FT /evidence="ECO:0007829|PDB:5SXA" FT STRAND 323..326 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 327..329 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 332..343 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 348..350 FT /evidence="ECO:0007829|PDB:4JPS" FT STRAND 353..362 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 365..368 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 378..380 FT /evidence="ECO:0007829|PDB:6PYS" FT STRAND 382..392 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 393..395 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 400..408 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 413..415 FT /evidence="ECO:0007829|PDB:8SBC" FT STRAND 420..430 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 434..436 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 439..444 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 446..448 FT /evidence="ECO:0007829|PDB:8GUA" FT STRAND 454..456 FT /evidence="ECO:0007829|PDB:6GVF" FT STRAND 458..460 FT /evidence="ECO:0007829|PDB:8V8V" FT STRAND 468..470 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 472..477 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 481..485 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 489..504 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 508..511 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 515..517 FT /evidence="ECO:0007829|PDB:4TUU" FT TURN 520..522 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 525..536 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 539..541 FT /evidence="ECO:0007829|PDB:4TUU" FT HELIX 545..553 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 555..558 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 562..564 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 565..569 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 570..572 FT /evidence="ECO:0007829|PDB:8W9A" FT HELIX 577..588 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 595..598 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 599..602 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 603..605 FT /evidence="ECO:0007829|PDB:8GUD" FT HELIX 609..622 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 625..630 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 632..638 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 639..641 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 643..646 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 648..657 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 661..672 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 673..676 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 678..680 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 681..694 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 698..721 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 724..726 FT /evidence="ECO:0007829|PDB:8DCP" FT HELIX 728..739 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 742..747 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 749..753 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 756..761 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 766..768 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 773..776 FT /evidence="ECO:0007829|PDB:8DCP" FT STRAND 779..784 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 786..789 FT /evidence="ECO:0007829|PDB:7MYN" FT HELIX 790..792 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 795..805 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 808..826 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 838..842 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 845..849 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 852..856 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 857..860 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 863..865 FT /evidence="ECO:0007829|PDB:7K6N" FT STRAND 866..868 FT /evidence="ECO:0007829|PDB:8TSA" FT HELIX 869..871 FT /evidence="ECO:0007829|PDB:7K6N" FT HELIX 872..874 FT /evidence="ECO:0007829|PDB:8DCP" FT HELIX 876..884 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 887..889 FT /evidence="ECO:0007829|PDB:7JIU" FT HELIX 890..911 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 920..924 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 925..927 FT /evidence="ECO:0007829|PDB:8GUD" FT STRAND 929..931 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 935..937 FT /evidence="ECO:0007829|PDB:8W9B" FT TURN 938..941 FT /evidence="ECO:0007829|PDB:7PG5" FT HELIX 942..945 FT /evidence="ECO:0007829|PDB:4JPS" FT HELIX 948..950 FT /evidence="ECO:0007829|PDB:7K6M" FT STRAND 951..954 FT /evidence="ECO:0007829|PDB:7K6M" FT HELIX 958..964 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 965..967 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 971..973 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 975..993 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 995..1003 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 1004..1007 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 1013..1015 FT /evidence="ECO:0007829|PDB:8EXV" FT HELIX 1016..1025 FT /evidence="ECO:0007829|PDB:8EXL" FT TURN 1026..1029 FT /evidence="ECO:0007829|PDB:8EXL" FT HELIX 1032..1047 FT /evidence="ECO:0007829|PDB:8EXL" FT STRAND 1048..1050 FT /evidence="ECO:0007829|PDB:5SW8" FT STRAND 1053..1055 FT /evidence="ECO:0007829|PDB:3HHM" FT STRAND 1056..1058 FT /evidence="ECO:0007829|PDB:4JPS" SQ SEQUENCE 1068 AA; 124284 MW; 041487231A9A1207 CRC64; MPPRPSSGEL WGIHLMPPRI LVECLLPNGM IVTLECLREA TLITIKHELF KEARKYPLHQ LLQDESSYIF VSVTQEAERE EFFDETRRLC DLRLFQPFLK VIEPVGNREE KILNREIGFA IGMPVCEFDM VKDPEVQDFR RNILNVCKEA VDLRDLNSPH SRAMYVYPPN VESSPELPKH IYNKLDKGQI IVVIWVIVSP NNDKQKYTLK INHDCVPEQV IAEAIRKKTR SMLLSSEQLK LCVLEYQGKY ILKVCGCDEY FLEKYPLSQY KYIRSCIMLG RMPNLMLMAK ESLYSQLPMD CFTMPSYSRR ISTATPYMNG ETSTKSLWVI NSALRIKILC ATYVNVNIRD IDKIYVRTGI YHGGEPLCDN VNTQRVPCSN PRWNEWLNYD IYIPDLPRAA RLCLSICSVK GRKGAKEEHC PLAWGNINLF DYTDTLVSGK MALNLWPVPH GLEDLLNPIG VTGSNPNKET PCLELEFDWF SSVVKFPDMS VIEEHANWSV SREAGFSYSH AGLSNRLARD NELRENDKEQ LKAISTRDPL SEITEQEKDF LWSHRHYCVT IPEILPKLLL SVKWNSRDEV AQMYCLVKDW PPIKPEQAME LLDCNYPDPM VRGFAVRCLE KYLTDDKLSQ YLIQLVQVLK YEQYLDNLLV RFLLKKALTN QRIGHFFFWH LKSEMHNKTV SQRFGLLLES YCRACGMYLK HLNRQVEAME KLINLTDILK QEKKDETQKV QMKFLVEQMR RPDFMDALQG FLSPLNPAHQ LGNLRLEECR IMSSAKRPLW LNWENPDIMS ELLFQNNEII FKNGDDLRQD MLTLQIIRIM ENIWQNQGLD LRMLPYGCLS IGDCVGLIEV VRNSHTIMQI QCKGGLKGAL QFNSHTLHQW LKDKNKGEIY DAAIDLFTRS CAGYCVATFI LGIGDRHNSN IMVKDDGQLF HIDFGHFLDH KKKKFGYKRE RVPFVLTQDF LIVISKGAQE CTKTREFERF QEMCYKAYLA IRQHANLFIN LFSMMLGSGM PELQSFDDIA YIRKTLALDK TEQEALEYFM KQMNDAHHGG WTTKMDWIFH TIKQHALN // ID PTEN_HUMAN Reviewed; 403 AA. AC P60484; B2R904; F2YHV0; O00633; O02679; Q6ICT7; DT 16-FEB-2004, integrated into UniProtKB/Swiss-Prot. DT 16-FEB-2004, sequence version 1. DT 28-JAN-2026, entry version 224. DE RecName: Full=Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN {ECO:0000305|PubMed:9256433, ECO:0000305|PubMed:9811831}; DE EC=3.1.3.16 {ECO:0000269|PubMed:9256433}; DE EC=3.1.3.48 {ECO:0000269|PubMed:9187108, ECO:0000269|PubMed:9256433}; DE EC=3.1.3.67 {ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:9811831}; DE AltName: Full=Inositol polyphosphate 3-phosphatase {ECO:0000305|PubMed:11418101, ECO:0000305|PubMed:9593664}; DE EC=3.1.3.- {ECO:0000305|PubMed:11418101, ECO:0000305|PubMed:9593664}; DE AltName: Full=Mutated in multiple advanced cancers 1; DE AltName: Full=Phosphatase and tensin homolog; GN Name=PTEN; Synonyms=MMAC1, TEP1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, RP SUBCELLULAR LOCATION, AND INDUCTION. RC TISSUE=Epithelium; RX PubMed=9187108; RA Li D.M., Sun H.; RT "TEP1, encoded by a candidate tumor suppressor locus, is a novel protein RT tyrosine phosphatase regulated by transforming growth factor beta."; RL Cancer Res. 57:2124-2129(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANTS RP GLIOMA SER-15; GLU-36; ARG-42; TRP-57 AND THR-319 DEL. RX PubMed=9090379; DOI=10.1038/ng0497-356; RA Steck P.A., Pershouse M.A., Jasser S.A., Lin H., Yung W.K.A., Ligon A.H., RA Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., RA Swedlund B., Teng D.H.-F., Tavtigian S.V.; RT "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome RT 10q23.3 that is mutated in multiple advanced cancers."; RL Nat. Genet. 15:356-363(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT GLIOBLASTOMA ARG-129, AND RP VARIANT PROSTATE CANCER LEU-134. RX PubMed=9072974; DOI=10.1126/science.275.5308.1943; RA Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., RA Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., RA Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R.; RT "PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, RT breast, and prostate cancer."; RL Science 275:1943-1947(1997). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=10817502; DOI=10.1054/bjoc.2000.1211; RA Hamilton J.A., Stewart L.M.D., Ajayi L., Gray I.C., Gray N.E., RA Roberts K.G., Watson G.J., Kaisary A.V., Snary D.; RT "The expression profile for the tumour suppressor gene PTEN and associated RT polymorphic markers."; RL Br. J. Cancer 82:1671-1676(2000). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Wang S., Li J., Liaw D., Bose S., Podsypanina K., Parsons R.; RL Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Jensen K., de la Bastide M., Parsons R., Parnell L.D., Dedhia N., RA Gottesman T., Gnoj L., Kaplan N., Lodhi M., Johnson A.F., Shohdy N., RA Hasegawa A., Haberman K., Huang E.N., Schutz K., Calma C., Granat S., RA Wigler M.H., McCombie W.R.; RT "Genomic sequence of PTEN/MMAC1."; RL Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3). RA Yang C.-W., Hsu Y.-F.; RT "Homo sapiens phosphatase and tensin homolog mRNA splicing variants."; RL Submitted (JAN-2011) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-290. RG NIEHS SNPs program; RL Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [13] RP FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANTS GLIOMA RP TRP-57; ENDOMETRIAL CANCER TYR-123; GLIOBLASTOMA ARG-129; CWS1 ARG-129; RP PROSTATE CANCER LEU-134; GLIOBLASTOMA ARG-165; BREAST CANCER PRO-167 AND BZ RP ARG-170. RX PubMed=9256433; DOI=10.1073/pnas.94.17.9052; RA Myers M.P., Stolarov J.P., Eng C., Li J., Wang S.I., Wigler M.H., RA Parsons R., Tonks N.K.; RT "P-TEN, the tumor suppressor from human chromosome 10q23, is a dual- RT specificity phosphatase."; RL Proc. Natl. Acad. Sci. U.S.A. 94:9052-9057(1997). RN [14] RP FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANT CWS1 SER-124. RX PubMed=9593664; DOI=10.1074/jbc.273.22.13375; RA Maehama T., Dixon J.E.; RT "The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second RT messenger, phosphatidylinositol 3,4,5-trisphosphate."; RL J. Biol. Chem. 273:13375-13378(1998). RN [15] RP FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF ARG-130, AND CHARACTERIZATION RP OF VARIANTS CWS1 SER-124 AND CWS1 GLU-129. RX PubMed=9811831; DOI=10.1073/pnas.95.23.13513; RA Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P., RA Hemmings B.A., Wigler M.H., Downes C.P., Tonks N.K.; RT "The lipid phosphatase activity of PTEN is critical for its tumor RT suppressor function."; RL Proc. Natl. Acad. Sci. U.S.A. 95:13513-13518(1998). RN [16] RP FUNCTION, MUTAGENESIS OF ASP-92 AND CYS-124, AND CHARACTERIZATION OF RP VARIANT GLU-129. RX PubMed=9616126; DOI=10.1126/science.280.5369.1614; RA Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., Yamada K.M.; RT "Inhibition of cell migration, spreading, and focal adhesions by tumor RT suppressor PTEN."; RL Science 280:1614-1617(1998). RN [17] RP FUNCTION, DOMAIN, AND CHARACTERIZATION OF VARIANTS THR-319 DEL; GLN-345 AND RP ILE-348. RX PubMed=10468583; DOI=10.1073/pnas.96.18.10182; RA Georgescu M.-M., Kirsch K.H., Akagi T., Shishido T., Hanafusa H.; RT "The tumor-suppressor activity of PTEN is regulated by its carboxyl- RT terminal region."; RL Proc. Natl. Acad. Sci. U.S.A. 96:10182-10187(1999). RN [18] RP INTERACTION WITH DLG1 AND MAST2, AND PHOSPHORYLATION AT THR-401. RX PubMed=10646847; RA Adey N.B., Huang L., Ormonde P.A., Baumgard M.L., Pero R., Byreddy D.V., RA Tavtigian S.V., Bartel P.L.; RT "Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both RT inhibits and stimulates PDZ binding."; RL Cancer Res. 60:35-37(2000). RN [19] RP INTERACTION WITH MAGI3. RX PubMed=10748157; DOI=10.1074/jbc.m909741199; RA Wu Y., Dowbenko D., Spencer S., Laura R., Lee J., Gu Q., Lasky L.A.; RT "Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, RT a novel membrane-associated guanylate kinase."; RL J. Biol. Chem. 275:21477-21485(2000). RN [20] RP INTERACTION WITH MAGI2. RX PubMed=10760291; DOI=10.1073/pnas.97.8.4233; RA Wu X., Hepner K., Castelino-Prabhu S., Do D., Kaye M.B., Yuan X.-J., RA Wood J., Ross C., Sawyers C.L., Whang Y.E.; RT "Evidence for regulation of the PTEN tumor suppressor by a membrane- RT localized multi-PDZ domain containing scaffold protein MAGI-2."; RL Proc. Natl. Acad. Sci. U.S.A. 97:4233-4238(2000). RN [21] RP FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=11418101; DOI=10.1016/s0014-5793(01)02500-5; RA Caffrey J.J., Darden T., Wenk M.R., Shears S.B.; RT "Expanding coincident signaling by PTEN through its inositol 1,3,4,5,6- RT pentakisphosphate 3-phosphatase activity."; RL FEBS Lett. 499:6-10(2001). RN [22] RP PHOSPHORYLATION AT SER-370; SER-380; THR-382; THR-383 AND SER-385. RX PubMed=11035045; DOI=10.1074/jbc.m009134200; RA Torres J., Pulido R.; RT "The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at RT its C terminus. Implications for PTEN stability to proteasome-mediated RT degradation."; RL J. Biol. Chem. 276:993-998(2001). RN [23] RP FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH MAGI2. RX PubMed=11707428; DOI=10.1074/jbc.c100556200; RA Vazquez F., Grossman S.R., Takahashi Y., Rokas M.V., Nakamura N., RA Sellers W.R.; RT "Phosphorylation of the PTEN tail acts as an inhibitory switch by RT preventing its recruitment into a protein complex."; RL J. Biol. Chem. 276:48627-48630(2001). RN [24] RP PHOSPHORYLATION AT THR-366; SER-370 AND SER-385. RX PubMed=12297295; DOI=10.1016/s0014-5793(02)03274-x; RA Miller S., Lou D., Seldin D., Lane W., Neel B.; RT "Direct identification of PTEN phosphorylation sites."; RL FEBS Lett. 528:145-153(2002). RN [25] RP INTERACTION WITH NOP53, REGION, AND CHARACTERIZATION OF VARIANTS CWS1 RP VAL-341; GLU-343 AND GLN-345. RX PubMed=15355975; DOI=10.1074/jbc.c400377200; RA Okahara F., Ikawa H., Kanaho Y., Maehama T.; RT "Regulation of PTEN phosphorylation and stability by a tumor suppressor RT candidate protein."; RL J. Biol. Chem. 279:45300-45303(2004). RN [26] RP INTERACTION WITH STK11, SUBCELLULAR LOCATION, AND PHOSPHORYLATION BY STK11. RX PubMed=15987703; DOI=10.1093/hmg/ddi225; RA Mehenni H., Lin-Marq N., Buchet-Poyau K., Reymond A., Collart M.A., RA Picard D., Antonarakis S.E.; RT "LKB1 interacts with and phosphorylates PTEN: a functional link between two RT proteins involved in cancer predisposing syndromes."; RL Hum. Mol. Genet. 14:2209-2219(2005). RN [27] RP INTERACTION WITH MAGI2; MAGI3; MAST1; MAST2 AND MAST3, MUTAGENESIS OF RP VAL-403, AND PHOSPHORYLATION. RX PubMed=15951562; DOI=10.1074/jbc.m504761200; RA Valiente M., Andres-Pons A., Gomar B., Torres J., Gil A., Tapparel C., RA Antonarakis S.E., Pulido R.; RT "Binding of PTEN to specific PDZ domains contributes to PTEN protein RT stability and phosphorylation by microtubule-associated serine/threonine RT kinases."; RL J. Biol. Chem. 280:28936-28943(2005). RN [28] RP FUNCTION. RX PubMed=15979280; DOI=10.1016/j.cellsig.2005.05.017; RA Deleu S., Choi K., Pesesse X., Cho J., Sulis M.L., Parsons R., Shears S.B.; RT "Physiological levels of PTEN control the size of the cellular RT Ins(1,3,4,5,6)P(5) pool."; RL Cell. Signal. 18:488-498(2006). RN [29] RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND FUNCTION. RX PubMed=16824732; DOI=10.1016/j.cellsig.2006.05.010; RA Vandeput F., Backers K., Villeret V., Pesesse X., Erneux C.; RT "The influence of anionic lipids on SHIP2 phosphatidylinositol 3,4,5- RT trisphosphate 5-phosphatase activity."; RL Cell. Signal. 18:2193-2199(2006). RN [30] RP INTERACTION WITH NEDD4. RX PubMed=17218260; DOI=10.1016/j.cell.2006.11.039; RA Wang X., Trotman L.C., Koppie T., Alimonti A., Chen Z., Gao Z., Wang J., RA Erdjument-Bromage H., Tempst P., Cordon-Cardo C., Pandolfi P.P., Jiang X.; RT "NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN."; RL Cell 128:129-139(2007). RN [31] RP FUNCTION, INTERACTION WITH USP7, UBIQUITINATION AT LYS-13 AND LYS-289, RP DEUBIQUITINATION BY USP7, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-13 AND RP LYS-289, AND CHARACTERIZATION OF VARIANT CWS1 GLU-289. RX PubMed=18716620; DOI=10.1038/nature07290; RA Song M.S., Salmena L., Carracedo A., Egia A., Lo-Coco F., RA Teruya-Feldstein J., Pandolfi P.P.; RT "The deubiquitinylation and localization of PTEN are regulated by a HAUSP- RT PML network."; RL Nature 455:813-817(2008). RN [32] RP INTERACTION WITH FRK, PHOSPHORYLATION AT TYR-336, AND MUTAGENESIS OF RP TYR-336. RX PubMed=19345329; DOI=10.1016/j.ccr.2009.02.012; RA Yim E.-K., Peng G., Dai H., Hu R., Li K., Lu Y., Mills G.B., RA Meric-Bernstam F., Hennessy B.T., Craven R.J., Lin S.-Y.; RT "Rak functions as a tumor suppressor by regulating PTEN protein stability RT and function."; RL Cancer Cell 15:304-314(2009). RN [33] RP UBIQUITINATION BY XIAP/BIRC4, SUBCELLULAR LOCATION, AND INTERACTION WITH RP XIAP/BIRC4. RX PubMed=19473982; DOI=10.1074/jbc.c109.009522; RA Van Themsche C., Leblanc V., Parent S., Asselin E.; RT "X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN RT ubiquitination, content, and compartmentalization."; RL J. Biol. Chem. 284:20462-20466(2009). RN [34] RP PHOSPHORYLATION AT THR-366 AND SER-370, AND MUTAGENESIS OF THR-366 AND RP SER-370. RX PubMed=20940307; DOI=10.1074/jbc.m110.166462; RA Xu D., Yao Y., Jiang X., Lu L., Dai W.; RT "Regulation of PTEN stability and activity by Plk3."; RL J. Biol. Chem. 285:39935-39942(2010). RN [35] RP INTERACTION WITH NDFIP1 AND NDFIP2. RX PubMed=20534535; DOI=10.1073/pnas.0911714107; RA Mund T., Pelham H.R.; RT "Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin RT ligase activators Ndfip1 and Ndfip2."; RL Proc. Natl. Acad. Sci. U.S.A. 107:11429-11434(2010). RN [36] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [37] RP FUNCTION IN CELL MIGRATION. RX PubMed=22279049; DOI=10.1101/gad.177642.111; RA Stohr N., Kohn M., Lederer M., Glass M., Reinke C., Singer R.H., RA Huttelmaier S.; RT "IGF2BP1 promotes cell migration by regulating MK5 and PTEN signaling."; RL Genes Dev. 26:176-189(2012). RN [38] RP ACETYLATION [LARGE SCALE ANALYSIS] AT THR-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [39] RP ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, FUNCTION (ISOFORM RP ALPHA), AND SUBCELLULAR LOCATION (ISOFORM ALPHA). RX PubMed=23744781; DOI=10.1126/science.1234907; RA Hopkins B.D., Fine B., Steinbach N., Dendy M., Rapp Z., Shaw J., Pappas K., RA Yu J.S., Hodakoski C., Mense S., Klein J., Pegno S., Sulis M.L., RA Goldstein H., Amendolara B., Lei L., Maurer M., Bruce J., Canoll P., RA Hibshoosh H., Parsons R.; RT "A secreted PTEN phosphatase that enters cells to alter signaling and RT survival."; RL Science 341:399-402(2013). RN [40] RP INTERACTION WITH PPP1R16B. RX PubMed=25007873; DOI=10.1152/ajprenal.00070.2014; RA Obeidat M., Li L., Ballermann B.J.; RT "TIMAP promotes angiogenesis by suppressing PTEN-mediated Akt inhibition in RT human glomerular endothelial cells."; RL Am. J. Physiol. 307:F623-F633(2014). RN [41] RP ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, SUBCELLULAR RP LOCATION (ISOFORM ALPHA), AND MUTAGENESIS OF MET-1. RX PubMed=24768297; DOI=10.1016/j.cmet.2014.03.023; RA Liang H., He S., Yang J., Jia X., Wang P., Chen X., Zhang Z., Zou X., RA McNutt M.A., Shen W.H., Yin Y.; RT "PTENalpha, a PTEN isoform translated through alternative initiation, RT regulates mitochondrial function and energy metabolism."; RL Cell Metab. 19:836-848(2014). RN [42] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-366, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [43] RP INTERACTION WITH NDFIP1, AND SUBCELLULAR LOCATION. RX PubMed=25801959; DOI=10.1093/jmcb/mjv020; RA Howitt J., Low L.H., Putz U., Doan A., Lackovic J., Goh C.P., Gunnersen J., RA Silke J., Tan S.S.; RT "Ndfip1 represses cell proliferation by controlling Pten localization and RT signaling specificity."; RL J. Mol. Cell Biol. 7:119-131(2015). RN [44] RP FUNCTION, INTERACTION WITH TNS3 AND PI3K, PHOSPHORYLATION AT THR-319 AND RP THR-321, AND MUTAGENESIS OF SER-229; THR-232; THR-319 AND THR-321. RX PubMed=26166433; DOI=10.1038/ncomms8721; RA Cao X., Kaneko T., Li J.S., Liu A.D., Voss C., Li S.S.; RT "A phosphorylation switch controls the spatiotemporal activation of Rho RT GTPases in directional cell migration."; RL Nat. Commun. 6:7721-7721(2015). RN [45] RP FUNCTION, AND UBIQUITINATION. RX PubMed=31492966; DOI=10.1007/s00018-019-03280-5; RA Zhang J., Zhang Y.L., Zhao L.W., Pi S.B., Zhang S.Y., Tong C., Fan H.Y.; RT "The CRL4-DCAF13 ubiquitin E3 ligase supports oocyte meiotic resumption by RT targeting PTEN degradation."; RL Cell. Mol. Life Sci. 77:2181-2197(2020). RN [46] RP FUNCTION, AND ISGYLATION. RX PubMed=37279284; DOI=10.1126/scisignal.abm1756; RA Du X., Sheng J., Chen Y., He S., Yang Y., Huang Y., Fu Y., Lie L., Han Z., RA Zhu B., Liu H., Wen Q., Zhou X., Zhou C., Hu S., Ma L.; RT "The E3 ligase HERC5 promotes antimycobacterial responses in macrophages by RT ISGylating the phosphatase PTEN."; RL Sci. Signal. 16:eabm1756-eabm1756(2023). RN [47] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 8-353 IN COMPLEX WITH RP L(+)-TARTRATE, SUBUNIT, DOMAIN, MUTAGENESIS OF ASP-92; HIS-93; LYS-125; RP LYS-128; THR-167; GLN-171; 263-LYS--ALA-269 AND 327-LYS--ALA-335, AND RP CATALYTIC ACTIVITY. RX PubMed=10555148; DOI=10.1016/s0092-8674(00)81663-3; RA Lee J.-O., Yang H., Georgescu M.-M., Di Cristofano A., Maehama T., Shi Y., RA Dixon J.E., Pandolfi P., Pavletich N.P.; RT "Crystal structure of the PTEN tumor suppressor: implications for its RT phosphoinositide phosphatase activity and membrane association."; RL Cell 99:323-334(1999). RN [48] RP VARIANT CWS1 ASN-137 INS. RX PubMed=9345101; DOI=10.1086/301607; RA Tsou H.C., Teng D.H.-F., Ping X.L., Brancolini V., Davis T., Hu R., RA Xie X.X., Gruener A.C., Schrager C.A., Christiano A.M., Eng C., Steck P., RA Ott J., Tavtigian S.V., Peacocke M.; RT "The role of MMAC1 mutations in early-onset breast cancer: causative in RT association with Cowden syndrome and excluded in BRCA1-negative cases."; RL Am. J. Hum. Genet. 61:1036-1043(1997). RN [49] RP VARIANTS CWS1 GLU-343 AND LEU-347. RX PubMed=9399897; DOI=10.1086/301639; RA Lynch E.D., Ostermeyer E.A., Lee M.K., Arena J.F., Ji H., Dann J., RA Swisshelm K., Suchard D., MacLeod P.M., Kvinnsland S., Gjertsen B.T., RA Heimdal K., Lubs H., Moeller P., King M.-C.; RT "Inherited mutations in PTEN that are associated with breast cancer, Cowden RT disease, and juvenile polyposis."; RL Am. J. Hum. Genet. 61:1254-1260(1997). RN [50] RP VARIANTS GLIOBLASTOMA TYR-107; PRO-121; ARG-129; ARG-165 AND GLN-345. RX PubMed=9331071; RA Wang S.I., Puc J., Li J., Bruce J.N., Cairns P., Sidransky D., Parsons R.; RT "Somatic mutations of PTEN in glioblastoma multiforme."; RL Cancer Res. 57:4183-4186(1997). RN [51] RP VARIANTS CWS1 ARG-123 AND ARG-124. RX PubMed=9259288; DOI=10.1093/hmg/6.8.1383; RA Nelen M.R., van Staveren W.C.G., Peeters E.A.J., Ben-Hassel M., RA Gorlin R.J., Hamm H., Lindboe C.F., Fryns J.-P., Sijmons R.H., Woods D.G., RA Mariman E.C.M., Padberg G.W., Kremer H.; RT "Germline mutations in the PTEN/MMAC1 gene in patients with Cowden RT disease."; RL Hum. Mol. Genet. 6:1383-1387(1997). RN [52] RP VARIANT CWS1 GLU-129. RX PubMed=9140396; DOI=10.1038/ng0597-64; RA Liaw D., Marsh D.J., Li J., Dahia P.L.M., Wang S.I., Zheng Z., Bose S., RA Call K.M., Tsou H.C., Peacocke M., Eng C., Parsons R.; RT "Germline mutations of the PTEN gene in Cowden disease, an inherited breast RT and thyroid cancer syndrome."; RL Nat. Genet. 16:64-67(1997). RN [53] RP VARIANT CWS1 ARG-170. RX PubMed=9241266; DOI=10.1038/ng0897-333; RA Marsh D.J., Dahia P.L.M., Zheng Z., Liaw D., Parsons R., Gorlin R.J., RA Eng C.; RT "Germline mutations in PTEN are present in Bannayan-Zonana syndrome."; RL Nat. Genet. 16:333-334(1997). RN [54] RP VARIANTS ENDOMETRIAL HYPERPLASIA ARG-36; LEU-130; CYS-173; ALA-191 AND RP ILE-348. RX PubMed=9635567; RA Maxwell G.L., Risinger J.I., Gumbs C., Shaw H., Bentley R.C., Barrett J.C., RA Berchuck A., Futreal P.A.; RT "Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias."; RL Cancer Res. 58:2500-2503(1998). RN [55] RP VARIANT CWS1 GLU-289. RX PubMed=9797362; DOI=10.1016/s0016-5085(98)70078-2; RA Chi S.-G., Kim H.-J., Park B.-J., Min H.-J., Park J.-H., Kim Y.-W., RA Dong S.-H., Kim B.-H., Lee J.-I., Chang Y.-W., Chang R., Kim W.-K., RA Yang M.-H.; RT "Mutational abrogation of the PTEN/MMAC1 gene in gastrointestinal polyps in RT patients with Cowden disease."; RL Gastroenterology 115:1084-1089(1998). RN [56] RP VARIANTS CWS1 HIS-68 AND PRO-112. RX PubMed=9600246; DOI=10.1007/s004390050723; RA Tsou H.C., Ping X.L., Xie X.X., Gruener A.C., Zhang H., Nini R., RA Swisshelm K., Sybert V., Diamond T.M., Sutphen R., Peacocke M.; RT "The genetic basis of Cowden's syndrome: three novel mutations in RT PTEN/MMAC1/TEP1."; RL Hum. Genet. 102:467-473(1998). RN [57] RP VARIANTS CWS1 ARG-67 AND VAL-165. RX PubMed=9467011; DOI=10.1093/hmg/7.3.507; RA Marsh D.J., Coulon V., Lunetta K.L., Rocca-Serra P., Dahia P.L.M., RA Zheng Z., Liaw D., Caron S., Duboue B., Lin A.Y., Richardson A.-L., RA Bonnetblanc J.-M., Bressieux J.-M., Cabarrot-Moreau A., Chompret A., RA Demange L., Eeles R.A., Yahanda A.M., Fearon E.R., Fricker J.-P., RA Gorlin R.J., Hodgson S.V., Huson S., Lacombe D., Leprat F., Odent S., RA Toulouse C., Olopade O.I., Sobol H., Tishler S., Woods C.G., Robinson B.G., RA Weber H.C., Parsons R., Peacocke M., Longy M., Eng C.; RT "Mutation spectrum and genotype-phenotype analyses in Cowden disease and RT Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN RT mutation."; RL Hum. Mol. Genet. 7:507-515(1998). RN [58] RP VARIANT CWS1 TYR-136. RX PubMed=9735393; DOI=10.3892/ijo.13.4.665; RA Scala S., Bruni P., Lo Muzio L., Mignogna M., Viglietto G., Fusco A.; RT "Novel mutation of the PTEN gene in an Italian Cowden's disease kindred."; RL Int. J. Oncol. 13:665-668(1998). RN [59] RP VARIANT CWS1 PRO-70. RX PubMed=9832031; DOI=10.1136/jmg.35.11.881; RA Marsh D.J., Dahia P.L.M., Caron S., Kum J.B., Frayling I.M., RA Tomlinson I.P.M., Hughes K.S., Eeles R.A., Hodgson S.V., Murday V.A., RA Houlston R., Eng C.; RT "Germline PTEN mutations in Cowden syndrome-like families."; RL J. Med. Genet. 35:881-885(1998). RN [60] RP VARIANT CWS1 ARG-35. RX PubMed=9425889; DOI=10.1038/ng0198-12; RA Olschwang S., Serova-Sinilnikova O.M., Lenoir G.M., Thomas G.; RT "PTEN germ-line mutations in juvenile polyposis coli."; RL Nat. Genet. 18:12-14(1998). RN [61] RP VARIANT CWS1 GLN-130. RX PubMed=9915974; DOI=10.1086/302207; RA Kurose K., Araki T., Matsunaka T., Takada Y., Emi M.; RT "Variant manifestation of Cowden disease in Japan: hamartomatous polyposis RT of the digestive tract with mutation of the PTEN gene."; RL Am. J. Hum. Genet. 64:308-310(1999). RN [62] RP VARIANT CWS1/LDD PRO-112. RX PubMed=10051160; RX DOI=10.1002/(sici)1096-8628(19990212)82:4<290::aid-ajmg3>3.0.co;2-0; RA Sutphen R., Diamond T.M., Minton S.E., Peacocke M., Tsou H.C., Root A.W.; RT "Severe Lhermitte-Duclos disease with unique germline mutation of PTEN."; RL Am. J. Med. Genet. 82:290-293(1999). RN [63] RP VARIANTS CWS1 ILE-33 DEL; ARG-123; ARG-124 AND GLU-165. RX PubMed=10234502; DOI=10.1038/sj.ejhg.5200289; RA Nelen M.R., Kremer H., Konings I.B.M., Schoute F., van Essen A.J., Koch R., RA Woods C.G., Fryns J.-P., Hamel B.C.J., Hoefsloot L.H., Peeters E.A.J., RA Padberg G.W.; RT "Novel PTEN mutations in patients with Cowden disease: absence of clear RT genotype-phenotype correlations."; RL Eur. J. Hum. Genet. 7:267-273(1999). RN [64] RP VARIANTS CWS1 ASP-34; HIS-68; TYR-105; VAL-135; ARG-170 AND LEU-246. RX PubMed=10400993; DOI=10.1093/hmg/8.8.1461; RA Marsh D.J., Kum J.B., Lunetta K.L., Bennett M.J., Gorlin R.J., Ahmed S.F., RA Bodurtha J., Crowe C., Curtis M.A., Dasouki M., Dunn T., Feit H., RA Geraghty M.T., Graham J.M. Jr., Hodgson S.V., Hunter A., Korf B.R., RA Manchester D., Miesfeldt S., Murday V.A., Nathanson K.L., Parisi M., RA Pober B., Romano C., Tolmie J.L., Trembath R., Winter R.M., Zackai E.H., RA Zori R.T., Weng L.-P., Dahia P.L.M., Eng C.; RT "PTEN mutation spectrum and genotype-phenotype correlations in Bannayan- RT Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome."; RL Hum. Mol. Genet. 8:1461-1472(1999). RN [65] RP CHARACTERIZATION OF VARIANTS ASN-10; CYS-16; GLU-20; SER-27; ARG-61; RP HIS-68; ARG-112; PRO-121; ARG-129; GLY-130; ILE-133; LEU-134; ARG-165; RP ASN-170; CYS-173; HIS-173; PRO-173; ASN-174; PHE-227; CYS-251; GLN-345; RP GLY-369 AND ILE-401, AND CHARACTERIZATION OF VARIANTS CWS1 TYR-71; TYR-93; RP PHE-105; TYR-107; PRO-112; ARG-124; GLU-129; LEU-130; GLN-130; TYR-136; RP CYS-155; ARG-170; GLU-289; GLY-331; VAL-341; ASN-342; GLU-343 AND LEU-347. RX PubMed=10866302; RA Han S.-Y., Kato H., Kato S., Suzuki T., Shibata H., Ishii S., Shiiba K., RA Matsuno S., Kanamaru R., Ishioka C.; RT "Functional evaluation of PTEN missense mutations using in vitro RT phosphoinositide phosphatase assay."; RL Cancer Res. 60:3147-3151(2000). RN [66] RP VARIANT CWS1 ARG-36. RX PubMed=10772390; DOI=10.1034/j.1600-0625.2000.009002152.x; RA Celebi J.T., Ping X.L., Zhang H., Remington T., Sulica V.I., Tsou H.C., RA Peacocke M.; RT "Germline PTEN mutations in three families with Cowden syndrome."; RL Exp. Dermatol. 9:152-156(2000). RN [67] RP VARIANTS MULTIPLE CANCERS LEU-119 AND LEU-158. RX PubMed=10807691; DOI=10.1136/jmg.37.5.336; RA De Vivo I., Gertig D.M., Nagase S., Hankinson S.E., O'Brien R., RA Speizer F.E., Parsons R., Hunter D.J.; RT "Novel germline mutations in the PTEN tumour suppressor gene found in women RT with multiple cancers."; RL J. Med. Genet. 37:336-341(2000). RN [68] RP VARIANTS MALIGNANT MELANOMA ASN-19 AND ILE-217. RX PubMed=10978354; DOI=10.1136/jmg.37.9.653; RA Celebi J.T., Shendrik I., Silvers D.N., Peacocke M.; RT "Identification of PTEN mutations in metastatic melanoma specimens."; RL J. Med. Genet. 37:653-657(2000). RN [69] RP CHARACTERIZATION OF VARIANTS CWS1 SER-124 AND GLU-129. RX PubMed=11230179; DOI=10.1093/hmg/10.6.599; RA Weng L.-P., Brown J.L., Eng C.; RT "PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein RT phosphatase activity and up-regulating p27 via its lipid phosphatase RT activity in a breast cancer model."; RL Hum. Mol. Genet. 10:599-604(2001). RN [70] RP VARIANT ASP-61. RX PubMed=11748304; DOI=10.1136/jmg.38.12.820; RA Reardon W., Zhou X.-P., Eng C.; RT "A novel germline mutation of the PTEN gene in a patient with macrocephaly, RT ventricular dilatation, and features of VATER association."; RL J. Med. Genet. 38:820-823(2001). RN [71] RP VARIANTS CWS1 ASP-34; GLY-47; HIS-68; TYR-105; VAL-135 AND ARG-170. RX PubMed=11494117; DOI=10.1038/sj.neo.7900154; RA Marsh D.J., Theodosopoulos G., Howell V., Richardson A.-L., Benn D.E., RA Proos A.L., Eng C., Robinson B.G.; RT "Rapid mutation scanning of genes associated with familial cancer syndromes RT using denaturing high-performance liquid chromatography."; RL Neoplasia 3:236-244(2001). RN [72] RP VARIANT GLM2 GLN-234, AND CHARACTERIZATION OF VARIANT GLM2 GLN-234. RX PubMed=12085208; DOI=10.1038/sj.bjc.6600206; RA Staal F.J.T., van der Luijt R.B., Baert M.R.M., van Drunen J., RA van Bakel H., Peters E., de Valk I., van Amstel H.K.P., Taphoorn M.J.B., RA Jansen G.H., van Veelen C.W.M., Burgering B., Staal G.E.J.; RT "A novel germline mutation of PTEN associated with brain tumours of RT multiple lineages."; RL Br. J. Cancer 86:1586-1591(2002). RN [73] RP VARIANT HNSCC GLY-121. RX PubMed=11801303; DOI=10.1016/s0165-4608(01)00509-x; RA Poetsch M., Lorenz G., Kleist B.; RT "Detection of new PTEN/MMAC1 mutations in head and neck squamous cell RT carcinomas with loss of chromosome 10."; RL Cancer Genet. Cytogenet. 132:20-24(2002). RN [74] RP DISCUSSION OF PTEN INVOLVEMENT IN PROTEUS SYNDROME. RX PubMed=12471211; DOI=10.1136/jmg.39.12.937; RA Smith J.M., Kirk E.P.E., Theodosopoulos G., Marshall G.M., Walker J., RA Rogers M., Field M., Brereton J.J., Marsh D.J.; RT "Germline mutation of the tumour suppressor PTEN in Proteus syndrome."; RL J. Med. Genet. 39:937-940(2002). RN [75] RP VARIANTS MCEPHAS ARG-93; SER-241 AND GLY-252. RX PubMed=15805158; DOI=10.1136/jmg.2004.024646; RA Butler M.G., Dasouki M.J., Zhou X.-P., Talebizadeh Z., Brown M., RA Takahashi T.N., Miles J.H., Wang C.H., Stratton R., Pilarski R., Eng C.; RT "Subset of individuals with autism spectrum disorders and extreme RT macrocephaly associated with germline PTEN tumour suppressor gene RT mutations."; RL J. Med. Genet. 42:318-321(2005). RN [76] RP VARIANT ENDMC GLU-36. RX PubMed=16506206; DOI=10.1002/ijc.21862; RA Bilbao C., Rodriguez G., Ramirez R., Falcon O., Leon L., Chirino R., RA Rivero J.F., Falcon O. Jr., Diaz-Chico B.N., Diaz-Chico J.C., Perucho M.; RT "The relationship between microsatellite instability and PTEN gene RT mutations in endometrial cancer."; RL Int. J. Cancer 119:563-570(2006). RN [77] RP INVOLVEMENT IN CHROMOSOME 10Q23 DELETION SYNDROME. RX PubMed=17436248; DOI=10.1086/513607; RA Balciuniene J., Feng N., Iyadurai K., Hirsch B., Charnas L., Bill B.R., RA Easterday M.C., Staaf J., Oseth L., Czapansky-Beilman D., Avramopoulos D., RA Thomas G.H., Borg A., Valle D., Schimmenti L.A., Selleck S.B.; RT "Recurrent 10q22-q23 deletions: a genomic disorder on 10q associated with RT cognitive and behavioral abnormalities."; RL Am. J. Hum. Genet. 80:938-947(2007). RN [78] RP VARIANT VAL-132. RX PubMed=16752378; DOI=10.1002/ajmg.a.31273; RA Tekin M., Hismi B.O., Fitoz S., Yalcinkaya F., Ekim M., Kansu A., Ertem M., RA Deda G., Tutar E., Arsan S., Zhou X.-P., Pilarski R., Eng C., Akar N.; RT "A germline PTEN mutation with manifestations of prenatal onset and RT verrucous epidermal nevus."; RL Am. J. Med. Genet. A 140:1472-1475(2006). RN [79] RP VARIANTS CWS1 SER-15; ASP-34; ARG-36; ARG-61; HIS-68; GLU-129; GLY-130; RP LEU-130; GLN-130; TYR-136; ARG-165; ARG-170; GLY-252 AND LEU-347. RX PubMed=21659347; DOI=10.1136/jmg.2011.088807; RA Pilarski R., Stephens J.A., Noss R., Fisher J.L., Prior T.W.; RT "Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan- RT Riley-Ruvalcaba syndrome clinical features."; RL J. Med. Genet. 48:505-512(2011). RN [80] RP VARIANTS MCEPHAS ILE-131 AND ASN-167. RX PubMed=23160955; DOI=10.1126/science.1227764; RA O'Roak B.J., Vives L., Fu W., Egertson J.D., Stanaway I.B., Phelps I.G., RA Carvill G., Kumar A., Lee C., Ankenman K., Munson J., Hiatt J.B., RA Turner E.H., Levy R., O'Day D.R., Krumm N., Coe B.P., Martin B.K., RA Borenstein E., Nickerson D.A., Mefford H.C., Doherty D., Akey J.M., RA Bernier R., Eichler E.E., Shendure J.; RT "Multiplex targeted sequencing identifies recurrently mutated genes in RT autism spectrum disorders."; RL Science 338:1619-1622(2012). RN [81] RP VARIANTS CWS1 ARG-61; TYR-93; GLY-130; GLN-130; LEU-130 AND CYS-173. RX PubMed=24778394; DOI=10.1200/jco.2013.53.6656; RA Ngeow J., Stanuch K., Mester J.L., Barnholtz-Sloan J.S., Eng C.; RT "Second malignant neoplasms in patients with Cowden syndrome with RT underlying germline PTEN mutations."; RL J. Clin. Oncol. 32:1818-1824(2014). RN [82] RP VARIANT MCEPHAS 65-TYR--VAL-403 DEL. RX PubMed=26637798; DOI=10.1016/j.neuron.2015.11.009; RA D'Gama A.M., Pochareddy S., Li M., Jamuar S.S., Reiff R.E., Lam A.T., RA Sestan N., Walsh C.A.; RT "Targeted DNA Sequencing from Autism Spectrum Disorder Brains Implicates RT Multiple Genetic Mechanisms."; RL Neuron 88:910-917(2015). RN [83] RP VARIANT PROSTATE CANCER GLY-126, CHARACTERIZATION OF VARIANT GLY-126, RP MUTAGENESIS OF ALA-126, AND FUNCTION. RX PubMed=26504226; DOI=10.1073/pnas.1422504112; RA Costa H.A., Leitner M.G., Sos M.L., Mavrantoni A., Rychkova A., RA Johnson J.R., Newton B.W., Yee M.C., De La Vega F.M., Ford J.M., RA Krogan N.J., Shokat K.M., Oliver D., Halaszovich C.R., Bustamante C.D.; RT "Discovery and functional characterization of a neomorphic PTEN mutation."; RL Proc. Natl. Acad. Sci. U.S.A. 112:13976-13981(2015). RN [84] RP VARIANT ASN-174. RX PubMed=39316756; DOI=10.1158/0008-5472.can-23-2216; RA Plitt G., Brewer T., Yehia L., Rabinowitz L., Griffith C.C., Eng C.; RT "The genomic landscape of benign and malignant thyroid tumors from RT individuals carrying germline PTEN variants is distinct from sporadic RT thyroid cancers."; RL Cancer Res. 84:3657-3668(2024). CC -!- FUNCTION: Dual-specificity protein phosphatase, dephosphorylating CC tyrosine-, serine- and threonine-phosphorylated proteins CC (PubMed:9187108, PubMed:9256433, PubMed:9616126). Also functions as a CC lipid phosphatase, removing the phosphate in the D3 position of the CC inositol ring of PtdIns(3,4,5)P3/phosphatidylinositol 3,4,5- CC trisphosphate, PtdIns(3,4)P2/phosphatidylinositol 3,4-diphosphate and CC PtdIns3P/phosphatidylinositol 3-phosphate with a preference for CC PtdIns(3,4,5)P3 (PubMed:16824732, PubMed:26504226, PubMed:9593664, CC PubMed:9811831). Furthermore, this enzyme can also act as a cytosolic CC inositol 3-phosphatase acting on Ins(1,3,4,5,6)P5/inositol 1,3,4,5,6 CC pentakisphosphate and possibly Ins(1,3,4,5)P4/1D-myo-inositol 1,3,4,5- CC tetrakisphosphate (PubMed:11418101, PubMed:15979280). Antagonizes the CC PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides CC and thereby modulating cell cycle progression and cell survival CC (PubMed:31492966, PubMed:37279284). The unphosphorylated form CC cooperates with MAGI2 to suppress AKT1 activation (PubMed:11707428). In CC motile cells, suppresses the formation of lateral pseudopods and CC thereby promotes cell polarization and directed movement CC (PubMed:22279049). Dephosphorylates tyrosine-phosphorylated focal CC adhesion kinase and inhibits cell migration and integrin-mediated cell CC spreading and focal adhesion formation (PubMed:22279049). Required for CC growth factor-induced epithelial cell migration; growth factor CC stimulation induces PTEN phosphorylation which changes its binding CC preference from the p85 regulatory subunit of the PI3K kinase complex CC to DLC1 and results in translocation of the PTEN-DLC1 complex to the CC posterior of migrating cells to promote RHOA activation CC (PubMed:26166433). Meanwhile, TNS3 switches binding preference from CC DLC1 to p85 and the TNS3-p85 complex translocates to the leading edge CC of migrating cells to activate RAC1 activation (PubMed:26166433). Plays CC a role as a key modulator of the AKT-mTOR signaling pathway controlling CC the tempo of the process of newborn neurons integration during adult CC neurogenesis, including correct neuron positioning, dendritic CC development and synapse formation (By similarity). Involved in the CC regulation of synaptic function in excitatory hippocampal synapses. CC Recruited to the postsynaptic membrane upon NMDA receptor activation, CC is required for the modulation of synaptic activity during plasticity. CC Enhancement of lipid phosphatase activity is able to drive depression CC of AMPA receptor-mediated synaptic responses, activity required for CC NMDA receptor-dependent long-term depression (LTD) (By similarity). May CC be a negative regulator of insulin signaling and glucose metabolism in CC adipose tissue. The nuclear monoubiquitinated form possesses greater CC apoptotic potential, whereas the cytoplasmic nonubiquitinated form CC induces less tumor suppressive ability (PubMed:10468583, CC PubMed:18716620). {ECO:0000250|UniProtKB:O08586, CC ECO:0000250|UniProtKB:O54857, ECO:0000269|PubMed:10468583, CC ECO:0000269|PubMed:11418101, ECO:0000269|PubMed:11707428, CC ECO:0000269|PubMed:15979280, ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:22279049, CC ECO:0000269|PubMed:26166433, ECO:0000269|PubMed:26504226, CC ECO:0000269|PubMed:31492966, ECO:0000269|PubMed:37279284, CC ECO:0000269|PubMed:9187108, ECO:0000269|PubMed:9256433, CC ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9616126, CC ECO:0000269|PubMed:9811831}. CC -!- FUNCTION: [Isoform alpha]: Functional kinase, like isoform 1 it CC antagonizes the PI3K-AKT/PKB signaling pathway. Plays a role in CC mitochondrial energetic metabolism by promoting COX activity and ATP CC production, via collaboration with isoform 1 in increasing protein CC levels of PINK1. {ECO:0000269|PubMed:23744781}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5- CC trisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- CC inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:25017, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57836, CC ChEBI:CHEBI:58456; EC=3.1.3.67; CC Evidence={ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:9811831}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:25018; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-seryl-[protein] + H2O = L-seryl-[protein] + CC phosphate; Xref=Rhea:RHEA:20629, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15377, ChEBI:CHEBI:29999, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:83421; EC=3.1.3.16; CC Evidence={ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:20630; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-threonyl-[protein] + H2O = L-threonyl-[protein] + CC phosphate; Xref=Rhea:RHEA:47004, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15377, ChEBI:CHEBI:30013, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:61977; EC=3.1.3.16; CC Evidence={ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:47005; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + CC phosphate; Xref=Rhea:RHEA:10684, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978; EC=3.1.3.48; Evidence={ECO:0000269|PubMed:9187108, CC ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10685; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5- CC trisphosphate) + H2O = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo- CC inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:43552, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83416, CC ChEBI:CHEBI:83419; Evidence={ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43553; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol- CC 3,4,5-trisphosphate) + H2O = 1,2-dihexadecanoyl-sn-glycero-3-phospho- CC (1D-myo-inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:43560, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83420, CC ChEBI:CHEBI:83423; Evidence={ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43561; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1D-myo-inositol 1,3,4,5,6-pentakisphosphate + H2O = 1D-myo- CC inositol 1,4,5,6-tetrakisphosphate + phosphate; Xref=Rhea:RHEA:77143, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57627, CC ChEBI:CHEBI:57733; Evidence={ECO:0000269|PubMed:11418101}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:77144; CC Evidence={ECO:0000269|PubMed:11418101}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1D-myo-inositol 1,3,4,5-tetrakisphosphate + H2O = 1D-myo- CC inositol 1,4,5-trisphosphate + phosphate; Xref=Rhea:RHEA:77155, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57895, CC ChEBI:CHEBI:203600; Evidence={ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:77156; CC Evidence={ECO:0000305|PubMed:9593664}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Enzymatic activity is enhanced in the presence of CC phosphatidylserine. {ECO:0000269|PubMed:16824732}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=26 uM for PtdIns(3,4,5)P3 {ECO:0000269|PubMed:11418101}; CC KM=11.5 uM for 1D-myo-inositol 1,3,4-trisphosphate CC {ECO:0000269|PubMed:11418101}; CC KM=4.6 uM for 1D-myo-inositol 1,3,4,5-tetrakisphosphate CC {ECO:0000269|PubMed:11418101}; CC KM=7.1 uM for 1D-myo-inositol 1,3,4,5,6-pentakisphosphate CC {ECO:0000269|PubMed:11418101}; CC Vmax=60 nmol/min/mg enzyme with PtdIns(3,4,5)P3 as substrate CC {ECO:0000269|PubMed:11418101}; CC Vmax=24 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4-trisphosphate CC as substrate {ECO:0000269|PubMed:11418101}; CC Vmax=112 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4,5- CC tetrakisphosphate as substrate {ECO:0000269|PubMed:11418101}; CC Vmax=67 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4,5,6- CC pentakisphosphate as substrate {ECO:0000269|PubMed:11418101}; CC -!- SUBUNIT: Monomer. The unphosphorylated form interacts with the second CC PDZ domain of MAGI2 and with DLG1 and MAST2 in vitro (PubMed:10646847, CC PubMed:10760291, PubMed:11707428). Interacts with MAGI2, MAGI3, MAST1 CC and MAST3, but neither with MAST4 nor with DLG5; interaction with MAGI2 CC increases protein stability (PubMed:10748157, PubMed:15951562). CC Interacts with NEDD4 (PubMed:17218260). Interacts with NDFIP1 and CC NDFIP2; in the presence of NEDD4 or ITCH, this interaction promotes CC PTEN ubiquitination (PubMed:20534535, PubMed:25801959). Interacts (via CC C2 domain) with FRK (PubMed:19345329). Interacts with USP7; the CC interaction is direct (PubMed:18716620). Interacts with ROCK1 (By CC similarity). Interacts with XIAP/BIRC4 (PubMed:19473982). Interacts CC with STK11; the interaction phosphorylates PTEN (PubMed:15987703). CC Interacts with PPP1R16B (PubMed:25007873). Interacts with NOP53; CC regulates PTEN phosphorylation and increases its stability CC (PubMed:15355975). Interacts (via PDZ domain-binding motif) with DLG4; CC the interaction is induced by NMDA and is required for PTEN location at CC postsynaptic density (By similarity). Interacts with the regulatory p85 CC subunit of the PI3K kinase complex and with Rho GTPase-activating CC protein DLC1; in resting cells, interacts (via C2 tensin-type domain) CC with p85 but, following growth factor stimulation, PTEN is CC phosphorylated which leads to weakened interaction with p85 and CC enhanced interaction (via C2 tensin-type domain) with DLC1 while p85 CC interaction with TNS3 increases (PubMed:26166433). CC {ECO:0000250|UniProtKB:O08586, ECO:0000250|UniProtKB:O54857, CC ECO:0000269|PubMed:10555148, ECO:0000269|PubMed:10646847, CC ECO:0000269|PubMed:10748157, ECO:0000269|PubMed:10760291, CC ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:15355975, CC ECO:0000269|PubMed:15951562, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:17218260, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19345329, ECO:0000269|PubMed:19473982, CC ECO:0000269|PubMed:20534535, ECO:0000269|PubMed:25007873, CC ECO:0000269|PubMed:25801959, ECO:0000269|PubMed:26166433}. CC -!- INTERACTION: CC P60484; Q9ULX6: AKAP8L; NbExp=2; IntAct=EBI-696162, EBI-357530; CC P60484; Q9NZN5-2: ARHGEF12; NbExp=4; IntAct=EBI-696162, EBI-10984307; CC P60484; P35226: BMI1; NbExp=7; IntAct=EBI-696162, EBI-2341576; CC P60484; P30260: CDC27; NbExp=7; IntAct=EBI-696162, EBI-994813; CC P60484; Q9P0U4: CXXC1; NbExp=2; IntAct=EBI-696162, EBI-949911; CC P60484; Q16643: DBN1; NbExp=5; IntAct=EBI-696162, EBI-351394; CC P60484; Q12959: DLG1; NbExp=2; IntAct=EBI-696162, EBI-357481; CC P60484; Q15700: DLG2; NbExp=2; IntAct=EBI-696162, EBI-80426; CC P60484; P78352: DLG4; NbExp=3; IntAct=EBI-696162, EBI-80389; CC P60484; P42685: FRK; NbExp=7; IntAct=EBI-696162, EBI-1383583; CC P60484; Q9HD26: GOPC; NbExp=4; IntAct=EBI-696162, EBI-349832; CC P60484; A4D2P6: GRID2IP; NbExp=4; IntAct=EBI-696162, EBI-15893226; CC P60484; Q92743: HTRA1; NbExp=4; IntAct=EBI-696162, EBI-352256; CC P60484; Q96QZ7: MAGI1; NbExp=5; IntAct=EBI-696162, EBI-924464; CC P60484; Q86UL8: MAGI2; NbExp=6; IntAct=EBI-696162, EBI-311035; CC P60484; Q5TCQ9: MAGI3; NbExp=9; IntAct=EBI-696162, EBI-310506; CC P60484; Q9Y2H9: MAST1; NbExp=4; IntAct=EBI-696162, EBI-3385920; CC P60484; Q6P0Q8: MAST2; NbExp=4; IntAct=EBI-696162, EBI-493777; CC P60484; O60307: MAST3; NbExp=4; IntAct=EBI-696162, EBI-311420; CC P60484; O75970: MPDZ; NbExp=4; IntAct=EBI-696162, EBI-821405; CC P60484; Q9Y6Q9: NCOA3; NbExp=2; IntAct=EBI-696162, EBI-81196; CC P60484; P46934: NEDD4; NbExp=4; IntAct=EBI-696162, EBI-726944; CC P60484; O14745: NHERF1; NbExp=9; IntAct=EBI-696162, EBI-349787; CC P60484; Q15599: NHERF2; NbExp=6; IntAct=EBI-696162, EBI-1149760; CC P60484; Q8NI35: PATJ; NbExp=3; IntAct=EBI-696162, EBI-724390; CC P60484; P09619: PDGFRB; NbExp=3; IntAct=EBI-696162, EBI-641237; CC P60484; Q9H5P4: PDZD7; NbExp=4; IntAct=EBI-696162, EBI-20859318; CC P60484; Q9NRD5: PICK1; NbExp=2; IntAct=EBI-696162, EBI-79165; CC P60484; P62136: PPP1CA; NbExp=2; IntAct=EBI-696162, EBI-357253; CC P60484; Q06830: PRDX1; NbExp=7; IntAct=EBI-696162, EBI-353193; CC P60484; P60484: PTEN; NbExp=19; IntAct=EBI-696162, EBI-696162; CC P60484; Q14160: SCRIB; NbExp=4; IntAct=EBI-696162, EBI-357345; CC P60484; Q13424: SNTA1; NbExp=4; IntAct=EBI-696162, EBI-717191; CC P60484; Q13884: SNTB1; NbExp=5; IntAct=EBI-696162, EBI-295843; CC P60484; Q9NY99: SNTG2; NbExp=3; IntAct=EBI-696162, EBI-8556870; CC P60484; Q96L92: SNX27; NbExp=4; IntAct=EBI-696162, EBI-2514865; CC P60484; O43791: SPOP; NbExp=4; IntAct=EBI-696162, EBI-743549; CC P60484; Q62696: Dlg1; Xeno; NbExp=2; IntAct=EBI-696162, EBI-389325; CC P60484; O88382: Magi2; Xeno; NbExp=3; IntAct=EBI-696162, EBI-696179; CC P60484; Q9JK71: Magi3; Xeno; NbExp=3; IntAct=EBI-696162, EBI-696226; CC P60484; Q9R1L5: Mast1; Xeno; NbExp=3; IntAct=EBI-696162, EBI-491771; CC P60484; Q60592: Mast2; Xeno; NbExp=4; IntAct=EBI-696162, EBI-493888; CC P60484; Q9JHL1: Nherf2; Xeno; NbExp=2; IntAct=EBI-696162, EBI-538451; CC P60484-1; Q19T08: ECSCR; NbExp=4; IntAct=EBI-15722967, EBI-15778214; CC P60484-1; Q5T2D3: OTUD3; NbExp=9; IntAct=EBI-15722967, EBI-16170539; CC P60484-1; P60484-1: PTEN; NbExp=3; IntAct=EBI-15722967, EBI-15722967; CC P60484-1; Q93009: USP7; NbExp=5; IntAct=EBI-15722967, EBI-302474; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19473982, CC ECO:0000269|PubMed:25801959, ECO:0000269|PubMed:9187108}. Nucleus CC {ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982, ECO:0000269|PubMed:25801959}. Nucleus, PML CC body {ECO:0000269|PubMed:18716620}. Cell projection, dendritic spine CC {ECO:0000250|UniProtKB:O54857}. Postsynaptic density CC {ECO:0000250|UniProtKB:O54857}. Note=Monoubiquitinated form is nuclear. CC Nonubiquitinated form is cytoplasmic. Colocalized with PML and USP7 in CC PML nuclear bodies (PubMed:18716620). XIAP/BIRC4 promotes its nuclear CC localization (PubMed:19473982). Associares with the postsynaptic CC density in response to NMDAR activation (By similarity). CC {ECO:0000250|UniProtKB:O54857, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982}. CC -!- SUBCELLULAR LOCATION: [Isoform alpha]: Secreted CC {ECO:0000269|PubMed:23744781, ECO:0000269|PubMed:24768297}. Note=May be CC secreted via a classical signal peptide and reenter into cells with the CC help of a poly-Arg motif. {ECO:0000269|PubMed:23744781, CC ECO:0000269|PubMed:24768297}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing, Alternative initiation; Named isoforms=3; CC Name=1; Synonyms=55kDa; CC IsoId=P60484-1; Sequence=Displayed; CC Name=alpha; Synonyms=70kDa, PTEN-long; CC IsoId=P60484-2; Sequence=VSP_055420; CC Name=3; CC IsoId=P60484-3; Sequence=VSP_055421, VSP_055422, VSP_055423; CC -!- TISSUE SPECIFICITY: Expressed at a relatively high level in all adult CC tissues, including heart, brain, placenta, lung, liver, muscle, kidney CC and pancreas. {ECO:0000269|PubMed:9090379}. CC -!- INDUCTION: Down-regulated by TGFB1. {ECO:0000269|PubMed:9187108}. CC -!- DOMAIN: The C2 domain binds phospholipid membranes in vitro in a CC Ca(2+)-independent manner; this binding is important for its tumor CC suppressor function. {ECO:0000269|PubMed:10468583, CC ECO:0000269|PubMed:10555148}. CC -!- PTM: Constitutively phosphorylated by CK2 under normal conditions. CC Phosphorylated in vitro by MAST1, MAST2, MAST3 and STK11. CC Phosphorylation results in an inhibited activity towards PIP3. CC Phosphorylation can both inhibit or promote PDZ-binding. CC Phosphorylation at Tyr-336 by FRK/PTK5 protects this protein from CC ubiquitin-mediated degradation probably by inhibiting its binding to CC NEDD4. Phosphorylation by ROCK1 is essential for its stability and CC activity. Phosphorylation by PLK3 promotes its stability and prevents CC its degradation by the proteasome. Phosphorylated on Thr-319 and Thr- CC 321 in the C2-type tensin domain following EGF stimulation which CC changes its binding preference from the p85 regulatory subunit of the CC PI3K kinase complex to DLC1 (PubMed:26166433). CC {ECO:0000269|PubMed:10646847, ECO:0000269|PubMed:11035045, CC ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:12297295, CC ECO:0000269|PubMed:15951562, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19345329, CC ECO:0000269|PubMed:20940307, ECO:0000269|PubMed:26166433}. CC -!- PTM: Monoubiquitinated; monoubiquitination is increased in presence of CC retinoic acid. Deubiquitinated by USP7; leading to its nuclear CC exclusion. Monoubiquitination of one of either Lys-13 and Lys-289 amino CC acid is sufficient to modulate PTEN compartmentalization. Ubiquitinated CC by XIAP/BIRC4. {ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982}. CC -!- PTM: Ubiquitinated by the DCX(DCAF13) E3 ubiquitin ligase complex, CC leading to its degradation. {ECO:0000269|PubMed:31492966}. CC -!- PTM: ISGylated. ISGylation promotes PTEN degradation. CC {ECO:0000269|PubMed:37279284}. CC -!- DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant CC hamartomatous polyposis syndrome with age-related penetrance. Cowden CC syndrome is characterized by hamartomatous lesions affecting CC derivatives of ectodermal, mesodermal and endodermal layers, CC macrocephaly, facial trichilemmomas (benign tumors of the hair follicle CC infundibulum), acral keratoses, papillomatous papules, and elevated CC risk for development of several types of malignancy, particularly CC breast carcinoma in women and thyroid carcinoma in both men and women. CC Colon cancer and renal cell carcinoma have also been reported. CC Hamartomas can be found in virtually every organ, but most commonly in CC the skin, gastrointestinal tract, breast and thyroid. CC {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, CC ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:10772390, CC ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11230179, CC ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:15355975, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:21659347, CC ECO:0000269|PubMed:24778394, ECO:0000269|PubMed:9140396, CC ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9259288, CC ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, CC ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9467011, CC ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9600246, CC ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, CC ECO:0000269|PubMed:9811831, ECO:0000269|PubMed:9832031, CC ECO:0000269|PubMed:9915974}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease CC characterized by the occurrence of a slowly enlarging mass within the CC cerebellar cortex corresponding histologically to a cerebellar CC hamartoma. It manifests, most commonly in the third and fourth decades CC of life, with increased intracranial pressure, headache, nausea, CC cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual CC disturbances and other cranial nerve palsies. Various associated CC abnormalities may be present such as megalencephaly, microgyria, CC hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part CC of the PTEN hamartoma tumor syndromes spectrum that also includes CC Cowden syndrome. Note=The disease is caused by variants affecting the CC gene represented in this entry. CC -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) CC [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. CC The hallmark of cutaneous SCC is malignant transformation of normal CC epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. {ECO:0000269|PubMed:16506206}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Note=PTEN mutations are found in a subset of patients with CC Proteus syndrome, a genetically heterogeneous condition. The molecular CC diagnosis of PTEN mutation positive cases classifies Proteus syndrome CC patients as part of the PTEN hamartoma syndrome spectrum. As such, CC patients surviving the early years of Proteus syndrome are likely at a CC greater risk of developing malignancies. CC -!- DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant CC central nervous system neoplasms derived from glial cells. They CC comprise astrocytomas and glioblastoma multiforme that are derived from CC astrocytes, oligodendrogliomas derived from oligodendrocytes and CC ependymomas derived from ependymocytes. {ECO:0000269|PubMed:12085208}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in CC tissues of the prostate. Most prostate cancers are adenocarcinomas that CC develop in the acini of the prostatic ducts. Other rare histopathologic CC types of prostate cancer that occur in approximately 5% of patients CC include small cell carcinoma, mucinous carcinoma, prostatic ductal CC carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal CC cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:26504226, CC ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients CC have autism spectrum disorders and macrocephaly, with head CC circumferences ranging from +2.5 to +8 SD for age and sex (average head CC circumference +4.0 SD). {ECO:0000269|PubMed:15805158, CC ECO:0000269|PubMed:23160955, ECO:0000269|PubMed:26637798}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and CC PTEN is a cause of chromosome 10q23 deletion syndrome, which shows CC overlapping features of the following three disorders: Bannayan-Zonana CC syndrome, Cowden disease and juvenile polyposis syndrome. CC -!- MISCELLANEOUS: [Isoform alpha]: Produced by alternative initiation at CC an upstream CTG start codon. May contain a signal peptide at positions CC 1-21. {ECO:0000269|PubMed:23744781, ECO:0000269|PubMed:24768297}. CC -!- SIMILARITY: Belongs to the PTEN phosphatase protein family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/158/PTEN"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U96180; AAB66902.1; -; mRNA. DR EMBL; U92436; AAC51182.1; -; mRNA. DR EMBL; U93051; AAC51183.1; -; mRNA. DR EMBL; AF143315; AAD38372.1; -; Genomic_DNA. DR EMBL; AF143312; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF143313; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF143314; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF000734; AAC08699.1; -; Genomic_DNA. DR EMBL; AF000726; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000727; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000728; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000729; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000730; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000731; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000732; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000733; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF067844; AAD13528.1; -; Genomic_DNA. DR EMBL; JF268690; ADZ48535.1; -; mRNA. DR EMBL; CR450306; CAG29302.1; -; mRNA. DR EMBL; AK313581; BAG36351.1; -; mRNA. DR EMBL; DQ073384; AAY57327.1; -; Genomic_DNA. DR EMBL; CH471066; EAW50174.1; -; Genomic_DNA. DR EMBL; BC005821; AAH05821.1; -; mRNA. DR CCDS; CCDS31238.1; -. [P60484-1] DR RefSeq; NP_000305.3; NM_000314.6. [P60484-1] DR RefSeq; NP_001291647.1; NM_001304718.1. DR PDB; 1D5R; X-ray; 2.10 A; A=8-353. DR PDB; 2KYL; NMR; -; B=391-403. DR PDB; 4O1V; X-ray; 2.00 A; B=354-368. DR PDB; 5BUG; X-ray; 2.40 A; A/B/C/D=14-351. DR PDB; 5BZX; X-ray; 2.50 A; A/B/C/D=14-351. DR PDB; 5BZZ; X-ray; 2.20 A; A/B/C/D=14-351. DR PDB; 7JTX; X-ray; 3.23 A; A=7-395. DR PDB; 7JUK; X-ray; 3.15 A; A=7-353, A=378-390. DR PDB; 7JUL; X-ray; 2.53 A; A=7-353, A=378-390. DR PDB; 7JVX; X-ray; 3.20 A; A=1-403. DR PDB; 7PC7; X-ray; 2.10 A; E/F=394-403. DR PDB; 8X3S; X-ray; 1.87 A; B=29-41. DR PDBsum; 1D5R; -. DR PDBsum; 2KYL; -. DR PDBsum; 4O1V; -. DR PDBsum; 5BUG; -. DR PDBsum; 5BZX; -. DR PDBsum; 5BZZ; -. DR PDBsum; 7JTX; -. DR PDBsum; 7JUK; -. DR PDBsum; 7JUL; -. DR PDBsum; 7JVX; -. DR PDBsum; 7PC7; -. DR PDBsum; 8X3S; -. DR AlphaFoldDB; P60484; -. DR SMR; P60484; -. DR BioGRID; 111700; 852. DR ComplexPortal; CPX-3153; PTEN phosphatase complex. DR CORUM; P60484; -. DR DIP; DIP-35019N; -. DR ELM; P60484; -. DR FunCoup; P60484; 3633. DR IntAct; P60484; 439. DR MINT; P60484; -. DR STRING; 9606.ENSP00000361021; -. DR BindingDB; P60484; -. DR ChEMBL; CHEMBL2052032; -. DR DrugBank; DB04327; Phosphatidylethanolamine. DR GuidetoPHARMACOLOGY; 2497; -. DR SwissLipids; SLP:000000849; -. DR TCDB; 1.A.51.2.4; the voltage-gated proton channel (vpc) family. DR CarbonylDB; P60484; -. DR DEPOD; PTEN; -. DR GlyGen; P60484; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P60484; -. DR MetOSite; P60484; -. DR PhosphoSitePlus; P60484; -. DR BioMuta; PTEN; -. DR DMDM; 42560209; -. DR CPTAC; CPTAC-5746; -. DR CPTAC; CPTAC-5747; -. DR CPTAC; CPTAC-5748; -. DR CPTAC; non-CPTAC-5426; -. DR CPTAC; non-CPTAC-5429; -. DR CPTAC; non-CPTAC-5430; -. DR CPTAC; non-CPTAC-5566; -. DR CPTAC; non-CPTAC-5567; -. DR jPOST; P60484; -. DR MassIVE; P60484; -. DR PaxDb; 9606-ENSP00000361021; -. DR PeptideAtlas; P60484; -. DR ProteomicsDB; 57209; -. [P60484-1] DR Pumba; P60484; -. DR Antibodypedia; 3420; 1732 antibodies from 53 providers. DR CPTC; P60484; 8 antibodies. DR DNASU; 5728; -. DR Ensembl; ENST00000371953.8; ENSP00000361021.3; ENSG00000171862.16. [P60484-1] DR Ensembl; ENST00000644628.2; ENSP00000494918.2; ENSG00000284792.2. [P60484-1] DR Ensembl; ENST00000688308.1; ENSP00000508752.1; ENSG00000171862.16. [P60484-1] DR Ensembl; ENST00000710385.1; ENSP00000518242.1; ENSG00000284792.2. [P60484-1] DR Ensembl; ENST00000710387.1; ENSP00000518244.1; ENSG00000284792.2. [P60484-2] DR GeneID; 5728; -. DR KEGG; hsa:5728; -. DR MANE-Select; ENST00000371953.8; ENSP00000361021.3; NM_000314.8; NP_000305.3. DR UCSC; uc001kfb.4; human. [P60484-1] DR AGR; HGNC:9588; -. DR CIViC; 5728; 123 evidence items across 65 molecular profiles. DR ClinPGx; PA33942; -. DR CTD; 5728; -. DR DisGeNET; 5728; -. DR GeneCards; PTEN; -. DR GeneReviews; PTEN; -. DR HGNC; HGNC:9588; PTEN. DR HPA; ENSG00000171862; Low tissue specificity. DR MalaCards; PTEN; -. DR MIM; 137800; phenotype. DR MIM; 158350; phenotype. DR MIM; 176807; phenotype. DR MIM; 275355; phenotype. DR MIM; 601728; gene. DR MIM; 605309; phenotype. DR MIM; 608089; phenotype. DR MIM; 612242; phenotype. DR MIM; 613028; phenotype. DR OpenTargets; ENSG00000171862; -. DR Orphanet; 109; Bannayan-Riley-Ruvalcaba syndrome. DR Orphanet; 201; Cowden syndrome. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 79076; Juvenile polyposis of infancy. DR Orphanet; 65285; Lhermitte-Duclos disease. DR Orphanet; 210548; Macrocephaly-intellectual disability-autism syndrome. DR Orphanet; 2969; Proteus-like syndrome. DR Orphanet; 137608; Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome. DR Orphanet; 494547; Squamous cell carcinoma of the hypopharynx. DR Orphanet; 494550; Squamous cell carcinoma of the larynx. DR Orphanet; 502366; Squamous cell carcinoma of the lip. DR Orphanet; 500464; Squamous cell carcinoma of the nasal cavity and paranasal sinuses. DR Orphanet; 502363; Squamous cell carcinoma of the oral cavity. DR Orphanet; 500478; Squamous cell carcinoma of the oropharynx. DR VEuPathDB; HostDB:ENSG00000171862; -. DR eggNOG; KOG2283; Eukaryota. DR GeneTree; ENSGT00940000154335; -. DR HOGENOM; CLU_020105_5_2_1; -. DR InParanoid; P60484; -. DR OMA; CKKFKQR; -. DR OrthoDB; 16692at2759; -. DR PAN-GO; P60484; 12 GO annotations based on evolutionary models. DR PhylomeDB; P60484; -. DR BioCyc; MetaCyc:HS10404-MONOMER; -. DR BRENDA; 3.1.3.16; 2681. DR BRENDA; 3.1.3.67; 2681. DR PathwayCommons; P60484; -. DR Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane. DR Reactome; R-HSA-1855204; Synthesis of IP3 and IP4 in the cytosol. DR Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network. DR Reactome; R-HSA-202424; Downstream TCR signaling. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5674404; PTEN Loss of Function in Cancer. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR Reactome; R-HSA-8943723; Regulation of PTEN mRNA translation. DR Reactome; R-HSA-8948747; Regulation of PTEN localization. DR Reactome; R-HSA-8948751; Regulation of PTEN stability and activity. DR Reactome; R-HSA-8986944; Transcriptional Regulation by MECP2. DR SignaLink; P60484; -. DR SIGNOR; P60484; -. DR Agora; ENSG00000171862; -. DR BioGRID-ORCS; 5728; 85 hits in 1159 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; B5B9A610; PML body. DR ChiTaRS; PTEN; human. DR EvolutionaryTrace; P60484; -. DR GeneWiki; PTEN_(gene); -. DR GenomeRNAi; 5728; -. DR Pharos; P60484; Tchem. DR PRO; PR:P60484; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; P60484; protein. DR Bgee; ENSG00000171862; Expressed in sperm and 191 other cell types or tissues. DR ExpressionAtlas; P60484; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IMP:UniProtKB. DR GO; GO:0042995; C:cell projection; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0043197; C:dendritic spine; IEA:UniProtKB-SubCell. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0035749; C:myelin sheath adaxonal region; ISS:BHF-UCL. DR GO; GO:0043005; C:neuron projection; ISS:BHF-UCL. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell. DR GO; GO:0014069; C:postsynaptic density; IEA:UniProtKB-SubCell. DR GO; GO:0043220; C:Schmidt-Lanterman incisure; ISS:BHF-UCL. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0010997; F:anaphase-promoting complex binding; IPI:BHF-UCL. DR GO; GO:0008013; F:beta-catenin binding; IPI:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0030351; F:inositol-1,3,4,5,6-pentakisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0051717; F:inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW. DR GO; GO:0140678; F:molecular function inhibitor activity; IMP:DisProt. DR GO; GO:0030165; F:PDZ domain binding; IPI:UniProtKB. DR GO; GO:0052866; F:phosphatidylinositol phosphate phosphatase activity; IDA:UniProt. DR GO; GO:0016314; F:phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0051800; F:phosphatidylinositol-3,4-bisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0004438; F:phosphatidylinositol-3-phosphate phosphatase activity; IDA:UniProtKB. DR GO; GO:0004721; F:phosphoprotein phosphatase activity; IDA:BHF-UCL. DR GO; GO:0004722; F:protein serine/threonine phosphatase activity; IDA:UniProtKB. DR GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB. DR GO; GO:1990757; F:ubiquitin ligase activator activity; ISS:BHF-UCL. DR GO; GO:1990381; F:ubiquitin-specific protease binding; IPI:MGI. DR GO; GO:0030534; P:adult behavior; ISS:BHF-UCL. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0016477; P:cell migration; ISS:UniProtKB. DR GO; GO:0048870; P:cell motility; IBA:GO_Central. DR GO; GO:0071257; P:cellular response to electrical stimulus; IMP:BHF-UCL. DR GO; GO:0007417; P:central nervous system development; ISS:UniProtKB. DR GO; GO:0032286; P:central nervous system myelin maintenance; ISS:BHF-UCL. DR GO; GO:0021955; P:central nervous system neuron axonogenesis; ISS:BHF-UCL. DR GO; GO:0060997; P:dendritic spine morphogenesis; ISS:BHF-UCL. DR GO; GO:0021542; P:dentate gyrus development; ISS:BHF-UCL. DR GO; GO:0048853; P:forebrain morphogenesis; ISS:BHF-UCL. DR GO; GO:0007507; P:heart development; ISS:UniProtKB. DR GO; GO:0007611; P:learning or memory; ISS:BHF-UCL. DR GO; GO:0045475; P:locomotor rhythm; ISS:BHF-UCL. DR GO; GO:0007626; P:locomotory behavior; ISS:BHF-UCL. DR GO; GO:0042711; P:maternal behavior; ISS:BHF-UCL. DR GO; GO:0033555; P:multicellular organismal response to stress; ISS:BHF-UCL. DR GO; GO:0050771; P:negative regulation of axonogenesis; ISS:BHF-UCL. DR GO; GO:1902807; P:negative regulation of cell cycle G1/S phase transition; IDA:UniProtKB. DR GO; GO:0030336; P:negative regulation of cell migration; IMP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0045792; P:negative regulation of cell size; ISS:BHF-UCL. DR GO; GO:2000773; P:negative regulation of cellular senescence; ISS:BHF-UCL. DR GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0090394; P:negative regulation of excitatory postsynaptic potential; ISS:BHF-UCL. DR GO; GO:0051895; P:negative regulation of focal adhesion assembly; IMP:UniProtKB. DR GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IDA:BHF-UCL. DR GO; GO:0051548; P:negative regulation of keratinocyte migration; IMP:BHF-UCL. DR GO; GO:0010977; P:negative regulation of neuron projection development; ISS:ARUK-UCL. DR GO; GO:0046621; P:negative regulation of organ growth; ISS:BHF-UCL. DR GO; GO:0045668; P:negative regulation of osteoblast differentiation; IDA:UniProt. DR GO; GO:0033137; P:negative regulation of peptidyl-serine phosphorylation; IMP:UniProtKB. DR GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProt. DR GO; GO:2000808; P:negative regulation of synaptic vesicle clustering; ISS:BHF-UCL. DR GO; GO:1904706; P:negative regulation of vascular associated smooth muscle cell proliferation; IMP:BHF-UCL. DR GO; GO:1903690; P:negative regulation of wound healing, spreading of epidermal cells; IMP:BHF-UCL. DR GO; GO:0007270; P:neuron-neuron synaptic transmission; ISS:BHF-UCL. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome. DR GO; GO:0046856; P:phosphatidylinositol dephosphorylation; IDA:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:BHF-UCL. DR GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISS:BHF-UCL. DR GO; GO:1902533; P:positive regulation of intracellular signal transduction; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL. DR GO; GO:2000060; P:positive regulation of ubiquitin-dependent protein catabolic process; IDA:BHF-UCL. DR GO; GO:0097107; P:postsynaptic density assembly; ISS:BHF-UCL. DR GO; GO:0060134; P:prepulse inhibition; ISS:BHF-UCL. DR GO; GO:0097105; P:presynaptic membrane assembly; ISS:BHF-UCL. DR GO; GO:0006470; P:protein dephosphorylation; IDA:UniProtKB. DR GO; GO:0050821; P:protein stabilization; IDA:BHF-UCL. DR GO; GO:0010975; P:regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0051896; P:regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB. DR GO; GO:0060024; P:rhythmic synaptic transmission; ISS:BHF-UCL. DR GO; GO:0035176; P:social behavior; ISS:BHF-UCL. DR GO; GO:0007056; P:spindle assembly involved in female meiosis; IDA:UniProt. DR GO; GO:0007416; P:synapse assembly; ISS:BHF-UCL. DR GO; GO:0060074; P:synapse maturation; ISS:BHF-UCL. DR CDD; cd14509; PTP_PTEN; 1. DR DisProt; DP03296; -. DR DisProt; DP03399; -. [P60484-2] DR FunFam; 2.60.40.1110:FF:000003; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; 1. DR FunFam; 3.90.190.10:FF:000029; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; 1. DR Gene3D; 2.60.40.1110; -; 1. DR Gene3D; 3.90.190.10; Protein tyrosine phosphatase superfamily; 1. DR InterPro; IPR017361; Bifunc_PIno_P3_Pase/Pase_PTEN. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR051281; Dual-spec_lipid-protein_phosph. DR InterPro; IPR029021; Prot-tyrosine_phosphatase-like. DR InterPro; IPR045101; PTP_PTEN. DR InterPro; IPR014020; Tensin_C2-dom. DR InterPro; IPR029023; Tensin_phosphatase. DR InterPro; IPR016130; Tyr_Pase_AS. DR InterPro; IPR003595; Tyr_Pase_cat. DR InterPro; IPR000387; Tyr_Pase_dom. DR PANTHER; PTHR12305; PHOSPHATASE WITH HOMOLOGY TO TENSIN; 1. DR PANTHER; PTHR12305:SF81; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 3-PHOSPHATASE AND DUAL-SPECIFICITY PROTEIN PHOSPHATASE PTEN; 1. DR Pfam; PF10409; PTEN_C2; 1. DR Pfam; PF22785; Tc-R-P; 1. DR PIRSF; PIRSF038025; PTEN; 1. DR SMART; SM01326; PTEN_C2; 1. DR SMART; SM00404; PTPc_motif; 1. DR SMART; SM01301; PTPlike_phytase; 1. DR SUPFAM; SSF52799; (Phosphotyrosine protein) phosphatases II; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR PROSITE; PS51182; C2_TENSIN; 1. DR PROSITE; PS51181; PPASE_TENSIN; 1. DR PROSITE; PS50056; TYR_PHOSPHATASE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative initiation; Alternative splicing; KW Apoptosis; Autism spectrum disorder; Cell projection; Cytoplasm; KW Disease variant; Hydrolase; Isopeptide bond; Lipid metabolism; KW Lipid-binding; Neurogenesis; Nucleus; Phosphoprotein; Protein phosphatase; KW Proteomics identification; Reference proteome; Secreted; Synapse; KW Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..403 FT /note="Phosphatidylinositol 3,4,5-trisphosphate 3- FT phosphatase and dual-specificity protein phosphatase PTEN" FT /id="PRO_0000215904" FT DOMAIN 14..185 FT /note="Phosphatase tensin-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00590" FT DOMAIN 190..350 FT /note="C2 tensin-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00589" FT REGION 338..348 FT /note="Required for interaction with NOP53" FT /evidence="ECO:0000269|PubMed:15355975" FT REGION 352..403 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 401..403 FT /note="PDZ domain-binding" FT /evidence="ECO:0000250|UniProtKB:O08586" FT COMPBIAS 360..369 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 383..393 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 124 FT /note="Phosphocysteine intermediate" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00590" FT MOD_RES 2 FT /note="N-acetylthreonine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 294 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O08586" FT MOD_RES 319 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:26166433" FT MOD_RES 321 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:26166433" FT MOD_RES 336 FT /note="Phosphotyrosine; by FRK" FT /evidence="ECO:0000269|PubMed:19345329" FT MOD_RES 366 FT /note="Phosphothreonine; by GSK3-beta and PLK3" FT /evidence="ECO:0000269|PubMed:12297295, FT ECO:0000269|PubMed:20940307, ECO:0007744|PubMed:24275569" FT MOD_RES 370 FT /note="Phosphoserine; by CK2 and PLK3" FT /evidence="ECO:0000269|PubMed:11035045, FT ECO:0000269|PubMed:12297295, ECO:0000269|PubMed:20940307" FT MOD_RES 380 FT /note="Phosphoserine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 382 FT /note="Phosphothreonine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 383 FT /note="Phosphothreonine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 385 FT /note="Phosphoserine; by CK2" FT /evidence="ECO:0000269|PubMed:11035045, FT ECO:0000269|PubMed:12297295" FT MOD_RES 401 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:10646847" FT CROSSLNK 13 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:18716620" FT CROSSLNK 289 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:18716620" FT VAR_SEQ 1 FT /note="M -> MERGGEAAAAAAAAAAAPGRGSESPVTISRAGNAGELVSPLLLPPTR FT RRRRRHIQGPGPVLNLPCAAAAPPVARAPEAAGGGSRSEDYSSSPHSAAAAARPLAAEE FT KQAQSLQPSSSRRSSHYPAAVQSQAAAERGASATAKSRAISILQKKPRHQQLLPSLSSF FT FFSHRLPDM (in isoform alpha)" FT /evidence="ECO:0000305" FT /id="VSP_055420" FT VAR_SEQ 55..70 FT /note="RFLDSKHKNHYKIYNL -> S (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055421" FT VAR_SEQ 165..190 FT /note="GVTIPSQRRYVYYYSYLLKNHLDYRP -> ADPTGGIPDKGIIVIGDGSSMD FT VIAP (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055422" FT VAR_SEQ 191..403 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055423" FT VARIANT 10 FT /note="S -> N (retains phosphatase activity towards FT Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the ability to FT bind phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026248" FT VARIANT 15 FT /note="R -> S (in CWS1; also found in glioma; FT dbSNP:rs1064794096)" FT /evidence="ECO:0000269|PubMed:21659347, FT ECO:0000269|PubMed:9090379" FT /id="VAR_007457" FT VARIANT 16 FT /note="Y -> C (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains the ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026249" FT VARIANT 19 FT /note="D -> N (in malignant melanoma; somatic mutation; FT dbSNP:rs121909233)" FT /evidence="ECO:0000269|PubMed:10978354" FT /id="VAR_018100" FT VARIANT 20 FT /note="G -> E (reduced phosphatase activity towards FT Ins(1,3,4,5)P4; retains phosphatase activity towards FT PtdIns(3,4,5)P3; dbSNP:rs1064795967)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026250" FT VARIANT 27 FT /note="Y -> S (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs886041877)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026251" FT VARIANT 33 FT /note="Missing (in CWS1; dbSNP:rs1554893765)" FT /evidence="ECO:0000269|PubMed:10234502" FT /id="VAR_008733" FT VARIANT 34 FT /note="A -> D (in CWS1)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:21659347" FT /id="VAR_008734" FT VARIANT 35 FT /note="M -> R (in CWS1; dbSNP:rs121909225)" FT /evidence="ECO:0000269|PubMed:9425889" FT /id="VAR_008036" FT VARIANT 36 FT /note="G -> E (in ENDMC; also found in glioma; FT dbSNP:rs1554893792)" FT /evidence="ECO:0000269|PubMed:16506206, FT ECO:0000269|PubMed:9090379" FT /id="VAR_007458" FT VARIANT 36 FT /note="G -> R (in CWS1; also found in a patient with FT endometrial hyperplasia; dbSNP:rs786204854)" FT /evidence="ECO:0000269|PubMed:10772390, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9635567" FT /id="VAR_026252" FT VARIANT 42 FT /note="L -> R (in glioma; retains phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the FT ability to bind phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:9090379" FT /id="VAR_007459" FT VARIANT 47 FT /note="R -> G (in CWS1; dbSNP:rs786204855)" FT /evidence="ECO:0000269|PubMed:11494117" FT /id="VAR_011587" FT VARIANT 57 FT /note="L -> W (in glioma; likely pathogenic; loss of FT protein phosphatase activity; dbSNP:rs786202398)" FT /evidence="ECO:0000269|PubMed:9090379, FT ECO:0000269|PubMed:9256433" FT /id="VAR_007460" FT VARIANT 61 FT /note="H -> D (found in a patient with congenital cardiac FT disease, macrocephaly, ventriculomegaly, skeletal defects, FT anal atresia, tracheoesophageal fistula, renal anomalies; FT likely pathogenic; dbSNP:rs121909236)" FT /evidence="ECO:0000269|PubMed:11748304" FT /id="VAR_018101" FT VARIANT 61 FT /note="H -> R (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; dbSNP:rs398123316)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394" FT /id="VAR_026253" FT VARIANT 65..403 FT /note="Missing (in MCEPHAS)" FT /evidence="ECO:0000269|PubMed:26637798" FT /id="VAR_078705" FT VARIANT 67 FT /note="I -> R (in CWS1)" FT /evidence="ECO:0000269|PubMed:9467011" FT /id="VAR_007461" FT VARIANT 68 FT /note="Y -> H (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the FT ability to bind phospholipid membranes; dbSNP:rs398123317)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11494117, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9600246" FT /id="VAR_007462" FT VARIANT 70 FT /note="L -> P (in CWS1; dbSNP:rs121909226)" FT /evidence="ECO:0000269|PubMed:9832031" FT /id="VAR_018102" FT VARIANT 71 FT /note="C -> Y (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026254" FT VARIANT 93 FT /note="H -> R (in MCEPHAS; dbSNP:rs121909238)" FT /evidence="ECO:0000269|PubMed:15805158" FT /id="VAR_032634" FT VARIANT 93 FT /note="H -> Y (in CWS1; dbSNP:rs786204927)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:24778394" FT /id="VAR_026255" FT VARIANT 105 FT /note="C -> F (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026256" FT VARIANT 105 FT /note="C -> Y (in CWS1; dbSNP:rs587782343)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117" FT /id="VAR_008735" FT VARIANT 107 FT /note="D -> Y (in CWS1; also found in glioblastoma; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs57374291)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026257" FT VARIANT 112 FT /note="L -> P (in CWS1 and LDD; loss of phosphatase FT activity towards Ins(1,3,4,5)P4; dbSNP:rs121909230)" FT /evidence="ECO:0000269|PubMed:10051160, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:9600246" FT /id="VAR_007807" FT VARIANT 112 FT /note="L -> R (loss of phosphatase activity towards FT Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026258" FT VARIANT 119 FT /note="V -> L (in multiple cancers; dbSNP:rs139767111)" FT /evidence="ECO:0000269|PubMed:10807691" FT /id="VAR_011588" FT VARIANT 121 FT /note="A -> G (in HNSCC; dbSNP:rs121909237)" FT /evidence="ECO:0000269|PubMed:11801303" FT /id="VAR_018103" FT VARIANT 121 FT /note="A -> P (in glioblastoma; loss of phosphatase FT activity towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026259" FT VARIANT 123 FT /note="H -> R (in CWS1; dbSNP:rs121909222)" FT /evidence="ECO:0000269|PubMed:10234502, FT ECO:0000269|PubMed:9259288" FT /id="VAR_007463" FT VARIANT 123 FT /note="H -> Y (in endometrial cancer; loss of protein FT phosphatase activity; dbSNP:rs786204931)" FT /evidence="ECO:0000269|PubMed:9256433" FT /id="VAR_026260" FT VARIANT 124 FT /note="C -> R (in CWS1; dbSNP:rs121909223)" FT /evidence="ECO:0000269|PubMed:10234502, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:9259288" FT /id="VAR_007464" FT VARIANT 124 FT /note="C -> S (in CWS1; phosphatase-dead protein with FT neither lipid nor protein phosphatase activity; loss of FT phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase FT activity; dbSNP:rs121909223)" FT /evidence="ECO:0000269|PubMed:11230179, FT ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9811831" FT /id="VAR_018104" FT VARIANT 126 FT /note="A -> G (in a patient with prostate cancer; reduced FT phosphatase activity towards PtdIns(3,4,5); shifts its FT activity from phosphatidylinositol phosphate 3-phosphatase FT to phosphatidylinositol phosphate 5-phosphatase; disrupts FT PI3K/ATK signaling; reduced cell migration)" FT /evidence="ECO:0000269|PubMed:26504226" FT /id="VAR_076551" FT VARIANT 129 FT /note="G -> E (in CWS1; no lipid phosphatase activity but FT retains protein phosphatase activity; retains ability to FT inhibit focal adhesion formation; dbSNP:rs121909218)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:11230179, ECO:0000269|PubMed:21659347, FT ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9616126, FT ECO:0000269|PubMed:9811831" FT /id="VAR_007465" FT VARIANT 129 FT /note="G -> R (in glioblastoma; severely reduced protein FT phosphatase activity; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs786204929)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9072974, ECO:0000269|PubMed:9256433, FT ECO:0000269|PubMed:9331071" FT /id="VAR_007466" FT VARIANT 130 FT /note="R -> G (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; FT dbSNP:rs121909224)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394" FT /id="VAR_026261" FT VARIANT 130 FT /note="R -> L (in CWS1; also found in endometrial FT hyperplasia; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes; dbSNP:rs121909229)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394, FT ECO:0000269|PubMed:9635567" FT /id="VAR_007467" FT VARIANT 130 FT /note="R -> Q (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes; dbSNP:rs121909229)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394, FT ECO:0000269|PubMed:9915974" FT /id="VAR_007468" FT VARIANT 131 FT /note="T -> I (in MCEPHAS; dbSNP:rs397514560)" FT /evidence="ECO:0000269|PubMed:23160955" FT /id="VAR_076762" FT VARIANT 132 FT /note="G -> V (in one patient with clinical findings FT suggesting hamartoma tumor syndrome; dbSNP:rs121909241)" FT /evidence="ECO:0000269|PubMed:16752378" FT /id="VAR_032635" FT VARIANT 133 FT /note="V -> I (loss of phosphatase activity towards FT Ins(1,3,4,5)P3)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026262" FT VARIANT 134 FT /note="M -> L (in prostate cancer; no effect on protein FT phosphatase activity; reduced phosphatase activity towards FT Ins(1,3,4,5)P3 but retains PtdIns(3,4,5)P3 phosphatase FT activity)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9072974, ECO:0000269|PubMed:9256433" FT /id="VAR_007469" FT VARIANT 135 FT /note="I -> V (in CWS1; dbSNP:rs587782360)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117" FT /id="VAR_008736" FT VARIANT 136 FT /note="C -> Y (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P3; dbSNP:rs786204859)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9735393" FT /id="VAR_007808" FT VARIANT 137 FT /note="A -> AN (in CWS1)" FT /evidence="ECO:0000269|PubMed:9345101" FT /id="VAR_008737" FT VARIANT 155 FT /note="Y -> C (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; dbSNP:rs1060500126)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026263" FT VARIANT 158 FT /note="V -> L (in multiple cancers)" FT /evidence="ECO:0000269|PubMed:10807691" FT /id="VAR_011589" FT VARIANT 165 FT /note="G -> E (in CWS1)" FT /evidence="ECO:0000269|PubMed:10234502" FT /id="VAR_008739" FT VARIANT 165 FT /note="G -> R (in CWS1; also found in glioblastoma; FT severely reduced protein phosphatase activity; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; retains FT ability to bind phospholipid membranes; dbSNP:rs587782603)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9256433, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026264" FT VARIANT 165 FT /note="G -> V (in CWS1; dbSNP:rs786204863)" FT /evidence="ECO:0000269|PubMed:9467011" FT /id="VAR_008738" FT VARIANT 167 FT /note="T -> N (in MCEPHAS; dbSNP:rs397514559)" FT /evidence="ECO:0000269|PubMed:23160955" FT /id="VAR_076763" FT VARIANT 167 FT /note="T -> P (in breast cancer; severely reduced protein FT phosphatase activity)" FT /evidence="ECO:0000269|PubMed:9256433" FT /id="VAR_026265" FT VARIANT 170 FT /note="S -> N (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026266" FT VARIANT 170 FT /note="S -> R (in CWS1; severely reduced protein FT phosphatase activity; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121909221)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11494117, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9241266, FT ECO:0000269|PubMed:9256433" FT /id="VAR_007470" FT VARIANT 173 FT /note="R -> C (in CWS1; also found in endometrial FT hyperplasia; loss of phosphatase activity towards FT Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains ability to bind FT phospholipid membranes; dbSNP:rs121913293)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:24778394, ECO:0000269|PubMed:9635567" FT /id="VAR_026267" FT VARIANT 173 FT /note="R -> H (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121913294)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026268" FT VARIANT 173 FT /note="R -> P (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121913294)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026269" FT VARIANT 174 FT /note="Y -> N (found in a thyroid tumor; somatic variant; FT loss of phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs587782316)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:39316756" FT /id="VAR_026270" FT VARIANT 191 FT /note="V -> A (in endometrial hyperplasia)" FT /evidence="ECO:0000269|PubMed:9635567" FT /id="VAR_026271" FT VARIANT 217 FT /note="V -> I (in malignant melanoma; somatic mutation; FT dbSNP:rs121909234)" FT /evidence="ECO:0000269|PubMed:10978354" FT /id="VAR_018105" FT VARIANT 227 FT /note="S -> F (reduced phosphatase activity towards FT Ins(1,3,4,5)P4; retains PtdIns(3,4,5)P3 phosphatase FT activity; dbSNP:rs905615413)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026272" FT VARIANT 234 FT /note="R -> Q (in GLM2; uncertain significance; not capable FT of inducing apoptosis; induced increased cell FT proliferation; led to high constitutive AKT1 activation FT which could not be increased further by stimulation with FT insulin; dbSNP:rs121909235)" FT /evidence="ECO:0000269|PubMed:12085208" FT /id="VAR_018106" FT VARIANT 241 FT /note="F -> S (in MCEPHAS; dbSNP:rs121909240)" FT /evidence="ECO:0000269|PubMed:15805158" FT /id="VAR_032636" FT VARIANT 246 FT /note="P -> L (in CWS1; dbSNP:rs587782350)" FT /evidence="ECO:0000269|PubMed:10400993" FT /id="VAR_008740" FT VARIANT 251 FT /note="G -> C (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026273" FT VARIANT 252 FT /note="D -> G (in MCEPHAS and CWS1; dbSNP:rs121909239)" FT /evidence="ECO:0000269|PubMed:15805158, FT ECO:0000269|PubMed:21659347" FT /id="VAR_032637" FT VARIANT 289 FT /note="K -> E (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes; predominantly nuclear; FT dbSNP:rs562015640)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:9797362" FT /id="VAR_008741" FT VARIANT 290 FT /note="V -> L (in dbSNP:rs35600253)" FT /evidence="ECO:0000269|Ref.10" FT /id="VAR_025167" FT VARIANT 319 FT /note="Missing (in glioma; reduced tumor suppressor FT activity; fails to inactivate AKT/PKB)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:9090379" FT /id="VAR_026274" FT VARIANT 331 FT /note="D -> G (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026275" FT VARIANT 341 FT /note="F -> V (in CWS1; loss of interaction with NOP53; FT decreased phosphorylation at S-380; decreased stability; FT loss of phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs1554825652)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:15355975" FT /id="VAR_026276" FT VARIANT 342 FT /note="K -> N (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4 but PtdIns(3,4,5)P3 phosphatase FT activity is similar to wild-type; dbSNP:rs398123314)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026277" FT VARIANT 343 FT /note="V -> E (in CWS1; loss of interaction with NOP53; FT decreased phosphorylation at S-380; decreased stability; FT loss of phosphatase activity towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:15355975, ECO:0000269|PubMed:9399897" FT /id="VAR_008742" FT VARIANT 345 FT /note="L -> Q (in glioblastoma; reduced tumor suppressor FT activity; loss of interaction with NOP53; decreased FT phosphorylation at S-380; decreased stability; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; reduced FT ability to inactivate AKT/PKB; retains ability to bind FT phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:15355975, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026278" FT VARIANT 347 FT /note="F -> L (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9399897" FT /id="VAR_008743" FT VARIANT 348 FT /note="T -> I (in endometrial hyperplasia; reduced FT phosphatase activity towards PtdIns(3,4,5)P3; mildly FT reduced tumor suppressor activity; reduced ability to FT inactivate AKT/PKB)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:9635567" FT /id="VAR_026279" FT VARIANT 369 FT /note="V -> G (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3 FT phosphatase activity; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026280" FT VARIANT 401 FT /note="T -> I (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3 FT phosphatase activity; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026281" FT MUTAGEN 1 FT /note="M->I: Prevents expression of isoform 1 and increased FT expression of isoform alpha." FT /evidence="ECO:0000269|PubMed:24768297" FT MUTAGEN 13 FT /note="K->E: Nuclear. Cytoplasmic; when associated with E- FT 289. Shows less tumor suppressive ability; when associated FT with E-289." FT /evidence="ECO:0000269|PubMed:18716620" FT MUTAGEN 92 FT /note="D->A: 700-fold reduction in phosphatase activity FT towards PtdIns(3,4,5)P3. Loss of protein phosphatase FT activity. Unable to inhibit focal adhesion formation." FT /evidence="ECO:0000269|PubMed:10555148, FT ECO:0000269|PubMed:9616126" FT MUTAGEN 93 FT /note="H->A: 75% reduction in phosphatase activity towards FT PtdIns(3,4,5)P3. Modest reduction in phosphatase activity FT towards PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 124 FT /note="C->A: Loss of protein phosphatase activity. Unable FT to inhibit focal adhesion formation." FT /evidence="ECO:0000269|PubMed:9616126" FT MUTAGEN 125 FT /note="K->M: Reduced phosphatase activity towards FT PtdIns(3,4,5)P3, PtdIns(3,4)P2 and PtdIns(3)P." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 126 FT /note="A->P: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 126 FT /note="A->S: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 126 FT /note="A->V: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 128 FT /note="K->M: 85% reduction in phosphatase activity towards FT PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 128 FT /note="K->R: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 130 FT /note="R->M: Does not affect the ability to inhibit AKT/PKB FT activation." FT /evidence="ECO:0000269|PubMed:9811831" FT MUTAGEN 167 FT /note="T->A,D: 60% reduction in phosphatase activity FT towards PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 171 FT /note="Q->A,E: 75% reduction in phosphatase activity FT towards PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 229 FT /note="S->A: No effect on interaction with DLC1 or p85." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 232 FT /note="T->A: No effect on interaction with DLC1 or p85." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 263..269 FT /note="KMLKKDK->AAGAADA: Reduces the growth suppression FT activity and cells show anchorage-independent growth. FT Reduces binding to phospholipid membranes in vitro. FT Phosphatase activity towards PtdIns(3,4,5)P3 is not FT affected." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 289 FT /note="K->E: Cytoplasmic; when associated with E-13. Shows FT less tumor suppressive ability; when associated with E-13." FT /evidence="ECO:0000269|PubMed:18716620" FT MUTAGEN 319 FT /note="T->A: Reduces phosphorylation of the C2 tensin-like FT domain and abolishes interaction with DLC1 following EGF FT stimulation. Abolishes phosphorylation of the C2 tensin- FT like domain; when associated with A-321." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 319 FT /note="T->E: Constitutive interaction with DLC1." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 319 FT /note="T->Y: Constitutive interaction with DLC1 and FT interaction with p85 following EGF stimulation." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 321 FT /note="T->A: Reduces phosphorylation of the C2 tensin-like FT domain and abolishes interaction with DLC1 following EGF FT stimulation. Abolishes phosphorylation of the C2 tensin- FT like domain; when associated with A-319." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 321 FT /note="T->E: Constitutive interaction with DLC1." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 327..335 FT /note="KANKDKANR->AAGADAANA: Reduces growth suppression FT activity and promotes anchorage-independent growth. Reduces FT binding to phospholipid membranes in vitro; phosphatase FT activity towards PtdIns(3,4,5)P3 is not affected." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 336 FT /note="Y->F: Significantly lower phosphatase activity, FT reduced protein stability and decreased growth-inhibitory FT effect." FT /evidence="ECO:0000269|PubMed:19345329" FT MUTAGEN 366 FT /note="T->A: Decreased stability." FT /evidence="ECO:0000269|PubMed:20940307" FT MUTAGEN 370 FT /note="S->A: Decreased stability." FT /evidence="ECO:0000269|PubMed:20940307" FT MUTAGEN 401 FT /note="T->A: Loss of DLG1-binding. No effect on MAGI2- and FT MAST2-binding." FT MUTAGEN 402 FT /note="K->A: No effect on MAGI2-, MAST2- and DLG1-binding." FT MUTAGEN 402 FT /note="K->W: Loss of DLG1-, MAGI2-, MAGI3- and MAST2- FT binding. Decrease of protein stability." FT MUTAGEN 403 FT /note="V->A: Loss of DLG1-, MAGI2-, MAGI3-, MAST1-, FT MAST2- and MAST3-binding." FT /evidence="ECO:0000269|PubMed:15951562" FT HELIX 8..10 FT /evidence="ECO:0007829|PDB:7JUL" FT TURN 19..22 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 23..29 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 32..35 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 39..41 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 44..47 FT /evidence="ECO:0007829|PDB:5BZZ" FT HELIX 50..60 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 61..63 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 65..73 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 78..80 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 81..83 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 85..90 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 98..100 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 101..112 FT /evidence="ECO:0007829|PDB:1D5R" FT TURN 113..115 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 118..123 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 125..128 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 129..141 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 148..159 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 161..163 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 169..184 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 192..202 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 206..209 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 213..219 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 222..226 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 232..235 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 238..259 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 262..264 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 268..276 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 277..279 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 280..284 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 310..312 FT /evidence="ECO:0007829|PDB:5BZX" FT STRAND 315..321 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 322..324 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 328..330 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 335..337 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 342..349 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 395..403 FT /evidence="ECO:0007829|PDB:2KYL" SQ SEQUENCE 403 AA; 47166 MW; 75F97C3DD6802BA9 CRC64; MTAIIKEIVS RNKRRYQEDG FDLDLTYIYP NIIAMGFPAE RLEGVYRNNI DDVVRFLDSK HKNHYKIYNL CAERHYDTAK FNCRVAQYPF EDHNPPQLEL IKPFCEDLDQ WLSEDDNHVA AIHCKAGKGR TGVMICAYLL HRGKFLKAQE ALDFYGEVRT RDKKGVTIPS QRRYVYYYSY LLKNHLDYRP VALLFHKMMF ETIPMFSGGT CNPQFVVCQL KVKIYSSNSG PTRREDKFMY FEFPQPLPVC GDIKVEFFHK QNKMLKKDKM FHFWVNTFFI PGPEETSEKV ENGSLCDQEI DSICSIERAD NDKEYLVLTL TKNDLDKANK DKANRYFSPN FKVKLYFTKT VEEPSNPEAS SSTSVTPDVS DNEPDHYRYS DTTDSDPENE PFDEDQHTQI TKV // ID PTK7_HUMAN Reviewed; 1070 AA. AC Q13308; A8K974; B7Z477; E9PFZ5; Q13417; Q5T650; Q6IQ54; Q8NFA5; Q8NFA6; AC Q8NFA7; Q8NFA8; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 2. DT 28-JAN-2026, entry version 224. DE RecName: Full=Inactive tyrosine-protein kinase 7; DE AltName: Full=Colon carcinoma kinase 4; DE Short=CCK-4; DE AltName: Full=Protein-tyrosine kinase 7; DE AltName: Full=Pseudo tyrosine kinase receptor 7; DE AltName: Full=Tyrosine-protein kinase-like 7; DE Flags: Precursor; GN Name=PTK7; Synonyms=CCK4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Colon carcinoma, and Placenta; RX PubMed=7478540; RA Mossie K., Jallal B., Alves F., Sures I., Plowman G.D., Ullrich A.; RT "Colon carcinoma kinase-4 defines a new subclass of the receptor tyrosine RT kinase family."; RL Oncogene 11:2179-2184(1995). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Fibroblast; RX PubMed=8882711; DOI=10.1093/oxfordjournals.jbchem.a021228; RA Park S.-K., Lee H.-S., Lee S.-T.; RT "Characterization of the human full-length PTK7 cDNA encoding a receptor RT protein tyrosine kinase-like molecule closely related to chick KLG."; RL J. Biochem. 119:235-239(1996). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS RP 1; 2; 3; 4 AND 5). RC TISSUE=Testis; RX PubMed=12427550; DOI=10.1016/s0167-4781(02)00536-5; RA Jung J.-W., Ji A.-R., Lee J., Kim U.-J., Lee S.-T.; RT "Organization of the human PTK7 gene encoding a receptor protein tyrosine RT kinase-like molecule and alternative splicing of its mRNA."; RL Biochim. Biophys. Acta 1579:153-163(2002). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 6). RC TISSUE=Testis, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP GLYCOSYLATION AT ASN-646. RX PubMed=12754519; DOI=10.1038/nbt827; RA Zhang H., Li X.-J., Martin D.B., Aebersold R.; RT "Identification and quantification of N-linked glycoproteins using RT hydrazide chemistry, stable isotope labeling and mass spectrometry."; RL Nat. Biotechnol. 21:660-666(2003). RN [9] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-646. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [10] RP FUNCTION. RX PubMed=18471990; DOI=10.1016/j.bbrc.2008.04.168; RA Shin W.-S., Maeng Y.-S., Jung J.-W., Min J.-K., Kwon Y.-G., Lee S.-T.; RT "Soluble PTK7 inhibits tube formation, migration, and invasion of RT endothelial cells and angiogenesis."; RL Biochem. Biophys. Res. Commun. 371:793-798(2008). RN [11] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-116; ASN-175; ASN-268 AND RP ASN-283. RC TISSUE=Leukemic T-cell; RX PubMed=19349973; DOI=10.1038/nbt.1532; RA Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M., RA Schiess R., Aebersold R., Watts J.D.; RT "Mass-spectrometric identification and relative quantification of N-linked RT cell surface glycoproteins."; RL Nat. Biotechnol. 27:378-386(2009). RN [12] RP FUNCTION. RX PubMed=20558616; DOI=10.1182/blood-2010-01-262352; RA Prebet T., Lhoumeau A.-C., Arnoulet C., Aulas A., Marchetto S., RA Audebert S., Puppo F., Chabannon C., Sainty D., Santoni M.-J., Sebbagh M., RA Summerour V., Huon Y., Shin W.-S., Lee S.-T., Esterni B., Vey N., RA Borg J.-P.; RT "The cell polarity PTK7 receptor acts as a modulator of the RT chemotherapeutic response in acute myeloid leukemia and impairs clinical RT outcome."; RL Blood 116:2315-2323(2010). RN [13] RP FUNCTION, SUBCELLULAR LOCATION, INDUCTION, CLEAVAGE, AND MUTAGENESIS OF RP LEU-622; MET-641 AND MET-701. RX PubMed=20837484; DOI=10.1074/jbc.m110.165159; RA Golubkov V.S., Chekanov A.V., Cieplak P., Aleshin A.E., Chernov A.V., RA Zhu W., Radichev I.A., Zhang D., Dong P.D., Strongin A.Y.; RT "The Wnt/planar cell polarity protein-tyrosine kinase-7 (PTK7) is a highly RT efficient proteolytic target of membrane type-1 matrix metalloproteinase: RT implications in cancer and embryogenesis."; RL J. Biol. Chem. 285:35740-35749(2010). RN [14] RP FUNCTION. RX PubMed=21103379; DOI=10.1371/journal.pone.0014018; RA Meng L., Sefah K., O'Donoghue M.B., Zhu G., Shangguan D., Noorali A., RA Chen Y., Zhou L., Tan W.; RT "Silencing of PTK7 in colon cancer cells: caspase-10-dependent apoptosis RT via mitochondrial pathway."; RL PLoS ONE 5:E14018-E14018(2010). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [16] RP FUNCTION, INTERACTION WITH CTNNB1, AND REGION. RX PubMed=21132015; DOI=10.1038/embor.2010.185; RA Puppo F., Thome V., Lhoumeau A.-C., Cibois M., Gangar A., Lembo F., RA Belotti E., Marchetto S., Lecine P., Prebet T., Sebbagh M., Shin W.-S., RA Lee S.-T., Kodjabachian L., Borg J.-P.; RT "Protein tyrosine kinase 7 has a conserved role in Wnt/beta-catenin RT canonical signalling."; RL EMBO Rep. 12:43-49(2011). RN [17] RP VARIANTS [LARGE SCALE ANALYSIS] HIS-276; SER-410; ASP-745; GLN-766; RP VAL-777; ARG-783; VAL-933; THR-1029 AND GLN-1038. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Inactive tyrosine kinase involved in Wnt signaling pathway. CC Component of both the non-canonical (also known as the Wnt/planar cell CC polarity signaling) and the canonical Wnt signaling pathway. Functions CC in cell adhesion, cell migration, cell polarity, proliferation, actin CC cytoskeleton reorganization and apoptosis. Has a role in embryogenesis, CC epithelial tissue organization and angiogenesis. CC {ECO:0000269|PubMed:18471990, ECO:0000269|PubMed:20558616, CC ECO:0000269|PubMed:20837484, ECO:0000269|PubMed:21103379, CC ECO:0000269|PubMed:21132015}. CC -!- SUBUNIT: Interacts with CTNNB1. {ECO:0000269|PubMed:21132015}. CC -!- INTERACTION: CC Q13308; P35222: CTNNB1; NbExp=5; IntAct=EBI-2803245, EBI-491549; CC Q13308; Q8IUG1: KRTAP1-3; NbExp=3; IntAct=EBI-2803245, EBI-11749135; CC Q13308; P60410: KRTAP10-8; NbExp=3; IntAct=EBI-2803245, EBI-10171774; CC Q13308; Q99750: MDFI; NbExp=3; IntAct=EBI-2803245, EBI-724076; CC Q13308; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-2803245, EBI-11522433; CC Q13308; P0DPK4: NOTCH2NLC; NbExp=3; IntAct=EBI-2803245, EBI-22310682; CC -!- SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:20837484}; Single- CC pass type I membrane protein {ECO:0000269|PubMed:20837484}. Cell CC junction {ECO:0000269|PubMed:20837484}. Note=Colocalizes with MMP14 at CC cell junctions. Also localizes at the leading edge of migrating cells. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Name=1; Synonyms=PTK7-1; CC IsoId=Q13308-1; Sequence=Displayed; CC Name=2; Synonyms=PTK7-2; CC IsoId=Q13308-2; Sequence=VSP_037182; CC Name=3; Synonyms=PTK7-3; CC IsoId=Q13308-3; Sequence=VSP_037181; CC Name=4; Synonyms=PTK7-4; CC IsoId=Q13308-4; Sequence=VSP_037183; CC Name=5; Synonyms=PTK7-5; CC IsoId=Q13308-5; Sequence=VSP_037184, VSP_037185; CC Name=6; CC IsoId=Q13308-6; Sequence=VSP_044775; CC -!- TISSUE SPECIFICITY: Highly expressed in lung, liver, pancreas, kidney, CC placenta and melanocytes. Weakly expressed in thyroid gland, ovary, CC brain, heart and skeletal muscle. Also expressed in erythroleukemia CC cells. But not expressed in colon. CC -!- INDUCTION: Higher expression in cell lines established from normal non- CC tumorigenic tissues compared to cell lines established from highly CC metastatic invasive carcinomas (at protein level). CC {ECO:0000269|PubMed:20837484}. CC -!- DOMAIN: The protein kinase domain is predicted to be catalytically CC inactive. CC -!- PTM: MMP14 cleaves PTK7 between Pro-621 and Leu-622 generating an N- CC terminal soluble (70 kDa) fragment and a membrane C-terminal (50 kDa) CC fragment. Proteolysis by MMP14 regulates PTK7 function in non-canonical CC Wnt signaling pathway. {ECO:0000269|PubMed:20837484}. CC -!- MISCELLANEOUS: [Isoform 5]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41901/PTK7"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U33635; AAA87565.1; -; mRNA. DR EMBL; U40271; AAC50484.2; -; mRNA. DR EMBL; AF447176; AAL39062.1; -; Genomic_DNA. DR EMBL; AF447157; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447158; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447162; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447164; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447167; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447170; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447171; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447173; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447174; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447175; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF531868; AAN04862.1; -; mRNA. DR EMBL; AF531869; AAN04863.1; -; mRNA. DR EMBL; AF531870; AAN04864.1; -; mRNA. DR EMBL; AF531871; AAN04865.1; -; mRNA. DR EMBL; AF531872; AAN04866.1; -; mRNA. DR EMBL; AK291016; BAF83705.1; -; mRNA. DR EMBL; AK292589; BAF85278.1; -; mRNA. DR EMBL; AK296953; BAH12463.1; -; mRNA. DR EMBL; AL355385; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471081; EAX04154.1; -; Genomic_DNA. DR EMBL; CH471081; EAX04155.1; -; Genomic_DNA. DR EMBL; CH471081; EAX04156.1; -; Genomic_DNA. DR EMBL; CH471081; EAX04158.1; -; Genomic_DNA. DR EMBL; CH471081; EAX04160.1; -; Genomic_DNA. DR EMBL; BC071557; AAH71557.1; -; mRNA. DR CCDS; CCDS4884.1; -. [Q13308-1] DR CCDS; CCDS4885.1; -. [Q13308-2] DR CCDS; CCDS4886.1; -. [Q13308-3] DR CCDS; CCDS4887.1; -. [Q13308-4] DR CCDS; CCDS59021.1; -. [Q13308-6] DR PIR; JC4593; JC4593. DR RefSeq; NP_001257327.1; NM_001270398.2. [Q13308-6] DR RefSeq; NP_002812.2; NM_002821.4. [Q13308-1] DR RefSeq; NP_690619.1; NM_152880.4. [Q13308-2] DR RefSeq; NP_690620.1; NM_152881.4. [Q13308-3] DR RefSeq; NP_690621.1; NM_152882.4. [Q13308-4] DR PDB; 6VG3; X-ray; 1.95 A; A/B/C=774-1069. DR PDBsum; 6VG3; -. DR AlphaFoldDB; Q13308; -. DR SMR; Q13308; -. DR BioGRID; 111721; 183. DR FunCoup; Q13308; 541. DR IntAct; Q13308; 121. DR MINT; Q13308; -. DR STRING; 9606.ENSP00000418754; -. DR GlyConnect; 655; 40 N-Linked glycans (6 sites). DR GlyCosmos; Q13308; 10 sites, 46 glycans. DR GlyGen; Q13308; 13 sites, 74 N-linked glycans (8 sites), 2 O-linked glycans (3 sites). DR iPTMnet; Q13308; -. DR MetOSite; Q13308; -. DR PhosphoSitePlus; Q13308; -. DR SwissPalm; Q13308; -. DR BioMuta; PTK7; -. DR DMDM; 116242736; -. DR jPOST; Q13308; -. DR MassIVE; Q13308; -. DR PaxDb; 9606-ENSP00000418754; -. DR PeptideAtlas; Q13308; -. DR ProteomicsDB; 20212; -. DR ProteomicsDB; 59293; -. [Q13308-1] DR ProteomicsDB; 59294; -. [Q13308-2] DR ProteomicsDB; 59295; -. [Q13308-3] DR ProteomicsDB; 59296; -. [Q13308-4] DR ProteomicsDB; 59297; -. [Q13308-5] DR Pumba; Q13308; -. DR TopDownProteomics; Q13308-3; -. [Q13308-3] DR ABCD; Q13308; 1 sequenced antibody. DR Antibodypedia; 1008; 616 antibodies from 38 providers. DR DNASU; 5754; -. DR Ensembl; ENST00000230418.8; ENSP00000230418.4; ENSG00000112655.17. [Q13308-5] DR Ensembl; ENST00000230419.9; ENSP00000230419.4; ENSG00000112655.17. [Q13308-1] DR Ensembl; ENST00000345201.6; ENSP00000325992.4; ENSG00000112655.17. [Q13308-2] DR Ensembl; ENST00000349241.6; ENSP00000325462.4; ENSG00000112655.17. [Q13308-3] DR Ensembl; ENST00000352931.6; ENSP00000326029.3; ENSG00000112655.17. [Q13308-4] DR Ensembl; ENST00000481273.5; ENSP00000418754.1; ENSG00000112655.17. [Q13308-6] DR GeneID; 5754; -. DR KEGG; hsa:5754; -. DR MANE-Select; ENST00000230419.9; ENSP00000230419.4; NM_002821.5; NP_002812.2. DR UCSC; uc003oub.3; human. [Q13308-1] DR AGR; HGNC:9618; -. DR ClinPGx; PA33961; -. DR CTD; 5754; -. DR DisGeNET; 5754; -. DR GeneCards; PTK7; -. DR HGNC; HGNC:9618; PTK7. DR HPA; ENSG00000112655; Low tissue specificity. DR MIM; 601890; gene. DR OpenTargets; ENSG00000112655; -. DR VEuPathDB; HostDB:ENSG00000112655; -. DR eggNOG; KOG1026; Eukaryota. DR eggNOG; KOG4475; Eukaryota. DR GeneTree; ENSGT00940000157908; -. DR HOGENOM; CLU_012268_0_0_1; -. DR InParanoid; Q13308; -. DR OMA; HKILTSC; -. DR OrthoDB; 2413561at2759; -. DR PAN-GO; Q13308; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q13308; -. DR PathwayCommons; Q13308; -. DR SignaLink; Q13308; -. DR SIGNOR; Q13308; -. DR Agora; ENSG00000112655; -. DR BioGRID-ORCS; 5754; 19 hits in 1197 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; PTK7; human. DR GeneWiki; PTK7; -. DR GenomeRNAi; 5754; -. DR Pharos; Q13308; Tbio. DR PRO; PR:Q13308; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q13308; protein. DR Bgee; ENSG00000112655; Expressed in stromal cell of endometrium and 127 other cell types or tissues. DR ExpressionAtlas; Q13308; baseline and differential. DR GO; GO:0030424; C:axon; IBA:GO_Central. DR GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005925; C:focal adhesion; HDA:UniProtKB. DR GO; GO:0043025; C:neuronal cell body; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:InterPro. DR GO; GO:0008046; F:axon guidance receptor activity; IBA:GO_Central. DR GO; GO:0015026; F:coreceptor activity; NAS:ParkinsonsUK-UCL. DR GO; GO:0004672; F:protein kinase activity; IEA:InterPro. DR GO; GO:0030036; P:actin cytoskeleton organization; IMP:UniProtKB. DR GO; GO:0003401; P:axis elongation; IEA:Ensembl. DR GO; GO:0016477; P:cell migration; IMP:UniProtKB. DR GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL. DR GO; GO:0090103; P:cochlea morphogenesis; IEA:Ensembl. DR GO; GO:0060026; P:convergent extension; IEA:Ensembl. DR GO; GO:0060976; P:coronary vasculature development; IEA:Ensembl. DR GO; GO:0045198; P:establishment of epithelial cell apical/basal polarity; IEA:Ensembl. DR GO; GO:0001736; P:establishment of planar polarity; IEA:Ensembl. DR GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; IBA:GO_Central. DR GO; GO:0001822; P:kidney development; IEA:Ensembl. DR GO; GO:0060484; P:lung-associated mesenchyme development; IEA:Ensembl. DR GO; GO:0001843; P:neural tube closure; IEA:Ensembl. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:UniProtKB. DR GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL. DR GO; GO:0060828; P:regulation of canonical Wnt signaling pathway; IBA:GO_Central. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0050808; P:synapse organization; IBA:GO_Central. DR GO; GO:0003281; P:ventricular septum development; IEA:Ensembl. DR GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW. DR GO; GO:0042060; P:wound healing; IEA:Ensembl. DR CDD; cd00096; Ig; 2. DR CDD; cd05760; Ig2_PTK7; 1. DR CDD; cd05046; PTK_CCK4; 1. DR FunFam; 1.10.510.10:FF:000200; inactive tyrosine-protein kinase 7; 1. DR FunFam; 2.60.40.10:FF:000341; inactive tyrosine-protein kinase 7; 1. DR FunFam; 2.60.40.10:FF:000343; inactive tyrosine-protein kinase 7; 1. DR FunFam; 2.60.40.10:FF:000377; Protein tyrosine kinase 7 (inactive); 1. DR FunFam; 2.60.40.10:FF:000390; Protein tyrosine kinase 7 (inactive); 1. DR FunFam; 2.60.40.10:FF:000395; Protein tyrosine kinase 7 (inactive); 1. DR FunFam; 2.60.40.10:FF:000402; Protein tyrosine kinase 7 (inactive); 1. DR FunFam; 2.60.40.10:FF:000432; Protein tyrosine kinase 7 (inactive); 1. DR FunFam; 3.30.200.20:FF:000167; Putative inactive tyrosine-protein kinase 7; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 7. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR050958; Cell_Adh-Cytoskel_Orgn. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR PANTHER; PTHR45080; CONTACTIN 5; 1. DR PANTHER; PTHR45080:SF21; INACTIVE TYROSINE-PROTEIN KINASE 7; 1. DR Pfam; PF07679; I-set; 2. DR Pfam; PF13927; Ig_3; 5. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 7. DR SMART; SM00408; IGc2; 7. DR SUPFAM; SSF48726; Immunoglobulin; 7. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 7. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cell adhesion; Cell junction; KW Disulfide bond; Glycoprotein; Immunoglobulin domain; Membrane; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Repeat; Signal; Transmembrane; Transmembrane helix; Wnt signaling pathway. FT SIGNAL 1..30 FT /evidence="ECO:0000255" FT CHAIN 31..1070 FT /note="Inactive tyrosine-protein kinase 7" FT /id="PRO_0000016748" FT TOPO_DOM 31..704 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 705..725 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 726..1070 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 31..120 FT /note="Ig-like C2-type 1" FT DOMAIN 128..218 FT /note="Ig-like C2-type 2" FT DOMAIN 225..317 FT /note="Ig-like C2-type 3" FT DOMAIN 309..407 FT /note="Ig-like C2-type 4" FT DOMAIN 412..497 FT /note="Ig-like C2-type 5" FT DOMAIN 503..586 FT /note="Ig-like C2-type 6" FT DOMAIN 578..680 FT /note="Ig-like C2-type 7" FT DOMAIN 796..1066 FT /note="Protein kinase; inactive" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 736..759 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 773..793 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 794..1070 FT /note="Interaction with CTNNB1" FT /evidence="ECO:0000269|PubMed:21132015" FT SITE 621..622 FT /note="Cleavage; by MMP14" FT MOD_RES 1064 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BKG3" FT CARBOHYD 116 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 175 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 184 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 214 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 268 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 283 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 405 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 463 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 567 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 646 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:12754519, FT ECO:0000269|PubMed:19159218" FT DISULFID 53..101 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 150..200 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 246..301 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 343..391 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 433..481 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 524..570 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 613..664 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 1..26 FT /note="MGAARGSPARPRRLPLLSVLLLPLLG -> MGSFLSGEKRPSAPTVGSAMEK FT KEFPTPPGRVGP (in isoform 6)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_044775" FT VAR_SEQ 410..540 FT /note="TVPSWLKKPQDSQLEEGKPGYLDCLTQATPKPTVVWYRNQMLISEDSRFEVF FT KNGTLRINSVEVYDGTWYRCMSSTPAGSIEAQARVQVLEKLKFTPPPQPQQCMEFDKEA FT TVPCSATGREKPTIKWERAD -> N (in isoform 3)" FT /evidence="ECO:0000303|PubMed:12427550" FT /id="VSP_037181" FT VAR_SEQ 500..539 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:12427550, FT ECO:0000303|PubMed:14702039" FT /id="VSP_037182" FT VAR_SEQ 627..682 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:12427550" FT /id="VSP_037183" FT VAR_SEQ 804..816 FT /note="KSEFGEVFLAKAQ -> RPQAVPEDFQEQG (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12427550" FT /id="VSP_037184" FT VAR_SEQ 817..1070 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12427550" FT /id="VSP_037185" FT VARIANT 276 FT /note="R -> H (in dbSNP:rs56188167)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041502" FT VARIANT 410 FT /note="T -> S (in dbSNP:rs34021075)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041503" FT VARIANT 745 FT /note="E -> D (in dbSNP:rs9472017)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041504" FT VARIANT 766 FT /note="E -> Q (in dbSNP:rs56216742)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041505" FT VARIANT 777 FT /note="A -> V (in dbSNP:rs34764696)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041506" FT VARIANT 783 FT /note="H -> R (in dbSNP:rs55820547)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041507" FT VARIANT 933 FT /note="A -> V (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041508" FT VARIANT 1029 FT /note="P -> T (in dbSNP:rs55755163)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041509" FT VARIANT 1038 FT /note="R -> Q (in dbSNP:rs34865794)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041510" FT MUTAGEN 622 FT /note="L->D: Prevents proteolysis by MMP14." FT /evidence="ECO:0000269|PubMed:20837484" FT MUTAGEN 641 FT /note="M->R: No impact on proteolysis by MMP14." FT /evidence="ECO:0000269|PubMed:20837484" FT MUTAGEN 701 FT /note="M->D: No impact on proteolysis by MMP14." FT /evidence="ECO:0000269|PubMed:20837484" FT CONFLICT 87 FT /note="F -> L (in Ref. 4; BAF85278)" FT /evidence="ECO:0000305" FT CONFLICT 92 FT /note="R -> P (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT CONFLICT 93 FT /note="L -> P (in Ref. 7; AAH71557)" FT /evidence="ECO:0000305" FT CONFLICT 147 FT /note="T -> K (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT CONFLICT 207 FT /note="G -> S (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT CONFLICT 495..496 FT /note="RV -> VL (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT CONFLICT 515 FT /note="E -> G (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT CONFLICT 755 FT /note="Q -> R (in Ref. 4; BAH12463)" FT /evidence="ECO:0000305" FT CONFLICT 799 FT /note="I -> F (in Ref. 4; BAF85278)" FT /evidence="ECO:0000305" FT CONFLICT 881 FT /note="G -> E (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT CONFLICT 969 FT /note="P -> A (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT CONFLICT 992 FT /note="F -> S (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT HELIX 793..795 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 796..804 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 806..816 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 823..832 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 837..852 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 861..865 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 867..876 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 879..882 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 883..890 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 904..923 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 933..935 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 936..938 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 944..946 FT /evidence="ECO:0007829|PDB:6VG3" FT TURN 952..956 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 957..959 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 961..963 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 966..968 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 970..972 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 975..980 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 985..1000 FT /evidence="ECO:0007829|PDB:6VG3" FT TURN 1006..1009 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 1012..1020 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 1034..1043 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 1048..1050 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 1054..1062 FT /evidence="ECO:0007829|PDB:6VG3" SQ SEQUENCE 1070 AA; 118392 MW; 304926A1774EB5F4 CRC64; MGAARGSPAR PRRLPLLSVL LLPLLGGTQT AIVFIKQPSS QDALQGRRAL LRCEVEAPGP VHVYWLLDGA PVQDTERRFA QGSSLSFAAV DRLQDSGTFQ CVARDDVTGE EARSANASFN IKWIEAGPVV LKHPASEAEI QPQTQVTLRC HIDGHPRPTY QWFRDGTPLS DGQSNHTVSS KERNLTLRPA GPEHSGLYSC CAHSAFGQAC SSQNFTLSIA DESFARVVLA PQDVVVARYE EAMFHCQFSA QPPPSLQWLF EDETPITNRS RPPHLRRATV FANGSLLLTQ VRPRNAGIYR CIGQGQRGPP IILEATLHLA EIEDMPLFEP RVFTAGSEER VTCLPPKGLP EPSVWWEHAG VRLPTHGRVY QKGHELVLAN IAESDAGVYT CHAANLAGQR RQDVNITVAT VPSWLKKPQD SQLEEGKPGY LDCLTQATPK PTVVWYRNQM LISEDSRFEV FKNGTLRINS VEVYDGTWYR CMSSTPAGSI EAQARVQVLE KLKFTPPPQP QQCMEFDKEA TVPCSATGRE KPTIKWERAD GSSLPEWVTD NAGTLHFARV TRDDAGNYTC IASNGPQGQI RAHVQLTVAV FITFKVEPER TTVYQGHTAL LQCEAQGDPK PLIQWKGKDR ILDPTKLGPR MHIFQNGSLV IHDVAPEDSG RYTCIAGNSC NIKHTEAPLY VVDKPVPEES EGPGSPPPYK MIQTIGLSVG AAVAYIIAVL GLMFYCKKRC KAKRLQKQPE GEEPEMECLN GGPLQNGQPS AEIQEEVALT SLGSGPAATN KRHSTSDKMH FPRSSLQPIT TLGKSEFGEV FLAKAQGLEE GVAETLVLVK SLQSKDEQQQ LDFRRELEMF GKLNHANVVR LLGLCREAEP HYMVLEYVDL GDLKQFLRIS KSKDEKLKSQ PLSTKQKVAL CTQVALGMEH LSNNRFVHKD LAARNCLVSA QRQVKVSALG LSKDVYNSEY YHFRQAWVPL RWMSPEAILE GDFSTKSDVW AFGVLMWEVF THGEMPHGGQ ADDEVLADLQ AGKARLPQPE GCPSKLYRLM QRCWALSPKD RPSFSEIASA LGDSTVDSKP // ID RASH_HUMAN Reviewed; 189 AA. AC P01112; B5BUA0; Q14080; Q6FHV9; Q9BR65; Q9UCE2; DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot. DT 21-JUL-1986, sequence version 1. DT 28-JAN-2026, entry version 279. DE RecName: Full=GTPase HRas; DE EC=3.6.5.2 {ECO:0000269|PubMed:9020151}; DE AltName: Full=H-Ras-1; DE AltName: Full=Ha-Ras; DE AltName: Full=Transforming protein p21; DE AltName: Full=c-H-ras; DE AltName: Full=p21ras; DE Contains: DE RecName: Full=GTPase HRas, N-terminally processed; DE Flags: Precursor; GN Name=HRAS; Synonyms=HRAS1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND INVOLVEMENT IN BLADDER CANCER. RX PubMed=6298635; DOI=10.1038/302033a0; RA Capon D.J., Chen E.Y., Levinson A.D., Seeburg P.H., Goeddel D.V.; RT "Complete nucleotide sequences of the T24 human bladder carcinoma oncogene RT and its normal homologue."; RL Nature 302:33-37(1983). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND INVOLVEMENT IN BLADDER CANCER. RX PubMed=6844927; DOI=10.1126/science.6844927; RA Reddy E.P.; RT "Nucleotide sequence analysis of the T24 human bladder carcinoma RT oncogene."; RL Science 220:1061-1063(1983). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=6087347; DOI=10.1073/pnas.81.15.4771; RA Sekiya T., Fushimi M., Hori H., Hirohashi S., Nishimura S., Sugimura T.; RT "Molecular cloning and the total nucleotide sequence of the human c-Ha-ras- RT 1 gene activated in a melanoma from a Japanese patient."; RL Proc. Natl. Acad. Sci. U.S.A. 81:4771-4775(1984). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, INTERACTION WITH RACK1, RP SUBCELLULAR LOCATION, ALTERNATIVE SPLICING, TISSUE SPECIFICITY, AND RP MUTAGENESIS OF SER-17. RX PubMed=14500341; RA Guil S., de La Iglesia N., Fernandez-Larrea J., Cifuentes D., Ferrer J.C., RA Guinovart J.J., Bach-Elias M.; RT "Alternative splicing of the human proto-oncogene c-H-ras renders a new Ras RT family protein that trafficks to cytoplasm and nucleus."; RL Cancer Res. 63:5178-5187(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RA Puhl H.L. III, Ikeda S.R., Aronstam R.S.; RT "cDNA clones of human proteins involved in signal transduction sequenced by RT the Guthrie cDNA resource center (www.cdna.org)."; RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P., RA Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y., RA LaBaer J.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (SEP-2006) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=19054851; DOI=10.1038/nmeth.1273; RA Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R., RA Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y., RA Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B., RA Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y., RA Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A., RA Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y., RA Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T., RA Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y., RA Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S., RA Nomura N.; RT "Human protein factory for converting the transcriptome into an in vitro- RT expressed proteome."; RL Nat. Methods 5:1011-1017(2008). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Lung carcinoma; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [12] RP PROTEIN SEQUENCE OF 1-41; 43-117; 129-161 AND 170-185, CLEAVAGE OF RP INITIATOR METHIONINE, ACETYLATION AT MET-1 AND THR-2, AND IDENTIFICATION BY RP MASS SPECTROMETRY. RC TISSUE=Cervix carcinoma; RA Bienvenut W.V., Calvo F., Kolch W.; RL Submitted (FEB-2008) to UniProtKB. RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37. RX PubMed=6290897; DOI=10.1038/300143a0; RA Tabin C.J., Bradley S.M., Bargmann C.I., Weinberg R.A., Papageorge A.G., RA Scolnick E.M., Dhar R., Lowy D.R., Chang E.H.; RT "Mechanism of activation of a human oncogene."; RL Nature 300:143-149(1982). RN [14] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16. RX PubMed=3670300; DOI=10.1128/mcb.7.8.2933-2940.1987; RA Honkawa H., Masahashi W., Hashimoto S., Hashimoto-Gotoh T.; RT "Identification of the principal promoter sequence of the c-H-ras RT transforming oncogene: deletion analysis of the 5'-flanking region by focus RT formation assay."; RL Mol. Cell. Biol. 7:2933-2940(1987). RN [15] RP PROTEIN SEQUENCE OF 108-117 AND 132-153. RX PubMed=8393791; DOI=10.1111/j.1432-1033.1993.tb18056.x; RA Loew A., Sprinzl M., Faulhammer H.G.; RT "Affinity labeling of c-H-ras p21 consensus elements with periodate- RT oxidized GDP and GTP."; RL Eur. J. Biochem. 215:473-479(1993). RN [16] RP MUTAGENESIS OF ALA-83; ASP-119 AND THR-144. RX PubMed=3088563; DOI=10.1073/pnas.83.13.4607; RA Feig L.A., Pan B.-T., Roberts T.M., Cooper G.M.; RT "Isolation of ras GTP-binding mutants using an in situ colony-binding RT assay."; RL Proc. Natl. Acad. Sci. U.S.A. 83:4607-4611(1986). RN [17] RP MUTAGENESIS OF 164-ARG-GLN-165. RX PubMed=3011420; DOI=10.1002/j.1460-2075.1986.tb04267.x; RA Lacal J.C., Anderson P.S., Aaronson S.A.; RT "Deletion mutants of Harvey ras p21 protein reveal the absolute requirement RT of at least two distant regions for GTP-binding and transforming RT activities."; RL EMBO J. 5:679-687(1986). RN [18] RP PALMITOYLATION AT CYS-181 AND CYS-184. RX PubMed=2661017; DOI=10.1016/0092-8674(89)90054-8; RA Hancock J.F., Magee A.I., Childs J.E., Marshall C.J.; RT "All ras proteins are polyisoprenylated but only some are palmitoylated."; RL Cell 57:1167-1177(1989). RN [19] RP GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION). RX PubMed=8626586; DOI=10.1074/jbc.271.17.10217; RA Popoff M.R., Chaves-Olarte E., Lemichez E., von Eichel-Streiber C., RA Thelestam M., Chardin P., Cussac D., Antonny B., Chavrier P., Flatau G., RA Giry M., de Gunzburg J., Boquet P.; RT "Ras, Rap, and Rac small GTP-binding proteins are targets for Clostridium RT sordellii lethal toxin glucosylation."; RL J. Biol. Chem. 271:10217-10224(1996). RN [20] RP GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION). RX PubMed=8626575; DOI=10.1074/jbc.271.17.10149; RA Just I., Selzer J., Hofmann F., Green G.A., Aktories K.; RT "Inactivation of Ras by Clostridium sordellii lethal toxin-catalyzed RT glucosylation."; RL J. Biol. Chem. 271:10149-10153(1996). RN [21] RP PALMITOYLATION AT CYS-181 AND CYS-184, ISOPRENYLATION AT CYS-186, RP METHYLATION AT CYS-186, AND MUTAGENESIS OF CYS-181 AND CYS-184. RX PubMed=8626715; DOI=10.1074/jbc.271.19.11541; RA Dudler T., Gelb M.H.; RT "Palmitoylation of Ha-Ras facilitates membrane binding, activation of RT downstream effectors, and meiotic maturation in Xenopus oocytes."; RL J. Biol. Chem. 271:11541-11547(1996). RN [22] RP S-NITROSYLATION AT CYS-118, FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS RP OF CYS-118. RX PubMed=9020151; DOI=10.1074/jbc.272.7.4323; RA Lander H.M., Hajjar D.P., Hempstead B.L., Mirza U.A., Chait B.T., RA Campbell S., Quilliam L.A.; RT "A molecular redox switch on p21(ras). Structural basis for the nitric RT oxide-p21(ras) interaction."; RL J. Biol. Chem. 272:4323-4326(1997). RN [23] RP GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION). RX PubMed=9632667; DOI=10.1074/jbc.273.26.16134; RA Herrmann C., Ahmadian M.R., Hofmann F., Just I.; RT "Functional consequences of monoglucosylation of Ha-Ras at effector domain RT amino acid threonine 35."; RL J. Biol. Chem. 273:16134-16139(1998). RN [24] RP INTERACTION WITH IKZF3. RX PubMed=10369681; DOI=10.1093/emboj/18.12.3419; RA Romero F., Martinez-A C., Camonis J., Rebollo A.; RT "Aiolos transcription factor controls cell death in T cells by regulating RT Bcl-2 expression and its cellular localization."; RL EMBO J. 18:3419-3430(1999). RN [25] RP INTERACTION WITH RAPGEF2. RX PubMed=10608844; DOI=10.1074/jbc.274.53.37815; RA Liao Y., Kariya K., Hu C.-D., Shibatohge M., Goshima M., Okada T., RA Watari Y., Gao X., Jin T.-G., Yamawaki-Kataoka Y., Kataoka T.; RT "RA-GEF, a novel Rap1A guanine nucleotide exchange factor containing a RT Ras/Rap1A-associating domain, is conserved between nematode and humans."; RL J. Biol. Chem. 274:37815-37820(1999). RN [26] RP INTERACTION WITH PLCE1, CHARACTERIZATION OF VARIANT VAL-12, AND MUTAGENESIS RP OF SER-17; ASN-26; VAL-29; TYR-32; PRO-34; THR-35; GLU-37; ASP-38 AND RP SER-39. RX PubMed=11022048; DOI=10.1074/jbc.m008324200; RA Song C., Hu C.-D., Masago M., Kariya K., Yamawaki-Kataoka Y., RA Shibatohge M., Wu D., Satoh T., Kataoka T.; RT "Regulation of a novel human phospholipase C, PLCepsilon, through membrane RT targeting by Ras."; RL J. Biol. Chem. 276:2752-2757(2001). RN [27] RP INTERACTION WITH RAPGEF2. RX PubMed=11598133; DOI=10.1074/jbc.m108373200; RA Pham N., Rotin D.; RT "Nedd4 regulates ubiquitination and stability of the guanine-nucleotide RT exchange factor CNrasGEF."; RL J. Biol. Chem. 276:46995-47003(2001). RN [28] RP IDENTIFICATION IN A COMPLEX WITH RASGRP1 AND DGKZ. RX PubMed=11257115; DOI=10.1083/jcb.152.6.1135; RA Topham M.K., Prescott S.M.; RT "Diacylglycerol kinase zeta regulates Ras activation by a novel RT mechanism."; RL J. Cell Biol. 152:1135-1143(2001). RN [29] RP INTERACTION WITH PDE6D. RX PubMed=11980706; DOI=10.1093/emboj/21.9.2095; RA Hanzal-Bayer M., Renault L., Roversi P., Wittinghofer A., Hillig R.C.; RT "The complex of Arl2-GTP and PDE delta: from structure to function."; RL EMBO J. 21:2095-2106(2002). RN [30] RP LIPIDATION AT CYS-184, AND MUTAGENESIS OF CYS-184. RX PubMed=12684535; DOI=10.1073/pnas.0735842100; RA Oliva J.L., Perez-Sala D., Castrillo A., Martinez N., Canada F.J., RA Bosca L., Rojas J.M.; RT "The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J2 binds to and RT activates H-Ras."; RL Proc. Natl. Acad. Sci. U.S.A. 100:4772-4777(2003). RN [31] RP FUNCTION, VARIANT CYS-89, AND CHARACTERIZATION OF VARIANT CYS-89. RX PubMed=22821884; DOI=10.1002/ajmg.a.35449; RA Gripp K.W., Bifeld E., Stabley D.L., Hopkins E., Meien S., Vinette K., RA Sol-Church K., Rosenberger G.; RT "A novel HRAS substitution (c.266C>G; p.S89C) resulting in decreased RT downstream signaling suggests a new dimension of RAS pathway dysregulation RT in human development."; RL Am. J. Med. Genet. A 158A:2106-2118(2012). RN [32] RP CHARACTERIZATION OF CSTLO VARIANT VAL-12. RX PubMed=15546861; DOI=10.1074/jbc.m410775200; RA Liu F., Iqbal K., Grundke-Iqbal I., Rossie S., Gong C.X.; RT "Dephosphorylation of tau by protein phosphatase 5: impairment in RT Alzheimer's disease."; RL J. Biol. Chem. 280:1790-1796(2005). RN [33] RP PALMITOYLATION AT CYS-181 AND CYS-184. RX PubMed=16000296; DOI=10.1074/jbc.m504113200; RA Swarthout J.T., Lobo S., Farh L., Croke M.R., Greentree W.K., RA Deschenes R.J., Linder M.E.; RT "DHHC9 and GCP16 constitute a human protein fatty acyltransferase with RT specificity for H- and N-Ras."; RL J. Biol. Chem. 280:31141-31148(2005). RN [34] RP PALMITOYLATION AT CYS-181 AND CYS-184, MUTAGENESIS OF CYS-181 AND CYS-184, RP AND SUBCELLULAR LOCATION. RX PubMed=15705808; DOI=10.1126/science.1105654; RA Rocks O., Peyker A., Kahms M., Verveer P.J., Koerner C., Lumbierres M., RA Kuhlmann J., Waldmann H., Wittinghofer A., Bastiaens P.I.H.; RT "An acylation cycle regulates localization and activity of palmitoylated RT Ras isoforms."; RL Science 307:1746-1752(2005). RN [35] RP INTERACTION WITH TBC1D10C. RX PubMed=17230191; DOI=10.1038/nature05476; RA Pan F., Sun L., Kardian D.B., Whartenby K.A., Pardoll D.M., Liu J.O.; RT "Feedback inhibition of calcineurin and Ras by a dual inhibitory protein RT Carabin."; RL Nature 445:433-436(2007). RN [36] RP GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION). RX PubMed=19744486; DOI=10.1016/j.febslet.2009.09.006; RA Huelsenbeck S.C., Klose I., Reichenbach M., Huelsenbeck J., Genth H.; RT "Distinct kinetics of (H/K/N)Ras glucosylation and Rac1 glucosylation RT catalysed by Clostridium sordellii lethal toxin."; RL FEBS Lett. 583:3133-3139(2009). RN [37] RP ACYLATION, AND MUTAGENESIS OF 167-LYS--LYS-185. RX PubMed=29239724; DOI=10.7554/elife.32436; RA Jing H., Zhang X., Wisner S.A., Chen X., Spiegelman N.A., Linder M.E., RA Lin H.; RT "SIRT2 and lysine fatty acylation regulate the transforming activity of K- RT Ras4a."; RL Elife 6:0-0(2017). RN [38] RP UBIQUITINATION AT LYS-170, AND MUTAGENESIS OF LYS-170. RX PubMed=30442762; DOI=10.1126/science.aap7607; RA Steklov M., Pandolfi S., Baietti M.F., Batiuk A., Carai P., Najm P., RA Zhang M., Jang H., Renzi F., Cai Y., Abbasi Asbagh L., Pastor T., RA De Troyer M., Simicek M., Radaelli E., Brems H., Legius E., Tavernier J., RA Gevaert K., Impens F., Messiaen L., Nussinov R., Heymans S., Eyckerman S., RA Sablina A.A.; RT "Mutations in LZTR1 drive human disease by dysregulating RAS RT ubiquitination."; RL Science 362:1177-1182(2018). RN [39] RP INTERACTION WITH PPP1CA; PPP1CB AND SHOC2. RX PubMed=36175670; DOI=10.1038/s41594-022-00841-4; RA Bonsor D.A., Alexander P., Snead K., Hartig N., Drew M., Messing S., RA Finci L.I., Nissley D.V., McCormick F., Esposito D., Rodriguez-Viciana P., RA Stephen A.G., Simanshu D.K.; RT "Structure of the SHOC2-MRAS-PP1c complex provides insights into RAF RT activation and Noonan syndrome."; RL Nat. Struct. Mol. Biol. 29:966-977(2022). RN [40] RP INTERACTION WITH PPP1CA; PPP1CB; PPP1CC AND SHOC2. RX PubMed=35768504; DOI=10.1038/s41586-022-04838-3; RA Liau N.P.D., Johnson M.C., Izadi S., Gerosa L., Hammel M., Bruning J.M., RA Wendorff T.J., Phung W., Hymowitz S.G., Sudhamsu J.; RT "Structural basis for SHOC2 modulation of RAS signalling."; RL Nature 609:400-407(2022). RN [41] RP INTERACTION WITH PPP1CA; PPP1CB; PPP1CC AND SHOC2, AND MUTAGENESIS OF RP GLN-61. RX PubMed=35831509; DOI=10.1038/s41586-022-04928-2; RA Kwon J.J., Hajian B., Bian Y., Young L.C., Amor A.J., Fuller J.R., RA Fraley C.V., Sykes A.M., So J., Pan J., Baker L., Lee S.J., Wheeler D.B., RA Mayhew D.L., Persky N.S., Yang X., Root D.E., Barsotti A.M., Stamford A.W., RA Perry C.K., Burgin A., McCormick F., Lemke C.T., Hahn W.C., Aguirre A.J.; RT "Structure-function analysis of the SHOC2-MRAS-PP1c holophosphatase RT complex."; RL Nature 609:408-415(2022). RN [42] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS). RX PubMed=2448879; DOI=10.1126/science.2448879; RA de Vos A.M., Tong L., Milburn M.V., Matias P.M., Jancarik J., Noguchi S., RA Nishimura S., Miura K., Ohtsuka E., Kim S.-H.; RT "Three-dimensional structure of an oncogene protein: catalytic domain of RT human c-H-ras p21."; RL Science 239:888-893(1988). RN [43] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS). RX PubMed=2476675; DOI=10.1038/341209a0; RA Pai E.F., Kabsch W., Krengel U., Holmes K.C., John J., Wittinghofer A.; RT "Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene RT product p21 in the triphosphate conformation."; RL Nature 341:209-214(1989). RN [44] {ECO:0007744|PDB:5P21} RP X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS). RX PubMed=2196171; DOI=10.1002/j.1460-2075.1990.tb07409.x; RA Pai E.F., Krengel U., Petsko G.A., Goody R.S., Kabsch W., Wittinghofer A.; RT "Refined crystal structure of the triphosphate conformation of H-ras p21 at RT 1.35-A resolution: implications for the mechanism of GTP hydrolysis."; RL EMBO J. 9:2351-2359(1990). RN [45] {ECO:0007744|PDB:1Q21, ECO:0007744|PDB:2Q21} RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS). RX PubMed=1899707; DOI=10.1016/0022-2836(91)90753-s; RA Tong L.A., de Vos A.M., Milburn M.V., Kim S.H.; RT "Crystal structures at 2.2-A resolution of the catalytic domains of normal RT ras protein and an oncogenic mutant complexed with GDP."; RL J. Mol. Biol. 217:503-516(1991). RN [46] {ECO:0007744|PDB:121P} RP STRUCTURE BY NMR OF 1-166. RX PubMed=8142349; DOI=10.1021/bi00178a008; RA Kraulis P.J., Domaille P.J., Campbell-Burk S.L., van Aken T., Laue E.D.; RT "Solution structure and dynamics of ras p21.GDP determined by heteronuclear RT three- and four-dimensional NMR spectroscopy."; RL Biochemistry 33:3515-3531(1994). RN [47] {ECO:0007744|PDB:1WQ1} RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-166 IN COMPLEX WITH RP RASA1/RASGAP. RX PubMed=9219684; DOI=10.1126/science.277.5324.333; RA Scheffzek K., Ahmadian M.R., Kabsch W., Wiesmuller L., Lautwein A., RA Schmitz F., Wittinghofer A.; RT "The Ras-RasGAP complex: structural basis for GTPase activation and its RT loss in oncogenic Ras mutants."; RL Science 277:333-338(1997). RN [48] {ECO:0007744|PDB:1CTQ, ECO:0007744|PDB:1QRA} RP X-RAY CRYSTALLOGRAPHY (1.26 ANGSTROMS). RX PubMed=10574788; DOI=10.1016/s0969-2126(00)80021-0; RA Scheidig A.J., Burmester C., Goody R.S.; RT "The pre-hydrolysis state of p21(ras) in complex with GTP: new insights RT into the role of water molecules in the GTP hydrolysis reaction of ras-like RT proteins."; RL Structure 7:1311-1324(1999). RN [49] {ECO:0007744|PDB:1LF0, ECO:0007744|PDB:1LF5} RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 1-166 IN COMPLEXES WITH GTP RP ANALOGS. RX PubMed=12213964; DOI=10.1073/pnas.192453199; RA Hall B.E., Bar-Sagi D., Nassar N.; RT "The structural basis for the transition from Ras-GTP to Ras-GDP."; RL Proc. Natl. Acad. Sci. U.S.A. 99:12138-12142(2002). RN [50] RP STRUCTURE BY NMR OF 1-166, S-NITROSYLATION, FUNCTION, MUTAGENESIS OF RP CYS-118, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=12740440; DOI=10.1073/pnas.1037299100; RA Williams J.G., Pappu K., Campbell S.L.; RT "Structural and biochemical studies of p21Ras S-nitrosylation and nitric RT oxide-mediated guanine nucleotide exchange."; RL Proc. Natl. Acad. Sci. U.S.A. 100:6376-6381(2003). RN [51] {ECO:0007744|PDB:2CE2, ECO:0007744|PDB:2CL0, ECO:0007744|PDB:2CL6, ECO:0007744|PDB:2CL7, ECO:0007744|PDB:2CLC, ECO:0007744|PDB:2CLD, ECO:0007744|PDB:2EVW} RP X-RAY CRYSTALLOGRAPHY (1.00 ANGSTROMS) OF 1-166 IN COMPLEX WITH GTP AND RP MAGNESIUM. RX PubMed=16698776; DOI=10.1529/biophysj.105.078931; RA Klink B.U., Goody R.S., Scheidig A.J.; RT "A newly designed microspectrofluorometer for kinetic studies on protein RT crystals in combination with x-ray diffraction."; RL Biophys. J. 91:981-992(2006). RN [52] {ECO:0007744|PDB:2RGA, ECO:0007744|PDB:2RGB, ECO:0007744|PDB:2RGC, ECO:0007744|PDB:2RGD, ECO:0007744|PDB:2RGE, ECO:0007744|PDB:2RGG} RP X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 1-166 IN COMPLEXES WITH GTP RP ANALOG, CHARACTERIZATION OF VARIANTS LEU-61 AND LYS-61, AND MUTAGENESIS OF RP GLN-61. RX PubMed=18073111; DOI=10.1016/j.str.2007.10.011; RA Buhrman G., Wink G., Mattos C.; RT "Transformation efficiency of RasQ61 mutants linked to structural features RT of the switch regions in the presence of Raf."; RL Structure 15:1618-1629(2007). RN [53] {ECO:0007744|PDB:3DDC} RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1-166 IN COMPLEX WITH RASSF5. RX PubMed=18596699; DOI=10.1038/emboj.2008.125; RA Stieglitz B., Bee C., Schwarz D., Yildiz O., Moshnikova A., RA Khokhlatchev A., Herrmann C.; RT "Novel type of Ras effector interaction established between tumour RT suppressor NORE1A and Ras switch II."; RL EMBO J. 27:1995-2005(2008). RN [54] {ECO:0007744|PDB:7VV8, ECO:0007744|PDB:7VV9, ECO:0007744|PDB:7VVG} RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 1-166 IN COMPLEX WITH MAPKAP1, RP AND INTERACTION WITH MAPKAP1. RX PubMed=35522713; DOI=10.1073/pnas.2119990119; RA Zheng Y., Ding L., Meng X., Potter M., Kearney A.L., Zhang J., Sun J., RA James D.E., Yang G., Zhou C.; RT "Structural insights into Ras regulation by SIN1."; RL Proc. Natl. Acad. Sci. U.S.A. 119:e2119990119-e2119990119(2022). RN [55] RP VARIANT SER-12. RX PubMed=1459726; DOI=10.1002/ijc.2910520606; RA Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S., RA Yamamoto H., Tsuchida N.; RT "The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous- RT cell carcinoma."; RL Int. J. Cancer 52:867-872(1992). RN [56] RP INVOLVEMENT IN NMTC2, AND VARIANT NMTC2 LYS-61. RX PubMed=12727991; DOI=10.1210/jc.2002-021907; RA Nikiforova M.N., Lynch R.A., Biddinger P.W., Alexander E.K., Dorn G.W. II, RA Tallini G., Kroll T.G., Nikiforov Y.E.; RT "RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: RT evidence for distinct molecular pathways in thyroid follicular carcinoma."; RL J. Clin. Endocrinol. Metab. 88:2318-2326(2003). RN [57] RP VARIANTS CSTLO ALA-12; SER-12; VAL-12 AND ASP-13. RX PubMed=16170316; DOI=10.1038/ng1641; RA Aoki Y., Niihori T., Kawame H., Kurosawa K., Ohashi H., Tanaka Y., RA Filocamo M., Kato K., Suzuki Y., Kure S., Matsubara Y.; RT "Germline mutations in HRAS proto-oncogene cause Costello syndrome."; RL Nat. Genet. 37:1038-1040(2005). RN [58] RP VARIANTS CSTLO ALA-12; SER-12 AND CYS-13. RX PubMed=16329078; DOI=10.1002/ajmg.a.31047; RA Gripp K.W., Lin A.E., Stabley D.L., Nicholson L., Scott C.I. Jr., Doyle D., RA Aoki Y., Matsubara Y., Zackai E.H., Lapunzina P., Gonzalez-Meneses A., RA Holbrook J., Agresta C.A., Gonzalez I.L., Sol-Church K.; RT "HRAS mutation analysis in Costello syndrome: genotype and phenotype RT correlation."; RL Am. J. Med. Genet. A 140:1-7(2006). RN [59] RP VARIANTS CSTLO SER-12; CYS-12; GLU-12; ALA-12 AND ARG-117. RX PubMed=16443854; DOI=10.1136/jmg.2005.040352; RA Kerr B., Delrue M.-A., Sigaudy S., Perveen R., Marche M., Burgelin I., RA Stef M., Tang B., Eden O.B., O'Sullivan J., De Sandre-Giovannoli A., RA Reardon W., Brewer C., Bennett C., Quarell O., M'Cann E., Donnai D., RA Stewart F., Hennekam R., Cave H., Verloes A., Philip N., Lacombe D., RA Levy N., Arveiler B., Black G.; RT "Genotype-phenotype correlation in Costello syndrome: HRAS mutation RT analysis in 43 cases."; RL J. Med. Genet. 43:401-405(2006). RN [60] RP VARIANTS CSTLO SER-12 AND THR-146. RX PubMed=17054105; DOI=10.1002/humu.20431; RA Zampino G., Pantaleoni F., Carta C., Cobellis G., Vasta I., Neri C., RA Pogna E.A., De Feo E., Delogu A., Sarkozy A., Atzeri F., Selicorni A., RA Rauen K.A., Cytrynbaum C.S., Weksberg R., Dallapiccola B., Ballabio A., RA Gelb B.D., Neri G., Tartaglia M.; RT "Diversity, parental germline origin, and phenotypic spectrum of de novo RT HRAS missense changes in Costello syndrome."; RL Hum. Mutat. 28:265-272(2007). RN [61] RP VARIANTS CMEMS VAL-12; SER-12; LYS-22 AND LYS-63. RX PubMed=17412879; DOI=10.1136/jmg.2007.049270; RA van der Burgt I., Kupsky W., Stassou S., Nadroo A., Barroso C., Diem A., RA Kratz C.P., Dvorsky R., Ahmadian M.R., Zenker M.; RT "Myopathy caused by HRAS germline mutations: implications for disturbed RT myogenic differentiation in the presence of constitutive HRas activation."; RL J. Med. Genet. 44:459-462(2007). RN [62] RP VARIANTS CSTLO ILE-58 AND VAL-146. RX PubMed=18247425; DOI=10.1002/ajmg.a.32227; RA Gripp K.W., Innes A.M., Axelrad M.E., Gillan T.L., Parboosingh J.S., RA Davies C., Leonard N.J., Lapointe M., Doyle D., Catalano S., Nicholson L., RA Stabley D.L., Sol-Church K.; RT "Costello syndrome associated with novel germline HRAS mutations: an RT attenuated phenotype?"; RL Am. J. Med. Genet. A 146:683-690(2008). RN [63] RP VARIANTS CSTLO ASP-12 AND CYS-12. RX PubMed=18039947; DOI=10.1136/jmg.2007.054411; RA Lo I.F., Brewer C., Shannon N., Shorto J., Tang B., Black G., Soo M.T., RA Ng D.K., Lam S.T., Kerr B.; RT "Severe neonatal manifestations of Costello syndrome."; RL J. Med. Genet. 45:167-171(2008). RN [64] RP VARIANT CSTLO GLU-37 INS. RX PubMed=19995790; DOI=10.1093/hmg/ddp548; RA Gremer L., De Luca A., Merbitz-Zahradnik T., Dallapiccola B., Morlot S., RA Tartaglia M., Kutsche K., Ahmadian M.R., Rosenberger G.; RT "Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP RT binding and underlies Costello syndrome by promoting enhanced growth RT factor-dependent MAPK and AKT activation."; RL Hum. Mol. Genet. 19:790-802(2010). RN [65] RP VARIANT SFM ARG-13, AND CHARACTERIZATION OF VARIANT SFM ARG-13. RX PubMed=22683711; DOI=10.1038/ng.2316; RA Groesser L., Herschberger E., Ruetten A., Ruivenkamp C., Lopriore E., RA Zutt M., Langmann T., Singer S., Klingseisen L., Schneider-Brachert W., RA Toll A., Real F.X., Landthaler M., Hafner C.; RT "Postzygotic HRAS and KRAS mutations cause nevus sebaceous and RT Schimmelpenning syndrome."; RL Nat. Genet. 44:783-787(2012). CC -!- FUNCTION: Involved in the activation of Ras protein signal transduction CC (PubMed:22821884). Ras proteins bind GDP/GTP and possess intrinsic CC GTPase activity (PubMed:12740440, PubMed:14500341, PubMed:9020151). CC {ECO:0000269|PubMed:12740440, ECO:0000269|PubMed:14500341, CC ECO:0000269|PubMed:22821884, ECO:0000269|PubMed:9020151}. CC -!- CATALYTIC ACTIVITY: CC Reaction=GTP + H2O = GDP + phosphate + H(+); Xref=Rhea:RHEA:19669, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:37565, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:58189; EC=3.6.5.2; CC Evidence={ECO:0000269|PubMed:9020151}; CC -!- ACTIVITY REGULATION: Alternates between an inactive form bound to GDP CC and an active form bound to GTP. Activated by a guanine nucleotide- CC exchange factor (GEF) and inactivated by a GTPase-activating protein CC (GAP). CC -!- SUBUNIT: In its GTP-bound form interacts with PLCE1 (PubMed:11022048). CC Interacts with TBC1D10C (PubMed:17230191). Interacts with RGL3 (By CC similarity). Interacts with HSPD1 (By similarity). Found in a complex CC with at least BRAF, HRAS, MAP2K1, MAPK3 and RGS14 (By similarity). CC Interacts (active GTP-bound form) with RGS14 (via RBD 1 domain) (By CC similarity). Forms a signaling complex with RASGRP1 and DGKZ CC (PubMed:11257115). Interacts with RASSF5 (PubMed:18596699). Interacts CC with PDE6D (PubMed:11980706). Interacts with IKZF3 (PubMed:10369681). CC Interacts with RACK1 (PubMed:14500341). Interacts with PIK3CG; the CC interaction is required for membrane recruitment and beta-gamma G CC protein dimer-dependent activation of the PI3K gamma complex CC PIK3CG:PIK3R6 (By similarity). Interacts with RAPGEF2 (PubMed:10608844, CC PubMed:11598133). Interacts (active GTP-bound form) with both SHOC2 and CC PP1c (all isoforms) to form a tertiary complex; SHOC2 and PP1c CC preferably bind M-Ras/MRAS, but they also bind K-Ras/KRAS, N-Ras/NRAS CC and H-Ras/HRAS (PubMed:35768504, PubMed:35831509, PubMed:36175670). CC Interacts (GTP-bound form) with MAPKAP1/SIN1; inhibiting H-Ras/HRAS CC activity (PubMed:35522713). {ECO:0000250|UniProtKB:P20171, CC ECO:0000250|UniProtKB:Q61411, ECO:0000269|PubMed:10369681, CC ECO:0000269|PubMed:10608844, ECO:0000269|PubMed:11022048, CC ECO:0000269|PubMed:11257115, ECO:0000269|PubMed:11598133, CC ECO:0000269|PubMed:11980706, ECO:0000269|PubMed:14500341, CC ECO:0000269|PubMed:17230191, ECO:0000269|PubMed:18596699, CC ECO:0000269|PubMed:35522713, ECO:0000269|PubMed:35768504, CC ECO:0000269|PubMed:35831509, ECO:0000269|PubMed:36175670}. CC -!- INTERACTION: CC P01112; Q99996-3: AKAP9; NbExp=3; IntAct=EBI-350145, EBI-11022349; CC P01112; P53677-2: AP3M2; NbExp=3; IntAct=EBI-350145, EBI-12177015; CC P01112; P10398: ARAF; NbExp=7; IntAct=EBI-350145, EBI-365961; CC P01112; Q9NXL2-1: ARHGEF38; NbExp=3; IntAct=EBI-350145, EBI-18172597; CC P01112; Q9UII2: ATP5IF1; NbExp=3; IntAct=EBI-350145, EBI-718459; CC P01112; Q9H7T9: AUNIP; NbExp=3; IntAct=EBI-350145, EBI-10693257; CC P01112; Q00994: BEX3; NbExp=3; IntAct=EBI-350145, EBI-741753; CC P01112; Q9H2G9: BLZF1; NbExp=4; IntAct=EBI-350145, EBI-2548012; CC P01112; P15056: BRAF; NbExp=9; IntAct=EBI-350145, EBI-365980; CC P01112; Q7Z569: BRAP; NbExp=3; IntAct=EBI-350145, EBI-349900; CC P01112; Q5PSV4: BRMS1L; NbExp=3; IntAct=EBI-350145, EBI-5666615; CC P01112; Q9ULD4-2: BRPF3; NbExp=3; IntAct=EBI-350145, EBI-23662416; CC P01112; Q96LL4: C8orf48; NbExp=3; IntAct=EBI-350145, EBI-751596; CC P01112; Q03135: CAV1; NbExp=2; IntAct=EBI-350145, EBI-603614; CC P01112; Q96HB5: CCDC120; NbExp=3; IntAct=EBI-350145, EBI-744556; CC P01112; Q49A88-3: CCDC14; NbExp=3; IntAct=EBI-350145, EBI-12105646; CC P01112; Q96GN5-2: CDCA7L; NbExp=3; IntAct=EBI-350145, EBI-9091443; CC P01112; P24941: CDK2; NbExp=3; IntAct=EBI-350145, EBI-375096; CC P01112; O95674: CDS2; NbExp=3; IntAct=EBI-350145, EBI-3913685; CC P01112; Q9H3R5: CENPH; NbExp=3; IntAct=EBI-350145, EBI-1003700; CC P01112; Q9Y4F5-3: CEP170B; NbExp=3; IntAct=EBI-350145, EBI-12950757; CC P01112; Q86XR8: CEP57; NbExp=3; IntAct=EBI-350145, EBI-308614; CC P01112; Q494V2-2: CFAP100; NbExp=3; IntAct=EBI-350145, EBI-11953200; CC P01112; Q8WUX9: CHMP7; NbExp=4; IntAct=EBI-350145, EBI-749253; CC P01112; Q14117: DPYS; NbExp=3; IntAct=EBI-350145, EBI-12275416; CC P01112; Q9Y6W6: DUSP10; NbExp=3; IntAct=EBI-350145, EBI-3443946; CC P01112; O14641: DVL2; NbExp=3; IntAct=EBI-350145, EBI-740850; CC P01112; A0AVK6: E2F8; NbExp=3; IntAct=EBI-350145, EBI-7779316; CC P01112; Q8NB25: FAM184A; NbExp=3; IntAct=EBI-350145, EBI-9917523; CC P01112; Q8IZU1: FAM9A; NbExp=3; IntAct=EBI-350145, EBI-8468186; CC P01112; Q969H0: FBXW7; NbExp=5; IntAct=EBI-350145, EBI-359574; CC P01112; O94868-3: FCHSD2; NbExp=3; IntAct=EBI-350145, EBI-11958845; CC P01112; P15407: FOSL1; NbExp=3; IntAct=EBI-350145, EBI-744510; CC P01112; P15408: FOSL2; NbExp=3; IntAct=EBI-350145, EBI-3893419; CC P01112; P52655: GTF2A1; NbExp=3; IntAct=EBI-350145, EBI-389518; CC P01112; Q96CS2: HAUS1; NbExp=3; IntAct=EBI-350145, EBI-2514791; CC P01112; Q9BT25: HAUS8; NbExp=3; IntAct=EBI-350145, EBI-2558143; CC P01112; Q8IV36: HID1; NbExp=3; IntAct=EBI-350145, EBI-743438; CC P01112; O43248: HOXC11; NbExp=3; IntAct=EBI-350145, EBI-2652631; CC P01112; Q53GQ0: HSD17B12; NbExp=3; IntAct=EBI-350145, EBI-2963255; CC P01112; P10809: HSPD1; NbExp=3; IntAct=EBI-350145, EBI-352528; CC P01112; Q8NDH6-2: ICA1L; NbExp=3; IntAct=EBI-350145, EBI-12141931; CC P01112; Q8IY31-2: IFT20; NbExp=3; IntAct=EBI-350145, EBI-11742277; CC P01112; Q8NA54: IQUB; NbExp=3; IntAct=EBI-350145, EBI-10220600; CC P01112; Q13352: ITGB3BP; NbExp=3; IntAct=EBI-350145, EBI-712105; CC P01112; P28290-2: ITPRID2; NbExp=3; IntAct=EBI-350145, EBI-25863618; CC P01112; Q9BVG8-5: KIFC3; NbExp=3; IntAct=EBI-350145, EBI-14069005; CC P01112; Q2M2Z5: KIZ; NbExp=3; IntAct=EBI-350145, EBI-2554344; CC P01112; Q6P597: KLC3; NbExp=3; IntAct=EBI-350145, EBI-1643885; CC P01112; P57682: KLF3; NbExp=3; IntAct=EBI-350145, EBI-8472267; CC P01112; Q9UH77: KLHL3; NbExp=3; IntAct=EBI-350145, EBI-8524663; CC P01112; P08727: KRT19; NbExp=3; IntAct=EBI-350145, EBI-742756; CC P01112; Q14525: KRT33B; NbExp=3; IntAct=EBI-350145, EBI-1049638; CC P01112; Q14847-2: LASP1; NbExp=3; IntAct=EBI-350145, EBI-9088686; CC P01112; Q96LR2: LURAP1; NbExp=3; IntAct=EBI-350145, EBI-741355; CC P01112; P27338: MAOB; NbExp=3; IntAct=EBI-350145, EBI-3911344; CC P01112; Q99558: MAP3K14; NbExp=3; IntAct=EBI-350145, EBI-358011; CC P01112; Q96EZ8: MCRS1; NbExp=3; IntAct=EBI-350145, EBI-348259; CC P01112; Q8TAC0: MGC27345; NbExp=3; IntAct=EBI-350145, EBI-25851300; CC P01112; Q5JXC2: MIIP; NbExp=3; IntAct=EBI-350145, EBI-2801965; CC P01112; Q8NEH6: MNS1; NbExp=3; IntAct=EBI-350145, EBI-743811; CC P01112; Q9Y605: MRFAP1; NbExp=3; IntAct=EBI-350145, EBI-995714; CC P01112; Q96HT8: MRFAP1L1; NbExp=3; IntAct=EBI-350145, EBI-748896; CC P01112; Q9GZM8: NDEL1; NbExp=3; IntAct=EBI-350145, EBI-928842; CC P01112; P21359: NF1; NbExp=3; IntAct=EBI-350145, EBI-1172917; CC P01112; Q8N5V2: NGEF; NbExp=3; IntAct=EBI-350145, EBI-718372; CC P01112; Q6PHZ7: NR2C2; NbExp=3; IntAct=EBI-350145, EBI-2802743; CC P01112; Q9BZ95-3: NSD3; NbExp=3; IntAct=EBI-350145, EBI-22002759; CC P01112; A5D8V7: ODAD3; NbExp=3; IntAct=EBI-350145, EBI-8466445; CC P01112; O43482: OIP5; NbExp=3; IntAct=EBI-350145, EBI-536879; CC P01112; Q9BR81: PCDHGC3; NbExp=3; IntAct=EBI-350145, EBI-22012354; CC P01112; O15534: PER1; NbExp=3; IntAct=EBI-350145, EBI-2557276; CC P01112; Q9BUL5: PHF23; NbExp=3; IntAct=EBI-350145, EBI-722852; CC P01112; O00329: PIK3CD; NbExp=2; IntAct=EBI-350145, EBI-718309; CC P01112; O00329-2: PIK3CD; NbExp=2; IntAct=EBI-350145, EBI-6470902; CC P01112; Q9UPR0: PLCL2; NbExp=3; IntAct=EBI-350145, EBI-311059; CC P01112; Q96I34: PPP1R16A; NbExp=3; IntAct=EBI-350145, EBI-710402; CC P01112; Q15435-3: PPP1R7; NbExp=3; IntAct=EBI-350145, EBI-10695066; CC P01112; P04049: RAF1; NbExp=30; IntAct=EBI-350145, EBI-365996; CC P01112; P11233: RALA; NbExp=2; IntAct=EBI-350145, EBI-1036803; CC P01112; Q15311: RALBP1; NbExp=3; IntAct=EBI-350145, EBI-749285; CC P01112; Q12967: RALGDS; NbExp=3; IntAct=EBI-350145, EBI-365861; CC P01112; P52306: RAP1GDS1; NbExp=2; IntAct=EBI-350145, EBI-746389; CC P01112; Q9NS23-2: RASSF1; NbExp=2; IntAct=EBI-350145, EBI-438698; CC P01112; Q9NS23-4: RASSF1; NbExp=4; IntAct=EBI-350145, EBI-438710; CC P01112; Q8WWW0: RASSF5; NbExp=2; IntAct=EBI-350145, EBI-367390; CC P01112; Q8TBY0: RBM46; NbExp=3; IntAct=EBI-350145, EBI-12068216; CC P01112; Q9P2K3-2: RCOR3; NbExp=3; IntAct=EBI-350145, EBI-1504830; CC P01112; Q9NZL6: RGL1; NbExp=4; IntAct=EBI-350145, EBI-365926; CC P01112; O15211: RGL2; NbExp=3; IntAct=EBI-350145, EBI-712355; CC P01112; Q8IXN7: RIMKLA; NbExp=3; IntAct=EBI-350145, EBI-21890191; CC P01112; Q13671: RIN1; NbExp=15; IntAct=EBI-350145, EBI-366017; CC P01112; Q13671-1: RIN1; NbExp=2; IntAct=EBI-350145, EBI-366030; CC P01112; Q8WVD3: RNF138; NbExp=3; IntAct=EBI-350145, EBI-749039; CC P01112; Q9BY12-3: SCAPER; NbExp=3; IntAct=EBI-350145, EBI-25837959; CC P01112; Q13435: SF3B2; NbExp=3; IntAct=EBI-350145, EBI-749111; CC P01112; Q13485: SMAD4; NbExp=5; IntAct=EBI-350145, EBI-347263; CC P01112; Q12824: SMARCB1; NbExp=3; IntAct=EBI-350145, EBI-358419; CC P01112; Q13573: SNW1; NbExp=3; IntAct=EBI-350145, EBI-632715; CC P01112; Q07889: SOS1; NbExp=11; IntAct=EBI-350145, EBI-297487; CC P01112; Q86W54-2: SPATA24; NbExp=3; IntAct=EBI-350145, EBI-12041693; CC P01112; P12931: SRC; NbExp=2; IntAct=EBI-350145, EBI-621482; CC P01112; Q92783-2: STAM; NbExp=3; IntAct=EBI-350145, EBI-12025738; CC P01112; O75886: STAM2; NbExp=3; IntAct=EBI-350145, EBI-373258; CC P01112; Q13586: STIM1; NbExp=4; IntAct=EBI-350145, EBI-448878; CC P01112; Q8N4C7: STX19; NbExp=3; IntAct=EBI-350145, EBI-8484990; CC P01112; O75528: TADA3; NbExp=3; IntAct=EBI-350145, EBI-473249; CC P01112; P54274-2: TERF1; NbExp=3; IntAct=EBI-350145, EBI-711018; CC P01112; Q9BXU0: TEX12; NbExp=3; IntAct=EBI-350145, EBI-12090309; CC P01112; Q5T0J7-2: TEX35; NbExp=3; IntAct=EBI-350145, EBI-12833746; CC P01112; Q5T1C6: THEM4; NbExp=3; IntAct=EBI-350145, EBI-7684443; CC P01112; Q8IUR5-4: TMTC1; NbExp=3; IntAct=EBI-350145, EBI-9089156; CC P01112; P36406: TRIM23; NbExp=3; IntAct=EBI-350145, EBI-740098; CC P01112; Q86WT6-2: TRIM69; NbExp=3; IntAct=EBI-350145, EBI-11525489; CC P01112; Q99598: TSNAX; NbExp=3; IntAct=EBI-350145, EBI-21353855; CC P01112; Q6PF05: TTC23L; NbExp=3; IntAct=EBI-350145, EBI-8656864; CC P01112; Q9UGJ1-2: TUBGCP4; NbExp=3; IntAct=EBI-350145, EBI-10964469; CC P01112; Q9Y5Z9: UBIAD1; NbExp=9; IntAct=EBI-350145, EBI-2819725; CC P01112; P22415: USF1; NbExp=3; IntAct=EBI-350145, EBI-1054489; CC P01112; Q495M9: USH1G; NbExp=3; IntAct=EBI-350145, EBI-8601749; CC P01112; Q9H270: VPS11; NbExp=3; IntAct=EBI-350145, EBI-373380; CC P01112; Q8NEZ2: VPS37A; NbExp=3; IntAct=EBI-350145, EBI-2850578; CC P01112; P19544-6: WT1; NbExp=3; IntAct=EBI-350145, EBI-11745701; CC P01112; O43829: ZBTB14; NbExp=3; IntAct=EBI-350145, EBI-10176632; CC P01112; Q9C0F3: ZNF436; NbExp=3; IntAct=EBI-350145, EBI-8489702; CC P01112; Q7Z637; NbExp=3; IntAct=EBI-350145, EBI-25831475; CC P01112; Q86V28; NbExp=3; IntAct=EBI-350145, EBI-10259496; CC P01112; P42337: Pik3ca; Xeno; NbExp=3; IntAct=EBI-350145, EBI-641748; CC P01112; Q9Z0S9: Rabac1; Xeno; NbExp=4; IntAct=EBI-350145, EBI-476965; CC P01112; Q9EQZ6: Rapgef4; Xeno; NbExp=3; IntAct=EBI-350145, EBI-772212; CC P01112; P27671: Rasgrf1; Xeno; NbExp=2; IntAct=EBI-350145, EBI-645522; CC P01112; Q5EBH1: Rassf5; Xeno; NbExp=13; IntAct=EBI-350145, EBI-960530; CC P01112; Q5EBH1-1: Rassf5; Xeno; NbExp=3; IntAct=EBI-350145, EBI-960543; CC P01112-2; P52306-5: RAP1GDS1; NbExp=5; IntAct=EBI-13290525, EBI-12832744; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:P20171}; CC Lipid-anchor; Cytoplasmic side. Golgi apparatus. Golgi apparatus CC membrane; Lipid-anchor. Note=The active GTP-bound form is localized CC most strongly to membranes than the inactive GDP-bound form (By CC similarity). Shuttles between the plasma membrane and the Golgi CC apparatus. {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus. Cytoplasm. Cytoplasm, CC perinuclear region. Note=Colocalizes with RACK1 to the perinuclear CC region. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=H-Ras4A, p21; CC IsoId=P01112-1; Sequence=Displayed; CC Name=2; Synonyms=H-RasIDX, p19; CC IsoId=P01112-2; Sequence=VSP_041597; CC -!- TISSUE SPECIFICITY: Widely expressed. {ECO:0000269|PubMed:14500341}. CC -!- PTM: Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of CC de- and re-palmitoylation regulates rapid exchange between plasma CC membrane and Golgi. CC -!- PTM: S-nitrosylated; critical for redox regulation. Important for CC stimulating guanine nucleotide exchange. No structural perturbation on CC nitrosylation. CC -!- PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14- CC prostaglandin-J2 is autocatalytic and reversible. It may occur as an CC alternative to other cysteine modifications, such as S-nitrosylation CC and S-palmitoylation. CC -!- PTM: Acetylation at Lys-104 prevents interaction with guanine CC nucleotide exchange factors (GEFs). {ECO:0000250}. CC -!- PTM: Fatty-acylated at Lys-170. {ECO:0000269|PubMed:29239724}. CC -!- PTM: Ubiquitinated by the BCR(LZTR1) E3 ubiquitin ligase complex at CC Lys-170 in a non-degradative manner, leading to inhibit Ras signaling CC by decreasing Ras association with membranes. CC {ECO:0000269|PubMed:30442762}. CC -!- PTM: (Microbial infection) Glucosylated at Thr-35 by P.sordellii toxin CC TcsL (PubMed:19744486, PubMed:8626575, PubMed:8626586, PubMed:9632667). CC Monoglucosylation completely prevents the recognition of the downstream CC effector, blocking the GTPases in their inactive form, leading to CC inhibit Ras signaling (PubMed:8626575, PubMed:8626586, PubMed:9632667). CC {ECO:0000269|PubMed:19744486, ECO:0000269|PubMed:8626575, CC ECO:0000269|PubMed:8626586, ECO:0000269|PubMed:9632667}. CC -!- DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition CC characterized by prenatally increased growth, postnatal growth CC deficiency, intellectual disability, distinctive facial appearance, CC cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic CC cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin CC and musculoskeletal abnormalities. {ECO:0000269|PubMed:16170316, CC ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854, CC ECO:0000269|PubMed:17054105, ECO:0000269|PubMed:18039947, CC ECO:0000269|PubMed:18247425, ECO:0000269|PubMed:19995790}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Congenital myopathy with excess of muscle spindles (CMEMS) CC [MIM:218040]: Variant of Costello syndrome. CC {ECO:0000269|PubMed:17412879}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Thyroid cancer, non-medullary, 2 (NMTC2) [MIM:188470]: A form CC of non-medullary thyroid cancer (NMTC), a cancer characterized by CC tumors originating from the thyroid follicular cells. NMTCs represent CC approximately 95% of all cases of thyroid cancer and are classified CC into papillary, follicular, Hurthle cell, and anaplastic neoplasms. CC {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is CC associated with variants affecting the gene represented in this entry. CC -!- DISEASE: Note=Mutations which change positions 12, 13 or 61 activate CC the potential of HRAS to transform cultured cells and are implicated in CC a variety of human tumors. {ECO:0000269|PubMed:3670300}. CC -!- DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in CC tissues of the urinary bladder. It often presents with multiple tumors CC appearing at different times and at different sites in the bladder. CC Most bladder cancers are transitional cell carcinomas that begin in CC cells that normally make up the inner lining of the bladder. Other CC types of bladder cancer include squamous cell carcinoma (cancer that CC begins in thin, flat cells) and adenocarcinoma (cancer that begins in CC cells that make and release mucus and other fluids). Bladder cancer is CC a complex disorder with both genetic and environmental influences. CC {ECO:0000269|PubMed:6298635, ECO:0000269|PubMed:6844927}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A CC disease characterized by sebaceous nevi, often on the face, associated CC with variable ipsilateral abnormalities of the central nervous system, CC ocular anomalies, and skeletal defects. Many oral manifestations have CC been reported, not only including hypoplastic and malformed teeth, and CC mucosal papillomatosis, but also ankyloglossia, hemihyperplastic CC tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone CC cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous CC nevi follow the lines of Blaschko and these can continue as linear CC intraoral lesions, as in mucosal papillomatosis. CC {ECO:0000269|PubMed:22683711}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the small GTPase superfamily. Ras family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/108/HRAS"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; J00277; AAB02605.1; -; Genomic_DNA. DR EMBL; AJ437024; CAD24594.1; -; mRNA. DR EMBL; AF493916; AAM12630.1; -; mRNA. DR EMBL; CR536579; CAG38816.1; -; mRNA. DR EMBL; CR542271; CAG47067.1; -; mRNA. DR EMBL; BT019421; AAV38228.1; -; mRNA. DR EMBL; EF015887; ABI97389.1; -; Genomic_DNA. DR EMBL; AB451336; BAG70150.1; -; mRNA. DR EMBL; AB451485; BAG70299.1; -; mRNA. DR EMBL; CH471158; EAX02337.1; -; Genomic_DNA. DR EMBL; CH471158; EAX02338.1; -; Genomic_DNA. DR EMBL; BC006499; AAH06499.1; -; mRNA. DR EMBL; BC095471; AAH95471.1; -; mRNA. DR EMBL; M17232; AAA35685.1; -; Genomic_DNA. DR CCDS; CCDS7698.1; -. [P01112-1] DR CCDS; CCDS7699.1; -. [P01112-2] DR PIR; A93299; TVHUH. DR RefSeq; NP_001123914.1; NM_001130442.3. [P01112-1] DR RefSeq; NP_001304983.1; NM_001318054.1. DR RefSeq; NP_005334.1; NM_005343.4. [P01112-1] DR RefSeq; NP_789765.1; NM_176795.5. [P01112-2] DR RefSeq; XP_054224585.1; XM_054368610.1. [P01112-1] DR PDB; 121P; X-ray; 1.54 A; A=1-166. DR PDB; 1AA9; NMR; -; A=1-171. DR PDB; 1AGP; X-ray; 2.30 A; A=1-166. DR PDB; 1BKD; X-ray; 2.80 A; R=1-166. DR PDB; 1CLU; X-ray; 1.70 A; A=1-166. DR PDB; 1CRP; NMR; -; A=1-166. DR PDB; 1CRQ; NMR; -; A=1-166. DR PDB; 1CRR; NMR; -; A=1-166. DR PDB; 1CTQ; X-ray; 1.26 A; A=1-166. DR PDB; 1GNP; X-ray; 2.70 A; A=1-166. DR PDB; 1GNQ; X-ray; 2.50 A; A=1-166. DR PDB; 1GNR; X-ray; 1.85 A; A=1-166. DR PDB; 1HE8; X-ray; 3.00 A; B=1-166. DR PDB; 1IAQ; X-ray; 2.90 A; A/B/C=1-166. DR PDB; 1IOZ; X-ray; 2.00 A; A=1-171. DR PDB; 1JAH; X-ray; 1.80 A; A=1-166. DR PDB; 1JAI; X-ray; 1.80 A; A=1-166. DR PDB; 1K8R; X-ray; 3.00 A; A=1-166. DR PDB; 1LF0; X-ray; 1.70 A; A=1-166. DR PDB; 1LF5; X-ray; 1.70 A; A=1-166. DR PDB; 1LFD; X-ray; 2.10 A; B/D=1-167. DR PDB; 1NVU; X-ray; 2.20 A; Q/R=1-166. DR PDB; 1NVV; X-ray; 2.18 A; Q/R=1-166. DR PDB; 1NVW; X-ray; 2.70 A; Q/R=1-166. DR PDB; 1NVX; X-ray; 3.20 A; Q/R=1-166. DR PDB; 1P2S; X-ray; 2.45 A; A=1-166. DR PDB; 1P2T; X-ray; 2.00 A; A=1-166. DR PDB; 1P2U; X-ray; 2.00 A; A=1-166. DR PDB; 1P2V; X-ray; 2.30 A; A=1-166. DR PDB; 1PLJ; X-ray; 2.80 A; A=1-166. DR PDB; 1PLK; X-ray; 2.80 A; A=1-166. DR PDB; 1PLL; X-ray; 2.80 A; A=1-166. DR PDB; 1Q21; X-ray; 2.20 A; A=1-171. DR PDB; 1QRA; X-ray; 1.60 A; A=1-166. DR PDB; 1RVD; X-ray; 1.90 A; A=1-166. DR PDB; 1WQ1; X-ray; 2.50 A; R=1-166. DR PDB; 1XCM; X-ray; 1.84 A; A=1-167. DR PDB; 1XD2; X-ray; 2.70 A; A/B=1-166. DR PDB; 1XJ0; X-ray; 1.70 A; A=1-166. DR PDB; 1ZVQ; X-ray; 2.00 A; A=1-166. DR PDB; 1ZW6; X-ray; 1.50 A; A=1-166. DR PDB; 221P; X-ray; 2.30 A; A=1-166. DR PDB; 2C5L; X-ray; 1.90 A; A/B=1-166. DR PDB; 2CE2; X-ray; 1.00 A; X=1-166. DR PDB; 2CL0; X-ray; 1.80 A; X=1-166. DR PDB; 2CL6; X-ray; 1.24 A; X=1-166. DR PDB; 2CL7; X-ray; 1.25 A; X=1-166. DR PDB; 2CLC; X-ray; 1.30 A; X=1-166. DR PDB; 2CLD; X-ray; 1.22 A; X=1-166. DR PDB; 2EVW; X-ray; 1.05 A; X=1-166. DR PDB; 2LCF; NMR; -; A=1-166. DR PDB; 2LWI; NMR; -; A=1-166. DR PDB; 2N42; NMR; -; A=1-166. DR PDB; 2N46; NMR; -; A=1-166. DR PDB; 2Q21; X-ray; 2.20 A; A=1-171. DR PDB; 2QUZ; X-ray; 1.49 A; A=1-166. DR PDB; 2RGA; X-ray; 1.90 A; A=1-166. DR PDB; 2RGB; X-ray; 1.35 A; A=1-166. DR PDB; 2RGC; X-ray; 1.60 A; A=1-166. DR PDB; 2RGD; X-ray; 2.00 A; A=1-166. DR PDB; 2RGE; X-ray; 1.40 A; A=1-166. DR PDB; 2RGG; X-ray; 1.45 A; A=1-166. DR PDB; 2UZI; X-ray; 2.00 A; R=1-166. DR PDB; 2VH5; X-ray; 2.70 A; R=1-166. DR PDB; 2X1V; X-ray; 1.70 A; A=1-166. DR PDB; 3DDC; X-ray; 1.80 A; A=1-166. DR PDB; 3I3S; X-ray; 1.36 A; R=1-166. DR PDB; 3K8Y; X-ray; 1.30 A; A=1-166. DR PDB; 3K9L; X-ray; 1.80 A; A/B/C=1-166. DR PDB; 3K9N; X-ray; 2.00 A; A=1-166. DR PDB; 3KKM; X-ray; 1.70 A; A=1-166. DR PDB; 3KKN; X-ray; 2.09 A; A=1-166. DR PDB; 3KUD; X-ray; 2.15 A; A=1-166. DR PDB; 3L8Y; X-ray; 2.02 A; A=1-166. DR PDB; 3L8Z; X-ray; 1.44 A; A=1-166. DR PDB; 3LBH; X-ray; 1.85 A; A=1-166. DR PDB; 3LBI; X-ray; 2.09 A; A=1-166. DR PDB; 3LBN; X-ray; 1.86 A; A=1-166. DR PDB; 3LO5; X-ray; 2.57 A; A/C/E=1-166. DR PDB; 3OIU; X-ray; 1.32 A; A=1-166. DR PDB; 3OIV; X-ray; 1.84 A; A=1-166. DR PDB; 3OIW; X-ray; 1.30 A; A=1-166. DR PDB; 3RRY; X-ray; 1.60 A; A=1-166. DR PDB; 3RRZ; X-ray; 1.60 A; A=1-166. DR PDB; 3RS0; X-ray; 1.40 A; A=1-166. DR PDB; 3RS2; X-ray; 1.84 A; A=1-166. DR PDB; 3RS3; X-ray; 1.52 A; A=1-166. DR PDB; 3RS4; X-ray; 1.70 A; A=1-166. DR PDB; 3RS5; X-ray; 1.68 A; A=1-166. DR PDB; 3RS7; X-ray; 1.70 A; A=1-166. DR PDB; 3RSL; X-ray; 1.70 A; A=1-166. DR PDB; 3RSO; X-ray; 1.60 A; A=1-166. DR PDB; 3TGP; X-ray; 1.31 A; A=1-166. DR PDB; 421P; X-ray; 2.20 A; A=1-166. DR PDB; 4DLR; X-ray; 1.32 A; A=1-166. DR PDB; 4DLS; X-ray; 1.82 A; A=1-166. DR PDB; 4DLT; X-ray; 1.70 A; A=1-166. DR PDB; 4DLU; X-ray; 1.60 A; A=1-166. DR PDB; 4DLV; X-ray; 1.57 A; A=1-166. DR PDB; 4DLW; X-ray; 1.72 A; A=1-166. DR PDB; 4DLX; X-ray; 1.73 A; A=1-166. DR PDB; 4DLY; X-ray; 1.57 A; A=1-166. DR PDB; 4DLZ; X-ray; 1.66 A; A=1-166. DR PDB; 4DST; X-ray; 2.30 A; A=2-167. DR PDB; 4DSU; X-ray; 1.70 A; A=2-167. DR PDB; 4EFL; X-ray; 1.90 A; A=1-166. DR PDB; 4EFM; X-ray; 1.90 A; A=1-166. DR PDB; 4EFN; X-ray; 2.30 A; A=1-166. DR PDB; 4G0N; X-ray; 2.45 A; A=1-166. DR PDB; 4G3X; X-ray; 3.25 A; A=1-166. DR PDB; 4K81; X-ray; 2.40 A; B/D/F/H=1-166. DR PDB; 4L9S; X-ray; 1.61 A; A=1-166. DR PDB; 4L9W; X-ray; 1.95 A; A=1-166. DR PDB; 4NYI; X-ray; 2.96 A; Q/R=1-166. DR PDB; 4NYJ; X-ray; 2.85 A; Q/R=1-166. DR PDB; 4NYM; X-ray; 3.55 A; Q/R=1-166. DR PDB; 4Q21; X-ray; 2.00 A; A=1-189. DR PDB; 4RSG; Neutron; 1.91 A; A=1-166. DR PDB; 4URU; X-ray; 2.83 A; R=1-166. DR PDB; 4URV; X-ray; 2.58 A; R=1-166. DR PDB; 4URW; X-ray; 2.76 A; R=1-166. DR PDB; 4URX; X-ray; 2.49 A; R=1-166. DR PDB; 4URY; X-ray; 2.47 A; R=1-166. DR PDB; 4URZ; X-ray; 2.24 A; R=1-166. DR PDB; 4US0; X-ray; 2.17 A; R=1-166. DR PDB; 4US1; X-ray; 2.65 A; R=1-166. DR PDB; 4US2; X-ray; 2.48 A; R=1-166. DR PDB; 4XVQ; X-ray; 1.89 A; A=1-166. DR PDB; 4XVR; X-ray; 2.03 A; A=1-166. DR PDB; 521P; X-ray; 2.60 A; A=1-166. DR PDB; 5B2Z; X-ray; 1.56 A; A=1-166. DR PDB; 5B30; X-ray; 1.60 A; A=1-166. DR PDB; 5E95; X-ray; 1.40 A; A=1-166. DR PDB; 5P21; X-ray; 1.35 A; A=1-166. DR PDB; 5VBE; X-ray; 1.57 A; A=1-166. DR PDB; 5VBZ; X-ray; 2.20 A; A/B/C=1-166. DR PDB; 5WDO; X-ray; 1.65 A; A=1-166. DR PDB; 5WDP; X-ray; 1.35 A; A=1-166. DR PDB; 5WDQ; X-ray; 1.25 A; A=1-166. DR PDB; 5WFO; X-ray; 1.99 A; Q/R=1-166. DR PDB; 5WFP; X-ray; 2.08 A; Q/R=1-166. DR PDB; 5WFQ; X-ray; 2.26 A; Q/R=1-166. DR PDB; 5WFR; X-ray; 2.46 A; Q/R=1-166. DR PDB; 5WPL; X-ray; 2.15 A; A/D/G/J=1-166. DR PDB; 5X9S; X-ray; 2.50 A; A=1-166. DR PDB; 5ZC6; NMR; -; A=1-166. DR PDB; 621P; X-ray; 2.40 A; A=1-166. DR PDB; 6AMB; X-ray; 2.50 A; A=1-168. DR PDB; 6AXG; X-ray; 3.30 A; B/D/F/H/J/L=1-166. DR PDB; 6BVI; X-ray; 1.75 A; A/C=1-166. DR PDB; 6BVJ; X-ray; 1.75 A; A/C=1-166. DR PDB; 6BVK; X-ray; 1.80 A; A/C=1-166. DR PDB; 6BVL; X-ray; 1.75 A; A/C=1-166. DR PDB; 6BVM; X-ray; 1.80 A; A/C=1-166. DR PDB; 6CUO; X-ray; 1.73 A; A/C=1-166. DR PDB; 6CUP; X-ray; 1.83 A; A/C=1-166. DR PDB; 6CUR; X-ray; 1.73 A; A/C=1-166. DR PDB; 6D55; X-ray; 1.68 A; A/C=1-166. DR PDB; 6D56; X-ray; 1.68 A; A/C=1-166. DR PDB; 6D59; X-ray; 1.70 A; A/C=1-166. DR PDB; 6D5E; X-ray; 1.75 A; A/C=1-166. DR PDB; 6D5G; X-ray; 1.92 A; A/C=1-166. DR PDB; 6D5H; X-ray; 1.80 A; A/C=1-166. DR PDB; 6D5J; X-ray; 1.75 A; A/C=1-166. DR PDB; 6D5L; X-ray; 1.70 A; A/C=1-166. DR PDB; 6D5M; X-ray; 2.08 A; Q/R=1-166. DR PDB; 6D5V; X-ray; 2.04 A; Q/R=1-166. DR PDB; 6D5W; X-ray; 2.48 A; Q/R=1-166. DR PDB; 6DZH; X-ray; 1.95 A; A/B/C=1-166. DR PDB; 6E6C; X-ray; 1.90 A; A=1-166. DR PDB; 6E6P; X-ray; 1.93 A; A/B/C=1-166. DR PDB; 6MQT; X-ray; 1.50 A; A/B/C/D/E/F/G/H=1-166. DR PDB; 6NTC; X-ray; 2.90 A; A=1-166. DR PDB; 6NTD; X-ray; 3.15 A; A=1-166. DR PDB; 6Q21; X-ray; 1.95 A; A/B/C/D=1-171. DR PDB; 6V94; X-ray; 1.80 A; A/C=1-166. DR PDB; 6V9F; X-ray; 1.85 A; A/C=1-166. DR PDB; 6V9J; X-ray; 1.76 A; A/C=1-166. DR PDB; 6V9L; X-ray; 1.70 A; A/C=1-166. DR PDB; 6V9M; X-ray; 1.65 A; A/C=1-166. DR PDB; 6V9N; X-ray; 1.65 A; A/C=1-166. DR PDB; 6V9O; X-ray; 1.80 A; A/C=1-166. DR PDB; 6ZJ0; X-ray; 1.76 A; A=1-166. DR PDB; 6ZL3; X-ray; 2.03 A; A=1-166. DR PDB; 721P; X-ray; 2.00 A; A=1-166. DR PDB; 7DPH; X-ray; 1.54 A; A=1-166. DR PDB; 7DPJ; X-ray; 1.98 A; A=1-166. DR PDB; 7JHP; X-ray; 2.77 A; A=1-166. DR PDB; 7JIF; X-ray; 1.76 A; A=1-166. DR PDB; 7JIG; X-ray; 2.32 A; A=1-166. DR PDB; 7JIH; X-ray; 1.99 A; A/B=1-166. DR PDB; 7JII; X-ray; 1.53 A; A/B=1-166. DR PDB; 7L0F; X-ray; 1.98 A; A/E/G/L=1-166. DR PDB; 7L0G; X-ray; 2.54 A; A/B/E/G=1-166. DR PDB; 7OG9; X-ray; 1.75 A; A=1-166. DR PDB; 7OGA; X-ray; 1.90 A; A=1-166. DR PDB; 7OGB; X-ray; 1.85 A; A=1-166. DR PDB; 7OGC; X-ray; 1.70 A; A=1-166. DR PDB; 7OGD; X-ray; 1.95 A; A=1-166. DR PDB; 7OGE; X-ray; 2.10 A; A=1-166. DR PDB; 7OGF; X-ray; 1.80 A; A=1-166. DR PDB; 7TAM; X-ray; 1.87 A; A=1-166. DR PDB; 7VV8; X-ray; 1.70 A; A=1-166. DR PDB; 7VV9; X-ray; 1.60 A; A=1-170. DR PDB; 7VVG; X-ray; 1.70 A; A=1-166. DR PDB; 821P; X-ray; 1.50 A; A=1-166. DR PDB; 8BE6; X-ray; 2.90 A; R=1-166. DR PDB; 8BE7; X-ray; 3.00 A; R=1-166. DR PDB; 8BE8; X-ray; 2.40 A; R=1-166. DR PDB; 8BE9; X-ray; 2.51 A; R=1-166. DR PDB; 8BEA; X-ray; 2.47 A; R=1-166. DR PDB; 8BOS; X-ray; 2.10 A; R=1-166. DR PDB; 8BWG; X-ray; 1.32 A; R=1-166. DR PDB; 8CNJ; X-ray; 1.35 A; A/B=1-166. DR PDB; 8CNN; X-ray; 1.48 A; A=1-166. DR PDB; 8ELK; X-ray; 1.80 A; A=1-189. DR PDB; 8ELR; X-ray; 2.05 A; A=1-189. DR PDB; 8ELS; X-ray; 2.27 A; A=1-189. DR PDB; 8ELT; X-ray; 1.66 A; A=1-189. DR PDB; 8ELU; X-ray; 1.93 A; A=1-189. DR PDB; 8ELV; X-ray; 2.15 A; A=1-189. DR PDB; 8ELW; X-ray; 1.70 A; A=1-189. DR PDB; 8ELX; X-ray; 1.98 A; A=1-189. DR PDB; 8ELY; X-ray; 1.75 A; A=1-189. DR PDB; 8ELZ; X-ray; 1.96 A; A=1-189. DR PDB; 8EM0; X-ray; 2.11 A; A=1-189. DR PDB; 8FG3; X-ray; 1.49 A; A=1-166. DR PDB; 8FG4; X-ray; 1.85 A; A=1-166. DR PDB; 8OSM; X-ray; 2.05 A; A=1-166. DR PDB; 8OSN; X-ray; 1.80 A; A=1-166. DR PDB; 8OSO; X-ray; 2.50 A; A=1-166. DR PDB; 8TBG; X-ray; 1.20 A; A/B=1-166. DR PDB; 8TLR; X-ray; 1.70 A; A=1-166. DR PDB; 8WWC; X-ray; 2.80 A; A/B=1-166. DR PDBsum; 121P; -. DR PDBsum; 1AA9; -. DR PDBsum; 1AGP; -. DR PDBsum; 1BKD; -. DR PDBsum; 1CLU; -. DR PDBsum; 1CRP; -. DR PDBsum; 1CRQ; -. DR PDBsum; 1CRR; -. DR PDBsum; 1CTQ; -. DR PDBsum; 1GNP; -. DR PDBsum; 1GNQ; -. DR PDBsum; 1GNR; -. DR PDBsum; 1HE8; -. DR PDBsum; 1IAQ; -. DR PDBsum; 1IOZ; -. DR PDBsum; 1JAH; -. DR PDBsum; 1JAI; -. DR PDBsum; 1K8R; -. DR PDBsum; 1LF0; -. DR PDBsum; 1LF5; -. DR PDBsum; 1LFD; -. DR PDBsum; 1NVU; -. DR PDBsum; 1NVV; -. DR PDBsum; 1NVW; -. DR PDBsum; 1NVX; -. DR PDBsum; 1P2S; -. DR PDBsum; 1P2T; -. DR PDBsum; 1P2U; -. DR PDBsum; 1P2V; -. DR PDBsum; 1PLJ; -. DR PDBsum; 1PLK; -. DR PDBsum; 1PLL; -. DR PDBsum; 1Q21; -. DR PDBsum; 1QRA; -. DR PDBsum; 1RVD; -. DR PDBsum; 1WQ1; -. DR PDBsum; 1XCM; -. DR PDBsum; 1XD2; -. DR PDBsum; 1XJ0; -. DR PDBsum; 1ZVQ; -. DR PDBsum; 1ZW6; -. DR PDBsum; 221P; -. DR PDBsum; 2C5L; -. DR PDBsum; 2CE2; -. DR PDBsum; 2CL0; -. DR PDBsum; 2CL6; -. DR PDBsum; 2CL7; -. DR PDBsum; 2CLC; -. DR PDBsum; 2CLD; -. DR PDBsum; 2EVW; -. DR PDBsum; 2LCF; -. DR PDBsum; 2LWI; -. DR PDBsum; 2N42; -. DR PDBsum; 2N46; -. DR PDBsum; 2Q21; -. DR PDBsum; 2QUZ; -. DR PDBsum; 2RGA; -. DR PDBsum; 2RGB; -. DR PDBsum; 2RGC; -. DR PDBsum; 2RGD; -. DR PDBsum; 2RGE; -. DR PDBsum; 2RGG; -. DR PDBsum; 2UZI; -. DR PDBsum; 2VH5; -. DR PDBsum; 2X1V; -. DR PDBsum; 3DDC; -. DR PDBsum; 3I3S; -. DR PDBsum; 3K8Y; -. DR PDBsum; 3K9L; -. DR PDBsum; 3K9N; -. DR PDBsum; 3KKM; -. DR PDBsum; 3KKN; -. DR PDBsum; 3KUD; -. DR PDBsum; 3L8Y; -. DR PDBsum; 3L8Z; -. DR PDBsum; 3LBH; -. DR PDBsum; 3LBI; -. DR PDBsum; 3LBN; -. DR PDBsum; 3LO5; -. DR PDBsum; 3OIU; -. DR PDBsum; 3OIV; -. DR PDBsum; 3OIW; -. DR PDBsum; 3RRY; -. DR PDBsum; 3RRZ; -. DR PDBsum; 3RS0; -. DR PDBsum; 3RS2; -. DR PDBsum; 3RS3; -. DR PDBsum; 3RS4; -. DR PDBsum; 3RS5; -. DR PDBsum; 3RS7; -. DR PDBsum; 3RSL; -. DR PDBsum; 3RSO; -. DR PDBsum; 3TGP; -. DR PDBsum; 421P; -. DR PDBsum; 4DLR; -. DR PDBsum; 4DLS; -. DR PDBsum; 4DLT; -. DR PDBsum; 4DLU; -. DR PDBsum; 4DLV; -. DR PDBsum; 4DLW; -. DR PDBsum; 4DLX; -. DR PDBsum; 4DLY; -. DR PDBsum; 4DLZ; -. DR PDBsum; 4DST; -. DR PDBsum; 4DSU; -. DR PDBsum; 4EFL; -. DR PDBsum; 4EFM; -. DR PDBsum; 4EFN; -. DR PDBsum; 4G0N; -. DR PDBsum; 4G3X; -. DR PDBsum; 4K81; -. DR PDBsum; 4L9S; -. DR PDBsum; 4L9W; -. DR PDBsum; 4NYI; -. DR PDBsum; 4NYJ; -. DR PDBsum; 4NYM; -. DR PDBsum; 4Q21; -. DR PDBsum; 4RSG; -. DR PDBsum; 4URU; -. DR PDBsum; 4URV; -. DR PDBsum; 4URW; -. DR PDBsum; 4URX; -. DR PDBsum; 4URY; -. DR PDBsum; 4URZ; -. DR PDBsum; 4US0; -. DR PDBsum; 4US1; -. DR PDBsum; 4US2; -. DR PDBsum; 4XVQ; -. DR PDBsum; 4XVR; -. DR PDBsum; 521P; -. DR PDBsum; 5B2Z; -. DR PDBsum; 5B30; -. DR PDBsum; 5E95; -. DR PDBsum; 5P21; -. DR PDBsum; 5VBE; -. DR PDBsum; 5VBZ; -. DR PDBsum; 5WDO; -. DR PDBsum; 5WDP; -. DR PDBsum; 5WDQ; -. DR PDBsum; 5WFO; -. DR PDBsum; 5WFP; -. DR PDBsum; 5WFQ; -. DR PDBsum; 5WFR; -. DR PDBsum; 5WPL; -. DR PDBsum; 5X9S; -. DR PDBsum; 5ZC6; -. DR PDBsum; 621P; -. DR PDBsum; 6AMB; -. DR PDBsum; 6AXG; -. DR PDBsum; 6BVI; -. DR PDBsum; 6BVJ; -. DR PDBsum; 6BVK; -. DR PDBsum; 6BVL; -. DR PDBsum; 6BVM; -. DR PDBsum; 6CUO; -. DR PDBsum; 6CUP; -. DR PDBsum; 6CUR; -. DR PDBsum; 6D55; -. DR PDBsum; 6D56; -. DR PDBsum; 6D59; -. DR PDBsum; 6D5E; -. DR PDBsum; 6D5G; -. DR PDBsum; 6D5H; -. DR PDBsum; 6D5J; -. DR PDBsum; 6D5L; -. DR PDBsum; 6D5M; -. DR PDBsum; 6D5V; -. DR PDBsum; 6D5W; -. DR PDBsum; 6DZH; -. DR PDBsum; 6E6C; -. DR PDBsum; 6E6P; -. DR PDBsum; 6MQT; -. DR PDBsum; 6NTC; -. DR PDBsum; 6NTD; -. DR PDBsum; 6Q21; -. DR PDBsum; 6V94; -. DR PDBsum; 6V9F; -. DR PDBsum; 6V9J; -. DR PDBsum; 6V9L; -. DR PDBsum; 6V9M; -. DR PDBsum; 6V9N; -. DR PDBsum; 6V9O; -. DR PDBsum; 6ZJ0; -. DR PDBsum; 6ZL3; -. DR PDBsum; 721P; -. DR PDBsum; 7DPH; -. DR PDBsum; 7DPJ; -. DR PDBsum; 7JHP; -. DR PDBsum; 7JIF; -. DR PDBsum; 7JIG; -. DR PDBsum; 7JIH; -. DR PDBsum; 7JII; -. DR PDBsum; 7L0F; -. DR PDBsum; 7L0G; -. DR PDBsum; 7OG9; -. DR PDBsum; 7OGA; -. DR PDBsum; 7OGB; -. DR PDBsum; 7OGC; -. DR PDBsum; 7OGD; -. DR PDBsum; 7OGE; -. DR PDBsum; 7OGF; -. DR PDBsum; 7TAM; -. DR PDBsum; 7VV8; -. DR PDBsum; 7VV9; -. DR PDBsum; 7VVG; -. DR PDBsum; 821P; -. DR PDBsum; 8BE6; -. DR PDBsum; 8BE7; -. DR PDBsum; 8BE8; -. DR PDBsum; 8BE9; -. DR PDBsum; 8BEA; -. DR PDBsum; 8BOS; -. DR PDBsum; 8BWG; -. DR PDBsum; 8CNJ; -. DR PDBsum; 8CNN; -. DR PDBsum; 8ELK; -. DR PDBsum; 8ELR; -. DR PDBsum; 8ELS; -. DR PDBsum; 8ELT; -. DR PDBsum; 8ELU; -. DR PDBsum; 8ELV; -. DR PDBsum; 8ELW; -. DR PDBsum; 8ELX; -. DR PDBsum; 8ELY; -. DR PDBsum; 8ELZ; -. DR PDBsum; 8EM0; -. DR PDBsum; 8FG3; -. DR PDBsum; 8FG4; -. DR PDBsum; 8OSM; -. DR PDBsum; 8OSN; -. DR PDBsum; 8OSO; -. DR PDBsum; 8TBG; -. DR PDBsum; 8TLR; -. DR PDBsum; 8WWC; -. DR AlphaFoldDB; P01112; -. DR BMRB; P01112; -. DR SMR; P01112; -. DR BioGRID; 109501; 710. DR ComplexPortal; CPX-26353; SHOC2-HRAS-PPP1CA complex. DR ComplexPortal; CPX-395; GTPase HRAS - Son of sevenless homolog 1 complex. DR CORUM; P01112; -. DR DIP; DIP-1050N; -. DR ELM; P01112; -. DR FunCoup; P01112; 3079. DR IntAct; P01112; 623. DR MINT; P01112; -. DR STRING; 9606.ENSP00000407586; -. DR BindingDB; P01112; -. DR ChEMBL; CHEMBL2167; -. DR DrugBank; DB04315; Guanosine-5'-Diphosphate. DR DrugBank; DB04137; Guanosine-5'-Triphosphate. DR DrugBank; DB02210; Hexane-1,6-Diol. DR DrugBank; DB08751; N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE. DR DrugBank; DB03226; Trifluoroethanol. DR DrugBank; DB15588; Ursolic acid. DR DrugCentral; P01112; -. DR GuidetoPHARMACOLOGY; 2822; -. DR GlyCosmos; P01112; 1 site, No reported glycans. DR GlyGen; P01112; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P01112; -. DR PhosphoSitePlus; P01112; -. DR SwissPalm; P01112; -. DR BioMuta; HRAS; -. DR DMDM; 131869; -. DR CPTAC; CPTAC-1551; -. DR CPTAC; CPTAC-1552; -. DR jPOST; P01112; -. DR MassIVE; P01112; -. DR PaxDb; 9606-ENSP00000407586; -. DR PeptideAtlas; P01112; -. DR ProteomicsDB; 51321; -. [P01112-1] DR ProteomicsDB; 51322; -. [P01112-2] DR Pumba; P01112; -. DR ABCD; P01112; 6 sequenced antibodies. DR Antibodypedia; 22506; 827 antibodies from 38 providers. DR CPTC; P01112; 4 antibodies. DR DNASU; 3265; -. DR Ensembl; ENST00000311189.8; ENSP00000309845.7; ENSG00000174775.19. [P01112-1] DR Ensembl; ENST00000397594.7; ENSP00000380722.3; ENSG00000174775.19. [P01112-2] DR Ensembl; ENST00000397596.6; ENSP00000380723.2; ENSG00000174775.19. [P01112-1] DR Ensembl; ENST00000417302.7; ENSP00000388246.1; ENSG00000174775.19. [P01112-2] DR Ensembl; ENST00000451590.5; ENSP00000407586.1; ENSG00000174775.19. [P01112-1] DR Ensembl; ENST00000493230.5; ENSP00000434023.1; ENSG00000174775.19. [P01112-2] DR Ensembl; ENST00000610977.3; ENSP00000480686.1; ENSG00000276536.4. [P01112-1] DR Ensembl; ENST00000615062.2; ENSP00000482366.1; ENSG00000276536.4. [P01112-1] DR Ensembl; ENST00000616241.4; ENSP00000480317.1; ENSG00000276536.4. [P01112-2] DR Ensembl; ENST00000631404.1; ENSP00000488757.1; ENSG00000276536.4. [P01112-1] DR Ensembl; ENST00000631967.1; ENSP00000488225.1; ENSG00000276536.4. [P01112-2] DR Ensembl; ENST00000634098.1; ENSP00000488296.1; ENSG00000276536.4. [P01112-2] DR GeneID; 3265; -. DR KEGG; hsa:3265; -. DR MANE-Select; ENST00000311189.8; ENSP00000309845.7; NM_005343.4; NP_005334.1. DR UCSC; uc010qvw.3; human. [P01112-1] DR AGR; HGNC:5173; -. DR CIViC; 3265; 22 evidence items across 22 molecular profiles. DR ClinPGx; PA29444; -. DR CTD; 3265; -. DR DisGeNET; 3265; -. DR GeneCards; HRAS; -. DR GeneReviews; HRAS; -. DR HGNC; HGNC:5173; HRAS. DR HPA; ENSG00000174775; Low tissue specificity. DR MalaCards; HRAS; -. DR MIM; 109800; phenotype. DR MIM; 163200; phenotype. DR MIM; 188470; phenotype. DR MIM; 190020; gene. DR MIM; 218040; phenotype. DR OpenTargets; ENSG00000174775; -. DR Orphanet; 3071; Costello syndrome. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 2612; Linear nevus sebaceus syndrome. DR Orphanet; 2874; Phakomatosis pigmentokeratotica. DR Orphanet; 79414; Woolly hair nevus. DR VEuPathDB; HostDB:ENSG00000174775; -. DR eggNOG; KOG0395; Eukaryota. DR GeneTree; ENSGT00940000155653; -. DR HOGENOM; CLU_041217_9_8_1; -. DR InParanoid; P01112; -. DR OMA; HYREQIR; -. DR OrthoDB; 5976022at2759; -. DR PAN-GO; P01112; 6 GO annotations based on evolutionary models. DR PhylomeDB; P01112; -. DR BRENDA; 3.6.5.2; 2681. DR PathwayCommons; P01112; -. DR Reactome; R-HSA-112412; SOS-mediated signalling. DR Reactome; R-HSA-1169092; Activation of RAS in B cells. DR Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1250347; SHC1 events in ERBB4 signaling. DR Reactome; R-HSA-1433557; Signaling by SCF-KIT. DR Reactome; R-HSA-167044; Signalling to RAS. DR Reactome; R-HSA-171007; p38MAPK events. DR Reactome; R-HSA-179812; GRB2 events in EGFR signaling. DR Reactome; R-HSA-180336; SHC1 events in EGFR signaling. DR Reactome; R-HSA-186763; Downstream signal transduction. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-210993; Tie2 Signaling. DR Reactome; R-HSA-2179392; EGFR Transactivation by Gastrin. DR Reactome; R-HSA-2424491; DAP12 signaling. DR Reactome; R-HSA-2428933; SHC-related events triggered by IGF1R. DR Reactome; R-HSA-2871796; FCERI mediated MAPK activation. DR Reactome; R-HSA-375165; NCAM signaling for neurite out-growth. DR Reactome; R-HSA-3928662; EPHB-mediated forward signaling. DR Reactome; R-HSA-442982; Ras activation upon Ca2+ influx through NMDA receptor. DR Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation. DR Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling. DR Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII. DR Reactome; R-HSA-5654688; SHC-mediated cascade:FGFR1. DR Reactome; R-HSA-5654693; FRS-mediated FGFR1 signaling. DR Reactome; R-HSA-5654699; SHC-mediated cascade:FGFR2. DR Reactome; R-HSA-5654700; FRS-mediated FGFR2 signaling. DR Reactome; R-HSA-5654704; SHC-mediated cascade:FGFR3. DR Reactome; R-HSA-5654706; FRS-mediated FGFR3 signaling. DR Reactome; R-HSA-5654712; FRS-mediated FGFR4 signaling. DR Reactome; R-HSA-5654719; SHC-mediated cascade:FGFR4. DR Reactome; R-HSA-5655253; Signaling by FGFR2 in disease. DR Reactome; R-HSA-5655291; Signaling by FGFR4 in disease. DR Reactome; R-HSA-5655302; Signaling by FGFR1 in disease. DR Reactome; R-HSA-5655332; Signaling by FGFR3 in disease. DR Reactome; R-HSA-5658442; Regulation of RAS by GAPs. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-5675221; Negative regulation of MAPK pathway. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802953; RAS signaling downstream of NF1 loss-of-function variants. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-74751; Insulin receptor signalling cascade. DR Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases. DR Reactome; R-HSA-8851805; MET activates RAS signaling. DR Reactome; R-HSA-9026519; Activated NTRK2 signals through RAS. DR Reactome; R-HSA-9027284; Erythropoietin activates RAS. DR Reactome; R-HSA-9028731; Activated NTRK2 signals through FRS2 and FRS3. DR Reactome; R-HSA-9034864; Activated NTRK3 signals through RAS. DR Reactome; R-HSA-9607240; FLT3 Signaling. DR Reactome; R-HSA-9634285; Constitutive Signaling by Overexpressed ERBB2. DR Reactome; R-HSA-9634635; Estrogen-stimulated signaling through PRKCZ. DR Reactome; R-HSA-9648002; RAS processing. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants. DR Reactome; R-HSA-9673767; Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants. DR Reactome; R-HSA-9673770; Signaling by PDGFRA extracellular domain mutants. DR Reactome; R-HSA-9703465; Signaling by FLT3 fusion proteins. DR Reactome; R-HSA-9703648; Signaling by FLT3 ITD and TKD mutants. DR Reactome; R-HSA-9753510; Signaling by RAS GAP mutants. DR Reactome; R-HSA-9753512; Signaling by RAS GTPase mutants. DR SABIO-RK; P01112; -. DR SignaLink; P01112; -. DR SIGNOR; P01112; -. DR Agora; ENSG00000174775; -. DR BioGRID-ORCS; 3265; 28 hits in 1176 CRISPR screens. DR EvolutionaryTrace; P01112; -. DR GeneWiki; HRAS; -. DR GenomeRNAi; 3265; -. DR Pharos; P01112; Tchem. DR PRO; PR:P01112; -. DR Proteomes; UP000005640; Chromosome 11. DR RNAct; P01112; protein. DR Bgee; ENSG00000174775; Expressed in skin of abdomen and 97 other cell types or tissues. DR ExpressionAtlas; P01112; baseline and differential. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; TAS:ProtInc. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome. DR GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO. DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:1905360; C:GTPase complex; IPI:ComplexPortal. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0003925; F:G protein activity; IEA:UniProtKB-EC. DR GO; GO:0019003; F:GDP binding; IMP:CAFA. DR GO; GO:0005525; F:GTP binding; IDA:UniProtKB. DR GO; GO:0003924; F:GTPase activity; IDA:WormBase. DR GO; GO:0160185; F:phospholipase C activator activity; IDA:UniProtKB. DR GO; GO:0043495; F:protein-membrane adaptor activity; IEA:Ensembl. DR GO; GO:0060612; P:adipose tissue development; IEA:Ensembl. DR GO; GO:0009887; P:animal organ morphogenesis; TAS:ProtInc. DR GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:CAFA. DR GO; GO:0090398; P:cellular senescence; IDA:BHF-UCL. DR GO; GO:0006935; P:chemotaxis; TAS:ProtInc. DR GO; GO:0042832; P:defense response to protozoan; IEA:Ensembl. DR GO; GO:0006897; P:endocytosis; IEA:Ensembl. DR GO; GO:0048144; P:fibroblast proliferation; IEA:Ensembl. DR GO; GO:0008286; P:insulin receptor signaling pathway; IEA:Ensembl. DR GO; GO:0097193; P:intrinsic apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; TAS:Reactome. DR GO; GO:0042552; P:myelination; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0010629; P:negative regulation of gene expression; IDA:BHF-UCL. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0090402; P:oncogene-induced cell senescence; IEA:Ensembl. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IMP:BHF-UCL. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL. DR GO; GO:0048146; P:positive regulation of fibroblast proliferation; IEA:Ensembl. DR GO; GO:0046330; P:positive regulation of JNK cascade; IDA:BHF-UCL. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL. DR GO; GO:2000630; P:positive regulation of miRNA metabolic process; IDA:BHF-UCL. DR GO; GO:0090314; P:positive regulation of protein targeting to membrane; IMP:UniProtKB. DR GO; GO:1900029; P:positive regulation of ruffle assembly; IDA:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL. DR GO; GO:0032729; P:positive regulation of type II interferon production; IEA:Ensembl. DR GO; GO:0090303; P:positive regulation of wound healing; IDA:BHF-UCL. DR GO; GO:0007265; P:Ras protein signal transduction; IDA:BHF-UCL. DR GO; GO:0032956; P:regulation of actin cytoskeleton organization; IDA:BHF-UCL. DR GO; GO:0051726; P:regulation of cell cycle; IDA:BHF-UCL. DR GO; GO:0042127; P:regulation of cell population proliferation; IDA:ComplexPortal. DR GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IEA:Ensembl. DR GO; GO:0098696; P:regulation of neurotransmitter receptor localization to postsynaptic specialization membrane; IDA:SynGO. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:ComplexPortal. DR GO; GO:0014044; P:Schwann cell development; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; NAS:ProtInc. DR GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl. DR GO; GO:0042088; P:T-helper 1 type immune response; IEA:Ensembl. DR CDD; cd04138; H_N_K_Ras_like; 1. DR DisProt; DP00153; -. DR FunFam; 3.40.50.300:FF:000096; KRAS proto-oncogene, GTPase; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR005225; Small_GTP-bd. DR InterPro; IPR001806; Small_GTPase. DR InterPro; IPR020849; Small_GTPase_Ras-type. DR NCBIfam; TIGR00231; small_GTP; 1. DR PANTHER; PTHR24070; RAS, DI-RAS, AND RHEB FAMILY MEMBERS OF SMALL GTPASE SUPERFAMILY; 1. DR Pfam; PF00071; Ras; 1. DR PRINTS; PR00449; RASTRNSFRMNG. DR SMART; SM00175; RAB; 1. DR SMART; SM00173; RAS; 1. DR SMART; SM00174; RHO; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR PROSITE; PS51421; RAS; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cell membrane; Cytoplasm; KW Direct protein sequencing; Disease variant; Glycoprotein; Golgi apparatus; KW GTP-binding; Hydrolase; Isopeptide bond; Lipoprotein; Membrane; KW Methylation; Nucleotide-binding; Nucleus; Palmitate; Prenylation; KW Proteomics identification; Proto-oncogene; Reference proteome; KW S-nitrosylation; Ubl conjugation. FT CHAIN 1..186 FT /note="GTPase HRas" FT /id="PRO_0000042996" FT INIT_MET 1 FT /note="Removed; alternate" FT /evidence="ECO:0000269|Ref.12" FT CHAIN 2..186 FT /note="GTPase HRas, N-terminally processed" FT /id="PRO_0000326476" FT PROPEP 187..189 FT /note="Removed in mature form" FT /id="PRO_0000042997" FT REGION 166..185 FT /note="Hypervariable region" FT MOTIF 32..40 FT /note="Effector region" FT BINDING 13..18 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:16698776, FT ECO:0000305|PubMed:35522713" FT BINDING 29..35 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:16698776, FT ECO:0000305|PubMed:35522713" FT BINDING 59..60 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:16698776, FT ECO:0000305|PubMed:35522713" FT BINDING 116..119 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:16698776, FT ECO:0000305|PubMed:35522713" FT BINDING 145..147 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:16698776, FT ECO:0000305|PubMed:35522713" FT MOD_RES 1 FT /note="N-acetylmethionine; in GTPase HRas; alternate" FT /evidence="ECO:0000269|Ref.12" FT MOD_RES 2 FT /note="N-acetylthreonine; in GTPase HRas, N-terminally FT processed" FT /evidence="ECO:0000269|Ref.12" FT MOD_RES 118 FT /note="S-nitrosocysteine" FT /evidence="ECO:0000269|PubMed:9020151" FT MOD_RES 186 FT /note="Cysteine methyl ester" FT /evidence="ECO:0000269|PubMed:8626715" FT LIPID 181 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000269|PubMed:15705808, FT ECO:0000269|PubMed:16000296, ECO:0000269|PubMed:2661017, FT ECO:0000269|PubMed:8626715" FT LIPID 184 FT /note="S-(15-deoxy-Delta12,14-prostaglandin J2-9- FT yl)cysteine; alternate" FT /evidence="ECO:0000269|PubMed:12684535" FT LIPID 184 FT /note="S-palmitoyl cysteine; alternate" FT /evidence="ECO:0000269|PubMed:15705808, FT ECO:0000269|PubMed:16000296, ECO:0000269|PubMed:2661017, FT ECO:0000269|PubMed:8626715" FT LIPID 186 FT /note="S-farnesyl cysteine" FT /evidence="ECO:0000269|PubMed:8626715" FT CARBOHYD 35 FT /note="(Microbial infection) O-linked (Glc) threonine; by FT P.sordellii toxin TcsL" FT /evidence="ECO:0000269|PubMed:19744486, FT ECO:0000269|PubMed:8626575, ECO:0000269|PubMed:8626586, FT ECO:0000269|PubMed:9632667" FT CROSSLNK 170 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:30442762" FT VAR_SEQ 152..189 FT /note="VEDAFYTLVREIRQHKLRKLNPPDESGPGCMSCKCVLS -> SRSGSSSSSG FT TLWDPPGPM (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14500341, FT ECO:0000303|PubMed:15489334" FT /id="VSP_041597" FT VARIANT 12 FT /note="G -> A (in CSTLO; dbSNP:rs104894230)" FT /evidence="ECO:0000269|PubMed:16170316, FT ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854" FT /id="VAR_026106" FT VARIANT 12 FT /note="G -> C (in CSTLO; dbSNP:rs104894229)" FT /evidence="ECO:0000269|PubMed:16443854, FT ECO:0000269|PubMed:18039947" FT /id="VAR_045975" FT VARIANT 12 FT /note="G -> D (in CSTLO; severe mutation; FT dbSNP:rs104894230)" FT /evidence="ECO:0000269|PubMed:18039947" FT /id="VAR_068816" FT VARIANT 12 FT /note="G -> E (in CSTLO)" FT /evidence="ECO:0000269|PubMed:16443854" FT /id="VAR_045976" FT VARIANT 12 FT /note="G -> S (in CSTLO and CMEMS; also found in patients FT with oral squamous cell carcinoma; dbSNP:rs104894229)" FT /evidence="ECO:0000269|PubMed:1459726, FT ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078, FT ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105, FT ECO:0000269|PubMed:17412879" FT /id="VAR_006837" FT VARIANT 12 FT /note="G -> V (in CSTLO, bladder carcinoma and CMEMS; FT constitutively activated; interacts and recruits PLCE1 to FT plasma membrane; dbSNP:rs104894230)" FT /evidence="ECO:0000269|PubMed:11022048, FT ECO:0000269|PubMed:15546861, ECO:0000269|PubMed:16170316, FT ECO:0000269|PubMed:17412879" FT /id="VAR_006836" FT VARIANT 13 FT /note="G -> C (in CSTLO; dbSNP:rs104894228)" FT /evidence="ECO:0000269|PubMed:16329078" FT /id="VAR_026107" FT VARIANT 13 FT /note="G -> D (in CSTLO; dbSNP:rs104894226)" FT /evidence="ECO:0000269|PubMed:16170316" FT /id="VAR_026108" FT VARIANT 13 FT /note="G -> R (in SFM; somatic mutation; shows constitutive FT activation of the MAPK and PI3K-AKT signaling pathways; FT dbSNP:rs104894228)" FT /evidence="ECO:0000269|PubMed:22683711" FT /id="VAR_068817" FT VARIANT 22 FT /note="Q -> K (in CMEMS; dbSNP:rs121917757)" FT /evidence="ECO:0000269|PubMed:17412879" FT /id="VAR_045977" FT VARIANT 37 FT /note="E -> EE (in CSTLO)" FT /evidence="ECO:0000269|PubMed:19995790" FT /id="VAR_068818" FT VARIANT 58 FT /note="T -> I (in CSTLO; dbSNP:rs121917758)" FT /evidence="ECO:0000269|PubMed:18247425" FT /id="VAR_045978" FT VARIANT 61 FT /note="Q -> K (in NMTC2; somatic mutation; increases FT transformation of cultured cell lines; dbSNP:rs28933406)" FT /evidence="ECO:0000269|PubMed:12727991, FT ECO:0000269|PubMed:18073111" FT /id="VAR_045979" FT VARIANT 61 FT /note="Q -> L (in melanoma; strongly reduced GTP hydrolysis FT in the presence of RAF1; increases transformation of FT cultured cell lines; dbSNP:rs121913233)" FT /evidence="ECO:0000269|PubMed:18073111" FT /id="VAR_006838" FT VARIANT 63 FT /note="E -> K (in CMEMS; dbSNP:rs121917756)" FT /evidence="ECO:0000269|PubMed:17412879" FT /id="VAR_045980" FT VARIANT 89 FT /note="S -> C (found in a patient with severe fetal hydrops FT and pleural effusion; uncertain significance; decreased FT activation of Ras protein signal transduction; FT dbSNP:rs755322824)" FT /evidence="ECO:0000269|PubMed:22821884" FT /id="VAR_078259" FT VARIANT 117 FT /note="K -> R (in CSTLO; dbSNP:rs104894227)" FT /evidence="ECO:0000269|PubMed:16443854" FT /id="VAR_045981" FT VARIANT 146 FT /note="A -> T (in CSTLO; dbSNP:rs104894231)" FT /evidence="ECO:0000269|PubMed:17054105" FT /id="VAR_045982" FT VARIANT 146 FT /note="A -> V (in CSTLO; dbSNP:rs121917759)" FT /evidence="ECO:0000269|PubMed:18247425" FT /id="VAR_045983" FT MUTAGEN 17 FT /note="S->N: Dominant negative. Prevents PLCE1 EGF-induced FT recruitment to plasma membrane. No effect on subcellular FT location of isoform 2." FT /evidence="ECO:0000269|PubMed:11022048, FT ECO:0000269|PubMed:14500341" FT MUTAGEN 26 FT /note="N->G: Loss of interaction with PLCE1; when FT associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 29 FT /note="V->A: No effect on interaction with PLCE1; when FT associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 32 FT /note="Y->F: Loss of interaction and recruitment to plasma FT membrane of PLCE1; when associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 34 FT /note="P->G: No effect on interaction with PLCE1; when FT associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 35 FT /note="T->S: Loss of interaction with PLCE1; when FT associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 37 FT /note="E->G: No effect on interaction with PLCE1; when FT associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 38 FT /note="D->N: No effect on interaction with PLCE1; when FT associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 39 FT /note="S->C: No effect on interaction with PLCE1; when FT associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 59 FT /note="A->T: Loss of GTPase activity and creation of an FT autophosphorylation site." FT MUTAGEN 61 FT /note="Q->I: Moderately increased transformation of FT cultured cell lines." FT /evidence="ECO:0000269|PubMed:18073111" FT MUTAGEN 61 FT /note="Q->R: Promotes interaction with SHOC2 and PP1C." FT /evidence="ECO:0000269|PubMed:35831509" FT MUTAGEN 61 FT /note="Q->V: Strongly increased transformation of cultured FT cell lines." FT /evidence="ECO:0000269|PubMed:18073111" FT MUTAGEN 83 FT /note="A->T: GTP-binding activity reduced by factor of 30." FT /evidence="ECO:0000269|PubMed:3088563" FT MUTAGEN 118 FT /note="C->S: Abolishes S-nitrosylation. No stimulation of FT guanine nucleotide exchange." FT /evidence="ECO:0000269|PubMed:12740440, FT ECO:0000269|PubMed:9020151" FT MUTAGEN 119 FT /note="D->N: Loss of GTP-binding activity." FT /evidence="ECO:0000269|PubMed:3088563" FT MUTAGEN 144 FT /note="T->I: GTP-binding activity reduced by factor of 25." FT /evidence="ECO:0000269|PubMed:3088563" FT MUTAGEN 164..165 FT /note="RQ->AV: Loss of GTP-binding activity." FT /evidence="ECO:0000269|PubMed:3011420" FT MUTAGEN 167..185 FT /note="KLRKLNPPDESGPGCMSCK->RLRRLNPPDESGPGCMSCR: In H-Ras- FT 3KR mutant; decreased fatty-acylation." FT /evidence="ECO:0000269|PubMed:29239724" FT MUTAGEN 170 FT /note="K->R: Increased Ras signaling due to impaired FT ubiquitination." FT /evidence="ECO:0000269|PubMed:30442762" FT MUTAGEN 181 FT /note="C->S: Exclusively localized in Golgi. Non- FT specifically localized on all endomembranes; when FT associated with S-184." FT /evidence="ECO:0000269|PubMed:15705808, FT ECO:0000269|PubMed:8626715" FT MUTAGEN 184 FT /note="C->S: Loss of S-(15-deoxy-Delta12,14-prostaglandin FT J2-9-yl)cysteine stimulation of Ras-GTPase activity. Mainly FT localized in Golgi. Non-specifically localized on all FT endomembranes; when associated with S-181." FT /evidence="ECO:0000269|PubMed:12684535, FT ECO:0000269|PubMed:15705808, ECO:0000269|PubMed:8626715" FT STRAND 3..11 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 12..15 FT /evidence="ECO:0007829|PDB:6V9M" FT HELIX 16..25 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 27..31 FT /evidence="ECO:0007829|PDB:1XCM" FT STRAND 34..37 FT /evidence="ECO:0007829|PDB:1XD2" FT STRAND 38..46 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 49..57 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 60..63 FT /evidence="ECO:0007829|PDB:2CLD" FT HELIX 66..74 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 76..83 FT /evidence="ECO:0007829|PDB:2CE2" FT TURN 84..86 FT /evidence="ECO:0007829|PDB:1CRP" FT HELIX 87..104 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:7VV9" FT STRAND 111..116 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 120..122 FT /evidence="ECO:0007829|PDB:2CLD" FT HELIX 127..136 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 141..144 FT /evidence="ECO:0007829|PDB:2CE2" FT TURN 146..148 FT /evidence="ECO:0007829|PDB:2CE2" FT HELIX 152..164 FT /evidence="ECO:0007829|PDB:2CE2" SQ SEQUENCE 189 AA; 21298 MW; EE6DC2D933E2856A CRC64; MTEYKLVVVG AGGVGKSALT IQLIQNHFVD EYDPTIEDSY RKQVVIDGET CLLDILDTAG QEEYSAMRDQ YMRTGEGFLC VFAINNTKSF EDIHQYREQI KRVKDSDDVP MVLVGNKCDL AARTVESRQA QDLARSYGIP YIETSAKTRQ GVEDAFYTLV REIRQHKLRK LNPPDESGPG CMSCKCVLS // ID RET_HUMAN Reviewed; 1114 AA. AC P07949; A8K6Z2; Q15250; Q9BTB0; Q9H4A2; DT 01-AUG-1988, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-1994, sequence version 3. DT 28-JAN-2026, entry version 284. DE RecName: Full=Proto-oncogene tyrosine-protein kinase receptor Ret {ECO:0000305}; DE EC=2.7.10.1 {ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:28846099}; DE AltName: Full=Cadherin family member 12; DE AltName: Full=Proto-oncogene c-Ret {ECO:0000303|PubMed:2660074}; DE Contains: DE RecName: Full=Soluble RET kinase fragment {ECO:0000305|PubMed:21357690}; DE Contains: DE RecName: Full=Extracellular cell-membrane anchored RET cadherin 120 kDa fragment {ECO:0000305|PubMed:21357690}; DE Flags: Precursor; GN Name=RET {ECO:0000303|PubMed:2660074, ECO:0000312|HGNC:HGNC:9967}; GN Synonyms=CDHF12, CDHR16, PTC; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Prostate; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT CYS-982. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-280 (ISOFORMS 1/2). RX PubMed=2660074; RA Takahashi M.; RT "Isolation of ret proto-oncogene cDNA with an amino-terminal signal RT sequence."; RL Oncogene 4:805-806(1989). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 255-1114 (ISOFORM 1). RX PubMed=3078962; RA Takahashi M., Buma Y., Iwamoto T., Inaguma Y., Ikeda H., Hiai H.; RT "Cloning and expression of the ret proto-oncogene encoding a tyrosine RT kinase with two potential transmembrane domains."; RL Oncogene 3:571-578(1988). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 588-1063 (ISOFORM 2), AND CHROMOSOMAL RP TRANSLOCATION WITH TRIM27. RX PubMed=3037315; DOI=10.1128/mcb.7.4.1378-1385.1987; RA Takahashi M., Cooper G.M.; RT "ret transforming gene encodes a fusion protein homologous to tyrosine RT kinases."; RL Mol. Cell. Biol. 7:1378-1385(1987). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 713-1114 (ISOFORM 1), AND CHROMOSOMAL RP TRANSLOCATION WITH GOLGA5. RC TISSUE=Fibroblast; RX PubMed=2734021; RA Ishizaka Y., Ochiai M., Tahira T., Suhimura T., Nahao M.; RT "Activation of the ret-II oncogene without a sequence encoding a RT transmembrane domain and transforming activity of two ret-II oncogene RT products differing in carboxy-termini due to alternative splicing."; RL Oncogene 4:789-794(1989). RN [8] RP ERRATUM OF PUBMED:2734021. RA Ishizaka Y., Ochiai M., Tahira T., Suhimura T., Nahao M.; RL Oncogene 4:1415-1415(1989). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 713-1114 (ISOFORM 1), AND CHROMOSOMAL RP TRANSLOCATION WITH CCDC6. RC TISSUE=Thyroid papillary carcinoma; RX PubMed=2406025; DOI=10.1016/0092-8674(90)90659-3; RA Grieco M., Santoro M., Berlingieri M.T., Melillo R.M., Donghi R., RA Bongarzone I., Pierotti M.A., Della Porta G., Fusco A., Vecchio G.; RT "PTC is a novel rearranged form of the ret proto-oncogene and is frequently RT detected in vivo in human thyroid papillary carcinomas."; RL Cell 60:557-563(1990). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] OF 713-770 (ISOFORMS 1/2), AND CHROMOSOMAL RP TRANSLOCATION WITH PCM1. RX PubMed=10980597; DOI=10.1038/sj.onc.1203772; RA Corvi R., Berger N., Balczon R., Romeo G.; RT "RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma."; RL Oncogene 19:4236-4242(2000). RN [11] RP SUBCELLULAR LOCATION, AND COFACTOR. RX PubMed=9575150; DOI=10.1074/jbc.273.20.12077; RA van Weering D.H., Moen T.C., Braakman I., Baas P.D., Bos J.L.; RT "Expression of the receptor tyrosine kinase Ret on the plasma membrane is RT dependent on calcium."; RL J. Biol. Chem. 273:12077-12081(1998). RN [12] RP CHROMOSOMAL TRANSLOCATION WITH TRIM33 AND TRIM24. RX PubMed=10439047; DOI=10.1038/sj.onc.1202824; RA Klugbauer S., Rabes H.M.; RT "The transcription coactivator HTIF1 and a related protein are fused to the RT RET receptor tyrosine kinase in childhood papillary thyroid carcinomas."; RL Oncogene 18:4388-4393(1999). RN [13] RP PHOSPHORYLATION AT TYR-1015 AND TYR-1062. RX PubMed=11061555; DOI=10.1210/jcem.85.10.6882; RA Salvatore D., Barone M.V., Salvatore G., Melillo R.M., Chiappetta G., RA Mineo A., Fenzi G., Vecchio G., Fusco A., Santoro M.; RT "Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and RT ret-derived oncoproteins."; RL J. Clin. Endocrinol. Metab. 85:3898-3907(2000). RN [14] RP COFACTOR, AND MUTAGENESIS OF TYR-36; TYR-41 AND TRP-85. RX PubMed=11445581; DOI=10.1074/jbc.m104968200; RA Anders J., Kjar S., Ibanez C.F.; RT "Molecular modeling of the extracellular domain of the RET receptor RT tyrosine kinase reveals multiple cadherin-like domains and a calcium- RT binding site."; RL J. Biol. Chem. 276:35808-35817(2001). RN [15] RP PHOSPHORYLATION AT TYR-806; TYR-809; TYR-900; TYR-905; TYR-981; TYR-1015; RP TYR-1062; TYR-1090 AND TYR-1096. RX PubMed=14711813; DOI=10.1074/jbc.m312600200; RA Kawamoto Y., Takeda K., Okuno Y., Yamakawa Y., Ito Y., Taguchi R., Kato M., RA Suzuki H., Takahashi M., Nakashima I.; RT "Identification of RET autophosphorylation sites by mass spectrometry."; RL J. Biol. Chem. 279:14213-14224(2004). RN [16] RP CHROMOSOMAL TRANSLOCATION WITH TRIM27. RX PubMed=12787916; DOI=10.1016/s0027-5107(03)00056-3; RA Saenko V., Rogounovitch T., Shimizu-Yoshida Y., Abrosimov A., Lushnikov E., RA Roumiantsev P., Matsumoto N., Nakashima M., Meirmanov S., Ohtsuru A., RA Namba H., Tsyb A., Yamashita S.; RT "Novel tumorigenic rearrangement, Delta rfp/ret, in a papillary thyroid RT carcinoma from externally irradiated patient."; RL Mutat. Res. 527:81-90(2003). RN [17] RP RETRACTED PAPER. RX PubMed=16778204; DOI=10.1158/0008-5472.can-06-0228; RA Iervolino A., Iuliano R., Trapasso F., Viglietto G., Melillo R.M., RA Carlomagno F., Santoro M., Fusco A.; RT "The receptor-type protein tyrosine phosphatase J antagonizes the RT biochemical and biological effects of RET-derived oncoproteins."; RL Cancer Res. 66:6280-6287(2006). RN [18] RP RETRACTION NOTICE OF PUBMED:16778204. RX PubMed=30552125; DOI=10.1158/0008-5472.can-18-3456; RA Iervolino A., Iuliano R., Trapasso F., Viglietto G., Melillo R.M., RA Carlomagno F., Santoro M., Fusco A.; RL Cancer Res. 78:6907-6907(2018). RN [19] RP ACTIVITY REGULATION. RX PubMed=17884497; DOI=10.1016/j.bmcl.2007.07.104; RA Graham Robinett R., Freemerman A.J., Skinner M.A., Shewchuk L., Lackey K.; RT "The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET RT kinase inhibitors."; RL Bioorg. Med. Chem. Lett. 17:5886-5893(2007). RN [20] RP ACTIVITY REGULATION BY SORAFENIB. RX PubMed=17664273; DOI=10.1074/jbc.m703461200; RA Plaza-Menacho I., Mologni L., Sala E., Gambacorti-Passerini C., Magee A.I., RA Links T.P., Hofstra R.M.W., Barford D., Isacke C.M.; RT "Sorafenib functions to potently suppress RET tyrosine kinase activity by RT direct enzymatic inhibition and promoting RET lysosomal degradation RT independent of proteasomal targeting."; RL J. Biol. Chem. 282:29230-29240(2007). RN [21] RP ACTIVITY REGULATION BY 3- AND 4-SUBSTITUTED BETA-CARBOLIN-1-ONES. RX PubMed=19053769; DOI=10.1021/jm8007823; RA Cincinelli R., Cassinelli G., Dallavalle S., Lanzi C., Merlini L., RA Botta M., Tuccinardi T., Martinelli A., Penco S., Zunino F.; RT "Synthesis, modeling, and RET protein kinase inhibitory activity of 3- and RT 4-substituted beta-carbolin-1-ones."; RL J. Med. Chem. 51:7777-7787(2008). RN [22] RP INTERACTION WITH CD2AP, AND MUTAGENESIS OF LYS-758. RX PubMed=18753381; DOI=10.1523/jneurosci.2738-08.2008; RA Tsui C.C., Pierchala B.A.; RT "CD2AP and Cbl-3/Cbl-c constitute a critical checkpoint in the regulation RT of ret signal transduction."; RL J. Neurosci. 28:8789-8800(2008). RN [23] RP INTERACTION WITH AIP. RX PubMed=19366855; DOI=10.1210/jc.2008-1980; RA Vargiolu M., Fusco D., Kurelac I., Dirnberger D., Baumeister R., Morra I., RA Melcarne A., Rimondini R., Romeo G., Bonora E.; RT "The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon RT receptor-interacting protein to alter survivin availability."; RL J. Clin. Endocrinol. Metab. 94:2571-2578(2009). RN [24] RP INDUCTION BY NKX2-1; PHOX2B; SOX10 AND PAX3. RX PubMed=19853745; DOI=10.1016/j.jpedsurg.2008.11.055; RA Leon T.Y.Y., Ngan E.S.W., Poon H.-C., So M.-T., Lui V.C.H., Tam P.K.H., RA Garcia-Barcelo M.M.; RT "Transcriptional regulation of RET by Nkx2-1, Phox2b, Sox10, and Pax3."; RL J. Pediatr. Surg. 44:1904-1912(2009). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-696, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [26] RP FUNCTION IN DEVELOPMENT OF MECHANORECEPTORS. RX PubMed=20064382; DOI=10.1016/j.neuron.2009.12.014; RA Ma Q.; RT "RETouching upon mechanoreceptors."; RL Neuron 64:773-776(2009). RN [27] RP ACTIVITY REGULATION, AND REVIEW ON KINASE INHIBITORS. RX PubMed=20605972; DOI=10.1210/er.2009-0031; RA Ye L., Santarpia L., Gagel R.F.; RT "The evolving field of tyrosine kinase inhibitors in the treatment of RT endocrine tumors."; RL Endocr. Rev. 31:578-599(2010). RN [28] RP ACTIVITY REGULATION. RX PubMed=20409618; DOI=10.1016/j.ejmech.2010.03.017; RA Brandt W., Mologni L., Preu L., Lemcke T., Gambacorti-Passerini C., RA Kunick C.; RT "Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3- RT thienyl)nicotinonitrile scaffold."; RL Eur. J. Med. Chem. 45:2919-2927(2010). RN [29] RP FUNCTION IN PITUITARY. RX PubMed=20616503; DOI=10.1159/000318502; RA Garcia-Lavandeira M., Diaz-Rodriguez E., Garcia-Rendueles M.E., RA Rodrigues J.S., Perez-Romero S., Bravo S.B., Alvarez C.V.; RT "Functional role of the RET dependence receptor, GFRa co-receptors and RT ligands in the pituitary."; RL Front. Horm. Res. 38:127-138(2010). RN [30] RP FUNCTION IN CELL ADHESION/MIGRATION. RX PubMed=20702524; DOI=10.1210/jc.2010-0771; RA Cockburn J.G., Richardson D.S., Gujral T.S., Mulligan L.M.; RT "RET-mediated cell adhesion and migration require multiple integrin RT subunits."; RL J. Clin. Endocrinol. Metab. 95:E342-E346(2010). RN [31] RP SUBCELLULAR LOCATION. RX PubMed=19823924; DOI=10.1007/s10895-009-0548-x; RA Richardson D.S., Mulligan L.M.; RT "Direct visualization of vesicle maturation and plasma membrane protein RT trafficking."; RL J. Fluoresc. 20:401-405(2010). RN [32] RP ACTIVITY REGULATION. RX PubMed=21134556; DOI=10.1016/j.surg.2010.09.026; RA Samadi A.K., Mukerji R., Shah A., Timmermann B.N., Cohen M.S.; RT "A novel RET inhibitor with potent efficacy against medullary thyroid RT cancer in vivo."; RL Surgery 148:1228-1236(2010). RN [33] RP FUNCTION IN CELL ADHESION, FUNCTION IN APOPTOSIS, PROTEOLYTIC PROCESSING BY RP CASPASE-3 AT ASP-707 AND ASP-1017, MUTAGENESIS OF ASP-707; LYS-758 AND RP 708-ALA--SER-1114, AND SUBUNIT. RX PubMed=21357690; DOI=10.1074/jbc.m110.195461; RA Cabrera J.R., Bouzas-Rodriguez J., Tauszig-Delamasure S., Mehlen P.; RT "RET modulates cell adhesion via its cleavage by caspase in sympathetic RT neurons."; RL J. Biol. Chem. 286:14628-14638(2011). RN [34] RP INTERACTION WITH PTK2/FAK1, AND FUNCTION IN PTK2/FAK1 PHOSPHORYLATION. RX PubMed=21454698; DOI=10.1074/jbc.m110.168500; RA Plaza-Menacho I., Morandi A., Mologni L., Boender P., RA Gambacorti-Passerini C., Magee A.I., Hofstra R.M.W., Knowles P., RA McDonald N.Q., Isacke C.M.; RT "Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming RT a direct and reciprocal RET-FAK transactivation mechanism."; RL J. Biol. Chem. 286:17292-17302(2011). RN [35] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=21994944; DOI=10.1074/jbc.m111.246413; RA Geng Z., Xu F.Y., Huang S.H., Chen Z.Y.; RT "Sorting protein-related receptor SorLA controls regulated secretion of RT glial cell line-derived neurotrophic factor."; RL J. Biol. Chem. 286:41871-41882(2011). RN [36] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=23333276; DOI=10.1016/j.celrep.2012.12.011; RA Glerup S., Lume M., Olsen D., Nyengaard J.R., Vaegter C.B., Gustafsen C., RA Christensen E.I., Kjolby M., Hay-Schmidt A., Bender D., Madsen P., RA Saarma M., Nykjaer A., Petersen C.M.; RT "SorLA controls neurotrophic activity by sorting of GDNF and its receptors RT GFRalpha1 and RET."; RL Cell Rep. 3:186-199(2013). RN [37] RP INTERACTION WITH GFRAL, SUBCELLULAR LOCATION, FUNCTION, AND MUTAGENESIS OF RP TYR-1062. RX PubMed=28953886; DOI=10.1038/nature24042; RA Hsu J.Y., Crawley S., Chen M., Ayupova D.A., Lindhout D.A., Higbee J., RA Kutach A., Joo W., Gao Z., Fu D., To C., Mondal K., Li B., Kekatpure A., RA Wang M., Laird T., Horner G., Chan J., McEntee M., Lopez M., RA Lakshminarasimhan D., White A., Wang S.P., Yao J., Yie J., Matern H., RA Solloway M., Haldankar R., Parsons T., Tang J., Shen W.D., Alice Chen Y., RA Tian H., Allan B.B.; RT "Non-homeostatic body weight regulation through a brainstem-restricted RT receptor for GDF15."; RL Nature 550:255-259(2017). RN [38] RP ERRATUM OF PUBMED:28953886. RX PubMed=29144449; DOI=10.1038/nature24481; RA Hsu J.Y., Crawley S., Chen M., Ayupova D.A., Lindhout D.A., Higbee J., RA Kutach A., Joo W., Gao Z., Fu D., To C., Mondal K., Li B., Kekatpure A., RA Wang M., Laird T., Horner G., Chan J., McEntee M., Lopez M., RA Lakshminarasimhan D., White A., Wang S.P., Yao J., Yie J., Matern H., RA Solloway M., Haldankar R., Parsons T., Tang J., Shen W.D., Alice Chen Y., RA Tian H., Allan B.B.; RT "Non-homeostatic body weight regulation through a brainstem-restricted RT receptor for GDF15."; RL Nature 551:398-398(2017). RN [39] RP FUNCTION, AND INTERACTION WITH GFRAL. RX PubMed=28846097; DOI=10.1038/nm.4392; RA Mullican S.E., Lin-Schmidt X., Chin C.N., Chavez J.A., Furman J.L., RA Armstrong A.A., Beck S.C., South V.J., Dinh T.Q., Cash-Mason T.D., RA Cavanaugh C.R., Nelson S., Huang C., Hunter M.J., Rangwala S.M.; RT "GFRAL is the receptor for GDF15 and the ligand promotes weight loss in RT mice and nonhuman primates."; RL Nat. Med. 23:1150-1157(2017). RN [40] RP FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH GFRAL, AND PHOSPHORYLATION RP AT TYR-905 AND TYR-1062. RX PubMed=28846099; DOI=10.1038/nm.4394; RA Yang L., Chang C.C., Sun Z., Madsen D., Zhu H., Padkjaer S.B., Wu X., RA Huang T., Hultman K., Paulsen S.J., Wang J., Bugge A., Frantzen J.B., RA Noergaard P., Jeppesen J.F., Yang Z., Secher A., Chen H., Li X., John L.M., RA Shan B., He Z., Gao X., Su J., Hansen K.T., Yang W., Joergensen S.B.; RT "GFRAL is the receptor for GDF15 and is required for the anti-obesity RT effects of the ligand."; RL Nat. Med. 23:1158-1166(2017). RN [41] RP GLYCOSYLATION AT SER-688. RX PubMed=26237509; DOI=10.1038/nsmb.3063; RA Pathak S., Alonso J., Schimpl M., Rafie K., Blair D.E., Borodkin V.S., RA Albarbarawi O., van Aalten D.M.F.; RT "The active site of O-GlcNAc transferase imposes constraints on substrate RT sequence."; RL Nat. Struct. Mol. Biol. 22:744-750(2015). RN [42] {ECO:0007744|PDB:2IVS, ECO:0007744|PDB:2IVT, ECO:0007744|PDB:2IVU, ECO:0007744|PDB:2IVV} RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 705-1013 ALONE AND IN COMPLEX WITH RP INHIBITORS, IDENTIFICATION BY MASS SPECTROMETRY, AND PHOSPHORYLATION AT RP TYR-900 AND TYR-905. RX PubMed=16928683; DOI=10.1074/jbc.m605604200; RA Knowles P.P., Murray-Rust J., Kjaer S., Scott R.P., Hanrahan S., RA Santoro M., Ibanez C.F., McDonald N.Q.; RT "Structure and chemical inhibition of the RET tyrosine kinase domain."; RL J. Biol. Chem. 281:33577-33587(2006). RN [43] {ECO:0007744|PDB:2X2K, ECO:0007744|PDB:2X2L, ECO:0007744|PDB:2X2M} RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 705-1013 IN COMPLEX WITH RP INHIBITORS, ACTIVITY REGULATION, AND PHOSPHORYLATION AT TYR-905. RX PubMed=20117004; DOI=10.1016/j.bmc.2010.01.011; RA Mologni L., Rostagno R., Brussolo S., Knowles P.P., Kjaer S., RA Murray-Rust J., Rosso E., Zambon A., Scapozza L., McDonald N.Q., RA Lucchini V., Gambacorti-Passerini C.; RT "Synthesis, structure-activity relationship and crystallographic studies of RT 3-substituted indolin-2-one RET inhibitors."; RL Bioorg. Med. Chem. 18:1482-1496(2010). RN [44] {ECO:0007744|PDB:2X2U} RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 29-270, GLYCOSYLATION AT ASN-151, RP AND DISULFIDE BONDS. RX PubMed=20473317; DOI=10.1038/nsmb.1808; RA Kjaer S., Hanrahan S., Totty N., McDonald N.Q.; RT "Mammal-restricted elements predispose human RET to folding impairment by RT HSCR mutations."; RL Nat. Struct. Mol. Biol. 17:726-731(2010). RN [45] {ECO:0007744|PDB:4UX8} RP STRUCTURE BY ELECTRON MICROSCOPY (24.00 ANGSTROMS) OF 29-635 IN COMPLEX RP WITH GFRA1; GDNF AND CALCIUM, FUNCTION, COFACTOR, AND DISULFIDE BONDS. RX PubMed=25242331; DOI=10.1016/j.celrep.2014.08.040; RA Goodman K.M., Kjaer S., Beuron F., Knowles P.P., Nawrotek A., Burns E.M., RA Purkiss A.G., George R., Santoro M., Morris E.P., McDonald N.Q.; RT "RET recognition of GDNF-GFRalpha1 ligand by a composite binding site RT promotes membrane-proximal self-association."; RL Cell Rep. 8:1894-1904(2014). RN [46] {ECO:0007744|PDB:4CKI, ECO:0007744|PDB:4CKJ} RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 705-1013 IN COMPLEX WITH RP ADENOSINE, FUNCTION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-687; RP TYR-826; TYR-900; TYR-905; TYR-981; TYR-1015; TYR-1029 AND TYR-1062, RP MUTAGENESIS OF GLU-734; LYS-758; ARG-912 AND ILE-913, VARIANT MEN2B RP THR-918, CHARACTERIZATION OF VARIANT MEN2B THR-918, VARIANT MTC MET-804, RP AND CHARACTERIZATION OF VARIANT MTC MET-804. RX PubMed=24560924; DOI=10.1016/j.molcel.2014.01.015; RA Plaza-Menacho I., Barnouin K., Goodman K., Martinez-Torres R.J., Borg A., RA Murray-Rust J., Mouilleron S., Knowles P., McDonald N.Q.; RT "Oncogenic RET kinase domain mutations perturb the autophosphorylation RT trajectory by enhancing substrate presentation in trans."; RL Mol. Cell 53:738-751(2014). RN [47] {ECO:0007744|PDB:6NE7, ECO:0007744|PDB:6NEC, ECO:0007744|PDB:6NJA} RP X-RAY CRYSTALLOGRAPHY (1.87 ANGSTROMS) OF 705-1013, FUNCTION, ACTIVITY RP REGULATION, VARIANT MTC VAL-881, CHARACTERIZATION OF VARIANT MTC VAL-881, RP VARIANT ALA-810, AND CHARACTERIZATION OF VARIANT ALA-810. RX PubMed=31118272; DOI=10.1074/jbc.ra119.007682; RA Terzyan S.S., Shen T., Liu X., Huang Q., Teng P., Zhou M., Hilberg F., RA Cai J., Mooers B.H.M., Wu J.; RT "Structural basis of resistance of mutant RET protein-tyrosine kinase to RT its inhibitors nintedanib and vandetanib."; RL J. Biol. Chem. 294:10428-10437(2019). RN [48] {ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, ECO:0007744|PDB:6Q2S} RP STRUCTURE BY ELECTRON MICROSCOPY (3.65 ANGSTROMS) OF 29-635 IN COMPLEX WITH RP CALCIUM; GDF15; GFRAL; GFRA1; GFRA2; GFRA3; GDNF; NRTN AND ARTN, COFACTOR, RP AND DISULFIDE BONDS. RX PubMed=31535977; DOI=10.7554/elife.47650; RA Li J., Shang G., Chen Y.J., Brautigam C.A., Liou J., Zhang X., Bai X.C.; RT "Cryo-EM analyses reveal the common mechanism and diversification in the RT activation of RET by different ligands."; RL Elife 8:0-0(2019). RN [49] RP REVIEW ON HSCR VARIANTS. RX PubMed=9359036; RA Hofstra R.M.W., Osinga J., Buys C.H.C.M.; RT "Mutations in Hirschsprung disease: when does a mutation contribute to the RT phenotype."; RL Eur. J. Hum. Genet. 5:180-185(1997). RN [50] RP VARIANTS MEN2A/MTC TYR-611; PHE-618; GLY-620 AND PHE-630. RX PubMed=9067749; RX DOI=10.1002/(sici)1098-1004(1997)9:2<97::aid-humu1>3.0.co;2-m; RA Eng C., Mulligan L.M.; RT "Mutations of the RET proto-oncogene in the multiple endocrine neoplasia RT type 2 syndromes, related sporadic tumours, and Hirschsprung disease."; RL Hum. Mutat. 9:97-109(1997). RN [51] RP VARIANTS MEN2A/MTC TRP-611; SER-618; TYR-618; ARG-620; TYR-620 AND ARG-634. RX PubMed=8103403; DOI=10.1093/hmg/2.7.851; RA Donis-Keller H., Dou S., Chi D., Carlson K.M., Toshima K., Lairmore T.C., RA Howe J.R., Moley J.F., Goodfellow P., Wells S.A. Jr.; RT "Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC."; RL Hum. Mol. Genet. 2:851-856(1993). RN [52] RP VARIANTS MEN2A GLY-618; 632-GLU--CYS-634 DELINS ASP-VAL-ARG; GLY-634; RP PHE-634; TYR-634 AND SER-634. RX PubMed=8099202; DOI=10.1038/363458a0; RA Mulligan L.M., Kwok J.B.J., Healey C.S., Elsdon M.J., Eng C., Gardner E., RA Love D.R., Mole S.E., Moore J.K., Papi L., Ponder M.A., Telenius H., RA Tunnacliffe A., Ponder B.A.J.; RT "Germ-line mutations of the RET proto-oncogene in multiple endocrine RT neoplasia type 2A."; RL Nature 363:458-460(1993). RN [53] RP VARIANTS HSCR1 PRO-40; LEU-399; GLN-762; PRO-765; GLN-897; GLY-972 AND RP LEU-973. RX PubMed=7704557; DOI=10.1159/000472371; RA Yin L., Barone V., Seri M., Bolino A., Bocciardi R., Ceccherini I., RA Pasini B., Tocco T., Lerone M., Cywes S., Moore S., Vanderwinden J.-M., RA Abramowicz M.J., Kristoffersson U., Larsson L.T., Hamel B.C.J., Silengo M., RA Martucciello G., Romeo G.; RT "Heterogeneity and low detection rate of RET mutations in Hirschsprung RT disease."; RL Eur. J. Hum. Genet. 2:272-280(1994). RN [54] RP VARIANT MEN2B THR-918. RX PubMed=7911697; DOI=10.1093/hmg/3.2.237; RA Eng C., Smith D.P., Mulligan L.M., Nagai M.A., Healey C.S., Ponder M.A., RA Gardner E., Scheumann G.F., Jackson C.E., Tunnacliffe A., Ponder B.A.J.; RT "Point mutation within the tyrosine kinase domain of the RET proto-oncogene RT in multiple endocrine neoplasia type 2B and related sporadic tumours."; RL Hum. Mol. Genet. 3:237-241(1994). RN [55] RP VARIANTS MEN2A/MTC ARG-618; SER-618; PHE-620; ARG-620; PHE-634; GLY-634 AND RP TYR-634. RX PubMed=7915165; DOI=10.1093/hmg/3.4.635; RA Xue F., Yu H., Maurer L.H., Memoli V.A., Nutile-Mcmenemy N., Schuster M.K., RA Browden D.W., Mao J.-I., Noll W.W.; RT "Germline RET mutations in MEN 2A and FMTC and their detection by simple RT DNA diagnostic tests."; RL Hum. Mol. Genet. 3:635-638(1994). RN [56] RP VARIANTS MTC/MEN2A TYR-609; ARG-618; SER-618 AND SER-620. RX PubMed=7849720; DOI=10.1093/hmg/3.10.1895; RA Blaugrund J.E., Johns M.M. Jr., Eby Y.J., Ball D.W., Baylin S.B., RA Hruban R.H., Sidransky D.; RT "RET proto-oncogene mutations in inherited and sporadic medullary thyroid RT cancer."; RL Hum. Mol. Genet. 3:1895-1897(1994). RN [57] RP VARIANTS MTC, AND VARIANTS MEN2A. RX PubMed=7874109; DOI=10.1093/hmg/3.11.1939; RA Schuffenecker I., Billaud M., Calender A., Chambe B., Ginet N., RA Calmettes C., Modigliani E., Lenoir G.M.; RT "RET proto-oncogene mutations in French MEN 2A and FMTC families."; RL Hum. Mol. Genet. 3:1939-1943(1994). RN [58] RP VARIANTS HSCR1 TRP-609; ARG-618 AND ARG-620, VARIANT MEN2A ARG-618, AND RP VARIANT MTC ARG-620. RX PubMed=7881414; DOI=10.1093/hmg/3.12.2163; RA Mulligan L.M., Eng C., Attie T., Lyonnet S., Marsh D.J., Hyland V.J., RA Robinson B.G., Frilling A., Verellen-Dumoulin C., Safar A., Venter D.J., RA Munnich A., Ponder B.A.J.; RT "Diverse phenotypes associated with exon 10 mutations of the RET proto- RT oncogene."; RL Hum. Mol. Genet. 3:2163-2167(1994). RN [59] RP VARIANT HSCR1 LYS-921. RX PubMed=7997019; DOI=10.1016/s0140-6736(94)92908-4; RA Pelet A., Attie T., Goulet O., Eng C., Ponder B.A., Munnich A., Lyonnet S.; RT "De-novo mutations of the RET proto-oncogene in Hirschsprung's disease."; RL Lancet 344:1769-1770(1994). RN [60] RP VARIANT MEN2B THR-918. RX PubMed=7906866; DOI=10.1038/367375a0; RA Hofstra R.M.W., Landsvater R.M., Ceccherini I., Stulp R.P., Stelwagen T., RA Luo Y., Pasini B., Hoeppener J.W.M., Ploos van Amstel H.K., Romeo G., RA Lips C.J.M., Buys C.H.C.M.; RT "A mutation in the RET proto-oncogene associated with multiple endocrine RT neoplasia type 2B and sporadic medullary thyroid carcinoma."; RL Nature 367:375-376(1994). RN [61] RP VARIANTS HSCR1 PRO-765; GLN-897 AND GLY-972. RX PubMed=8114938; DOI=10.1038/367377a0; RA Romeo G., Ronchetto P., Luo Y., Barone V., Seri M., Ceccherini I., RA Pasini B., Bocciardi R., Lerone M., Kaarlainen H., Martucciello G.; RT "Point mutations affecting the tyrosine kinase domain of the RET proto- RT oncogene in Hirschsprung's disease."; RL Nature 367:377-378(1994). RN [62] RP VARIANTS HSCR1 LEU-32; LEU-64; GLN-330 AND LEU-393. RX PubMed=8114939; DOI=10.1038/367378a0; RA Edery P., Lyonnet S., Mulligan L.M., Pelet A., Dow E., Abel L., Holder S., RA Nihoul-Fkete C., Ponder B.A.J., Munnich A.; RT "Mutations of the RET proto-oncogene in Hirschsprung's disease."; RL Nature 367:378-380(1994). RN [63] RP VARIANT MEN2B THR-918. RX PubMed=7906417; DOI=10.1073/pnas.91.4.1579; RA Carlson K.M., Dou S., Chi D., Scavarda N., Toshima K., Jackson C.E., RA Wells S.A. Jr., Goodfellow P.J., Donis-Keller H.; RT "Single missense mutation in the tyrosine kinase catalytic domain of the RT RET protooncogene is associated with multiple endocrine neoplasia type RT 2B."; RL Proc. Natl. Acad. Sci. U.S.A. 91:1579-1583(1994). RN [64] RP VARIANTS MTC; MEN2A AND MEN2B. RX PubMed=8625130; RX DOI=10.1002/1097-0142(19950801)76:3<479::aid-cncr2820760319>3.0.co;2-m; RA Komminoth P., Kunz E.K., Matias-Guiu X., Hiort O., Christiansen G., RA Colomer A., Roth J., Heitz P.U.; RT "Analysis of RET protooncogene point mutations distinguishes heritable from RT nonheritable medullary thyroid carcinomas."; RL Cancer 76:479-489(1995). RN [65] RP VARIANTS MEN2A SER-618; SER-620; ARG-634 AND TYR-634. RX PubMed=7860065; DOI=10.1007/bf00209399; RA Takiguchi-Shirahama S., Koyama K., Miyauchi A., Wakasugi T., Oishi S., RA Takami H., Hikiji K., Nakamura Y.; RT "Germline mutations of the RET proto-oncogene in eight Japanese patients RT with multiple endocrine neoplasia type 2A (MEN2A)."; RL Hum. Genet. 95:187-190(1995). RN [66] RP VARIANTS HSCR1 LEU-20; SER-93; GLN-330; TYR-609 AND ARG-620, AND VARIANT RP CYS-982. RC TISSUE=Blood; RX PubMed=7633441; DOI=10.1093/hmg/4.5.821; RA Angrist M., Bolk S., Thiel B., Puffenberger E.G., Hofstra R.M.W., RA Buys C.H.C.M., Cass D.T., Chakravarti A.; RT "Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung RT disease."; RL Hum. Mol. Genet. 4:821-830(1995). RN [67] RP VARIANTS HSCR1 HIS-231 AND LYS-251. RC TISSUE=Leukocyte; RX PubMed=7581377; DOI=10.1093/hmg/4.8.1381; RA Attie T., Pelet A., Edery P., Eng C., Mulligan L.M., Amiel J., Boutrand L., RA Beldjord C., Nihoul-Fekete C., Munnich A., Ponder B.A.J., Lyonnet S.; RT "Diversity of RET proto-oncogene mutations in familial and sporadic RT Hirschsprung disease."; RL Hum. Mol. Genet. 4:1381-1386(1995). RN [68] RP VARIANT MEN2B THR-918, AND VARIANT TYR-922. RX PubMed=8595427; DOI=10.1093/hmg/4.10.1987; RA Kitamura Y., Scavarda N., Wells S.A. Jr., Jackson C.E., Goodfellow P.J.; RT "Two maternally derived missense mutations in the tyrosine kinase domain of RT the RET protooncogene in a patient with de novo MEN 2B."; RL Hum. Mol. Genet. 4:1987-1988(1995). RN [69] RP VARIANT MTC ASP-768. RX PubMed=7845675; RA Eng C., Smith D.P., Mulligan L.M., Healey C.S., Zvelebil M.J., RA Stonehouse T.J., Ponder M.A., Jackson C.E., Waterfield M.D., Ponder B.A.J.; RT "A novel point mutation in the tyrosine kinase domain of the RET proto- RT oncogene in sporadic medullary thyroid carcinoma and in a family with RT FMTC."; RL Oncogene 10:509-513(1995). RN [70] RP VARIANTS MTC ASP-768 AND LEU-804. RX PubMed=7784092; RA Bolino A., Schuffenecker I., Luo Y., Seri M., Silengo M., Tocco T., RA Chabrier G., Houdent C., Murat A., Schlumberger M., Tournaire J., RA Lenoir G.M., Romeo G.; RT "RET mutations in exons 13 and 14 of FMTC patients."; RL Oncogene 10:2415-2419(1995). RN [71] RP VARIANTS HSCR1 TYR-157; LYS-359; TYR-609; ARG-620; ASN-1059 DEL AND RP PRO-1061. RA Hofstra R.M.W., Osinga J., Stulp R.P., Scheffer H., Meijers C., RA Buys C.H.C.M.; RT "Mutations in three genes are found associated with the development of RT Hirschsprung disease: RET, EDNRB and EDN3."; RL Am. J. Hum. Genet. 59:A263-A263(1996). RN [72] RP VARIANTS HSCR1 PRO-40 AND PRO-765. RX PubMed=9043870; DOI=10.1159/000472232; RA Yin L., Seri M., Barone V., Tocco T., Scaranari M., Romeo G.; RT "Prevalence and parental origin of de novo RET mutations in Hirschsprung's RT disease."; RL Eur. J. Hum. Genet. 4:356-358(1996). RN [73] RP VARIANTS MTC/MEN2A. RX PubMed=8557249; DOI=10.1007/bf00218825; RA Landsvater R.M., Jansen R.P.M., Hofstra R.M.W., Buys C.H.C.M., Lips C.J.M., RA van Amstel H.K.P.; RT "Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, RT MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A."; RL Hum. Genet. 97:11-14(1996). RN [74] RP VARIANT MTC ASP-768, VARIANTS MEN2A ARG-609; GLY-609; SER-611 AND ARG-611, RP AND VARIANT MEN2B THR-918. RX PubMed=8807338; RX DOI=10.1002/(sici)1098-1004(1996)8:1<64::aid-humu9>3.0.co;2-p; RA Kambouris M., Jackson C.E., Feldman G.L.; RT "Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial RT medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses RT of RET proto-oncogene mutations."; RL Hum. Mutat. 8:64-70(1996). RN [75] RP VARIANTS MEN2A. RX PubMed=8626834; DOI=10.1210/jcem.81.5.8626834; RA Frank-Raue K., Hoeppner W., Frilling A., Kotzerke J., Dralle H., Haase R., RA Mann K., Seif F., Kirchner R., Rendl J., Deckart H.F., Ritter M.M., RA Hampel R., Klempa J., Scholz G.H., Raue F., Bogner U., Brabant G., RA Grussendorf M., Hartenstein C.H., Heidemann P., Hensen J., Doerr A.G., RA Hoehne T., Hoernig-Franz I., Huefner M., Kress J., Langer H.J., RA Lottermoser K., Schweikert H.U., Kusterer K., Menken U., Mercier J., RA Oelkers W., Sauer J., Simon D., Starrach G., Ziegler R.; RT "Mutations of the ret protooncogene in German multiple endocrine neoplasia RT families: relation between genotype and phenotype."; RL J. Clin. Endocrinol. Metab. 81:1780-1783(1996). RN [76] RP VARIANT HSCR1 LEU-893. RX PubMed=9174404; DOI=10.1002/bies.950190506; RA Edery P., Eng C., Munnich A., Lyonnet S.; RT "RET in human development and oncogenesis."; RL Bioessays 19:389-395(1997). RN [77] RP VARIANT MEN2A HIS-GLU-LEU-CYS-634 INS. RX PubMed=9097963; DOI=10.1093/hmg/6.4.587; RA Hoeppner W., Ritter M.M.; RT "A duplication of 12 bp in the critical cysteine rich domain of the RET RT proto-oncogene results in a distinct phenotype of multiple endocrine RT neoplasia type 2A."; RL Hum. Mol. Genet. 6:587-590(1997). RN [78] RP VARIANTS HSCR1 PRO-180; GLN-313; ARG-620 AND PHE-791. RX PubMed=9090527; RX DOI=10.1002/(sici)1098-1004(1997)9:3<243::aid-humu5>3.0.co;2-8; RA Seri M., Yin L., Barone V., Bolino A., Celli I., Bocciardi R., Pasini B., RA Ceccherini I., Lerone M., Kristoffersson U., Larsson L.T., Casasa J.M., RA Cass D.T., Abramowicz M.J., Vanderwinden J.-M., Kravcenkiene I., Baric I., RA Silengo M., Martucciello G., Romeo G.; RT "Frequency of RET mutations in long- and short-segment Hirschsprung RT disease."; RL Hum. Mutat. 9:243-249(1997). RN [79] RP VARIANT MTC ARG-618, AND VARIANT HSCR1 ARG-618. RX PubMed=9259198; RX DOI=10.1002/(sici)1098-1004(1997)10:2<155::aid-humu7>3.0.co;2-j; RA Peretz H., Luboshitsky R., Baron E., Biton A., Gershoni R., Usher S., RA Grynberg E., Yakobson E., Graff E., Lapidot M.; RT "Cys 618 Arg mutation in the RET proto-oncogene associated with familial RT medullary thyroid carcinoma and maternally transmitted Hirschsprung's RT disease suggesting a role for imprinting."; RL Hum. Mutat. 10:155-159(1997). RN [80] RP VARIANT MEN2B PHE-883. RC TISSUE=Peripheral blood leukocyte; RX PubMed=9360560; DOI=10.1210/jcem.82.11.4508; RA Gimm O., Marsh D.J., Andrew S.D., Frilling A., Dahia P.L.M., Mulligan L.M., RA Zajac J.D., Robinson B.G., Eng C.; RT "Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in RT multiple endocrine neoplasia type 2B without codon 918 mutation."; RL J. Clin. Endocrinol. Metab. 82:3902-3904(1997). RN [81] RP VARIANT MTC ALA-891. RX PubMed=9398735; DOI=10.1210/jcem.82.12.4439; RA Hofstra R.M.W., Fattoruso O., Quadro L., Wu Y., Libroia A., Verga U., RA Colantuoni V., Buys C.H.C.M.; RT "A novel point mutation in the intracellular domain of the ret RT protooncogene in a family with medullary thyroid carcinoma."; RL J. Clin. Endocrinol. Metab. 82:4176-4178(1997). RN [82] RP VARIANTS HSCR1 SER-174 AND TYR-197. RX PubMed=9094028; DOI=10.1016/s0022-3468(97)90616-3; RA Kusafuka T., Wang Y., Puri P.; RT "Mutation analysis of the RET, the endothelin-B receptor, and the RT endothelin-3 genes in sporadic cases of Hirschsprung's disease."; RL J. Pediatr. Surg. 32:501-504(1997). RN [83] RP VARIANTS MTC TYR-630 AND SER-630, AND VARIANT SER-691. RX PubMed=9223675; DOI=10.1038/sj.onc.1201102; RA Kitamura Y., Goodfellow P.J., Shimizu K., Nagahama M., Ito K., Kitagawa W., RA Akasu H., Takami H., Tanaka S., Wells S.A. Jr.; RT "Novel germline RET proto-oncogene mutations associated with medullary RT thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC."; RL Oncogene 14:3103-3106(1997). RN [84] RP VARIANT MEN2B PHE-883. RX PubMed=9294615; DOI=10.1038/sj.onc.1201481; RA Smith D.P., Houghton C., Ponder B.A.J.; RT "Germline mutation of RET codon 883 in two cases of de novo MEN 2B."; RL Oncogene 15:1213-1217(1997). RN [85] RP VARIANT HSCR1 LEU-1039, AND VARIANT SER-691. RX PubMed=9497256; DOI=10.1086/301759; RA Amiel J., Salomon R., Attie T., Pelet A., Trang H., Mokhtari M., RA Gaultier C., Munnich A., Lyonnet S.; RT "Mutations of the RET-GDNF signaling pathway in Ondine's curse."; RL Am. J. Hum. Genet. 62:715-717(1998). RN [86] RP VARIANT MTC GLY-611. RX PubMed=9677065; RX DOI=10.1002/(sici)1096-8628(19980707)78:3<271::aid-ajmg13>3.0.co;2-c; RA Oriola J., Paramo C., Halperin I., Garcia-Mayor R.V., Rivera-Fillat F.; RT "Novel point mutation in exon 10 of the RET proto-oncogene in a family with RT medullary thyroid carcinoma."; RL Am. J. Med. Genet. 78:271-273(1998). RN [87] RP VARIANT CYS-982. RX PubMed=9760196; DOI=10.1007/s004390050797; RA Svensson P.J., Anvret M., Molander M.L., Nordenskjold A.; RT "Phenotypic variation in a family with mutations in two Hirschsprung- RT related genes (RET and endothelin receptor B)."; RL Hum. Genet. 103:145-148(1998). RN [88] RP VARIANTS MEN2A TYR-609; SER-618; ARG-620 AND TRP-620, AND VARIANTS HSCR1 RP TYR-609; SER-618; ARG-620 AND TRP-620. RX PubMed=9384613; DOI=10.1093/hmg/7.1.129; RA Decker R.A., Peacock M.L., Watson P.; RT "Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 RT genotypes and strong genotype-phenotype correlation."; RL Hum. Mol. Genet. 7:129-134(1998). RN [89] RP VARIANT MEN2A CYS-ARG-THR-636 INS. RX PubMed=9452064; DOI=10.1002/humu.1380110143; RA Hoeppner W., Dralle H., Brabant G.; RT "Duplication of 9 base pairs in the critical cysteine-rich domain of the RT RET proto-oncogene causes multiple endocrine neoplasia type 2A."; RL Hum. Mutat. Suppl. 1:S128-S130(1998). RN [90] RP VARIANT MTC MET-804. RX PubMed=9452077; DOI=10.1002/humu.1380110156; RA Fattoruso O., Quadro L., Libroia A., Verga U., Lupoli G., Cascone E., RA Colantuoni V.; RT "A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET RT proto-oncogene in two families affected by familial medullary thyroid RT carcinoma."; RL Hum. Mutat. Suppl. 1:S167-S171(1998). RN [91] RP VARIANTS MTC/MEN2A PHE-790 AND PHE-791. RX PubMed=9506724; DOI=10.1210/jcem.83.3.4619; RA Berndt I., Reuter M., Saller B., Frank-Raue K., Groth P., Grussendorf M., RA Raue F., Ritter M.M., Hoeppner W.; RT "A new hot spot for mutations in the ret protooncogene causing familial RT medullary thyroid carcinoma and multiple endocrine neoplasia type 2A."; RL J. Clin. Endocrinol. Metab. 83:770-774(1998). RN [92] RP VARIANTS MTC AND MEN2A. RX PubMed=9621513; DOI=10.1007/s100380050048; RA Shirahama S., Ogura K., Takami H., Ito K., Tohsen T., Miyauchi A., RA Nakamura Y.; RT "Mutational analysis of the RET proto-oncogene in 71 Japanese patients with RT medullary thyroid carcinoma."; RL J. Hum. Genet. 43:101-106(1998). RN [93] RP VARIANTS HSCR1 LYS-626 AND GLN-813. RX PubMed=10090908; DOI=10.1086/302329; RA Auricchio A., Griseri P., Carpentieri M.L., Betsos N., Staiano A., RA Tozzi A., Priolo M., Thompson H., Bocciardi R., Romeo G., Ballabio A., RA Ceccherini I.; RT "Double heterozygosity for a RET substitution interfering with splicing and RT an EDNRB missense mutation in Hirschsprung disease."; RL Am. J. Hum. Genet. 64:1216-1221(1999). RN [94] RP VARIANTS HSCR1 ASN-1059 DEL AND PRO-1061. RX PubMed=10484767; DOI=10.1093/hmg/8.11.1989; RA Geneste O., Bidaud C., De Vita G., Hofstra R.M.W., Tartare-Deckert S., RA Buys C.H.C.M., Lenoir G.M., Santoro M., Billaud M.; RT "Two distinct mutations of the RET receptor causing Hirschsprung's disease RT impair the binding of signalling effectors to a multifunctional docking RT site."; RL Hum. Mol. Genet. 8:1989-1999(1999). RN [95] RP VARIANT MTC GLU-GLU-CYS-531 INS. RX PubMed=10323403; DOI=10.1210/jcem.84.5.5665; RA Pigny P., Bauters C., Wemeau J.-L., Houcke M.L., Crepin M., Caron P., RA Giraud S., Calender A., Buisine M.-P., Kerckaert J.-P., Porchet N.; RT "A novel 9-base pair duplication in RET exon 8 in familial medullary RT thyroid carcinoma."; RL J. Clin. Endocrinol. Metab. 84:1700-1704(1999). RN [96] RP VARIANT MEN2A GLY-640. RX PubMed=10522989; DOI=10.1210/jcem.84.10.6056; RA Tessitore A., Sinisi A.A., Pasquali D., Cardone M., Vitale D., RA Bellastella A., Colantuoni V.; RT "A novel case of multiple endocrine neoplasia type 2A associated with two RT de novo mutations of the RET protooncogene."; RL J. Clin. Endocrinol. Metab. 84:3522-3527(1999). RN [97] RP VARIANTS HSCR1 GLN-287; PRO-690; ARG-767 AND GLN-873. RX PubMed=10664228; DOI=10.1007/s004310050043; RA Sakai T., Nirasawa Y., Itoh Y., Wakizaka A.; RT "Japanese patients with sporadic Hirschsprung: mutation analysis of the RT receptor tyrosine kinase proto-oncogene, endothelin-B receptor, endothelin- RT 3, glial cell line-derived neurotrophic factor and neurturin genes: a RT comparison with similar studies."; RL Eur. J. Pediatr. 159:160-167(2000). RN [98] RP VARIANTS MTC MET-804 AND LEU-844. RX PubMed=10826520; DOI=10.1055/s-2000-5806; RA Bartsch D.K., Hasse C., Schug C., Barth P., Rothmund M., Hoeppner W.; RT "A RET double mutation in the germline of a kindred with FMTC."; RL Exp. Clin. Endocrinol. Diabetes 108:128-132(2000). RN [99] RP VARIANT GLN-600. RX PubMed=10612852; RX DOI=10.1002/(sici)1098-1004(200001)15:1<122::aid-humu41>3.0.co;2-7; RA Saez M.E., Ruiz A., Cebrian A., Morales F., Robledo M., Antinolo G., RA Borrego S.; RT "A new germline mutation, R600Q, within the coding region of RET proto- RT oncogene: a rare polymorphism or a MEN 2 causing mutation?"; RL Hum. Mutat. 15:122-122(2000). RN [100] RP VARIANT HSCR1 GLU-907. RX PubMed=10790203; RX DOI=10.1002/(sici)1098-1004(200005)15:5<418::aid-humu3>3.0.co;2-2; RA Hofstra R.M., Wu Y., Stulp R.P., Elfferich P., Osinga J., Maas S.M., RA Siderius L., Brooks A.S., vd Ende J.J., Heydendael V.M., Severijnen R.S., RA Bax K.M., Meijers C., Buys C.H.; RT "RET and GDNF gene scanning in Hirschsprung patients using two dual RT denaturing gel systems."; RL Hum. Mutat. 15:418-429(2000). RN [101] RP VARIANTS HSCR1 LEU-32; CYS-77; TRP-360 AND LYS-394. RX PubMed=10618407; DOI=10.1073/pnas.97.1.268; RA Bolk S., Pelet A., Hofstra R.M.W., Angrist M., Salomon R., Croaker D., RA Buys C.H.C.M., Lyonnet S., Chakravarti A.; RT "A human model for multigenic inheritance: phenotypic expression in RT Hirschsprung disease requires both the RET gene and a new 9q31 locus."; RL Proc. Natl. Acad. Sci. U.S.A. 97:268-273(2000). RN [102] RP VARIANTS MTC GLY-639; GLY-641 AND PHE-922. RX PubMed=11692159; DOI=10.1007/s001090100250; RA Kalinin V.N., Amosenko F.A., Shabanov M.A., Lubchenko L.N., Hosch S.B., RA Garkavtseva R.F., Izbicki J.R.; RT "Three novel mutations in the RET proto-oncogene."; RL J. Mol. Med. 79:609-612(2001). RN [103] RP VARIANTS PHEOCHROMOCYTOMA ARG-634; GLY-634; TYR-634; SER-634; PHE-634; RP TRP-634 AND PHE-791. RX PubMed=12000816; DOI=10.1056/nejmoa020152; RG The Freiburg-Warsaw-Columbus pheochromocytoma study group; RA Neumann H.P.H., Bausch B., McWhinney S.R., Bender B.U., Gimm O., Franke G., RA Schipper J., Klisch J., Altehoefer C., Zerres K., Januszewicz A., RA Smith W.M., Munk R., Manz T., Glaesker S., Apel T.W., Treier M., RA Reineke M., Walz M.K., Hoang-Vu C., Brauckhoff M., Klein-Franke A., RA Klose P., Schmidt H., Maier-Woelfle M., Peczkowska M., Szmigielski C., RA Eng C.; RT "Germ-line mutations in nonsyndromic pheochromocytoma."; RL N. Engl. J. Med. 346:1459-1466(2002). RN [104] RP VARIANT HIS-114. RX PubMed=12086152; DOI=10.1620/tjem.196.241; RA Kanai M., Numakura C., Sasaki A., Shirahata E., Akaba K., Hashimoto M., RA Hasegawa H., Shirasawa S., Hayasaka K.; RT "Congenital central hypoventilation syndrome: a novel mutation of the RET RT gene in an isolated case."; RL Tohoku J. Exp. Med. 196:241-246(2002). RN [105] RP VARIANTS HIS-67; HIS-114; GLU-432; ASN-489; SER-691 AND CYS-982. RX PubMed=14566559; DOI=10.1007/s00439-003-1036-z; RA Sasaki A., Kanai M., Kijima K., Akaba K., Hashimoto M., Hasegawa H., RA Otaki S., Koizumi T., Kusuda S., Ogawa Y., Tuchiya K., Yamamoto W., RA Nakamura T., Hayasaka K.; RT "Molecular analysis of congenital central hypoventilation syndrome."; RL Hum. Genet. 114:22-26(2003). RN [106] RP VARIANTS [LARGE SCALE ANALYSIS] GLY-145; TRP-360 AND GLU-593. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [107] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-163; ASN-278; MET-292; ASN-489; RP SER-691; THR-749; SER-826; LEU-844; CYS-982 AND TYR-1112. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [108] RP VARIANTS THR-198; ALA-376; HIS-394; ILE-778; SER-894; THR-918; LEU-1049 AND RP SER-1067, POSSIBLE INVOLVEMENT IN RENAL AGENESIS, AND CHARACTERIZATION OF RP VARIANTS THR-198; ALA-376; HIS-394; ILE-778; SER-894; LEU-1049 AND RP SER-1067. RX PubMed=18252215; DOI=10.1016/j.ajhg.2007.10.008; RA Skinner M.A., Safford S.D., Reeves J.G., Jackson M.E., Freemerman A.J.; RT "Renal aplasia in humans is associated with RET mutations."; RL Am. J. Hum. Genet. 82:344-351(2008). RN [109] RP VARIANTS HSCR1 549-LYS-GLY-550 DEL; CYS-114; GLY-145; LEU-155; PRO-175; RP ALA-278; PRO-278; ASN-300; GLN-313; ILE-316; LEU-339; TYR-353; GLN-360; RP MET-397; MET-412; ARG-423; LYS-480; GLN-595; LEU-679; GLN-694; SER-783; RP ARG-830; THR-907; LEU-961; VAL-1052; CYS-1062 AND THR-1064, AND VARIANTS RP HIS-114; ASN-278 AND MET-292. RX PubMed=22174939; DOI=10.1371/journal.pone.0028986; RA So M.T., Leon T.Y., Cheng G., Tang C.S., Miao X.P., Cornes B.K., Diem N.N., RA Cui L., Ngan E.S., Lui V.C., Wu X.Z., Wang B., Wang H., Yuan Z.W., RA Huang L.M., Li L., Xia H., Zhu D., Liu J., Nguyen T.L., Chan I.H., RA Chung P.H., Liu X.L., Zhang R., Wong K.K., Sham P.C., Cherny S.S., RA Tam P.K., Garcia-Barcelo M.M.; RT "RET mutational spectrum in Hirschsprung disease: evaluation of 601 Chinese RT patients."; RL PLoS ONE 6:E28986-E28986(2011). RN [110] RP ACTIVITY REGULATION, VARIANTS ILE-730; VAL-730; LYS-732; ALA-738; ASN-806; RP VAL-807; ALA-810; SER-810; ILE-871 AND VAL-998, CHARACTERIZATION OF RP VARIANTS ILE-730; VAL-730; LYS-732; ALA-738; ASN-806; VAL-807; ALA-810; RP SER-810; ILE-871 AND VAL-998, VARIANTS MTC LEU-804; MET-804 AND THR-918, RP AND CHARACTERIZATION OF VARIANTS MTC LEU-804; MET-804 AND THR-918. RX PubMed=29908090; DOI=10.1111/bph.14395; RA Liu X., Shen T., Mooers B.H.M., Hilberg F., Wu J.; RT "Drug resistance profiles of mutations in the RET kinase domain."; RL Br. J. Pharmacol. 175:3504-3515(2018). CC -!- FUNCTION: Receptor tyrosine-protein kinase involved in numerous CC cellular mechanisms including cell proliferation, neuronal navigation, CC cell migration, and cell differentiation in response to glia cell line- CC derived growth family factors (GDNF, NRTN, ARTN, PSPN and GDF15) CC (PubMed:20064382, PubMed:20616503, PubMed:20702524, PubMed:21357690, CC PubMed:21454698, PubMed:24560924, PubMed:28846097, PubMed:28846099, CC PubMed:28953886, PubMed:31118272). In contrast to most receptor CC tyrosine kinases, RET requires not only its cognate ligands but also CC coreceptors, for activation (PubMed:21994944, PubMed:23333276, CC PubMed:28846097, PubMed:28846099, PubMed:28953886). GDNF ligands (GDNF, CC NRTN, ARTN, PSPN and GDF15) first bind their corresponding GDNFR CC coreceptors (GFRA1, GFRA2, GFRA3, GFRA4 and GFRAL, respectively), CC triggering RET autophosphorylation and activation, leading to CC activation of downstream signaling pathways, including the MAPK- and CC AKT-signaling pathways (PubMed:21994944, PubMed:23333276, CC PubMed:24560924, PubMed:25242331, PubMed:28846097, PubMed:28846099, CC PubMed:28953886). Acts as a dependence receptor via the GDNF-GFRA1 CC signaling: in the presence of the ligand GDNF in somatotrophs within CC pituitary, promotes survival and down regulates growth hormone (GH) CC production, but triggers apoptosis in absence of GDNF (PubMed:20616503, CC PubMed:21994944). Required for the molecular mechanisms orchestration CC during intestine organogenesis via the ARTN-GFRA3 signaling: involved CC in the development of enteric nervous system and renal organogenesis CC during embryonic life, and promotes the formation of Peyer's patch-like CC structures, a major component of the gut-associated lymphoid tissue (By CC similarity). Mediates, through interaction with GDF15-receptor GFRAL, CC GDF15-induced cell-signaling in the brainstem which triggers an CC aversive response, characterized by nausea, vomiting, and/or loss of CC appetite in response to various stresses (PubMed:28846097, CC PubMed:28846099, PubMed:28953886). Modulates cell adhesion via its CC cleavage by caspase in sympathetic neurons and mediates cell migration CC in an integrin (e.g. ITGB1 and ITGB3)-dependent manner CC (PubMed:20702524, PubMed:21357690). Also active in the absence of CC ligand, triggering apoptosis through a mechanism that requires receptor CC intracellular caspase cleavage (PubMed:21357690). Triggers the CC differentiation of rapidly adapting (RA) mechanoreceptors CC (PubMed:20064382). Involved in the development of the neural crest (By CC similarity). Regulates nociceptor survival and size (By similarity). CC Phosphorylates PTK2/FAK1 (PubMed:21454698). CC {ECO:0000250|UniProtKB:P35546, ECO:0000269|PubMed:20064382, CC ECO:0000269|PubMed:20616503, ECO:0000269|PubMed:20702524, CC ECO:0000269|PubMed:21357690, ECO:0000269|PubMed:21454698, CC ECO:0000269|PubMed:21994944, ECO:0000269|PubMed:23333276, CC ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:25242331, CC ECO:0000269|PubMed:28846097, ECO:0000269|PubMed:28846099, CC ECO:0000269|PubMed:28953886, ECO:0000269|PubMed:31118272}. CC -!- FUNCTION: [Isoform 1]: Isoform 1 in complex with GFRAL induces higher CC activation of MAPK-signaling pathway than isoform 2 in complex with CC GFRAL. {ECO:0000269|PubMed:28846099}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:28846099}; CC -!- COFACTOR: CC Name=Ca(2+); Xref=ChEBI:CHEBI:29108; CC Evidence={ECO:0000269|PubMed:11445581, ECO:0000269|PubMed:25242331, CC ECO:0000269|PubMed:31535977, ECO:0000269|PubMed:9575150}; CC -!- ACTIVITY REGULATION: Repressed by 4-(3-hydroxyanilino)-quinolines CC derivatives, indolin-2-one-derivatives, 2-(alkylsulfanyl)-4-(3-thienyl) CC nicotinonitrile analogs, 3- and 4-substituted beta-carbolin-1-ones, CC vandetanib, motesanib, sorafenib (BAY 43-9006), cabozantinib (XL184), CC lenvatinib, sunitinib, nintedanib, and withaferin A (WA) CC (PubMed:17664273, PubMed:17884497, PubMed:19053769, PubMed:20117004, CC PubMed:20409618, PubMed:20605972, PubMed:21134556, PubMed:29908090, CC PubMed:31118272). Inactivation by sorafenib both reduces kinase CC activity and promotes lysosomal degradation (PubMed:17664273). CC {ECO:0000269|PubMed:17664273, ECO:0000269|PubMed:17884497, CC ECO:0000269|PubMed:19053769, ECO:0000269|PubMed:20117004, CC ECO:0000269|PubMed:20409618, ECO:0000269|PubMed:20605972, CC ECO:0000269|PubMed:21134556, ECO:0000269|PubMed:29908090, CC ECO:0000269|PubMed:31118272}. CC -!- SUBUNIT: Phosphorylated form interacts with the PBT domain of DOK2, CC DOK4 and DOK5 (By similarity). The phosphorylated form interacts with CC PLCG1 and GRB7 (By similarity). Interacts (not phosphorylated) with CC PTK2/FAK1 (via FERM domain) (PubMed:21454698). Extracellular cell- CC membrane anchored RET cadherin fragments form complex in neurons with CC reduced trophic status, preferentially at the contact sites between CC somas (PubMed:21357690). Interacts with AIP in the pituitary gland; CC this interaction prevents the formation of the AIP-survivin complex CC (PubMed:19366855). Interacts (inactive) with CBLC and CD2AP; CC dissociates upon activation by GDNF which increases CBLC:CD2AP CC interaction (PubMed:18753381). {ECO:0000250|UniProtKB:P35546, CC ECO:0000269|PubMed:18753381, ECO:0000269|PubMed:19366855, CC ECO:0000269|PubMed:21357690, ECO:0000269|PubMed:21454698}. CC -!- INTERACTION: CC P07949; Q9UM73: ALK; NbExp=2; IntAct=EBI-2480756, EBI-357361; CC P07949; P22681: CBL; NbExp=8; IntAct=EBI-2480756, EBI-518228; CC P07949; P62861: FAU; NbExp=4; IntAct=EBI-2480756, EBI-358093; CC P07949; P22455: FGFR4; NbExp=2; IntAct=EBI-2480756, EBI-6256193; CC P07949; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-2480756, EBI-945833; CC P07949; P40763: STAT3; NbExp=3; IntAct=EBI-2480756, EBI-518675; CC P07949; Q9Y490: TLN1; NbExp=2; IntAct=EBI-2480756, EBI-2462036; CC P07949; Q62985: Sh2b1; Xeno; NbExp=3; IntAct=EBI-2480756, EBI-7395583; CC P07949-2; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-4423689, EBI-945833; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19823924, CC ECO:0000269|PubMed:21994944, ECO:0000269|PubMed:23333276, CC ECO:0000269|PubMed:28953886, ECO:0000269|PubMed:9575150}; Single-pass CC type I membrane protein {ECO:0000269|PubMed:19823924}. Endosome CC membrane {ECO:0000269|PubMed:19823924, ECO:0000269|PubMed:23333276}; CC Single-pass type I membrane protein {ECO:0000269|PubMed:19823924}. CC Note=Predominantly located on the plasma membrane (PubMed:23333276, CC PubMed:9575150). In the presence of SORL1 and GFRA1, directed to CC endosomes (PubMed:23333276). {ECO:0000269|PubMed:23333276, CC ECO:0000269|PubMed:9575150}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=RET51; CC IsoId=P07949-1; Sequence=Displayed; CC Name=2; Synonyms=RET9; CC IsoId=P07949-2; Sequence=VSP_040735; CC -!- INDUCTION: Positively regulated by NKX2-1, PHOX2B, SOX10 and PAX3. CC {ECO:0000269|PubMed:19853745}. CC -!- PTM: Autophosphorylated on C-terminal tyrosine residues upon ligand CC stimulation. {ECO:0000269|PubMed:11061555, ECO:0000269|PubMed:14711813, CC ECO:0000269|PubMed:16928683, ECO:0000269|PubMed:20117004, CC ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:28846099}. CC -!- PTM: Proteolytically cleaved by caspase-3. The soluble RET kinase CC fragment is able to induce cell death. The extracellular cell-membrane CC anchored RET cadherin fragment accelerates cell adhesion in sympathetic CC neurons. {ECO:0000269|PubMed:21357690}. CC -!- DISEASE: Hirschsprung disease 1 (HSCR1) [MIM:142623]: A disorder of CC neural crest development characterized by absence of enteric ganglia CC along a variable length of the intestine. It is the most common cause CC of congenital intestinal obstruction. Early symptoms range from CC complete acute neonatal obstruction, characterized by vomiting, CC abdominal distention and failure to pass stool, to chronic constipation CC in the older child. {ECO:0000269|PubMed:10090908, CC ECO:0000269|PubMed:10484767, ECO:0000269|PubMed:10618407, CC ECO:0000269|PubMed:10664228, ECO:0000269|PubMed:10790203, CC ECO:0000269|PubMed:22174939, ECO:0000269|PubMed:7581377, CC ECO:0000269|PubMed:7633441, ECO:0000269|PubMed:7704557, CC ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7997019, CC ECO:0000269|PubMed:8114938, ECO:0000269|PubMed:8114939, CC ECO:0000269|PubMed:9043870, ECO:0000269|PubMed:9090527, CC ECO:0000269|PubMed:9094028, ECO:0000269|PubMed:9174404, CC ECO:0000269|PubMed:9259198, ECO:0000269|PubMed:9384613, CC ECO:0000269|PubMed:9497256, ECO:0000269|Ref.71}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- DISEASE: Medullary thyroid carcinoma (MTC) [MIM:155240]: Rare tumor CC derived from the C cells of the thyroid. Three hereditary forms are CC known, that are transmitted in an autosomal dominant fashion: (a) CC multiple neoplasia type 2A (MEN2A), (b) multiple neoplasia type IIB CC (MEN2B) and (c) familial MTC (FMTC), which occurs in 25-30% of MTC CC cases and where MTC is the only clinical manifestation. CC {ECO:0000269|PubMed:10323403, ECO:0000269|PubMed:10826520, CC ECO:0000269|PubMed:11692159, ECO:0000269|PubMed:24560924, CC ECO:0000269|PubMed:29908090, ECO:0000269|PubMed:31118272, CC ECO:0000269|PubMed:7784092, ECO:0000269|PubMed:7845675, CC ECO:0000269|PubMed:7849720, ECO:0000269|PubMed:7874109, CC ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165, CC ECO:0000269|PubMed:8103403, ECO:0000269|PubMed:8557249, CC ECO:0000269|PubMed:8625130, ECO:0000269|PubMed:8807338, CC ECO:0000269|PubMed:9223675, ECO:0000269|PubMed:9259198, CC ECO:0000269|PubMed:9398735, ECO:0000269|PubMed:9452077, CC ECO:0000269|PubMed:9506724, ECO:0000269|PubMed:9621513, CC ECO:0000269|PubMed:9677065}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Multiple neoplasia 2B (MEN2B) [MIM:162300]: Uncommon inherited CC cancer syndrome characterized by predisposition to MTC and CC phaeochromocytoma which is associated with marfanoid habitus, mucosal CC neuromas, skeletal and ophthalmic abnormalities, and ganglioneuromas of CC the intestine tract. Then the disease progresses rapidly with the CC development of metastatic MTC and a pheochromocytome in 50% of cases. CC {ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:7906417, CC ECO:0000269|PubMed:7906866, ECO:0000269|PubMed:7911697, CC ECO:0000269|PubMed:8595427, ECO:0000269|PubMed:8807338, CC ECO:0000269|PubMed:9294615, ECO:0000269|PubMed:9360560}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Pheochromocytoma (PCC) [MIM:171300]: A catecholamine-producing CC tumor of chromaffin tissue of the adrenal medulla or sympathetic CC paraganglia. The cardinal symptom, reflecting the increased secretion CC of epinephrine and norepinephrine, is hypertension, which may be CC persistent or intermittent. {ECO:0000269|PubMed:12000816}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Multiple neoplasia 2A (MEN2A) [MIM:171400]: The most frequent CC form of medullary thyroid cancer (MTC). It is an inherited cancer CC syndrome characterized by MTC, phaeochromocytoma and/or CC hyperparathyroidism. {ECO:0000269|PubMed:10522989, CC ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:7874109, CC ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165, CC ECO:0000269|PubMed:8099202, ECO:0000269|PubMed:8103403, CC ECO:0000269|PubMed:8626834, ECO:0000269|PubMed:8807338, CC ECO:0000269|PubMed:9067749, ECO:0000269|PubMed:9097963, CC ECO:0000269|PubMed:9384613, ECO:0000269|PubMed:9452064}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=Various chromosomal aberrations involving RET are known. CC Some of them have been found in papillary thyroid carcinomas (PTCs) CC (PubMed:10439047, PubMed:10980597, PubMed:12787916, PubMed:2406025). CC Inversion inv(10)(q11.2;q21) generates the RET/CCDC6 (PTC1) oncogene CC (PubMed:2406025). Inversion inv(10)(q11.2;q11.2) generates the CC RET/NCOA4 (PTC3) oncogene. Translocation t(10;14)(q11;q32) with GOLGA5 CC generates the RET/GOLGA5 (PTC5) oncogene (PubMed:2734021). CC Translocation t(8;10)(p21.3;q11.2) with PCM1 generates the PCM1/RET CC fusion (PubMed:10980597). Translocation t(6;10)(p21.3;q11.2) with CC TRIM27/RFP generates the Delta RFP/RET oncogene (PubMed:12787916). CC Translocation t(1;10)(p13;q11) with TRIM33 generates the TRIM33/RET CC (PTC7) oncogene (PubMed:10439047). Translocation t(7;10)(q32;q11) with CC TRIM24/TIF1 generates the TRIM24/RET (PTC6) oncogene (PubMed:10439047). CC Translocation t(6;10)(p21.3;q11.2) with TRIM27/RFP generates the CC TRIM27/RET oncogene (PubMed:3037315). {ECO:0000269|PubMed:10439047, CC ECO:0000269|PubMed:10980597, ECO:0000269|PubMed:12787916, CC ECO:0000269|PubMed:2406025, ECO:0000269|PubMed:2734021, CC ECO:0000269|PubMed:3037315}. CC -!- DISEASE: Note=Mutations in RET have been detected in patients with CC renal agenesis suggesting a possible involvement of this gene in CC disease pathogenesis. {ECO:0000269|PubMed:18252215}. CC -!- MISCELLANEOUS: Treatment with withaferin A (WA) leads tumor regression CC in medullary thyroid carcinomas (MTC). CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- CAUTION: Original thought to be dephosphorylated by PTPRJ on Tyr-905, CC Tyr-1015 and Tyr-1062. However this paper was retracted due to CC manipulation of immunoblot data. {ECO:0000305|PubMed:16778204, CC ECO:0000305|PubMed:30552125}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA36524.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAA36786.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAA33787.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAC14882.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/76/RET"; CC -!- WEB RESOURCE: Name=MEN2 RET database; CC URL="http://www.arup.utah.edu/database/MEN2/MEN2_welcome.php"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK291807; BAF84496.1; -; mRNA. DR EMBL; AC010864; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC004257; AAH04257.1; -; mRNA. DR EMBL; X15262; CAA33333.1; -; mRNA. DR EMBL; X12949; CAA31408.1; -; mRNA. DR EMBL; M16029; AAA36786.1; ALT_INIT; mRNA. DR EMBL; X15786; CAA33787.1; ALT_INIT; mRNA. DR EMBL; M31213; AAA36524.1; ALT_INIT; mRNA. DR EMBL; AJ297349; CAC14882.1; ALT_INIT; mRNA. DR CCDS; CCDS53525.1; -. [P07949-2] DR CCDS; CCDS7200.1; -. [P07949-1] DR PIR; A27203; TVHURE. DR PIR; A34630; A34630. DR PIR; B34735; B34735. DR PIR; S05582; S05582. DR RefSeq; NP_001393672.1; NM_001406743.1. [P07949-1] DR RefSeq; NP_065681.1; NM_020630.7. [P07949-2] DR RefSeq; NP_066124.1; NM_020975.6. [P07949-1] DR PDB; 2IVS; X-ray; 2.00 A; A/B=705-1013. DR PDB; 2IVT; X-ray; 2.60 A; A=705-1013. DR PDB; 2IVU; X-ray; 2.50 A; A=705-1013. DR PDB; 2IVV; X-ray; 2.25 A; A=705-1013. DR PDB; 2X2K; X-ray; 2.60 A; A=705-1013. DR PDB; 2X2L; X-ray; 2.00 A; A=705-1013. DR PDB; 2X2M; X-ray; 2.50 A; A/B=705-1013. DR PDB; 2X2U; X-ray; 2.00 A; A=29-270. DR PDB; 4CKI; X-ray; 2.12 A; A=705-1013. DR PDB; 4CKJ; X-ray; 1.65 A; A=705-1013. DR PDB; 4UX8; EM; 24.00 A; A/B=29-635. DR PDB; 5AMN; X-ray; 2.57 A; A=705-1012. DR PDB; 5FM2; X-ray; 3.30 A; A=659-1013. DR PDB; 5FM3; X-ray; 2.95 A; A=659-1013. DR PDB; 6FEK; X-ray; 2.30 A; A=705-1013. DR PDB; 6GL7; EM; 6.30 A; E/F=29-635. DR PDB; 6I82; X-ray; 2.05 A; A/B=705-1013. DR PDB; 6I83; X-ray; 1.88 A; A=705-1013. DR PDB; 6NE7; X-ray; 1.99 A; A=705-1013. DR PDB; 6NEC; X-ray; 1.87 A; A/C=705-1013. DR PDB; 6NJA; X-ray; 1.92 A; A=705-1013. DR PDB; 6Q2J; EM; 4.10 A; E/F=29-635. DR PDB; 6Q2N; EM; 4.40 A; E/F=29-635. DR PDB; 6Q2O; EM; 3.65 A; E/F=29-635. DR PDB; 6Q2R; EM; 4.30 A; E/F/Y/Z=29-635. DR PDB; 6Q2S; EM; 3.80 A; E/F=29-635. DR PDB; 6VHG; X-ray; 2.30 A; A=705-1013. DR PDB; 7DU8; X-ray; 2.75 A; A/B=705-1013. DR PDB; 7DU9; X-ray; 2.31 A; A/B=705-1013. DR PDB; 7DUA; X-ray; 1.64 A; A/B=705-1013. DR PDB; 7JU5; X-ray; 1.90 A; A/B=705-1013. DR PDB; 7JU6; X-ray; 2.06 A; A/B=705-1013. DR PDB; 7NZN; X-ray; 2.39 A; A=705-1013. DR PDB; 7RUN; X-ray; 3.51 A; A/B=705-1013. DR PDBsum; 2IVS; -. DR PDBsum; 2IVT; -. DR PDBsum; 2IVU; -. DR PDBsum; 2IVV; -. DR PDBsum; 2X2K; -. DR PDBsum; 2X2L; -. DR PDBsum; 2X2M; -. DR PDBsum; 2X2U; -. DR PDBsum; 4CKI; -. DR PDBsum; 4CKJ; -. DR PDBsum; 4UX8; -. DR PDBsum; 5AMN; -. DR PDBsum; 5FM2; -. DR PDBsum; 5FM3; -. DR PDBsum; 6FEK; -. DR PDBsum; 6GL7; -. DR PDBsum; 6I82; -. DR PDBsum; 6I83; -. DR PDBsum; 6NE7; -. DR PDBsum; 6NEC; -. DR PDBsum; 6NJA; -. DR PDBsum; 6Q2J; -. DR PDBsum; 6Q2N; -. DR PDBsum; 6Q2O; -. DR PDBsum; 6Q2R; -. DR PDBsum; 6Q2S; -. DR PDBsum; 6VHG; -. DR PDBsum; 7DU8; -. DR PDBsum; 7DU9; -. DR PDBsum; 7DUA; -. DR PDBsum; 7JU5; -. DR PDBsum; 7JU6; -. DR PDBsum; 7NZN; -. DR PDBsum; 7RUN; -. DR AlphaFoldDB; P07949; -. DR EMDB; EMD-0026; -. DR EMDB; EMD-11777; -. DR EMDB; EMD-20572; -. DR EMDB; EMD-20575; -. DR EMDB; EMD-20576; -. DR EMDB; EMD-20578; -. DR EMDB; EMD-20579; -. DR EMDB; EMD-2712; -. DR SMR; P07949; -. DR BioGRID; 111911; 272. DR CORUM; P07949; -. DR DIP; DIP-41449N; -. DR FunCoup; P07949; 619. DR IntAct; P07949; 231. DR MINT; P07949; -. DR STRING; 9606.ENSP00000347942; -. DR BindingDB; P07949; -. DR ChEMBL; CHEMBL2041; -. DR DrugBank; DB01809; 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine. DR DrugBank; DB15068; Agerafenib. DR DrugBank; DB12742; Amuvatinib. DR DrugBank; DB08875; Cabozantinib. DR DrugBank; DB12147; Erdafitinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB00619; Imatinib. DR DrugBank; DB09078; Lenvatinib. DR DrugBank; DB08901; Ponatinib. DR DrugBank; DB15822; Pralsetinib. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB15685; Selpercatinib. DR DrugBank; DB06436; Semaxanib. DR DrugBank; DB15036; Sitravatinib. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB07159; Tamatinib. DR DrugBank; DB05294; Vandetanib. DR DrugBank; DB05014; XL999. DR DrugCentral; P07949; -. DR GuidetoPHARMACOLOGY; 2185; -. DR TCDB; 8.A.23.1.44; the basigin (basigin) family. DR GlyCosmos; P07949; 12 sites, No reported glycans. DR GlyGen; P07949; 19 sites, 4 N-linked glycans (4 sites). DR iPTMnet; P07949; -. DR PhosphoSitePlus; P07949; -. DR BioMuta; RET; -. DR DMDM; 547807; -. DR CPTAC; CPTAC-3059; -. DR jPOST; P07949; -. DR MassIVE; P07949; -. DR PaxDb; 9606-ENSP00000347942; -. DR PeptideAtlas; P07949; -. DR ProteomicsDB; 52047; -. [P07949-1] DR ProteomicsDB; 52048; -. [P07949-2] DR TopDownProteomics; P07949-2; -. [P07949-2] DR Antibodypedia; 1904; 1292 antibodies from 41 providers. DR DNASU; 5979; -. DR Ensembl; ENST00000340058.6; ENSP00000344798.4; ENSG00000165731.23. [P07949-2] DR Ensembl; ENST00000355710.8; ENSP00000347942.3; ENSG00000165731.23. [P07949-1] DR GeneID; 5979; -. DR KEGG; hsa:5979; -. DR MANE-Select; ENST00000355710.8; ENSP00000347942.3; NM_020975.6; NP_066124.1. DR UCSC; uc001jak.2; human. [P07949-1] DR AGR; HGNC:9967; -. DR CIViC; 5979; 1 clinical assertion and 61 evidence items across 114 molecular profiles. DR ClinPGx; PA34335; -. DR CTD; 5979; -. DR DisGeNET; 5979; -. DR GeneCards; RET; -. DR GeneReviews; RET; -. DR HGNC; HGNC:9967; RET. DR HPA; ENSG00000165731; Tissue enhanced (adrenal gland, brain, parathyroid gland). DR MalaCards; RET; -. DR MIM; 114500; phenotype. DR MIM; 142623; phenotype. DR MIM; 155240; phenotype. DR MIM; 162300; phenotype. DR MIM; 164761; gene. DR MIM; 171300; phenotype. DR MIM; 171400; phenotype. DR OpenTargets; ENSG00000165731; -. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 99803; Haddad syndrome. DR Orphanet; 29072; Hereditary pheochromocytoma-paraganglioma. DR Orphanet; 388; Hirschsprung disease. DR Orphanet; 99361; Isolated familial medullary thyroid carcinoma. DR Orphanet; 247698; Multiple endocrine neoplasia type 2A. DR Orphanet; 247709; Multiple endocrine neoplasia type 2B. DR Orphanet; 1848; Renal agenesis, bilateral. DR Orphanet; 93100; Renal agenesis, unilateral. DR Orphanet; 276621; Sporadic pheochromocytoma/secreting paraganglioma. DR VEuPathDB; HostDB:ENSG00000165731; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00940000158499; -. DR HOGENOM; CLU_009530_0_0_1; -. DR InParanoid; P07949; -. DR OMA; VENQDPH; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P07949; 7 GO annotations based on evolutionary models. DR PhylomeDB; P07949; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P07949; -. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-8853659; RET signaling. DR Reactome; R-HSA-9768919; NPAS4 regulates expression of target genes. DR Reactome; R-HSA-9830364; Formation of the nephric duct. DR Reactome; R-HSA-9830674; Formation of the ureteric bud. DR SignaLink; P07949; -. DR SIGNOR; P07949; -. DR Agora; ENSG00000165731; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 5979; 18 hits in 1194 CRISPR screens. DR ChiTaRS; RET; human. DR EvolutionaryTrace; P07949; -. DR GeneWiki; RET_proto-oncogene; -. DR GenomeRNAi; 5979; -. DR Pharos; P07949; Tclin. DR PRO; PR:P07949; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; P07949; protein. DR Bgee; ENSG00000165731; Expressed in substantia nigra pars reticulata and 130 other cell types or tissues. DR ExpressionAtlas; P07949; baseline and differential. DR GO; GO:0030424; C:axon; IBA:GO_Central. DR GO; GO:0010008; C:endosome membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0098797; C:plasma membrane protein complex; IDA:CAFA. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; TAS:ProtInc. DR GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0007411; P:axon guidance; TAS:Reactome. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL. DR GO; GO:0001838; P:embryonic epithelial tube formation; IEA:Ensembl. DR GO; GO:0048484; P:enteric nervous system development; IEA:Ensembl. DR GO; GO:0160144; P:GDF15-GFRAL signaling pathway; IDA:UniProt. DR GO; GO:0035860; P:glial cell-derived neurotrophic factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; IEA:InterPro. DR GO; GO:0097021; P:lymphocyte migration into lymphoid organs; ISS:UniProtKB. DR GO; GO:0000165; P:MAPK cascade; IEA:Ensembl. DR GO; GO:0033619; P:membrane protein proteolysis; IDA:UniProtKB. DR GO; GO:0001755; P:neural crest cell migration; IEA:Ensembl. DR GO; GO:0007158; P:neuron cell-cell adhesion; IMP:UniProtKB. DR GO; GO:0042551; P:neuron maturation; IEA:Ensembl. DR GO; GO:0061146; P:Peyer's patch morphogenesis; ISS:UniProtKB. DR GO; GO:0033630; P:positive regulation of cell adhesion mediated by integrin; IDA:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB. DR GO; GO:0045793; P:positive regulation of cell size; IEA:Ensembl. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISS:UniProtKB. DR GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB. DR GO; GO:0072300; P:positive regulation of metanephric glomerulus development; ISS:UniProtKB. DR GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:UniProtKB. DR GO; GO:0007497; P:posterior midgut development; TAS:ProtInc. DR GO; GO:0050770; P:regulation of axonogenesis; IEA:Ensembl. DR GO; GO:0030155; P:regulation of cell adhesion; IDA:UniProtKB. DR GO; GO:0048265; P:response to pain; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0035799; P:ureter maturation; IEA:Ensembl. DR GO; GO:0001657; P:ureteric bud development; IEA:Ensembl. DR CDD; cd11304; Cadherin_repeat; 1. DR CDD; cd05045; PTKc_RET; 1. DR FunFam; 1.10.510.10:FF:000190; Proto-oncogene tyrosine-protein kinase receptor Ret; 1. DR FunFam; 2.60.40.60:FF:000132; Proto-oncogene tyrosine-protein kinase receptor Ret; 1. DR FunFam; 2.60.40.60:FF:000205; Proto-oncogene tyrosine-protein kinase receptor Ret; 1. DR FunFam; 3.30.200.20:FF:000234; Proto-oncogene tyrosine-protein kinase receptor Ret; 1. DR Gene3D; 2.60.40.60; Cadherins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR002126; Cadherin-like_dom. DR InterPro; IPR015919; Cadherin-like_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR041163; Ret_CLD1. DR InterPro; IPR040667; Ret_CLD3. DR InterPro; IPR041317; RET_CLD4. DR InterPro; IPR055162; RET_CRD. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016249; Tyr_kinase_Ret_rcpt. DR PANTHER; PTHR24416:SF485; PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00028; Cadherin; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF17756; RET_CLD1; 1. DR Pfam; PF17812; RET_CLD3; 1. DR Pfam; PF17813; RET_CLD4; 1. DR Pfam; PF22540; RET_CRD; 1. DR PIRSF; PIRSF000631; TyrPK_receptor_Ret; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49313; Cadherin-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50268; CADHERIN_2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell adhesion; KW Cell membrane; Chromosomal rearrangement; Disease variant; Disulfide bond; KW Endosome; Glycoprotein; Hirschsprung disease; Kinase; Membrane; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Proto-oncogene; Receptor; Reference proteome; Signal; Transferase; KW Transmembrane; Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..28 FT /evidence="ECO:0000255" FT CHAIN 29..1114 FT /note="Proto-oncogene tyrosine-protein kinase receptor Ret" FT /id="PRO_0000024450" FT CHAIN 29..707 FT /note="Extracellular cell-membrane anchored RET cadherin FT 120 kDa fragment" FT /evidence="ECO:0000305|PubMed:21357690" FT /id="PRO_0000415292" FT CHAIN 708..1017 FT /note="Soluble RET kinase fragment" FT /evidence="ECO:0000305|PubMed:21357690" FT /id="PRO_0000415293" FT TOPO_DOM 29..635 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 636..657 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 658..1114 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 168..272 FT /note="Cadherin" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 724..1016 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 29..153 FT /note="Cadherin-like region 1 (CLD1)" FT /evidence="ECO:0000305|PubMed:11445581" FT REGION 265..379 FT /note="Cadherin-like region 3 (CLD3)" FT /evidence="ECO:0000305|PubMed:11445581" FT REGION 405..506 FT /note="Cadherin-like region 4 (CLD4)" FT /evidence="ECO:0000305|PubMed:11445581" FT ACT_SITE 874 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 178 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 179 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 230 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 232 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 232 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 264 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 265 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 266 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 267 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 267 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 268 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 300 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 302 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 302 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 378 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 564 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 565 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 567 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 569 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 574 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 584 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 730..738 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000305|PubMed:24560924, ECO:0007744|PDB:4CKI" FT BINDING 758 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000305|PubMed:24560924" FT BINDING 805..807 FT /ligand="semaxanib" FT /ligand_id="ChEBI:CHEBI:91083" FT /ligand_note="inhibitor" FT /evidence="ECO:0000269|PubMed:20117004, FT ECO:0007744|PDB:2X2M" FT SITE 587..588 FT /note="Breakpoint for translocation to form the TRIM27/RET FT oncogene" FT /evidence="ECO:0000269|PubMed:3037315" FT SITE 707..708 FT /note="Cleavage; by caspase-3" FT /evidence="ECO:0000269|PubMed:21357690" FT SITE 712..713 FT /note="Breakpoint for translocation to form PCM1-RET; RET- FT CCDC6; RET-GOLGA5; RET-TRIM24 and RET-TRIM33 oncogenes" FT /evidence="ECO:0000269|PubMed:10439047, FT ECO:0000269|PubMed:10980597, ECO:0000269|PubMed:2406025, FT ECO:0000269|PubMed:2734021" FT SITE 1017..1018 FT /note="Cleavage; by caspase-3" FT /evidence="ECO:0000269|PubMed:21357690" FT MOD_RES 687 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:24560924" FT MOD_RES 696 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 806 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813" FT MOD_RES 809 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813" FT MOD_RES 826 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:24560924" FT MOD_RES 900 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813, FT ECO:0000269|PubMed:16928683, ECO:0000269|PubMed:24560924" FT MOD_RES 905 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813, FT ECO:0000269|PubMed:16928683, ECO:0000269|PubMed:20117004, FT ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:28846099" FT MOD_RES 981 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813, FT ECO:0000269|PubMed:24560924" FT MOD_RES 1015 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11061555, FT ECO:0000269|PubMed:24560924" FT MOD_RES 1029 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:24560924" FT MOD_RES 1062 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11061555, FT ECO:0000269|PubMed:14711813, ECO:0000269|PubMed:24560924, FT ECO:0000269|PubMed:28846099" FT MOD_RES 1090 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813" FT MOD_RES 1096 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813" FT CARBOHYD 98 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 151 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20473317" FT CARBOHYD 199 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 336 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 343 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 361 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 367 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 377 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 394 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 448 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 468 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 554 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 688 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:26237509" FT DISULFID 137..142 FT /evidence="ECO:0000269|PubMed:20473317, FT ECO:0000269|PubMed:25242331, ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:2X2U, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6GL7, ECO:0007744|PDB:6Q2J, FT ECO:0007744|PDB:6Q2N, ECO:0007744|PDB:6Q2O, FT ECO:0007744|PDB:6Q2R, ECO:0007744|PDB:6Q2S" FT DISULFID 157..197 FT /evidence="ECO:0000269|PubMed:20473317, FT ECO:0000269|PubMed:25242331, ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:2X2U, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6GL7, ECO:0007744|PDB:6Q2J, FT ECO:0007744|PDB:6Q2N, ECO:0007744|PDB:6Q2O, FT ECO:0007744|PDB:6Q2R, ECO:0007744|PDB:6Q2S" FT DISULFID 166..243 FT /evidence="ECO:0000269|PubMed:20473317, FT ECO:0000269|PubMed:25242331, ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:2X2U, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6GL7, ECO:0007744|PDB:6Q2J, FT ECO:0007744|PDB:6Q2N, ECO:0007744|PDB:6Q2O, FT ECO:0007744|PDB:6Q2R, ECO:0007744|PDB:6Q2S" FT DISULFID 426..430 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 449..478 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6GL7, ECO:0007744|PDB:6Q2J, FT ECO:0007744|PDB:6Q2N, ECO:0007744|PDB:6Q2O, FT ECO:0007744|PDB:6Q2R, ECO:0007744|PDB:6Q2S" FT DISULFID 515..531 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 519..541 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 528..558 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 565..581 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 570..585 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 609..620 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 611..618 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 630..634 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT VAR_SEQ 1064..1114 FT /note="MSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMDTFDS FT -> RISHAFTRF (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:3037315" FT /id="VSP_040735" FT VARIANT 20 FT /note="P -> L (in HSCR1; sporadic form; FT dbSNP:rs1837067697)" FT /evidence="ECO:0000269|PubMed:7633441" FT /id="VAR_009459" FT VARIANT 32 FT /note="S -> L (in HSCR1; familial form; dbSNP:rs76764689)" FT /evidence="ECO:0000269|PubMed:10618407, FT ECO:0000269|PubMed:8114939" FT /id="VAR_006295" FT VARIANT 40 FT /note="L -> P (in HSCR1; dbSNP:rs2132657920)" FT /evidence="ECO:0000269|PubMed:7704557, FT ECO:0000269|PubMed:9043870" FT /id="VAR_009492" FT VARIANT 64 FT /note="P -> L (in HSCR1; familial form; dbSNP:rs77596424)" FT /evidence="ECO:0000269|PubMed:8114939" FT /id="VAR_006296" FT VARIANT 67 FT /note="R -> H (in dbSNP:rs192489011)" FT /evidence="ECO:0000269|PubMed:14566559" FT /id="VAR_018153" FT VARIANT 77 FT /note="R -> C (in HSCR1; dbSNP:rs1588862595)" FT /evidence="ECO:0000269|PubMed:10618407" FT /id="VAR_009460" FT VARIANT 93 FT /note="G -> S (in HSCR1; uncertain significance; FT dbSNP:rs1477699803)" FT /evidence="ECO:0000269|PubMed:7633441" FT /id="VAR_006297" FT VARIANT 114 FT /note="R -> C (in HSCR1; uncertain significance; FT dbSNP:rs747483905)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067101" FT VARIANT 114 FT /note="R -> H (in dbSNP:rs76397662)" FT /evidence="ECO:0000269|PubMed:12086152, FT ECO:0000269|PubMed:14566559, ECO:0000269|PubMed:22174939" FT /id="VAR_018154" FT VARIANT 142 FT /note="C -> S (in HSCR1; sporadic form; FT dbSNP:rs2132680131)" FT /id="VAR_006298" FT VARIANT 145 FT /note="V -> G (in HSCR1; also in a colorectal cancer FT sample; somatic mutation; dbSNP:rs1588863999)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:22174939" FT /id="VAR_035711" FT VARIANT 155 FT /note="P -> L (in HSCR1; dbSNP:rs999019810)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067102" FT VARIANT 157 FT /note="C -> Y (in HSCR1; uncertain significance; FT dbSNP:rs2132681401)" FT /evidence="ECO:0000269|Ref.71" FT /id="VAR_009461" FT VARIANT 163 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs149403911)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041762" FT VARIANT 174 FT /note="F -> S (in HSCR1; sporadic form)" FT /evidence="ECO:0000269|PubMed:9094028" FT /id="VAR_009462" FT VARIANT 175 FT /note="R -> P (in HSCR1; dbSNP:rs774097284)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067103" FT VARIANT 180 FT /note="R -> P (in HSCR1; sporadic form; dbSNP:rs370736139)" FT /evidence="ECO:0000269|PubMed:9090527" FT /id="VAR_009463" FT VARIANT 197 FT /note="C -> Y (in HSCR1; sporadic form)" FT /evidence="ECO:0000269|PubMed:9094028" FT /id="VAR_009464" FT VARIANT 198 FT /note="P -> T (in a patient with renal agenesis; uncertain FT significance; prevents phosphorylation in response to GDNF; FT dbSNP:rs76736111)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044392" FT VARIANT 231 FT /note="R -> H (in HSCR1; familial form; dbSNP:rs79661516)" FT /evidence="ECO:0000269|PubMed:7581377" FT /id="VAR_006299" FT VARIANT 251 FT /note="E -> K (in HSCR1; familial form; dbSNP:rs562449603)" FT /evidence="ECO:0000269|PubMed:7581377" FT /id="VAR_006300" FT VARIANT 278 FT /note="T -> A (in HSCR1; dbSNP:rs541929171)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067104" FT VARIANT 278 FT /note="T -> N (found in two patients with Hirschsprung FT disease; dbSNP:rs35118262)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:22174939" FT /id="VAR_041763" FT VARIANT 278 FT /note="T -> P (in HSCR1; dbSNP:rs541929171)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067105" FT VARIANT 287 FT /note="R -> Q (in HSCR1; sporadic form; FT dbSNP:rs1564491460)" FT /evidence="ECO:0000269|PubMed:10664228" FT /id="VAR_006301" FT VARIANT 292 FT /note="V -> M (found in patients with Hirschsprung disease; FT uncertain significance; dbSNP:rs34682185)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:22174939" FT /id="VAR_041764" FT VARIANT 300 FT /note="D -> N (in HSCR1; dbSNP:rs2132719351)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067106" FT VARIANT 313 FT /note="R -> Q (in HSCR1; dbSNP:rs77702891)" FT /evidence="ECO:0000269|PubMed:22174939, FT ECO:0000269|PubMed:9090527" FT /id="VAR_009465" FT VARIANT 316 FT /note="S -> I (in HSCR1; dbSNP:rs1060499894)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067107" FT VARIANT 330 FT /note="R -> Q (in HSCR1; dbSNP:rs80236571)" FT /evidence="ECO:0000269|PubMed:7633441, FT ECO:0000269|PubMed:8114939" FT /id="VAR_006302" FT VARIANT 339 FT /note="S -> L (in HSCR1; dbSNP:rs774829203)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067108" FT VARIANT 353 FT /note="D -> Y (in HSCR1; dbSNP:rs1837785429)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067109" FT VARIANT 359 FT /note="N -> K (in HSCR1; uncertain significance)" FT /evidence="ECO:0000269|Ref.71" FT /id="VAR_009466" FT VARIANT 360 FT /note="R -> Q (in HSCR1; dbSNP:rs762472027)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067110" FT VARIANT 360 FT /note="R -> W (in HSCR1; dbSNP:rs1424549058)" FT /evidence="ECO:0000269|PubMed:10618407, FT ECO:0000269|PubMed:16959974" FT /id="VAR_009467" FT VARIANT 376 FT /note="V -> A (in a patient with renal agenesis; uncertain FT significance; constitutively phosphorylated; expressed only FT the immature intracellular form)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044393" FT VARIANT 393 FT /note="F -> L (in HSCR1; familial form; dbSNP:rs78098482)" FT /evidence="ECO:0000269|PubMed:8114939" FT /id="VAR_006303" FT VARIANT 394 FT /note="N -> H (in a patient with renal agenesis; uncertain FT significance; prevents phosphorylation in response to FT GDNF)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044394" FT VARIANT 394 FT /note="N -> K (in HSCR1; dbSNP:rs376465385)" FT /evidence="ECO:0000269|PubMed:10618407" FT /id="VAR_009468" FT VARIANT 397 FT /note="V -> M (in HSCR1; dbSNP:rs183729115)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067111" FT VARIANT 399 FT /note="P -> L (in HSCR1; sporadic form; FT dbSNP:rs1554818362)" FT /evidence="ECO:0000269|PubMed:7704557" FT /id="VAR_006304" FT VARIANT 412 FT /note="V -> M (in HSCR1; dbSNP:rs746970700)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067112" FT VARIANT 423 FT /note="G -> R (in HSCR1; dbSNP:rs767601598)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067113" FT VARIANT 432 FT /note="A -> E (found in a patient with congenital central FT hypoventilation syndrome; uncertain significance; FT dbSNP:rs552057730)" FT /evidence="ECO:0000269|PubMed:14566559" FT /id="VAR_018155" FT VARIANT 475 FT /note="R -> Q (in HSCR1; sporadic form; dbSNP:rs138624658)" FT /id="VAR_006305" FT VARIANT 480 FT /note="E -> K (in HSCR1; dbSNP:rs537874538)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067114" FT VARIANT 489 FT /note="D -> N (in dbSNP:rs9282834)" FT /evidence="ECO:0000269|PubMed:14566559, FT ECO:0000269|PubMed:17344846" FT /id="VAR_018156" FT VARIANT 531 FT /note="C -> CEEC (in MTC; familial form)" FT /evidence="ECO:0000269|PubMed:10323403" FT /id="VAR_009469" FT VARIANT 549..550 FT /note="Missing (in HSCR1)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067115" FT VARIANT 593 FT /note="G -> E (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035712" FT VARIANT 595 FT /note="E -> Q (in HSCR1; dbSNP:rs1483605155)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067116" FT VARIANT 600 FT /note="R -> Q (in dbSNP:rs377767393)" FT /evidence="ECO:0000269|PubMed:10612852" FT /id="VAR_008966" FT VARIANT 609 FT /note="C -> G (in MEN2A; dbSNP:rs77558292)" FT /evidence="ECO:0000269|PubMed:8807338" FT /id="VAR_009470" FT VARIANT 609 FT /note="C -> R (in MEN2A; dbSNP:rs77558292)" FT /evidence="ECO:0000269|PubMed:8807338" FT /id="VAR_009471" FT VARIANT 609 FT /note="C -> W (in HSCR1; familial form; dbSNP:rs377767396)" FT /evidence="ECO:0000269|PubMed:7881414" FT /id="VAR_006307" FT VARIANT 609 FT /note="C -> Y (in MTC, MEN2A and HSCR1; familial and FT sporadic forms; dbSNP:rs77939446)" FT /evidence="ECO:0000269|PubMed:7633441, FT ECO:0000269|PubMed:7849720, ECO:0000269|PubMed:9384613, FT ECO:0000269|Ref.71" FT /id="VAR_006306" FT VARIANT 611 FT /note="C -> G (in MTC; familial form; dbSNP:rs377767391)" FT /evidence="ECO:0000269|PubMed:9677065" FT /id="VAR_009472" FT VARIANT 611 FT /note="C -> R (in MEN2A; dbSNP:rs377767391)" FT /evidence="ECO:0000269|PubMed:8807338" FT /id="VAR_009473" FT VARIANT 611 FT /note="C -> S (in MEN2A; dbSNP:rs377767391)" FT /evidence="ECO:0000269|PubMed:8807338" FT /id="VAR_009474" FT VARIANT 611 FT /note="C -> W (in MEN2A and MTC; familial form; FT dbSNP:rs80069458)" FT /evidence="ECO:0000269|PubMed:8103403" FT /id="VAR_006308" FT VARIANT 611 FT /note="C -> Y (in MEN2A; dbSNP:rs377767397)" FT /evidence="ECO:0000269|PubMed:9067749" FT /id="VAR_006309" FT VARIANT 618 FT /note="C -> F (in MEN2A and MTC; familial form; FT dbSNP:rs79781594)" FT /evidence="ECO:0000269|PubMed:9067749" FT /id="VAR_006312" FT VARIANT 618 FT /note="C -> G (in MEN2A; dbSNP:rs76262710)" FT /evidence="ECO:0000269|PubMed:8099202" FT /id="VAR_006310" FT VARIANT 618 FT /note="C -> R (in MEN2A, MTC and HSCR1; dbSNP:rs76262710)" FT /evidence="ECO:0000269|PubMed:7849720, FT ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165, FT ECO:0000269|PubMed:9259198" FT /id="VAR_006311" FT VARIANT 618 FT /note="C -> S (in MEN2A, HSCR1 and MTC; familial and FT sporadic forms; dbSNP:rs79781594)" FT /evidence="ECO:0000269|PubMed:7849720, FT ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:7915165, FT ECO:0000269|PubMed:8103403, ECO:0000269|PubMed:9384613" FT /id="VAR_006313" FT VARIANT 618 FT /note="C -> Y (in MEN2A and MTC; familial form; FT dbSNP:rs79781594)" FT /evidence="ECO:0000269|PubMed:8103403" FT /id="VAR_006314" FT VARIANT 620 FT /note="C -> F (in MEN2A and MTC; familial form; FT dbSNP:rs77503355)" FT /evidence="ECO:0000269|PubMed:7915165" FT /id="VAR_006318" FT VARIANT 620 FT /note="C -> G (in MEN2A and MTC; familial and sporadic FT forms; dbSNP:rs77316810)" FT /evidence="ECO:0000269|PubMed:9067749" FT /id="VAR_006315" FT VARIANT 620 FT /note="C -> R (in MEN2A, MTC and HSCR1; familial and FT sporadic forms; dbSNP:rs77316810)" FT /evidence="ECO:0000269|PubMed:7633441, FT ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165, FT ECO:0000269|PubMed:8103403, ECO:0000269|PubMed:9090527, FT ECO:0000269|PubMed:9384613, ECO:0000269|Ref.71" FT /id="VAR_006316" FT VARIANT 620 FT /note="C -> S (in MEN2A and MTC; familial form; FT dbSNP:rs77503355)" FT /evidence="ECO:0000269|PubMed:7849720, FT ECO:0000269|PubMed:7860065" FT /id="VAR_006317" FT VARIANT 620 FT /note="C -> W (in MEN2A and HSCR1; dbSNP:rs79890926)" FT /evidence="ECO:0000269|PubMed:9384613" FT /id="VAR_009475" FT VARIANT 620 FT /note="C -> Y (in MEN2A; dbSNP:rs77503355)" FT /evidence="ECO:0000269|PubMed:8103403" FT /id="VAR_006319" FT VARIANT 626 FT /note="Q -> K (in HSCR1; sporadic form; FT dbSNP:rs1255575160)" FT /evidence="ECO:0000269|PubMed:10090908" FT /id="VAR_009476" FT VARIANT 630 FT /note="C -> F (in MEN2A and MTC; familial form; FT dbSNP:rs377767405)" FT /evidence="ECO:0000269|PubMed:9067749" FT /id="VAR_006320" FT VARIANT 630 FT /note="C -> S (in MTC; sporadic form; dbSNP:rs377767405)" FT /evidence="ECO:0000269|PubMed:9223675" FT /id="VAR_009477" FT VARIANT 630 FT /note="C -> Y (in MTC; familial and sporadic forms; FT dbSNP:rs377767405)" FT /evidence="ECO:0000269|PubMed:9223675" FT /id="VAR_009478" FT VARIANT 631 FT /note="D -> G (in thyroid carcinoma; somatic mutation; FT dbSNP:rs121913308)" FT /id="VAR_006321" FT VARIANT 632..634 FT /note="ELC -> DVR (in MEN2A; dbSNP:rs377767408)" FT /evidence="ECO:0000269|PubMed:8099202" FT /id="VAR_006322" FT VARIANT 634..635 FT /note="CR -> WG (in MEN2A)" FT /id="VAR_006329" FT VARIANT 634 FT /note="C -> CHELC (in MEN2A)" FT /evidence="ECO:0000269|PubMed:9097963" FT /id="VAR_009479" FT VARIANT 634 FT /note="C -> F (in MEN2A and pheochromocytoma; FT dbSNP:rs75996173)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:7915165, ECO:0000269|PubMed:8099202" FT /id="VAR_006324" FT VARIANT 634 FT /note="C -> G (in MEN2A and pheochromocytoma; FT dbSNP:rs75076352)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:7915165, ECO:0000269|PubMed:8099202" FT /id="VAR_006323" FT VARIANT 634 FT /note="C -> R (in MEN2A, pheochromocytoma and MTC; familial FT form; also found as somatic mutation in a sporadic thyroid FT carcinoma; dbSNP:rs75076352)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:8103403" FT /id="VAR_006326" FT VARIANT 634 FT /note="C -> S (in MEN2A, pheochromocytoma and MTC; familial FT form; dbSNP:rs75076352)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:8099202" FT /id="VAR_006327" FT VARIANT 634 FT /note="C -> W (in MEN2A, pheochromocytoma and MTC; familial FT form; dbSNP:rs77709286)" FT /evidence="ECO:0000269|PubMed:12000816" FT /id="VAR_006328" FT VARIANT 634 FT /note="C -> Y (in MEN2A, pheochromocytoma and MTC; familial FT form; dbSNP:rs75996173)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:7915165, FT ECO:0000269|PubMed:8099202" FT /id="VAR_006325" FT VARIANT 636 FT /note="T -> TCRT (in MEN2A)" FT /evidence="ECO:0000269|PubMed:9452064" FT /id="VAR_006330" FT VARIANT 639 FT /note="A -> G (in MTC; sporadic form; dbSNP:rs2132845622)" FT /evidence="ECO:0000269|PubMed:11692159" FT /id="VAR_012743" FT VARIANT 640 FT /note="A -> G (in MEN2A; dbSNP:rs78935588)" FT /evidence="ECO:0000269|PubMed:10522989" FT /id="VAR_009480" FT VARIANT 641 FT /note="A -> G (in MTC; sporadic form)" FT /evidence="ECO:0000269|PubMed:11692159" FT /id="VAR_012744" FT VARIANT 679 FT /note="P -> L (in HSCR1; dbSNP:rs2132851042)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067117" FT VARIANT 690 FT /note="S -> P (in HSCR1; sporadic form)" FT /evidence="ECO:0000269|PubMed:10664228" FT /id="VAR_006331" FT VARIANT 691 FT /note="G -> S (in dbSNP:rs1799939)" FT /evidence="ECO:0000269|PubMed:14566559, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9223675, FT ECO:0000269|PubMed:9497256" FT /id="VAR_006332" FT VARIANT 694 FT /note="R -> Q (in HSCR1; dbSNP:rs141185224)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067118" FT VARIANT 730 FT /note="L -> I (confers resistance to vandetanib, FT lenvatinib, cabozantinib and nintedanib inhibitors; FT dbSNP:rs1838076782)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088874" FT VARIANT 730 FT /note="L -> V (confers resistance to vandetanib, FT cabozantinib and nintedanib inhibitors; FT dbSNP:rs1838076782)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088875" FT VARIANT 732 FT /note="E -> K (confers resistance to cabozantinib FT inhibitor)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088876" FT VARIANT 738 FT /note="V -> A (confers resistance to vandetanib, FT lenvatinib, cabozantinib and nintedanib inhibitors; FT dbSNP:rs2132906265)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088877" FT VARIANT 749 FT /note="R -> T (in dbSNP:rs34288963)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041765" FT VARIANT 762 FT /note="E -> Q (in HSCR1; sporadic form; FT dbSNP:rs2132910256)" FT /evidence="ECO:0000269|PubMed:7704557" FT /id="VAR_009481" FT VARIANT 765 FT /note="S -> P (in HSCR1; dbSNP:rs75075748)" FT /evidence="ECO:0000269|PubMed:7704557, FT ECO:0000269|PubMed:8114938, ECO:0000269|PubMed:9043870" FT /id="VAR_009493" FT VARIANT 767 FT /note="S -> R (in HSCR1; sporadic form; FT dbSNP:rs2132928081)" FT /evidence="ECO:0000269|PubMed:10664228" FT /id="VAR_006334" FT VARIANT 768 FT /note="E -> D (in MTC; familial and sporadic forms; FT dbSNP:rs78014899)" FT /evidence="ECO:0000269|PubMed:7784092, FT ECO:0000269|PubMed:7845675, ECO:0000269|PubMed:8807338" FT /id="VAR_006335" FT VARIANT 778 FT /note="V -> I (in a patient with renal agenesis; uncertain FT significance; constitutively phosphorylated; FT dbSNP:rs75686697)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044395" FT VARIANT 783 FT /note="N -> S (in HSCR1; dbSNP:rs587778656)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067119" FT VARIANT 790 FT /note="L -> F (in MEN2A and MTC; familial form; FT dbSNP:rs75030001)" FT /evidence="ECO:0000269|PubMed:9506724" FT /id="VAR_009482" FT VARIANT 791 FT /note="Y -> F (in HSCR1, pheochromocytoma, MTC and MEN2A; FT familial form; dbSNP:rs77724903)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:9090527, ECO:0000269|PubMed:9506724" FT /id="VAR_009483" FT VARIANT 804 FT /note="V -> L (in MTC; familial form; confers resistance to FT vandetanib, lenvatinib, cabozantinib and nintedanib FT inhibitors; dbSNP:rs79658334)" FT /evidence="ECO:0000269|PubMed:29908090, FT ECO:0000269|PubMed:7784092" FT /id="VAR_006336" FT VARIANT 804 FT /note="V -> M (in MTC; familial form; faster FT autophosphorylation and activation, leading to enhanced FT activity; confers resistance to vandetanib, lenvatinib, FT cabozantinib and nintedanib inhibitors; dbSNP:rs79658334)" FT /evidence="ECO:0000269|PubMed:10826520, FT ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:29908090, FT ECO:0000269|PubMed:9452077" FT /id="VAR_006337" FT VARIANT 806 FT /note="Y -> N (confers resistance to vandetanib, FT lenvatinib, cabozantinib and nintedanib inhibitors; FT dbSNP:rs1838154415)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088878" FT VARIANT 807 FT /note="A -> V (confers resistance to vandetanib, lenvatinib FT and cabozantinib inhibitors; dbSNP:rs1554819523)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088879" FT VARIANT 810 FT /note="G -> A (found in a patient with lung adenocarcinoma; FT confers resistance to vandetanib inhibitor; FT dbSNP:rs2132943470)" FT /evidence="ECO:0000269|PubMed:31118272" FT /id="VAR_088880" FT VARIANT 810 FT /note="G -> S (confers resistance to vandetanib, FT lenvatinib, cabozantinib and nintedanib inhibitors; FT dbSNP:rs764784013)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088881" FT VARIANT 813 FT /note="R -> Q (in HSCR1; sporadic form; FT dbSNP:rs1318733775)" FT /evidence="ECO:0000269|PubMed:10090908" FT /id="VAR_009484" FT VARIANT 826 FT /note="Y -> S (in dbSNP:rs34617196)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041766" FT VARIANT 830 FT /note="G -> R (in HSCR1; dbSNP:rs200127630)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067120" FT VARIANT 844 FT /note="R -> L (in MTC; familial form; dbSNP:rs55947360)" FT /evidence="ECO:0000269|PubMed:10826520, FT ECO:0000269|PubMed:17344846" FT /id="VAR_011582" FT VARIANT 871 FT /note="V -> I (confers resistance to vandetanib, lenvatinib FT and cabozantinib inhibitors; dbSNP:rs145170911)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088882" FT VARIANT 873 FT /note="R -> Q (in HSCR1; sporadic form; FT dbSNP:rs1451004715)" FT /evidence="ECO:0000269|PubMed:10664228" FT /id="VAR_006338" FT VARIANT 881 FT /note="L -> V (in MTC; confers resistance to nintedanib FT inhibitor; dbSNP:rs377767427)" FT /evidence="ECO:0000269|PubMed:29908090, FT ECO:0000269|PubMed:31118272" FT /id="VAR_088883" FT VARIANT 883 FT /note="A -> F (in MEN2B; somatic mutation in sporadic FT medullary thyroid carcinoma; requires 2 nucleotide FT substitutions; dbSNP:rs377767429)" FT /evidence="ECO:0000269|PubMed:9294615, FT ECO:0000269|PubMed:9360560" FT /id="VAR_009485" FT VARIANT 891 FT /note="S -> A (in MTC; familial form; dbSNP:rs75234356)" FT /evidence="ECO:0000269|PubMed:9398735" FT /id="VAR_009486" FT VARIANT 893 FT /note="F -> L (in HSCR1; sporadic form; dbSNP:rs768188546 FT and dbSNP:rs2132962164)" FT /evidence="ECO:0000269|PubMed:9174404" FT /id="VAR_006339" FT VARIANT 894 FT /note="G -> S (in a patient with renal agenesis; uncertain FT significance; constitutively phosphorylated; expressed only FT the immature intracellular form; dbSNP:rs2132962245)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044396" FT VARIANT 897 FT /note="R -> Q (in HSCR1; sporadic form; dbSNP:rs76087194)" FT /evidence="ECO:0000269|PubMed:7704557, FT ECO:0000269|PubMed:8114938" FT /id="VAR_006340" FT VARIANT 907 FT /note="K -> E (in HSCR1; sporadic form; dbSNP:rs377767430)" FT /evidence="ECO:0000269|PubMed:10790203" FT /id="VAR_006341" FT VARIANT 907 FT /note="K -> T (in HSCR1)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067121" FT VARIANT 918 FT /note="M -> T (in MEN2B and MTC; sporadic form; somatic FT mutation; also found in a patient with renal agenesis; FT faster autophosphorylation and activation, leading to FT enhanced activity; dbSNP:rs74799832)" FT /evidence="ECO:0000269|PubMed:18252215, FT ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:29908090, FT ECO:0000269|PubMed:7906417, ECO:0000269|PubMed:7906866, FT ECO:0000269|PubMed:7911697, ECO:0000269|PubMed:8595427, FT ECO:0000269|PubMed:8807338" FT /id="VAR_006342" FT VARIANT 921 FT /note="E -> K (in HSCR1; sporadic form; FT dbSNP:rs2132985306)" FT /evidence="ECO:0000269|PubMed:7997019" FT /id="VAR_006343" FT VARIANT 922 FT /note="S -> F (in MTC; sporadic form; dbSNP:rs377767432)" FT /evidence="ECO:0000269|PubMed:11692159" FT /id="VAR_012745" FT VARIANT 922 FT /note="S -> Y (in dbSNP:rs377767432)" FT /evidence="ECO:0000269|PubMed:8595427" FT /id="VAR_009487" FT VARIANT 946 FT /note="T -> M (in MEN2B and MTC; familial form)" FT /id="VAR_006345" FT VARIANT 961 FT /note="F -> L (in HSCR1)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067122" FT VARIANT 972 FT /note="R -> G (in HSCR1; familial form; dbSNP:rs76534745)" FT /evidence="ECO:0000269|PubMed:7704557, FT ECO:0000269|PubMed:8114938" FT /id="VAR_006346" FT VARIANT 973 FT /note="P -> L (in HSCR1; familial form)" FT /evidence="ECO:0000269|PubMed:7704557" FT /id="VAR_006347" FT VARIANT 980 FT /note="M -> T (in HSCR1; sporadic form)" FT /id="VAR_006348" FT VARIANT 982 FT /note="R -> C (in dbSNP:rs17158558)" FT /evidence="ECO:0000269|PubMed:14566559, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7633441, ECO:0000269|PubMed:9760196" FT /id="VAR_006349" FT VARIANT 998 FT /note="F -> V (confers resistance to lenvatinib and FT cabozantinib inhibitors; dbSNP:rs2133017302)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088884" FT VARIANT 1039 FT /note="P -> L (in HSCR1; dbSNP:rs79853121)" FT /evidence="ECO:0000269|PubMed:9497256" FT /id="VAR_018157" FT VARIANT 1039 FT /note="P -> Q (in dbSNP:rs79853121)" FT /id="VAR_009488" FT VARIANT 1049 FT /note="P -> L (in a patient with renal agenesis; uncertain FT significance; prevents phosphorylation in response to GDNF; FT dbSNP:rs1490712863)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044397" FT VARIANT 1052 FT /note="L -> V (in HSCR1; dbSNP:rs1564501947)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067123" FT VARIANT 1059 FT /note="Missing (in HSCR1)" FT /evidence="ECO:0000269|PubMed:10484767, ECO:0000269|Ref.71" FT /id="VAR_009489" FT VARIANT 1061 FT /note="L -> P (in HSCR1; dbSNP:rs536486113)" FT /evidence="ECO:0000269|PubMed:10484767, ECO:0000269|Ref.71" FT /id="VAR_009490" FT VARIANT 1062 FT /note="Y -> C (in HSCR1; dbSNP:rs587778659)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067124" FT VARIANT 1064 FT /note="M -> T (in HSCR1; familial form; dbSNP:rs149513065)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_009491" FT VARIANT 1067 FT /note="P -> S (in a patient with renal agenesis; uncertain FT significance; prevents phosphorylation in response to GDNF; FT dbSNP:rs775583354)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044398" FT VARIANT 1112 FT /note="F -> Y (in a bladder transitional cell carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041767" FT MUTAGEN 36 FT /note="Y->S: Defects in maturation and processing." FT /evidence="ECO:0000269|PubMed:11445581" FT MUTAGEN 41 FT /note="Y->A: Defects in maturation and processing." FT /evidence="ECO:0000269|PubMed:11445581" FT MUTAGEN 85 FT /note="W->A: Defects in maturation and processing." FT /evidence="ECO:0000269|PubMed:11445581" FT MUTAGEN 707 FT /note="D->N: Impaired cleavage by caspase-3 and loss of FT induced cell death." FT /evidence="ECO:0000269|PubMed:21357690" FT MUTAGEN 708..1114 FT /note="Missing: Loss of induced cell death, but increased FT cell aggregation." FT /evidence="ECO:0000269|PubMed:21357690" FT MUTAGEN 734 FT /note="E->A: Enhanced protein autophosphorylation due to FT enhanced substrate presentation in trans." FT /evidence="ECO:0000269|PubMed:24560924" FT MUTAGEN 758 FT /note="K->R,M: Loss of kinase activity. No effect on FT interaction with and dissociation from CBLC and CD2AP." FT /evidence="ECO:0000269|PubMed:18753381, FT ECO:0000269|PubMed:21357690, ECO:0000269|PubMed:24560924" FT MUTAGEN 912 FT /note="R->A: Enhanced protein autophosphorylation due to FT enhanced substrate presentation in trans." FT /evidence="ECO:0000269|PubMed:24560924" FT MUTAGEN 913 FT /note="I->A: Enhanced protein autophosphorylation due to FT enhanced substrate presentation in trans." FT /evidence="ECO:0000269|PubMed:24560924" FT MUTAGEN 1062 FT /note="Y->F: Abolishes GFRAL-mediated MAPK1/MAPK2 FT phosphorylation." FT /evidence="ECO:0000269|PubMed:28953886" FT CONFLICT 647 FT /note="I -> V (in Ref. 6; AAA36786)" FT /evidence="ECO:0000305" FT CONFLICT 664 FT /note="A -> S (in Ref. 1; BAF84496)" FT /evidence="ECO:0000305" FT CONFLICT 750 FT /note="A -> G (in Ref. 9; AAA36524)" FT /evidence="ECO:0000305" FT CONFLICT 904 FT /note="S -> P (in Ref. 6; AAA36786)" FT /evidence="ECO:0000305" FT STRAND 30..32 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 34..41 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 49..52 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 70..73 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 75..77 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 79..82 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 85..88 FT /evidence="ECO:0007829|PDB:2X2U" FT TURN 90..92 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 94..99 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 103..111 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 120..126 FT /evidence="ECO:0007829|PDB:2X2U" FT TURN 139..141 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 142..152 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 157..159 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 162..166 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 174..178 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 184..187 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 191..196 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 202..208 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 212..215 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 222..227 FT /evidence="ECO:0007829|PDB:2X2U" FT TURN 231..233 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 235..245 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 252..263 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 705..710 FT /evidence="ECO:0007829|PDB:7DUA" FT TURN 715..717 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 721..723 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 724..733 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 736..744 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 746..748 FT /evidence="ECO:0007829|PDB:6NEC" FT STRAND 751..759 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 766..781 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 790..794 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 796..798 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 801..805 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 812..819 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 822..826 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 844..846 FT /evidence="ECO:0007829|PDB:6NJA" FT HELIX 848..867 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 877..879 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 880..883 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 884..886 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 887..890 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 893..895 FT /evidence="ECO:0007829|PDB:7JU5" FT TURN 900..902 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 915..917 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 920..925 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 930..945 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 957..959 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 960..965 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 978..987 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 992..994 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 998..1010 FT /evidence="ECO:0007829|PDB:7DUA" SQ SEQUENCE 1114 AA; 124319 MW; A3DA0CE01A19A441 CRC64; MAKATSGAAG LRLLLLLLLP LLGKVALGLY FSRDAYWEKL YVDQAAGTPL LYVHALRDAP EEVPSFRLGQ HLYGTYRTRL HENNWICIQE DTGLLYLNRS LDHSSWEKLS VRNRGFPLLT VYLKVFLSPT SLREGECQWP GCARVYFSFF NTSFPACSSL KPRELCFPET RPSFRIRENR PPGTFHQFRL LPVQFLCPNI SVAYRLLEGE GLPFRCAPDS LEVSTRWALD REQREKYELV AVCTVHAGAR EEVVMVPFPV TVYDEDDSAP TFPAGVDTAS AVVEFKRKED TVVATLRVFD ADVVPASGEL VRRYTSTLLP GDTWAQQTFR VEHWPNETSV QANGSFVRAT VHDYRLVLNR NLSISENRTM QLAVLVNDSD FQGPGAGVLL LHFNVSVLPV SLHLPSTYSL SVSRRARRFA QIGKVCVENC QAFSGINVQY KLHSSGANCS TLGVVTSAED TSGILFVNDT KALRRPKCAE LHYMVVATDQ QTSRQAQAQL LVTVEGSYVA EEAGCPLSCA VSKRRLECEE CGGLGSPTGR CEWRQGDGKG ITRNFSTCSP STKTCPDGHC DVVETQDINI CPQDCLRGSI VGGHEPGEPR GIKAGYGTCN CFPEEEKCFC EPEDIQDPLC DELCRTVIAA AVLFSFIVSV LLSAFCIHCY HKFAHKPPIS SAEMTFRRPA QAFPVSYSSS GARRPSLDSM ENQVSVDAFK ILEDPKWEFP RKNLVLGKTL GEGEFGKVVK ATAFHLKGRA GYTTVAVKML KENASPSELR DLLSEFNVLK QVNHPHVIKL YGACSQDGPL LLIVEYAKYG SLRGFLRESR KVGPGYLGSG GSRNSSSLDH PDERALTMGD LISFAWQISQ GMQYLAEMKL VHRDLAARNI LVAEGRKMKI SDFGLSRDVY EEDSYVKRSQ GRIPVKWMAI ESLFDHIYTT QSDVWSFGVL LWEIVTLGGN PYPGIPPERL FNLLKTGHRM ERPDNCSEEM YRLMLQCWKQ EPDKRPVFAD ISKDLEKMMV KRRDYLDLAA STPSDSLIYD DGLSEEETPL VDCNNAPLPR ALPSTWIENK LYGMSDPNWP GESPVPLTRA DGTNTGFPRY PNDSVYANWM LSPSAAKLMD TFDS // ID S35F6_HUMAN Reviewed; 371 AA. AC Q8N357; D6W543; Q53GK2; Q8NBX6; Q9NWX0; DT 18-APR-2006, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2002, sequence version 1. DT 28-JAN-2026, entry version 162. DE RecName: Full=Solute carrier family 35 member F6; DE AltName: Full=ANT2-binding protein; DE Short=ANT2BP; DE AltName: Full=Transport and Golgi organization 9 homolog; DE Flags: Precursor; GN Name=SLC35F6; Synonyms=C2orf18; ORFNames=UNQ3047/PRO9863; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=12975309; DOI=10.1101/gr.1293003; RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J., RA Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P., RA Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A., RA Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D., RA Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L., RA Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C., RA Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J., RA Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.; RT "The secreted protein discovery initiative (SPDI), a large-scale effort to RT identify novel human secreted and transmembrane proteins: a bioinformatics RT assessment."; RL Genome Res. 13:2265-2270(2003). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Placenta; RX PubMed=16303743; DOI=10.1093/dnares/12.2.117; RA Otsuki T., Ota T., Nishikawa T., Hayashi K., Suzuki Y., Yamamoto J., RA Wakamatsu A., Kimura K., Sakamoto K., Hatano N., Kawai Y., Ishii S., RA Saito K., Kojima S., Sugiyama T., Ono T., Okano K., Yoshikawa Y., RA Aotsuka S., Sasaki N., Hattori A., Okumura K., Nagai K., Sugano S., RA Isogai T.; RT "Signal sequence and keyword trap in silico for selection of full-length RT human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA RT libraries."; RL DNA Res. 12:117-126(2005). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Kidney; RA Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y., RA Tanaka A., Yokoyama S.; RL Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Blood; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [11] RP FUNCTION, INTERACTION WITH SLC25A5, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=19154410; DOI=10.1111/j.1349-7006.2008.01058.x; RA Kashiwaya K., Hosokawa M., Eguchi H., Ohigashi H., Ishikawa O., RA Shinomura Y., Nakamura Y., Nakagawa H.; RT "Identification of C2orf18, termed ANT2BP (ANT2-binding protein), as one of RT the key molecules involved in pancreatic carcinogenesis."; RL Cancer Sci. 100:457-464(2009). RN [12] RP REVIEW, AND SUBCELLULAR LOCATION. RX PubMed=20957757; DOI=10.1002/pmic.201000196; RA Schroeder B.A., Wrocklage C., Hasilik A., Saftig P.; RT "The proteome of lysosomes."; RL Proteomics 10:4053-4076(2010). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). CC -!- FUNCTION: Involved in the maintenance of mitochondrial membrane CC potential in pancreatic ductal adenocarcinoma (PDAC) cells. Promotes CC pancreatic ductal adenocarcinoma (PDAC) cell growth. May play a role as CC a nucleotide-sugar transporter. {ECO:0000269|PubMed:19154410}. CC -!- SUBUNIT: Interacts with SLC25A5. {ECO:0000269|PubMed:19154410}. CC -!- INTERACTION: CC Q8N357; Q13520: AQP6; NbExp=3; IntAct=EBI-713484, EBI-13059134; CC Q8N357; Q8N350-4: CBARP; NbExp=3; IntAct=EBI-713484, EBI-19051169; CC Q8N357; Q9HA82: CERS4; NbExp=3; IntAct=EBI-713484, EBI-2622997; CC Q8N357; P15328: FOLR1; NbExp=3; IntAct=EBI-713484, EBI-2556557; CC Q8N357; P48165: GJA8; NbExp=3; IntAct=EBI-713484, EBI-17458373; CC Q8N357; Q8TDT2: GPR152; NbExp=3; IntAct=EBI-713484, EBI-13345167; CC Q8N357; P05141: SLC25A5; NbExp=2; IntAct=EBI-713484, EBI-355133; CC Q8N357; Q9NPL8: TIMMDC1; NbExp=3; IntAct=EBI-713484, EBI-6268651; CC Q8N357; Q9NUH8: TMEM14B; NbExp=3; IntAct=EBI-713484, EBI-8638294; CC -!- SUBCELLULAR LOCATION: Mitochondrion. Lysosome membrane; Multi-pass CC membrane protein. CC -!- TISSUE SPECIFICITY: Expressed in pancreatic ductal adenocarcinoma CC (PDAC) (at protein level). Strongly expressed in prostate and thyroid. CC Weakly expressed in lung, heart, liver and kidney. CC {ECO:0000269|PubMed:19154410}. CC -!- SIMILARITY: Belongs to the SLC35F solute transporter family. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY358820; AAQ89179.1; -; mRNA. DR EMBL; AK000562; BAA91255.1; -; mRNA. DR EMBL; AK075164; BAC11445.1; -; mRNA. DR EMBL; CR457243; CAG33524.1; -; mRNA. DR EMBL; AK222929; BAD96649.1; -; mRNA. DR EMBL; AC011740; AAX93265.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00673.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00676.1; -; Genomic_DNA. DR EMBL; BC028081; AAH28081.1; -; mRNA. DR CCDS; CCDS1728.1; -. DR RefSeq; NP_060347.2; NM_017877.3. DR AlphaFoldDB; Q8N357; -. DR SMR; Q8N357; -. DR BioGRID; 120314; 135. DR FunCoup; Q8N357; 2332. DR IntAct; Q8N357; 105. DR MINT; Q8N357; -. DR STRING; 9606.ENSP00000345528; -. DR TCDB; 2.A.7.12.13; the drug/metabolite transporter (dmt) superfamily. DR GlyCosmos; Q8N357; 1 site, No reported glycans. DR GlyGen; Q8N357; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q8N357; -. DR PhosphoSitePlus; Q8N357; -. DR SwissPalm; Q8N357; -. DR BioMuta; SLC35F6; -. DR DMDM; 74728772; -. DR jPOST; Q8N357; -. DR MassIVE; Q8N357; -. DR PaxDb; 9606-ENSP00000345528; -. DR PeptideAtlas; Q8N357; -. DR ProteomicsDB; 71766; -. DR Pumba; Q8N357; -. DR Antibodypedia; 28001; 132 antibodies from 20 providers. DR DNASU; 54978; -. DR Ensembl; ENST00000344420.10; ENSP00000345528.5; ENSG00000213699.10. DR GeneID; 54978; -. DR KEGG; hsa:54978; -. DR MANE-Select; ENST00000344420.10; ENSP00000345528.5; NM_017877.4; NP_060347.2. DR UCSC; uc002rhp.2; human. DR AGR; HGNC:26055; -. DR ClinPGx; PA134913368; -. DR CTD; 54978; -. DR DisGeNET; 54978; -. DR GeneCards; SLC35F6; -. DR HGNC; HGNC:26055; SLC35F6. DR HPA; ENSG00000213699; Low tissue specificity. DR MIM; 619667; gene. DR OpenTargets; ENSG00000213699; -. DR VEuPathDB; HostDB:ENSG00000213699; -. DR eggNOG; KOG3912; Eukaryota. DR GeneTree; ENSGT00390000017237; -. DR HOGENOM; CLU_025028_1_0_1; -. DR InParanoid; Q8N357; -. DR OMA; FIYKHNV; -. DR OrthoDB; 29773at2759; -. DR PAN-GO; Q8N357; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q8N357; -. DR PathwayCommons; Q8N357; -. DR SignaLink; Q8N357; -. DR Agora; ENSG00000213699; -. DR BioGRID-ORCS; 54978; 12 hits in 1161 CRISPR screens. DR ChiTaRS; SLC35F6; human. DR GeneWiki; C2orf18; -. DR GenomeRNAi; 54978; -. DR Pharos; Q8N357; Tbio. DR PRO; PR:Q8N357; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q8N357; protein. DR Bgee; ENSG00000213699; Expressed in nipple and 182 other cell types or tissues. DR ExpressionAtlas; Q8N357; baseline and differential. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; IBA:GO_Central. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0022857; F:transmembrane transporter activity; IEA:InterPro. DR GO; GO:1901029; P:negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB. DR InterPro; IPR037185; EmrE-like. DR InterPro; IPR009262; SLC35_F1/F2/F6. DR InterPro; IPR012404; UCP036436. DR PANTHER; PTHR13146; -; 1. DR PANTHER; PTHR13146:SF0; SOLUTE CARRIER FAMILY 35 MEMBER F6; 1. DR Pfam; PF06027; SLC35F; 1. DR PIRSF; PIRSF036436; UCP036436; 1. DR SUPFAM; SSF103481; Multidrug resistance efflux transporter EmrE; 1. PE 1: Evidence at protein level; KW Glycoprotein; Lysosome; Membrane; Mitochondrion; Phosphoprotein; KW Proteomics identification; Reference proteome; Signal; Transmembrane; KW Transmembrane helix; Transport. FT SIGNAL 1..18 FT /evidence="ECO:0000255" FT CHAIN 19..371 FT /note="Solute carrier family 35 member F6" FT /id="PRO_0000232514" FT TRANSMEM 48..68 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 89..109 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 117..137 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 140..160 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 176..196 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 216..236 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 261..281 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 295..312 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 317..336 FT /note="Helical" FT /evidence="ECO:0000255" FT DOMAIN 104..160 FT /note="EamA" FT REGION 352..371 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 365 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT CARBOHYD 110 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CONFLICT 107 FT /note="V -> A (in Ref. 5; BAD96649)" FT /evidence="ECO:0000305" FT CONFLICT 163 FT /note="L -> P (in Ref. 5; BAD96649)" FT /evidence="ECO:0000305" FT CONFLICT 215 FT /note="E -> K (in Ref. 2; BAA91255)" FT /evidence="ECO:0000305" FT CONFLICT 274 FT /note="A -> V (in Ref. 5; BAD96649)" FT /evidence="ECO:0000305" FT CONFLICT 295 FT /note="L -> S (in Ref. 3; BAC11445)" FT /evidence="ECO:0000305" SQ SEQUENCE 371 AA; 40214 MW; 225AFE41FA555B12 CRC64; MAWTKYQLFL AGLMLVTGSI NTLSAKWADN FMAEGCGGSK EHSFQHPFLQ AVGMFLGEFS CLAAFYLLRC RAAGQSDSSV DPQQPFNPLL FLPPALCDMT GTSLMYVALN MTSASSFQML RGAVIIFTGL FSVAFLGRRL VLSQWLGILA TIAGLVVVGL ADLLSKHDSQ HKLSEVITGD LLIIMAQIIV AIQMVLEEKF VYKHNVHPLR AVGTEGLFGF VILSLLLVPM YYIPAGSFSG NPRGTLEDAL DAFCQVGQQP LIAVALLGNI SSIAFFNFAG ISVTKELSAT TRMVLDSLRT VVIWALSLAL GWEAFHALQI LGFLILLIGT ALYNGLHRPL LGRLSRGRPL AEESEQERLL GGTRTPINDA S // ID TINAL_HUMAN Reviewed; 467 AA. AC Q9GZM7; A8K9Q5; B4DPK6; D3DPN8; Q8TEJ9; Q8WZ23; Q96GZ4; Q96JW3; DT 15-MAR-2005, integrated into UniProtKB/Swiss-Prot. DT 01-MAR-2001, sequence version 1. DT 28-JAN-2026, entry version 190. DE RecName: Full=Tubulointerstitial nephritis antigen-like; DE AltName: Full=Glucocorticoid-inducible protein 5; DE AltName: Full=Oxidized LDL-responsive gene 2 protein; DE Short=OLRG-2; DE AltName: Full=Tubulointerstitial nephritis antigen-related protein; DE Short=TIN Ag-related protein; DE Short=TIN-Ag-RP; DE Flags: Precursor; GN Name=TINAGL1; Synonyms=GIS5, LCN7, OLRG2, TINAGL; GN ORFNames=PP6614, PSEC0088, UNQ204/PRO230; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND SUBCELLULAR LOCATION. RC TISSUE=Muscle; RX PubMed=10799322; DOI=10.1006/bbrc.2000.2639; RA Broemme N.C., Wex T., Wex H., Levy B., Lipyansky A., Broemme D.; RT "Cloning, characterization, and expression of the human TIN-ag-RP gene RT encoding a novel putative extracellular matrix protein."; RL Biochem. Biophys. Res. Commun. 271:474-480(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 22-27, TISSUE RP SPECIFICITY, GLYCOSYLATION, AND SUBCELLULAR LOCATION. RC TISSUE=Muscle; RX PubMed=11170462; DOI=10.1021/bi002266o; RA Wex T., Lipyansky A., Broemme N.C., Wex H., Guan X.Q., Broemme D.; RT "TIN-ag-RP, a novel catalytically inactive cathepsin B-related protein with RT EGF domains, is predominantly expressed in vascular smooth muscle cells."; RL Biochemistry 40:1350-1357(2001). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Zhang K.M., Chen B.S.; RT "Identification of oxidized-LDL responsive gene 2 (OLRG-2), encoding a RT novel extracellular matrix protein in vascular endothelial cells."; RL Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1). RA Yoshida H., Takaishi K., Harada M., Nagasaka T., Tsurufuji S., RA Taniguchi M.; RT "Identification of a novel glucocorticoid-inducible cDNA partially RT homologous to tubulointerstitial nephritis antigen."; RL Submitted (NOV-2000) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Placenta; RA Jikuya H., Takano J., Nomura N., Kikuno R., Nagase T., Ohara O.; RT "The nucleotide sequence of a long cDNA clone isolated from human spleen."; RL Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=12975309; DOI=10.1101/gr.1293003; RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J., RA Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P., RA Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A., RA Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D., RA Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L., RA Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C., RA Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J., RA Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.; RT "The secreted protein discovery initiative (SPDI), a large-scale effort to RT identify novel human secreted and transmembrane proteins: a bioinformatics RT assessment."; RL Genome Res. 13:2265-2270(2003). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RX PubMed=15498874; DOI=10.1073/pnas.0404089101; RA Wan D., Gong Y., Qin W., Zhang P., Li J., Wei L., Zhou X., Li H., Qiu X., RA Zhong F., He L., Yu J., Yao G., Jiang H., Qian L., Yu Y., Shu H., Chen X., RA Xu H., Guo M., Pan Z., Chen Y., Ge C., Yang S., Gu J.; RT "Large-scale cDNA transfection screening for genes related to cancer RT development and progression."; RL Proc. Natl. Acad. Sci. U.S.A. 101:15724-15729(2004). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Kidney, Placenta, and Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Placenta; RX PubMed=16303743; DOI=10.1093/dnares/12.2.117; RA Otsuki T., Ota T., Nishikawa T., Hayashi K., Suzuki Y., Yamamoto J., RA Wakamatsu A., Kimura K., Sakamoto K., Hatano N., Kawai Y., Ishii S., RA Saito K., Kojima S., Sugiyama T., Ono T., Okano K., Yoshikawa Y., RA Aotsuka S., Sasaki N., Hattori A., Okumura K., Nagai K., Sugano S., RA Isogai T.; RT "Signal sequence and keyword trap in silico for selection of full-length RT human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA RT libraries."; RL DNA Res. 12:117-126(2005). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Colon, and Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [13] RP PROTEIN SEQUENCE OF 22-36. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [14] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-78 AND ASN-161. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). CC -!- FUNCTION: May be implicated in the adrenocortical zonation and in CC mechanisms for repressing the CYP11B1 gene expression in adrenocortical CC cells. This is a non catalytic peptidase C1 family protein (By CC similarity). {ECO:0000250}. CC -!- INTERACTION: CC Q9GZM7; O95429: BAG4; NbExp=3; IntAct=EBI-715869, EBI-2949658; CC Q9GZM7; P59991: KRTAP12-2; NbExp=3; IntAct=EBI-715869, EBI-10176379; CC Q9GZM7; Q99697-2: PITX2; NbExp=3; IntAct=EBI-715869, EBI-12138495; CC Q9GZM7; O75360: PROP1; NbExp=3; IntAct=EBI-715869, EBI-9027467; CC Q9GZM7; Q15645: TRIP13; NbExp=6; IntAct=EBI-715869, EBI-358993; CC Q9GZM7-3; P59991: KRTAP12-2; NbExp=3; IntAct=EBI-10303636, EBI-10176379; CC Q9GZM7-3; Q9BYR5: KRTAP4-2; NbExp=3; IntAct=EBI-10303636, EBI-10172511; CC Q9GZM7-3; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-10303636, EBI-945833; CC Q9GZM7-3; Q93062: RBPMS; NbExp=3; IntAct=EBI-10303636, EBI-740322; CC Q9GZM7-3; Q15645: TRIP13; NbExp=3; IntAct=EBI-10303636, EBI-358993; CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:10799322, CC ECO:0000269|PubMed:11170462}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q9GZM7-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9GZM7-2; Sequence=VSP_013094, VSP_013095, VSP_013096, CC VSP_013097, VSP_013098; CC Name=3; CC IsoId=Q9GZM7-3; Sequence=VSP_043712; CC -!- TISSUE SPECIFICITY: Highly expressed in aorta, heart, placenta, kidney CC and a colorectal adenocarcinoma cell line. Moderately expressed in CC skeletal muscle, pancreas, lung, lymph nodes, adrenal gland, bone CC marrow and thyroid. Weakly expressed in colon, small intestine, ovary, CC spleen, testis and prostate. Predominantly found in vascular smooth CC muscle cells, but also in cardiac and skeletal muscle cells as well as CC kidney. {ECO:0000269|PubMed:11170462}. CC -!- PTM: Glycosylated. {ECO:0000269|PubMed:11170462, CC ECO:0000269|PubMed:19159218}. CC -!- SIMILARITY: Belongs to the peptidase C1 family. {ECO:0000255|PROSITE- CC ProRule:PRU10089}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH09048.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=BAB55403.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF236155; AAG40154.1; -; Genomic_DNA. DR EMBL; AF236151; AAG40154.1; JOINED; Genomic_DNA. DR EMBL; AF236152; AAG40154.1; JOINED; Genomic_DNA. DR EMBL; AF236153; AAG40154.1; JOINED; Genomic_DNA. DR EMBL; AF236154; AAG40154.1; JOINED; Genomic_DNA. DR EMBL; AF236150; AAG38876.1; -; mRNA. DR EMBL; AF205436; AAG33699.1; -; mRNA. DR EMBL; AB050716; BAB18636.1; -; mRNA. DR EMBL; AB050719; BAB18727.1; -; Genomic_DNA. DR EMBL; AK074124; BAB84950.1; -; mRNA. DR EMBL; AY358421; AAQ88787.1; -; mRNA. DR EMBL; AF289569; AAL55753.1; -; mRNA. DR EMBL; AK027839; BAB55403.1; ALT_INIT; mRNA. DR EMBL; AK292770; BAF85459.1; -; mRNA. DR EMBL; AK298382; BAG60618.1; -; mRNA. DR EMBL; AK075398; BAC11596.1; -; mRNA. DR EMBL; AC114488; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471059; EAX07604.1; -; Genomic_DNA. DR EMBL; CH471059; EAX07605.1; -; Genomic_DNA. DR EMBL; CH471059; EAX07606.1; -; Genomic_DNA. DR EMBL; BC009048; AAH09048.1; ALT_INIT; mRNA. DR EMBL; BC064633; AAH64633.1; -; mRNA. DR CCDS; CCDS343.1; -. [Q9GZM7-1] DR CCDS; CCDS55586.1; -. [Q9GZM7-3] DR RefSeq; NP_001191343.1; NM_001204414.2. [Q9GZM7-3] DR RefSeq; NP_001191344.1; NM_001204415.1. DR RefSeq; NP_071447.1; NM_022164.3. [Q9GZM7-1] DR AlphaFoldDB; Q9GZM7; -. DR SMR; Q9GZM7; -. DR BioGRID; 122078; 73. DR FunCoup; Q9GZM7; 214. DR IntAct; Q9GZM7; 79. DR MINT; Q9GZM7; -. DR STRING; 9606.ENSP00000271064; -. DR MEROPS; C01.975; -. DR GlyConnect; 1864; 7 N-Linked glycans (2 sites). DR GlyCosmos; Q9GZM7; 2 sites, 7 glycans. DR GlyGen; Q9GZM7; 3 sites, 100 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; Q9GZM7; -. DR PhosphoSitePlus; Q9GZM7; -. DR SwissPalm; Q9GZM7; -. DR BioMuta; TINAGL1; -. DR DMDM; 61213628; -. DR jPOST; Q9GZM7; -. DR MassIVE; Q9GZM7; -. DR PaxDb; 9606-ENSP00000271064; -. DR PeptideAtlas; Q9GZM7; -. DR ProteomicsDB; 80089; -. [Q9GZM7-1] DR ProteomicsDB; 80090; -. [Q9GZM7-2] DR ProteomicsDB; 80091; -. [Q9GZM7-3] DR Antibodypedia; 31121; 191 antibodies from 26 providers. DR DNASU; 64129; -. DR Ensembl; ENST00000271064.12; ENSP00000271064.7; ENSG00000142910.17. [Q9GZM7-1] DR Ensembl; ENST00000457433.6; ENSP00000395137.2; ENSG00000142910.17. [Q9GZM7-3] DR GeneID; 64129; -. DR KEGG; hsa:64129; -. DR MANE-Select; ENST00000271064.12; ENSP00000271064.7; NM_022164.3; NP_071447.1. DR UCSC; uc001bta.4; human. [Q9GZM7-1] DR AGR; HGNC:19168; -. DR ClinPGx; PA38810; -. DR CTD; 64129; -. DR DisGeNET; 64129; -. DR GeneCards; TINAGL1; -. DR HGNC; HGNC:19168; TINAGL1. DR HPA; ENSG00000142910; Low tissue specificity. DR MIM; 616064; gene. DR OpenTargets; ENSG00000142910; -. DR VEuPathDB; HostDB:ENSG00000142910; -. DR eggNOG; KOG1544; Eukaryota. DR GeneTree; ENSGT00940000160023; -. DR InParanoid; Q9GZM7; -. DR OMA; AEIYHSG; -. DR OrthoDB; 190265at2759; -. DR PAN-GO; Q9GZM7; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q9GZM7; -. DR PathwayCommons; Q9GZM7; -. DR SignaLink; Q9GZM7; -. DR Agora; ENSG00000142910; -. DR BioGRID-ORCS; 64129; 14 hits in 1151 CRISPR screens. DR ChiTaRS; TINAGL1; human. DR GeneWiki; TINAGL1; -. DR GenomeRNAi; 64129; -. DR Pharos; Q9GZM7; Tbio. DR PRO; PR:Q9GZM7; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q9GZM7; protein. DR Bgee; ENSG00000142910; Expressed in metanephros cortex and 138 other cell types or tissues. DR ExpressionAtlas; Q9GZM7; baseline and differential. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0031012; C:extracellular matrix; HDA:BHF-UCL. DR GO; GO:0005576; C:extracellular region; NAS:UniProtKB. DR GO; GO:0005615; C:extracellular space; IBA:GO_Central. DR GO; GO:0005764; C:lysosome; IBA:GO_Central. DR GO; GO:0005201; F:extracellular matrix structural constituent; NAS:UniProtKB. DR GO; GO:0043236; F:laminin binding; IEA:Ensembl. DR GO; GO:0016197; P:endosomal transport; TAS:UniProtKB. DR CDD; cd02620; Peptidase_C1A_CathepsinB; 1. DR FunFam; 3.90.70.10:FF:000037; Tubulointerstitial nephritis antigen-like 1; 1. DR Gene3D; 3.90.70.10; Cysteine proteinases; 1. DR InterPro; IPR038765; Papain-like_cys_pep_sf. DR InterPro; IPR025660; Pept_his_AS. DR InterPro; IPR013128; Peptidase_C1A. DR InterPro; IPR000668; Peptidase_C1A_C. DR InterPro; IPR001212; Somatomedin_B_dom. DR PANTHER; PTHR12411; CYSTEINE PROTEASE FAMILY C1-RELATED; 1. DR Pfam; PF00112; Peptidase_C1; 1. DR SMART; SM00645; Pept_C1; 1. DR SUPFAM; SSF54001; Cysteine proteinases; 1. DR PROSITE; PS00524; SMB_1; 1. DR PROSITE; PS50958; SMB_2; 1. DR PROSITE; PS00639; THIOL_PROTEASE_HIS; 1. PE 1: Evidence at protein level; KW Alternative splicing; Direct protein sequencing; Disulfide bond; KW Glycoprotein; Proteomics identification; Reference proteome; Secreted; KW Signal. FT SIGNAL 1..21 FT /evidence="ECO:0000269|PubMed:11170462, FT ECO:0000269|PubMed:15340161" FT CHAIN 22..467 FT /note="Tubulointerstitial nephritis antigen-like" FT /id="PRO_0000026482" FT DOMAIN 50..98 FT /note="SMB" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00350" FT CARBOHYD 78 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19159218" FT CARBOHYD 161 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19159218" FT DISULFID 54..73 FT /note="Alternate" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00350" FT DISULFID 71..85 FT /note="Alternate" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00350" FT DISULFID 71..73 FT /note="Alternate" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00350" FT DISULFID 77..84 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00350" FT DISULFID 85..92 FT /note="Alternate" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00350" FT VAR_SEQ 1..134 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15498874, ECO:0000303|Ref.5" FT /id="VSP_013094" FT VAR_SEQ 126..156 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_043712" FT VAR_SEQ 135..194 FT /note="CDQEPCLVDPDMIKAINQGNYGWQAGNHSAFWGMTLDEGIRYRLGTIRPSSS FT VMNMHEIY -> MVLGSSTQVKIGGSWNPAAAGGLKIKLQKALDLVALQCQWAPEGQAR FT AEQEADRATFILQ (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15498874, ECO:0000303|Ref.5" FT /id="VSP_013095" FT VAR_SEQ 286 FT /note="G -> GYAATGDVGREEGKELRGHGLGHDALSLSAFAPSCCLCR (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:15498874, ECO:0000303|Ref.5" FT /id="VSP_013096" FT VAR_SEQ 365..381 FT /note="ALMEVHEDFFLYKGGIY -> GKPPYPAPWFQKLVPA (in isoform FT 2)" FT /evidence="ECO:0000303|PubMed:15498874, ECO:0000303|Ref.5" FT /id="VSP_013097" FT VAR_SEQ 382..467 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15498874, ECO:0000303|Ref.5" FT /id="VSP_013098" FT VARIANT 69 FT /note="A -> S (in dbSNP:rs17497479)" FT /id="VAR_051514" FT CONFLICT 333 FT /note="N -> Y (in Ref. 7; AAL55753)" FT /evidence="ECO:0000305" FT CONFLICT 377 FT /note="K -> E (in Ref. 8; BAB55403)" FT /evidence="ECO:0000305" SQ SEQUENCE 467 AA; 52387 MW; E9D72220E3E7B7D5 CRC64; MWRCPLGLLL LLPLAGHLAL GAQQGRGRRE LAPGLHLRGI RDAGGRYCQE QDLCCRGRAD DCALPYLGAI CYCDLFCNRT VSDCCPDFWD FCLGVPPPFP PIQGCMHGGR IYPVLGTYWD NCNRCTCQEN RQWQCDQEPC LVDPDMIKAI NQGNYGWQAG NHSAFWGMTL DEGIRYRLGT IRPSSSVMNM HEIYTVLNPG EVLPTAFEAS EKWPNLIHEP LDQGNCAGSW AFSTAAVASD RVSIHSLGHM TPVLSPQNLL SCDTHQQQGC RGGRLDGAWW FLRRRGVVSD HCYPFSGRER DEAGPAPPCM MHSRAMGRGK RQATAHCPNS YVNNNDIYQV TPVYRLGSND KEIMKELMEN GPVQALMEVH EDFFLYKGGI YSHTPVSLGR PERYRRHGTH SVKITGWGEE TLPDGRTLKY WTAANSWGPA WGERGHFRIV RGVNECDIES FVLGVWGRVG MEDMGHH // ID TOPRS_HUMAN Reviewed; 1045 AA. AC Q9NS56; O43273; Q6P987; Q9NS55; Q9UNR9; DT 18-APR-2006, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2000, sequence version 1. DT 28-JAN-2026, entry version 187. DE RecName: Full=E3 ubiquitin-protein ligase Topors; DE EC=2.3.2.27; DE AltName: Full=RING-type E3 ubiquitin transferase Topors {ECO:0000305}; DE AltName: Full=SUMO1-protein E3 ligase Topors; DE AltName: Full=Topoisomerase I-binding RING finger protein; DE AltName: Full=Topoisomerase I-binding arginine/serine-rich protein; DE AltName: Full=Tumor suppressor p53-binding protein 3; DE Short=p53-binding protein 3; DE Short=p53BP3; GN Name=TOPORS; Synonyms=LUN, TP53BPL; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH TOP1, AND RP SUBCELLULAR LOCATION. RX PubMed=10352183; DOI=10.1093/nar/27.12.2538; RA Haluska P. Jr., Saleem A., Rasheed Z., Ahmed F., Su E.W., Liu L.F., RA Rubin E.H.; RT "Interaction between human topoisomerase I and a novel RING RT finger/arginine-serine protein."; RL Nucleic Acids Res. 27:2538-2544(1999). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), PUTATIVE DNA-BINDING, RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RC TISSUE=Lung; RX PubMed=11278651; DOI=10.1074/jbc.m010262200; RA Chu D., Kakazu N., Gorrin-Rivas M.J., Lu H.P., Kawata M., Abe T., Ueda K., RA Adachi Y.; RT "Cloning and characterization of LUN, a novel RING-finger protein that is RT highly expressed in lung and specifically binds to a palindromic RT sequence."; RL J. Biol. Chem. 276:14004-14013(2001). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS THR-154; RP LYS-517 AND ASP-749. RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 51-1045 (ISOFORM 1), INTERACTION WITH TP53, RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=10415337; DOI=10.1016/s0378-1119(99)00203-6; RA Zhou R., Wen H., Ao S.-Z.; RT "Identification of a novel gene encoding a p53-associated protein."; RL Gene 235:93-101(1999). RN [6] RP SUBCELLULAR LOCATION. RX PubMed=12083797; DOI=10.1006/excr.2002.5550; RA Rasheed Z.A., Saleem A., Ravee Y., Pandolfi P.P., Rubin E.H.; RT "The topoisomerase I-binding RING protein, topors, is associated with RT promyelocytic leukemia nuclear bodies."; RL Exp. Cell Res. 277:152-160(2002). RN [7] RP INTERACTION WITH SUMO1 AND UBE2I, SUBCELLULAR LOCATION, SUMOYLATION, AND RP MUTAGENESIS OF LYS-76; LYS-301; LYS-485; LYS-560 AND LYS-921. RX PubMed=14516784; DOI=10.1016/s0014-4827(03)00292-1; RA Weger S., Hammer E., Engstler M.; RT "The DNA topoisomerase I binding protein topors as a novel cellular target RT for SUMO-1 modification: characterization of domains necessary for RT subcellular localization and sumolation."; RL Exp. Cell Res. 290:13-27(2003). RN [8] RP FUNCTION, AND MUTAGENESIS OF TRP-131. RX PubMed=15247280; DOI=10.1074/jbc.c400300200; RA Rajendra R., Malegaonkar D., Pungaliya P., Marshall H., Rasheed Z., RA Brownell J., Liu L.F., Lutzker S., Saleem A., Rubin E.H.; RT "Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and RT ubiquitinates p53."; RL J. Biol. Chem. 279:36440-36444(2004). RN [9] RP REDUCED EXPRESSION IN LUNG CANCERS. RX PubMed=15364129; DOI=10.1016/j.lungcan.2004.03.009; RA Oyanagi H., Takenaka K., Ishikawa S., Kawano Y., Adachi Y., Ueda K., RA Wada H., Tanaka F.; RT "Expression of LUN gene that encodes a novel RING finger protein is RT correlated with development and progression of non-small cell lung RT cancer."; RL Lung Cancer 46:21-28(2004). RN [10] RP TISSUE SPECIFICITY, AND REDUCED EXPRESSION IN COLON CANCERS. RX PubMed=15107820; DOI=10.1038/sj.onc.1207700; RA Saleem A., Dutta J., Malegaonkar D., Rasheed F., Rasheed Z., Rajendra R., RA Marshall H., Luo M., Li H., Rubin E.H.; RT "The topoisomerase I- and p53-binding protein topors is differentially RT expressed in normal and malignant human tissues and may function as a tumor RT suppressor."; RL Oncogene 23:5293-5300(2004). RN [11] RP FUNCTION, AND SUMOYLATION. RX PubMed=16122737; DOI=10.1016/j.febslet.2005.07.088; RA Weger S., Hammer E., Heilbronn R.; RT "Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo."; RL FEBS Lett. 579:5007-5012(2005). RN [12] RP FUNCTION, AND INDUCTION. RX PubMed=15735665; DOI=10.1038/sj.onc.1208554; RA Lin L., Ozaki T., Takada Y., Kageyama H., Nakamura Y., Hata A., Zhang J.H., RA Simonds W.F., Nakagawara A., Koseki H.; RT "Topors, a p53 and topoisomerase I-binding RING finger protein, is a RT coactivator of p53 in growth suppression induced by DNA damage."; RL Oncogene 24:3385-3396(2005). RN [13] RP INVOLVEMENT IN RP31. RX PubMed=17924349; DOI=10.1086/521953; RA Chakarova C.F., Papaioannou M.G., Khanna H., Lopez I., Waseem N., Shah A., RA Theis T., Friedman J., Maubaret C., Bujakowska K., Veraitch B., RA El-Aziz M.M.A., Prescott de Q., Parapuram S.K., Bickmore W.A., RA Munro P.M.G., Gal A., Hamel C.P., Marigo V., Ponting C.P., Wissinger B., RA Zrenner E., Matter K., Swaroop A., Koenekoop R.K., Bhattacharya S.S.; RT "Mutations in TOPORS cause autosomal dominant retinitis pigmentosa with RT perivascular retinal pigment epithelium atrophy."; RL Am. J. Hum. Genet. 81:1098-1103(2007). RN [14] RP FUNCTION, AND INTERACTION WITH SIN3A. RX PubMed=17803295; DOI=10.1021/pr0703674; RA Pungaliya P., Kulkarni D., Park H.J., Marshall H., Zheng H., Lackland H., RA Saleem A., Rubin E.H.; RT "TOPORS functions as a SUMO-1 E3 ligase for chromatin-modifying proteins."; RL J. Proteome Res. 6:3918-3923(2007). RN [15] RP PHOSPHORYLATION AT SER-98; SER-499; SER-585 AND SER-866, MUTAGENESIS OF RP SER-98, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=19053840; DOI=10.1021/bi801904q; RA Park H.J., Zheng H., Kulkarni D., Kerrigan J., Pungaliya P., Saleem A., RA Rubin E.H.; RT "Identification of phosphorylation sites of TOPORS and a role for serine 98 RT in the regulation of ubiquitin but not SUMO E3 ligase activity."; RL Biochemistry 47:13887-13896(2008). RN [16] RP FUNCTION, INTERACTION WITH NKX3-1, AND SUBCELLULAR LOCATION. RX PubMed=18077445; DOI=10.1074/jbc.m708630200; RA Guan B., Pungaliya P., Li X., Uquillas C., Mutton L.N., Rubin E.H., RA Bieberich C.J.; RT "Ubiquitination by TOPORS regulates the prostate tumor suppressor NKX3.1."; RL J. Biol. Chem. 283:4834-4840(2008). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [18] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [19] RP FUNCTION, INTERACTION WITH PLK1, PHOSPHORYLATION AT SER-718 BY PLK1, RP MUTAGENESIS OF SER-718, AND SUBCELLULAR LOCATION. RX PubMed=19473992; DOI=10.1074/jbc.c109.001560; RA Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X.; RT "Plk1-mediated phosphorylation of Topors regulates p53 stability."; RL J. Biol. Chem. 284:18588-18592(2009). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98; SER-864 AND SER-866, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [21] RP FUNCTION, INTERACTION WITH IKBKE, AND SUBCELLULAR LOCATION. RX PubMed=20188669; DOI=10.1016/j.molcel.2010.01.018; RA Renner F., Moreno R., Schmitz M.L.; RT "SUMOylation-dependent localization of IKKepsilon in PML nuclear bodies is RT essential for protection against DNA-damage-triggered cell death."; RL Mol. Cell 37:503-515(2010). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98; SER-864 AND SER-866, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98; SER-194; SER-585 AND RP SER-734, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [26] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-76; LYS-83; LYS-249 AND LYS-701, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25218447; DOI=10.1038/nsmb.2890; RA Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M., RA Vertegaal A.C.; RT "Uncovering global SUMOylation signaling networks in a site-specific RT manner."; RL Nat. Struct. Mol. Biol. 21:927-936(2014). RN [27] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-76 AND LYS-701, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033; RA Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V., RA Vertegaal A.C.; RT "SUMO-2 orchestrates chromatin modifiers in response to DNA damage."; RL Cell Rep. 10:1778-1791(2015). RN [28] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-76 AND LYS-701, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25755297; DOI=10.1074/mcp.o114.044792; RA Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V., RA Vertegaal A.C.; RT "System-wide analysis of SUMOylation dynamics in response to replication RT stress reveals novel small ubiquitin-like modified target proteins and RT acceptor lysines relevant for genome stability."; RL Mol. Cell. Proteomics 14:1419-1434(2015). RN [29] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-73; LYS-76; LYS-83; LYS-88; RP LYS-159; LYS-249; LYS-701; LYS-819 AND LYS-837, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). CC -!- FUNCTION: Functions as an E3 ubiquitin-protein ligase and as an E3 CC SUMO1-protein ligase. Probable tumor suppressor involved in cell CC growth, cell proliferation and apoptosis that regulates p53/TP53 CC stability through ubiquitin-dependent degradation. May regulate CC chromatin modification through sumoylation of several chromatin CC modification-associated proteins. May be involved in DNA damage-induced CC cell death through IKBKE sumoylation. {ECO:0000269|PubMed:15247280, CC ECO:0000269|PubMed:15735665, ECO:0000269|PubMed:16122737, CC ECO:0000269|PubMed:17803295, ECO:0000269|PubMed:18077445, CC ECO:0000269|PubMed:19473992, ECO:0000269|PubMed:20188669}. CC -!- CATALYTIC ACTIVITY: CC Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine + CC [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L- CC cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.; CC EC=2.3.2.27; CC -!- SUBUNIT: Interacts with PARK7/DJ-1 (By similarity). Interacts with CC TOP1. Interacts with p53/TP53; can both ubiquitinate and sumoylate CC p53/TP53. Interacts with the SUMO1 conjugating enzyme UBE2I. Interacts CC with SUMO1. Interacts with NKX3-1; polyubiquitinates NKX3-1 and induces CC its proteasomal degradation. Interacts with SIN3A; sumoylates SIN3A. CC Interacts with IKBKE; induced by DNA damage. CC {ECO:0000250|UniProtKB:Q80Z37, ECO:0000269|PubMed:10352183, CC ECO:0000269|PubMed:10415337, ECO:0000269|PubMed:14516784, CC ECO:0000269|PubMed:17803295, ECO:0000269|PubMed:18077445, CC ECO:0000269|PubMed:19473992, ECO:0000269|PubMed:20188669}. CC -!- INTERACTION: CC Q9NS56; P03132: Rep68; Xeno; NbExp=3; IntAct=EBI-1996473, EBI-7387242; CC -!- SUBCELLULAR LOCATION: Nucleus. Nucleus, PML body. Note=Localizes to CC discrete nuclear foci which partly overlap with PML nuclear bodies. CC Targeted to PML nuclear bodies upon DNA damage. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=LUN-1; CC IsoId=Q9NS56-1; Sequence=Displayed; CC Name=2; Synonyms=LUN-2; CC IsoId=Q9NS56-2; Sequence=VSP_017916, VSP_017917; CC -!- TISSUE SPECIFICITY: Expressed at highest levels in testis and at lower CC levels in adrenal gland, bone marrow, brain, colon, heart, kidney, CC liver, muscle, ovary, pancreas, placenta, prostate, skeletal muscle, CC skin, small intestine, spleen, stomach, testis, thymus, thyroid and CC uterus. Expressed in the alveolar epithelium of the lung. Expression is CC commonly decreased in colon adenocarcinomas and lung cancers. CC {ECO:0000269|PubMed:10415337, ECO:0000269|PubMed:11278651, CC ECO:0000269|PubMed:15107820}. CC -!- INDUCTION: By genotoxic agents such as cisplatin and camptothecin. CC {ECO:0000269|PubMed:15735665}. CC -!- PTM: Phosphorylation at Ser-98 regulates the E3 ubiquitin-protein CC ligase activity but not the SUMO1-protein ligase activity. CC Phosphorylation at Ser-718 increases the E3 ubiquitin-protein ligase CC activity versus the SUMO1-protein ligase activity resulting in CC increased p53/TP53 ubiquitination and degradation. CC {ECO:0000269|PubMed:19053840, ECO:0000269|PubMed:19473992}. CC -!- PTM: Sumoylated. {ECO:0000269|PubMed:14516784, CC ECO:0000269|PubMed:16122737}. CC -!- DISEASE: Retinitis pigmentosa 31 (RP31) [MIM:609923]: A retinal CC dystrophy belonging to the group of pigmentary retinopathies. Retinitis CC pigmentosa is characterized by retinal pigment deposits visible on CC fundus examination and primary loss of rod photoreceptor cells followed CC by secondary loss of cone photoreceptors. Patients typically have night CC vision blindness and loss of midperipheral visual field. As their CC condition progresses, they lose their far peripheral visual field and CC eventually central vision as well. {ECO:0000269|PubMed:17924349}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- CAUTION: Was originally thought to bind to the palindromic consensus CC sequence 5'-TCCCAGCACTTTGGGA-3' and to regulate the transcription of CC numerous genes in the lung. {ECO:0000305|PubMed:11278651}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC98530.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/42663/TOPORS"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF098300; AAD23379.1; -; mRNA. DR EMBL; AB045732; BAB03714.1; -; mRNA. DR EMBL; AB045733; BAB03715.1; -; mRNA. DR EMBL; AL353671; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC060884; AAH60884.1; -; mRNA. DR EMBL; U82939; AAC98530.1; ALT_INIT; mRNA. DR CCDS; CCDS56566.1; -. [Q9NS56-2] DR CCDS; CCDS6527.1; -. [Q9NS56-1] DR RefSeq; NP_001182551.1; NM_001195622.2. [Q9NS56-2] DR RefSeq; NP_005793.2; NM_005802.4. [Q9NS56-1] DR AlphaFoldDB; Q9NS56; -. DR SMR; Q9NS56; -. DR BioGRID; 115505; 99. DR FunCoup; Q9NS56; 1905. DR IntAct; Q9NS56; 49. DR MINT; Q9NS56; -. DR STRING; 9606.ENSP00000353735; -. DR GlyGen; Q9NS56; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9NS56; -. DR PhosphoSitePlus; Q9NS56; -. DR BioMuta; TOPORS; -. DR DMDM; 74752935; -. DR jPOST; Q9NS56; -. DR MassIVE; Q9NS56; -. DR PaxDb; 9606-ENSP00000353735; -. DR PeptideAtlas; Q9NS56; -. DR ProteomicsDB; 82481; -. [Q9NS56-1] DR ProteomicsDB; 82482; -. [Q9NS56-2] DR Pumba; Q9NS56; -. DR Antibodypedia; 25068; 220 antibodies from 25 providers. DR DNASU; 10210; -. DR Ensembl; ENST00000360538.7; ENSP00000353735.2; ENSG00000197579.9. [Q9NS56-1] DR Ensembl; ENST00000379858.1; ENSP00000369187.1; ENSG00000197579.9. [Q9NS56-2] DR GeneID; 10210; -. DR KEGG; hsa:10210; -. DR MANE-Select; ENST00000360538.7; ENSP00000353735.2; NM_005802.5; NP_005793.2. DR UCSC; uc003zrb.4; human. [Q9NS56-1] DR AGR; HGNC:21653; -. DR ClinPGx; PA134979531; -. DR CTD; 10210; -. DR DisGeNET; 10210; -. DR GeneCards; TOPORS; -. DR GeneReviews; TOPORS; -. DR HGNC; HGNC:21653; TOPORS. DR HPA; ENSG00000197579; Low tissue specificity. DR MalaCards; TOPORS; -. DR MIM; 609507; gene. DR MIM; 609923; phenotype. DR OpenTargets; ENSG00000197579; -. DR Orphanet; 2754; Orofaciodigital syndrome type 6. DR Orphanet; 791; Retinitis pigmentosa. DR VEuPathDB; HostDB:ENSG00000197579; -. DR eggNOG; KOG4430; Eukaryota. DR GeneTree; ENSGT00530000064170; -. DR HOGENOM; CLU_012046_0_0_1; -. DR InParanoid; Q9NS56; -. DR OMA; DCVIVGF; -. DR OrthoDB; 21204at2759; -. DR PAN-GO; Q9NS56; 7 GO annotations based on evolutionary models. DR PhylomeDB; Q9NS56; -. DR PathwayCommons; Q9NS56; -. DR Reactome; R-HSA-3899300; SUMOylation of transcription cofactors. DR Reactome; R-HSA-4085377; SUMOylation of SUMOylation proteins. DR Reactome; R-HSA-4755510; SUMOylation of immune response proteins. DR SignaLink; Q9NS56; -. DR SIGNOR; Q9NS56; -. DR Agora; ENSG00000197579; -. DR BioGRID-ORCS; 10210; 13 hits in 1201 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; B5B9A610; PML body. DR ChiTaRS; TOPORS; human. DR GeneWiki; TOPORS; -. DR GenomeRNAi; 10210; -. DR Pharos; Q9NS56; Tbio. DR PRO; PR:Q9NS56; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q9NS56; protein. DR Bgee; ENSG00000197579; Expressed in secondary oocyte and 207 other cell types or tissues. DR GO; GO:0005814; C:centriole; IDA:BHF-UCL. DR GO; GO:0036064; C:ciliary basal body; IDA:BHF-UCL. DR GO; GO:0000930; C:gamma-tubulin complex; IDA:BHF-UCL. DR GO; GO:0030496; C:midbody; TAS:BHF-UCL. DR GO; GO:0016607; C:nuclear speck; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0032391; C:photoreceptor connecting cilium; IDA:BHF-UCL. DR GO; GO:0016605; C:PML body; IDA:UniProtKB. DR GO; GO:0000922; C:spindle pole; IDA:BHF-UCL. DR GO; GO:0000151; C:ubiquitin ligase complex; IDA:BHF-UCL. DR GO; GO:0003823; F:antigen binding; IPI:UniProtKB. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0044547; F:DNA topoisomerase binding; IPI:UniProtKB. DR GO; GO:0019789; F:SUMO transferase activity; IDA:UniProtKB. DR GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:BHF-UCL. DR GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0006351; P:DNA-templated transcription; NAS:UniProtKB. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IDA:UniProtKB. DR GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl. DR GO; GO:0051457; P:maintenance of protein location in nucleus; IDA:UniProtKB. DR GO; GO:0043066; P:negative regulation of apoptotic process; ISS:BHF-UCL. DR GO; GO:0035845; P:photoreceptor cell outer segment organization; ISS:BHF-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IEA:Ensembl. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IMP:UniProtKB. DR GO; GO:0070936; P:protein K48-linked ubiquitination; IDA:BHF-UCL. DR GO; GO:0034504; P:protein localization to nucleus; IMP:UniProtKB. DR GO; GO:0006513; P:protein monoubiquitination; IDA:BHF-UCL. DR GO; GO:0000209; P:protein polyubiquitination; IDA:BHF-UCL. DR GO; GO:0016925; P:protein sumoylation; IDA:UniProtKB. DR GO; GO:0042127; P:regulation of cell population proliferation; IEA:Ensembl. DR GO; GO:0010842; P:retina layer formation; ISS:BHF-UCL. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IMP:UniProtKB. DR CDD; cd16574; RING-HC_Topors; 1. DR FunFam; 3.30.40.10:FF:000136; E3 ubiquitin-protein ligase Topors; 1. DR Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1. DR InterPro; IPR058745; PWI_Topors. DR InterPro; IPR018957; Znf_C3HC4_RING-type. DR InterPro; IPR001841; Znf_RING. DR InterPro; IPR058746; Znf_RING-type_Topors. DR InterPro; IPR013083; Znf_RING/FYVE/PHD. DR InterPro; IPR017907; Znf_RING_CS. DR PANTHER; PTHR46077; E3 UBIQUITIN-PROTEIN LIGASE TOPORS; 1. DR PANTHER; PTHR46077:SF2; E3 UBIQUITIN-PROTEIN LIGASE TOPORS; 1. DR Pfam; PF26084; PWI_Topors; 1. DR Pfam; PF00097; zf-C3HC4; 1. DR SMART; SM00184; RING; 1. DR SUPFAM; SSF57850; RING/U-box; 1. DR PROSITE; PS00518; ZF_RING_1; 1. DR PROSITE; PS50089; ZF_RING_2; 1. PE 1: Evidence at protein level; KW Alternative splicing; DNA damage; Isopeptide bond; Metal-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Retinitis pigmentosa; Transferase; Ubl conjugation; KW Ubl conjugation pathway; Zinc; Zinc-finger. FT CHAIN 1..1045 FT /note="E3 ubiquitin-protein ligase Topors" FT /id="PRO_0000232626" FT ZN_FING 103..142 FT /note="RING-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00175" FT REGION 1..195 FT /note="E3 ubiquitin-protein ligase activity" FT REGION 1..35 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 51..374 FT /note="Required for DNA-binding" FT REGION 437..654 FT /note="Interaction with SUMO1" FT /evidence="ECO:0000269|PubMed:14516784" FT REGION 437..574 FT /note="Required for sumoylation and localization to FT discrete nuclear foci" FT REGION 442..475 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 456..882 FT /note="Interaction with TOP1" FT /evidence="ECO:0000269|PubMed:10352183" FT REGION 456..731 FT /note="Interaction with p53/TP53" FT /evidence="ECO:0000269|PubMed:10415337" FT REGION 511..692 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 713..936 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 854..917 FT /note="Interaction with UBE2I" FT /evidence="ECO:0000269|PubMed:14516784" FT COMPBIAS 453..463 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 521..534 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 539..565 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 566..578 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 588..597 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 613..630 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 637..647 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 654..669 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 721..730 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 731..747 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 755..766 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 816..825 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 854..863 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 880..897 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 913..923 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 98 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:19053840, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 194 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 499 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:19053840" FT MOD_RES 585 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:19053840, FT ECO:0007744|PubMed:23186163" FT MOD_RES 718 FT /note="Phosphoserine; by PLK1" FT /evidence="ECO:0000269|PubMed:19473992" FT MOD_RES 734 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 864 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:21406692" FT MOD_RES 866 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:19053840, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692" FT MOD_RES 912 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80Z37" FT MOD_RES 914 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80Z37" FT MOD_RES 1028 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80Z37" FT CROSSLNK 73 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 76 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 83 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 88 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 159 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 249 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 560 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO)" FT CROSSLNK 701 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 819 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 837 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 1..65 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:11278651" FT /id="VSP_017916" FT VAR_SEQ 66 FT /note="E -> M (in isoform 2)" FT /evidence="ECO:0000303|PubMed:11278651" FT /id="VSP_017917" FT VARIANT 154 FT /note="A -> T (in dbSNP:rs17855104)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_037629" FT VARIANT 517 FT /note="E -> K (in dbSNP:rs17855103)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_037630" FT VARIANT 749 FT /note="N -> D (in dbSNP:rs17857515)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_037631" FT VARIANT 812 FT /note="P -> R (in dbSNP:rs36034138)" FT /id="VAR_037632" FT MUTAGEN 76 FT /note="K->R: No effect on sumoylation." FT /evidence="ECO:0000269|PubMed:14516784" FT MUTAGEN 98 FT /note="S->A: Loss of phosphorylation but no effect on E3 FT ubiquitin-protein ligase activity." FT /evidence="ECO:0000269|PubMed:19053840" FT MUTAGEN 98 FT /note="S->D: Increase in E3 ubiquitin-protein ligase FT activity and increased binding to UBE2D1. No effect on FT SUMO1-protein ligase activity." FT /evidence="ECO:0000269|PubMed:19053840" FT MUTAGEN 131 FT /note="W->A: Abrogates E3 ubiquitin-protein ligase FT activity." FT /evidence="ECO:0000269|PubMed:15247280" FT MUTAGEN 301 FT /note="K->R: No effect on sumoylation." FT /evidence="ECO:0000269|PubMed:14516784" FT MUTAGEN 485 FT /note="K->R: No effect on sumoylation." FT /evidence="ECO:0000269|PubMed:14516784" FT MUTAGEN 560 FT /note="K->R: Strongly reduces sumoylation." FT /evidence="ECO:0000269|PubMed:14516784" FT MUTAGEN 718 FT /note="S->A: Loss of phosphorylation by PLK1 and increases FT in p53/TP53 stability." FT /evidence="ECO:0000269|PubMed:19473992" FT MUTAGEN 921 FT /note="K->R: No effect on sumoylation." FT /evidence="ECO:0000269|PubMed:14516784" FT CONFLICT 124..125 FT /note="CF -> K (in Ref. 5; AAC98530)" FT /evidence="ECO:0000305" FT CONFLICT 257 FT /note="N -> S (in Ref. 1; AAD23379)" FT /evidence="ECO:0000305" FT CONFLICT 308 FT /note="F -> S (in Ref. 1; AAD23379)" FT /evidence="ECO:0000305" FT CONFLICT 922 FT /note="E -> G (in Ref. 1; AAD23379)" FT /evidence="ECO:0000305" FT CONFLICT 1040 FT /note="R -> K (in Ref. 1; AAD23379)" FT /evidence="ECO:0000305" SQ SEQUENCE 1045 AA; 119198 MW; 3DA635FDB5C83B77 CRC64; MGSQPPLGSP LSREEGEAPP PAPASEGRRR SRRVRLRGSC RHRPSFLGCR ELAASAPARP APASSEIMAS AAKEFKMDNF SPKAGTSKLQ QTVPADASPD SKCPICLDRF DNVSYLDRCL HKFCFRCVQE WSKNKAECPL CKQPFDSIFH SVRAEDDFKE YVLRPSYNGS FVTPDRRFRY RTTLTRERNA SVYSPSGPVN RRTTTPPDSG VLFEGLGIST RPRDVEIPQF MRQIAVRRPT TADERSLRKI QEQDIINFRR TLYRAGARVR NIEDGGRYRD ISAEFFRRNP ACLHRLVPWL KRELTVLFGA HGSLVNIVQH IIMSNVTRYD LESQAFVSDL RPFLLNRTEH FIHEFISFAR SPFNMAAFDQ HANYDCPAPS YEEGSHSDSS VITISPDEAE TQELDINVAT VSQAPWDDET PGPSYSSSEQ VHVTMSSLLN TSDSSDEELV TGGATSQIQG VQTNDDLNND SDDSSDNCVI VGFVKPLAER TPELVELSSD SEDLGSYEKM ETVKTQEQEQ SYSSGDSDVS RCSSPHSVLG KDEQINKGHC DSSTRIKSKK EEKRSTSLSS PRNLNSSVRG DRVYSPYNHR HRKRGRSRSS DSRSQSRSGH DQKNHRKHHG KKRMKSKRSR SRESSRPRGR RDKKRSRTRD SSWSRRSQTL SLSSESTSRS RSRSSDHGKR RSRSRNRDRY YLRNNYGSRY KWEYTYYSRN KDRDGYESSY RRRTLSRAHY SRQSSSPEFR VQSFSERTNA RKKNNHSERK YYYYERHRSR SLSSNRSRTA STGTDRVRNE KPGGKRKYKT RHLEGTNEVA QPSREFASKA KDSHYQKSSS KLDGNYKNES DTFSDSRSSD RETKHKRRKR KTRSLSVEIV YEGKATDTTK HHKKKKKKHK KKHKKHHGDN ASRSPVVITI DSDSDKDSEV KEDTECDNSG PQDPLQNEFL APSLEPFETK DVVTIEAEFG VLDKECDIAT LSNNLNNANK TVDNIPPLAA SVEQTLDVRE ESTFVSDLEN QPSNIVSLQT EPSRQLPSPR TSLMSVCLGR DCDMS // ID TRI33_HUMAN Reviewed; 1127 AA. AC Q9UPN9; O95855; Q5TG72; Q5TG73; Q5TG74; Q9C017; Q9UJ79; DT 24-JAN-2001, integrated into UniProtKB/Swiss-Prot. DT 30-NOV-2010, sequence version 3. DT 28-JAN-2026, entry version 224. DE RecName: Full=E3 ubiquitin-protein ligase TRIM33; DE EC=2.3.2.27; DE AltName: Full=Ectodermin homolog; DE AltName: Full=RET-fused gene 7 protein; DE Short=Protein Rfg7; DE AltName: Full=RING-type E3 ubiquitin transferase TRIM33 {ECO:0000305}; DE AltName: Full=Transcription intermediary factor 1-gamma; DE Short=TIF1-gamma; DE AltName: Full=Tripartite motif-containing protein 33; GN Name=TRIM33; Synonyms=KIAA1113, RFG7, TIF1G; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA), FUNCTION, SUBUNIT, AND VARIANT RP THR-840. RX PubMed=10022127; DOI=10.1038/sj.onc.1202655; RA Venturini L., You J., Stadler M., Galien R., Lallemand V., Koken M.H.M., RA Mattei M.-G., Ganser A., Chambon P., Losson R., De The H.; RT "TIF1gamma, a novel member of the transcriptional intermediary factor 1 RT family."; RL Oncogene 18:1209-1217(1999). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA AND BETA), AND VARIANT THR-840. RX PubMed=11331580; DOI=10.1093/emboj/20.9.2140; RA Reymond A., Meroni G., Fantozzi A., Merla G., Cairo S., Luzi L., RA Riganelli D., Zanaria E., Messali S., Cainarca S., Guffanti A., Minucci S., RA Pelicci P.G., Ballabio A.; RT "The tripartite motif family identifies cell compartments."; RL EMBO J. 20:2140-2151(2001). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA), AND VARIANT RP THR-840. RC TISSUE=Brain; RX PubMed=10470851; DOI=10.1093/dnares/6.3.197; RA Kikuno R., Nagase T., Ishikawa K., Hirosawa M., Miyajima N., Tanaka A., RA Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XIV. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 6:197-205(1999). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 76-1127 (ISOFORMS ALPHA AND BETA), RP CHROMOSOMAL TRANSLOCATION WITH RET, AND VARIANT THR-840. RC TISSUE=Thyroid; RX PubMed=10439047; DOI=10.1038/sj.onc.1202824; RA Klugbauer S., Rabes H.M.; RT "The transcription coactivator HTIF1 and a related protein are fused to the RT RET receptor tyrosine kinase in childhood papillary thyroid carcinomas."; RL Oncogene 18:4388-4393(1999). RN [6] RP SUBUNIT. RX PubMed=12096914; DOI=10.1016/s0022-2836(02)00477-1; RA Peng H., Feldman I., Rauscher F.J. III; RT "Hetero-oligomerization among the TIF family of RBCC/TRIM domain-containing RT nuclear cofactors: a potential mechanism for regulating the switch between RT coactivation and corepression."; RL J. Mol. Biol. 320:629-644(2002). RN [7] RP FUNCTION AS AN E3 UBIQUITIN-PROTEIN LIGASE, UBIQUITINATION OF SMAD4, RP INTERACTION WITH SMAD4, MUTAGENESIS OF CYS-125 AND CYS-128, AND SUBCELLULAR RP LOCATION. RX PubMed=15820681; DOI=10.1016/j.cell.2005.01.033; RA Dupont S., Zacchigna L., Cordenonsi M., Soligo S., Adorno M., Rugge M., RA Piccolo S.; RT "Germ-layer specification and control of cell growth by Ectodermin, a Smad4 RT ubiquitin ligase."; RL Cell 121:87-99(2005). RN [8] RP FUNCTION, IDENTIFICATION IN A COMPLEX WITH SMAD2 AND SMAD3, INTERACTION RP WITH SMAD2 AND SMAD3, AND SUBCELLULAR LOCATION. RX PubMed=16751102; DOI=10.1016/j.cell.2006.03.045; RA He W., Dorn D.C., Erdjument-Bromage H., Tempst P., Moore M.A., Massague J.; RT "Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the RT TGFbeta pathway."; RL Cell 125:929-941(2006). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-862; THR-1102 AND SER-1105, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [10] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH SMAD2 AND SMAD4. RX PubMed=19135894; DOI=10.1016/j.cell.2008.10.051; RA Dupont S., Mamidi A., Cordenonsi M., Montagner M., Zacchigna L., Adorno M., RA Martello G., Stinchfield M.J., Soligo S., Morsut L., Inui M., Moro S., RA Modena N., Argenton F., Newfeld S.J., Piccolo S.; RT "FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, RT controls Smad4 monoubiquitination."; RL Cell 136:123-135(2009). RN [11] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-763; LYS-769 AND LYS-953, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-862; THR-1102 AND SER-1105, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-862; THR-1102 AND SER-1105, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-862; THR-1051 AND SER-1119, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [16] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [17] RP METHYLATION [LARGE SCALE ANALYSIS] AT ARG-515; ARG-535; ARG-577; ARG-591; RP ARG-598 AND ARG-604, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [18] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-334; LYS-763; LYS-769; LYS-776; RP LYS-793; LYS-953; LYS-1007 AND LYS-1057, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25218447; DOI=10.1038/nsmb.2890; RA Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M., RA Vertegaal A.C.; RT "Uncovering global SUMOylation signaling networks in a site-specific RT manner."; RL Nat. Struct. Mol. Biol. 21:927-936(2014). RN [19] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-776 AND LYS-793, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25114211; DOI=10.1073/pnas.1413825111; RA Impens F., Radoshevich L., Cossart P., Ribet D.; RT "Mapping of SUMO sites and analysis of SUMOylation changes induced by RT external stimuli."; RL Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014). RN [20] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-763; LYS-769; LYS-776; LYS-793; RP LYS-861; LYS-1057 AND LYS-1118, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033; RA Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V., RA Vertegaal A.C.; RT "SUMO-2 orchestrates chromatin modifiers in response to DNA damage."; RL Cell Rep. 10:1778-1791(2015). RN [21] RP SUBCELLULAR LOCATION. RX PubMed=25593309; DOI=10.1101/gad.252189.114; RA Gong F., Chiu L.Y., Cox B., Aymard F., Clouaire T., Leung J.W., RA Cammarata M., Perez M., Agarwal P., Brodbelt J.S., Legube G., Miller K.M.; RT "Screen identifies bromodomain protein ZMYND8 in chromatin recognition of RT transcription-associated DNA damage that promotes homologous RT recombination."; RL Genes Dev. 29:197-211(2015). RN [22] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-763; LYS-769; LYS-776; LYS-793 RP AND LYS-1057, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RX PubMed=25755297; DOI=10.1074/mcp.o114.044792; RA Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V., RA Vertegaal A.C.; RT "System-wide analysis of SUMOylation dynamics in response to replication RT stress reveals novel small ubiquitin-like modified target proteins and RT acceptor lysines relevant for genome stability."; RL Mol. Cell. Proteomics 14:1419-1434(2015). RN [23] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-329; LYS-481; LYS-504; LYS-527; RP LYS-763; LYS-769; LYS-774; LYS-776; LYS-793; LYS-796; LYS-861; LYS-953; RP LYS-1043; LYS-1057 AND LYS-1118, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [24] RP INVOLVEMENT IN DDH4, AND VARIANT DDH4 THR-550 INS. RX PubMed=39054052; DOI=10.1136/jmg-2024-109928; RA Gombosh M., Proskorovski-Ohayon R., Yogev Y., Eskin-Schwartz M., Hadar N., RA Aharoni S., Dolgin V., Cohen E., Birk O.S.; RT "Developmental dysplasia of the hip caused by homozygous TRIM33 pathogenic RT variant affecting downstream BMP pathway."; RL J. Med. Genet. 61:959-965(2024). RN [25] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-580; SER-696; LYS-811; SER-885; MET-961 RP AND THR-1090. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Acts as an E3 ubiquitin-protein ligase. Promotes SMAD4 CC ubiquitination, nuclear exclusion and degradation via the ubiquitin CC proteasome pathway. According to PubMed:16751102, does not promote a CC decrease in the level of endogenous SMAD4. May act as a transcriptional CC repressor. Inhibits the transcriptional response to TGF-beta/BMP CC signaling cascade. Plays a role in the control of cell proliferation. CC Its association with SMAD2 and SMAD3 stimulates erythroid CC differentiation of hematopoietic stem/progenitor (By similarity). CC Monoubiquitinates SMAD4 and acts as an inhibitor of SMAD4-dependent CC TGF-beta/BMP signaling cascade (Monoubiquitination of SMAD4 hampers its CC ability to form a stable complex with activated SMAD2/3 resulting in CC inhibition of TGF-beta/BMP signaling cascade). {ECO:0000250, CC ECO:0000269|PubMed:10022127, ECO:0000269|PubMed:15820681, CC ECO:0000269|PubMed:16751102, ECO:0000269|PubMed:19135894}. CC -!- CATALYTIC ACTIVITY: CC Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine + CC [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L- CC cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.; CC EC=2.3.2.27; CC -!- PATHWAY: Protein modification; protein ubiquitination. CC -!- SUBUNIT: Homooligomer and heterooligomer with TRIM24 and TRIM28 family CC members. Interacts with SMAD4 in unstimulated cells. Found in a complex CC with SMAD2 and SMAD3 upon addition of TGF-beta. Interacts with SMAD2 CC and SMAD3. Interacts with SMAD4 under basal and induced conditions and, CC upon TGF-beta signaling, with activated SMAD2. Forms a ternary complex CC with SMAD4 and SMAD2 upon TGF-beta signaling. CC {ECO:0000269|PubMed:10022127, ECO:0000269|PubMed:12096914, CC ECO:0000269|PubMed:15820681, ECO:0000269|PubMed:16751102, CC ECO:0000269|PubMed:19135894}. CC -!- INTERACTION: CC Q9UPN9; Q03154: ACY1; NbExp=2; IntAct=EBI-2214398, EBI-742064; CC Q9UPN9; Q15796: SMAD2; NbExp=6; IntAct=EBI-2214398, EBI-1040141; CC Q9UPN9; Q13485: SMAD4; NbExp=6; IntAct=EBI-2214398, EBI-347263; CC Q9UPN9; O15164: TRIM24; NbExp=6; IntAct=EBI-2214398, EBI-2130378; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15820681, CC ECO:0000269|PubMed:16751102, ECO:0000269|PubMed:19135894, CC ECO:0000269|PubMed:25593309}. Note=In discrete nuclear dots resembling CC nuclear bodies (By similarity). Localizes to sites of DNA damage CC (PubMed:25593309). {ECO:0000250|UniProtKB:Q99PP7, CC ECO:0000269|PubMed:25593309}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=Alpha; CC IsoId=Q9UPN9-1; Sequence=Displayed; CC Name=Beta; CC IsoId=Q9UPN9-2; Sequence=VSP_005774; CC -!- TISSUE SPECIFICITY: Expressed in stem cells at the bottom of the crypts CC of the colon (at protein level). Expressed in colon adenomas and CC adenocarcinomas (at protein level). Expressed in brain, lung, liver, CC spleen, thymus, prostate, kidney, testis, heart, placenta, pancreas, CC small intestine, ovary, colon, skeletal muscle and hematopoietic CC progenitors. CC -!- PTM: Sumoylated with SUMO1. {ECO:0000250|UniProtKB:Q99PP7}. CC -!- DISEASE: Note=A chromosomal aberration involving TRIM33 is found in CC papillary thyroid carcinomas (PTCs). Translocation t(1;10)(p13;q11) CC with RET. The translocation generates the TRIM33/RET (PTC7) oncogene. CC {ECO:0000269|PubMed:10439047}. CC -!- DISEASE: Developmental dysplasia of the hip 4 (DDH4) [MIM:621311]: An CC autosomal recessive form of congenital dysplasia of the hip, a common CC skeletal anomaly in which the normal seating of the femoral head in the CC acetabulum is disrupted. Its severity ranges from mild instability of CC the femoral head with slight capsular laxity, permitting minimal CC lateral displacement, through moderate lateral displacement of the CC femoral head, without loss of contact of the head with the acetabulum, CC up to complete dislocation of the femoral head from the acetabulum. CC {ECO:0000269|PubMed:39054052}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the TRIM/RBCC family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAD17259.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=BAA83065.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF119043; AAD17259.1; ALT_FRAME; mRNA. DR EMBL; AF220136; AAG53509.1; -; mRNA. DR EMBL; AF220137; AAG53510.1; -; mRNA. DR EMBL; AB029036; BAA83065.1; ALT_INIT; mRNA. DR EMBL; AL035410; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL390241; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AJ132948; CAB55313.1; -; mRNA. DR CCDS; CCDS872.1; -. [Q9UPN9-1] DR CCDS; CCDS873.1; -. [Q9UPN9-2] DR RefSeq; NP_056990.3; NM_015906.3. [Q9UPN9-1] DR RefSeq; NP_148980.2; NM_033020.3. [Q9UPN9-2] DR PDB; 3U5M; X-ray; 3.08 A; A/B/C/D/E/F/G/H/I/J/K/L=882-1087. DR PDB; 3U5N; X-ray; 1.95 A; A/B=882-1087. DR PDB; 3U5O; X-ray; 2.70 A; A/B/C/D/E/F/G/H=882-1087. DR PDB; 3U5P; X-ray; 2.80 A; A/B/C/D/E/F/G/H=882-1087. DR PDB; 5MR8; X-ray; 1.74 A; A=882-1090. DR PDB; 7ZDD; X-ray; 1.62 A; A=882-1090. DR PDB; 8BD8; X-ray; 3.10 A; A=882-1087. DR PDB; 8BD9; X-ray; 3.20 A; A=882-1087. DR PDB; 8BDY; X-ray; 3.05 A; A=882-1087. DR PDBsum; 3U5M; -. DR PDBsum; 3U5N; -. DR PDBsum; 3U5O; -. DR PDBsum; 3U5P; -. DR PDBsum; 5MR8; -. DR PDBsum; 7ZDD; -. DR PDBsum; 8BD8; -. DR PDBsum; 8BD9; -. DR PDBsum; 8BDY; -. DR AlphaFoldDB; Q9UPN9; -. DR SMR; Q9UPN9; -. DR BioGRID; 119625; 483. DR CORUM; Q9UPN9; -. DR DIP; DIP-54262N; -. DR FunCoup; Q9UPN9; 4535. DR IntAct; Q9UPN9; 151. DR MINT; Q9UPN9; -. DR STRING; 9606.ENSP00000351250; -. DR BindingDB; Q9UPN9; -. DR ChEMBL; CHEMBL2176772; -. DR GlyCosmos; Q9UPN9; 1 site, 1 glycan. DR GlyGen; Q9UPN9; 7 sites, 1 O-linked glycan (6 sites). DR iPTMnet; Q9UPN9; -. DR PhosphoSitePlus; Q9UPN9; -. DR BioMuta; TRIM33; -. DR DMDM; 313104270; -. DR jPOST; Q9UPN9; -. DR MassIVE; Q9UPN9; -. DR PaxDb; 9606-ENSP00000351250; -. DR PeptideAtlas; Q9UPN9; -. DR ProteomicsDB; 85392; -. [Q9UPN9-1] DR ProteomicsDB; 85393; -. [Q9UPN9-2] DR Pumba; Q9UPN9; -. DR ABCD; Q9UPN9; 1 sequenced antibody. DR Antibodypedia; 1303; 439 antibodies from 37 providers. DR DNASU; 51592; -. DR Ensembl; ENST00000358465.7; ENSP00000351250.2; ENSG00000197323.13. [Q9UPN9-1] DR Ensembl; ENST00000369543.6; ENSP00000358556.2; ENSG00000197323.13. [Q9UPN9-2] DR GeneID; 51592; -. DR KEGG; hsa:51592; -. DR MANE-Select; ENST00000358465.7; ENSP00000351250.2; NM_015906.4; NP_056990.3. DR UCSC; uc001eew.3; human. [Q9UPN9-1] DR AGR; HGNC:16290; -. DR ClinPGx; PA38118; -. DR CTD; 51592; -. DR DisGeNET; 51592; -. DR GeneCards; TRIM33; -. DR HGNC; HGNC:16290; TRIM33. DR HPA; ENSG00000197323; Low tissue specificity. DR MalaCards; TRIM33; -. DR MIM; 605769; gene. DR MIM; 621311; phenotype. DR OpenTargets; ENSG00000197323; -. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 2412; Dislocation of the hip-dysmorphism syndrome. DR VEuPathDB; HostDB:ENSG00000197323; -. DR eggNOG; KOG2177; Eukaryota. DR GeneTree; ENSGT00940000156361; -. DR InParanoid; Q9UPN9; -. DR OMA; ICQNCVM; -. DR OrthoDB; 1870062at2759; -. DR PAN-GO; Q9UPN9; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q9UPN9; -. DR PathwayCommons; Q9UPN9; -. DR Reactome; R-HSA-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity. DR Reactome; R-HSA-9754189; Germ layer formation at gastrulation. DR SignaLink; Q9UPN9; -. DR SIGNOR; Q9UPN9; -. DR UniPathway; UPA00143; -. DR Agora; ENSG00000197323; -. DR BioGRID-ORCS; 51592; 47 hits in 1223 CRISPR screens. DR ChiTaRS; TRIM33; human. DR EvolutionaryTrace; Q9UPN9; -. DR GeneWiki; TRIM33; -. DR GenomeRNAi; 51592; -. DR Pharos; Q9UPN9; Tchem. DR PRO; PR:Q9UPN9; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q9UPN9; protein. DR Bgee; ENSG00000197323; Expressed in endometrium epithelium and 209 other cell types or tissues. DR ExpressionAtlas; Q9UPN9; baseline and differential. DR GO; GO:0000785; C:chromatin; IBA:GO_Central. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0070410; F:co-SMAD binding; IPI:BHF-UCL. DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW. DR GO; GO:0070412; F:R-SMAD binding; IPI:BHF-UCL. DR GO; GO:0061630; F:ubiquitin protein ligase activity; IEA:UniProtKB-EC. DR GO; GO:0004842; F:ubiquitin-protein transferase activity; TAS:Reactome. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0030514; P:negative regulation of BMP signaling pathway; IDA:UniProtKB. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; NAS:UniProtKB. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; TAS:Reactome. DR GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB. DR GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; IDA:UniProtKB. DR CDD; cd19847; Bbox1_TIF1g_C-VI; 1. DR CDD; cd19830; Bbox2_TIF1g_C-VI; 1. DR CDD; cd05502; Bromo_tif1_like; 1. DR CDD; cd15624; PHD_TIF1gamma; 1. DR CDD; cd16766; RING-HC_TIF1gamma; 1. DR FunFam; 3.30.40.10:FF:000123; E3 ubiquitin-protein ligase TRIM33; 1. DR FunFam; 3.30.40.10:FF:000246; E3 ubiquitin-protein ligase TRIM33 isoform X2; 1. DR FunFam; 1.20.920.10:FF:000024; Transcription intermediary factor 1-alpha; 1. DR FunFam; 3.30.160.60:FF:000074; Tripartite motif containing 66; 1. DR Gene3D; 1.20.920.10; Bromodomain-like; 1. DR Gene3D; 3.30.160.60; Classic Zinc Finger; 1. DR Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 2. DR IDEAL; IID00505; -. DR InterPro; IPR003649; Bbox_C. DR InterPro; IPR001487; Bromodomain. DR InterPro; IPR036427; Bromodomain-like_sf. DR InterPro; IPR019786; Zinc_finger_PHD-type_CS. DR InterPro; IPR000315; Znf_B-box. DR InterPro; IPR011011; Znf_FYVE_PHD. DR InterPro; IPR001965; Znf_PHD. DR InterPro; IPR019787; Znf_PHD-finger. DR InterPro; IPR001841; Znf_RING. DR InterPro; IPR013083; Znf_RING/FYVE/PHD. DR InterPro; IPR017907; Znf_RING_CS. DR PANTHER; PTHR45915:SF3; E3 UBIQUITIN-PROTEIN LIGASE TRIM33; 1. DR PANTHER; PTHR45915; TRANSCRIPTION INTERMEDIARY FACTOR; 1. DR Pfam; PF00439; Bromodomain; 1. DR Pfam; PF00628; PHD; 1. DR Pfam; PF00643; zf-B_box; 1. DR PRINTS; PR00503; BROMODOMAIN. DR SMART; SM00502; BBC; 1. DR SMART; SM00336; BBOX; 2. DR SMART; SM00297; BROMO; 1. DR SMART; SM00249; PHD; 2. DR SMART; SM00184; RING; 2. DR SUPFAM; SSF57845; B-box zinc-binding domain; 1. DR SUPFAM; SSF47370; Bromodomain; 1. DR SUPFAM; SSF57903; FYVE/PHD zinc finger; 1. DR SUPFAM; SSF57850; RING/U-box; 1. DR PROSITE; PS50014; BROMODOMAIN_2; 1. DR PROSITE; PS50119; ZF_BBOX; 2. DR PROSITE; PS01359; ZF_PHD_1; 1. DR PROSITE; PS50016; ZF_PHD_2; 1. DR PROSITE; PS00518; ZF_RING_1; 1. DR PROSITE; PS50089; ZF_RING_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Bromodomain; KW Chromosomal rearrangement; Coiled coil; DNA-binding; Isopeptide bond; KW Metal-binding; Methylation; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Repressor; KW Transcription; Transcription regulation; Transferase; Ubl conjugation; KW Ubl conjugation pathway; Zinc; Zinc-finger. FT CHAIN 1..1127 FT /note="E3 ubiquitin-protein ligase TRIM33" FT /id="PRO_0000056395" FT DOMAIN 957..1080 FT /note="Bromo" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT ZN_FING 125..154 FT /note="RING-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00175" FT ZN_FING 212..259 FT /note="B box-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT ZN_FING 271..312 FT /note="B box-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT ZN_FING 887..934 FT /note="PHD-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00146" FT REGION 1..147 FT /note="Necessary for E3 ubiquitin-protein ligase activity FT and repression of SMAD4 signaling and transcriptional FT repression" FT REGION 1..118 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 299..401 FT /note="Necessary for oligomerization" FT REGION 536..563 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 608..629 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 673..692 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 703..818 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1088..1127 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 299..401 FT /evidence="ECO:0000255" FT COMPBIAS 1..18 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 19..37 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 52..64 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 65..97 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 98..118 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 723..759 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 793..802 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 807..818 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1092..1109 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1118..1127 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 217 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT BINDING 220 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT BINDING 241 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT BINDING 245 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT BINDING 276 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT BINDING 279 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT BINDING 299 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT BINDING 304 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT SITE 964..965 FT /note="Breakpoint for translocation to form TRIM33-RET FT oncogene" FT MOD_RES 515 FT /note="Asymmetric dimethylarginine; alternate" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 515 FT /note="Omega-N-methylarginine; alternate" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 535 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 577 FT /note="Asymmetric dimethylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 591 FT /note="Asymmetric dimethylarginine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q99PP7" FT MOD_RES 591 FT /note="Omega-N-methylarginine; alternate" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 598 FT /note="Asymmetric dimethylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 604 FT /note="Asymmetric dimethylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 763 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 769 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 793 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q99PP7" FT MOD_RES 803 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q99PP7" FT MOD_RES 815 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q99PP7" FT MOD_RES 862 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 951 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:Q99PP7" FT MOD_RES 953 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 1051 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1102 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692" FT MOD_RES 1105 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692" FT MOD_RES 1119 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 329 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 334 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447" FT CROSSLNK 481 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 504 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 527 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 763 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2); alternate" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 769 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2); alternate" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 774 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 776 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO1); alternate" FT /evidence="ECO:0007744|PubMed:25114211" FT CROSSLNK 776 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2); alternate" FT /evidence="ECO:0007744|PubMed:25114211, FT ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25755297, FT ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733" FT CROSSLNK 793 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO1); alternate" FT /evidence="ECO:0007744|PubMed:25114211" FT CROSSLNK 793 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2); alternate" FT /evidence="ECO:0007744|PubMed:25114211, FT ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25755297, FT ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733" FT CROSSLNK 796 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 861 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25772364, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 953 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2); alternate" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 1007 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447" FT CROSSLNK 1043 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 1057 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 1118 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25772364, FT ECO:0007744|PubMed:28112733" FT VAR_SEQ 1041..1057 FT /note="Missing (in isoform Beta)" FT /evidence="ECO:0000303|PubMed:10439047, FT ECO:0000303|PubMed:11331580" FT /id="VSP_005774" FT VARIANT 67 FT /note="V -> A (in dbSNP:rs6691166)" FT /id="VAR_029494" FT VARIANT 550 FT /note="T -> TT (in DDH4; uncertain significance)" FT /evidence="ECO:0000269|PubMed:39054052" FT /id="VAR_091062" FT VARIANT 580 FT /note="M -> I (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042376" FT VARIANT 696 FT /note="L -> S (in dbSNP:rs56151583)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042377" FT VARIANT 811 FT /note="E -> K (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042378" FT VARIANT 840 FT /note="I -> T (in dbSNP:rs6537825)" FT /evidence="ECO:0000269|PubMed:10022127, FT ECO:0000269|PubMed:10439047, ECO:0000269|PubMed:10470851, FT ECO:0000269|PubMed:11331580" FT /id="VAR_024616" FT VARIANT 885 FT /note="P -> S (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042379" FT VARIANT 961 FT /note="V -> M (in dbSNP:rs55688622)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042380" FT VARIANT 1090 FT /note="P -> T (in dbSNP:rs55784699)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042381" FT MUTAGEN 125 FT /note="C->A: Abolishes E3 activity but does not affect FT interaction with SMAD4; when associated with A-128." FT /evidence="ECO:0000269|PubMed:15820681" FT MUTAGEN 128 FT /note="C->A: Abolishes E3 activity but does not affect FT interaction with SMAD4; when associated with A-125." FT /evidence="ECO:0000269|PubMed:15820681" FT CONFLICT 89 FT /note="V -> E (in Ref. 5; CAB55313)" FT /evidence="ECO:0000305" FT CONFLICT 451..453 FT /note="PAA -> LLH (in Ref. 5; CAB55313)" FT /evidence="ECO:0000305" FT CONFLICT 909 FT /note="F -> S (in Ref. 5; CAB55313)" FT /evidence="ECO:0000305" FT CONFLICT 1037 FT /note="R -> T (in Ref. 1; AAD17259)" FT /evidence="ECO:0000305" FT STRAND 888..890 FT /evidence="ECO:0007829|PDB:3U5N" FT TURN 891..893 FT /evidence="ECO:0007829|PDB:7ZDD" FT STRAND 897..901 FT /evidence="ECO:0007829|PDB:7ZDD" FT STRAND 903..906 FT /evidence="ECO:0007829|PDB:7ZDD" FT TURN 911..913 FT /evidence="ECO:0007829|PDB:7ZDD" FT STRAND 914..916 FT /evidence="ECO:0007829|PDB:7ZDD" FT STRAND 918..920 FT /evidence="ECO:0007829|PDB:3U5P" FT TURN 929..931 FT /evidence="ECO:0007829|PDB:7ZDD" FT STRAND 934..936 FT /evidence="ECO:0007829|PDB:7ZDD" FT HELIX 944..949 FT /evidence="ECO:0007829|PDB:5MR8" FT TURN 950..952 FT /evidence="ECO:0007829|PDB:5MR8" FT HELIX 960..975 FT /evidence="ECO:0007829|PDB:7ZDD" FT HELIX 980..982 FT /evidence="ECO:0007829|PDB:7ZDD" FT HELIX 993..996 FT /evidence="ECO:0007829|PDB:7ZDD" FT HELIX 1003..1010 FT /evidence="ECO:0007829|PDB:7ZDD" FT STRAND 1011..1013 FT /evidence="ECO:0007829|PDB:3U5O" FT HELIX 1021..1038 FT /evidence="ECO:0007829|PDB:7ZDD" FT TURN 1044..1048 FT /evidence="ECO:0007829|PDB:8BDY" FT HELIX 1061..1080 FT /evidence="ECO:0007829|PDB:7ZDD" FT TURN 1081..1083 FT /evidence="ECO:0007829|PDB:7ZDD" SQ SEQUENCE 1127 AA; 122533 MW; 7A36013799E9933C CRC64; MAENKGGGEA ESGGGGSGSA PVTAGAAGPA AQEAEPPLTA VLVEEEEEEG GRAGAEGGAA GPDDGGVAAA SSGSAQAASS PAASVGTGVA GGAVSTPAPA PASAPAPGPS AGPPPGPPAS LLDTCAVCQQ SLQSRREAEP KLLPCLHSFC LRCLPEPERQ LSVPIPGGSN GDIQQVGVIR CPVCRQECRQ IDLVDNYFVK DTSEAPSSSD EKSEQVCTSC EDNASAVGFC VECGEWLCKT CIEAHQRVKF TKDHLIRKKE DVSESVGASG QRPVFCPVHK QEQLKLFCET CDRLTCRDCQ LLEHKEHRYQ FLEEAFQNQK GAIENLLAKL LEKKNYVHFA ATQVQNRIKE VNETNKRVEQ EIKVAIFTLI NEINKKGKSL LQQLENVTKE RQMKLLQQQN DITGLSRQVK HVMNFTNWAI ASGSSTALLY SKRLITFQLR HILKARCDPV PAANGAIRFH CDPTFWAKNV VNLGNLVIES KPAPGYTPNV VVGQVPPGTN HISKTPGQIN LAQLRLQHMQ QQVYAQKHQQ LQQMRMQQPP APVPTTTTTT QQHPRQAAPQ MLQQQPPRLI SVQTMQRGNM NCGAFQAHQM RLAQNAARIP GIPRHSGPQY SMMQPHLQRQ HSNPGHAGPF PVVSVHNTTI NPTSPTTATM ANANRGPTSP SVTAIELIPS VTNPENLPSL PDIPPIQLED AGSSSLDNLL SRYISGSHLP PQPTSTMNPS PGPSALSPGS SGLSNSHTPV RPPSTSSTGS RGSCGSSGRT AEKTSLSFKS DQVKVKQEPG TEDEICSFSG GVKQEKTEDG RRSACMLSSP ESSLTPPLST NLHLESELDA LASLENHVKI EPADMNESCK QSGLSSLVNG KSPIRSLMHR SARIGGDGNN KDDDPNEDWC AVCQNGGDLL CCEKCPKVFH LTCHVPTLLS FPSGDWICTF CRDIGKPEVE YDCDNLQHSK KGKTAQGLSP VDQRKCERLL LYLYCHELSI EFQEPVPASI PNYYKIIKKP MDLSTVKKKL QKKHSQHYQI PDDFVADVRL IFKNCERFNE MMKVVQVYAD TQEINLKADS EVAQAGKAVA LYFEDKLTEI YSDRTFAPLP EFEQEEDDGE VTEDSDEDFI QPRRKRLKSD ERPVHIK // ID TRPM6_HUMAN Reviewed; 2022 AA. AC Q9BX84; Q6VPR8; Q6VPR9; Q6VPS0; Q6VPS1; Q6VPS2; DT 07-DEC-2004, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-2002, sequence version 2. DT 28-JAN-2026, entry version 184. DE RecName: Full=Transient receptor potential cation channel subfamily M member 6; DE EC=2.7.11.1 {ECO:0000269|PubMed:18258429, ECO:0000269|PubMed:18365021}; DE AltName: Full=Channel kinase 2; DE AltName: Full=Melastatin-related TRP cation channel 6; DE Contains: DE RecName: Full=TRPM6 kinase, cleaved form {ECO:0000303|PubMed:28784805}; GN Name=TRPM6; Synonyms=CHAK2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRPM6A). RC TISSUE=Kidney; RX PubMed=11357414; RA Riazanova L.V., Pavur K.S., Petrov A.N., Dorovkov M.V., Riazanov A.G.; RT "Novel type of signaling molecules: protein kinases covalently linked to RT ion channels."; RL Mol. Biol. (Mosk.) 35:321-332(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRPM6A), AND VARIANT HOMG1 LEU-141. RC TISSUE=Kidney, and Small intestine; RX PubMed=12032568; DOI=10.1038/ng889; RA Schlingmann K.P., Weber S., Peters M., Niemann Nejsum L.N., Vitzthum H., RA Klingel K., Kratz M., Haddad E., Ristoff E., Dinour D., Syrrou M., RA Nielsen S., Sassen M.C., Waldegger S., Seyberth H.W., Konrad M.; RT "Hypomagnesemia with secondary hypocalcemia is caused by mutations in RT TRPM6, a new member of the TRPM gene family."; RL Nat. Genet. 31:166-170(2002). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TRPM6A; TRPM6B; TRPM6C; TRPM6T; RP M6-KINASE 1; M6-KINASE 2 AND M6-KINASE 3), CHARACTERIZATION OF VARIANT RP HOMG1 LEU-141, INTERACTION WITH TRPM7, AND SUBUNIT. RC TISSUE=Lung cancer; RX PubMed=14976260; DOI=10.1073/pnas.0305252101; RA Chubanov V., Waldegger S., Mederos y Schnitzler M., Vitzthum H., RA Sassen M.C., Seyberth H.W., Konrad M., Gudermann T.; RT "Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 RT gene causes hypomagnesemia with secondary hypocalcemia."; RL Proc. Natl. Acad. Sci. U.S.A. 101:2894-2899(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [5] RP FUNCTION, TRANSPORTER ACTIVITY, ACTIVITY REGULATION, AND SUBCELLULAR RP LOCATION. RX PubMed=14576148; DOI=10.1074/jbc.m311201200; RA Voets T., Nilius B., Hoefs S., van der Kemp A.W., Droogmans G., RA Bindels R.J., Hoenderop J.G.; RT "TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ RT absorption."; RL J. Biol. Chem. 279:19-25(2004). RN [6] RP FUNCTION, TRANSPORTER ACTIVITY, ACTIVITY REGULATION, SUBUNIT, AND RP CHARACTERIZATION OF VARIANT HOMG1 LEU-141. RX PubMed=16636202; DOI=10.1085/jgp.200609502; RA Li M., Jiang J., Yue L.; RT "Functional characterization of homo- and heteromeric channel kinases TRPM6 RT and TRPM7."; RL J. Gen. Physiol. 127:525-537(2006). RN [7] RP SUBUNIT, AND VARIANT HOMG1 ARG-1017. RX PubMed=17197439; DOI=10.1074/jbc.m611117200; RA Chubanov V., Schlingmann K.P., Waering J., Heinzinger J., Kaske S., RA Waldegger S., Mederos y Schnitzler M., Gudermann T.; RT "Hypomagnesemia with secondary hypocalcemia due to a missense mutation in RT the putative pore-forming region of TRPM6."; RL J. Biol. Chem. 282:7656-7667(2007). RN [8] RP FUNCTION, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION. RX PubMed=18365021; DOI=10.1371/journal.pone.0001876; RA Clark K., Middelbeek J., Morrice N.A., Figdor C.G., Lasonder E., RA van Leeuwen F.N.; RT "Massive autophosphorylation of the Ser/Thr-rich domain controls protein RT kinase activity of TRPM6 and TRPM7."; RL PLoS ONE 3:e1876-e1876(2008). RN [9] RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, INTERACTION WITH RACK1, RP PHOSPHORYLATION AT THR-1851, AND MUTAGENESIS OF LYS-1804 AND THR-1851. RX PubMed=18258429; DOI=10.1016/j.cub.2007.12.058; RA Cao G., Thebault S., van der Wijst J., van der Kemp A., Lasonder E., RA Bindels R.J., Hoenderop J.G.; RT "RACK1 inhibits TRPM6 activity via phosphorylation of the fused alpha- RT kinase domain."; RL Curr. Biol. 18:168-176(2008). RN [10] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=24385424; DOI=10.1074/jbc.m113.512285; RA Zhang Z., Yu H., Huang J., Faouzi M., Schmitz C., Penner R., Fleig A.; RT "The TRPM6 kinase domain determines the Mg.ATP sensitivity of TRPM7/M6 RT heteromeric ion channels."; RL J. Biol. Chem. 289:5217-5227(2014). RN [11] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF 1063-ASN--LEU-1065. RX PubMed=28784805; DOI=10.1073/pnas.1708427114; RA Krapivinsky G., Krapivinsky L., Renthal N.E., Santa-Cruz A., Manasian Y., RA Clapham D.E.; RT "Histone phosphorylation by TRPM6's cleaved kinase attenuates adjacent RT arginine methylation to regulate gene expression."; RL Proc. Natl. Acad. Sci. U.S.A. 114:E7092-E7100(2017). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-75; ILE-338; CYS-1007; ARG-1243; RP ARG-1274; ILE-1393; GLU-1584; ARG-1663; SER-1673 AND ILE-1724. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [13] RP VARIANTS HOMG1 PRO-708; GLY-872; CYS-1053; PRO-1143 AND ASN-1754, VARIANT RP ARG-1663, CHARACTERIZATION OF VARIANTS HOMG1 PRO-708; GLY-872; CYS-1053; RP PRO-1143 AND ASN-1754, CHARACTERIZATION OF VARIANT ARG-1663, AND RP SUBCELLULAR LOCATION. RX PubMed=23942199; DOI=10.1038/ejhg.2013.178; RA Lainez S., Schlingmann K.P., van der Wijst J., Dworniczak B., RA van Zeeland F., Konrad M., Bindels R.J., Hoenderop J.G.; RT "New TRPM6 missense mutations linked to hypomagnesemia with secondary RT hypocalcemia."; RL Eur. J. Hum. Genet. 22:497-504(2014). CC -!- FUNCTION: Bifunctional protein that combines an ion channel with an CC intrinsic kinase domain, enabling it to modulate cellular functions CC either by conducting ions through the pore or by phosphorylating CC downstream proteins via its kinase domain (PubMed:14576148, CC PubMed:16636202, PubMed:18258429, PubMed:18365021). Crucial for Mg(2+) CC homeostasis. Has an important role in epithelial Mg(2+) transport and CC in the active Mg(2+) absorption in the gut and kidney CC (PubMed:14576148). However, whether TRPM6 forms functional homomeric CC channels by itself or functions primarily as a subunit of heteromeric CC TRPM6-TRPM7 channels, is still under debate (PubMed:14576148, CC PubMed:16636202, PubMed:24385424). {ECO:0000269|PubMed:14576148, CC ECO:0000269|PubMed:16636202, ECO:0000269|PubMed:18258429, CC ECO:0000269|PubMed:18365021, ECO:0000269|PubMed:24385424}. CC -!- FUNCTION: [TRPM6 kinase, cleaved form]: The C-terminal kinase domain CC can be cleaved from the channel segment in a cell-type-specific CC fashion. The cleaved kinase fragments can translocate to the nucleus, CC and bind chromatin-remodeling complex proteins to ultimately CC phosphorylate specific Ser/Thr residues of histones known to be CC functionally important for cell differentiation and development. CC {ECO:0000269|PubMed:28784805}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:18365021}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:18258429, ECO:0000269|PubMed:18365021}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Mg(2+)(in) = Mg(2+)(out); Xref=Rhea:RHEA:29827, CC ChEBI:CHEBI:18420; Evidence={ECO:0000269|PubMed:14576148, CC ECO:0000269|PubMed:16636202}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:14576148, CC ECO:0000269|PubMed:16636202}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Zn(2+)(in) = Zn(2+)(out); Xref=Rhea:RHEA:29351, CC ChEBI:CHEBI:29105; Evidence={ECO:0000269|PubMed:16636202}; CC -!- ACTIVITY REGULATION: Strongly inhibited by intracellular Mg(2+); CC unlikely to be active at physiological levels of intracellular Mg(2+) CC (PubMed:14576148, PubMed:16636202, PubMed:24385424). In the heteromeric CC TRPM6-TRPM7 channels complexes, TRPM7 are able to offset the very high CC sensitivity of TRPM6 to cytosolic Mg(2+) to physiologically relevant CC concentrations, whereas TRPM6 relieve TRPM7 from the inhibitory action CC of Mg-ATP. Consequently, the association of TRPM6 with TRPM7 allow for CC high constitutive activity of TRPM6/7 in the presence of physiological CC levels of Mg(2+) and Mg-ATP (By similarity). The kinase activity is CC controlled through the autophosphorylation of a serine/threonine-rich CC region located to the N-terminal of the catalytic domain CC (PubMed:18258429, PubMed:18365021). {ECO:0000250|UniProtKB:Q8CIR4, CC ECO:0000269|PubMed:14576148, ECO:0000269|PubMed:16636202, CC ECO:0000269|PubMed:18258429, ECO:0000269|PubMed:18365021, CC ECO:0000269|PubMed:24385424}. CC -!- SUBUNIT: Homomers (PubMed:16636202). Forms heteromers with TRPM7; TRPM6 CC increases the current amplitude of TRPM6/7 heteromers as compared to CC TRPM7 homomer (PubMed:14976260, PubMed:16636202, PubMed:17197439). CC Interacts (via kinase domain) with RACK1 (PubMed:18258429). CC {ECO:0000269|PubMed:14976260, ECO:0000269|PubMed:16636202, CC ECO:0000269|PubMed:17197439, ECO:0000269|PubMed:18258429}. CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:23942199}; CC Multi-pass membrane protein {ECO:0000305}. Apical cell membrane CC {ECO:0000269|PubMed:14576148}; Multi-pass membrane protein CC {ECO:0000305}. Note=TRPM6 requires the presence of TRPM7 to be targeted CC to the cell membrane (in HEK 293 cells). {ECO:0000269|PubMed:14976260, CC ECO:0000269|PubMed:17197439}. CC -!- SUBCELLULAR LOCATION: [TRPM6 kinase, cleaved form]: Nucleus CC {ECO:0000269|PubMed:28784805}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Name=TRPM6a {ECO:0000303|PubMed:14976260}; CC IsoId=Q9BX84-1; Sequence=Displayed; CC Name=TRPM6b {ECO:0000303|PubMed:14976260}; CC IsoId=Q9BX84-2; Sequence=VSP_012069; CC Name=TRPM6c {ECO:0000303|PubMed:14976260}; CC IsoId=Q9BX84-3; Sequence=VSP_012070; CC Name=TRPM6t {ECO:0000303|PubMed:14976260}; CC IsoId=Q9BX84-4; Sequence=VSP_012075, VSP_012076; CC Name=M6-kinase 1 {ECO:0000303|PubMed:14976260}; CC IsoId=Q9BX84-5; Sequence=VSP_012074; CC Name=M6-kinase 2 {ECO:0000303|PubMed:14976260}; CC IsoId=Q9BX84-6; Sequence=VSP_012073; CC Name=M6-kinase 3 {ECO:0000303|PubMed:14976260}; CC IsoId=Q9BX84-7; Sequence=VSP_012071, VSP_012072; CC -!- TISSUE SPECIFICITY: Highly expressed in kidney and colon. Isoform CC TRPM6a and isoform TRPM6b, are coexpressed with TRPM7 in kidney, and CC testis, and are also found in several cell lines of lung origin. CC Isoform TRPM6c is detected only in testis and in NCI-H510A small cell CC lung carcinoma cells. CC -!- PTM: Autophosphorylated; autophosphorylation controlls the protein CC kinase activity of TRPM6 towards their substrates (PubMed:18258429, CC PubMed:18365021). Autophosphorylation of Thr-1851 in the kinase domain CC is essential for the inhibitory effect of RACK1 (PubMed:18258429). CC {ECO:0000269|PubMed:18258429, ECO:0000269|PubMed:18365021}. CC -!- PTM: The C-terminus of TRPM6 is proteolytically cleaved in vivo, in a CC cell type-specific fashion, releasing the kinase module from the CC transmembrane domain. The cleaved kinase fragments are translocated to CC the nucleus to phosphorylate histones and regulate gene expression. CC {ECO:0000269|PubMed:28784805}. CC -!- DISEASE: Hypomagnesemia 1 (HOMG1) [MIM:602014]: A disorder due to a CC primary defect in intestinal magnesium absorption. It is characterized CC by low levels of serum magnesium alongside with a normal renal CC magnesium secretion, secondary hypocalcemia and calcinocis. Affected CC individuals show neurologic symptoms of hypomagnesemic hypocalcemia, CC including seizures and muscle spasms, during infancy. Hypocalcemia is CC secondary to parathyroid failure resulting from magnesium deficiency. CC Untreated, the disorder may be fatal or may result in neurological CC damage. {ECO:0000269|PubMed:12032568, ECO:0000269|PubMed:14976260, CC ECO:0000269|PubMed:16636202, ECO:0000269|PubMed:17197439, CC ECO:0000269|PubMed:23942199}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform M6-kinase 1]: Lacks the ion channel region. CC {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform M6-kinase 2]: Lacks the ion channel region. CC {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform M6-kinase 3]: Lacks the ion channel region. CC {ECO:0000305}. CC -!- SIMILARITY: In the C-terminal section; belongs to the protein kinase CC superfamily. Alpha-type protein kinase family. ALPK subfamily. CC {ECO:0000305}. CC -!- SIMILARITY: In the N-terminal section; belongs to the transient CC receptor (TC 1.A.4) family. LTrpC subfamily. TRPM6 sub-subfamily. CC {ECO:0000305}. CC -!- CAUTION: Whether TRPM6 forms functional homomeric channels by itself is CC still under debate. According to PubMed:14576148 and PubMed:16636202, CC TRPM6 are able to form TRPM6 channels with similar properties to those CC of TRPM7, with biophysical characteristics resembling those of TRPM7 CC including the high channel pore selectivity for divalent cations and CC regulation by intracellular Mg(2+) (PubMed:14576148, PubMed:16636202). CC In contrast, others studies report that TRPM6 does not produce CC functional currents by itself and TRPM6 does not efficiently form CC homotetramers channels in the plasma membrane, but requires TRPM7 to be CC co-targeted to the cell surface (PubMed:14976260, PubMed:17197439). CC Further, homotetramers TRPM6 are highly sensitive to intracellular free CC Mg(2+) and therefore unlikely to be active at physiological levels of CC intracellular Mg(2+) (PubMed:24385424). {ECO:0000269|PubMed:14576148, CC ECO:0000269|PubMed:14976260, ECO:0000269|PubMed:16636202, CC ECO:0000269|PubMed:17197439, ECO:0000269|PubMed:24385424}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF350881; AAK31202.2; -; mRNA. DR EMBL; AF448232; AAM21562.1; -; mRNA. DR EMBL; AY333282; AAR03487.1; -; mRNA. DR EMBL; AY333283; AAR03488.1; -; mRNA. DR EMBL; AY333284; AAR03489.1; -; mRNA. DR EMBL; AY333285; AAR03490.1; -; mRNA. DR EMBL; AY333286; AAR03491.1; -; mRNA. DR EMBL; AY333287; AAR03492.1; -; mRNA. DR EMBL; AY333288; AAR03493.1; -; mRNA. DR EMBL; AL354795; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS55318.1; -. [Q9BX84-3] DR CCDS; CCDS55319.1; -. [Q9BX84-2] DR CCDS; CCDS6647.1; -. [Q9BX84-1] DR RefSeq; NP_001170781.1; NM_001177310.2. [Q9BX84-2] DR RefSeq; NP_001170782.1; NM_001177311.2. [Q9BX84-3] DR RefSeq; NP_060132.3; NM_017662.4. [Q9BX84-1] DR AlphaFoldDB; Q9BX84; -. DR SMR; Q9BX84; -. DR BioGRID; 126713; 8. DR CORUM; Q9BX84; -. DR FunCoup; Q9BX84; 552. DR IntAct; Q9BX84; 3. DR MINT; Q9BX84; -. DR STRING; 9606.ENSP00000354006; -. DR BindingDB; Q9BX84; -. DR ChEMBL; CHEMBL1628470; -. DR DrugBank; DB14513; Magnesium. DR DrugBank; DB09481; Magnesium carbonate. DR GuidetoPHARMACOLOGY; 498; -. DR TCDB; 1.A.4.5.8; the transient receptor potential ca2+/cation channel (trp-cc) family. DR GlyGen; Q9BX84; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9BX84; -. DR MetOSite; Q9BX84; -. DR PhosphoSitePlus; Q9BX84; -. DR BioMuta; TRPM6; -. DR DMDM; 56404951; -. DR CPTAC; CPTAC-2831; -. DR CPTAC; CPTAC-2987; -. DR jPOST; Q9BX84; -. DR MassIVE; Q9BX84; -. DR PaxDb; 9606-ENSP00000354006; -. DR PeptideAtlas; Q9BX84; -. DR ProteomicsDB; 79380; -. [Q9BX84-1] DR ProteomicsDB; 79381; -. [Q9BX84-2] DR ProteomicsDB; 79382; -. [Q9BX84-3] DR ProteomicsDB; 79383; -. [Q9BX84-4] DR ProteomicsDB; 79384; -. [Q9BX84-5] DR ProteomicsDB; 79385; -. [Q9BX84-6] DR ProteomicsDB; 79386; -. [Q9BX84-7] DR ABCD; Q9BX84; 1 sequenced antibody. DR Antibodypedia; 2049; 136 antibodies from 24 providers. DR DNASU; 140803; -. DR Ensembl; ENST00000360774.6; ENSP00000354006.1; ENSG00000119121.23. [Q9BX84-1] DR Ensembl; ENST00000361255.7; ENSP00000354962.3; ENSG00000119121.23. [Q9BX84-3] DR Ensembl; ENST00000449912.6; ENSP00000396672.2; ENSG00000119121.23. [Q9BX84-2] DR Ensembl; ENST00000715553.1; ENSP00000520473.1; ENSG00000119121.23. [Q9BX84-4] DR GeneID; 140803; -. DR KEGG; hsa:140803; -. DR MANE-Select; ENST00000360774.6; ENSP00000354006.1; NM_017662.5; NP_060132.3. DR UCSC; uc004ajk.1; human. [Q9BX84-1] DR AGR; HGNC:17995; -. DR ClinPGx; PA38479; -. DR CTD; 140803; -. DR DisGeNET; 140803; -. DR GeneCards; TRPM6; -. DR HGNC; HGNC:17995; TRPM6. DR HPA; ENSG00000119121; Tissue enriched (intestine). DR MalaCards; TRPM6; -. DR MIM; 602014; phenotype. DR MIM; 607009; gene. DR OpenTargets; ENSG00000119121; -. DR Orphanet; 30924; Primary hypomagnesemia with secondary hypocalcemia. DR VEuPathDB; HostDB:ENSG00000119121; -. DR eggNOG; KOG3614; Eukaryota. DR GeneTree; ENSGT00940000158164; -. DR HOGENOM; CLU_001390_2_0_1; -. DR InParanoid; Q9BX84; -. DR OMA; EVVQTWY; -. DR OrthoDB; 301415at2759; -. DR PAN-GO; Q9BX84; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q9BX84; -. DR PathwayCommons; Q9BX84; -. DR Reactome; R-HSA-3295583; TRP channels. DR SignaLink; Q9BX84; -. DR SIGNOR; Q9BX84; -. DR Agora; ENSG00000119121; -. DR BioGRID-ORCS; 140803; 7 hits in 1184 CRISPR screens. DR ChiTaRS; TRPM6; human. DR GeneWiki; TRPM6; -. DR GenomeRNAi; 140803; -. DR Pharos; Q9BX84; Tchem. DR PRO; PR:Q9BX84; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q9BX84; protein. DR Bgee; ENSG00000119121; Expressed in colonic mucosa and 125 other cell types or tissues. DR ExpressionAtlas; Q9BX84; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB. DR GO; GO:0031526; C:brush border membrane; IEA:Ensembl. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005262; F:calcium channel activity; IBA:GO_Central. DR GO; GO:0015085; F:calcium ion transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0015095; F:magnesium ion transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; IBA:GO_Central. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0070588; P:calcium ion transmembrane transport; IDA:UniProtKB. DR GO; GO:0006816; P:calcium ion transport; IBA:GO_Central. DR GO; GO:1903830; P:magnesium ion transmembrane transport; IDA:UniProtKB. DR GO; GO:0098655; P:monoatomic cation transmembrane transport; IBA:GO_Central. DR GO; GO:0051262; P:protein tetramerization; IEA:InterPro. DR GO; GO:0009636; P:response to toxic substance; IDA:UniProtKB. DR CDD; cd16972; Alpha_kinase_ChaK2_TRPM6; 1. DR FunFam; 1.20.5.1010:FF:000002; Transient receptor potential cation channel subfamily M member 7; 1. DR FunFam; 3.20.200.10:FF:000001; Transient receptor potential cation channel, subfamily M, member 7; 1. DR FunFam; 3.30.200.20:FF:000129; Transient receptor potential cation channel, subfamily M, member 7; 1. DR Gene3D; 3.20.200.10; MHCK/EF2 kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.20.5.1010; TRPM, tetramerisation domain; 1. DR InterPro; IPR004166; a-kinase_dom. DR InterPro; IPR005821; Ion_trans_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050927; TRPM. DR InterPro; IPR057366; TRPM-like. DR InterPro; IPR029597; TRPM6_a-kinase_dom. DR InterPro; IPR041491; TRPM_SLOG. DR InterPro; IPR032415; TRPM_tetra. DR InterPro; IPR037162; TRPM_tetra_sf. DR PANTHER; PTHR13800:SF15; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY M MEMBER 6; 1. DR PANTHER; PTHR13800; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 6; 1. DR Pfam; PF02816; Alpha_kinase; 1. DR Pfam; PF00520; Ion_trans; 1. DR Pfam; PF18139; LSDAT_euk; 1. DR Pfam; PF25508; TRPM2; 1. DR Pfam; PF16519; TRPM_tetra; 1. DR SMART; SM00811; Alpha_kinase; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51158; ALPHA_KINASE; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Calcium; Calcium channel; KW Calcium transport; Cell membrane; Disease variant; Ion channel; KW Ion transport; Kinase; Membrane; Metal-binding; Nucleotide-binding; KW Nucleus; Phosphoprotein; Primary hypomagnesemia; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Transmembrane; Transmembrane helix; Transport; Zinc. FT CHAIN 1..2022 FT /note="Transient receptor potential cation channel FT subfamily M member 6" FT /id="PRO_0000215329" FT CHAIN ?..2022 FT /note="TRPM6 kinase, cleaved form" FT /evidence="ECO:0000269|PubMed:28784805" FT /id="PRO_0000461405" FT TOPO_DOM 1..741 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 742..762 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 763..841 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 842..862 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 863..905 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 906..926 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 927..939 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 940..960 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 961..972 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 973..993 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 994..1012 FT /note="Extracellular" FT /evidence="ECO:0000255" FT INTRAMEM 1013..1033 FT /note="Pore-forming" FT /evidence="ECO:0000255" FT TOPO_DOM 1034..1047 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 1048..1068 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 1069..2022 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 1750..1980 FT /note="Alpha-type protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00501" FT REGION 1479..1516 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1997..2022 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1483..1493 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1494..1512 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1998..2016 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 1923 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 1777 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1778 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1779 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1780 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1804 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1876 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1879 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1909 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1933 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1966 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1968 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1972 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1851 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18258429" FT VAR_SEQ 1..11 FT /note="MKEQPVLERLQ -> MIILSK (in isoform TRPM6b)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012069" FT VAR_SEQ 1..11 FT /note="MKEQPVLERLQ -> MTAPVT (in isoform TRPM6c)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012070" FT VAR_SEQ 281 FT /note="R -> P (in isoform M6-kinase 3)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012071" FT VAR_SEQ 282..1734 FT /note="Missing (in isoform M6-kinase 3)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012072" FT VAR_SEQ 500..1666 FT /note="Missing (in isoform M6-kinase 2)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012073" FT VAR_SEQ 547..1595 FT /note="Missing (in isoform M6-kinase 1)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012074" FT VAR_SEQ 1926..1943 FT /note="GVGENLTDPSVIKPEVKQ -> ALWFWDSMLKARLGGWRM (in isoform FT TRPM6t)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012075" FT VAR_SEQ 1944..2022 FT /note="Missing (in isoform TRPM6t)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012076" FT VARIANT 75 FT /note="G -> V (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs1193127627)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042387" FT VARIANT 141 FT /note="S -> L (in HOMG1; abolishes channel activity. FT Impairs homo- and heterooligomeric formation with TRPM7 FT resulting in intracellular retention; dbSNP:rs121912625)" FT /evidence="ECO:0000269|PubMed:12032568, FT ECO:0000269|PubMed:14976260, ECO:0000269|PubMed:16636202" FT /id="VAR_019963" FT VARIANT 338 FT /note="M -> I (in dbSNP:rs56155062)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042388" FT VARIANT 708 FT /note="L -> P (in HOMG1; abolishes channel activity; no FT effect on cell membrane localization)" FT /evidence="ECO:0000269|PubMed:23942199" FT /id="VAR_071480" FT VARIANT 872 FT /note="E -> G (in HOMG1; abolishes channel activity; no FT effect on cell membrane localization)" FT /evidence="ECO:0000269|PubMed:23942199" FT /id="VAR_071481" FT VARIANT 948 FT /note="F -> L (in dbSNP:rs13290391)" FT /id="VAR_052380" FT VARIANT 1007 FT /note="W -> C (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042389" FT VARIANT 1017 FT /note="P -> R (in HOMG1; does not affect protein FT expression. Does not affect coassembly with TRPM7. Impairs FT channel activity of TRPM6/7 complexes)" FT /evidence="ECO:0000269|PubMed:17197439" FT /id="VAR_089905" FT VARIANT 1053 FT /note="Y -> C (in HOMG1; abolishes channel activity; no FT effect on cell membrane localization)" FT /evidence="ECO:0000269|PubMed:23942199" FT /id="VAR_071482" FT VARIANT 1071 FT /note="N -> D (in dbSNP:rs2274922)" FT /id="VAR_019964" FT VARIANT 1143 FT /note="L -> P (in HOMG1; abolishes channel activity; no FT effect on cell membrane localization)" FT /evidence="ECO:0000269|PubMed:23942199" FT /id="VAR_071483" FT VARIANT 1243 FT /note="H -> R (in dbSNP:rs55694430)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042390" FT VARIANT 1274 FT /note="Q -> R (in dbSNP:rs34608911)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042391" FT VARIANT 1393 FT /note="V -> I (in dbSNP:rs3750425)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_019965" FT VARIANT 1584 FT /note="K -> E (in dbSNP:rs2274924)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_019966" FT VARIANT 1663 FT /note="Q -> R (no effect on channel activity or cell FT membrane localization; dbSNP:rs55679040)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:23942199" FT /id="VAR_042392" FT VARIANT 1673 FT /note="L -> S (in dbSNP:rs56254742)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042393" FT VARIANT 1724 FT /note="T -> I (in dbSNP:rs56290308)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042394" FT VARIANT 1754 FT /note="S -> N (in HOMG1; abolishes channel activity; no FT effect on cell membrane localization)" FT /evidence="ECO:0000269|PubMed:23942199" FT /id="VAR_071484" FT MUTAGEN 1063..1065 FT /note="NLL->FAP: Abolishes channel activity. Abolishes FT endogenous protein cleavage." FT /evidence="ECO:0000269|PubMed:28784805" FT MUTAGEN 1804 FT /note="K->R: Abolishes kinase activity but does not affect FT expression levels or binding to RACK1." FT /evidence="ECO:0000269|PubMed:18258429" FT MUTAGEN 1851 FT /note="T->A: Significantly decreases autophosphorylation. FT Does not alter binding to RACK1 but prevents inhibition by FT RACK1." FT /evidence="ECO:0000269|PubMed:18258429" FT MUTAGEN 1851 FT /note="T->D: Significantly decreases autophosphorylation. FT Does not alter binding to RACK1 or inhibition by RACK1." FT /evidence="ECO:0000269|PubMed:18258429" SQ SEQUENCE 2022 AA; 231708 MW; 59346B3BE3300466 CRC64; MKEQPVLERL QSQKSWIKGV FDKRECSTII PSSKNPHRCT PVCQVCQNLI RCYCGRLIGD HAGIDYSWTI SAAKGKESEQ WSVEKHTTKS PTDTFGTINF QDGEHTHHAK YIRTSYDTKL DHLLHLMLKE WKMELPKLVI SVHGGIQNFT MPSKFKEIFS QGLVKAAETT GAWIITEGIN TGVSKHVGDA LKSHSSHSLR KIWTVGIPPW GVIENQRDLI GKDVVCLYQT LDNPLSKLTT LNSMHSHFIL SDDGTVGKYG NEMKLRRNLE KYLSLQKIHC RSRQGVPVVG LVVEGGPNVI LSVWETVKDK DPVVVCEGTG RAADLLAFTH KHLADEGMLR PQVKEEIICM IQNTFNFSLK QSKHLFQILM ECMVHRDCIT IFDADSEEQQ DLDLAILTAL LKGTNLSASE QLNLAMAWDR VDIAKKHILI YEQHWKPDAL EQAMSDALVM DRVDFVKLLI EYGVNLHRFL TIPRLEELYN TKQGPTNTLL HHLVQDVKQH TLLSGYRITL IDIGLVVEYL IGRAYRSNYT RKHFRALYNN LYRKYKHQRH SSGNRNESAE STLHSQFIRT AQPYKFKEKS IVLHKSRKKS KEQNVSDDPE STGFLYPYND LLVWAVLMKR QKMAMFFWQH GEEATVKAVI ACILYRAMAH EAKESHMVDD ASEELKNYSK QFGQLALDLL EKAFKQNERM AMTLLTYELR NWSNSTCLKL AVSGGLRPFV SHTCTQMLLT DMWMGRLKMR KNSWLKIIIS IILPPTILTL EFKSKAEMSH VPQSQDFQFM WYYSDQNASS SKESASVKEY DLERGHDEKL DENQHFGLES GHQHLPWTRK VYEFYSAPIV KFWFYTMAYL AFLMLFTYTV LVEMQPQPSV QEWLVSIYIF TNAIEVVREI CISEPGKFTQ KVKVWISEYW NLTETVAIGL FSAGFVLRWG DPPFHTAGRL IYCIDIIFWF SRLLDFFAVN QHAGPYVTMI AKMTANMFYI VIIMAIVLLS FGVARKAILS PKEPPSWSLA RDIVFEPYWM IYGEVYAGEI DVCSSQPSCP PGSFLTPFLQ AVYLFVQYII MVNLLIAFFN NVYLDMESIS NNLWKYNRYR YIMTYHEKPW LPPPLILLSH VGLLLRRLCC HRAPHDQEEG DVGLKLYLSK EDLKKLHDFE EQCVEKYFHE KMEDVNCSCE ERIRVTSERV TEMYFQLKEM NEKVSFIKDS LLSLDSQVGH LQDLSALTVD TLKVLSAVDT LQEDEALLAK RKHSTCKKLP HSWSNVICAE VLGSMEIAGE KKYQYYSMPS SLLRSLAGGR HPPRVQRGAL LEITNSKREA TNVRNDQERQ ETQSSIVVSG VSPNRQAHSK YGQFLLVPSN LKRVPFSAET VLPLSRPSVP DVLATEQDIQ TEVLVHLTGQ TPVVSDWASV DEPKEKHEPI AHLLDGQDKA EQVLPTLSCT PEPMTMSSPL SQAKIMQTGG GYVNWAFSEG DETGVFSIKK KWQTCLPSTC DSDSSRSEQH QKQAQDSSLS DNSTRSAQSS ECSEVGPWLQ PNTSFWINPL RRYRPFARSH SFRFHKEEKL MKICKIKNLS GSSEIGQGAW VKAKMLTKDR RLSKKKKNTQ GLQVPIITVN ACSQSDQLNP EPGENSISEE EYSKNWFTVS KFSHTGVEPY IHQKMKTKEI GQCAIQISDY LKQSQEDLSK NSLWNSRSTN LNRNSLLKSS IGVDKISASL KSPQEPHHHY SAIERNNLMR LSQTIPFTPV QLFAGEEITV YRLEESSPLN LDKSMSSWSQ RGRAAMIQVL SREEMDGGLR KAMRVVSTWS EDDILKPGQV FIVKSFLPEV VRTWHKIFQE STVLHLCLRE IQQQRAAQKL IYTFNQVKPQ TIPYTPRFLE VFLIYCHSAN QWLTIEKYMT GEFRKYNNNN GDEITPTNTL EELMLAFSHW TYEYTRGELL VLDLQGVGEN LTDPSVIKPE VKQSRGMVFG PANLGEDAIR NFIAKHHCNS CCRKLKLPDL KRNDYSPERI NSTFGLEIKI ESAEEPPARE TGRNSPEDDM QL // ID UB2V1_HUMAN Reviewed; 147 AA. AC Q13404; E1P629; Q13403; Q13532; Q5TGE0; Q5TGE3; Q96H34; Q9GZT0; Q9GZW1; AC Q9H4J3; Q9H4J4; Q9UKL1; Q9UM48; Q9UM49; Q9UM50; DT 31-AUG-2004, integrated into UniProtKB/Swiss-Prot. DT 22-SEP-2009, sequence version 2. DT 28-JAN-2026, entry version 224. DE RecName: Full=Ubiquitin-conjugating enzyme E2 variant 1; DE Short=UEV-1; DE AltName: Full=CROC-1; DE AltName: Full=TRAF6-regulated IKK activator 1 beta Uev1A; GN Name=UBE2V1; Synonyms=CROC1, UBE2V, UEV1; ORFNames=P/OKcl.19; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, AND SUBCELLULAR RP LOCATION. RC TISSUE=Brain; RX PubMed=9305758; DOI=10.1016/s0378-1119(97)00097-8; RA Rothofsky M.L., Lin S.L.; RT "CROC-1 encodes a protein which mediates transcriptional activation of the RT human FOS promoter."; RL Gene 195:141-149(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 4), FUNCTION, INDUCTION, AND RP TISSUE SPECIFICITY. RC TISSUE=Colon adenocarcinoma; RX PubMed=9418904; DOI=10.1128/mcb.18.1.576; RA Sancho E., Vila M.R., Sanchez-Pulido L., Lozano J.J., Paciucci R., RA Nadal M., Fox M., Harvey C., Bercovich B., Loukili N., Ciechanover A., RA Lin S.L., Sanz F., Estivill X., Valencia A., Thomson T.M.; RT "Role of UEV-1, an inactive variant of the E2 ubiquitin-conjugating RT enzymes, in in vitro differentiation and cell cycle behavior of HT-29-M6 RT intestinal mucosecretory cells."; RL Mol. Cell. Biol. 18:576-589(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), FUNCTION, INTERACTION WITH TRAF6 RP AND UBE2N, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=11057907; DOI=10.1016/s0092-8674(00)00126-4; RA Deng L., Wang C., Spencer E., Yang L., Braun A., You J., Slaughter C., RA Pickart C., Chen Z.J.; RT "Activation of the IkappaB kinase complex by TRAF6 requires a dimeric RT ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain."; RL Cell 103:351-361(2000). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 6). RC TISSUE=Lung; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11780052; DOI=10.1038/414865a; RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M., RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D., RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M., RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L., RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 20."; RL Nature 414:865-871(2001). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP PROTEIN SEQUENCE OF 2-13 (ISOFORM 3), CLEAVAGE OF INITIATOR METHIONINE, RP ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Lung fibroblast; RA Bienvenut W.V., Pchelintsev N., Adams P.D.; RL Submitted (JUL-2009) to UniProtKB. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 8-147 (ISOFORMS 1 AND 3). RC TISSUE=Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP FUNCTION. RX PubMed=9580084; DOI=10.1016/s0014-5793(98)00060-x; RA Thomson T.M., Khalid H., Lozano J.J., Sancho E., Arino J.; RT "Role of UEV-1A, a homologue of the tumor suppressor protein TSG101, in RT protection from DNA damage."; RL FEBS Lett. 423:49-52(1998). RN [11] RP FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=9705497; DOI=10.1093/nar/26.17.3908; RA Xiao W., Lin S.L., Broomfield S., Chow B.L., Wei Y.-F.; RT "The products of the yeast MMS2 and two human homologs (hMMS2 and CROC-1) RT define a structurally and functionally conserved Ubc-like protein family."; RL Nucleic Acids Res. 26:3908-3914(1998). RN [12] RP SUBCELLULAR LOCATION, AND IDENTIFICATION OF PESD1-UBE2V1 FUSION PROTEIN. RC TISSUE=Colon cancer; RX PubMed=11076860; DOI=10.1101/gr.gr-1405r; RA Thomson T.M., Lozano J.J., Loukili N., Carrio R., Serras F., Cormand B., RA Valeri M., Diaz V.M., Abril J., Burset M., Merino J., Macaya A., RA Corominas M., Guigo R.; RT "Fusion of the human gene for the polyubiquitination coeffector UEV1 with RT Kua, a newly identified gene."; RL Genome Res. 10:1743-1756(2000). RN [13] RP FUNCTION. RX PubMed=19825828; DOI=10.1126/scisignal.2000382; RA Liu C., Qian W., Qian Y., Giltiay N.V., Lu Y., Swaidani S., Misra S., RA Deng L., Chen Z.J., Li X.; RT "Act1, a U-box E3 ubiquitin ligase for IL-17 signaling."; RL Sci. Signal. 2:ra63-ra63(2009). RN [14] RP FUNCTION. RX PubMed=20061386; DOI=10.1074/jbc.m109.089003; RA David Y., Ziv T., Admon A., Navon A.; RT "The E2 ubiquitin-conjugating enzymes direct polyubiquitination to RT preferred lysines."; RL J. Biol. Chem. 285:8595-8604(2010). RN [15] RP FUNCTION. RX PubMed=21512573; DOI=10.1038/nature09976; RA Pertel T., Hausmann S., Morger D., Zueger S., Guerra J., Lascano J., RA Reinhard C., Santoni F.A., Uchil P.D., Chatel L., Bisiaux A., Albert M.L., RA Strambio-De-Castillia C., Mothes W., Pizzato M., Gruetter M.G., Luban J.; RT "TRIM5 is an innate immune sensor for the retrovirus capsid lattice."; RL Nature 472:361-365(2011). RN [16] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [17] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [18] RP FUNCTION. RX PubMed=31006531; DOI=10.1016/j.cell.2019.03.017; RA Cadena C., Ahmad S., Xavier A., Willemsen J., Park S., Park J.W., Oh S.W., RA Fujita T., Hou F., Binder M., Hur S.; RT "Ubiquitin-Dependent and -Independent Roles of E3 Ligase RIPLET in Innate RT Immunity."; RL Cell 177:1187-1200(2019). RN [19] RP X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 8-147 IN COMPLEX WITH STUB1 AND RP UBE2N. RX PubMed=16307917; DOI=10.1016/j.molcel.2005.09.023; RA Zhang M., Windheim M., Roe S.M., Peggie M., Cohen P., Prodromou C., RA Pearl L.H.; RT "Chaperoned ubiquitylation -- crystal structures of the CHIP U box E3 RT ubiquitin ligase and a CHIP-Ubc13-Uev1a complex."; RL Mol. Cell 20:525-538(2005). RN [20] {ECO:0007744|PDB:2HLW} RP STRUCTURE BY NMR OF 7-147, AND INTERACTION WITH UBE2N. RX PubMed=16893187; DOI=10.1021/bi060631r; RA Hau D.D., Lewis M.J., Saltibus L.F., Pastushok L., Xiao W., RA Spyracopoulos L.; RT "Structure and interactions of the ubiquitin-conjugating enzyme variant RT human Uev1a: implications for enzymatic synthesis of polyubiquitin RT chains."; RL Biochemistry 45:9866-9877(2006). RN [21] {ECO:0007744|PDB:2A4D} RP X-RAY CRYSTALLOGRAPHY (1.69 ANGSTROMS) OF 7-147. RX PubMed=22496338; DOI=10.1074/mcp.o111.013706; RA Sheng Y., Hong J.H., Doherty R., Srikumar T., Shloush J., Avvakumov G.V., RA Walker J.R., Xue S., Neculai D., Wan J.W., Kim S.K., Arrowsmith C.H., RA Raught B., Dhe-Paganon S.; RT "A human ubiquitin conjugating enzyme (E2)-HECT E3 ligase structure- RT function screen."; RL Mol. Cell. Proteomics 11:329-341(2012). CC -!- FUNCTION: Has no ubiquitin ligase activity on its own. The UBE2V1-UBE2N CC heterodimer catalyzes the synthesis of non-canonical poly-ubiquitin CC chains that are linked through Lys-63. This type of poly-ubiquitination CC activates IKK and does not seem to involve protein degradation by the CC proteasome. Plays a role in the activation of NF-kappa-B mediated by CC IL1B, TNF, TRAF6 and TRAF2. Mediates transcriptional activation of CC target genes. Plays a role in the control of progress through the cell CC cycle and differentiation. Plays a role in the error-free DNA repair CC pathway and contributes to the survival of cells after DNA damage. CC Promotes TRIM5 capsid-specific restriction activity and the UBE2V1- CC UBE2N heterodimer acts in concert with TRIM5 to generate 'Lys-63'- CC linked polyubiquitin chains which activate the MAP3K7/TAK1 complex CC which in turn results in the induction and expression of NF-kappa-B and CC MAPK-responsive inflammatory genes. Together with RNF135 and UBE2N, CC catalyzes the viral RNA-dependent 'Lys-63'-linked polyubiquitination of CC RIGI to activate the downstream signaling pathway that leads to CC interferon beta production (PubMed:31006531). UBE2V1-UBE2N together CC with TRAF3IP2 E3 ubiquitin ligase mediate 'Lys-63'-linked CC polyubiquitination of TRAF6, a component of IL17A-mediated signaling CC pathway. {ECO:0000269|PubMed:11057907, ECO:0000269|PubMed:19825828, CC ECO:0000269|PubMed:20061386, ECO:0000269|PubMed:21512573, CC ECO:0000269|PubMed:31006531, ECO:0000269|PubMed:9305758, CC ECO:0000269|PubMed:9418904, ECO:0000269|PubMed:9580084, CC ECO:0000269|PubMed:9705497}. CC -!- SUBUNIT: Heterodimer with UBE2N (PubMed:11057907, PubMed:16307917, CC PubMed:16893187). Interacts (UBE2V2-UBE2N heterodimer) with the E3 CC ligase STUB1 (via the U-box domain); the complex has a specific 'Lys- CC 63'-linked polyubiquitination activity (PubMed:16307917). Interacts CC with TRAF6 (PubMed:11057907, PubMed:16307917). CC {ECO:0000269|PubMed:11057907, ECO:0000269|PubMed:16307917, CC ECO:0000269|PubMed:16893187}. CC -!- INTERACTION: CC Q13404; Q92870-2: APBB2; NbExp=3; IntAct=EBI-1050671, EBI-21535880; CC Q13404; P54253: ATXN1; NbExp=6; IntAct=EBI-1050671, EBI-930964; CC Q13404; P02489: CRYAA; NbExp=3; IntAct=EBI-1050671, EBI-6875961; CC Q13404; P78358: CTAG1B; NbExp=3; IntAct=EBI-1050671, EBI-1188472; CC Q13404; Q15038: DAZAP2; NbExp=3; IntAct=EBI-1050671, EBI-724310; CC Q13404; G5E9A7: DMWD; NbExp=3; IntAct=EBI-1050671, EBI-10976677; CC Q13404; Q92567: FAM168A; NbExp=4; IntAct=EBI-1050671, EBI-7957930; CC Q13404; P22607: FGFR3; NbExp=3; IntAct=EBI-1050671, EBI-348399; CC Q13404; Q14957: GRIN2C; NbExp=3; IntAct=EBI-1050671, EBI-8285963; CC Q13404; P06396: GSN; NbExp=3; IntAct=EBI-1050671, EBI-351506; CC Q13404; P11021: HSPA5; NbExp=3; IntAct=EBI-1050671, EBI-354921; CC Q13404; O60333-2: KIF1B; NbExp=3; IntAct=EBI-1050671, EBI-10975473; CC Q13404; Q92876: KLK6; NbExp=3; IntAct=EBI-1050671, EBI-2432309; CC Q13404; O60260-5: PRKN; NbExp=3; IntAct=EBI-1050671, EBI-21251460; CC Q13404; Q9Y3C5: RNF11; NbExp=4; IntAct=EBI-1050671, EBI-396669; CC Q13404; Q6ZNA4: RNF111; NbExp=2; IntAct=EBI-1050671, EBI-2129175; CC Q13404; Q96DD7: SHISA4; NbExp=3; IntAct=EBI-1050671, EBI-18035902; CC Q13404; Q13148: TARDBP; NbExp=3; IntAct=EBI-1050671, EBI-372899; CC Q13404; Q13049: TRIM32; NbExp=4; IntAct=EBI-1050671, EBI-742790; CC Q13404; P61088: UBE2N; NbExp=22; IntAct=EBI-1050671, EBI-1052908; CC Q13404; Q9UMX0: UBQLN1; NbExp=9; IntAct=EBI-1050671, EBI-741480; CC Q13404; Q9UMX0-2: UBQLN1; NbExp=3; IntAct=EBI-1050671, EBI-10173939; CC Q13404; Q9UHD9: UBQLN2; NbExp=3; IntAct=EBI-1050671, EBI-947187; CC Q13404; P17861: XBP1; NbExp=3; IntAct=EBI-1050671, EBI-6942961; CC Q13404; P98170: XIAP; NbExp=3; IntAct=EBI-1050671, EBI-517127; CC Q13404; Q8ND25: ZNRF1; NbExp=2; IntAct=EBI-1050671, EBI-2129250; CC Q13404-2; P61088: UBE2N; NbExp=2; IntAct=EBI-15972179, EBI-1052908; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11076860, CC ECO:0000269|PubMed:9305758}. Note=Excluded from the nucleolus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Comment=Additional isoforms seem to exist.; CC Name=3; Synonyms=Isoform 2; CC IsoId=Q13404-4; Sequence=Displayed; CC Name=1; Synonyms=CROC-1B, UEV-1B, Isoform 4; CC IsoId=Q13404-1; Sequence=VSP_038034; CC Name=2; Synonyms=CROC-1A, UEV-1A; CC IsoId=Q13404-2; Sequence=VSP_038033; CC Name=4; Synonyms=UEV-1As; CC IsoId=Q13404-6; Sequence=VSP_038032, VSP_038036; CC Name=5; Synonyms=Isoform 3; CC IsoId=Q13404-7; Sequence=VSP_038035; CC Name=6; CC IsoId=Q13404-8; Sequence=VSP_044818; CC -!- TISSUE SPECIFICITY: Highly expressed in thyroid, pancreas, spinal cord, CC lymph node, trachea, adrenal gland, bone marrow and pancreas. Detected CC at low levels in heart, breast, placenta, brain, liver, kidney, stomach CC and lung. {ECO:0000269|PubMed:9418904, ECO:0000269|PubMed:9705497}. CC -!- INDUCTION: Down-regulated during differentiation of cultured colon CC adenocarcinoma cells. {ECO:0000269|PubMed:9418904}. CC -!- MISCELLANEOUS: In human, PESD1/KUA and UBE2V1/UEV1 are adjacent genes CC which can produce independent proteins and can also be fused to form a CC PESD1-UBE2V1 hybrid protein. CC -!- SIMILARITY: Belongs to the ubiquitin-conjugating enzyme family. CC {ECO:0000255|PROSITE-ProRule:PRU00388}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH08944.2; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U39360; AAB72015.1; -; mRNA. DR EMBL; U39361; AAB72016.1; -; mRNA. DR EMBL; U49278; AAC02757.1; -; mRNA. DR EMBL; U97279; AAC02780.1; -; mRNA. DR EMBL; U97280; AAC02755.1; -; mRNA. DR EMBL; U97281; AAC02756.1; -; mRNA. DR EMBL; AY008273; AAG24229.1; -; mRNA. DR EMBL; BT007382; AAP36046.1; -; mRNA. DR EMBL; DA580976; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AL034423; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471077; EAW75635.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75634.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75636.1; -; Genomic_DNA. DR EMBL; BC000468; AAH00468.1; -; mRNA. DR EMBL; BC008944; AAH08944.2; ALT_INIT; mRNA. DR CCDS; CCDS13426.1; -. [Q13404-7] DR CCDS; CCDS13427.1; -. [Q13404-6] DR CCDS; CCDS33483.1; -. [Q13404-4] DR CCDS; CCDS58775.1; -. [Q13404-8] DR RefSeq; NP_001027459.1; NM_001032288.3. [Q13404-4] DR RefSeq; NP_001244322.1; NM_001257393.2. [Q13404-7] DR RefSeq; NP_001244323.1; NM_001257394.2. [Q13404-6] DR RefSeq; NP_001244325.1; NM_001257396.2. [Q13404-8] DR RefSeq; NP_068823.2; NM_021988.5. [Q13404-7] DR RefSeq; NP_071887.1; NM_022442.6. [Q13404-6] DR RefSeq; NP_954595.1; NM_199144.3. [Q13404-7] DR RefSeq; NP_954673.2; NM_199203.3. DR PDB; 2A4D; X-ray; 1.69 A; A=8-147. DR PDB; 2C2V; X-ray; 2.90 A; C/F/I/L=8-147. DR PDB; 2HLW; NMR; -; A=8-147. DR PDB; 6D6I; X-ray; 2.55 A; A/D=8-147. DR PDBsum; 2A4D; -. DR PDBsum; 2C2V; -. DR PDBsum; 2HLW; -. DR PDBsum; 6D6I; -. DR AlphaFoldDB; Q13404; -. DR BMRB; Q13404; -. DR SMR; Q13404; -. DR BioGRID; 113183; 125. DR BioGRID; 132321; 42. DR ComplexPortal; CPX-485; UBC13-UEV1A ubiquitin-conjugating enzyme E2 complex. DR CORUM; Q13404; -. DR DIP; DIP-41911N; -. DR FunCoup; Q13404; 3253. DR IntAct; Q13404; 144. DR MINT; Q13404; -. DR MoonDB; Q13404; Predicted. DR GlyGen; Q13404; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q13404; -. DR PhosphoSitePlus; Q13404; -. DR SwissPalm; Q13404; -. DR BioMuta; UBE2V1; -. DR DMDM; 259016163; -. DR jPOST; Q13404; -. DR MassIVE; Q13404; -. DR PeptideAtlas; Q13404; -. DR ProteomicsDB; 59382; -. [Q13404-4] DR ProteomicsDB; 59383; -. [Q13404-1] DR ProteomicsDB; 59384; -. [Q13404-2] DR ProteomicsDB; 59385; -. [Q13404-6] DR ProteomicsDB; 59386; -. [Q13404-7] DR ProteomicsDB; 65114; -. DR Pumba; Q13404; -. DR TopDownProteomics; Q13404-4; -. [Q13404-4] DR Antibodypedia; 35021; 274 antibodies from 33 providers. DR DNASU; 7335; -. DR Ensembl; ENST00000340309.7; ENSP00000340305.3; ENSG00000244687.14. [Q13404-7] DR Ensembl; ENST00000371657.9; ENSP00000360720.5; ENSG00000244687.14. [Q13404-8] DR Ensembl; ENST00000371674.8; ENSP00000360739.4; ENSG00000244687.14. [Q13404-4] DR Ensembl; ENST00000371677.7; ENSP00000360742.3; ENSG00000244687.14. [Q13404-7] DR Ensembl; ENST00000415862.6; ENSP00000407770.2; ENSG00000244687.14. [Q13404-6] DR GeneID; 7335; -. DR KEGG; hsa:387522; -. DR KEGG; hsa:7335; -. DR MANE-Select; ENST00000371674.8; ENSP00000360739.4; NM_001032288.3; NP_001027459.1. DR UCSC; uc002xva.5; human. [Q13404-4] DR AGR; HGNC:12494; -. DR AGR; HGNC:33521; -. DR ClinPGx; PA37142; -. DR CTD; 7335; -. DR DisGeNET; 387522; -. DR DisGeNET; 7335; -. DR GeneCards; UBE2V1; -. DR HGNC; HGNC:12494; UBE2V1. DR HPA; ENSG00000244687; Low tissue specificity. DR MIM; 602995; gene. DR OpenTargets; ENSG00000244687; -. DR VEuPathDB; HostDB:ENSG00000244687; -. DR eggNOG; KOG0896; Eukaryota. DR GeneTree; ENSGT00940000158854; -. DR HOGENOM; CLU_063065_1_2_1; -. DR InParanoid; Q13404; -. DR OMA; GPESCSY; -. DR OrthoDB; 6508832at2759; -. DR PAN-GO; Q13404; 3 GO annotations based on evolutionary models. DR BRENDA; 2.3.2.23; 2681. DR BRENDA; 2.3.2.24; 2681. DR PathwayCommons; Q13404; -. DR Reactome; R-HSA-168638; NOD1/2 Signaling Pathway. DR Reactome; R-HSA-168927; TICAM1, RIP1-mediated IKK complex recruitment. DR Reactome; R-HSA-202424; Downstream TCR signaling. DR Reactome; R-HSA-2871837; FCERI mediated NF-kB activation. DR Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation. DR Reactome; R-HSA-450302; activated TAK1 mediates p38 MAPK activation. DR Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1. DR Reactome; R-HSA-5205685; PINK1-PRKN Mediated Mitophagy. DR Reactome; R-HSA-5607764; CLEC7A (Dectin-1) signaling. DR Reactome; R-HSA-9020702; Interleukin-1 signaling. DR Reactome; R-HSA-937039; IRAK1 recruits IKK complex. DR Reactome; R-HSA-937041; IKK complex recruitment mediated by RIP1. DR Reactome; R-HSA-9646399; Aggrephagy. DR Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses. DR Reactome; R-HSA-975110; TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling. DR Reactome; R-HSA-975144; IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation. DR Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation. DR SignaLink; Q13404; -. DR SIGNOR; Q13404; -. DR Agora; ENSG00000244687; -. DR BioGRID-ORCS; 387522; 76 hits in 964 CRISPR screens. DR BioGRID-ORCS; 7335; 228 hits in 1089 CRISPR screens. DR ChiTaRS; UBE2V1; human. DR EvolutionaryTrace; Q13404; -. DR GeneWiki; UBE2V1; -. DR Pharos; Q13404; Tbio. DR PRO; PR:Q13404; -. DR Proteomes; UP000005640; Chromosome 20. DR RNAct; Q13404; protein. DR Bgee; ENSG00000244687; Expressed in colonic epithelium and 104 other cell types or tissues. DR ExpressionAtlas; Q13404; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:HGNC-UCL. DR GO; GO:0005829; C:cytosol; IDA:ComplexPortal. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0032991; C:protein-containing complex; IDA:MGI. DR GO; GO:0031372; C:UBC13-MMS2 complex; IDA:UniProtKB. DR GO; GO:0031371; C:ubiquitin conjugating enzyme complex; IDA:HGNC-UCL. DR GO; GO:0000151; C:ubiquitin ligase complex; IDA:UniProtKB. DR GO; GO:0061631; F:ubiquitin conjugating enzyme activity; IEA:Ensembl. DR GO; GO:0031624; F:ubiquitin conjugating enzyme binding; IEA:Ensembl. DR GO; GO:0030154; P:cell differentiation; NAS:UniProtKB. DR GO; GO:0006301; P:DNA damage tolerance; IBA:GO_Central. DR GO; GO:0042275; P:error-free postreplication DNA repair; IEA:Ensembl. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IMP:HGNC-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; TAS:UniProtKB. DR GO; GO:1902533; P:positive regulation of intracellular signal transduction; IDA:ComplexPortal. DR GO; GO:1902523; P:positive regulation of protein K63-linked ubiquitination; IDA:ComplexPortal. DR GO; GO:0070534; P:protein K63-linked ubiquitination; IDA:UniProtKB. DR GO; GO:0000209; P:protein polyubiquitination; TAS:ProtInc. DR GO; GO:0006282; P:regulation of DNA repair; TAS:ProtInc. DR GO; GO:0006355; P:regulation of DNA-templated transcription; TAS:UniProtKB. DR CDD; cd23807; UEV_UBE2V; 1. DR FunFam; 3.10.110.10:FF:000012; Ubiquitin-conjugating enzyme E2 variant 2; 1. DR Gene3D; 3.10.110.10; Ubiquitin Conjugating Enzyme; 1. DR InterPro; IPR000608; UBC. DR InterPro; IPR016135; UBQ-conjugating_enzyme/RWD. DR PANTHER; PTHR24068; UBIQUITIN-CONJUGATING ENZYME E2; 1. DR Pfam; PF00179; UQ_con; 1. DR SMART; SM00212; UBCc; 1. DR SUPFAM; SSF54495; UBC-like; 1. DR PROSITE; PS50127; UBC_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Direct protein sequencing; KW Nucleus; Proteomics identification; Reference proteome; KW Ubl conjugation pathway. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:22814378, FT ECO:0007744|PubMed:25944712" FT CHAIN 2..147 FT /note="Ubiquitin-conjugating enzyme E2 variant 1" FT /id="PRO_0000082600" FT DOMAIN 12..147 FT /note="UBC core" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00388" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:22814378, FT ECO:0007744|PubMed:25944712" FT VAR_SEQ 1..44 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:9418904" FT /id="VSP_038032" FT VAR_SEQ 1..14 FT /note="MAATTGSGVKVPRN -> MPGEVQASYLKSQSKLSDEGRLEPRKFHCKGSKS FT PSQ (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9305758, FT ECO:0000303|PubMed:9418904" FT /id="VSP_038033" FT VAR_SEQ 1..7 FT /note="MAATTGS -> MAYKFRTHSPEALEQLYPWECFVFCLIIFGTFTNQIHKWSH FT TYFGLPRWVTLLQDWHVILPRKHHRIHHVSPHETYFCITT (in isoform 1)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:9305758, ECO:0000303|PubMed:9418904" FT /id="VSP_038034" FT VAR_SEQ 1..7 FT /note="MAATTGS -> MPGEVQASYLKSQSKLSDEGRLEPRKFHCK (in FT isoform 5)" FT /evidence="ECO:0000303|PubMed:11057907" FT /id="VSP_038035" FT VAR_SEQ 45..57 FT /note="LTRWTGMIIGPPR -> MKEDLNLENFTAK (in isoform 4)" FT /evidence="ECO:0000303|PubMed:9418904" FT /id="VSP_038036" FT VAR_SEQ 58..99 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_044818" FT HELIX 11..25 FT /evidence="ECO:0007829|PDB:2A4D" FT STRAND 31..39 FT /evidence="ECO:0007829|PDB:2A4D" FT STRAND 47..53 FT /evidence="ECO:0007829|PDB:2A4D" FT STRAND 56..58 FT /evidence="ECO:0007829|PDB:2HLW" FT TURN 59..62 FT /evidence="ECO:0007829|PDB:2A4D" FT STRAND 64..70 FT /evidence="ECO:0007829|PDB:2A4D" FT TURN 73..77 FT /evidence="ECO:0007829|PDB:2A4D" FT STRAND 81..86 FT /evidence="ECO:0007829|PDB:2A4D" FT STRAND 91..93 FT /evidence="ECO:0007829|PDB:2HLW" FT TURN 95..97 FT /evidence="ECO:0007829|PDB:2A4D" FT HELIX 102..104 FT /evidence="ECO:0007829|PDB:2A4D" FT HELIX 106..109 FT /evidence="ECO:0007829|PDB:2A4D" FT HELIX 117..128 FT /evidence="ECO:0007829|PDB:2A4D" FT TURN 131..135 FT /evidence="ECO:0007829|PDB:2A4D" FT CONFLICT Q13404-1:71..81 FT /note="SPHETYFCITT -> WPTSSAQCYSP (in Ref. 2; AAC02755)" FT /evidence="ECO:0000305" SQ SEQUENCE 147 AA; 16495 MW; BA53837F21977B3F CRC64; MAATTGSGVK VPRNFRLLEE LEEGQKGVGD GTVSWGLEDD EDMTLTRWTG MIIGPPRTIY ENRIYSLKIE CGPKYPEAPP FVRFVTKINM NGVNSSNGVV DPRAISVLAK WQNSYSIKVV LQELRRLMMS KENMKLPQPP EGQCYSN // ID UFO_HUMAN Reviewed; 894 AA. AC P30530; Q8N5L2; Q9UD27; DT 01-APR-1993, integrated into UniProtKB/Swiss-Prot. DT 28-MAR-2018, sequence version 4. DT 28-JAN-2026, entry version 241. DE RecName: Full=Tyrosine-protein kinase receptor UFO; DE EC=2.7.10.1 {ECO:0000269|PubMed:28076778}; DE AltName: Full=AXL oncogene; DE Flags: Precursor; GN Name=AXL; Synonyms=UFO; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=2247464; DOI=10.1073/pnas.87.22.8913; RA Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.; RT "Putative tyrosine kinases expressed in K-562 human leukemia cells."; RL Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), AND ROLE IN MYELOID LEUKEMIA. RC TISSUE=Fibroblast; RX PubMed=1656220; DOI=10.1128/mcb.11.10.5016-5031.1991; RA O'Bryan J.P., Frye R.A., Cogswell P.C., Neubauer A., Kitch B., Prokop C., RA Espinosa R., le Beau M.M., Earp H., Liu E.T.; RT "AXL, a transforming gene isolated from primary human myeloid leukemia RT cells, encodes a novel receptor tyrosine kinase."; RL Mol. Cell. Biol. 11:5016-5031(1991). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG). RX PubMed=1834974; RA Janssen J.W.G., Schulz A.S., Steenvoorden A.C.M., Schmidberger M., RA Strehl S., Ambros P., Bartram C.R.; RT "A novel putative tyrosine kinase receptor with oncogenic potential."; RL Oncogene 6:2113-2120(1991). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 674-730. RX PubMed=8247543; RA Lee S.-T., Strunk K.M., Spritz R.A.; RT "A survey of protein tyrosine kinase mRNAs expressed in normal human RT melanocytes."; RL Oncogene 8:3403-3410(1993). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 677-730, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RC TISSUE=Colon tumor; RX PubMed=7896447; DOI=10.1002/ijc.2910600611; RA Craven R.J., Xu L.H., Weiner T.M., Fridell Y.-W., Dent G.A., Srivastava S., RA Varnum B., Liu E.T., Cance W.G.; RT "Receptor tyrosine kinases expressed in metastatic colon cancer."; RL Int. J. Cancer 60:791-797(1995). RN [8] RP INTERACTION WITH LIGAND GAS6. RX PubMed=7854420; DOI=10.1038/373623a0; RA Varnum B.C., Young C., Elliott G., Garcia A., Bartley T.D., Fridell Y.W., RA Hunt R.W., Trail G., Clogston C., Toso R.J., Yanagihara D., Bennett L., RA Silber M., Merewether L.A., Tseng A., Escobar E., Liu E.T., Yamane H.K.; RT "Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein RT encoded by growth-arrest-specific gene 6."; RL Nature 373:623-626(1995). RN [9] RP INTERACTION WITH GAS6, AND ACTIVITY REGULATION. RX PubMed=8621659; DOI=10.1074/jbc.271.16.9785; RA Mark M.R., Chen J., Hammonds R.G., Sadick M., Godowski P.J.; RT "Characterization of Gas6, a member of the superfamily of G domain- RT containing proteins, as a ligand for Rse and Axl."; RL J. Biol. Chem. 271:9785-9789(1996). RN [10] RP PHOSPHORYLATION AT TYR-779; TYR-821 AND TYR-866, AND INTERACTION WITH GRB2; RP LCK; PIK3R1; PIK3R2 AND PLCG1. RX PubMed=9178760; DOI=10.1038/sj.onc.1201123; RA Braunger J., Schleithoff L., Schulz A.S., Kessler H., Lammers R., RA Ullrich A., Bartram C.R., Janssen J.W.; RT "Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is RT mediated mainly by a multi-substrate docking-site."; RL Oncogene 14:2619-2631(1997). RN [11] RP ROLE IN PROSTATIC CARCINOMA. RX PubMed=10403904; DOI=10.1046/j.1525-1500.1999.99034.x; RA Jacob A.N., Kalapurakal J., Davidson W.R., Kandpal G., Dunson N., RA Prashar Y., Kandpal R.P.; RT "A receptor tyrosine kinase, UFO/Axl, and other genes isolated by a RT modified differential display PCR are overexpressed in metastatic prostatic RT carcinoma cell line DU145."; RL Cancer Detect. Prev. 23:325-332(1999). RN [12] RP ROLE IN BREAST CANCER. RX PubMed=11484958; DOI=10.1023/a:1011126330233; RA Berclaz G., Altermatt H.J., Rohrbach V., Kieffer I., Dreher E., RA Andres A.C.; RT "Estrogen dependent expression of the receptor tyrosine kinase axl in RT normal and malignant human breast."; RL Ann. Oncol. 12:819-824(2001). RN [13] RP INTERACTION WITH NCK2; PIK3R3; SOCS1 AND TNS2. RX PubMed=12470648; DOI=10.1016/s0006-291x(02)02718-3; RA Hafizi S., Alindri F., Karlsson R., Dahlbaeck B.; RT "Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1 RT domain-containing protein with homology to tensin."; RL Biochem. Biophys. Res. Commun. 299:793-800(2002). RN [14] RP FUNCTION OF THE GAS6/AXL SIGNALING PATHWAY. RX PubMed=12364394; DOI=10.1161/01.res.0000036753.50601.e9; RA D'Arcangelo D., Gaetano C., Capogrossi M.C.; RT "Acidification prevents endothelial cell apoptosis by Axl activation."; RL Circ. Res. 91:E4-12(2002). RN [15] RP ROLE IN THYROID CARCINOMAS. RX PubMed=12490074; DOI=10.1089/105072502320908303; RA Ito M., Nakashima M., Nakayama T., Ohtsuru A., Nagayama Y., Takamura N., RA Demedchik E.P., Sekine I., Yamashita S.; RT "Expression of receptor-type tyrosine kinase, Axl, and its ligand, Gas6, in RT pediatric thyroid carcinomas around Chernobyl."; RL Thyroid 12:971-975(2002). RN [16] RP INTERACTION WITH CBL AND GAS6, AND UBIQUITINATION. RX PubMed=15958209; DOI=10.1016/j.bbrc.2005.05.086; RA Valverde P.; RT "Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and RT downregulation."; RL Biochem. Biophys. Res. Commun. 333:180-185(2005). RN [17] RP ACTIVITY REGULATION, AND FUNCTION. RX PubMed=15507525; DOI=10.1182/blood-2004-04-1469; RA Gallicchio M., Mitola S., Valdembri D., Fantozzi R., Varnum B., RA Avanzi G.C., Bussolino F.; RT "Inhibition of vascular endothelial growth factor receptor 2-mediated RT endothelial cell activation by Axl tyrosine kinase receptor."; RL Blood 105:1970-1976(2005). RN [18] RP FUNCTION IN PLATELET ACTIVATION AND THROMBOTIC RESPONSE REGULATION. RX PubMed=15733062; DOI=10.1111/j.1538-7836.2005.01186.x; RA Gould W.R., Baxi S.M., Schroeder R., Peng Y.W., Leadley R.J., RA Peterson J.T., Perrin L.A.; RT "Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate RT thrombotic responses."; RL J. Thromb. Haemost. 3:733-741(2005). RN [19] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=17005688; DOI=10.1128/jvi.01157-06; RA Shimojima M., Takada A., Ebihara H., Neumann G., Fujioka K., Irimura T., RA Jones S., Feldmann H., Kawaoka Y.; RT "Tyro3 family-mediated cell entry of Ebola and Marburg viruses."; RL J. Virol. 80:10109-10116(2006). RN [20] RP INTERACTION WITH GRB2; PIK3R1 AND PIK3R2, AND PHOSPHORYLATION AT TYR-779; RP TYR-821 AND TYR-866. RX PubMed=18346204; DOI=10.1111/j.1471-4159.2008.05343.x; RA Weinger J.G., Gohari P., Yan Y., Backer J.M., Varnum B., Shafit-Zagardo B.; RT "In brain, Axl recruits Grb2 and the p85 regulatory subunit of PI3 kinase; RT in vitro mutagenesis defines the requisite binding sites for downstream Akt RT activation."; RL J. Neurochem. 106:134-146(2008). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-884, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [22] RP FUNCTION OF THE GAS6/AXL SIGNALING PATHWAY. RX PubMed=18840707; DOI=10.1182/blood-2008-05-157073; RA Park I.K., Giovenzana C., Hughes T.L., Yu J., Trotta R., Caligiuri M.A.; RT "The Axl/Gas6 pathway is required for optimal cytokine signaling during RT human natural killer cell development."; RL Blood 113:2470-2477(2009). RN [23] RP INTERACTION WITH GRB2 AND TNK2. RX PubMed=19815557; DOI=10.1074/jbc.m109.072660; RA Pao-Chun L., Chan P.M., Chan W., Manser E.; RT "Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is RT mediated by Grb2: an analysis of ACK1 effects on Axl signaling."; RL J. Biol. Chem. 284:34954-34963(2009). RN [24] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=21501828; DOI=10.1016/j.chom.2011.03.012; RA Morizono K., Xie Y., Olafsen T., Lee B., Dasgupta A., Wu A.M., Chen I.S.; RT "The soluble serum protein Gas6 bridges virion envelope phosphatidylserine RT to the TAM receptor tyrosine kinase Axl to mediate viral entry."; RL Cell Host Microbe 9:286-298(2011). RN [25] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=22156524; DOI=10.1128/jvi.06451-11; RA Shimojima M., Stroher U., Ebihara H., Feldmann H., Kawaoka Y.; RT "Identification of cell surface molecules involved in dystroglycan- RT independent Lassa virus cell entry."; RL J. Virol. 86:2067-2078(2012). RN [26] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=22673088; DOI=10.1292/jvms.12-0176; RA Shimojima M., Kawaoka Y.; RT "Cell surface molecules involved in infection mediated by lymphocytic RT choriomeningitis virus glycoprotein."; RL J. Vet. Med. Sci. 74:1363-1366(2012). RN [27] RP FUNCTION (MICROBIAL INFECTION), AND REVIEW. RX PubMed=25277499; DOI=10.1016/j.virol.2014.09.009; RA Moller-Tank S., Maury W.; RT "Phosphatidylserine receptors: enhancers of enveloped virus entry and RT infection."; RL Virology 468:565-580(2014). RN [28] RP FUNCTION (MICROBIAL INFECTION), MUTAGENESIS OF LYS-567, CATALYTIC ACTIVITY, RP AND SUBCELLULAR LOCATION. RX PubMed=28076778; DOI=10.1016/j.celrep.2016.12.045; RA Meertens L., Labeau A., Dejarnac O., Cipriani S., Sinigaglia L., RA Bonnet-Madin L., Le Charpentier T., Hafirassou M.L., Zamborlini A., RA Cao-Lormeau V.M., Coulpier M., Misse D., Jouvenet N., Tabibiazar R., RA Gressens P., Schwartz O., Amara A.; RT "Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate RT Immune Responses."; RL Cell Rep. 18:324-333(2017). RN [29] RP INDUCTION BY MOSQUITO LYMPHOTOXIN BETA RECEPTOR INHIBITOR DURING ZIKA VIRUS RP INFECTION (MICROBIAL INFECTION). RX PubMed=29507355; DOI=10.1038/s41590-018-0063-9; RA Jin L., Guo X., Shen C., Hao X., Sun P., Li P., Xu T., Hu C., Rose O., RA Zhou H., Yang M., Qin C.F., Guo J., Peng H., Zhu M., Cheng G., Qi X., RA Lai R.; RT "Salivary factor LTRIN from Aedes aegypti facilitates the transmission of RT Zika virus by interfering with the lymphotoxin-beta receptor."; RL Nat. Immunol. 19:342-353(2018). RN [30] RP FUNCTION (MICROBIAL INFECTION), AND SUBCELLULAR LOCATION. RX PubMed=29379210; DOI=10.1038/s41564-017-0092-4; RA Chen J., Yang Y.F., Yang Y., Zou P., Chen J., He Y., Shui S.L., Cui Y.R., RA Bai R., Liang Y.J., Hu Y., Jiang B., Lu L., Zhang X., Liu J., Xu J.; RT "AXL promotes Zika virus infection in astrocytes by antagonizing type I RT interferon signalling."; RL Nat. Microbiol. 3:302-309(2018). RN [31] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=31311882; DOI=10.1128/mbio.01372-19; RA Strange D.P., Jiyarom B., Pourhabibi Zarandi N., Xie X., Baker C., RA Sadri-Ardekani H., Shi P.Y., Verma S.; RT "Axl Promotes Zika Virus Entry and Modulates the Antiviral State of Human RT Sertoli Cells."; RL MBio 10:0-0(2019). RN [32] RP X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 33-227 IN COMPLEX WITH GAS6, RP MUTAGENESIS OF GLU-63; GLU-66 AND THR-84, AND SUBUNIT. RX PubMed=16362042; DOI=10.1038/sj.emboj.7600912; RA Sasaki T., Knyazev P.G., Clout N.J., Cheburkin Y., Goehring W., Ullrich A., RA Timpl R., Hohenester E.; RT "Structural basis for Gas6-Axl signalling."; RL EMBO J. 25:80-87(2006). RN [33] RP VARIANTS [LARGE SCALE ANALYSIS] MET-112; TRP-295; CYS-499 AND GLY-515. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Receptor tyrosine kinase that transduces signals from the CC extracellular matrix into the cytoplasm by binding growth factor GAS6 CC and which is thus regulating many physiological processes including CC cell survival, cell proliferation, migration and differentiation. CC Ligand binding at the cell surface induces dimerization and CC autophosphorylation of AXL. Following activation by ligand, AXL binds CC and induces tyrosine phosphorylation of PI3-kinase subunits PIK3R1, CC PIK3R2 and PIK3R3; but also GRB2, PLCG1, LCK and PTPN11. Other CC downstream substrate candidates for AXL are CBL, NCK2, SOCS1 and TNS2. CC Recruitment of GRB2 and phosphatidylinositol 3 kinase regulatory CC subunits by AXL leads to the downstream activation of the AKT kinase. CC GAS6/AXL signaling plays a role in various processes such as CC endothelial cell survival during acidification by preventing apoptosis, CC optimal cytokine signaling during human natural killer cell CC development, hepatic regeneration, gonadotropin-releasing hormone CC neuron survival and migration, platelet activation, or regulation of CC thrombotic responses. Also plays an important role in inhibition of CC Toll-like receptors (TLRs)-mediated innate immune response. CC {ECO:0000269|PubMed:10403904, ECO:0000269|PubMed:11484958, CC ECO:0000269|PubMed:12364394, ECO:0000269|PubMed:12490074, CC ECO:0000269|PubMed:15507525, ECO:0000269|PubMed:15733062, CC ECO:0000269|PubMed:1656220, ECO:0000269|PubMed:18840707}. CC -!- FUNCTION: (Microbial infection) Acts as a receptor for lassa virus and CC lymphocytic choriomeningitis virus, possibly through GAS6 binding to CC phosphatidyl-serine at the surface of virion envelope. CC {ECO:0000269|PubMed:17005688, ECO:0000269|PubMed:21501828, CC ECO:0000269|PubMed:22156524, ECO:0000269|PubMed:25277499}. CC -!- FUNCTION: (Microbial infection) Acts as a receptor for Ebolavirus, CC possibly through GAS6 binding to phosphatidyl-serine at the surface of CC virion envelope. {ECO:0000269|PubMed:22673088}. CC -!- FUNCTION: (Microbial infection) Promotes Zika virus entry in glial CC cells, Sertoli cells and astrocytes (PubMed:28076778, PubMed:29379210, CC PubMed:31311882). Additionally, Zika virus potentiates AXL kinase CC activity to antagonize type I interferon signaling and thereby promotes CC infection (PubMed:28076778). Interferon signaling inhibition occurs via CC an SOCS1-dependent mechanism (PubMed:29379210). CC {ECO:0000269|PubMed:28076778, ECO:0000269|PubMed:29379210, CC ECO:0000269|PubMed:31311882}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:28076778}; CC -!- ACTIVITY REGULATION: Activated by GAS6-binding and subsequent CC autophosphorylation. {ECO:0000269|PubMed:15507525, CC ECO:0000269|PubMed:8621659}. CC -!- SUBUNIT: Heterodimer and heterotetramer with ligand GAS6. Interacts CC with CBL, GRB2, LCK, NCK2, PIK3R1, PIK3R2, PIK3R3, PLCG1, SOCS1 and CC TNS2. Part of a complex including AXL, TNK2 and GRB2, in which GRB2 CC promotes AXL recruitment by TNK2. {ECO:0000269|PubMed:12470648, CC ECO:0000269|PubMed:15958209, ECO:0000269|PubMed:16362042, CC ECO:0000269|PubMed:18346204, ECO:0000269|PubMed:19815557, CC ECO:0000269|PubMed:7854420, ECO:0000269|PubMed:8621659, CC ECO:0000269|PubMed:9178760}. CC -!- INTERACTION: CC P30530; P00533: EGFR; NbExp=5; IntAct=EBI-2850927, EBI-297353; CC P30530; P29317: EPHA2; NbExp=2; IntAct=EBI-2850927, EBI-702104; CC P30530; Q14393-2: GAS6; NbExp=8; IntAct=EBI-2850927, EBI-21517417; CC P30530; P62993: GRB2; NbExp=4; IntAct=EBI-2850927, EBI-401755; CC P30530; P08238: HSP90AB1; NbExp=3; IntAct=EBI-2850927, EBI-352572; CC P30530; Q01638: IL1RL1; NbExp=2; IntAct=EBI-2850927, EBI-993762; CC P30530; P27986: PIK3R1; NbExp=3; IntAct=EBI-2850927, EBI-79464; CC P30530; O43791: SPOP; NbExp=5; IntAct=EBI-2850927, EBI-743549; CC P30530; P0DTC2: S; Xeno; NbExp=9; IntAct=EBI-2850927, EBI-25474821; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:28076778, CC ECO:0000269|PubMed:29379210, ECO:0000269|PubMed:7896447}; Single-pass CC type I membrane protein {ECO:0000269|PubMed:7896447}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=Long; CC IsoId=P30530-1; Sequence=Displayed; CC Name=Short; CC IsoId=P30530-2; Sequence=VSP_005017; CC -!- TISSUE SPECIFICITY: Highly expressed in metastatic colon tumors. CC Expressed in primary colon tumors. Weakly expressed in normal colon CC tissue. {ECO:0000269|PubMed:7896447}. CC -!- INDUCTION: (Microbial infection) Up-regulated by Aedes aegypti CC lymphotoxin beta receptor inhibitor during Zika virus infection. CC {ECO:0000269|PubMed:29507355}. CC -!- PTM: Monoubiquitinated upon GAS6-binding. A very small proportion of CC the receptor could be subjected to polyubiquitination in a very CC transient fashion. {ECO:0000269|PubMed:15958209}. CC -!- PTM: Phosphorylated at tyrosine residues by autocatalysis, which CC activates kinase activity. {ECO:0000269|PubMed:18346204, CC ECO:0000269|PubMed:9178760}. CC -!- DISEASE: Note=AXL and its ligand GAS6 are highly expressed in thyroid CC carcinoma tissues, and might thus be involved in thyroid tumorigenesis. CC Overexpression of AXL and its ligand was also detected in many other CC cancers such as myeloproliferative disorders, prostatic carcinoma CC cells, or breast cancer. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. AXL/UFO subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/733/AXL"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M76125; AAA61243.1; -; mRNA. DR EMBL; S65125; AAB20305.1; -; mRNA. DR EMBL; X57019; CAA40338.1; -; mRNA. DR EMBL; AC011510; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC032229; AAH32229.1; -; mRNA. DR CCDS; CCDS12574.1; -. [P30530-2] DR CCDS; CCDS12575.1; -. [P30530-1] DR PIR; A41527; A41527. DR RefSeq; NP_001690.2; NM_001699.5. [P30530-2] DR RefSeq; NP_068713.2; NM_021913.4. [P30530-1] DR PDB; 2C5D; X-ray; 3.30 A; C/D=33-227. DR PDB; 4RA0; X-ray; 3.07 A; C/D=33-227. DR PDB; 5U6B; X-ray; 2.84 A; A/B/C/D=514-818. DR PDB; 5VXZ; X-ray; 2.30 A; C/D=34-135. DR PDBsum; 2C5D; -. DR PDBsum; 4RA0; -. DR PDBsum; 5U6B; -. DR PDBsum; 5VXZ; -. DR AlphaFoldDB; P30530; -. DR SMR; P30530; -. DR BioGRID; 107036; 404. DR CORUM; P30530; -. DR FunCoup; P30530; 354. DR IntAct; P30530; 298. DR MINT; P30530; -. DR STRING; 9606.ENSP00000301178; -. DR BindingDB; P30530; -. DR ChEMBL; CHEMBL4895; -. DR DrugBank; DB12411; Bemcentinib. DR DrugBank; DB15187; Dubermatinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB12141; Gilteritinib. DR DrugBank; DB19201; Tamnorzatinib. DR DrugCentral; P30530; -. DR GuidetoPHARMACOLOGY; 1835; -. DR GlyConnect; 1983; 12 N-Linked glycans (4 sites). DR GlyCosmos; P30530; 8 sites, 12 glycans. DR GlyGen; P30530; 10 sites, 13 N-linked glycans (4 sites), 1 O-linked glycan (2 sites). DR iPTMnet; P30530; -. DR PhosphoSitePlus; P30530; -. DR BioMuta; AXL; -. DR DMDM; 239938818; -. DR CPTAC; CPTAC-1766; -. DR CPTAC; CPTAC-2791; -. DR jPOST; P30530; -. DR MassIVE; P30530; -. DR PaxDb; 9606-ENSP00000301178; -. DR PeptideAtlas; P30530; -. DR ProteomicsDB; 54712; -. [P30530-1] DR ProteomicsDB; 54713; -. [P30530-2] DR Pumba; P30530; -. DR ABCD; P30530; 23 sequenced antibodies. DR Antibodypedia; 30709; 1302 antibodies from 46 providers. DR CPTC; P30530; 2 antibodies. DR DNASU; 558; -. DR Ensembl; ENST00000301178.9; ENSP00000301178.3; ENSG00000167601.13. [P30530-1] DR Ensembl; ENST00000359092.7; ENSP00000351995.2; ENSG00000167601.13. [P30530-2] DR GeneID; 558; -. DR KEGG; hsa:558; -. DR MANE-Select; ENST00000301178.9; ENSP00000301178.3; NM_021913.5; NP_068713.2. DR UCSC; uc010ehj.5; human. [P30530-1] DR AGR; HGNC:905; -. DR CIViC; 558; 1 evidence item across 1 molecular profile. DR ClinPGx; PA25197; -. DR CTD; 558; -. DR DisGeNET; 558; -. DR GeneCards; AXL; -. DR GeneReviews; AXL; -. DR HGNC; HGNC:905; AXL. DR HPA; ENSG00000167601; Low tissue specificity. DR MalaCards; AXL; -. DR MIM; 109135; gene. DR OpenTargets; ENSG00000167601; -. DR VEuPathDB; HostDB:ENSG00000167601; -. DR eggNOG; ENOG502QQQ3; Eukaryota. DR GeneTree; ENSGT00940000160232; -. DR InParanoid; P30530; -. DR OMA; WTIMSTL; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P30530; 13 GO annotations based on evolutionary models. DR PhylomeDB; P30530; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P30530; -. DR Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway. DR SignaLink; P30530; -. DR SIGNOR; P30530; -. DR Agora; ENSG00000167601; -. DR BioGRID-ORCS; 558; 17 hits in 1198 CRISPR screens. DR ChiTaRS; AXL; human. DR EvolutionaryTrace; P30530; -. DR GeneWiki; AXL_receptor_tyrosine_kinase; -. DR GenomeRNAi; 558; -. DR Pharos; P30530; Tchem. DR PRO; PR:P30530; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; P30530; protein. DR Bgee; ENSG00000167601; Expressed in synovial joint and 206 other cell types or tissues. DR ExpressionAtlas; P30530; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IDA:HPA. DR GO; GO:0009986; C:cell surface; IDA:UniProtKB. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005615; C:extracellular space; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0001786; F:phosphatidylserine binding; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0001618; F:virus receptor activity; IDA:FlyBase. DR GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl. DR GO; GO:0048469; P:cell maturation; IEP:UniProtKB. DR GO; GO:0016477; P:cell migration; IBA:GO_Central. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0035457; P:cellular response to interferon-alpha; IDA:UniProtKB. DR GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:UniProtKB. DR GO; GO:0097028; P:dendritic cell differentiation; IEP:UniProtKB. DR GO; GO:0034101; P:erythrocyte homeostasis; IEA:Ensembl. DR GO; GO:0051649; P:establishment of localization in cell; IEA:Ensembl. DR GO; GO:0021885; P:forebrain cell migration; IEA:Ensembl. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW. DR GO; GO:0001779; P:natural killer cell differentiation; IBA:GO_Central. DR GO; GO:0043066; P:negative regulation of apoptotic process; IBA:GO_Central. DR GO; GO:2000669; P:negative regulation of dendritic cell apoptotic process; IDA:UniProtKB. DR GO; GO:0051250; P:negative regulation of lymphocyte activation; IEA:Ensembl. DR GO; GO:0010936; P:negative regulation of macrophage cytokine production; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IEA:Ensembl. DR GO; GO:0032689; P:negative regulation of type II interferon production; IDA:UniProtKB. DR GO; GO:0007399; P:nervous system development; IBA:GO_Central. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0001764; P:neuron migration; IEA:Ensembl. DR GO; GO:0097350; P:neutrophil clearance; IEA:Ensembl. DR GO; GO:0042698; P:ovulation cycle; IEA:Ensembl. DR GO; GO:0006909; P:phagocytosis; IDA:UniProtKB. DR GO; GO:0030168; P:platelet activation; IBA:GO_Central. DR GO; GO:0001961; P:positive regulation of cytokine-mediated signaling pathway; IDA:UniProtKB. DR GO; GO:0032825; P:positive regulation of natural killer cell differentiation; IDA:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0048549; P:positive regulation of pinocytosis; IMP:CACAO. DR GO; GO:1903902; P:positive regulation of viral life cycle; IMP:FlyBase. DR GO; GO:0032940; P:secretion by cell; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl. DR GO; GO:0046718; P:symbiont entry into host cell; IMP:CACAO. DR GO; GO:0060068; P:vagina development; IEA:Ensembl. DR GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome. DR CDD; cd00063; FN3; 2. DR CDD; cd20966; IgI_1_Axl_like; 1. DR CDD; cd05749; IgI_2_Axl_Tyro3_like; 1. DR CDD; cd05075; PTKc_Axl; 1. DR FunFam; 2.60.40.10:FF:000865; AXL receptor tyrosine kinase; 1. DR FunFam; 1.10.510.10:FF:000089; Tyrosine-protein kinase receptor TYRO3; 1. DR FunFam; 2.60.40.10:FF:000662; Tyrosine-protein kinase receptor UFO; 1. DR FunFam; 2.60.40.10:FF:000810; Tyrosine-protein kinase receptor UFO; 1. DR FunFam; 3.30.200.20:FF:000509; Tyrosine-protein kinase receptor UFO; 1. DR FunFam; 2.60.40.10:FF:000696; tyrosine-protein kinase receptor UFO isoform X1; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 4. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR PANTHER; PTHR24416:SF323; TYROSINE-PROTEIN KINASE RECEPTOR UFO; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00060; FN3; 2. DR SMART; SM00409; IG; 2. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF48726; Immunoglobulin; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS50835; IG_LIKE; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Differentiation; Disulfide bond; Glycoprotein; KW Host cell receptor for virus entry; Host-virus interaction; Immunity; KW Immunoglobulin domain; Innate immunity; Kinase; Membrane; KW Nucleotide-binding; Oncogene; Phosphoprotein; Proteomics identification; KW Proto-oncogene; Receptor; Reference proteome; Repeat; Signal; Transferase; KW Transmembrane; Transmembrane helix; Tyrosine-protein kinase; KW Ubl conjugation. FT SIGNAL 1..25 FT /evidence="ECO:0000255" FT CHAIN 26..894 FT /note="Tyrosine-protein kinase receptor UFO" FT /id="PRO_0000024481" FT TOPO_DOM 26..451 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 452..472 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 473..894 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 27..128 FT /note="Ig-like C2-type 1" FT DOMAIN 139..222 FT /note="Ig-like C2-type 2" FT DOMAIN 227..331 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 336..428 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 536..807 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 26..92 FT /note="Interaction with GAS6" FT REGION 823..853 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 866..894 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 672 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 542..550 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 567 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 703 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 779 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18346204, FT ECO:0000269|PubMed:9178760" FT MOD_RES 821 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18346204, FT ECO:0000269|PubMed:9178760" FT MOD_RES 866 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18346204, FT ECO:0000269|PubMed:9178760" FT MOD_RES 884 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT CARBOHYD 43 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 157 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 198 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 339 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 345 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 401 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 56..117 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 160..205 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 429..437 FT /note="Missing (in isoform Short)" FT /evidence="ECO:0000303|PubMed:1656220" FT /id="VSP_005017" FT VARIANT 112 FT /note="T -> M (in dbSNP:rs35202236)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045596" FT VARIANT 266 FT /note="D -> N (in dbSNP:rs7249222)" FT /id="VAR_057990" FT VARIANT 295 FT /note="R -> W (in a lung neuroendocrine carcinoma sample; FT somatic mutation; dbSNP:rs751738506)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045597" FT VARIANT 499 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs747576071)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041877" FT VARIANT 515 FT /note="S -> G (in dbSNP:rs1240393707)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041878" FT MUTAGEN 63 FT /note="E->R: Slightly reduced affinity for GAS6." FT /evidence="ECO:0000269|PubMed:16362042" FT MUTAGEN 66 FT /note="E->R: Reduced affinity for GAS6." FT /evidence="ECO:0000269|PubMed:16362042" FT MUTAGEN 84 FT /note="T->R: Reduced affinity for GAS6." FT /evidence="ECO:0000269|PubMed:16362042" FT MUTAGEN 567 FT /note="K->M: Catalytically inactive mutant." FT /evidence="ECO:0000269|PubMed:28076778" FT CONFLICT 303 FT /note="T -> P (in Ref. 3; AAB20305/CAA40338)" FT /evidence="ECO:0000305" FT CONFLICT 338 FT /note="E -> K (in Ref. 2; AAA61243)" FT /evidence="ECO:0000305" FT CONFLICT 430 FT /note="Q -> E (in Ref. 3; AAB20305/CAA40338)" FT /evidence="ECO:0000305" FT CONFLICT 639 FT /note="D -> G (in Ref. 3; AAB20305/CAA40338)" FT /evidence="ECO:0000305" FT CONFLICT 696 FT /note="K -> I (in Ref. 7; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 764 FT /note="Q -> R (in Ref. 5; AAH32229)" FT /evidence="ECO:0000305" FT STRAND 37..39 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 44..46 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 52..63 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 68..71 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 80..87 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 89..91 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 94..106 FT /evidence="ECO:0007829|PDB:5VXZ" FT HELIX 109..111 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 113..121 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 124..127 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 131..134 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 140..143 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 148..150 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 156..159 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 161..163 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 165..167 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 170..175 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 178..187 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 190..194 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 201..209 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 212..215 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 219..223 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 515..517 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 524..529 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 533..535 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 536..544 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 546..556 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 558..571 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 576..590 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 602..605 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 616..621 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 628..637 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 638..640 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 646..665 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 675..677 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 678..680 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 686..688 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 698..700 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 713..715 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 718..723 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 728..743 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 755..763 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 776..785 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 790..792 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 796..809 FT /evidence="ECO:0007829|PDB:5U6B" SQ SEQUENCE 894 AA; 98337 MW; 262D3659218E3202 CRC64; MAWRCPRMGR VPLAWCLALC GWACMAPRGT QAEESPFVGN PGNITGARGL TGTLRCQLQV QGEPPEVHWL RDGQILELAD STQTQVPLGE DEQDDWIVVS QLRITSLQLS DTGQYQCLVF LGHQTFVSQP GYVGLEGLPY FLEEPEDRTV AANTPFNLSC QAQGPPEPVD LLWLQDAVPL ATAPGHGPQR SLHVPGLNKT SSFSCEAHNA KGVTTSRTAT ITVLPQQPRN LHLVSRQPTE LEVAWTPGLS GIYPLTHCTL QAVLSDDGMG IQAGEPDPPE EPLTSQASVP PHQLRLGSLH PHTPYHIRVA CTSSQGPSSW THWLPVETPE GVPLGPPENI SATRNGSQAF VHWQEPRAPL QGTLLGYRLA YQGQDTPEVL MDIGLRQEVT LELQGDGSVS NLTVCVAAYT AAGDGPWSLP VPLEAWRPGQ AQPVHQLVKE PSTPAFSWPW WYVLLGAVVA AACVLILALF LVHRRKKETR YGEVFEPTVE RGELVVRYRV RKSYSRRTTE ATLNSLGISE ELKEKLRDVM VDRHKVALGK TLGEGEFGAV MEGQLNQDDS ILKVAVKTMK IAICTRSELE DFLSEAVCMK EFDHPNVMRL IGVCFQGSER ESFPAPVVIL PFMKHGDLHS FLLYSRLGDQ PVYLPTQMLV KFMADIASGM EYLSTKRFIH RDLAARNCML NENMSVCVAD FGLSKKIYNG DYYRQGRIAK MPVKWIAIES LADRVYTSKS DVWSFGVTMW EIATRGQTPY PGVENSEIYD YLRQGNRLKQ PADCLDGLYA LMSRCWELNP QDRPSFTELR EDLENTLKAL PPAQEPDEIL YVNMDEGGGY PEPPGAAGGA DPPTQPDPKD SCSCLTAAEV HPAGRYVLCP STTPSPAQPA DRGSPAAPGQ EDGA //